BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
jonathanu@blbglaw.com
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Counsel for Lead Plaintiff Indiana Public Retirement System and Lead Counsel for the Class

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

JONNIE HOMYK, et al.,

Plaintiffs,

v.

CHEMOCENTRYX, INC. et al.,

Defendants.

Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357

DECLARATION OF JONATHAN D. USLANER IN SUPPORT OF (I) LEAD PLAINTIFF'S MOTION FOR FINAL APPROVAL OF SETTLEMENT AND PLAN OF ALLOCATION, AND (II) LEAD COUNSEL'S MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES

Judge: Honorable Jon S. Tigar
Date: October 29, 2026
Time: 2:00 p.m.

TABLE OF CONTENTS

Page

EXHIBIT LIST

Ex. No.	Description
1	Declaration of Jeffrey M. Gill, General Counsel of Indiana Public Retirement System, in Support of (I) Lead Plaintiff's Motion for Final Approval of Settlement and Plan of Allocation; and (II) Lead Counsel's Motion for Attorneys' Fees and Litigation Expenses ("Gill Decl.")
2	CORNERSTONE RESEARCH, SECURITIES CLASS ACTION SETTLEMENTS: 2025 REVIEW AND ANALYSIS (2026)
3	Declaration of Lindsey Marquez Regarding Mailing, Posting, and Publication of Settlement Notice
4	Lead Counsel's Summary Lodestar Chart
5	BLB&G Firm Resume
6	Biographies of Lead Counsel's Attorneys
7	Lead Counsel's Work by Timekeeper, Task Category, and Month
8	Summary of Task Categories by Month
9	Summary of Task Categories by Timekeeper
10	Summary of Lead Counsel's Expenses by Category
11	Detailed Listing of Lead Counsel's Expenses
12A	Expert Expenses - Receipts & Invoices
12B	Other Expenses Over $5,000 - Receipts & Invoices
13	[Proposed] Judgment Approving Class Action Settlement
14	[Proposed] Order Approving Plan of Allocation of Net Settlement Fund
15	[Proposed] Order Awarding Attorneys' Fees and Litigation Expenses
16	Compendium of Unpublished Authorities Cited in Fee and Expense Motion

I, JONATHAN D. USLANER, declare as follows:

1. I am a partner in the law firm of Bernstein Litowitz Berger & Grossmann LLP ("BLB&G" or "Lead Counsel"). BLB&G was appointed as Lead Counsel for Lead Plaintiff Indiana Public Retirement System ("Lead Plaintiff" or "Indiana") and Class Counsel for the certified Class in the above-captioned action (the "Action"). I have personal knowledge of the matters set forth herein based on my active participation in all aspects of the prosecution and settlement of the Action.[1]

2. The proposed Settlement before the Court provides for the resolution of all claims in the Action in exchange for a cash payment of $69,000,000 plus interest, for the benefit of the Class. The Settlement Amount has been paid into an escrow account and is earning interest. As detailed herein, the Settlement is a highly favorable outcome for the Class because it confers a substantial, certain, and near-term recovery for Class Members while avoiding the significant risks of continued litigation, including the risk that the Class could recover nothing or less than the Settlement Amount after years of additional litigation, appeals, and delay. The Settlement is a particularly favorable result for the Class because this case is pending on appeal after the Court dismissed all claims in its August 15, 2025 Summary Judgment Order (Dkt. No. 345).

3. The proposed Settlement is the result of extensive efforts by Lead Plaintiff and Lead Counsel over the course of more than five years, which included, among other things: (1) conducting an extensive investigation into the alleged fraud, including interviews with dozens of former ChemoCentryx employees and a thorough review of public information such as filings with the U.S. Securities and Exchange Commission ("SEC"), analyst reports, conference call transcripts, and news articles; (2) drafting a detailed Amended Consolidated Class Action Complaint (the "Complaint") based on Lead Counsel's extensive investigation; (3) successfully opposing Defendants' motion to dismiss in substantial part; (4) completing fact discovery, including

[1] All capitalized terms that are not otherwise defined herein shall have the meanings provided in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 (Dkt. No. 366-1) (the "Stipulation"), which was entered into by and among (i) Lead Plaintiff, on behalf of itself and the Class, and (ii) Defendants ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") and Thomas J. Schall (together, "Defendants").

exchanging initial disclosures, propounding thorough document requests, preparing and serving over 50 third-party subpoenas, obtaining and reviewing approximately 8 million pages of documents from Defendants and third parties, and conducting 21 fact depositions; (5) successfully obtaining class certification; (6) defeating Defendants' Rule 23(f) petition for interlocutory review; (7) working extensively with experts in the fields of financial economics (including market efficiency, loss causation, and damages), medicine (including hepatology and rheumatology), biostatistics, the pharmaceutical industry, and regulations by the U.S. Food and Drug Administration ("FDA"); (8) completing expert discovery, which included a total of 24 expert reports and 17 expert depositions; (9) briefing and arguing 11 *Daubert* motions; (10) briefing and arguing cross-motions for summary judgment; (11) preparing and filing an appeal to the Ninth Circuit; and (12) participating in extended arm's-length negotiations with Defendants' Counsel, including concerning the disputed impact of certain post-appeal developments, including the FDA's proposed withdrawal of TAVNEOS. Due to these extensive efforts, Lead Plaintiff and Lead Counsel were well informed of the strengths and weaknesses of the claims and defenses in the Action at the time they achieved the proposed Settlement.

4. Lead Plaintiff Indiana is a sophisticated institutional investor that actively participated in the Action, closely supervised the work of Lead Counsel, and endorses the approval of the Settlement. *See* Declaration of Jeffrey M. Gill ("Gill Decl."), attached hereto as Exhibit 1 at ¶¶ 3-7.

5. As discussed in further detail below, the proposed Plan of Allocation, which was developed with the assistance of Lead Plaintiff's damages expert, provides for the equitable distribution of the Net Settlement Fund to Class Members who submit Claim Forms that are approved for payment by the Court on a *pro rata* basis according to losses attributable to the alleged fraud.

6. For its efforts in achieving the Settlement, Lead Counsel requests attorneys' fees in the amount of 22% of the Settlement Fund, which is below the 25% benchmark for percentage fee awards in the Ninth Circuit and is well within the range of percentage fees that courts in this District and Circuit typically award in connection with comparable settlements. Lead Counsel respectfully

submits that the requested fee is fair and reasonable in light of the result achieved in the Action, the efforts of Lead Counsel, and the risks and complexity of the litigation.

I. HISTORY OF THE ACTION

A. Background

7. Defendant ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") is a biopharmaceutical company incorporated under the laws of the State of Delaware, with its corporate headquarters and principal place of business in California. ChemoCentryx's common stock traded on the NASDAQ stock exchange under the ticker symbol "CCXI" until October 19, 2022, at which time the Company was acquired by Amgen, Inc. ("Amgen").

8. In the Action, Lead Plaintiff alleged that Defendants ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall, made misstatements to investors during the Class Period about the safety and efficacy of ChemoCentryx's vasculitis drug, avacopan, and the Company's application for FDA approval of avacopan, thereby artificially inflating the price of ChemoCentryx common stock and causing investors to suffer losses.

B. The Commencement of the Action and the Appointment of Lead Plaintiff and Lead Counsel

9. On May 5, 2021, Jonnie Homyk ("Homyk"), through counsel, filed the initial complaint in this Action in the United States District Court for the Northern District of California (the "Court"), alleging violations of the federal securities laws against ChemoCentryx and Defendant Schall. Dkt. No. 1.

10. In accordance with the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), on May 5, 2021, Homyk's counsel caused a notice to be published over a national business newswire service advising potential class members of the pendency of the Action, the claims asserted, and the deadline by which putative class members could move the Court for appointment as Lead Plaintiff. Dkt. No. 7.

11. On July 6, 2021, Indiana moved for appointment as Lead Plaintiff. Dkt. No. 18. As set forth in its motion, Indiana had the largest financial interest of any competing movant—having suffered losses of approximately $4 million on its purchases of more than 95,000 shares of

ChemoCentryx common stock during the Class Period—and was an adequate representative of the proposed class. *Id.* at 3. Indiana's motion was opposed by the Public Employees Retirement Association of New Mexico. Dkt. No. 27. Indiana filed a reply demonstrating that its motion fully complied with the PSLRA and the Local Rules. Dkt. No. 29.

12. On January 28, 2022, the Court entered an order appointing Indiana as Lead Plaintiff for the Action, approving Lead Plaintiff's selection of BLB&G as Lead Counsel, and consolidating two related actions. Dkt. No. 32.

C. The Investigation and Filing of the Complaint

13. Beginning prior to the Court's appointment of Indiana as Lead Plaintiff and continuing through preparation of the Complaint on behalf of Lead Plaintiff, Lead Counsel undertook an extensive investigation into the alleged fraud and potential claims that could be asserted in the Action. This investigation included a detailed review and analysis of: (a) ChemoCentryx's public filings with the SEC, including the Company's annual and quarterly reports, proxy statements, registration statements, and prospectuses; (b) research reports from securities and financial analysts; (c) Company press releases and reports; (d) Company website and marketing materials; (e) news and media reports concerning ChemoCentryx, the ADVOCATE clinical trial, avacopan, and other facts related to this Action; (f) price and volume data for ChemoCentryx common stock; and (g) publicly available information about ChemoCentryx's interactions with the FDA, including the FDA's Briefing Documents and Advisory Committee Meeting materials. In addition, Lead Counsel submitted several Freedom of Information Act ("FOIA") requests to the FDA to obtain additional information relevant to the claims.

14. In connection with its investigation, Lead Counsel and its investigators conducted an extensive search to locate former employees of ChemoCentryx and other industry participants who might have relevant information pertaining to the claims asserted in the Action. This included contacting 116 former ChemoCentryx employees who were believed to have potentially relevant information. Lead Counsel and/or their investigators spoke to 28 of these individuals. Lead Counsel ultimately included detailed information received from one of these former ChemoCentryx employees in the Complaint.

15. In preparing the Complaint, Lead Counsel also consulted with an expert financial economist about, among other things, the impact of Defendants' alleged misstatements and omissions on the market price of ChemoCentryx common stock and the damages suffered by ChemoCentryx shareholders.

16. On March 28, 2022, Lead Plaintiff filed the Amended Consolidated Class Action Complaint for Violations of the Federal Securities Laws (Dkt. No. 47) (the "Complaint"). The detailed, 201-page Complaint asserts claims against (a) Defendants ChemoCentryx and Schall under Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder; (b) Defendant Schall under Section 20(a) of the Exchange Act as a control person; and (c) Defendant Schall under Section 20A of the Exchange Act for insider trading.

17. The Complaint alleges that, during the period from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), Defendants made materially false or misleading representations and omissions regarding avacopan's safety and efficacy, the design and results of ChemoCentryx's pivotal Phase 3 ADVOCATE clinical trial, and ChemoCentryx's interactions with the FDA relating to the ADVOCATE trial and the avacopan New Drug Application ("NDA"). The Complaint alleges that Defendants made false and misleading statements concerning, among other things, avacopan's supposed superior safety profile compared to steroid-based therapy, avacopan's ability to replace steroid-based standard of care as a monotherapy, and ChemoCentryx's communications with the FDA, while concealing the FDA's repeated warnings about serious flaws in ADVOCATE's design and deficiencies in its results. The Complaint asserts that the Defendants' alleged misrepresentations and omissions caused investors to purchase ChemoCentryx common stock at artificially inflated prices. The Complaint further alleges that the truth was revealed to the public through corrective disclosures on May 4, 2021 and May 6, 2021, when the FDA published its Advisory Committee Briefing Documents and held the Advisory Committee Meeting, which disclosed the FDA's serious concerns about ADVOCATE's design and results—concerns that the FDA had privately communicated to ChemoCentryx throughout the Class Period. These disclosures caused the price of ChemoCentryx common stock to decline nearly 79%, from $48.82 to $10.46, causing investors to suffer damages when the truth was revealed.

D. Defendants' Motion to Dismiss

18. On May 19, 2022, Defendants filed a motion to dismiss the Complaint, which included more than 29 exhibits totaling more than 1,000 pages. Dkt. Nos. 50, 52. The motion argued that the Complaint should be dismissed because it relied on "puzzle pleading," failed to adequately allege falsity, and failed to plead a strong inference of scienter. Defendants contended that all of the challenged statements were true, that Lead Plaintiff did not allege any facts inconsistent with or contradicting Defendants' statements regarding the ADVOCATE trial results, the NDA submission, or the prospects for FDA approval, and that ChemoCentryx had no obligation to disclose the details of its ongoing communications with the FDA.

19. On July 11, 2022, Lead Plaintiff filed a detailed opposition brief, demonstrating that the Complaint properly alleged that Defendants concealed serious problems with ADVOCATE from investors, including the FDA's repeated private warnings that the trial's design was inadequate to support Defendants' safety and efficacy claims. Dkt. No. 56. Lead Plaintiff's opposition further demonstrated that Defendants had powerful motives to withhold these adverse facts, including ChemoCentryx's dependence on investor capital to survive and Dr. Schall's stock sales during the Class Period. *Id*.

20. On August 12, 2022, Defendants filed a reply brief in support of their motion. Dkt. No. 57. The reply reiterated that Lead Plaintiff's claims relied on impermissible puzzle pleading, that none of the challenged statements was false, and that the FDA's feedback did not conflict with Defendants' public statements.

21. On February 23, 2023, the Court issued an order granting in part and denying in part Defendants' motion to dismiss. Dkt. No. 61. The Court denied the motion as to the vast majority of the challenged statements, finding that Lead Plaintiff had sufficiently alleged falsity and scienter. Specifically, the Court found that Lead Plaintiff had adequately alleged that Defendants' omissions regarding the FDA's privately expressed concerns about the trial's design and results rendered their statements misleading because investors were led to believe the efficacy and safety results were "far stronger and more meaningful than they actually were." *Id.* at 16. The Court further found that the allegations raised a "strong inference" of scienter, noting that Dr. Schall was personally aware

of the FDA's concerns, had witnessed discussions of serious adverse liver events that were not publicly disclosed, and was financially motivated to mislead investors given ChemoCentryx's reliance on investor capital. *Id.* at 32-33. The Court dismissed Lead Plaintiff's Section 10(b) claims based on a limited subset of challenged statements, while denying the motion as to all other claims. *Id.* at 34.

22. On April 27, 2023, Defendants filed their Answer to the Complaint. Dkt. No. 71. Among other things, Defendants' Answer denied Lead Plaintiff's allegations of wrongdoing and asserted numerous affirmative defenses, including, among others, that the allegedly omitted information was publicly available in Defendants' own filings or widely known to the market (truth on the market); that Defendants acted in good faith and in conformity with applicable law; that the misstatements and omissions alleged were forward-looking and protected by the PSLRA safe harbor or the "bespeaks caution" doctrine; that Dr. Schall had reasonable grounds to believe his statements were true and had reasonably relied on subject matter experts; and that any decline in the market price of ChemoCentryx stock resulted from factors other than the purported misrepresentations and omissions alleged in the Complaint.

E. The Parties Conduct Extensive Fact Discovery

23. Discovery in the Action commenced in March 2023, following the Court's decision on Defendants' motion to dismiss. On April 6, 2023, the Parties filed a Joint Case Management Statement and Proposed Order setting forth a proposed schedule for the case. Dkt. No. 65. On April 10, 2023, the Court entered a Scheduling Order establishing deadlines for class certification briefing and for amendment of the pleadings. Dkt. No. 66. On April 24, 2023, the Court entered a Stipulated Protective Order governing the treatment of confidential materials produced in discovery. Dkt. No. 69.

24. The Parties exchanged their Initial Disclosure Statements pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure on April 5, 2023.

25. Lead Counsel also worked to prepare for, and follow up on, the initial conference with Defendants under Federal Rule of Civil Procedure 26(f) and served Lead Plaintiff's Initial Disclosure Statement on Defendants. This included Lead Counsel's conferral with Lead Plaintiff

concerning, among other things: (a) Lead Plaintiff's document preservation processes; (b) the location of relevant documents and the identification of systems where those documents resided; and (c) individuals for inclusion in Lead Plaintiff's Initial Disclosure Statement pursuant to Federal Rule of Civil Procedure 26(a).

26. On April 22, 2024, the Court entered a Scheduling Order setting out a schedule for expert discovery, dispositive motions, and trial. Dkt. No. 148. The Scheduling Order set September 22, 2025 as the trial date.

1. Document Discovery

27. Commencing March 22, 2023, Lead Plaintiff served two sets of requests for production of documents on Defendants. On March 22, 2023, Lead Plaintiff served its First Set of Requests for Production of Documents on Defendants, seeking documents relating to, among other things, the ADVOCATE clinical trial, avacopan, communications with the FDA, the New Drug Application, and Defendants' public statements. On March 29, 2024, Lead Plaintiff served its Second Set of Requests for Production of Documents. Defendants served their responses to Lead Plaintiff's document requests and began the production of documents. In the nearly two years that followed, Lead Counsel participated in numerous meet-and-confer sessions with Defendants' Counsel and conducted extensive negotiations over the scope and adequacy of Defendants' discovery responses, including the search terms and date ranges to be used for the document collection. The Parties also had multiple conferences with the Court concerning discovery disputes. In response to Lead Plaintiff's requests for production of documents, Defendants produced more than 7.8 million pages of documents to Lead Plaintiff.

28. Lead Plaintiff also subpoenaed 51 third parties, including (a) the FDA; (b) physicians who participated in the ADVOCATE clinical trial, such as Dr. David Jayne, Dr. Peter Merkel, and Dr. John Stone; (c) individuals who worked on ChemoCentryx's New Drug Application for avacopan, such as Dr. Pirow Bekker and Susan Kanaya; (d) consultants retained by ChemoCentryx, including Medpace, Inc., Certara USA, Inc., and LVM Pharmaceuticals Consulting, LLC; (e) investment banks and analysts such as Goldman Sachs & Co. LLC; (f) Amgen, which acquired ChemoCentryx in October 2022; and (g) other pharmaceutical

companies and industry participants. In response to Lead Plaintiff's subpoenas, these third parties produced tens of thousands of pages of additional documents to Lead Plaintiff.

29. Lead Counsel reviewed, analyzed, and coded the voluminous documents received. In reviewing the documents, attorneys were tasked with making several analytical determinations as to the documents' importance and relevance. Specifically, they determined whether the documents were "hot," "relevant," or "not relevant." They also assessed which specific issues the documents concerned and determined the identities of the ChemoCentryx employees or other potential deponents to whom the documents related so that the documents could be retrieved when preparing for depositions. Lead Counsel structured the document review to include regular team meetings to discuss the documents of highest interest and other issues that arose during the document review. Through these meetings, Lead Counsel ensured that all attorneys involved in the review understood the developing nature of the evidence and focused their document review on the key issues in the Action. The documents discussed included those that were particularly relevant to Lead Plaintiff's claims and that offered insight into other important aspects of the case, including Defendants' defenses. Lead Plaintiff also served and received responses to three sets of interrogatories on Defendants: on April 17, 2023, Lead Plaintiff served its First Set of Interrogatories; on September 20, 2023, Lead Plaintiff served its Second Set of Interrogatories; and on April 3, 2024, Lead Plaintiff served its Third Set of Interrogatories.

30. In addition, Lead Plaintiff served and received responses to three sets of requests for admission on Defendants: on November 3, 2023, Lead Plaintiff served its First Set of Requests for Admission; on April 1, 2024, Lead Plaintiff served its Second Set of Requests for Admission; and on July 22, 2024, Lead Plaintiff served its Third Set of Requests for Admission. Defendants responded to each set of requests for admission.

31. With Lead Counsel's assistance, Lead Plaintiff searched for and gathered documents in its own files that were responsive to Defendants' requests for production of documents, which documents were then reviewed by Lead Counsel. On April 17, 2023, Defendants served their First Set of Requests for Production of Documents on Lead Plaintiff. Defendants' document requests included requests concerning Lead Plaintiff's transactions in ChemoCentryx stock and any related

communications, Lead Plaintiff's involvement in the Action, and its engagement of Lead Counsel. Lead Plaintiff produced documents to Defendants in response to their requests.

32. Defendants also served three sets of interrogatories on Lead Plaintiff: on May 24, 2023, Defendants served their First Set of Interrogatories; on September 7, 2023, Defendants served their Second Set of Interrogatories; and on July 22, 2024, Defendants served their Third Set of Interrogatories. Lead Plaintiff responded to each set of interrogatories.

33. In addition, Lead Plaintiff responded to Defendants' First Set of Requests for Admission on July 22, 2024.

2. Discovery Disputes

34. Discovery in the Action was highly contested. Lead Counsel and Defendants' Counsel exchanged numerous letters and participated in numerous meet-and-confer sessions regarding, among other things, the scope of the documents produced, the adequacy of the search terms and date range of productions, and the adequacy of responses to interrogatories. The Parties filed multiple Joint Discovery Letter Briefs with the Court, resulting in four discovery dispute orders. Dkt. Nos. 128, 136, 164, 185. Among other things, the discovery disputes concerned Lead Plaintiff's request to disclose confidential case materials to the FDA and Defendants' supplemental disclosures of fact witnesses near the close of fact discovery.

3. Depositions

35. The Parties took numerous depositions throughout the history of the Action, at which the Parties introduced approximately 700 exhibits into the record.

36. ***First***, in connection with Lead Plaintiff's Motion for Class Certification, Defendants deposed Lead Plaintiff's market efficiency expert, Dr. Matthew Cain; a representative of Lead Plaintiff; and a representative of Lead Plaintiff's investment manager. Lead Plaintiff also deposed Defendants' market efficiency expert, Dr. Allen Ferrell.

37. ***Second***, the Parties took 21 fact depositions. Lead Plaintiff deposed numerous current and former ChemoCentryx employees, including Defendant Schall, who sat for two days of deposition testimony, as well as Dr. Pirow Bekker (ChemoCentryx's Chief Medical Officer), Susan Kanaya (ChemoCentryx's CFO), Dr. Jan Hillson, and numerous other witnesses with knowledge of

the ADVOCATE trial and the FDA regulatory process. Lead Plaintiff also deposed third-party witnesses, including analysts from Raymond James and H.C. Wainwright, as well as clinical investigators who participated in the ADVOCATE trial.

38. ***Third***, the Parties took 17 expert depositions. The Parties exchanged 24 expert reports and deposed numerous experts, including experts on market efficiency, loss causation, damages, FDA regulatory matters, hepatology, rheumatology, and biostatistics.

F. Lead Plaintiff's Motion for Class Certification

39. On August 25, 2023, Lead Plaintiff filed its motion for class certification. Dkt. No. 74. The motion was supported by a memorandum of law and an expert report from Lead Plaintiff's market efficiency expert, Dr. Cain, who opined that ChemoCentryx's common stock traded in an efficient market during the Class Period and that per-share damages could be measured for all class members using a common methodology. Dkt. No. 75-1.

40. As discussed above, Defendants deposed Dr. Cain in connection with his opening and reply reports in support of class certification, and Lead Plaintiff deposed Defendants' market efficiency expert, Dr. Ferrell. Defendants also deposed a representative of Lead Plaintiff and a representative of Lead Plaintiff's investment manager.

41. Defendants opposed the motion for class certification on November 22, 2023, with support from their market efficiency expert, Dr. Ferrell, and regulatory expert, Dr. Steven Weisman, based on a purported lack of price impact. Dkt. Nos. 87-89. Defendants challenged class certification by arguing that their alleged misstatements had no impact on the price of ChemoCentryx stock, notwithstanding that ChemoCentryx's stock price increased more than 300% in a single day after the first alleged misrepresentations and fell roughly 80% in response to the corrective disclosures. On January 23, 2024, Lead Plaintiff filed a reply in further support of its motion for class certification and a rebuttal expert report from Dr. Cain. Dkt. Nos. 101-02.

42. On January 30, 2024, Defendants filed objections to Lead Plaintiff's reply evidence. Dkt. No. 109. On February 7, 2024, Lead Plaintiff filed its response to Defendants' objections. Dkt. No. 115-2. On February 15, 2024, the Court held a hearing on Lead Plaintiff's motion for class certification.

43. On March 6, 2024, the Court granted Lead Plaintiff's motion for class certification and denied Defendants' objections to Lead Plaintiff's reply evidence. Dkt. No. 131. The Court found that Defendants had failed to rebut the *Basic* presumption of reliance by proving a complete lack of price impact. *Id.* at 12. The Court certified a class of all persons or entities who purchased ChemoCentryx common stock during the Class Period and appointed Lead Plaintiff as Class Representative and Lead Counsel as Class Counsel.

44. On March 22, 2024, Defendants filed a petition to the U.S. Court of Appeals for the Ninth Circuit, pursuant to Rule 23(f), for permission to appeal from the order granting class certification. Dkt. No. 141. Lead Plaintiff opposed that petition on April 2, 2024. *See* Answer, *Homyk v. ChemoCentryx, Inc.*, No. 24-1720 (9th Cir. Apr. 2, 2024), Dkt. No. 5. On May 23, 2024, the Court of Appeals denied the Defendants' petition for permission to appeal the Court's order granting class certification. Dkt. No. 153.

G. Lead Plaintiff's Motion to Notify the Class

45. On September 25, 2024, Lead Plaintiff filed its unopposed motion to approve the form and manner of class notice. Dkt. No. 174. In the motion, Lead Plaintiff set forth a proposal for notifying the certified Class of, among other things: (a) the Action pending against Defendants; (b) the Court's certification of the Action to proceed as a class action on behalf of the Class; and (c) Class Members' right to request to be excluded from the Class, the effect of remaining in the Class or requesting exclusion, and the requirements for requesting exclusion. Lead Plaintiff also sought approval of the retention of Kroll Settlement Administration LLC ("Kroll") as the Notice Administrator to supervise and disseminate notice to the Class.

46. On October 17, 2024, the Court granted Lead Plaintiff's motion for approval of the Class Notice. *See* Dkt. No. 179 ("Notice Order").

47. In accordance with the Court's Notice Order, on November 13, 2024, the Notice Administrator began disseminating the Notice of Pendency of Class Action (the "Class Notice") to potential Class Members by first-class mail and via the case website, www.ChemoCentryxSecuritiesLitigation.com. Dkt. No. 187 ¶¶ 3-6, 13. As of February 5, 2025, a total of 35,220 Class Notices had been disseminated to potential Class Members and nominees. *Id.*

¶ 11. The Class Notice provided Class Members with the opportunity to request exclusion from the Class, explained that right, and set forth the procedures for doing so. *See* Dkt. No. 187-1. The Class Notice informed Class Members that, if they chose to remain a Class Member, they would "be legally bound by all determinations, orders, and judgments that the Court makes in the Action, whether favorable or unfavorable." *Id*. at 4.

48. On November 26, 2024, Kroll also caused the Summary Notice of Pendency of Class Action ("Summary Class Notice") to be published in the *Wall Street Journal* and transmitted over *PR Newswire* in accordance with the Court's Notice Order. Dkt. No. 187, ¶ 12.

49. The deadline for requesting exclusion from the Class pursuant to the Class Notice was January 14, 2025. Dkt. No. 187-1 at 5.

50. On February 5, 2025, as required by the Notice Order, Lead Plaintiff filed a declaration from Kroll providing proof of dissemination of the Class Notice and publication of the Summary Class Notice. Dkt. No. 187. The declaration also provided a list of the persons and entities who submitted requests for exclusion from the Class. Dkt. No. 187-5. Only two requests for exclusion were received. Dkt. No. 187, ¶ 15.

H. The Parties Conduct Extensive Expert Discovery

51. On September 25, 2024, Lead Plaintiff submitted expert reports from six expert witnesses. Specifically, Lead Plaintiff submitted reports from hepatologist Dr. Alan Bonder; loss causation and damages expert Dr. Matthew Cain; rheumatologist Dr. Simon Helfgott; biostatistician Dr. David Madigan; pharmaceutical industry expert Ahmed Ragab; and FDA regulatory expert Dr. Marc Walton. Defendants deposed each of Lead Plaintiff's experts.

52. On October 28, 2024, Defendants submitted expert reports from eight expert witnesses. Specifically, Defendants submitted reports from hepatologist Dr. Naga Chalasani; rheumatologist Dr. Anisha Dua; loss causation and damages expert Dr. Allen Ferrell; biostatistician Dr. Robert Gibbons; health economist Dr. Anupam Jena; nephrologist Dr. Lindsay Lally; securities analyst Carl Seiden; and FDA regulatory expert Dr. Steven Weisman. Lead Plaintiff deposed each of Defendants' experts.

53. On November 25, 2024, Lead Plaintiff submitted reply reports from all six of Lead Plaintiff's expert witnesses who authored opening reports. All told, the Parties exchanged 24 expert reports and conducted 17 expert depositions, not including the reports and depositions concerning class certification.

I. The Parties' *Daubert* Motions

54. On February 13, 2025, Lead Plaintiff filed motions to exclude certain opinions and testimony from seven of Defendants' expert witnesses, namely Dr. Lindsay Lally, Dr. Steven Weisman, Carl Seiden, Dr. Robert Gibbons, Dr. Anisha Dua, Dr. Naga Chalasani, and Dr. Anupam Jena. Dkt. Nos. 193-99. In these *Daubert* motions, Lead Plaintiff argued, among other things, that certain of Defendants' experts offered improper opinions about post-Class Period events regarding TAVNEOS, including its efficacy, label, and usage by physicians; that certain experts improperly speculated about the state of mind of the FDA and ChemoCentryx; and that certain experts were not qualified to opine on the views of the medical community.

55. Also on February 13, 2025, Defendants filed motions to exclude opinions and testimony from Lead Plaintiff's expert witnesses, namely Dr. Alan Bonder, Dr. Matthew Cain, Dr. Simon Helfgott, and Dr. David Madigan. Dkt. Nos. 188-91, 206. Defendants argued, among other things, that Lead Plaintiff's experts offered improper opinions about the state of mind of ChemoCentryx and its employees, that certain opinions were based on inadequate data, and that Dr. Cain's loss causation and damages methodology was unreliable.

56. The Parties' respective opening, opposition, and reply briefs spanned dozens of docket entries and included hundreds of exhibits. Dkt. Nos. 188-251. Briefing on the Parties' motions to exclude expert testimony was completed on March 20, 2025, and the Court conducted a hearing on the Parties' *Daubert* motions on April 10, 2025. Dkt. No. 259.

57. On May 30, 2025, the Court issued its order resolving the Parties' *Daubert* motions. Dkt. No. 289. The Court granted Lead Plaintiff's motions to exclude the testimony of Dr. Anupam Jena and Dr. Lindsay Lally, finding their testimony about post-Class Period events regarding TAVNEOS to be irrelevant. The Court denied Defendants' motion to exclude the testimony of Dr. Matthew Cain, upholding the reliability of his loss causation and damages methodology. The

Court granted in part and denied in part the remainder of the motions. While the Court permitted most experts to testify in certain areas, it imposed limitations on the scope of their testimony. For example, the Court excluded expert testimony on TAVNEOS's efficacy, its label, and its usage by clinicians as irrelevant, and precluded experts from testifying about the state of mind of the FDA, ChemoCentryx, or what the "medical community" believed.

58. Under the Court's scheduling order, motions *in limine* were due September 11, 2025. Prior to the Court's August 15, 2025 order granting summary judgment to Defendants, Lead Plaintiff had begun work on approximately one dozen motions in *limine*, including a motion to bifurcate the trial and other motions to exclude certain categories of evidence that Lead Plaintiff believed Defendants might seek to introduce and that Lead Plaintiff viewed as irrelevant, prejudicial, confusing, and/or misleading. Lead Counsel engaged in other trial preparations including preparing an order of proof, a list of potential trial exhibits, and researching and drafting proposed jury instructions. Lead Counsel also retained a jury consultant and conducted a two-day mock jury exercise in the fall of 2024 and prepared for a second mock jury exercise in the summer of 2025.

J. The Parties' Cross-Motions for Summary Judgment

59. On May 8, 2025, Lead Plaintiff filed a motion for partial summary judgment pursuant to Rule 56 of the Federal Rules of Civil Procedure. Dkt. No. 267. Lead Plaintiff sought summary judgment on three of the elements for the rebuttable presumption of reliance under the fraud-on-the-market doctrine: (1) that Defendants' alleged false and misleading statements were publicly known; (2) that ChemoCentryx's common stock traded in an efficient market during the Class Period; and (3) that Lead Plaintiff and members of the Class purchased ChemoCentryx stock during the Class Period. Lead Plaintiff's motion was supported by a Declaration of Jonathan D. Uslaner (Dkt. No. 268) and accompanying exhibits, including expert analysis from financial economist Dr. Matthew D. Cain (Dkt. No. 267 at 5-7).

60. On May 29, 2025, Defendants filed their cross-motion for summary judgment and opposition to Lead Plaintiff's motion for partial summary judgment, supported by 90 exhibits. Dkt. Nos. 279-282. Defendants argued that the entire case should be dismissed because all of the

challenged statements were non-actionable opinions. Dkt. No. 279 at 11-18. Specifically, Defendants argued that where a defendant speaks about the results of a clinical trial and expresses views about the implications of that trial data, those statements are opinions, and that when the FDA approves the drug at issue, that approval precludes a plaintiff from showing that a defendant's favorable interpretation of trial data was fraudulent. *Id.* at 13-14. Defendants argued that because the FDA had approved avacopan (now TAVNEOS) for use in the United States based on the ADVOCATE trial data in October 2021, Defendants' positive interpretation of that data was "per se reasonable" as a matter of law. *Id*. at 13-15. Defendants further argued that even without such a *per se* rule, Lead Plaintiff could not demonstrate that the statements were affirmatively untrue or misleading by omission. *Id.* at 14-18.

61. In addition, Defendants sought partial summary judgment on several independent grounds, including that: (a) Lead Plaintiff could not establish loss causation as to the May 7, 2021 stock price decline because the information disclosed at the FDA Advisory Committee meeting on May 6 was not new and corrective and merely repeated facts already disclosed in the FDA's Briefing Book published on May 4, 2021 (Dkt. No. 279 at 19-23); (b) Lead Plaintiff could not establish its claim that Defendants violated the ADVOCATE trial protocol in reporting primary efficacy results (*id*. at 23-25); (c) Lead Plaintiff could not establish claims based on allegedly omitted facts about steroid use and subgroup efficacy results because those facts were disclosed during the Class Period (*id*. at 25-29); and (d) several additional categories of statements failed for statement-specific reasons, including that certain statements were forward-looking and/or puffery, certain statements pre-dated the Class Period, Lead Plaintiff's own expert foreclosed claims based on alleged FDA feedback in 2020, and claims based on previously dismissed statements were barred (*id*. at 29-33). Defendants also argued that Lead Plaintiff's Section 20A insider trading claim and Section 20(a) control person claim against Dr. Schall failed because they lacked a predicate violation of the federal securities laws. *Id*. at 33-34.

62. Lead Plaintiff opposed Defendants' cross-motion for summary judgment and filed a reply in support of its own motion for partial summary judgment on June 19, 2025, supported by 146 more exhibits. Dkt. Nos. 300-301. Lead Plaintiff argued, for example, that the challenged

statements were statements of fact, not opinions, and that, even if analyzed as opinions, they were actionable because Defendants possessed information that did not "fairly align" with their statements.

63. On July 3, 2025, Defendants filed their reply in further support of their cross-motion for summary judgment. Dkt. No. 322.

64. On August 7, 2025, the Court held oral argument on the Parties' cross-motions for summary judgment. Dkt. Nos. 343, 349.

K. The Court's Order Granting Summary Judgment to Defendants

65. On August 15, 2025, the Court issued its Order granting Defendants' motion for summary judgment and entered a Judgment dismissing this action. Dkt. Nos. 345-347.

66. The Court held that Defendants were entitled to summary judgment because Lead Plaintiff could not establish a material misrepresentation. Dkt. No. 345 at 7. The Court found that "all of the challenged statements are opinions largely dealing with Defendants' interpretations of trial data or scientific methodology—some of which contain embedded facts, and all of which are subject to the standard established in *Omnicare* for proving falsity." *Id.* at 8. The Court stated that "[i]n cases alleging that a drug manufacturer has misled investors in its presentation of clinical trial data, courts consistently find that those statements are opinions because 'there is no single "correct" way to interpret data [, and] qualified data scientists often and reasonably "disagree over how to analyze data and interpret results."'" *Id.*

67. The Court organized the challenged statements into five categories: (1) statements about ADVOCATE's safety results; (2) statements about ADVOCATE's secondary endpoints; (3) statements about ADVOCATE's primary endpoints; (4) statements about avacopan's ability to replace steroid therapy; and (5) statements about the NDA and ChemoCentryx's interactions with the FDA. *Id.* at 8-9.

68. As to the safety statements, the Court held that Defendants' statement that they "believe[d]" that avacopan had "a very acceptable safety profile" based on there being "fewer adverse events and fewer serious adverse events" in the avacopan group than in the prednisone group was "per se reasonable" in light of the FDA's ultimate approval of avacopan. *Id.* at 13-14.

The Court further held that Defendants had published the safety statistics on which they based their safety statements during the Class Period, and that Lead Plaintiff's challenge to the safety statements was "little more than a dispute about the proper interpretation of data." *Id.* at 14-16. The Court also found that "Plaintiff's 'data manipulation' allegations do not affect the significance of the FDA's approval as to safety based on ADVOCATE's data" *Id*. at 13 n.7.

69. As to the secondary endpoints, the Court held that, reading the challenged statements in the context of the "hedges, disclaimers, [and] qualifications," they were not misleading. *Id.* at 15-17. The Court noted that Defendants had conducted a "'meaningful' inquiry," citing multiple academic papers supporting their views on the GTI's validity. *Id.* at 16-17.

70. As to the primary endpoints, the Court found that Defendants had accurately described how ADVOCATE achieved its primary endpoints, and that Lead Plaintiff's disagreement with the legitimacy of those endpoints was not actionable. *Id.* at 17-20. The Court noted that the FDA had ultimately found the ADVOCATE results to be sufficient for approval.

71. As to the steroid statements, the Court found that Lead Plaintiff had not explained why Defendants' interpretation of the trial data—that ADVOCATE demonstrated avacopan could begin to replace chronic steroid usage—was "irrational or unreasonable" such that their opinions were actionable (*id.* at 20-23) and that "the full context of Defendants' various 'steroid statements' demonstrates that a reasonable investor would have understood Defendants' 'steroid statements' as far more limited opinion statements than as depicted by Plaintiff" (*id.* at 20).

72. As to statements regarding Defendants' interactions with the FDA, the Court held that the fact that the FDA ultimately approved avacopan "may by itself be enough to demonstrate that Defendants had a reasonable basis for interpreting the regulatory path to be clear." *Id.* at 23-24. The Court further held that Defendants have "no legal obligation to loop the public into each detail of every communication with the FDA," and that Defendants had cautioned investors that FDA approval was not guaranteed. *Id.* at 23-25.

73. The Court also granted summary judgment on Lead Plaintiff's Section 20(a) and Section 20A claims against Dr. Schall, finding those claims lacked a predicate violation. *Id.* at 25.

Because the Court granted Defendants' motion for summary judgment, it denied Lead Plaintiff's motion for partial summary judgment as moot. *Id.* at 25-26.

L. Lead Plaintiff's Appeal to the Ninth Circuit

74. On September 12, 2025, Lead Plaintiff filed a timely Notice of Appeal to the United States Court of Appeals for the Ninth Circuit from the Court's Order Granting Defendants' Motion for Summary Judgment and Judgment. Dkt. No. 354. *See Indiana Public Ret. Sys. v. ChemoCentryx, Inc.*, No. 25-5859 (9th Cir.).

75. On January 5, 2026, Lead Plaintiff filed its opening brief in support of its appeal together with an eight-volume Excerpts of Record, totaling over 1,250 pages. Lead Plaintiff argued that the summary judgment order should be reversed for several reasons and that a reasonable jury could return a verdict in Lead Plaintiff's favor. Opening Br., *Indiana Public Ret. Sys. v. ChemoCentryx, Inc.*, No. 25-5859 (Jan. 5, 2026), Dkt. No. 12.

76. Lead Plaintiff argued the Court erred by holding "all" of Defendants' statements were opinions that "interpret" or "present" trial data. Lead Plaintiff contended that many of the challenged statements contained factual assertions—not merely interpretations of data—and should have been analyzed as statements of fact. *Id.* at 27-36.

77. Lead Plaintiff further argued the Court erred by holding that opinions about clinical trials are subject to a "heightened standard" that protects them from liability unless they lack a "reasonable basis." *Id.* at 35. Lead Plaintiff contended that this heightened standard contravenes *Omnicare*, which requires not only that an opinion have some basis but that it "fairly align" with facts known to the speaker. *Id.* at 35-38. Lead Plaintiff further argued the Court erred by adopting a *per se* rule that FDA approval makes all statements about clinical trials "per se reasonable," (*id.* at 37-40), by crediting Defendants' version of disputed facts, and by crediting Defendants' "truth on the market" defense (*id.* at 35, 40-41).

78. In light of the Parties' settlement, Defendants never filed an answering brief.

M. The Settlement

79. In early 2024, while discovery was still ongoing and before the Court had certified the Class, the Parties engaged in mediation to see if they could resolve the Action through

Settlement. On February 9, 2024, the Parties held an in-person mediation session with Greg Danilow of Phillips ADR Enterprises, an experienced mediator of securities class actions and other complex litigation. In advance of the mediation, the Parties submitted and exchanged detailed mediation briefs addressing liability and damages. Despite the Parties' efforts, no agreement was reached at the February 2024 mediation.

80. The Parties continued intermittent settlement negotiation as the Action continued. The Parties' settlement negotiations continued while Lead Plaintiff's appeal was pending before the Ninth Circuit. On January 26, 2026, the Parties executed a Memorandum of Understanding ("MOU") reflecting an agreement in principle to settle all claims in the Action against Defendants in return for a cash payment of $35,000,000, subject to certain terms and conditions and the execution of a customary "long form" stipulation and agreement of settlement and related papers.

81. On March 9, 2026, the Parties entered into the original Settlement Stipulation setting forth the terms and conditions of the proposed $35,000,000 settlement (Dkt. No. 361-1), and on March 13, 2026, Lead Plaintiff filed a motion for preliminary approval of the original Settlement (Dkt. No. 361).

82. On April 27, 2026, the Center for Drug Evaluation and Research ("CDER") of the FDA filed a public notice proposing the withdrawal of TAVNEOS.

83. The Parties disputed the significance of CDER's announcement. Defendants contended that CDER's statements in the announcement were "neither accurate nor relevant to the Action." *See* Dkt. No. 366 at 1. Lead Plaintiff contended that CDER's statements in the announcement warranted an increase in the amount of the original Settlement, including because "they may have improved Lead Plaintiff's possibility of success on the pending appeal of the Court's Summary Judgment Order or otherwise." *Id.* The Parties engaged in further extended negotiations culminating in the Revised Stipulation and Agreement of Settlement to settle all claims in this Action in return for a cash payment of $69,000,000—nearly double the original Settlement Amount.

84. On May 15, 2026, the Parties executed the Revised Stipulation and Agreement of Settlement, which supersedes and voids the original Settlement Stipulation and the original Settlement. Dkt. No. 366-1.

N. The Court Grants Preliminary Approval of the Settlement

85. On June 12, 2026, the Court entered the Order Preliminarily Approving Settlement and Providing for Notice of Settlement as Modified (Dkt. No. 368) (the "Preliminary Approval Order") which, among other things: (1) preliminarily approved the Settlement; (2) approved the form of Postcard Notice, Settlement Notice, Claim Form, and Summary Settlement Notice; authorized notice to be given to Class Members through mailing of the Postcard Notice, posting the Settlement Notice and Claim Form on the case website, and publication of the Summary Settlement Notice in the *Wall Street Journal* and over the *PR Newswire*; (3) established procedures and deadlines by which Class Members could participate in the Settlement, and/or object to the Settlement, the proposed Plan of Allocation, and/or the fee and expense application; and (4) set a schedule for the filing of opening papers and reply papers in support of the proposed Settlement, Plan of Allocation, and the Fee and Expense Application. The Preliminary Approval Order also scheduled the Settlement Hearing to determine, among other things, whether the Settlement should be finally approved. The Settlement Hearing was subsequently rescheduled for October 29, 2026 at 2:00 p.m. Dkt. No. 370.

O. Recent Developments Related to TAVNEOS

86. Lead Plaintiff's litigation efforts were followed by regulatory and related actions around the world concerning TAVNEOS. Among other things:

(a) In January 2026, the FDA "requested that ChemoCentryx voluntarily withdraw TAVNEOS from the U.S. market," citing "concerns about the process followed by ChemoCentryx to re-adjudicate primary endpoint results for 9 of the 331 patients in the ADVOCATE trial" and about the drug's hepatotoxicity risks.[2] *See* Dkt. No. 361 at 3.

(b) On April 27, 2026, the Center for Drug Evaluation and Research ("CDER") of the FDA proposed the withdrawal of TAVNEOS after determining that it "can no longer

[2] *See An Important Update Regarding TAVNEOS® (avacopan)*, Amgen (Feb. 4, 2026), https://www.amgen.com/tavneos-prescribers [https://web.archive.org/web/20260204183410/https://www.amgen.com/tavneos-prescribers].

conclude that there is, or has ever been, a valid demonstration of substantial evidence of effectiveness for TAVNEOS" and that ChemoCentryx's "improper actions forever taint the [ADVOCATE] study results reported in the NDA and render them uninterpretable."[3] *See* Dkt. No. 366 at 2; Ninth Cir. No. 25-5859, Dkt. No. 20.1 (May 8, 2026).

(c) On June 29, 2026, the *New England Journal of Medicine* announced the retraction of the 2021 article that published the results of the ADVOCATE study. The authors requested retraction because "according to an ongoing Food and Drug Administration investigation conducted after publication, and without the knowledge of these two authors, the primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding."[4]

(d) On August 4, 2026, the European Commission revoked TAVNEOS's marketing authorization, adopting the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP").[5] The CHMP stated that "[o]n balance, considering that the pivotal study supporting the marketing authorisation is considered as not reliable due to the serious [good clinical practice] breach, it is concluded that there is no longer demonstration of benefit outweighing the risks of Tavneos, in particular the serious hepatic risks."[6]

87. These regulatory actions specifically cited evidence developed in this Action in support of their reconsideration of the ADVOCATE study and the risk-benefit profile of the drug. For example, the FDA's formal notice proposing withdrawal of TAVNEOS discussed the expert report of Marc Walton, Lead Plaintiff's expert on drug development and regulatory approval, at length (Dkt. No. 332-61). The FDA said:

> On May 29, 2025, plaintiffs in the securities fraud litigation filed with the court the expert report from Marc Walton, M.D., Ph.D. (Walton Report), (Ref. 3). The Walton Report stated that a statistical analysis of the ADVOCATE study was conducted after database lock and that the initial analysis had found that the avacopan treatment group did not achieve a statistically significant superiority outcome on the primary endpoint of sustained remission compared with the control group. The Walton Report stated

[3] *See* Letter from Tracy B. Hoeg, Acting Dir. of Ctr. for Drug Evaluation and Rsch., to Dr. Nicole Cheung, Manager, Glob. Regul. Affs. of Amgen, Inc. at 17, 19 (Apr. 27, 2026), https://www.fda.gov/media/192160/download (on file with the FDA).

[4] *See* Eric J. Rubin, M.D., Ph.D., *Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis*, NEJM (June 29, 2026), https://www.nejm.org/doi/10.1056/NEJMe2608684.

[5] *See Tavneos*, European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos

[6] *Annex: Scientific conclusions* at 3, European Medicines Agency, https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-scientific-conclusions_en.pdf.

> that, upon reviewing these results, unblinded ChemoCentryx personnel had selected nine ADVOCATE study subjects for readjudication following the initial blinded analysis, including five avacopan patients whose clinical outcome would be changed from "not in sustained remission" to "sustained remission." The Walton Report further stated that, before sending the patient data for readjudication, ChemoCentryx personnel confirmed that changing the remission outcomes for the five avacopan patients would change the study results to reflect that avacopan demonstrated statistically significant superiority over therapy in the control arm. Finally, the Walton Report stated that the five avacopan patients were readjudicated to "sustained remission," and the revised statistical analysis was submitted to FDA in the NDA without disclosing this readjudication of the pivotal study results. Specifically, the Walton Report noted that the applicant did not disclose the original statistical analysis of the study, the unblinded selection of subjects for readjudication after the clinical database was locked, or that the post-database lock changes changed the study result from not statistically significant to statistically significant.
>
> After learning about the Walton Report, CDER sent an information request on July 23, 2025, seeking detailed information regarding the handling of unblinded data in the ADVOCATE study. On August 22, 2025, Amgen responded to the information request on behalf of the applicant (Ref. 4). Amgen's response confirmed the key factual allegations outlined above from the Walton Report. Amgen nevertheless claimed in its response that the data in the NDA are accurate and that the readjudications were appropriate.

Proposal to Withdraw Marketing Approval at 3, Dkt. No. FDA-2026-N-1321 (Apr. 27, 2026), https://www.fda.gov/media/192160/download?attachment.

II. RISKS OF CONTINUED LITIGATION

88. The Settlement provides certain and near-term benefit to the Class in the form of a $69,000,000 cash payment. Lead Plaintiff and Lead Counsel believe that the proposed Settlement is a very favorable result for the Class in light of the substantial risk of no recovery if Lead Plaintiff were unsuccessful on its appeal, as well as the significant additional risks presented by continued litigation even if Lead Plaintiff succeeded on appeal.

A. Risks of the Appeal

89. The risk of no recovery was very significant in this case because the Action had been dismissed in its entirety by the Court in its Summary Judgment Order. As discussed above, the Court granted summary judgment because it found that "the challenged statements are opinions largely dealing with Defendants' interpretations of trial data or scientific methodology," which were "subject to the standard established in *Omnicare* for proving falsity" (Dkt. No. 345 at 8), and

determined that none of the alleged misstatements met that standard. Among other things, the Court found that Defendants' safety statements were "per se reasonable" given that the FDA "ultimately agreed that avacopan had an acceptable safety profile" (*id*. at 14); that Defendants "accurately described how ADVOCATE achieved its primary endpoints" and the FDA's interim disagreement with the Company's trial methodology did not create an actionable omission (*id*. at 18); and there was no "serious conflict between the FDA's interim, albeit repeated, concerns about methodology and Defendants' optimism about FDA approval," especially given that the FDA ultimately approved the drug (*id*. at 25).

90. While Lead Plaintiff believed it had meritorious arguments for reversal, there was a substantial risk that the Court of Appeals might affirm the Court's order granting summary judgment. Lead Plaintiff recognizes the challenges of successfully appealing any summary judgment order, especially an opinion issued by this Court. The Ninth Circuit's overall reversal rate in private civil appeals is just 13.3%.[7] Moreover, obtaining a reversal here may have been more difficult than in many cases because the appeal primarily challenged the Court's application of law to a complex set of factual allegations. And while Lead Plaintiff would point to recent developments related to TAVNEOS in support of its appeal, Defendants would argue that these post-Class Period facts did not have any bearing on the appeal.

91. Even if Lead Plaintiff succeeded in persuading the Ninth Circuit to reverse certain aspects of the Court's Summary Judgment Order, there were substantial risks that any reversal might only be a partial reversal that would allow Lead Plaintiff to go forward with a much narrower set of claims.

B. Risks of Continued Litigation Following a Successful Appeal

92. Even if the appeal succeeded, Lead Plaintiff would still have faced a number of additional substantial risks in continued litigation in this Court after remand.

---

[7] *See* U.S. Courts of Appeals—Decisions in Cases Terminated on the Merits, by Circuit and Nature of Proceeding, During the 12-Month Period Ending June 30, 2026, Table B-5, Statistical Tables for the Federal Judiciary (June 30, 2026), https://www.uscourts.gov/statistics/table/b-5/statistical-tables-federal-judiciary/2026/06/30.

93. First, Defendants would likely have filed renewed motions for summary judgment, and there was a possibility that the Court would still have granted Defendants' motion for summary judgment on grounds that the Court did not reach the first time. The Court's Summary Judgment Order disposed of the case based on a finding that the statements were not actionable as a matter of law. If the case were remanded, the Court may still have granted summary judgment based on the various other grounds asserted by Defendants in their summary judgment motion that the Court had not needed to reach in its prior opinion.

94. Even if the case had been able to proceed to trial, Lead Plaintiff would have faced meaningful risks with respect to proving liability to a jury and recovering full damages in this case. To prevail in this case, Lead Plaintiff had the burden to convince a unanimous jury by a preponderance of the evidence of each of the elements of its claims, including that (1) Defendants made misstatements; (2) the misstatements were material; (3) the misstatements were made with *scienter* (*i.e.*, knowingly or with deliberate recklessness); (4) investors relied upon the misstatements; and (5) Defendants' fraud caused investors' losses.

1. Falsity

95. As to "falsity," Defendants would argue that ChemoCentryx disclosed the underlying trial results of ADVOCATE, and no further disclosures or commentary were needed and that any omitted information was immaterial to a reasonable investor.

96. For example, as to Defendants' challenged statements about the ADVOCATE trial's results concerning avacopan's safety, including its safety relative to steroid-based treatment, Defendants would continue to argue that these were opinion statements reflecting Defendants' genuinely held opinions and that the statements were not rendered false or misleading by information Defendants had at the time that was not disclosed to the public. Specifically, Defendants would argue that they simply did not agree with the Data Monitoring Committee ("DMC") about the gravity of the liver-related risks posed by avacopan based on the study data; that those concerns were not required to be disclosed to investors; and that ChemoCentryx had publicly disclosed the safety concerns, including by sending "safety letters" to health authorities

outlining the concerns, disclosing "serious adverse events" related to liver injuries in the medical journal article on the ADVOCATE study, and submitting the DMC's findings to the FDA.

97. With respect to Defendants' alleged misstatements about the ADVOCATE trial's results concerning avacopan's efficacy, Defendants would have similar arguments. They would argue that their view of the trial data was that the ADVOCATE study had established that avacopan was "non-inferior" to steroid-based therapy at week 26 of the study and "superior" at week 52 of the study. Further, Defendants could point to "caveats" in their statements to investors—such as statements that ADVOCATE showed that avacopan eliminated the need to use "chronic" or "daily" doses of "high dose" steroids—and would argue that those caveats made clear that avacopan did not eliminate the need to use steroids altogether. There was a risk that a jury might accept Defendants' interpretation of their statements to investors and find them not liable for this category of alleged misstatements.

98. Finally, Lead Plaintiff would face challenges with respect to proving the falsity of Defendants' statements that the FDA's review of the New Drug Application was proceeding as expected. Despite evidence that the FDA repeatedly warned Defendants during the Class Period about flaws in ADVOCATE's trial design, Defendants had arguments in response. Defendants would contend—backed by testimony from their FDA regulatory experts—that it is routine for the FDA to express concerns during meetings with pharmaceutical companies seeking approval for a new drug and that the Company was not required to disclose all of these interim concerns. Defendants would argue that the FDA's decision to allow ADVOCATE to proceed notwithstanding its stated concerns, its failure to stop the trial at any point, and its ultimate approval of the drug indicated that Defendants' optimistic statements about the FDA approval process were not misleading.

2. Scienter

99. Even if Lead Plaintiff were able to prove that Defendants' statements were materially false or misleading, it would still need to prove to a jury that Defendants made the alleged false statements with the intent to mislead investors or with deliberate recklessness. Defendants would argue that they genuinely believed their statements were accurate, and their optimism was justified

by the FDA's subsequent approval of the drug. Certain documents obtained in discovery, including emails authored by ChemoCentryx executives, could be used to support Defendants' position that they genuinely disputed the concerns raised about avacopan's safety and ADVOCATE study design and continued to hold genuinely optimistic views regarding avacopan's NDA. Thus, there was a real risk that a jury could conclude that Defendants did not act with fraudulent intent, even if Defendants' statements to investors were found to be inaccurate.

3. Loss Causation and Damages

100. Even assuming that Lead Plaintiff overcame Defendants' arguments and established liability, Lead Plaintiff would have still confronted additional challenges in establishing loss causation and damages at any trial. Defendants would continue to argue that the declines in the price of ChemoCentryx common stock were not caused entirely—or at all—by the alleged corrective disclosures. Here, the Complaint alleged two "corrective disclosures" that Lead Plaintiff asserted revealed the truth and caused investors' losses: (1) the FDA's release of its "briefing materials" on May 4, 2021, which set forth the FDA's concerns about the ADVOCATE trial's design; and (2) the FDA's public Advisory Committee meeting on May 6, 2021, during which clinicians expressed their concerns about the ADVOCATE trial and avacopan's safety.

101. Defendants would continue to argue that ChemoCentryx's stock price declined on these dates for reasons unrelated to the alleged fraud, and that information regarding the alleged data manipulation was not revealed on either of the corrective disclosure dates. Specifically, with respect to the May 4, 2021 disclosure, Defendants would argue that the "briefing materials" did not "correct" any misstatements because the truth regarding ADVOCATE's design and results had already been fully disclosed earlier in two medical journal articles: an October 12, 2019 article in the *Journal of Medical Internet Research* and a February 18, 2021 article in the *New England Journal of Medicine*. Defendants would contend that those articles had already revealed the substance of the FDA's concerns regarding the ADVOCATE trial.

102. With respect to the second corrective disclosure, Defendants had a particularly threatening argument that nothing substantively new was disclosed concerning the ADVOCATE trial's design or results during the May 6, 2021 Advisory Committee meeting that had not already

been fully disclosed in the briefing materials on May 4, 2021 and thus could not have caused the price decline at issue. Defendants would likely argue that the only new information was the opinions of the independent group of clinicians on the Advisory Committee, who provided their opinions about the materials previously published by the FDA. Defendants would argue that the market had simply reacted to those opinions, rather than to the revelation of any prior misstatements.

103. Finally, as to "damages," Defendants would argue that—even if Lead Plaintiff prevailed—damages should be "offset" by the amount by which ChemoCentryx's stock price increased following the FDA's approval of TAVNEOS shortly after the Class Period and disaggregated from other contributing factors.

104. Moreover, even if Lead Plaintiff had prevailed on all of these issues at trial after remand, Lead Plaintiff would have faced further risks related to post-trial motions, including an individualized damages process in which Defendants could attempt to "pick off" Class Members based on reliance issues, as well as the risk of a post-trial appeal of any verdict in Lead Plaintiff's favor.

C. The Settlement Amount Compared to the Likely Maximum Damages that Could Be Proved at Trial

105. The Settlement Amount—$69 million in cash, plus interest—represents a significant recovery for the Class. The Settlement is more than six times the size of the median securities class-action settlement in the Ninth Circuit from 2016 to 2025 ($11 million). *See* CORNERSTONE RESEARCH, SECURITIES CLASS ACTION SETTLEMENTS: 2025 REVIEW AND ANALYSIS (2026), attached hereto as Exhibit 2 at 19.

106. The $69 million Settlement is also a highly favorable result when it is considered in relation to the maximum amount of damages that could be realistically obtained in further litigation. Assuming complete success on the pending appeal and complete success after remand and at trial, the absolute maximum possible damages that could be established in the Action, based on Lead Plaintiff's damages expert's estimate, was $1.3 billion. Meanwhile, if Lead Plaintiff recovered on the first corrective disclosure, but not the second—as Defendants vigorously argued—the maximum damages would be reduced to $513.6 million. Both of these estimates aggressively

assume that Lead Plaintiff would reverse the dismissal of its claims with respect to all categories of alleged misstatements and then prevail at trial on all categories of misstatements for the entire Class Period and successfully defeat Defendants' arguments for an "offset" based on ChemoCentryx's share price recovery following the FDA's approval of TAVNEOS in October 2021.

107. Accordingly, the $69 million Settlement represents a recovery of 5.3% to 13.4% of the absolute maximum damages that could be obtained at trial under these scenarios. This range of maximum recovery is well within the range typically seen in comparable securities actions. *See, e.g.*, *In re Lyft, Inc. Sec. Litig.*, 2022 WL 17740302, at *6 (N.D. Cal. Dec. 16, 2022) (finding the settlement equal to 3.2% to 4.7% of estimated maximum damages was "well within the range of possible approval"); *Vataj v. Johnson*, 2021 WL 1550478, at *9 (N.D. Cal. Apr. 20, 2021) (settlement amounting to 2% of damages was "consistent with the typical recovery in securities class action settlements"); *In re Extreme Networks, Inc. Sec. Litig.*, 2019 WL 3290770, at *9 (N.D. Cal. July 22, 2019) (approving settlement representing between 5% and 9.5% of maximum potential damages). Indeed, the recovery achieved here is particularly noteworthy given that the Settlement was reached following the dismissal of all claims at summary judgment.

108. Given all of these meaningful litigation risks, and the immediacy and amount of the $69,000,000 recovery for the Class, Lead Plaintiff and Lead Counsel believe that the Settlement is fair, reasonable, and adequate, and is in the best interests of the Class.

III. LEAD PLAINTIFF'S COMPLIANCE WITH THE COURT'S PRELIMINARY APPROVAL ORDER REQUIRING ISSUANCE OF NOTICE

109. The Court's Preliminary Approval Order directed that the postcard notice concerning the Settlement ("Postcard Notice"), the Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice"), and Proof of Claim and Release Form ("Claim Form") be disseminated to potential Class Members as set forth in that Order. The Preliminary Approval Order also set September 21, 2026 as the deadline for Class Members to submit objections to the Settlement, the Plan of Allocation, or the Fee and Expense Application, or to opt back into the Class.

110. In accordance with the Preliminary Approval Order, Lead Counsel instructed Kroll, the Court-approved Claims Administrator, to begin disseminating copies of the Postcard Notice, Settlement Notice, and Claim Form and to publish the Summary Settlement Notice. The Postcard Notice contains a summary of the Settlement, the date of the final approval hearing, the deadlines for submission of Claim Forms and objections, and refers recipients to the case website, www.ChemoCentryxSecuritiesLitigation.com, where the Settlement Notice, Claim Form, and other documents can be obtained. The longer Settlement Notice contains, among other things, a description of the Action, the Settlement, the reasons for the Settlement, the full proposed Plan of Allocation, information about Class Members' rights to participate in the Settlement and object to the Settlement, and the Plan of Allocation and/or the Fee and Expense Application. Both the Postcard Notice and Settlement Notice inform Class Members of Lead Counsel's intent to apply for an award of attorneys' fees in an amount not to exceed 22% of the Settlement Fund, and for Litigation Expenses in an amount not to exceed $5 million.

111. On July 6, 2026, Kroll mailed copies of the Postcard Notice to all persons and entities who had been identified as potential Class Members in connection with the mailing of the Class Notice. In addition, copies of the Settlement Notice and Postcard Notice were mailed to brokers and nominees, who were instructed to either forward Postcard Notices to the beneficial owners on whose behalf they had purchased ChemoCentryx common stock during the Class Period or to provide names and addresses of any potential Class Members who they had not previously provided in connection with the Class Notice (or to provide any updated or changed address information). The accompanying Declaration of Lindsey Marquez ("Marquez Decl."), attached hereto as Exhibit 3, provides additional information about the Claims Administrator's distribution of the notices. *See* Marquez Decl. ¶¶ 3-9. Attorneys at BLB&G have had regular conference calls and communications with Kroll to oversee the process of disseminating notice to Class Members and the initial processing of claims received.

112. Kroll began mailing copies of the notices to potential Class Members and nominee owners on July 6, 2026. *Id.* ¶¶ 3-6. As of September 9, 2026, Kroll disseminated a total of 77,834

Postcard Notices and 1,551 Summary Notice Packets to potential Class Members and nominees. *Id.* ¶ 9.

113. On July 20, 2026, in accordance with the Preliminary Approval Order, Kroll caused the Summary Settlement Notice to be published in the *Wall Street Journal* and to be transmitted over the *PR Newswire*. *Id*. ¶ 10.

114. Lead Counsel also caused Kroll to update the previously established case website, www.ChemoCentryxSecuritiesLitigation.com, to provide Class Members with information concerning the Settlement and access to copies of the Settlement Notice and Claim Form, as well as copies of the Stipulation, Preliminary Approval Order, and other relevant documents. *See* Marquez Decl. ¶ 11. The website also allows Class Members to submit their claims online if they wish to do so. *Id*. That website became operational on July 6, 2026. *Id*. Lead Counsel also made copies of the Settlement Notice and Claim Form and other documents available on its own website, www.blbglaw.com. Lead Counsel and Kroll have regularly monitored the settlement website to ensure that it is operating correctly. Lead Counsel and Kroll will continue to monitor and to update the settlement website as the settlement process continues. For example, Lead Plaintiff's papers in support of its motion for final approval of the Settlement and Lead Counsel's papers in support of its motion for attorneys' fees and litigation expenses will be made available on the website after they are filed, and any orders entered by the Court in connection with the motions will also be posted.

115. As noted above, the deadline for Class Members to file objections to the Settlement, Plan of Allocation, or Fee and Expense Application is September 21, 2026. To date, no objections to the Settlement, Plan of Allocation, or Lead Counsel's Fee and Expense Application have been received. Lead Counsel will file reply papers on or before September 28, 2026, that will address any objections that may be received.

IV. ALLOCATION OF THE PROCEEDS OF THE SETTLEMENT

116. Pursuant to the Preliminary Approval Order, and as set forth in the notices, all Class Members who want to be eligible to participate in the distribution of the Net Settlement Fund must submit a valid Claim Form postmarked (if mailed) or submitted online no later than October 1,

2026. The Net Settlement Fund will be distributed among Class Members who submit eligible claims according to the plan of allocation approved by the Court.

117. Lead Counsel developed the proposed plan of allocation (the "Plan of Allocation") in consultation with Lead Plaintiff's damages expert. The Plan is based generally on the calculation for Section 10(b) damages set forth in the Expert Report of Matthew D. Cain concerning damages dated September 25, 2024 (Dkt. No. 340-35). Lead Counsel believes that the Plan of Allocation provides a fair and reasonable method to equitably allocate the Net Settlement Fund among Class Members who suffered losses as a result of the conduct alleged in the Action.

118. The Plan of Allocation is set forth at pages 16 to 24 of the Settlement Notice. *See* Marquez Decl., Ex. B at pp. 16-24. As described in the Settlement Notice, calculations under the Plan of Allocation are intended as a method to weigh the claims of Class Members against one another for the purposes of making an equitable allocation of the Net Settlement Fund. *See* Settlement Notice ¶ 81.

119. In developing the Plan of Allocation, Lead Plaintiff's damages expert calculated the estimated amount of artificial inflation in the per-share closing price of ChemoCentryx common stock which allegedly was proximately caused by Defendants' alleged materially false and misleading statements and omissions during the Class Period. *See Id.* ¶ 82. In calculating the estimated artificial inflation allegedly caused by those misrepresentations and omissions, Lead Plaintiff's damages expert considered price changes in ChemoCentryx common stock on May 5, 2021 and May 7, 2021 in reaction to the public disclosures that allegedly corrected the alleged misrepresentations and omissions, adjusting the price change for factors that were attributable to market or industry forces, and for non-fraud related information.

120. To determine the daily artificial inflation per share, the Plan utilizes the minimum of constant-percentage inflation and constant-dollar inflation. *Id.* ¶ 83. Specifically, for any given trading day during the Class Period, the artificial inflation is the lesser of (i) Constant-Percentage Inflation: 78.44% of ChemoCentryx's closing share price from November 26, 2019 through May 3, 2021, and 62.21% of the closing share price from May 4, 2021 through May 5, 2021; or,

(ii) Constant-Dollar Inflation: a fixed amount of $38.07 per share from November 26, 2019 through May 3, 2021, and $17.10 per share from May 4, 2021 through May 5, 2021. *Id*.

121. In order to have recoverable damages in connection with purchases or acquisitions of ChemoCentryx common stock during the Class Period, disclosure of the alleged misrepresentations or omissions must be the cause of the decline in the price of the ChemoCentryx common stock. In this case, Lead Plaintiff alleges that Defendants made false statements and omitted material facts during the Class Period (from November 26, 2019 through May 6, 2021), which had the effect of artificially inflating the prices of ChemoCentryx common stock and that the artificial inflation was removed from the price of ChemoCentryx common stock as the result of the alleged corrective disclosures on May 4, 2021 and May 6, 2021. In order to be eligible under the Plan of Allocation, shares of ChemoCentryx common stock must have been purchased or otherwise acquired during the Class Period and held at least the close of trading on May 3, 2021.

122. Recognized Loss Amounts are calculated under the Plan of Allocation for each purchase or acquisition of ChemoCentryx common stock during the Class Period that is listed on a Claimant's Claim Form and for which adequate documentation is provided. For shares purchased during the Class Period and sold before the close of trading on May 3, 2021, the Recognized Loss Amount is zero, because, as discussed above, those shares were not damaged by the alleged fraud. *See* Settlement Notice ¶ 86.A. For shares purchased during the Class Period and sold from May 4, 2021 through May 6, 2021, Recognized Loss Amounts are calculated as *the lesser of*: (a) the amount of alleged artificial inflation in ChemoCentryx common stock on the date of purchase *minus* the amount of alleged artificial inflation on the sale date, or (b) the difference between the purchase price and the sale price. *See id.* ¶ 86.B. For shares purchased during the Class Period and sold during the 90-day period after the Class Period, Recognized Loss Amounts are calculated as *the least of*: (a) the amount of alleged artificial inflation in ChemoCentryx common stock on the date of purchase, (b) the difference between the purchase price and the sale price; or (c) the difference between the purchase price and the average closing price from May 7, 2021 and the date of sale. *See id.* ¶ 86.C. For shares purchased during the Class Period and held until the end of 90-day period after the Class Period (August 4, 2021) or longer, the Recognized Loss Amount is *the lesser of*:

(a) the amount of alleged artificial inflation in ChemoCentryx common stock on the date of purchase, or (b) the difference between the purchase price and the average closing price of ChemoCentryx during the 90-day period ($12.85 per share). *See id.* ¶ 86.D.

123. The sum of a Claimant's Recognized Loss Amounts for all of his, her, or its purchases of ChemoCentryx common stock during the Class Period is the Claimant's "Recognized Claim." Settlement Notice ¶ 87. The Plan of Allocation also limits Claimants' Recognized Claim based on whether they had an overall market loss in their transactions in ChemoCentryx common stock during the Class Period. A Claimant's Recognized Claim will be limited to the amount of his, her, or its market loss in ChemoCentryx common stock transactions during the Class Period, and Claimants who have an overall market gain are not eligible for a recovery. *Id.* ¶¶ 94-95.

124. The Net Settlement Fund will be allocated to Authorized Claimants on a *pro rata* basis based on the relative size of their Recognized Claims. Settlement Notice ¶ 96. If an Authorized Claimant's *pro rata* distribution amount calculates to less than ten dollars, no payment will be made to that Authorized Claimant. *Id.* ¶ 97. Those funds will be included in the distribution to the Authorized Claimants whose payments exceed the ten-dollar minimum.

125. One-hundred percent of the Net Settlement Fund will be distributed to Authorized Claimants. If any funds remain after the initial *pro rata* distribution, as a result of uncashed or returned checks or other reasons, subsequent cost-effective distributions to Authorized Claimants will be conducted. Settlement Notice ¶ 98. Only when the residual amount left for re-distribution to Class Members is so small that a further re-distribution would not be cost effective (for example, where the administrative costs of conducting the additional distribution would largely subsume the funds available), will those funds be donated to the *cy pres* recipient. *Id.*

126. The Plan of Allocation identifies the Bluhm Legal Clinic Complex Civil Litigation and Investor Protection Center at the Northwestern Pritzker School of Law ("IPC") as the proposed *cy pres* recipient if there are any residual funds remaining after all cost-effective distributions to Class Members have been completed. Settlement Notice ¶ 98. The IPC is a law school clinic that provides law students with the opportunity to represent clients with limited income in securities matters against stockbrokers, investment advisers, or securities firms. IPC also provides case-

screening services to regulators, including FINRA, the SEC, and state regulators, as well as brokerage houses trying to identify legitimate claims. *See Complex Civil Litigation and Investor Protection Center*, NW Univ., https://www.law.northwestern.edu/legalclinic/investorprotection/. Lead Plaintiff and Lead Counsel have no relationship with the IPC.

127. The Plan of Allocation was designed to fairly and rationally allocate the proceeds of the Net Settlement Fund among Class Members based on damages they suffered on purchases of ChemoCentryx common stock that were attributable to the misconduct alleged in the Action. To date, no objections to the proposed Plan of Allocation have been received.

V. THE FEE AND EXPENSE APPLICATION

128. Lead Counsel is applying to the Court on behalf of Plaintiffs' Counsel for an award of attorneys' fees of 22% of the Settlement Fund, including any interest earned (the "Fee Application"). Lead Counsel also requests payment for expenses it incurred in connection with the prosecution of the Action from the Settlement Fund in the amount of $4,898,136.90.

129. The legal authorities supporting the requested fee and expenses are discussed in Lead Counsel's Fee Memorandum. As discussed in the Fee Memorandum, the 22% fee award requested is below the benchmark for percentage fee awards in the Ninth Circuit, is well within the range of percentage fees typically awarded in comparable securities class actions in this Circuit and elsewhere, and is fair and reasonable in light of all the circumstances in this case.

A. The Fee Application

130. For its efforts on behalf of the Class, Lead Counsel is applying for a fee award to be paid from the Settlement Fund on a percentage basis. As discussed in the accompanying Fee Memorandum, the percentage method is the standard and appropriate method of fee recovery because it aligns the lawyers' interest in being paid a fair fee with the interests of the Class in achieving the maximum recovery in the shortest amount of time required under the circumstances. Use of the percentage method has been recognized as appropriate by the Supreme Court and Ninth Circuit for cases of this nature where an all-cash common fund has been recovered for a class.

1. Lead Plaintiff Has Authorized and Supports the Fee Application

131. Lead Plaintiff Indiana is a sophisticated institutional investor that closely supervised and monitored the prosecution and settlement of this Action. *See* Declaration of Jeffrey M. Gill on behalf of Indiana ("Gill Decl."), attached hereto as Exhibit 1 at ¶¶ 3-6. Lead Counsel's 22% fee request is made pursuant to a retainer agreement that Indiana negotiated and entered into with BLB&G in July 2021, at the outset of the litigation, which provided for different levels of percentage fees based on the stage of litigation at which settlement was reached. *Id*. ¶ 8. Following the agreement to settle the Action, Indiana has again evaluated the proposed fee and believes it is fair and reasonable in light of the result obtained for the Class, the amount and quality of the work performed by Lead Counsel, and the significant risks undertaken by counsel in this Action. *Id*.

2. The Work Performed by Lead Counsel

132. Lead Counsel devoted extensive time to the prosecution of the Action. The work that Lead Counsel performed in this Action included, among other things: (i) conducting a thorough investigation and filing a detailed Amended Consolidated Class Action Complaint; (ii) defeating Defendants' motion to dismiss; (iii) completing fact discovery involving the exchange and review of 8 million pages of documents, 21 fact depositions, and dozens of third-party subpoenas; (iv) successfully obtaining class certification; (v) defeating Defendants' Rule 23(f) petition for interlocutory review; (vi) disseminating notice of pendency of class action to the Class; (vii) completing expert discovery, which included 24 expert reports and 17 expert depositions; (viii) briefing and arguing 11 *Daubert* motions; (ix) briefing and arguing cross-motions for summary judgment; (x) preparing and filing an appeal to the Ninth Circuit; and (xi) engaging in settlement negotiations.

133. As set forth in Exhibit 4, Lead Counsel expended a total of 61,688.50 hours in the investigation and prosecution of the Action from its inception through August 31, 2026, for a lodestar of $40,480,287.50 at current rates, and $34,304,506.25 based on the hourly rates in effect at the time the work was performed ("historical rates"). The requested fee of 22% of the Settlement Fund represents $15,180,000 (plus interest accrued at the same rate as the Settlement Fund), and therefore represents a "negative" multiplier of approximately 0.37 of Lead Counsel's lodestar at

current rates, and 0.44 at historical rates. As discussed in further detail in the Fee Memorandum, the requested multiplier cross-check is substantially below the range of multipliers typically seen in comparable securities class actions and in other class actions involving significant contingency fee risk, in this Circuit and elsewhere.

134. Consistent with the Northern District of California's Procedural Guidance for Class Action Settlements and the Court's requests of plaintiffs' counsel in *Rodman v. Safeway, Inc*., 125 F. Supp. 3d 922 (N.D. Cal. 2015), Lead Counsel has included detailed exhibits, attached hereto as Exhibits 7, 8, and 9 showing the hours worked by each of the professionals who worked on the matter, broken down by month and by 17 different substantive categories of work, and various summaries of that information, as well as biographical information for each timekeeper. No time expended in preparing the application for fees and expenses has been included. Lead Counsel also notes that there will not be any additional fees charged for any work by counsel following this application, notwithstanding that counsel already has and will continue to invest substantial time and effort in this case after the August 31, 2026 cut-off imposed for its lodestar in this application.

135. As noted above, Exhibits 7, 8, and 9 include charts summarizing work performed by Lead Counsel's professionals who dedicated more than ten hours to the matter, broken down by month and by 17 different substantive categories of work. The categories of work used (and total hours expended on each category) are set forth here:

(1) **Investigation and Pre-Filing Case Analysis (664.5 hours):** includes time spent on the thorough investigation into the claims asserted in the Action, including reviewing the voluminous public record and identifying, contacting, and interviewing potential witnesses; initial case development; and analysis of clients' and class losses;

(2) **Lead-Plaintiff Motion (301.25 hours):** includes time spent researching and drafting motion papers for appointment of Indiana as Lead Plaintiff and BLB&G as Lead Counsel;

(3) **Complaint (566.5 hours):** includes time incurred by Lead Counsel in researching and preparing the Amended Consolidated Class Action Complaint for Violations of the Federal Securities Laws, including associated legal and factual research;

(4) **Opposition to Motion to Dismiss (495.5 hours):** includes time incurred in researching and drafting Lead Plaintiff's opposition to Defendants' motion to dismiss the Complaint, and preparing for potential oral argument on the motion;

(5) **Class Certification (1,107 hours):** includes the time spent on Lead Plaintiff's motion for class certification, including related legal research and briefing, as well as Lead Plaintiff's opposition to Defendants' petition for interlocutory review under Rule 23(f), Lead Plaintiff's motion for approval of class notice, and overseeing Kroll's distribution of Class Notice;

(6) **Discovery Communications, Disputes & General (2,265 hours):** includes time spent on discovery correspondence, numerous meet-and-confer sessions with Defendants' Counsel, preparing Lead Plaintiff's Initial Disclosure Statement under Rule 26(a), drafting and negotiating the proposed protective order, discovery disputes (including communications re same and research and briefing), and strategy and planning related to discovery efforts;

(7) **Written/Document Discovery (23,513.25 hours):** includes the time incurred in drafting requests for production of documents and subpoenas, interrogatories, and requests for admission; preparing responses and objections to requests for production of documents, interrogatories and requests for admission served on Lead Plaintiff; reviewing Lead Plaintiff's documents for production; reviewing and analyzing documents produced by Defendants and third parties, including preparation of related analyses based on the document productions; preparing and reviewing privilege logs; and work related to the electronic document database;

(8) **Fact Depositions (7,869.25 hours):** includes time incurred by Lead Counsel in preparing a deposition plan; preparing to take and defend non-expert depositions; and taking and defending depositions, including document review undertaken specifically for purposes of deposition preparation;

(9) **Experts (14,728.25 hours):** includes time spent communicating with experts and consultants; working on preparing expert reports and engaging in expert discovery, including preparing to take and defend expert depositions, drafting *Daubert* motions, responding to Defendants' *Daubert* motions, and oral argument re same;

(10) **Summary Judgment Motions (2,507.75 hours):** includes time spent researching and drafting Lead Plaintiff's motion for partial summary judgment and Lead Plaintiff's opposition to Defendants' motion for summary judgment, and preparing for and participating in oral argument on the summary judgment motions;

(11) **Pre-Trial Motions and Trial Preparation (4,450.25 hours):** includes time spent researching and drafting Lead Plaintiff's motions *in limine*, preparing for and conducting a mock jury exercise, and other trial preparation efforts, including drafting jury instructions, an order of proof and lists of trial exhibits;

(12) **Appeal (1,369.50 hours):** includes time spent initiating Lead Plaintiff's appeal from the Court's Summary Judgment Order, researching and drafting the opening brief on appeal, and compiling the voluminous excerpts of record for the Court of Appeals;

(13) **Mediation & Settlement (994 hours):** includes time incurred in extended settlement negotiations with Defendants throughout the Action; preparing for and attending the February 2024 mediation session; drafting the mediation statement in

advance of that session; drafting and negotiating the Memorandum of Understanding, the original Settlement Stipulation, the Revised Stipulation and Agreement of Settlement, and related documents in 2026; and drafting Lead Plaintiff's motions for preliminary and final approval of the Settlement (but does not include any work related to Lead Counsel's motion for fees and expenses);

(14) **Case Management (416.75 hours):** includes time incurred in preparing status reports to the Court, *pro hac vice* motions, participating in case management conferences and status hearings, negotiating and preparing stipulations and proposed scheduling orders, and other procedural and administrative tasks not connected to one of the other substantive tasks;

(15) **Case Strategy & Analysis (217 hours):** includes time devoted to overall case strategy and analysis, including litigation strategy and damages issues;

(16) **Docket/News Monitoring (22 hours):** includes time incurred in reviewing docket updates on the case or related cases and monitoring of news and SEC filings of ChemoCentryx or other industry news; and

(17) **Client Communications (200.75 hours):** includes time incurred in communications with Lead Plaintiff Indiana, including preparing status reports and memoranda.

3. The Experience and Standing of Lead Counsel

136. A copy of Lead Counsel BLB&G's firm resume, which includes information about the standing of the firm, is attached as Exhibit 5. Brief biographical summaries for each attorney listed in Exhibit 4, including information about their position, education, and relevant experience, are attached as Exhibit 6. As demonstrated by the firm resume, BLB&G is among the most experienced and skilled law firms in the securities litigation field, with a long and successful track record representing investors in such cases and is consistently ranked among the top plaintiffs' firms in the country. In addition, ISS/Securities Class Action Services' 2025 report on the "Top 100 U.S. Class Action Settlements of All Time" shows that BLB&G has been lead or co-lead counsel in more top recoveries than any other firm in history. Further, BLB&G has taken complex cases such as this to trial, and it is among the few firms with experience doing so on behalf of plaintiffs in securities class actions. I believe this willingness and ability added valuable leverage in the settlement negotiations.

137. As reflected in the Firm Resume, BLB&G is among the most experienced securities class action law firms in the country. BLB&G served as Lead Counsel in *In re WorldCom, Inc.*

Securities Litigation, No. 1:02-cv-03288 (S.D.N.Y.), in which settlements were obtained for the class totaling in excess of $6 billion. BLB&G also secured a resolution of $2.43 billion for the class in *In re Bank of America Corp. Securities, Derivative, & Employee Retirement Income Security Act (ERISA) Litigation*, No. 1:09-md-02058 (S.D.N.Y.); a $1.06 billion recovery for the class in *In re Merck & Co., Inc. Securities, Derivative & "ERISA" Litigation*, No. 2:05-cv-01151 (D.N.J.); a $1 billion recovery for the class in *In re Wells Fargo & Co. Securities Litigation*, No. 1:20-cv-04494 (S.D.N.Y.); and a $730 million settlement on behalf of the class in *In re Citigroup Inc. Bond Action Litigation*, No. 1:08-cv-09522 (S.D.N.Y.).

138. Courts in this District and Circuit have recognized BLB&G as qualified class counsel in securities class actions. Such examples include *In re McKesson HBOC, Inc. Securities Litigation*, No. 5:99-cv-20743 (N.D. Cal.), in which BLB&G recovered $1.05 billion for investors, the largest recovery in a securities class action in the Ninth Circuit; *Hefler v. Wells Fargo & Co.*, No. 4:16-cv-05479 (N.D. Cal.), in which BLB&G recovered $480 million for investors; *In re Allergan, Inc. Proxy Violation Securities Litigation*, No. 8:14-cv-02004 (C.D. Cal.), in which BLB&G recovered $250 million for investors; and *In re New Century*, No. 2:07-cv-00931 (C.D. Cal.), in which BLB&G secured an approximately $125 million recovery for investors.

4. Standing and Caliber of Defendants' Counsel

139. The quality of the work performed by Lead Counsel in attaining the Settlement should also be evaluated in light of the quality of the opposition. Defendants were represented in the Action by a team of extremely able counsel from Latham & Watkins LLP, who vigorously litigated the Action. In the face of this skillful and well-financed opposition, Lead Counsel was nonetheless able to persuade Defendants and their counsel to settle the case on terms that are favorable to the Class.

5. The Risks of Litigation and the Need to Ensure the Availability of Competent Counsel in High-Risk Contingent Cases

140. The prosecution of these claims was undertaken entirely on a contingent-fee basis, and the considerable risks assumed by Lead Counsel in bringing this Action to a successful

conclusion are described above. The risks assumed by Lead Counsel here, and the time and expenses incurred by Lead Counsel without any payment, were extensive.

141. From the outset, Lead Counsel understood that it was embarking on a complex, expensive, lengthy, and hard-fought litigation with no guarantee of ever being compensated for the substantial investment of time and the outlay of money that the prosecution of the case would require. In undertaking that responsibility, Lead Counsel was obligated to ensure that sufficient resources (in terms of attorney and support staff time) were dedicated to the litigation, and that Lead Counsel would further advance all of the costs necessary to pursue the case vigorously on a fully contingent basis, including funds to compensate vendors and consultants and to cover the considerable out-of-pocket costs that a case such as this typically demands. Because complex shareholder litigation often proceeds for several years before reaching a conclusion, the financial burden on contingent-fee counsel is far greater than on a firm that is paid on an ongoing basis. Indeed, here Lead Counsel has received no compensation during the five-year duration of this Action and has incurred more than $4.9 million in litigation expenses.

142. Lead Counsel also bore the risk that no recovery would be achieved in the Action. As discussed above, this case presented a number of significant trial risks and uncertainties from the outset, including challenges in proving the materiality and falsity of Defendants’ statements, establishing scienter, and establishing loss causation and damages. These risks were elevated in this case. Defendants vigorously denied making any false statements and denied that the price decline at issue was caused by revelation of the truth related to the challenged statements.

143. Lead Counsel’s persistent efforts in the face of significant risks and uncertainties have resulted in a significant and certain recovery for the Class.

6. The Reaction of the Class to the Fee Application

144. As noted above, as of September 9, 2026, over 77,000 Postcard Notices and 1,500 Settlement Notice Packets had been sent to potential Class Members advising them that Lead Counsel would apply for attorneys’ fees in an amount not to exceed 22% of the Settlement Fund. *See* Marquez Decl. ¶ 9 and Ex. A (Postcard Notice), Ex. B (Settlement Notice), ¶¶ 5, 56. In addition, the Court-approved Summary Settlement Notice was published in the *Wall Street Journal* and

transmitted over the *PR Newswire* on July 20, 2026. *See* Marquez Decl. ¶ 10. To date, no objections to the request for attorneys' fees have been received.

B. The Expense Application

145. Lead Counsel also seeks payment from the Settlement Fund of $4,898,136.90 in litigation expenses that it reasonably incurred in connection with commencing, litigating and settling the claims asserted in the Action.

146. From the outset of the Action, Lead Counsel has been aware that they might not recover any of the expenses they incurred, and, further, if there were to be reimbursement of expenses, it would not occur until the Action was successfully resolved, often a period lasting several years. Lead Counsel also understood that, even assuming that the case was ultimately successful, reimbursement of expenses would not necessarily compensate it for the lost use of funds advanced by them to prosecute the Action. Consequently, Lead Counsel was motivated to, and did, take significant steps to minimize expenses whenever practicable without jeopardizing the vigorous and efficient prosecution of the case.

147. As set forth in Exhibits 10 and 11 hereto, Lead Counsel has incurred a total of $4,898,136.90 in litigation expenses in connection with the prosecution of the Action. These expense items are billed separately by Lead Counsel, and such charges are not duplicated in Lead Counsel's hourly rates.

148. Of the total amount of expenses, $3,571,480.31, or approximately 73%, was expended for the retention of experts and consultants. As discussed above, Lead Counsel consulted with a number of different experts in the Action, including experts in financial economics (including Lead Plaintiff's principal economic expert Dr. Matthew Cain and several consulting experts); an expert hepatologist, Dr. Alan Bonder; an expert rheumatologist, Dr. Simon Helfgott; an expert in biostatistics, Dr. David Madigan; a pharmaceutical industry expert Ahmed Ragab; and an FDA regulatory expert, Dr. Marc Walton. Each of these experts prepared opening and reply reports and was deposed by Defendants. More detail on these expert expenses is included in Exhibit 12A.

149. Another large component of the litigation expenses was for legal and factual research, which was necessary to prepare the Complaint, research the law pertaining to the claims

asserted in the Action, oppose Defendants' motion to dismiss, prepare Lead Plaintiff's motion for class certification, brief the cross-motions for summary judgment, litigate certain discovery disputes, and brief the appeal. The charges for such research amounted to $350,039.24, or 7% of the total amount of expenses. The factual research costs included costs paid to the FDA for its search time and duplication costs in connection with Lead Counsel's FOIA requests, and for access to articles in medical research journals, as well as costs incurred for on-line databases and information services such as AlphaSense, Refinitiv, Bureau of National Affairs, Court Alert, and PACER. The legal research costs included out-of-pocket payments to vendors such as Westlaw and LexisNexis. These resources were used to obtain factual information regarding the claims asserted, obtain access to court filings, and conduct legal research and cite-checking of briefs. These expenses represent the actual expenses incurred by BLB&G for use of these services in connection with this litigation. There are no administrative charges included in these figures. Online research is billed to each case based on actual usage at a charge set by the vendor. When BLB&G utilizes online services provided by a vendor with a flat-rate contract, access to the service is by a billing code entered for the specific case being litigated. At the end of each billing period, BLB&G's costs for such services are allocated to specific cases based on the percentage of use in connection with that specific case in the billing period.

150. Lead Plaintiff's share of the mediation costs paid to Phillips ADR Enterprises for the services of Greg Danilow totaled $21,250.00, or 0.4% of Lead Counsel's Litigation Expenses. As noted above, the Parties retained Mr. Danilow, an experienced mediator of securities class actions and other complex litigation, to assist with settlement negotiations in the Action, including a formal mediation session on February 9, 2024. The mediation expenses were divided evenly between Lead Plaintiff and Defendants.

151. The other expenses for which Lead Counsel seeks payment are the types of expenses that are necessarily incurred in litigation and routinely charged to clients who are billed by the hour. These expenses include, among others, court fees, document management, court reporting, express mail, and travel. All of the litigation expenses incurred by Lead Counsel were reasonable and

necessary to the successful litigation of the Action, and have been approved by Lead Plaintiff. *See* Gill Decl. ¶ 9. The following is additional information regarding certain of these expenses:

(a) **Document Hosting & Management** ($179,994.60). BLB&G seeks $179,994.60 for document hosting and management costs, which represents BLB&G's costs associated with establishing and maintaining the internal document database that BLB&G employed to process and review the substantial number of documents produced to Lead Plaintiff by Defendants and non-parties. BLB&G charges a rate of $4 per gigabyte of data per month and $17 per user to recover the costs associated with maintaining its document database management system, which includes the costs to BLB&G of necessary software licenses and hardware. BLB&G has conducted a review of market rates charged for similar services performed by third-party document management vendors and found that its rate was at least 80% below the market rates charged by these vendors, resulting in a savings to the class.

(b) **Independent Counsel for Witnesses** ($168,028.39). Lead Counsel incurred $168,028.39 in attorneys' fees for the retention of independent counsel, Hach Rose Schirripa & Cheverie LLP and Slarskey LLC, to represent former ChemoCentryx employees whom Lead Counsel contacted during its investigation and who wished to be represented by independent counsel. Similar expenses have routinely been approved by courts. *See, e.g.*, Order Awarding Att'ys' Fees and Litigation Expenses at 1-2, *In re Qualcomm Inc. Sec. Litig.*, No. 3:17-cv-00121 (S.D. Cal. Sept. 27, 2024), Dkt. No. 450 (awarding class counsel reimbursement for the costs of paying for independent counsel for third-party witnesses); Order Granting Mot. for Settlement and Mot. for Att'y's Fees at 15, *SEB Inv. Mgmt. AB v. Symantec Corp.*, No. 3:18-cv-02902 (N.D. Cal. Feb. 10, 2022), Dkt. No. 421 (same); Order Awarding Att'ys' Fees and Litigation Expenses at 1, *In re Impinj, Inc. Sec. Litig.*, No. 3:18-cv-05704-RSL (W.D. Wash. Nov. 20, 2020), Dkt. No. 106 (same).

(c) **Taxable Litigation Costs** ($139,246.01). Lead Counsel also incurred $139,246.01 in taxable costs that it paid to Defendants under Rule 54(d) following entry of the judgment in favor of Defendants. Those costs were necessary to allow Lead Plaintiff to continue litigating on appeal and ultimately achieve the $69 million settlement.

(d) **Out-of-Town Travel** ($149,712.13). BLB&G seeks reimbursement of $149,712.13 in costs incurred for travel in connection with the Action, which includes travel for BLB&G attorneys to attend Court hearings, depositions, client meetings, and mediation, and travel for staff of Lead Plaintiff to attend a deposition and the mediation. Airfare is capped at coach rates, hotel charges are capped at $350 per night, and travel meals are capped at $20 per person for breakfast, $25 per person for lunch, and $50 per person for dinner.

(e) **Working Meals** ($5,866.86). Out-of-office working meals are capped at $25 per person for lunch and $50 per person for dinner; in-office working meals are capped at $25 per person for lunch and $40 per person for dinner.

152. The amount requested for Lead Counsel's expenses, $4,898,136.90, is below the $5 million that Class Members were advised could be sought in the Postcard Notice and Settlement Notice. To date, no objection has been raised as to the maximum amount of expenses set forth in the notice.

153. Copies of the (i) proposed Judgment Approving Class Action Settlement, (ii) proposed Order Approving Plan of Allocation of Net Settlement Fund, and (iii) proposed Order Awarding Attorneys' Fees and Litigation Expenses are attached hereto as Exhibits 13, 14, and 15, respectively, and will be submitted to the Court's email in Word format. Attached as Exhibit 16 is a compendium of true and correct copies of the unpublished opinions and authority cited in the Fee and Expense Motion.

VI. CONCLUSION

154. For all the reasons set forth above, Lead Plaintiff and Lead Counsel respectfully submit that the Settlement and the Plan of Allocation should be approved as fair, reasonable, and adequate. Lead Counsel further submits that the requested fee in the amount of 22% of the Settlement Fund should be approved as fair and reasonable, and its request for Litigation Expenses in the amount of $4,898,136.90, should also be approved.

I declare, under penalty of perjury, that the foregoing is true and correct. Executed on September 10, 2026.

/s/ Jonathan D. Uslaner
Jonathan D. Uslaner

Exhibit 1

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
JONATHAN D. USLANER (Bar No. 256898)
jonathanu@blbglaw.com
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Counsel for Lead Plaintiff Indiana Public Retirement System and Lead Counsel for the Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357 **DECLARATION OF JEFFREY M. GILL, GENERAL COUNSEL OF INDIANA PUBLIC RETIREMENT SYSTEM, IN SUPPORT OF (I) LEAD PLAINTIFF'S MOTION FOR FINAL APPROVAL OF SETTLEMENT AND PLAN OF ALLOCATION; AND (II) LEAD COUNSEL'S MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES** Judge: Hon. Jon S. Tigar Courtroom: 6 Date: October 29, 2026 Time: 2:00 p.m.

I, JEFFREY M. GILL, declare as follows:

1. I am the General Counsel of the Indiana Public Retirement System ("Indiana" or "Lead Plaintiff"). I submit this Declaration in support of (a) Lead Plaintiff's motion for final approval of the proposed Settlement and Plan of Allocation, and (b) Lead Counsel's motion for attorneys' fees and Litigation Expenses.[1]

2. I am aware of and understand the requirements and responsibilities of a representative plaintiff in a securities class action, including those set forth in the Private Securities Litigation Reform Act of 1995 ("PSLRA"). I have knowledge of the matters set forth in this Declaration based on my personal knowledge in monitoring and overseeing the prosecution of the Action and the negotiations leading to the Settlement, and I could and would testify competently to these matters.

I. Indiana's Oversight of the Action

3. Indiana is a pension fund operated for the benefit of members and retirees of public universities, schools, municipalities, and state agencies of the State of Indiana. As of June 30, 2025, Indiana had $54.9 billion in assets under management on behalf of over 553,000 members. Indiana purchased ChemoCentryx common stock during the Class Period and suffered damages as a result of the alleged violations of the federal securities laws asserted in the Action.

4. On January 28, 2022, the Court entered an Order appointing Indiana as the Lead Plaintiff in the Action pursuant to the PSLRA, and approved its selection of Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") as Lead Counsel. On March 6, 2024, the Court entered an Order certifying the Action to proceed as a class action and appointed Indiana as the Class Representative for the Class.

5. Indiana has closely supervised, carefully monitored, and been actively involved in all material aspects of the prosecution and resolution of the Action. Indiana's personnel had numerous communications during the litigation with Lead Counsel BLB&G. I received periodic status reports from BLB&G on case developments and participated in discussions with counsel concerning the

[1] Unless otherwise indicated, capitalized terms shall have their meaning as defined in the Revised Stipulation and Agreement of Settlement, dated May 15, 2026 (Dkt. No. 366-1).

prosecution of the Action, the strengths of and risks to the claims, and potential settlement. Throughout the course of this Action, I:

(a) communicated with BLB&G by email and telephone calls regarding the posture and progress of the case;

(b) reviewed the significant pleadings and briefs filed in this Action, including the Amended Consolidated Class Action Complaint for Violations of Federal Securities Laws ("Complaint"), Lead Plaintiff's opposition to Defendants' motion to dismiss the Complaint, Lead Plaintiff's motion for class certification, Lead Plaintiff's opposition to Defendants' motion for summary judgment, and Lead Plaintiff's opening brief in support of its appeal;

(c) reviewed and commented on the discovery requests served on Lead Plaintiff in this Action;

(d) assisted in searching for and producing documents and electronically stored information in response to Defendants' document requests to Lead Plaintiff;

(e) attended and actively participated in the mediation process and consulted with BLB&G concerning the settlement negotiations as they progressed; and

(f) evaluated and approved the proposed Settlement.

6. In addition, Indiana's Director of Public Equity and Absolute Return, David Stelsel, prepared for and sat for his deposition by Defendants as a Rule 30(b)(6) representative of Indiana on September 28, 2023.

II. Indiana Endorses Approval of the Settlement

7. Based on its involvement throughout the prosecution and resolution of the Action, Indiana believes that the proposed Settlement is fair, reasonable, and adequate to the Class. Indiana believes that the Settlement represents a favorable recovery for the Class, in light of the significant risks of continuing to prosecute the claims in this case, including the risks of prevailing on the appeal and in establishing liability and proving damages on any remand. Therefore, Indiana endorses approval of the Settlement by the Court.

III. Indiana Approves of and Supports Lead Counsel's Motion for Attorneys' Fees and Litigation Expenses

8. Indiana also supports Lead Counsel's request for attorneys' fees and reimbursement of litigation expenses. Indiana takes seriously its role as a Lead Plaintiff to ensure that the attorneys' fees are fair in light of the result achieved for the Class and reasonably compensate Lead Counsel for the work involved and the substantial risks it undertook in litigating the Action. Indiana negotiated and entered into a retention agreement with BLB&G in July 2021, at the outset of the litigation, providing for different levels of percentage fees based on the state of litigation at which settlement was reached. Following the agreement to settle the Action, Indiana has again reviewed the proposed fee and believes it is fair and reasonable in light of the result obtained for the Class, the excellent work performed by Lead Counsel, and the significant risks undertaken by counsel in this Action.

9. Indiana further believes that Lead Counsel's Litigation Expenses are reasonable and represent costs and expenses necessary for the prosecution and resolution of the claims in the Action. Based on the foregoing, and consistent with its obligation to the class to obtain the best result at the most efficient cost, Indiana fully supports Lead Counsel's motion for attorneys' fees and Litigation Expenses.

IV. Conclusion

10. In conclusion, Indiana was actively involved throughout the prosecution and settlement of the Action. Indiana endorses the Settlement as fair, reasonable, and adequate, and believes that the Settlement represents a favorable recovery for the Class in light of the risks of continued litigation. Indiana further supports Lead Counsel's motion for attorneys' fees and Litigation Expenses and believes that it represents fair and reasonable compensation for counsel in light of the recovery obtained for the Class, the substantial work conducted, and the litigation risks. Accordingly, Indiana respectfully requests that the Court approve (i) Lead Plaintiff's motion for final approval of the proposed Settlement and Plan of Allocation; and (ii) Lead Counsel's motion for attorneys' fees and Litigation Expenses.

I declare under penalty of perjury that the foregoing is true and correct, to the best of my knowledge and belief, and that I have authority to execute this Declaration on behalf of Indiana.

Executed this 31 day of August, 2026.

Signed by:

Jeffrey M. Gill

296FE2138E584D2...

JEFFREY M. GILL

Exhibit 2

2025 REVIEW & ANALYSIS

Securities Class Action Settlements

REVIEW & ANALYSIS

CORNERSTONE RESEARCH

Economic and Financial Consulting and Expert Testimony

Table of Contents

Figures and Appendices

2025 Highlights

While the number of securities class action settlements declined 16% from 2024, the median settlement amount grew by 20%, driven by an increase in settlement sizes for cases with only Securities Act of 1933 ('33 Act) claims.

In 2025, there were 74 securities class action settlements totaling $3.0 billion, compared to 88 settlements totaling $3.8 billion in 2024. (page 3)

The median settlement amount of $17.3 million was the highest since 1997. For cases with only '33 Act claims, the median settlement amount more than tripled year-over-year to a historic high of $32.5 million. Excluding cases with only '33 Act claims, the median settlement amount increased 11% from 2024 to $16.0 million. (page 5)

The average settlement amount ($40.6 million) decreased 7% from 2024, which reflects in part mega settlements (of $100 million or greater) that were smaller compared to those in recent years. (page 5)

Median plaintiff-style damages for cases with Section 10(b) claims[1] were flat year-over-year.[2] (page 6)

Median statutory damages for cases with only '33 Act claims declined 19%. (page 8)

Defendant firms involved in 2025 settlements were 9% smaller, as measured by median total assets, reflecting an eight-year low. (page 6)

The median "time to settle" (duration of case from filing to settlement hearing) of 3.5 years continues to be historically elevated, in line with the median in 2023–2024 (3.4 years). (page 13)

Health Care and Financials/Real Estate have historically been the industry sectors with the largest share of settlement dollars. However, in 2025, settlement dollars for these sectors declined to 10-year lows. (page 4)

Figure 1: Settlement Statistics
(Dollars in millions)

	2016–2024	2024	2025
Number of Settlements	752	88	74
Total Amount	$38,135.6	$3,833.8	$3,006.5
Minimum	$0.4	$0.6	$0.3
Median	$12.1	$14.4	$17.3
Average	$50.7	$43.6	$40.6
Maximum	$3,849.7	$503.3	$433.5

Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented.

Author Commentary

FINDINGS

Securities class action settlement activity declined in 2025 as measured by the 16% drop in the number of settled cases. Aggregate settlement dollars were also lower, reflecting in part mega settlements that were significantly smaller compared to prior years.

The median settlement amount, however, reached a historic high, even though median plaintiff-style damages—a proxy for the amount of potential investor losses that plaintiffs may claim in a securities class action with Rule 10b-5 claims—remained essentially unchanged from 2024.

The higher median settlement amount in 2025 is attributable in part to larger settlements for cases with only ’33 Act claims. The median settlement amount for cases with only ’33 Act claims surged to a historic high of $32.5 million in 2025, despite a decrease in median statutory damages. One factor that may explain these larger settlements is that these cases may have been unusually complex; the median number of docket entries—a proxy for the time and effort expended by the litigants and/or case complexity—was at an all-time high.

Eric Tam, Principal at Cornerstone Research

“The shift of settlement dollars from the Health Care and Financials/Real Estate sectors to the Communication Services/Information Technology sectors in recent years may reflect changes in case filing trends.”

Only nine settlements (12%) were related to special purpose acquisition companies (SPACs), down from 17 such settlements (19%) in 2024.

Laarni T. Bulan, Vice President at Cornerstone Research

“Median plaintiff-style damages stayed flat as the median size (measured by total assets) of issuer defendants declined 9% from 2024. In contrast, the median settlement amount reached the highest level since 1997, due in part to larger ’33 Act only settlements.”

For the second year in a row, the median ($11.0 million) and average ($31.4 million) settlement amounts for SPAC cases were substantially smaller than the corresponding amounts for non-SPAC cases. The smaller number of SPAC-related settlements may also have contributed to the higher median settlement amount in 2025.

Longer-term settlement trends are potentially evolving across industry sectors. While the Health Care and Financials/Real Estate sectors had the largest aggregate settlement dollars and number of mega settlements during 2016–2020, the Communication Services/Information Technology sectors took the lead in the most recent five-year period.

LOOKING AHEAD

The lower number of settled cases compared to prior years may continue given the relatively stable number of securities case filings in the first half of this decade. In addition, COVID-19-related cases, while comprising a large percentage of filings in 2022–2023, have been dismissed at a high rate.[3] On the other hand, several large settlements pending court approval may boost aggregate settlement dollars in 2026.

Total Settlement Dollars

In 2025, total settlement dollars declined by 22%, consistent with a 16% decline in the number of settled cases from the prior year.

Mega settlements (of $100 million or greater) that were smaller compared to those in recent years also contributed to the lower total settlement dollars. While the number of mega settlements (eight) increased by one from 2024, the average mega settlement in 2025 was $200 million, down 33% from the prior year.

−22%

Change in total settlement dollars from 2024 to 2025

−16%

Change in number of settled cases from 2024 to 2025

Figure 2: Total Settlement Dollars
2016–2025
(Dollars in billions)



Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. “N” refers to the number of settlements.

Figure 3: Mega Settlements
(Dollars in millions)

Year	Number of Mega Settlements	Number of Mega Settlements as a Percentage of All Settlements	Total Mega Settlement Dollars as a Percentage of All Settlement Dollars	Median Mega Settlement	Average Mega Settlement
2016–2024	56	7%	65%	$214	$441
2024	7	8%	54%	$205	$298
2025	8	11%	53%	$144	$200

Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. Mega settlements are defined as total settlement funds of $100 million or greater before adjusting for inflation.

Industry Sectors

Consistent with case filing trends, Health Care and Financials/Real Estate represent the industry sectors with the largest share of settlement dollars over the last 10 years (2016–2025).[4] However, total settlement dollars in the Health Care and Financials/Real Estate sectors in 2025 declined by 56% and 37%, respectively, year-over-year and reached their lowest levels in the past 10 years.

For the fourth time in the past five years, settlement dollars in the Communication Services/Information Technology sectors were greater than any other industry sector.

See Appendix 1 for additional analysis of settlements by industry sectors.

Figure 4: Total Settlement Dollars by Year and Industry Sectors
2016–2025
(Dollars in Millions)

Year	Communication Services/ Information Technology	Consumer Discretionary	Consumer Staples	Energy/ Materials	Financials/ Real Estate	Health Care	Industrials	Utilities
2016	$239	$712	$63	$422	$3,192	$2,903	$29	$2
2017	$134	$206	$4	$429	$434	$614	$106	$4
2018	$572	$246	$54	$3,863	$1,129	$437	$117	$81
2019	$135	$802	$247	$611	$167	$504	$164	$0
2020	$609	$469	$77	$112	$1,432	$1,940	$333	$240
2021	$715	$32	$65	$164	$212	$574	$229	$120
2022	$1,318	$621	$259	$175	$188	$1,169	$466	$7
2023	$453	$278	$504	$202	$1,663	$735	$134	$183
2024	$1,281	$570	$225	$224	$164	$853	$517	$0
2025	$705	$664	$121	$502	$104	$377	$511	$23
2016–2025	$6,162	$4,599	$1,621	$6,703	$8,683	$10,107	$2,607	$661

$0–$249 | $250–$749 | $750–$1,499 | $1,500+

Note: Industry sectors are based on the Global Industry Classification Standard (GICS). Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented.

Figure 5: Number of Settlements by Year and Industry Sectors
2016–2025

Year	Communication Services/ Information Technology	Consumer Discretionary	Consumer Staples	Energy/ Materials	Financials/ Real Estate	Health Care	Industrials	Utilities
2016	18	12	1	11	10	26	5	1
2017	16	10	2	10	14	14	11	1
2018	23	8	3	2	8	24	8	2
2019	10	13	4	5	10	22	10	0
2020	14	10	4	6	7	24	10	1
2021	23	5	3	10	8	26	8	3
2022	18	16	5	7	10	30	18	1
2023	16	8	4	10	12	22	10	1
2024	19	9	5	11	12	21	11	0
2025	19	10	4	6	7	19	8	1
2016–2025	176	101	35	78	98	228	99	11

0–4 | 5–14 | 15–24 | 25+

Note: Industry sectors are based on the Global Industry Classification Standard (GICS).

Settlement Size

The median settlement amount in 2025 was $17.3 million, a 20% increase from 2024 and the highest since 1997.

Settlements in the $10 million to $50 million range accounted for 43% of settlements in 2025.

The average settlement amount of $40.6 million declined 7% from 2024, reflecting in part the smaller mega settlements in 2025.

The proportion of settlements involving issuers that had been delisted from a major exchange and/or declared bankruptcy prior to settlement increased from 15% in 2024 to 23% in 2025. The number of settled cases related to SPACs declined nearly 50% from 2024 to nine such cases in 2025. The median and average settlement amounts for these cases were $11.0 million and $31.4 million, respectively, compared to $19.5 million and $41.9 million for non-SPAC cases in 2025.

See Appendix 2 for a distribution of settlement amounts.

Figure 6: Proportion of Settled Cases by Settlement Dollar Range
2025
(Dollars in millions)



Note: Percentages indicate the proportion of settled cases in the given settlement dollar range. Percentages may not sum to 100% due to rounding.

Type of Claim and Potential Investor Losses

RULE 10B-5 CLAIMS AND PLAINTIFF-STYLE DAMAGES

For cases with Rule 10b-5 claims, Cornerstone Research's analysis finds a proxy for potential investor losses—referred to here as plaintiff-style damages—to be the most important determinant of settlement outcomes based on regression analysis. However, plaintiff-style damages do not represent actual economic losses borne by shareholders. Determining any such economic losses for a given case requires more in-depth analysis.

–0.6%

Change in median plaintiff-style damages from 2024 to 2025

$16.0 million

Median settlement for cases with Rule 10b-5 claims in 2025

In 2025, median plaintiff-style damages were essentially unchanged year-over-year and remained at the elevated levels observed in recent years.

Median total assets of issuer defendants decreased 9% from 2024 to an eight-year low.

Figure 7: Median and Average Plaintiff-Style Damages
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)



Note: Plaintiff-style damages are adjusted for inflation based on class period end dates and are estimated for common stock/ADR/ADS only; 2025 dollar equivalent figures are presented. Plaintiff-style damages are estimated for cases that allege a claim under Rule 10b-5 (whether alone or in addition to other claims).

Larger cases, as measured by plaintiff-style damages, typically settle for a smaller percentage of those damages.

In 2025, nearly 40% of settlements were in the Ninth Circuit, the highest percentage since 1999. The median settlement as a percentage of plaintiff-style damages (4.7%) was the lowest ever observed for Ninth Circuit settlements.

For the second year in a row, the Second Circuit comprised 23% of settlements in 2025, below the prior nine-year average (2016–2024) of 28%. The median settlement as a percentage of plaintiff-style damages (11.9%) was the highest observed in the Second Circuit since 2019.

The median settlement as a percentage of plaintiff-style damages for issuers in the Financials/Real Estate industry sector was 9.9% over the past 10 years, higher than the median of 6.8% for issuers in all other industry sectors.

In 2025, the median settlement as a percentage of plaintiff-style damages was 6.5%—a decrease from 2024 (7.0%) and lower than the 2016–2024 median (7.3%).

See Appendix 3 and Appendix 4 for more information on settlements as a percentage of plaintiff-style damages and settlement statistics by federal circuit court, respectively.

Figure 8: Median Settlement as a Percentage of Plaintiff-Style Damages by Damages Ranges
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)



Note: Plaintiff-style damages are adjusted for inflation based on class period end dates and are estimated for common stock/ADR/ADS only; 2025 dollar equivalent figures are presented. Plaintiff-style damages are estimated for cases that allege a claim under Rule 10b-5 (whether alone or in addition to other claims).

’33 ACT CLAIMS AND STATUTORY DAMAGES

For cases with only ’33 Act claims—those involving Section 11 and/or Section 12(a)(2) claims and no Rule 10b-5 claims—potential investor losses (referred to here as “statutory damages”) are estimated based on the difference between the statutory purchase and sales prices for those shares that are assumed to be traceable to the registration statement at issue.[5]

There were nine settlements with only ’33 Act claims in 2025, of which six cases involved an initial public offering (IPO).

-19%

Change in median statutory damages from 2024 to 2025

$32.5 million

Median settlement for cases with only ’33 Act claims in 2025

The median settlement amount for cases with only ’33 Act claims ($32.5 million) reached an all-time high in 2025 and was 3.1 times the median for the prior nine years.

Figure 9: Median and Average Statutory Damages
2016–2025, Settlements with Only ’33 Act Claims
(Dollars in millions)



Note: Statutory damages are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis excludes cases that allege Rule 10b-5 claims.

In 2025, the median settlement as a percentage of statutory damages (12.9%) reached its highest level since 2018.

Similarly, the median number of docket entries for cases with only '33 Act claims reached an all-time high in 2025. This is consistent with the historically high median settlement and the increase in median settlement as a percentage of statutory damages for these cases. Cornerstone Research's analysis finds that the number of docket entries—a proxy for the time and effort expended by the litigants and/or case complexity—is positively associated with settlement amounts.

See Appendix 5 and Appendix 6 for additional information on statutory damages and settlement as a percentage of statutory damages, respectively.

12.9%

Median settlement as a percentage of statutory damages in 2025

206

Median number of docket entries for cases with only '33 Act claims in 2025

Figure 10: Median Settlement Amount and Settlement as a Percentage of Statutory Damages
2016–2025, Settlements with Only '33 Act Claims
(Dollars in millions)



Note: "N" refers to the number of cases. Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis excludes cases that allege Rule 10b-5 claims.

Analysis of Settlement Characteristics

GAAP VIOLATIONS

This analysis examines allegations of GAAP violations in settlements of securities class actions with Rule 10b-5 claims, including two subcategories of GAAP violations—financial restatements and accounting irregularities.[6]

The percentages of settled cases involving GAAP violations generally and financial restatements specifically have declined substantially in the past five years (2021–2025) compared to the prior five years (2016–2020).

While cases with accounting irregularities comprised only a small proportion of total settled cases between 2016 and 2025, the median settlement amount for cases with Rule 10b-5 claims involving accounting irregularities was $32 million, significantly higher than the $13 million median for cases without such allegations.

For additional details regarding securities class action settlements that involve accounting allegations, see Cornerstone Research's forthcoming annual report on *Accounting Class Action Filings and Settlements*.[7]

Figure 11: Percentage of Settled Cases Involving Accounting Allegations

	2016–2020	2021–2025
GAAP Violations	50%	37%
Financial Restatements	24%	14%
Accounting Irregularities	3%	1%
Auditor Codefendant	7%	3%

Note: This analysis is limited to cases that allege Rule 10b-5 claims (whether alone or in addition to other claims).

DERIVATIVE ACTIONS

Securities class actions often involve an accompanying (parallel) derivative action with similar claims, and all else being equal, such cases have historically settled for higher amounts than securities class actions without an accompanying derivative matter.[8]

In 2025, the median settlement for cases with an accompanying derivative action declined by 16% from the 2024 median.

For more information on settlement outcomes of the accompanying derivative actions, see Cornerstone Research's *Parallel Derivative Action Settlement Outcomes*.[9]

49%

Percentage of 2025 cases involving an accompanying derivative action

$16.0 million

Median settlement for 2025 cases involving an accompanying derivative action

Figure 12: Median Settlement Amount for Cases with an Accompanying Derivative Action
2016–2025
(Dollars in millions)

Year	With Accompanying Derivative Action	Without Accompanying Derivative Action	Percentage of Cases with Accompanying Derivative Action
2016	$16.1	$11.4	41.7%
2017	$5.9	$8.2	47.4%
2018	$23.8	$7.7	51.3%
2019	$12.3	$17.6	54.1%
2020	$19.3	$10.6	53.9%
2021	$10.0	$8.9	41.9%
2022	$15.5	$12.1	44.8%
2023	$20.6	$13.2	41.0%
2024	$19.1	$10.4	52.3%
2025	$16.0	$19.8	48.6%
2016–2025	**$15.1**	**$11.0**	**47.5%**

Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented.

INSTITUTIONAL INVESTORS

Institutional investors are often involved as lead or co-lead plaintiff in larger cases,[10] that is, cases with higher plaintiff-style damages and higher issuer defendant total assets.

In 2025, settlements involving an institutional investor as lead or co-lead plaintiff had median plaintiff-style damages and median total assets that were 4.1 times and 5.6 times higher, respectively, than the median values for cases without an institutional investor in that role.

Similarly, the median settlement amount for cases with an institutional investor lead or co-lead plaintiff was 4.8 times higher than for cases without such participation.

Figure 13: Median Statistics by Institutional Investor Participation as Lead or Co-Lead Plaintiff
2025
(Dollars in millions)

	With an Institutional Investor	Without an Institutional Investor
Settlement Amount	$38	$8
Plaintiff-Style Damages	$669	$164
Settlement Amount as a Percentage of Plaintiff-Style Damages	6.6%	6.3%
Issuer Defendant Total Assets	$3,303	$594
Percentage of Settlements	45%	55%

Note: Plaintiff-style damages are estimated for cases that allege Rule 10b-5 claims (whether alone or in addition to other claims) and are adjusted for inflation based on class period end dates; 2025 dollar equivalent figures are presented.

Figure 14: Median Settlement Amount by Institutional Investor Participation as Lead or Co-Lead Plaintiff
2016–2025
(Dollars in millions)



Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented.

Time to Settlement and Case Complexity

The median duration from case filing to settlement hearing was 3.5 years, which increased nearly 10% from the median time to settle in 2024 (3.2 years) and was slightly below the peak over the last decade observed in 2023 (3.7 years). The median time to settle in 2025 was the second-longest duration in the last decade.

This finding is consistent with heightened case activity among 2025 settled cases, as measured by the number of docket entries—a proxy for the time and effort expended by the litigants and/or case complexity. In 2025, the median number of docket entries was at its highest level since 2010.

3.5 years

2025 median time to settlement

150

Median number of docket entries for 2025 cases

Figure 15: Median Settlement Amount and Settlement as a Percentage of Plaintiff-Style Damages by Duration from Filing Date to Settlement Hearing Date
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)



Note: "N" refers to the number of cases. Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis is limited to cases that allege Rule 10b-5 claims (whether alone or in addition to other claims).

Case Stage at the Time of Settlement

In 2025, 8% of cases settled prior to the filing of a motion to dismiss (MTD), up from 2% in 2024 and equal to the 2016–2024 average.

Moreover, 54% of settlements occurred prior to the filing of a motion for class certification (MCC), up from 48% in 2024 and equal to the 2016–2024 average. Cases that settled after the filing of a MCC were twice as likely to have an institutional investor serving as lead or co-lead plaintiff than cases that settled prior to the filing of a MCC.

In the 10-year period from 2016 to 2025, median plaintiff-style damages for cases that settled after the filing of a motion for summary judgment (MSJ) was over six times the median for cases that settled before a MSJ filing.

Figure 16: Median Settlement Amount and Stage of Litigation at Time of Settlement
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)



Note: "N" refers to the number of cases. Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. MTD refers to "motion to dismiss," MCC refers to "motion for class certification," and MSJ refers to "motion for summary judgment." This analysis is limited to cases that allege Rule 10b-5 claims (whether alone or in addition to other claims).

Figure 17: Median Statistics for Cases that Settled Prior to and After MCC Filing
2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)

	Settled Prior to MCC Filing	Settled After MCC Filing
Settlement Amount	$6	$38
Plaintiff-Style Damages	$94	$490
Settlement Amount as a Percentage of Plaintiff-Style Damages	5.3%	7.1%
Total Assets	$599	$6,069
Percentage of Settlements	58%	42%

Note: MCC refers to "motion for class certification." Plaintiff-style damages are estimated for cases that allege Rule 10b-5 claims (whether alone or in addition to other claims) and are adjusted for inflation based on class period end dates; 2025 dollar equivalent figures are presented.

Cornerstone Research's Settlement Analysis

This research examines the relationship between settlement outcomes and certain securities case characteristics. Regression analysis is employed to better understand the factors that inform case settlements given the characteristics of a particular securities class action.

DETERMINANTS OF SETTLEMENT OUTCOMES

Based on regression analysis, important determinants of settlement amounts include the following:

- Plaintiff-style damages
- The most recently reported total assets prior to the settlement hearing date for the defendant issuer
- Whether there were accounting irregularities
- Whether there were criminal charges against the issuer, officers, directors, or other defendants with allegations similar to those included in the underlying class action complaint
- Whether there was a derivative action with allegations similar to those included in the underlying class action complaint
- Whether, in addition to Rule 10b-5 claims, Section 11 claims were alleged and not dismissed prior to settlement
- Whether the issuer had been delisted from a major exchange and/or had declared bankruptcy
- Whether an institutional investor acted as lead or co-lead plaintiff
- Whether securities other than common stock/ADR/ADS were included in the alleged class

Cornerstone Research analyses show that, all else being equal, settlement amounts tended to be higher in cases involving larger plaintiff-style damages, greater issuer defendant total assets, or cases in which Section 11 claims were alleged in addition to Rule 10b-5 claims.

Settlement amounts also tended to be higher in cases that involved accounting irregularities, criminal charges, an accompanying derivative action, an institutional investor lead or co-lead plaintiff, or with securities in addition to common stock/ADR/ADS included in the alleged class.

Settlement amounts tended to be lower if the issuer had been delisted from a major exchange and/or had declared bankruptcy.

Collectively, the factors above explain approximately 75% of the variation in settlement outcomes.

Research Sample

The database compiled for this report is limited to cases that allege Rule 10b-5, Section 11, and/or Section 12(a)(2) claims brought by purchasers of a corporation's common stock.

Cases with alleged classes of only bondholders, preferred stockholders, etc.; cases that allege fraudulent deflation in price; and mergers and acquisitions cases are excluded. These criteria are imposed to ensure data availability and to utilize a relatively homogeneous set of cases in terms of the nature of the allegations.

The database includes over 2,340 securities class actions filed after passage of the Reform Act (1995) and settled from 1996 through 2025. These securities class actions correspond to approximately $155.5 billion in total settlement dollars, adjusted for inflation and expressed in 2025 dollars. These settlements are identified based on a review of case activity collected by Securities Class Action Services LLC (SCAS).[11]

The designated settlement year, for purposes of this report, corresponds to the year in which the hearing to approve the settlement was held.[12] Cases involving multiple settlements are reflected in the year of the most recent partial settlement, provided certain conditions are met.[13]

In addition to SCAS, data sources include Bloomberg, the Center for Research in Security Prices (CRSP) at the University of Chicago Booth School of Business, LSEG Workspace, court filings and dockets, SEC registrant filings, SEC litigation releases and administrative proceedings, LexisNexis, Stanford Securities Litigation Analytics (SSLA), and public press.

Endnotes

[1] For purposes of the settlement research and modeling, this report utilizes a measure of potential investor losses that allows for consistency across a large volume of cases, thus enabling the identification and analysis of potential trends. This measure, "settlement model plaintiff-style damages" ("plaintiff-style damages" as referred to in this report), is estimated using a methodology that more closely aligns with approaches used by plaintiffs in the current securities class action litigation environment. For example, when estimating the number of shares eligible for damages, the plaintiff-style damages approach adjusts for short interest positions and shares estimated to be held by institutional investors throughout the entire class period.

[2] Plaintiff-style damages are calculated for cases that settled in 2014 or later, and account for the U.S. Supreme Court's 2005 landmark decision in *Dura Pharmaceuticals Inc. v. Broudo*, 544 U.S. 336. Plaintiff-style damages are based on the stock-price movements associated with the alleged disclosure dates that are described in the settlement plan of allocation.

[3] *Securities Class Action Filings—2025 Year in Review*, Cornerstone Research (2026).

[4] *Securities Class Action Filings—2025 Year in Review*, Cornerstone Research (2026).

[5] Statutory damages are estimated using an approach that more closely aligns with approaches used by plaintiffs in the current securities class action litigation environment. For example, when estimating the number of shares eligible for damages, the statutory damages approach adjusts for short interest positions. Statutory damages are calculated using data through the settlement hearing date.

[6] The two subcategories of accounting issues analyzed in this report are (1) financial restatements—cases involving a restatement (or announcement of a restatement) of financial statements, and (2) accounting irregularities—cases in which the defendant has reported the occurrence of accounting irregularities (intentional misstatements or omissions) in its financial statements.

[7] *Accounting Class Action Filings and Settlements—2025 Review and Analysis*, Cornerstone Research, forthcoming in spring 2026.

[8] To be considered an accompanying (parallel) derivative action, the derivative action must have underlying allegations that are similar or related to the underlying allegations of the securities class action and either be active or settling at the same time as the securities class action.

[9] *Parallel Derivative Action Settlements Update: August 2025*, Cornerstone Research (2025).

[10] As discussed in prior reports, increasing institutional investor participation as lead plaintiff in securities litigation was a focus of the Private Securities Litigation Reform Act of 1995 (Reform Act). In the years following passage of the Reform Act, institutional investor involvement as lead plaintiff did increase, particularly in cases with higher plaintiff-style damages.

[11] Available on a subscription basis. For further details, see https://www.issgovernance.com/securities-class-action-services/.

[12] Movements of partial settlements between years can cause settlement amounts reported for prior years to differ from those presented in earlier reports.

[13] This categorization is based on the timing of the settlement hearing date. If a new partial settlement equals or exceeds 50% of the then-current settlement fund amount, the entirety of the settlement amount is recategorized to reflect the settlement hearing date of the most recent partial settlement. If a subsequent partial settlement is less than 50% of the then-current total, the partial settlement is added to the total settlement amount and the settlement hearing date is left unchanged.

Appendices

Appendix 1: Settlements by Industry Sectors
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)

Industry	Number of Settlements	Median Settlement	Median Plaintiff-Style Damages	Median Settlement as a Percentage of Plaintiff-Style Damages
Consumer Services/ Information Technology	142	$10.1	$242.4	6.4%
Consumer Discretionary	92	$14.1	$278.0	6.9%
Consumer Staples	28	$14.9	$361.0	6.0%
Energy/Materials	70	$17.3	$281.1	8.4%
Financials/Real Estate	90	$19.3	$252.5	9.9%
Health Care	209	$12.1	$226.7	6.7%
Industrials	87	$8.7	$180.6	6.6%
Utilities	10	$15.4	$147.4	9.4%

Note: Settlement dollars and plaintiff-style damages are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis is limited to cases that allege Rule 10b-5 claims (whether alone or in addition to other claims). Industry sectors are based on the Global Industry Classification Standard (GICS).

Appendix 2: Distribution of Settlements Amounts
2016–2025
(Dollars in millions)



Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. Percentages may not sum to 100% due to rounding.

Appendix 3: Median and Average Settlements as a Percentage of Plaintiff-Style Damages
2016–2025, Settlements with Rule 10b-5 Claims



Note: Plaintiff-style damages are calculated for cases that allege Rule 10b-5 claims (whether alone or in addition to other claims).

Appendix 4: Settlement Statistics by Federal Circuit Court
2016–2025, Settlements with Rule 10b-5 Claims
(Dollars in millions)

Circuit	Number of Settlements	Median Settlement	Median Settlement as a Percentage of Plaintiff-Style Damages
First	21	$23.2	4.1%
Second	203	$9.8	7.7%
Third	90	$9.2	7.0%
Fourth	24	$30.3	4.6%
Fifth	40	$13.8	5.6%
Sixth	32	$18.1	9.7%
Seventh	38	$20.1	6.7%
Eighth	12	$51.1	5.6%
Ninth	205	$11.0	7.0%
Tenth	23	$20.0	10.1%
Eleventh	36	$12.7	7.8%
DC	4	$29.5	4.8%

Note: Settlement dollars are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis is limited to cases that allege Rule 10b-5 claims (whether alone or in addition to other claims).

Appendix 5: Median Settlement as a Percentage of Statutory Damages by Damages Ranges
2016–2025, Settlements with Only ’33 Act Claims
(Dollars in millions)



Note: “N” refers to the number of cases. Statutory damages are adjusted for inflation; 2025 dollar equivalent figures are presented. This analysis excludes cases that allege Rule 10b-5 claims.

Appendix 6: Median and Average Settlement as a Percentage of Statutory Damages
2016–2025, Settlements with Only ’33 Act Claims



Note: This analysis excludes cases that allege Rule 10b-5 claims.

Appendix 7: Settlements by Nature of Claim
2016–2025

	Number of Settlements	Median Settlement	Median Statutory Damages	Median Settlement as a Percentage of Statutory Damages
'33 Act Only	98	$10.8	$155.9	7.8%

	Number of Settlements	Median Settlement	Median Plaintiff-Style Damages	Median Settlement as a Percentage of Plaintiff-Style Damages
Both Rule 10b-5 and '33 Act Claims	123	$16.7	$244.7	10.8%
Rule 10b-5 Only	605	$12.3	$236.3	6.8%

Note: Settlement dollars and damages are adjusted for inflation; 2025 dollar equivalent figures are presented.

About the Authors

Laarni T. Bulan
Vice President, Cornerstone Research

Laarni Bulan has over 14 years of experience consulting on complex litigation involving economic and financial issues. Dr. Bulan specializes in securities, mergers and acquisitions and other corporate transactions, firm valuation, risk management, executive compensation, and corporate governance matters.

Dr. Bulan serves as co-head of the firm's corporate governance practice. She is a member of the Advisory Board of the Institute for Law and Economics, University of Pennsylvania Carey Law School.

Dr. Bulan has published numerous articles in peer-reviewed journals, including *Financial Management*, the *Journal of Banking and Finance*, the *Journal of Economics and Business*, and the *Journal of Urban Economics*. Her research covers dividend policy, capital structure, executive compensation, corporate governance, and real options. Prior to joining Cornerstone Research, Dr. Bulan held a joint appointment at Brandeis University, where she served as an assistant professor of finance in the International Business School and also in the economics department.

Eric Tam
Principal, Cornerstone Research

Eric Tam specializes in securities litigation. Mr. Tam has more than 20 years of experience consulting to clients and addressing financial economics issues and class actions in federal and state courts, including the Delaware Court of Chancery. His experience spans all stages of the litigation process, including exposure analysis, class certification, expert support, summary judgment filings, mediation and settlement analysis, trial preparation, and regulatory proceedings.

Mr. Tam has extensive expertise with securities litigation involving alleged misrepresentations under Section 10(b) of the Exchange Act and Sections 11 and 12 of the Securities Act. He also addresses allegations of market manipulation under Sections 9 and 10(b) of the Exchange Act and claims under Section 14(a) of the Exchange Act.

Mr. Tam has analyzed class certification issues (market efficiency, price impact, and evaluation of damages methodologies in the context of *Comcast* standards), as well as loss causation, damages, and materiality in numerous securities class actions.

CORNERSTONE RESEARCH
Economic and Financial Consulting and Expert Testimony

The authors request that you reference Cornerstone Research in any reprint of the information or figures included in this report.

Please direct any questions to:

Laarni Bulan
617-927-3093
lbulan@cornerstone.com

Eric Tam
650-470-7071
etam@cornerstone.com

Cornerstone Research

Cornerstone Research provides economic and financial consulting and expert testimony in all phases of complex disputes and regulatory investigations. The firm works with an extensive network of prominent academics and industry practitioners to identify the best-qualified expert for each assignment. With a reputation for high quality and effectiveness, Cornerstone Research has consistently delivered rigorous, state-of-the-art analysis since 1989. The firm has more than 1,000 professionals in nine offices across the United States, UK, and EU.

www.cornerstone.com

Exhibit 3

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
(jonathanu@blbglaw.com)
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Salvatore J. Graziano (admitted *pro hac vice*)
(salvatore@blbglaw.com)
Katherine M. Sinderson (admitted *pro hac vice*)
(katiem@blbglaw.com)
John Esmay (admitted *pro hac vice*)
(john.esmay@blbglaw.com)
1251 Avenue of the Americas
New York, NY 10020
Tel: 212-554-1400
Fax: 212-554-1444

Counsel for Lead Plaintiff Indiana Public Retirement System and Lead Counsel for the Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357 **DECLARATION OF LINDSEY MARQUEZ REGARDING MAILING, POSTING, AND PUBLICATION OF SETTLEMENT NOTICE**

I, LINDSEY MARQUEZ, declare as follows:

1. I am a Director of Kroll Settlement Administration LLC ("Kroll"),[1] the Claims Administrator appointed in the above-captioned case, whose principal office is located at One World Trade Center, 285 Fulton Street, 31st Floor, New York, New York 10007. I am over 21 years of age and am authorized to make this declaration on behalf of Kroll and myself. The following statements are based on my personal knowledge and information provided by other experienced Kroll employees working under my general supervision.

2. I submit this declaration in order to provide the Court and the Parties with information regarding the dissemination of notice pursuant to the Preliminary Approval Order, including but not limited to: (a) dissemination of the Postcard Notice; (b) dissemination of the Settlement Notice and Claim Form (together, the "Settlement Notice Packet") to brokers and other nominees ("Nominees"); (c) publication of the Summary Settlement Notice; and (d) posting of the Summary Settlement Notice on the case website.

DISSEMINATION OF POSTCARD NOTICE AND SETTLEMENT NOTICE PACKET

3. Pursuant to the Preliminary Approval Order, on July 6, 2026, Kroll caused the mailing of 33,758 Postcard Notices via first-class mail to potential Class Members. A true and correct copy of the Postcard Notice is attached hereto as **Exhibit A**. This mailing included the forty-five (45) potential Class Members previously provided to Kroll on or about October 30, 2024, by ChemoCentryx's transfer agent, as well as the 3,413 to all other potential Class Members who were previously sent Class Notice and 30,300 Postcard Notices in bulk to nominees who previously requested settlement notice in bulk to forward directly to their customers.

4. In an effort to ensure that Postcard Notices would be deliverable to the foregoing potential Class Members, Kroll ran the foregoing records through the United States Postal Services'

[1] Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Revised Stipulation and Agreement of Settlement, filed May 15, 2026 (ECF No. 366-1) (the "Stipulation").

National Change of Address ("NCOA") database prior to the mailing and updated the records with address changes received from NCOA.

5. Pursuant to the Preliminary Approval Order, on July 6, 2026, Kroll also caused the Settlement Notice Packet to be mailed to the 1,475 records contained in Kroll's proprietary database of Nominees. A true and correct copy of the Settlement Notice Packet is attached hereto as **Exhibit B**. Also on July 6, 2026, Kroll sent a link to the Settlement Notice Packet to be sent by email to the 547 email records contained in its Nominee Database.

6. On July 6, 2026, Kroll also provided a copy of the Settlement Notice to the Depository Trust Company ("DTC") for posting on its Legal Notice System ("LENS"). The LENS may be accessed by any nominee that is a participant in DTC's security system.

7. Through September 9, 2026, Kroll has mailed or emailed an additional 3,355 Postcard Notices to potential Class Members whose names and mailing or email addresses were received from individuals or nominees requesting that Postcard Notices be mailed to such persons and entities. Kroll has also mailed 40,721 Postcard Notices in bulk to nominees who requested Postcard Notices to forward directly to their customers. Kroll will continue to comply with and address all such requests in a timely manner.

8. Subsequent to the initial mailing of the Postcard Notices, Kroll received fifteen (15) individual requests for a copy of the Settlement Notice Packet to be sent via first-class mail, and sixty-one (61) individual requests for a copy of the Settlement Notice Packet to be sent via email.

9. In summary, through September 9, 2026, a total of 77,834 Postcard Notices and 1,551 Settlement Notice Packets have been mailed or emailed by Kroll or a Nominee to potential Class Members and their nominees.

PUBLICATION OF THE SUMMARY NOTICE

10. Pursuant to the Preliminary Approval Order, Kroll caused the Summary Settlement Notice to be published in *The Wall Street Journal* and released via *PR Newswire* on July 20, 2026. Copies of proof of publication of the Summary Settlement Notice in *The Wall Street Journal* and

over *PR Newswire* are attached hereto as **Exhibit C**. The Summary Settlement Notice released via *PR Newswire* has been available online since its publication on July 20, 2026.

SETTLEMENT WEBSITE

11. On July 6, 2026, Kroll updated the previously established case website, available at www.ChemoCentryxSecuritiesLitigation.com, to include a summary of the Settlement, the deadlines for objecting to the Settlement and for submitting Claim Forms, and details about the Settlement Hearing. Copies of the Settlement Notice and Claim Form, as well as the Stipulation and Preliminary Approval Order are posted on the website and are available for downloading. The website also contains a secure online filing portal that allows Class Members to file a Claim and receive a confirmation that their Claim has been received by the Claims Administrator.

TELEPHONE HELPLINE

12. On July 6, 2026, Kroll updated the previously established case-specific, toll-free telephone helpline, (833) 522-2606, to accommodate potential Class Members with questions about the Settlement. The telephone helpline includes an interactive voice response system which provides callers with the option to be transferred to a live operator during business hours.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct to the best of my knowledge.

Executed in Austin, Texas, on September 10, 2026.

LINDSEY MARQUEZ

Exhibit A

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration LLC
P.O. Box 5013
New York, NY 10150-5013

FIRST-CLASS MAIL
U.S. POSTAGE PAID
CITY, ST
PERMIT NO. XXXX

ELECTRONIC SERVICE REQUESTED

COURT-ORDERED LEGAL NOTICE

Homyk v. ChemoCentryx, Inc.,
Master File No. 4:21-cv-03343-JST (N.D. Cal.)

Your legal rights may be affected by this securities class action. You may be eligible for a cash payment from the Settlement. Please read this Postcard Notice carefully.

For more information, please visit <u>www.ChemoCentryxSecuritiesLitigation.com</u> or call 1-833-522-2606.

<<Refnum Barcode>>

Class Member ID: <<Refnum>>

Postal Service: Please do not mark barcode

<<FirstName>> <<LastName>>
<<Address1>>
<<Address2>>
<<City>>, <<State>> <<Zip>>-<<zip4>>
<<Country>>

THIS POSTCARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.
Please visit www.ChemoCentryxSecuritiesLitigation.com for more information.

The parties in the securities class action, *Homyk v. ChemoCentryx, Inc.,* Master File No. 4:21-cv-03343-JST (N.D. Cal.) (the "Action"), have reached a proposed settlement of all claims in the Action against ChemoCentryx, Inc. ("ChemoCentryx") and its former Chief Executive Officer, Dr. Thomas J. Schall (together, "Defendants"). In the Action, Class Representative Indiana Public Retirement System alleges that Defendants made material misrepresentations concerning a clinical trial of ChemoCentryx's vasculitis drug, avacopan, and the Company's communications with the FDA related to the approval of avacopan from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"). Defendants deny any liability or wrongdoing. You received this notice because you may be a member of the following certified Class: all persons who purchased or otherwise acquired the common stock of ChemoCentryx during the Class Period, and were damaged thereby.

Pursuant to the Settlement, Defendants have agreed to pay **$69,000,000 in cash**, which, after deducting any Court-awarded fees and expenses, notice and administration costs, and taxes, will be allocated among Class Members who submit valid claims, in exchange for the Settlement of the Action and the release of all claims asserted in the Action and related claims. **For additional information regarding the Settlement, please review the full Settlement Notice available at www.ChemoCentryxSecuritiesLitigation.com**. If you are a Class Member, your *pro rata* share of the Settlement will depend on the number of valid claims submitted, and the number, size, and timing of your transactions in ChemoCentryx common stock during the relevant time period. If all Class Members elect to participate in the Settlement, the estimated average recovery per eligible share will be approximately $2.88 before deducting any Court-approved fees, expenses, and costs. Your actual share of the Settlement will be determined pursuant to the Plan of Allocation set forth in the full Settlement Notice, or other plan ordered by the Court.

To be eligible for a payment, you must submit a valid Claim Form. The Claim Form can be found and submitted on **www.ChemoCentryxSecuritiesLitigation.com**, or you can request that one be mailed to you. **Claim Forms must be postmarked (if mailed), or submitted online, by October 1, 2026.** If you want to object to any aspect of the Settlement, you must file an objection by **September 21, 2026**. The full Settlement Notice provides instructions on how to submit a Claim Form and how to object, and you must comply with all the instructions in the Settlement Notice. Class Members were previously provided the opportunity to request exclusion from the Class in connection with class certification, and there will not be a second opportunity to request exclusion in connection with the Settlement. If you previously requested exclusion, however, you may opt back into the Class by following the instructions in the full Settlement Notice.

The Court will hold a hearing on **October 29, 2026, at 2:00 p.m. Pacific Time**, to consider, among other things, whether to approve the Settlement and a request by the lawyers representing the Class for up to 22% of the Settlement Fund in attorneys' fees, plus expenses of no more than $5 million (which equals a cost of approximately $0.84 per eligible share). You may attend the hearing and ask to be heard by the Court, but you do not have to. **For more information, call 1-833-522-2606, email info@ChemoCentryxSecuritiesLitigation.com, or visit www.ChemoCentryxSecuritiesLitigation.com.**

Exhibit B

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357

NOTICE OF (I) PROPOSED CLASS ACTION SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES

TO: All persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), and were damaged thereby.

A Federal Court authorized this Settlement Notice.
This is not a solicitation from a lawyer.

NOTICE OF SETTLEMENT: Please be advised that Class Representative Indiana Public Retirement System ("Class Representative" or "Lead Plaintiff"), on behalf of itself and the Class (as defined in ¶ 28 below), has reached a proposed settlement of the Action for **$69,000,000** in cash that, if approved, will resolve all claims in the Action (the "Settlement").

PLEASE READ THIS NOTICE CAREFULLY. This Notice explains important rights you may have, including the possible receipt of cash from the Settlement. If you are a member of the Class, your legal rights will be affected whether or not you act.

If you have any questions about this Notice, the proposed Settlement, or your eligibility to participate in the Settlement, please DO NOT contact the Court, the Office of the Clerk of the Court, ChemoCentryx, any other Defendants in the Action, or their counsel. All questions should be directed to Class Counsel or the Claims Administrator (*see* ¶ 78 below). [1]

1. **Description of the Action and the Class:** This Notice relates to a proposed Settlement of claims in a pending securities class action brought by investors alleging that ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall (together, "Defendants"), violated the federal securities laws by making material misrepresentations during the Class Period regarding ChemoCentryx's ADVOCATE study, the Company's Phase 3 clinical trial of its vasculitis drug avacopan, and concerning the Company's communications with the FDA related to the approval of avacopan. Defendants deny all allegations in the Action and deny any violations of the federal securities law. A more detailed description of the Action is set forth in paragraphs 10-27 below. If the Court approves the proposed Settlement, the Action will be dismissed and members of the Class (defined in paragraph 28 below) will settle and release all Released Plaintiff's Claims (defined in paragraph 37 below).

---

[1] All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings set forth in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 (the "Stipulation"), which is available at www.ChemoCentryxSecuritiesLitigation.com.

2. **Statement of the Class's Recovery:** Subject to Court approval, Class Representative, on behalf of itself and the Class, has agreed to settle the Action in exchange for a settlement payment of **$69,000,000** in cash (the "Settlement Amount") to be deposited into an escrow account. The Net Settlement Fund (*i.e.*, the Settlement Amount plus any and all interest earned thereon (the "Settlement Fund") less (a) any Taxes, (b) any reasonable Notice and Administration Costs, (c) any Litigation Expenses awarded by the Court, (d) any attorneys' fees awarded by the Court; and (e) any other costs or fees approved by the Court) will be distributed in accordance with a plan of allocation that is approved by the Court, which will determine how the Net Settlement Fund shall be allocated among members of the Class. The proposed plan of allocation (the "Plan of Allocation") is attached hereto as Appendix A.

3. **Estimate of Average Amount of Recovery Per Share:** Based on Class Representative's damages expert's estimate of the number of ChemoCentryx common stock shares that may have been affected by the misstatements alleged in the Action and assuming that all Class Members elect to participate in the Settlement, the estimated average recovery (before the deduction of any Court-approved fees, expenses, and costs as described herein) is $2.88 per eligible share of ChemoCentryx common stock. **Class Members should note, however, that the foregoing average recovery per share is only an estimate.** Some Class Members may recover more or less than this estimated amount depending on, among other factors, when and at what prices they purchased or sold their ChemoCentryx common stock, and the total number and value of valid Claim Forms submitted. Distributions to Class Members will be made based on the Plan of Allocation set forth in Appendix A or such other plan of allocation as may be ordered by the Court.

4. **Average Amount of Damages Per Share:** The Parties disagree about both liability and damages and do not agree on the average amount of damages per share that would be recoverable if Class Representative were to prevail in the Action. Among other things, Defendants do not agree with the assertion that they violated the federal securities laws or that any damages were suffered by any Class Members as a result of their conduct.

5. **Attorneys' Fees and Expenses Sought:** Court-appointed Class Counsel, Bernstein Litowitz Berger & Grossmann LLP, which has been prosecuting the Action on a wholly contingent basis for more than four years, has not received any payment of attorneys' fees for its representation of the Class and has advanced the funds to pay expenses necessarily incurred to prosecute this Action. Class Counsel will apply to the Court for an award of attorneys' fees in an amount not to exceed 22% of the Settlement Fund. In addition, Class Counsel will apply for payment of the Litigation Expenses incurred in connection with the institution, prosecution, and resolution of the Action, in an amount not to exceed $5 million. Any fees and expenses awarded by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses. If the Court approves Class Counsel's fee and expense application, the estimated average cost will be $0.84 per affected share of ChemoCentryx common stock.

6. **Identification of Attorneys' Representatives:** Class Representative and the Class are represented by Jonathan D. Uslaner of Bernstein Litowitz Berger & Grossmann LLP, 2121 Avenue of the Stars, Suite 2575, Los Angeles, CA 90067, 1-800-380-8496, settlements@blbglaw.com. Further information regarding the Action, the Settlement, and this Settlement Notice may be obtained by contacting the Claims Administrator at: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013; info@ChemoCentryxSecuritiesLitigation.com; (833) 522-2606; or by visiting the case website, www.ChemoCentryxSecuritiesLitigation.com.

7. **Reasons for the Settlement:** Class Representative's principal reason for entering into the Settlement is the near-term cash benefit for the Class without the substantial risks and the delays inherent in further litigation. The substantial cash benefit provided under the Settlement must be considered against the significant risk that no recovery at all might be obtained. At the time the Settlement was reached, the Action had been dismissed in its entirety on Defendants' motion for summary judgment, and any recovery for the Class was dependent on the resolution of the pending appeal in favor of Class Representative, and the potential outcome at trial (if the appeal succeeded). Moreover, any recovery obtained for the Class through litigation could not be expected for at least several years. Defendants, who deny all allegations of wrongdoing or liability whatsoever, are entering into the Settlement solely to eliminate the uncertainty, burden, and expense of further protracted litigation.

YOUR LEGAL RIGHTS AND OPTIONS IN THE SETTLEMENT:	
SUBMIT A CLAIM FORM *POSTMARKED OR SUBMITTED ONLINE* NO LATER THAN OCTOBER 1, 2026.	This is the only way to be eligible to receive a payment from the Settlement Fund. If you are a Class Member, you will be bound by the Settlement as approved by the Court and you will give up any Released Plaintiff's Claims (defined in ¶ 37 below) that you have against Defendants and the other Defendants' Releasees (defined in ¶ 38 below), so it is in your interest to submit a Claim Form.
OBJECT TO THE SETTLEMENT BY SUBMITTING A WRITTEN OBJECTION SO THAT IT IS *POSTMARKED OR FILED* NO LATER THAN SEPTEMBER 21, 2026.	If you do not like the proposed Settlement, the proposed Plan of Allocation, or the request for attorneys' fees and Litigation Expenses, you may write to the Court and explain why you do not like them. You cannot object to the Settlement, the Plan of Allocation, or the fee and expense request unless you are a Class Member.
GO TO A HEARING ON OCTOBER 29, 2026 AT 2:00 P.M. PACIFIC TIME, AND FILE A NOTICE OF INTENTION TO APPEAR SO THAT IT IS *RECEIVED* NO LATER THAN SEPTEMBER 21, 2026.	Filing a written objection and notice of intention to appear by September 21, 2026 allows you to speak in Court, at the discretion of the Court, about the fairness of the proposed Settlement, the Plan of Allocation, and/or the request for attorneys' fees and Litigation Expenses. If you submit a written objection, you may (but you do not have to) attend the hearing and, at the discretion of the Court, speak to the Court about your objection. If you do not submit a written objection, you are unlikely to be allowed to speak in Court about the fairness of the settlement.
DO NOTHING.	If you are a member of the Class and you do not submit a valid Claim Form, you will not be eligible to receive any payment from the Settlement Fund. You will, however, remain a member of the Class, which means that you give up your right to sue about the claims that are resolved by the Settlement and you will be bound by any judgments or orders entered by the Court in the Action.

These rights and options—and the deadlines to exercise them—are further explained in this Notice. Please Note: the date and time of the Settlement Hearing—currently scheduled for October 29, 2026 at 2:00 p.m. Pacific Time by Zoom videoconference —is subject to change without further notice to the Class. If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com, or with Class Counsel as set forth above, to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.

WHAT THIS NOTICE CONTAINS

WHY DID I GET THIS SETTLEMENT NOTICE?

8. The purpose of this Settlement Notice is to inform potential Class Members of the terms of the proposed Settlement, and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and the motion by Class Counsel for attorneys' fees and Litigation Expenses (the "Settlement Hearing"). *See* ¶¶ 62-63 below for details about the Settlement Hearing, including the date and time of the hearing.

9. The issuance of this Settlement Notice is not an expression of any opinion by the Court concerning the merits of any claim in the Action, and the Court still has to decide whether to approve the Settlement. If the Court approves the Settlement and a plan of allocation, then payments to Authorized Claimants will be made after any appeals are resolved and after the completion of all claims processing. Please be patient, as this process can take some time to complete.

WHAT IS THIS CASE ABOUT?

10. ChemoCentryx is a biopharmaceutical company incorporated under the laws of the State of Delaware, with its corporate headquarters and principal place of business in California. Until October 19, 2022, ChemoCentryx's common stock traded on the NASDAQ stock exchange under the ticker symbol "CCXI." In the Action, Class Representative alleged that Defendants made misstatements to investors during the Class Period about the safety and efficacy of ChemoCentryx's vasculitis drug called avacopan, and the Company's application for FDA approval of avacopan.

11. The initial complaint in this action was filed on May 5, 2021. On January 28, 2022, the Honorable Jon S. Tigar appointed Indiana Public Retirement System as Lead Plaintiff and Bernstein Litowitz Berger & Grossmann LLP as Lead Counsel for the potential Class.

12. On March 28, 2022, Lead Plaintiff filed the Amended Consolidated Class Action Complaint for Violations of Federal Securities Laws (the "Complaint"). In the Complaint, Lead Plaintiff alleged that Defendants ChemoCentryx and Schall violated Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Securities and Exchange Commission Rule 10b-5, by making alleged misrepresentations concerning ChemoCentryx's ADVOCATE study, the Company's Phase 3 clinical trial of avacopan, and the Company's communications with the FDA related to the approval of avacopan. Lead Plaintiff alleged that these misstatements and omissions caused the price of ChemoCentryx common stock to be artificially inflated during the Class Period and caused damages to investors when the market later allegedly learned the truth allegedly concealed by Defendants' misleading statements. Lead Plaintiff further alleged claims under Sections 20(a) and 20A of the Exchange Act against Defendant Schall, alleging that Schall controlled ChemoCentryx when the Company made the alleged misstatements concerning avacopan in violation of Section 20(a); and that Schall sold ChemoCentryx stock while in possession of material non-public information about avacopan, and that Lead Plaintiff and other Class Members purchased ChemoCentryx stock contemporaneously with those sales, in violation of Section 20A.

13. Defendants moved to dismiss the Complaint on May 19, 2022. On February 23, 2023, the Court issued an order granting in part and denying in part Defendants' motion to dismiss. Defendants filed their Answer to the Complaint on April 27, 2023.

14. On August 25, 2023, Lead Plaintiff filed a motion for class certification. After full briefing and a hearing, on March 6, 2024, Judge Tigar issued an Order granting the motion and certifying the Class as defined in ¶ 28 below, appointing Lead Plaintiff as Class Representative for the Class, and appointing Lead Counsel as Class Counsel. On May 23, 2024, the United States Court of Appeals for the Ninth Circuit denied Defendants' petition for leave to take an immediate appeal of the Court's order certifying the Class pursuant to Rule 23(f) of the Federal Rules of Civil Procedure.

15. The Parties conducted a private mediation in February 2024. No settlement was reached at that time.

16. On September 25, 2024, Class Representative filed an unopposed motion for Court approval of the Parties' agreed form and manner of providing notice to the Class of pendency of the class action. On October 17, 2024, the Court entered an Order granting that motion (the "Class Notice Order").

17. Pursuant to the Class Notice Order, the Class Notice provided Class Members with the opportunity to request exclusion from the Class, explained that right, and set forth the deadline and procedures for doing so. The Class Notice informed Class Members that if they chose to remain a member of the Class, they would "be legally bound by all determinations, orders, and judgments that the Court makes in the Action, whether favorable or unfavorable."

18. The Class Notice was mailed to 35,220 potential Class Members beginning on November 13, 2024. The deadline for requesting exclusion from the Class pursuant to the Class Notice was January 14, 2025. A list of the persons and entities who requested exclusion from the Class pursuant to the Class Notice is available at www.ChemoCentryxSecuritiesLitigation.com.

19. During discovery, Defendants produced approximately 7.8 million pages of documents and dozens of third parties (including the FDA, Amgen, and ChemoCentryx's consultants, bankers, and former employees) produced tens of thousands of additional pages of documents. The Parties conducted 21 depositions of fact witnesses and 17 depositions of expert witnesses; and prepared and exchanged 24 expert reports.

20. On February 13, 2025, Class Representative and Defendants filed a total of 11 motions to exclude portions of expert testimony offered by the adverse party. The Court heard oral argument on April 10, 2025 and decided those motions on May 21, 2025.

21. Class Representative filed a motion for partial summary judgment on May 8, 2025, and Defendants filed a motion for summary judgment on May 29, 2025. The Court heard oral argument on those motions on August 7, 2025.

22. On August 15, 2025, the Court issued an Order granting Defendants' motion for summary judgment and denying Class Representative's motion as moot. On the same day, the Court issued its Judgment.

23. On September 12, 2025, Class Representative appealed the Court's Order Granting Defendants' Motion for Summary Judgment and the Judgment to the Ninth Circuit Court of Appeals. On January 5, 2026, Class Representative filed its opening brief in support of its appeal.

24. On January 26, 2026, while Class Representative's appeal was pending, the Parties executed a Memorandum of Understanding ("MOU") reflecting an agreement in principle to settle all claims in this Action against Defendants and Defendants' Releasees (defined below) in return for a cash payment of $35,000,000 for the benefit of the Class, subject to the execution of a customary "long form" stipulation and agreement of settlement and related papers.

25. The Parties entered into a Settlement and Agreement of Settlement dated March 9, 2026 (the "Original Settlement Stipulation") setting forth the terms and conditions of the proposed $35,000,000 settlement (the "Original Settlement"), and on March 13, 2026, Class Representative filed a motion for preliminary approval of the Original Settlement.

26. On April 27, 2026, after the filing of Class Representative's motion for preliminary approval of the Original Settlement, the Center for Drug Evaluation and Research ("CDER") of the Food and Drug Administration ("FDA") filed a public notice proposing the withdrawal of TAVNEOS (avacopan). Following CDER's announcement, the Parties engaged in further negotiations culminating in a revised agreement to settle all claims in this Action against Defendants and Defendants' Releasees in return for a cash payment of $69,000,000 for the benefit of the Class. On May 15, 2026, the Parties entered into the Revised Stipulation and Agreement of Settlement (the "Stipulation"), which sets forth the full terms and conditions of the $69,000,000 Settlement and supersedes and voids the Original Settlement Stipulation and the Original Settlement. The Stipulation can be viewed at www.ChemoCentryxSecuritiesLitigation.com.

27. On June 12, 2026, the Court preliminarily approved the Settlement, authorized notice of the Settlement to be disseminated to potential Class Members, and scheduled the Settlement Hearing to consider whether to grant final approval to the Settlement.

HOW DO I KNOW IF I AM AFFECTED BY THE SETTLEMENT?
WHO IS INCLUDED IN THE CLASS?

28. If you are a member of the Class, you are subject to the Settlement, unless you previously requested to be excluded from the Class. The Class was certified by the Court's Order dated March 6, 2024 and consists of:

> **all persons who purchased or otherwise acquired the common stock of ChemoCentryx between November 26, 2019 and May 6, 2021, inclusive, and were damaged thereby**

Excluded from the Class are: (a) Defendants; (b) their respective successors and assigns; (c) the past and current executive officers and directors of Defendants; (d) the Immediate Family Members of Defendant Thomas J. Schall; and (e) the legal representatives, heirs, successors, or assigns of any excluded person, and any entity in which any of the above excluded persons have or had a direct or controlling ownership interest, and the legal representatives, heirs, successors-in-interest or assigns of any such excluded persons or entities. Also excluded from the Class are persons and entities who excluded themselves from the Class pursuant to the Class Notice (a list of the persons and entities who requested exclusion is available at www.ChemoCentryxSecuritiesLitigation.com). However, those persons or entities may choose to participate in the Settlement by following the instructions in ¶ 59 below.

Please Note: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive proceeds from the Settlement.

If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit a Claim Form and the required supporting documentation as set forth therein postmarked (or submitted online) no later than October 1, 2026. The Claim Form is available at www.ChemoCentryxSecuritiesLitigation.com, and an online claim can be submitted through that website.

WHAT ARE CLASS REPRESENTATIVE'S REASONS FOR THE SETTLEMENT?

29. At the time the Settlement was reached, all claims asserted by Class Representative had been dismissed by the District Court when it entered its Order granting Defendants' motion for summary judgment. The Court found that all of Class Representative's alleged misrepresentations were inactionable either because they were statements of opinion or were not misleading. Therefore, any recovery for the Class through litigation could only be obtained if (a) Class Representative obtained a reversal of the Court's order granting Defendants' motion for summary judgment through its pending appeal, and (b) thereafter succeeded at trial on remand. There were very significant risks presented by the current appeal that could have led to no recovery at all, and—even if Class Representative had succeeded on appeal and proceeded to trial—it would have faced a number of substantial arguments regarding liability and damages from Defendants.

30. First, there was a significant risk that Class Representative might not prevail on its pending appeal. While Class Representative believed that it had meritorious arguments for reversal, there was a substantial risk that the Court of Appeals might affirm the District Court's order granting summary judgment. Moreover, even if Class Representative prevailed on the appeal, the District Court could still potentially grant summary judgment again to Defendants on other grounds that the Court did not reach the first time. Finally, even if Class Representative was able to bring its claims to trial, it would still face significant challenges at trial in proving that the alleged misstatements were false and misleading and in proving damages.

31. In light of these and other risks, the amount of the Settlement, and the immediacy of recovery to the Class, Class Representative and Class Counsel believe that the proposed Settlement is fair, reasonable, and adequate, and in the best interests of the Class. The Settlement provides a substantial benefit to the Class, namely $69,000,000 in cash (less the various deductions described in this Notice), as compared to the risk that the claims in the Action would produce a smaller recovery, or no recovery at all, after further pretrial proceedings, at trial, and on any appeals, possibly years in the future.

32. Defendants expressly deny that Class Representative has asserted any valid claims as to any of them, and expressly deny any and all allegations of fault, liability, or wrongdoing whatsoever. Defendants further deny that Class Members were harmed or suffered any damages as a result of the conduct alleged in the Action. Defendants have agreed to the Settlement solely to eliminate the risks, burdens, and expense of continued litigation. Accordingly, the Settlement may not be construed as an admission of any wrongdoing by Defendants.

WHAT MIGHT HAPPEN IF THERE WERE NO SETTLEMENT?

33. If there were no Settlement and Class Representative did not obtain a reversal of the District Court's Order Granting Defendants' Motion for Summary Judgment on its pending appeal, then neither Class Representative nor the other Class Members would recover anything from Defendants. Likewise, if the appeal was successful, but Class Representative failed to establish any essential legal or factual element of its claims against Defendants at trial, Class Members would recover nothing from Defendants. Also, if Defendants were successful in proving any of their defenses, either at trial or on a subsequent appeal, the Class could recover less than the amount provided in the Settlement, or nothing at all.

HOW ARE CLASS MEMBERS AFFECTED BY THE ACTION AND THE SETTLEMENT?

34. As a Class Member, you are represented by Class Representative and Class Counsel, unless you enter an appearance through counsel of your own choice at your own expense. You are not required to retain your own counsel, but if you choose to do so, such counsel must file a notice of appearance on your behalf and must serve copies of his or her appearance on the attorneys listed in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?," on page 13 below.

35. If you are a Class Member and you wish to object to the Settlement, the Plan of Allocation, or Class Counsel's application for attorneys' fees and Litigation Expenses, you may present your objections by following the instructions in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?," on page 13 below.

36. If you are a Class Member, you will be bound by any orders issued by the Court. If the Settlement is approved, the Court will enter a judgment (the "Judgment"). The Judgment will dismiss with prejudice the claims against Defendants and will provide that, upon the Effective Date of the Settlement, Class Representative and each of the other Class Members, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, shall be deemed to have, and by operation of law and of the Judgment or the Alternate Judgment, if applicable, shall have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Plaintiff's Claim (as defined in ¶ 37 below) against Defendants and the other Defendants' Releasees (as defined in ¶ 38 below), and shall forever be barred and enjoined from prosecuting any or all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants and the other Defendants' Releasees.

37. "Released Plaintiff's Claims" means all claims (including "Unknown Claims" as defined in ¶ 39), disputes, demands, losses, liabilities, rights, damages, losses, actions or causes of action, obligations, sums of money due, judgments, suits, amounts, matters, issues and charges of any kind whatsoever (including, but not limited to, any claims for interest, attorneys' fees, expert or consulting fees, and any other costs, expenses, amounts, or liabilities whatsoever) of every nature and description whatsoever, whether in law or in equity, that have been or could have been asserted in the Action or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common, or foreign law, by Class Representative, any member of the Class, or their respective successors, assigns, parents, affiliates, executors, administrators, representatives, attorneys, and agents, in their capacities as such, whether brought directly or indirectly against any of the Defendants' Releasees, that (a) arise out of, are based on, or relate in any way to any of the allegations, claims, disclosures, acts, transactions, facts, events, circumstances, matters, occurrences, conduct, failures to act, statements, representations or omissions involved, set forth, alleged or referred to in the Action (or any complaint filed in the Action) or which could have been alleged or referred to in the Action, and (b) arise out of, are based on, or relate to the purchase or acquisition of ChemoCentryx common stock during the Class Period. "Released Plaintiff's Claims" does not, however, include (i) any claims to enforce the settlement; or (ii) any claims of any person or entity who or which is excluded from the Class.

38. "Defendants' Releasees" means (i) Defendants, (ii) each of their respective past, present and future Immediate Family Members (for individuals) and each of their direct or indirect parent entities, subsidiaries, related entities and affiliates, any trust of which Defendant Thomas J. Schall is the settler or which is for the benefit of any Defendant and/or member(s) of his or his family, (iii) Amgen, Inc., and (iv) for any of the entities included in (i), (ii) or (iii), their respective past, present and future general partners, limited partners, principals, shareholders, joint venturers, parent entities, subsidiaries, related entities and affiliates, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, experts, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys (including Defendants' counsel and all other counsel who have represented any current or former Defendant in the Action), professionals, parents, predecessors, successors, assigns, heirs, executors, administrators, estates, beneficiaries, foundations and any controlling person thereof, in their capacities as such, and any entity in which a Defendant has a controlling interest.

39. "Unknown Claims" means any and all Released Plaintiff's Claims against the Defendants' Releasees that Class Representative, Class Counsel, or any Class Member does not know or suspect to exist in his, her, their, or its favor at the time of their release, and any and all Released Defendants' Claims against the Plaintiff's Releasees that any Defendant does not know or suspect to exist in his, her, their, or its favor at the time of their release, including without limitation those that, if known might have affected in any way his, her, their, or its decision(s) with respect to the settlement or the releases. With respect to any and all Released Claims, the Parties agree that, upon the Effective Date of the Settlement, Class Representative and each Defendant shall expressly waive, and each Class Member shall be deemed to have waived, and by operation of the judgment shall have waived, any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to Cal. Civ. Code §1542, which provides:

> A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Class Representative, other Class Members, and Defendants may hereafter discover facts, legal theories, or authorities in addition to or different from those which any of them now knows or believes to be true with respect to the subject matter of the Released Claims, but Class Representative, each Class Member, and Defendants shall be deemed to have settled and released, and upon the Effective Date and by operation of the Judgment have settled and released, fully, finally, and forever, any and all Released Claims, as applicable, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. Class Representative and Defendants acknowledge, and each of the other Class Members shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement.

40. The Judgment will also provide that, upon the Effective Date of the Settlement, Defendants, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, will have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Defendants' Claim (as defined in ¶ 41 below) against Class Representative and the other Plaintiff's Releasees (as defined in ¶ 42 below), and shall forever be barred and enjoined from prosecuting any or all of the Released Defendants' Claims directly or indirectly against any of the Plaintiff's Releasees.

41. "Released Defendants' Claims" means all claims (including "Unknown Claims" as defined in ¶ 39), disputes, demands, liabilities, losses, rights, and causes of action of any nature whatsoever, obligations, sums of money due, judgments, suits, amounts, matters, issues and charges of any kind whatsoever (including, but not limited to, any claims for interest, attorneys' fees, expert or consulting fees, and any other costs, expenses, amounts, or liabilities whatsoever) of every nature and description whatsoever, whether in law or in equity, that have been or could have been asserted in the Action or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common, or foreign law, by the Defendants' Releasees or any of them against Class Representative, members of the Class, or Class Counsel (including, but not limited to, any of its current and former partners or employees), which: (a) arise out of or relate in any way to the institution, prosecution, assertion, settlement, or resolution of the Action (except for claims to enforce the settlement) or (b) relate to conduct of, or acts undertaken by, Class Counsel during the prosecution or investigation of the Action or any claims asserted in the Action; including without limitation any claims for defamation, slander, or libel.

42. "Plaintiff's Releasees" means (i) Lead Plaintiff and the members of the Class, and (ii) each of their respective past, present and future family members, and their respective past, present and future general partners, limited partners, principals, shareholders, joint venturers, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, experts, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys (including Lead Counsel and all other counsel who have represented any current or former plaintiff or proposed putative class in the Action), professionals, parents, predecessors, successors, assigns, heirs, executors, administrators, estates, beneficiaries, foundations and any controlling person thereof, in their capacities as such.

HOW DO I PARTICIPATE IN THE SETTLEMENT? WHAT DO I NEED TO DO?

43. To be eligible for a payment from the Settlement, you must be a member of the Class and you must timely complete and return the Claim Form with adequate supporting documentation ***postmarked (if mailed), or submitted online*** **at www.ChemoCentryxSecuritiesLitigation.com no later than October 1, 2026**. You may obtain a Claim Form from the website maintained by the Claims Administrator for the case, www.ChemoCentryxSecuritiesLitigation.com. You may also request that a Claim Form be mailed to you by calling the Claims Administrator toll-free at 1-833-522-2606 or by emailing the Claims Administrator at info@ChemoCentryxSecuritiesLitigation.com. **Please retain all records of your ownership of and transactions in ChemoCentryx common stock, as they will be needed to document your Claim.** The Parties and Claims Administrator do not have information about your transactions and holdings in ChemoCentryx common stock.

44. If you do not submit a timely and valid Claim Form, you will not be eligible to share in the Net Settlement Fund.

HOW MUCH WILL MY PAYMENT BE?

45. At this time, it is not possible to make any determination as to how much any individual Class Member may receive from the Settlement.

46. Pursuant to the Settlement, Defendants have agreed to cause $69,000,000 in cash (the "Settlement Amount") to be paid into an escrow account. The Settlement Amount plus any interest earned thereon is referred to as the "Settlement Fund." If the Settlement is approved by the Court and the Effective Date occurs, the "Net Settlement Fund" (that is, the Settlement Fund less (a) all federal, state and/or local taxes on any income earned by the Settlement Fund and the reasonable costs incurred in connection with determining the amount of and paying taxes owed by the Settlement Fund (including reasonable expenses of tax attorneys and accountants); (b) the reasonable costs and expenses incurred in connection with providing notices to Class Members and administering the Settlement on behalf of Class Members; (c) any

attorneys' fees and Litigation Expenses awarded by the Court; and (d) any other costs or fees approved by the Court) will be distributed to Class Members who submit valid Claim Forms, in accordance with the proposed Plan of Allocation or such other plan of allocation as the Court may approve.

47. The Net Settlement Fund will not be distributed unless and until the Court has approved the Settlement and a plan of allocation, and the time for any petition for rehearing, appeal or review, whether by certiorari or otherwise, has expired.

48. Neither Defendants nor any other person or entity that paid any portion of the Settlement Amount on their behalf are entitled to get back any portion of the Settlement Fund once the Court's order or judgment approving the Settlement becomes Final. Defendants shall not have any liability, obligation, or responsibility for the administration of the Settlement, the disbursement of the Net Settlement Fund, or the plan of allocation.

49. Approval of the Settlement is independent from approval of a plan of allocation. Any determination with respect to a plan of allocation will not affect the Settlement, if approved.

50. Unless the Court otherwise orders, any Class Member who fails to submit a Claim Form postmarked (or submitted online) on or before October 1, 2026 shall be fully and forever barred from receiving payments pursuant to the Settlement but will in all other respects remain a Class Member and be subject to the provisions of the Stipulation, including the terms of any Judgment entered and the releases given. This means that each Class Member releases the Released Plaintiff's Claims (as defined in ¶ 37 above) against the Defendants and other Defendants' Releasees (as defined in ¶ 38 above) and will be barred and enjoined from prosecuting any or all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants and the other Defendants' Releasees whether or not such Class Member submits a Claim Form.

51. Participants in and beneficiaries of any employee retirement and/or benefit plan covered by ERISA ("ERISA Plan") should NOT include any information relating to shares of ChemoCentryx common stock purchased or held through the ERISA Plan in any Claim Form they submit in this Action. They should include ONLY shares of ChemoCentryx common stock purchased or held outside of an ERISA Plan. Claims based on any ERISA Plan's purchases or holdings of ChemoCentryx common stock may be made by the plan's trustees.

52. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the claim of any Class Member.

53. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to his, her, or its Claim Form.

54. Only Class Members or persons authorized to submit a claim on their behalf will be eligible to share in the distribution of the Net Settlement Fund. Persons and entities that are excluded from the Class by definition or that previously excluded themselves from the Class pursuant to request will not be eligible to receive a distribution from the Net Settlement Fund and should not submit Claim Forms.

55. **Appendix A to this Notice sets forth the Plan of Allocation for allocating the Net Settlement Fund among Authorized Claimants, as proposed by Class Representative. At the Settlement Hearing, Class Representative will request that the Court approve the Plan of Allocation. The Court may modify the Plan of Allocation, or approve a different plan of allocation, without further notice to the Class.**

**WHAT PAYMENT ARE THE ATTORNEYS FOR THE CLASS SEEKING?
HOW WILL THE LAWYERS BE PAID?**

56. Class Counsel has not received any payment for its services in pursuing claims against the Defendants on behalf of the Class, and has not been reimbursed for its out-of-pocket expenses. Before final approval of the Settlement, Class Counsel will apply to the Court for an award of attorneys' fees in an amount not to exceed 22% of the Settlement Fund. At the same time, Class Counsel also intends to apply for payment of Litigation Expenses in an amount not to exceed $5 million.

57. Class Counsel's motion for attorneys' fees and Litigation Expenses will be filed by September 10, 2026. A copy of Class Counsel's motion will be available for review at www.ChemoCentryxSecuritiesLitigation.com. The Court will determine the amount of any award of attorneys' fees or Litigation Expenses. Such sums as may be approved by the Court will be paid from the Settlement Fund. ***Class Members are not personally liable for any such fees or expenses***.

WHAT IF I PREVIOUSLY REQUESTED EXCLUSION FROM THE CLASS AND NOW WANT TO BE ELIGIBLE TO RECEIVE A PAYMENT FROM THE SETTLEMENT? HOW DO I OPT BACK INTO THE CLASS?

58. As this Class was previously certified and Class Members had the opportunity to request exclusion from the Class in connection with class certification, the Court has exercised its discretion not to allow a second opportunity to request exclusion in connection with the Settlement proceedings.

59. However, if you previously submitted a request for exclusion from the Class in connection with the Class Notice, you may elect to opt back into the Class and be eligible to receive a payment from the Settlement. In order to opt back into the Class, you, individually or through counsel, must submit a written Request to Opt Back Into the Class addressed as follows: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration P.O. Box 5013 New York, NY 10150-5013. This request must be *received* no later than September 21, 2026. Your Request to Opt Back Into the Class must (a) state the name, address and telephone number of the person or entity requesting to opt back into the Class; (b) state that such person or entity "requests to opt back into the Class in *Homyk v. ChemoCentryx, Inc*., Master File No. 4:21-cv-03343-JST" and (c) be signed by the person or entity requesting to opt back into the Class or an authorized representative. **If you opt back into the Class, you will be bound by the Judgment and the release discussed in ¶¶ 37-38 above and you will not be able to bring or continue your own litigation concerning any of the Released Plaintiff's Claims.**

60. **Please note:** Opting back into the Class in accordance with the requirements set forth above does not mean that you will automatically be entitled to receive proceeds from the Settlement. If you opt back into the Class and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are also required to submit the Claim Form and the required supporting documentation as set forth therein by no later than October 1, 2026.

WHEN AND WHERE WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT? DO I HAVE TO COME TO THE HEARING? MAY I SPEAK AT THE HEARING IF I DON'T LIKE THE SETTLEMENT?

61. **Class Members do not need to attend the Settlement Hearing. The Court will consider any submission made in accordance with the provisions below even if a Class Member does not attend the hearing. You can participate in the Settlement without attending the Settlement Hearing**.

62. **Please Note**: The date and time of the Settlement Hearing may change without further written notice to Class Members. **In order to determine whether the date and time of the Settlement Hearing have changed, it is important that you monitor the Court's docket in the Action through the Federal Court's Public Access to Court Electronic Records (PACER) system at https://ecf.cand.uscourts.gov or the Settlement website, www.ChemoCentryxSecuritiesLitigation.com, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website, www.ChemoCentryxSecuritiesLitigation.com.**

63. The Settlement Hearing will be held on **October 29, 2026 at 2:00 p.m. Pacific time**, before the Honorable Jon S. Tigar of the United States District Court for the Northern District of California, by Zoom videoconference. At the Settlement Hearing, the Court will consider: (a) whether the proposed Settlement is fair, reasonable, and adequate to the Class, and should be finally approved; (b) whether a Judgment substantially in the form attached as Exhibit B to the Stipulation should be entered dismissing the Action with prejudice against Defendants; (c) whether the proposed Plan of Allocation for the proceeds of the Settlement is fair and reasonable and should be approved; (d) whether the motion by Class Counsel for attorneys' fees and Litigation Expenses should be approved; and (e) other matters that may properly be brought before the Court in connection with the Settlement. **If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com, or with Class Counsel to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.** The Court reserves the right to approve the Settlement, the Plan of Allocation, Class Counsel's motion for attorneys' fees and Litigation Expenses, and/or any other matter related to the Settlement at or after the Settlement Hearing without further notice to the members of the Class.

64. Any Class Member may file an objection. You may object to the proposed Settlement, the Plan of Allocation or the requested fees and expenses. If you wish to object, your objection must be made in writing and include the following: your full name, the basis for your belief that you are a member of the Class, the basis of your objection (including whether the objection applies only to the objector, to a specific subset of the Class, or to the entire Class), and your signature. You can ask the Court to deny approval of the Settlement by filing an objection. You can't ask the Court to order a different settlement; the Court can only approve or reject the Settlement. If the Court denies approval, no settlement payments will be sent out, and the lawsuit will continue. If that is what you want to happen, you should object.

65. Any objection must be in writing. If you file a timely written objection, you may, but are not required to, appear at the Settlement Hearing, either in person or through your own attorney. If you appear through your own attorney, you are responsible for hiring and paying that attorney. All written objections and supporting papers must (a) clearly identify the case name and number *Homyk v. ChemoCentryx, Inc.*, Master File No. 4:21-cv-03343-JST; (b) be submitted to the Court either by filing them electronically, by mailing them to the Clerk of the Court, United States District Court for the Northern District of California, 1301 Clay Street, Suite 400S, Oakland, CA 94612, or by filing them in person at any location of the United States District Court for the Northern District of California; and (c) **be filed or postmarked on or before September 21, 2026**.

66. **You may not object to the Settlement, the Plan of Allocation, or Class Counsel's motion for attorneys' fees and Litigation Expenses if you are not a member of the Class.**

67. You may file a written objection without having to appear at the Settlement Hearing. You may not, however, appear at the Settlement Hearing to present your objection unless you first file and serve a written objection in accordance with the procedures described above, unless the Court orders otherwise.

68. If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, the Plan of Allocation, or Class Counsel's motion for attorneys' fees and Litigation Expenses, and if you timely file and serve a written objection as described above, you must also file a notice of appearance with the Clerk's Office so that it is ***received*** **on or before September 21, 2026**. Such persons may be heard orally at the discretion of the Court.

69. You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. However, if you decide to hire an attorney, it will be at your own expense, and that attorney must file a notice of appearance with the Court so that the notice is ***received*** **on or before September 21, 2026**.

70. The Settlement Hearing may be adjourned by the Court without further written notice to the Class, other than a posting of the adjournment on the case website, www.ChemoCentryxSecuritiesLitigation.com. If you plan to attend the Settlement Hearing, you should confirm the date and time with Class Counsel.

71. **Unless the Court orders otherwise, any Class Member who does not object in the manner described above will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation or Class Counsel's motion for attorneys' fees and Litigation Expenses. Class Members do not need to appear at the Settlement Hearing or take any other action to indicate their approval.**

WHAT IF I BOUGHT CHEMOCENTRYX COMMON STOCK ON SOMEONE ELSE'S BEHALF?

72. In connection with the previously disseminated Class Notice, Nominees were advised that, if they purchased or otherwise acquired ChemoCentryx common stock during the Class Period (from November 26, 2019 through May 6, 2021, inclusive) for the beneficial interest of persons or entities other than themselves, they must either (a) provide a list of the names, addresses, and, if available, email addresses of all such beneficial owners to Kroll Settlement Administration ("Kroll"); or (b) request from Kroll sufficient copies of the Class Notice to forward to all such beneficial owners for whom email addresses were not available, and then forward those Class Notices to all such beneficial owners.

73. **If you previously provided the names and addresses of such beneficial owners identified above in connection with the Class Notice, and (i) those names and addresses remain current and (ii) you have no additional names and addresses for potential Class Members to provide to the Claims Administrator, *you need do nothing further at this time*.** The Claims Administrator will mail the Postcard Notice of the Settlement ("Postcard Notice") to the beneficial owners whose names and addresses were previously provided in connection with the Class Notice mailing.

74. If you elected to mail or email the Class Notice directly to beneficial owners, you were advised that you must retain the mailing records for use in connection with any further notices that may be provided in the Action. If you elected this option, the Claims Administrator will forward the same number of Postcard Notices to you to send to the beneficial owners, **and you must mail and/or email the Postcard Notices to those beneficial owners by no later than seven (7) calendar days after receipt of the Settlement Notice Packets.** If you require more copies of the Postcard Notice than you previously requested in connection with the Class Notice mailing, please contact the Claims Administrator, Kroll, toll-free at 1-833-522-2606, and let them know how many notices you require.

75. If you have not already provided the names and addresses for all persons and entities on whose behalf you purchased or acquired ChemoCentryx common stock from November 26, 2019 through May 6, 2021, inclusive; or if you have additional names or updated or changed information, then the Court has ordered that you must, WITHIN SEVEN (7) CALENDAR DAYS OF YOUR RECEIPT OF THIS SETTLEMENT NOTICE, either: (i) send a list of the names, addresses, and, if available, email addresses of such beneficial owners to the Claims Administrator at *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013, in which event the Claims Administrator shall promptly mail the Postcard Notice to such beneficial owners, or (ii) request from Kroll sufficient copies of the Postcard Notice to forward to all such beneficial owners, and mail or email the Postcard Notice to the beneficial owners within seven (7) calendar days of receipt. **As stated above, if you have already provided this information in connection with the Class Notice, unless that information has changed (*e.g.*, beneficial owner has changed address), it is unnecessary to provide such information again.**

76. **Nominees, and their agents shall forward the Postcard Notice to (or identify names, mailing addresses, and e-mail addresses of) *all* beneficial owners who purchased or otherwise acquired ChemoCentryx common stock during the Class Period, regardless of whether or not those beneficial owners have enrolled in a claim-filing program with their broker or financial institution**.

77. Upon full and timely compliance with these directions, nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought. Reasonable expenses shall not exceed $0.05 plus postage at the pre-sort rate used by the Claims Administrator per Postcard Notice mailed; $0.05 per Postcard Notice emailed; or $0.05 per mailing record provided to the Claims Administrator. Such properly documented expenses incurred by Nominees in compliance with these directions shall be paid from the Settlement Fund, with any disputes as to the reasonableness or documentation of expenses incurred subject to review by the Court.

CAN I SEE THE COURT FILE? WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?

78. This Settlement Notice contains only a summary of the terms of the proposed Settlement. For more detailed information about the matters involved in this Action, you are referred to the papers on file in the Action, including the Stipulation, which may be reviewed by accessing the Court docket in this case through the Court's Public Access to Court Electronic Records (PACER) system at https://ecf.cand.uscourts.gov, or by visiting the office of the Clerk of the Court for the United States District Court for the Northern District of California, Ronald V. Dellums Federal Building & United States Courthouse, 1301 Clay Street, Suite 400S, Oakland, CA 94612, between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays. Additionally, copies of the Stipulation and any related orders entered by the Court will be posted on the website maintained by the Claims Administrator, www.ChemoCentryxSecuritiesLitigation.com.

All inquiries concerning this Settlement Notice and the Claim Form should be directed to:

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5013
New York, NY 10150-5013

(833) 522-2606
info@ChemoCentryxSecuritiesLitigation.com

and/or

BERNSTEIN LITOWITZ
BERGER & GROSSMANN LLP
Jonathan D. Uslaner, Esq.
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067

(800) 380-8496
settlements@blbglaw.com

DO NOT CALL OR WRITE THE COURT, THE OFFICE OF THE CLERK OF THE COURT, DEFENDANTS OR THEIR COUNSEL REGARDING THIS NOTICE.

Dated: July 2, 2026

By Order of the Court
United States District Court
Northern District of California

APPENDIX A

PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

79. As discussed above, the Settlement provides $69,000,000 in cash for the benefit of the Class. The Settlement Amount and any interest it earns constitute the "Settlement Fund." The Settlement Fund, after deduction of Court-approved attorneys' fees and Litigation Expenses, Notice and Administration Costs, Taxes, and any other fees or expenses approved by the Court, is the "Net Settlement Fund." If the Settlement is approved by the Court, the Net Settlement Fund will be distributed to eligible Authorized Claimants, i.e., Class Members who timely submit valid Claim Forms that are accepted for payment by the Court, in accordance with a plan of allocation to be adopted by the Court. Class Members who do not timely submit valid Claim Forms will not share in the Net Settlement Fund, but will otherwise be bound by the Settlement.

80. The Plan of Allocation (the "Plan") set forth herein is the plan that is being proposed to the Court for approval by Lead Plaintiff after consultation with its damages experts. The Court may approve the Plan with or without modification, or approve another plan of allocation, without further notice to the Class. Any Orders regarding a modification to the Plan will be posted to www.ChemoCentryxSecuritiesLitigation.com. Defendants have had, and will have, no involvement or responsibility for the terms or application of the Plan.

81. The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Authorized Claimants who suffered economic losses as a proximate result of the wrongdoing alleged in the Action. The calculations made pursuant to the Plan of Allocation are not intended to be estimates of, nor indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations pursuant to the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants pursuant to the Settlement. The computations under the Plan of Allocation are only a method to weigh the claims of Authorized Claimants against one another for the purposes of making *pro rata* allocations of the Net Settlement Fund.

82. The Plan of Allocation was developed in consultation with Lead Plaintiff's damages experts and is based generally on the calculation for Section 10(b) damages set forth in the Expert Report of Matthew D. Cain concerning damages dated September 25, 2024. The Plan reflects the assumption that Defendants' alleged false and misleading statements and material omissions proximately caused the price of ChemoCentryx common stock to be artificially inflated throughout the Class Period. In calculating the estimated artificial inflation allegedly caused by Defendants' alleged misrepresentations and omissions, Lead Plaintiff's damages expert considered price change in ChemoCentryx common stock on May 4, 2021 and May 7, 2021, in reaction to the public disclosures, adjusting for price changes attributable to market or industry factors on those days.

83. To determine the daily artificial inflation per share, the Plan utilizes the minimum of a constant-percentage inflation and a constant-dollar inflation. Specifically, for any given trading day during the Class Period, the artificial inflation is the lesser of (i) Constant-Percentage Inflation: 78.44% of ChemoCentryx's closing share price from November 26, 2019 through May 3, 2021, and 62.21% of the closing share price from May 4, 2021 through May 5, 2021; or, (ii) Constant-Dollar Inflation: A fixed amount of $38.07 per share from November 26, 2019 through May 3, 2021, and $17.10 per share from May 4, 2021 through May 5, 2021. The dollar amount inflation in the price of each share of ChemoCentryx common stock based on this analysis for each trading day in the Class Period is set forth in Table A below.

84. Under the Plan, Recognized Loss Amounts are based primarily on the difference in the amount of alleged artificial inflation in the prices of ChemoCentryx common stock at the time of purchase or acquisition and at the time of sale, or the difference between the actual purchase price and sale price. In order to have a Recognized Loss Amount under the Plan of Allocation, a Class Member who purchased or otherwise acquired ChemoCentryx common stock during the Class Period must have held those shares through at least the close of trading on May 3, 2021, and purchasers on May 4, 2021 or May 5, 2021 must have held those shares through at least the close of trading on May 5, 2021.[2]

CALCULATION OF RECOGNIZED LOSS AMOUNT

85. Based on the formula stated below, a "Recognized Loss Amount" will be calculated for each purchase or acquisition of ChemoCentryx common stock during the Class Period that is listed on the Claim Form and for which adequate documentation is provided. If a Recognized Loss Amount calculates to a negative number or zero under the formula below, that Recognized Loss Amount will be zero.[3]

86. For each share of ChemoCentryx common stock purchased or otherwise acquired during the Class Period (that is, the period from November 26, 2019 through May 6, 2021, inclusive), and:

A. Sold prior to the close of trading on May 3, 2021, the Recognized Loss Amount will be $0.00.

B. Sold from May 4, 2021 through and including the close of trading on May 6, 2021, the Recognized Loss Amount will be ***the lesser of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below *minus* the amount of artificial inflation on the sale date as stated in Table A below; or (ii) the purchase/acquisition price minus the sale price.

---

[2] Trading in ChemoCentryx common stock was halted before the opening of trading on May 6, 2021 and did not resume until May 7, 2021, after the end of the Class Period.

[3] Any transactions in ChemoCentryx common stock executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

C. Sold from May 7, 2021 through and including the close of trading on August 4, 2021, the Recognized Loss Amount will be ***the least of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below; (ii) the purchase/acquisition price minus the average closing price from May 7, 2021 through the date of sale as stated in Table B below; or (iii) the purchase/acquisition price minus the sale price.

D. Held as of the close of trading on August 4, 2021, the Recognized Loss Amount will be ***the lesser of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below, or (ii) the purchase/acquisition price *minus* $12.85.[4]

ADDITIONAL PROVISIONS

87. **Calculation of Claimant's "Recognized Claim":** A Claimant's "Recognized Claim" will be the sum of his, her, or its Recognized Loss Amounts as calculated under ¶ 86 above.

88. **FIFO Matching:** If a Claimant made more than one purchase/acquisition or sale of ChemoCentryx common stock during the Class Period, all purchases/acquisitions and sales will be matched on a First In, First Out ("FIFO") basis. Class Period sales will be matched first against any holdings at the beginning of the Class Period and then against purchases/acquisitions in chronological order, beginning with the earliest purchase/acquisition made during the Class Period.

89. **Purchase/Sale Prices:** For the purposes of calculations in ¶ 86 above, "purchase/acquisition price" means the actual price paid, excluding any fees, commissions, and taxes, and "sale price" means the actual amount received, not deducting any fees, commissions, and taxes.

90. **"Purchase/Acquisition/Sale" Dates:** Purchases or acquisitions and sales of ChemoCentryx common stock will be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date. The receipt or grant by gift, inheritance, or operation of law of ChemoCentryx common stock during the Class Period will not be deemed a purchase, acquisition, or sale of ChemoCentryx common stock for the calculation of a Claimant's Recognized Loss Amount, nor will the receipt or grant be deemed an assignment of any claim relating to the purchase/acquisition/sale of ChemoCentryx common stock unless (i) the donor or decedent purchased or otherwise acquired or sold such ChemoCentryx common stock during the Class Period; (ii) the instrument of gift or assignment specifically provides that it is intended to transfer such rights; and (iii) no Claim was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such shares of ChemoCentryx common stock.

91. **Short Sales:** The date of covering a "short sale" is deemed to be the date of purchase or acquisition of the ChemoCentryx common stock. The date of a "short sale" is deemed to be the date of sale of the ChemoCentryx common stock. In accordance with the Plan of Allocation, however, the Recognized Loss Amount on "short sales" and the purchases covering "short sales" is zero.

---

[4] Pursuant to Section 21D(e)(1) of the Exchange Act, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market." Consistent with the requirements of the Exchange Act, Recognized Loss Amounts are reduced to an appropriate extent by taking into account the closing prices of ChemoCentryx common stock during the "90-day look-back period" from May 7, 2021 through August 4, 2021. The mean (average) closing price for ChemoCentryx common stock during this period was $12.85.

92. In the event that a Claimant has an opening short position in ChemoCentryx common stock, the earliest purchases or acquisitions of ChemoCentryx common stock during the Class Period will be matched against such opening short position, and not be entitled to a recovery, until that short position is fully covered.

93. **Common Stock Purchased/Sold Through the Exercise of Options:** Option contracts are not securities eligible to participate in the Settlement. With respect to ChemoCentryx common stock purchased or sold through the exercise of an option, the purchase/sale date of the common stock is the exercise date of the option and the purchase/sale price is the exercise price of the option.

94. **Market Gains and Losses:** The Claims Administrator will determine if the Claimant had a "Market Gain" or a "Market Loss" with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period. For purposes of making this calculation, the Claims Administrator shall determine the difference between (i) the Claimant's Total Purchase Amount[5] and (ii) the sum of the Claimant's Total Sales Proceeds[6] and the Claimant's Holding Value.[7] If the Claimant's Total Purchase Amount *minus* the sum of the Claimant's Total Sales Proceeds and the Holding Value is a positive number, that number will be the Claimant's Market Loss; if the number is a negative number or zero, that number will be the Claimant's Market Gain.

95. If a Claimant had a Market Gain with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period, the value of the Claimant's Recognized Claim will be zero, and the Claimant will in any event be bound by the Settlement. If a Claimant suffered an overall Market Loss with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period but that Market Loss was less than the Claimant's Recognized Claim, then the Claimant's Recognized Claim will be limited to the amount of the Market Loss.

96. **Determination of Distribution Amount:** The Net Settlement Fund will be distributed to Authorized Claimants on a *pro rata* basis based on the relative size of their Recognized Claims. Specifically, a "Distribution Amount" will be calculated for each Authorized Claimant, which will be the Authorized Claimant's Recognized Claim divided by the total Recognized Claims of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund.

97. If an Authorized Claimant's Distribution Amount calculates to less than $10.00, no distribution will be made to that Authorized Claimant. Those funds will be included in the distribution to Authorized Claimants whose Distribution Amount is $10.00 or more.

98. After the initial distribution of the Net Settlement Fund, the Claims Administrator will make reasonable and diligent efforts to have Authorized Claimants cash their distribution checks. To the extent any monies remain in the Net Settlement Fund six (6) months after the initial distribution, if Class Counsel, in consultation with the Claims Administrator, determines that it is cost-effective to do so, the

---

[5] The "Total Purchase Amount" is the total amount the Claimant paid (excluding all fees, taxes, and commissions) for all shares of ChemoCentryx common stock purchased or acquired during Class Period.

[6] The Claims Administrator shall match any sales of ChemoCentryx common stock during the Class Period first against the Claimant's opening position in ChemoCentryx common stock (the proceeds of those sales will not be considered for purposes of calculating market gains or losses). The total amount received (not deducting any fees, taxes and commissions) for sales of the remaining shares of ChemoCentryx common stock sold during the Class Period is the "Total Sales Proceeds."

[7] The Claims Administrator shall ascribe a "Holding Value" of $10.46 to each share of ChemoCentryx common stock purchased or acquired during the Class Period that was still held as of the close of trading on May 5, 2021.

Claims Administrator will conduct a re-distribution of the funds remaining after payment of any unpaid fees and expenses incurred in administering the Settlement, including for such re-distribution, to Authorized Claimants who have cashed their initial distributions and who would receive at least $10.00 from such re-distribution. Additional re-distributions to Authorized Claimants who have cashed their prior checks may occur thereafter if Lead Counsel, in consultation with the Claims Administrator, determines that additional re-distributions, after the deduction of any additional fees and expenses incurred in administering the Settlement, including for such re-distributions, would be cost-effective. At such time as it is determined that the re-distribution of funds remaining in the Net Settlement Fund is not cost-effective, the remaining balance will be contributed to the Bluhm Legal Clinic Complex Civil Litigation and Investor Protection Center at the Northwestern Pritzker School of Law.

99. Payment pursuant to the Plan of Allocation, or such other plan of allocation as may be approved by the Court, will be conclusive against all Claimants. No person shall have any claim against Lead Plaintiff, Class Counsel, Lead Plaintiff's damages experts, Lead Plaintiff's consulting experts, Defendants, Defendants' Counsel, or any of the other Plaintiffs' Releasees or Defendants' Releasees, or the Claims Administrator or other agent designated by Class Counsel arising from distributions made substantially in accordance with the Stipulation, the plan of allocation approved by the Court, or further Orders of the Court. Lead Plaintiff, Defendants, and their respective counsel, and all other Defendants' Releasees, shall have no responsibility or liability whatsoever for the investment or distribution of the Settlement Fund or the Net Settlement Fund; the plan of allocation; the determination, administration, calculation, or payment of any Claim or nonperformance of the Claims Administrator; the payment or withholding of Taxes; or any losses incurred in connection therewith.

TABLE A

Artificial Inflation in ChemoCentryx Common Stock
November 26, 2019 through May 6, 2021

Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share
November 26, 2019	$24.10	January 28, 2020	$32.29	March 26, 2020	$31.30
November 27, 2019	$23.34	January 29, 2020	$31.96	March 27, 2020	$30.24
November 29, 2019	$23.79	January 30, 2020	$32.08	March 30, 2020	$31.06
December 2, 2019	$22.84	January 31, 2020	$33.27	March 31, 2020	$31.52
December 3, 2019	$23.03	February 3, 2020	$35.21	April 1, 2020	$30.26
December 4, 2019	$22.03	February 4, 2020	$35.50	April 2, 2020	$31.18
December 5, 2019	$24.35	February 5, 2020	$36.99	April 3, 2020	$30.56
December 6, 2019	$24.54	February 6, 2020	$37.49	April 6, 2020	$34.12
December 9, 2019	$23.24	February 7, 2020	$37.25	April 7, 2020	$33.41
December 10, 2019	$24.42	February 10, 2020	$38.07	April 8, 2020	$33.92
December 11, 2019	$24.48	February 11, 2020	$38.07	April 9, 2020	$35.29
December 12, 2019	$26.10	February 12, 2020	$38.07	April 13, 2020	$36.38
December 13, 2019	$24.64	February 13, 2020	$38.07	April 14, 2020	$38.07
December 16, 2019	$26.49	February 14, 2020	$37.65	April 15, 2020	$36.13
December 17, 2019	$26.72	February 18, 2020	$38.07	April 16, 2020	$36.74
December 18, 2019	$26.07	February 19, 2020	$38.07	April 17, 2020	$38.07
December 19, 2019	$27.16	February 20, 2020	$38.07	April 20, 2020	$38.07
December 20, 2019	$28.43	February 21, 2020	$38.07	April 21, 2020	$37.96
December 23, 2019	$28.32	February 24, 2020	$36.87	April 22, 2020	$38.07
December 24, 2019	$29.21	February 25, 2020	$36.37	April 23, 2020	$38.07
December 26, 2019	$29.29	February 26, 2020	$36.12	April 24, 2020	$38.07
December 27, 2019	$28.42	February 27, 2020	$34.65	April 27, 2020	$38.07
December 30, 2019	$29.81	February 28, 2020	$35.10	April 28, 2020	$38.07
December 31, 2019	$31.02	March 2, 2020	$36.49	April 29, 2020	$38.07
January 2, 2020	$28.58	March 3, 2020	$36.54	April 30, 2020	$38.07
January 3, 2020	$28.20	March 4, 2020	$38.07	May 1, 2020	$38.07
January 6, 2020	$27.27	March 5, 2020	$38.07	May 4, 2020	$38.07
January 7, 2020	$27.76	March 6, 2020	$37.12	May 5, 2020	$38.07
January 8, 2020	$28.86	March 9, 2020	$34.62	May 6, 2020	$38.07
January 9, 2020	$30.18	March 10, 2020	$35.91	May 7, 2020	$38.07
January 10, 2020	$29.97	March 11, 2020	$32.58	May 8, 2020	$38.07
January 13, 2020	$28.78	March 12, 2020	$30.66	May 11, 2020	$38.07
January 14, 2020	$29.74	March 13, 2020	$34.86	May 12, 2020	$38.07
January 15, 2020	$29.53	March 16, 2020	$27.01	May 13, 2020	$38.07
January 16, 2020	$32.10	March 17, 2020	$27.49	May 14, 2020	$38.07
January 17, 2020	$34.25	March 18, 2020	$25.67	May 15, 2020	$38.07
January 21, 2020	$33.51	March 19, 2020	$27.43	May 18, 2020	$38.07
January 22, 2020	$33.35	March 20, 2020	$28.89	May 19, 2020	$38.07
January 23, 2020	$31.96	March 23, 2020	$29.45	May 20, 2020	$38.07
January 24, 2020	$32.37	March 24, 2020	$30.81	May 21, 2020	$38.07
January 27, 2020	$31.86	March 25, 2020	$30.48	May 22, 2020	$38.07

Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share
May 26, 2020	$38.07	July 29, 2020	$38.07	October 1, 2020	$38.07
May 27, 2020	$38.07	July 30, 2020	$38.07	October 2, 2020	$38.07
May 28, 2020	$38.07	July 31, 2020	$38.07	October 5, 2020	$38.07
May 29, 2020	$38.07	August 3, 2020	$38.07	October 6, 2020	$38.07
June 1, 2020	$38.07	August 4, 2020	$38.07	October 7, 2020	$38.07
June 2, 2020	$38.07	August 5, 2020	$38.07	October 8, 2020	$38.07
June 3, 2020	$38.07	August 6, 2020	$38.07	October 9, 2020	$38.07
June 4, 2020	$38.07	August 7, 2020	$38.07	October 12, 2020	$38.07
June 5, 2020	$38.07	August 10, 2020	$38.07	October 13, 2020	$38.07
June 8, 2020	$38.07	August 11, 2020	$38.07	October 14, 2020	$38.07
June 9, 2020	$38.07	August 12, 2020	$38.07	October 15, 2020	$38.07
June 10, 2020	$38.07	August 13, 2020	$38.07	October 16, 2020	$38.07
June 11, 2020	$38.07	August 14, 2020	$38.07	October 19, 2020	$38.07
June 12, 2020	$38.07	August 17, 2020	$38.07	October 20, 2020	$38.07
June 15, 2020	$38.07	August 18, 2020	$38.07	October 21, 2020	$38.07
June 16, 2020	$38.07	August 19, 2020	$38.07	October 22, 2020	$38.07
June 17, 2020	$38.07	August 20, 2020	$38.07	October 23, 2020	$38.07
June 18, 2020	$38.07	August 21, 2020	$38.07	October 26, 2020	$38.07
June 19, 2020	$38.07	August 24, 2020	$38.07	October 27, 2020	$38.07
June 22, 2020	$38.07	August 25, 2020	$38.07	October 28, 2020	$38.07
June 23, 2020	$38.07	August 26, 2020	$38.07	October 29, 2020	$38.07
June 24, 2020	$38.07	August 27, 2020	$38.07	October 30, 2020	$37.65
June 25, 2020	$38.07	August 28, 2020	$38.07	November 2, 2020	$37.06
June 26, 2020	$38.07	August 31, 2020	$38.07	November 3, 2020	$37.86
June 29, 2020	$38.07	September 1, 2020	$38.07	November 4, 2020	$38.07
June 30, 2020	$38.07	September 2, 2020	$38.07	November 5, 2020	$38.07
July 1, 2020	$38.07	September 3, 2020	$37.74	November 6, 2020	$38.07
July 2, 2020	$38.07	September 4, 2020	$37.30	November 9, 2020	$38.07
July 6, 2020	$38.07	September 8, 2020	$36.36	November 10, 2020	$38.07
July 7, 2020	$38.07	September 9, 2020	$38.07	November 11, 2020	$38.07
July 8, 2020	$38.07	September 10, 2020	$37.16	November 12, 2020	$38.07
July 9, 2020	$38.07	September 11, 2020	$37.71	November 13, 2020	$38.07
July 10, 2020	$38.07	September 14, 2020	$38.07	November 16, 2020	$38.07
July 13, 2020	$38.07	September 15, 2020	$38.07	November 17, 2020	$38.07
July 14, 2020	$38.07	September 16, 2020	$38.07	November 18, 2020	$38.07
July 15, 2020	$38.07	September 17, 2020	$38.07	November 19, 2020	$38.07
July 16, 2020	$38.07	September 18, 2020	$38.07	November 20, 2020	$38.07
July 17, 2020	$38.07	September 21, 2020	$38.07	November 23, 2020	$38.07
July 20, 2020	$38.07	September 22, 2020	$38.07	November 24, 2020	$38.07
July 21, 2020	$38.07	September 23, 2020	$38.07	November 25, 2020	$38.07
July 22, 2020	$38.07	September 24, 2020	$38.07	November 27, 2020	$38.07
July 23, 2020	$38.07	September 25, 2020	$38.07	November 30, 2020	$38.07
July 24, 2020	$38.07	September 28, 2020	$38.07	December 1, 2020	$38.07
July 27, 2020	$38.07	September 29, 2020	$38.07	December 2, 2020	$38.07
July 28, 2020	$38.07	September 30, 2020	$38.07	December 3, 2020	$38.07

Date	Artificial Inflation Per-Share
December 4, 2020	$38.07
December 7, 2020	$38.07
December 8, 2020	$38.07
December 9, 2020	$38.07
December 10, 2020	$38.07
December 11, 2020	$38.07
December 14, 2020	$38.07
December 15, 2020	$38.07
December 16, 2020	$38.07
December 17, 2020	$38.07
December 18, 2020	$38.07
December 21, 2020	$38.07
December 22, 2020	$38.07
December 23, 2020	$38.07
December 24, 2020	$38.07
December 28, 2020	$38.07
December 29, 2020	$38.07
December 30, 2020	$38.07
December 31, 2020	$38.07
January 4, 2021	$38.07
January 5, 2021	$38.07
January 6, 2021	$38.07
January 7, 2021	$38.07
January 8, 2021	$38.07
January 11, 2021	$38.07
January 12, 2021	$38.07
January 13, 2021	$38.07
January 14, 2021	$38.07
January 15, 2021	$38.07
January 19, 2021	$38.07
January 20, 2021	$38.07
January 21, 2021	$38.07
January 22, 2021	$38.07
January 25, 2021	$38.07
January 26, 2021	$38.07
January 27, 2021	$38.07
January 28, 2021	$38.07
January 29, 2021	$38.07
February 1, 2021	$38.07
February 2, 2021	$38.07
February 3, 2021	$38.07
February 4, 2021	$38.07
February 5, 2021	$38.07
February 8, 2021	$38.07
February 9, 2021	$38.07
February 10, 2021	$38.07
February 11, 2021	$38.07
February 12, 2021	$38.07
February 16, 2021	$38.07
February 17, 2021	$38.07
February 18, 2021	$38.07
February 19, 2021	$38.07
February 22, 2021	$38.07
February 23, 2021	$38.07
February 24, 2021	$38.07
February 25, 2021	$38.07
February 26, 2021	$38.07
March 1, 2021	$38.07
March 2, 2021	$38.07
March 3, 2021	$38.07
March 4, 2021	$38.07
March 5, 2021	$38.07
March 8, 2021	$38.07
March 9, 2021	$38.07
March 10, 2021	$38.07
March 11, 2021	$38.07
March 12, 2021	$38.07
March 15, 2021	$38.07
March 16, 2021	$38.07
March 17, 2021	$38.07
March 18, 2021	$38.07
March 19, 2021	$38.07
March 22, 2021	$38.07
March 23, 2021	$38.07
March 24, 2021	$38.07
March 25, 2021	$38.07
March 26, 2021	$38.07
March 29, 2021	$38.07
March 30, 2021	$38.07
March 31, 2021	$38.07
April 1, 2021	$38.07
April 5, 2021	$38.07
April 6, 2021	$38.07
April 7, 2021	$37.65
April 8, 2021	$38.07
April 9, 2021	$38.07
April 12, 2021	$36.32
April 13, 2021	$37.01
April 14, 2021	$37.13
April 15, 2021	$36.98
April 16, 2021	$36.50
April 19, 2021	$35.14
April 20, 2021	$35.52
April 21, 2021	$36.42
April 22, 2021	$36.29
April 23, 2021	$36.00
April 26, 2021	$37.15
April 27, 2021	$36.05
April 28, 2021	$36.08
April 29, 2021	$35.30
April 30, 2021	$37.91
May 3, 2021	$38.07
May 4, 2021	$16.57
May 5, 2021	$17.10
May 6, 2021[8]	$0.00

8. Trading in ChemoCentryx common stock was halted before the opening of trading on May 6, 2021 and did not resume until May 7, 2021.

TABLE B

90-Day Look-back Table for ChemoCentryx Common Stock
Closing Price and Average Closing Price
May 7, 2021 through August 4, 2021

Date	Closing Price	Average Closing Price from May 7, 2021 through Date Shown	Date	Closing Price	Average Closing Price from May 7, 2021 through Date Shown
May 7, 2021	$10.46	$10.46	June 22, 2021	$12.89	$10.98
May 10, 2021	$10.97	$10.72	June 23, 2021	$12.76	$11.04
May 11, 2021	$10.75	$10.73	June 24, 2021	$13.06	$11.10
May 12, 2021	$10.05	$10.56	June 25, 2021	$13.77	$11.17
May 13, 2021	$9.97	$10.44	June 28, 2021	$14.29	$11.26
May 14, 2021	$10.44	$10.44	June 29, 2021	$14.09	$11.34
May 17, 2021	$9.89	$10.36	June 30, 2021	$13.39	$11.39
May 18, 2021	$10.36	$10.36	July 1, 2021	$13.20	$11.44
May 19, 2021	$9.96	$10.32	July 2, 2021	$13.18	$11.48
May 20, 2021	$10.06	$10.29	July 6, 2021	$14.05	$11.54
May 21, 2021	$9.59	$10.23	July 7, 2021	$14.47	$11.61
May 24, 2021	$9.81	$10.19	July 8, 2021	$15.10	$11.69
May 25, 2021	$9.67	$10.15	July 9, 2021	$16.77	$11.81
May 26, 2021	$9.77	$10.13	July 12, 2021	$17.34	$11.93
May 27, 2021	$10.41	$10.14	July 13, 2021	$16.29	$12.03
May 28, 2021	$10.15	$10.14	July 14, 2021	$15.72	$12.10
June 1, 2021	$10.16	$10.15	July 15, 2021	$15.49	$12.18
June 2, 2021	$10.20	$10.15	July 16, 2021	$15.85	$12.25
June 3, 2021	$9.98	$10.14	July 19, 2021	$15.63	$12.32
June 4, 2021	$10.03	$10.13	July 20, 2021	$16.12	$12.39
June 7, 2021	$10.72	$10.16	July 21, 2021	$15.83	$12.46
June 8, 2021	$10.94	$10.20	July 22, 2021	$14.99	$12.51
June 9, 2021	$11.18	$10.24	July 23, 2021	$14.37	$12.54
June 10, 2021	$11.54	$10.29	July 26, 2021	$14.54	$12.58
June 11, 2021	$12.18	$10.37	July 27, 2021	$14.66	$12.61
June 14, 2021	$13.17	$10.48	July 28, 2021	$15.51	$12.67
June 15, 2021	$12.81	$10.56	July 29, 2021	$14.97	$12.71
June 16, 2021	$13.24	$10.66	July 30, 2021	$14.78	$12.74
June 17, 2021	$13.53	$10.76	August 2, 2021	$14.89	$12.78
June 18, 2021	$13.51	$10.85	August 3, 2021	$15.11	$12.81
June 21, 2021	$13.06	$10.92	August 4, 2021	$15.32	$12.85

8 3 0 7 4 0 0 0 0 0 0 0 0

ChemoCentryx Securities Litigation
Toll-Free Number: (833) 522-2606
Email: info@ChemoCentryxSecuritiesLitigation.com
Website: www.ChemoCentryxSecuritiesLitigation.com

PROOF OF CLAIM AND RELEASE FORM

To be eligible to receive a share of the Net Settlement Fund in connection with the Settlement of this Action, you must complete and sign this Proof of Claim and Release Form ("Claim Form") and mail it by First-Class Mail to the address below, or submit it online at www.ChemoCentryxSecuritiesLitigation.com, with supporting documentation, ***postmarked* (if mailed) or submitted online no later than October 1, 2026**.

Mail to:

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5013
New York, NY 10150-5013

Failure to submit your Claim Form by the date specified will subject your claim to rejection and may preclude you from being eligible to receive any money in connection with the Settlement.

Do not mail or deliver your Claim Form to the Court, the Parties to the Action, or their counsel. Submit your Claim Form only to the Claims Administrator at the address set forth above.

TABLE OF CONTENTS	**PAGE #**

Need help? If you have questions concerning this Claim Form or need assistance in filling out the Claim Form, you may contact the Claims Administrator at the above mailing address, by email at info@ChemoCentryxSecuritiesLitigation.com, or by toll-free phone at (833) 522-2606, or you can visit the website, www.ChemoCentryxSecuritiesLitigation.com.

8 3 0 7 4 0 0 0 0 0 0 0 0

PART I – CLAIMANT INFORMATION

The Claims Administrator will use this information for all communications regarding this Claim Form. If this information changes, you MUST notify the Claims Administrator in writing at the address above. Complete names of all persons and entities must be provided.

Name of the Beneficial Owner of ChemoCentryx common stock (see ¶ 9 on page 4 for details)

________________________ ________________________

First Name Last Name

Joint Owner's Name (*if applicable*)

________________________ ________________________

First Name Last Name

If this claim is submitted for an IRA, and if you would like any check that you MAY be eligible to receive made payable to the IRA, please include "IRA" in the "Last Name" box above (*e.g.*, Jones IRA).

____

Entity Name (if the Owner is not an individual)

____

Name of Representative, if applicable (*executor, administrator, trustee, c/o, etc.*), if different from Owner

____ ____ ____ ____

Last 4 digits of Social Security Number or Taxpayer Identification Number

____

Street Address

____

Street Address (second line, if needed)

________________________________ ____ ____ ____ ____ ____ ____ ____

City State/Province Zip Code

________________________ ________________________

Foreign Postal Code (if applicable) Foreign Country (if applicable)

(____ ____ ____) ____ ____ ____ - ____ ____ ____ ____ (____ ____ ____) ____ ____ ____ - ____ ____ ____ ____

Telephone Number (Day) Telephone Number (Evening)

________________________ @ ________________________

Email Address (email address is not required, but if you provide it you authorize the Claims Administrator to use it in providing you with information relevant to this claim)

Type of Owner:

Specify one of the following:

☐ Individual(s) ☐ Corporation ☐ UGMA Custodian ☐ IRA

☐ Partnership ☐ Estate ☐ Trust ☐ Other (describe: ____________________)

PART II – GENERAL INSTRUCTIONS

1. It is important that you completely read and understand the Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses ("Settlement Notice"), including the proposed Plan of Allocation set forth in the Settlement Notice ("Plan of Allocation"). The Settlement Notice describes the proposed Settlement, how Class Members are affected by the Settlement, and the manner in which the Net Settlement Fund will be distributed if the Settlement and Plan of Allocation are approved by the Court. The Settlement Notice also contains the definitions of many of the defined terms (which are indicated by initial capital letters) used in this Claim Form. By signing and submitting this Claim Form, you will be certifying that you have read and that you understand the Settlement Notice, including the terms of the Releases described therein and provided for herein.

2. This Claim Form is directed to **all persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx") between November 26, 2019 and May 6, 2021, inclusive ("Class Period"), and were damaged thereby ("Class")**. Certain persons and entities are excluded from the Class by definition as set forth in ¶ 28 of the Settlement Notice.

3. By submitting this Claim Form, you are making a request to share in the proceeds of the Settlement described in the Settlement Notice. IF YOU ARE NOT A CLASS MEMBER (*see* definition of "Class" contained in ¶ 28 of the Settlement Notice), OR IF YOU PREVIOUSLY SUBMITTED A REQUEST FOR EXCLUSION FROM THE CLASS IN CONNECTION WITH CLASS NOTICE AND DO NOT OPT BACK INTO THE CLASS IN CONNECTION WITH THE SETTLEMENT, DO NOT SUBMIT A CLAIM FORM AS **YOU MAY NOT, DIRECTLY OR INDIRECTLY, PARTICIPATE IN THE SETTLEMENT.** THUS, IF YOU ARE EXCLUDED FROM THE CLASS, ANY CLAIM FORM THAT YOU SUBMIT, OR THAT MAY BE SUBMITTED ON YOUR BEHALF, WILL NOT BE ACCEPTED.

4. **Submission of this Claim Form does not guarantee that you will share in the proceeds of the Settlement. The distribution of the Net Settlement Fund will be governed by the Plan of Allocation set forth in the Settlement Notice, if it is approved by the Court, or by such other plan of allocation as the Court approves.**

5. Use the Schedule of Transactions in Part III of this Claim Form to supply all required details of your transaction(s) (including free transfers and deliveries) in and holdings of ChemoCentryx common stock. In this Schedule, please provide all of the requested information with respect to your holdings, purchases, acquisitions, and sales of ChemoCentryx common stock, whether such transactions resulted in a profit or a loss. **Failure to report all transaction and holding information during the requested time periods may result in the rejection of your claim.**

6. **Please note**: Only ChemoCentryx common stock purchased or acquired during the Class Period (i.e., the period from November 26, 2019 through May 6, 2021, inclusive) is eligible under the Settlement. However, because the PSLRA provides for a "90-day look-back period" (described in the Plan of Allocation set forth in the Settlement Notice), you must provide documentation related to your purchases, acquisitions, and sales of ChemoCentryx common stock during the period from May 7, 2021 through August 4, 2021 (i.e., the 90-day look-back period) in order for the Claims Administrator to calculate your Recognized Loss Amount under the Plan of Allocation and process your claim. **Failure to report all transaction and holding information during the requested time periods may result in the rejection of your claim.**

7. You are required to submit genuine and sufficient documentation for all of your transactions in and holdings of the ChemoCentryx common stock set forth in the Schedule of Transactions in Part III of this Claim Form. Documentation may consist of copies of trade confirmations or account statements, or an authorized statement from your broker or other financial institution containing the transactional and holding information found in a trade confirmation or account statement. The Parties and the Claims Administrator do not independently have information about your investments in ChemoCentryx common stock. IF SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN COPIES OF THE DOCUMENTS OR EQUIVALENT DOCUMENTS FROM YOUR BROKER. FAILURE TO SUPPLY THIS DOCUMENTATION MAY RESULT IN THE REJECTION OF YOUR CLAIM. DO NOT SEND ORIGINAL DOCUMENTS. **Please keep a copy of all documents that you send to the Claims Administrator. Also, do not highlight any portion of the Claim Form or any supporting documents.**

8. **One Claim Form should be submitted for each separate legal entity or separately managed account.** Separate Claim Forms should be submitted for each separate legal entity (e.g., an individual should not combine his or her IRA transactions with transactions made solely in the individual's name). Generally, a single Claim Form should be submitted on behalf of one legal entity including all holdings and transactions made by that entity on one Claim Form. However, if a single person or legal entity had multiple accounts that were separately managed, separate Claims may be submitted for each such account. The Claims Administrator reserves the right to request information on all the holdings and transactions in ChemoCentryx common stock made on behalf of a single beneficial owner.

9. All joint beneficial owners must sign this Claim Form and their names must appear as "Claimants" in Part II of this Claim Form. The complete name(s) of the beneficial owner(s) must be entered. If you purchased or acquired ChemoCentryx common stock during the Class Period and held the shares in your name, you are the beneficial owner as well as the record owner. If you purchased or acquired ChemoCentryx common stock during the Class Period and the shares were registered in the name of a third party, such as a nominee or brokerage firm, you are the beneficial owner of these shares/options, but the third party is the record owner. The beneficial owner, not the record owner, must sign this Claim Form.

10. Agents, executors, administrators, guardians, and trustees must complete and sign the Claim Form on behalf of persons represented by them, and they must:

(a) expressly state the capacity in which they are acting;

(b) identify the name, account number, last four digits of the Social Security Number (or Taxpayer Identification Number), address, and telephone number of the beneficial owner of (or other person or entity on whose behalf they are acting with respect to) the ChemoCentryx common stock; and

(c) furnish herewith evidence of their authority to bind to the Claim Form the person or entity on whose behalf they are acting. (Authority to complete and sign a Claim Form cannot be established by stockbrokers demonstrating only that they have discretionary authority to trade securities in another person's accounts.)

11. By submitting a signed Claim Form, you will be swearing to the truth of the statements contained therein and the genuineness of the documents attached thereto, subject to penalties of perjury under the laws of the United States of America. The making of false statements, or the submission of forged or fraudulent documentation, will result in the rejection of your claim and may subject you to civil liability or criminal prosecution.

12. If the Court approves the Settlement, payments to eligible Authorized Claimants pursuant to the Plan of Allocation (or such other plan of allocation as the Court approves) will be made after any appeals are resolved, and after the completion of all claims processing. The claims process will take substantial time to complete fully and fairly. Please be patient.

13. **PLEASE NOTE**: As set forth in the Plan of Allocation, each Authorized Claimant shall receive their *pro rata* share of the Net Settlement Fund. If the prorated payment to any Authorized Claimant calculates to less than $10.00, it will not be included in the calculation and no distribution will be made to that Authorized Claimant.

14. If you have questions concerning the Claim Form, or need additional copies of the Claim Form or a copy of the Settlement Notice, you may contact the Claims Administrator, Kroll Settlement Administration, at the above address, by email at info@ChemoCentryxSecuritiesLitigation.com, or by toll-free phone at 833-522-2606, or you can visit the website maintained by the Claims Administrator, www.ChemoCentryxSecuritiesLitigation.com, where copies of the Claim Form and Settlement Notice are available for downloading.

15. **NOTICE REGARDING ELECTRONIC FILES**: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. To obtain the ***mandatory*** electronic filing requirements and file layout, you may visit the website www.ChemoCentryxSecuritiesLitigation.com, or you may email the Claims Administrator's electronic filing department at info@ChemoCentryxSecuritiesLitigation.com. **Any file that is not in accordance with the required electronic filing format will be subject to rejection.** No electronic files will be considered to have been properly submitted unless the Claims Administrator issues an email to you to that effect. **Do not assume that your file has been received until you receive this email. If you do not receive such an email within 10 days of your submission, you should contact the Claims Administrator's electronic filing department at info@ChemoCentryxSecuritiesLitigation.com to inquire about your file and confirm it was received.**

IMPORTANT PLEASE NOTE:

YOUR CLAIM IS NOT DEEMED SUBMITTED UNTIL YOU RECEIVE AN ACKNOWLEDGMENT POSTCARD. THE CLAIMS ADMINISTRATOR WILL ACKNOWLEDGE RECEIPT OF YOUR CLAIM FORM BY MAIL WITHIN 60 DAYS. IF YOU DO NOT RECEIVE AN ACKNOWLEDGMENT POSTCARD WITHIN 60 DAYS, CALL THE CLAIMS ADMINISTRATOR TOLL FREE AT 833-522-2606.

830740000000000

PART III – SCHEDULE OF TRANSACTIONS IN CHEMOCENTRYX COMMON STOCK

The only eligible security is the common stock of ChemoCentryx, Inc. ("ChemoCentryx"). During the Class Period, ChemoCentryx common stock traded on the NASDAQ. Its ticker symbol was **CCXI**, and its **CUSIP** was **16383L106**. Do not include information regarding securities other than ChemoCentryx common stock. Please include proper documentation with your Claim Form as described in detail in Part II – General Instructions ¶ 7, above.

1. HOLDINGS AS OF NOVEMBER 26, 2019 – State the total number of shares of ChemoCentryx common stock held as of the opening of trading on November 26, 2019. (Must be documented.) If none, write "zero" or "0." ______	Confirm Proof of Position Enclosed ☐

2. PURCHASES/ACQUISITIONS FROM NOVEMBER 26, 2019 THROUGH MAY 6, 2021, INCLUSIVE – Separately list each and every purchase or acquisition (including free receipts) of ChemoCentryx common stock from November 26, 2019 through the close of trading on May 6, 2021. (Must be documented.)

Date of Purchase/ Acquisition (List Chronologically) (Month/Day/Year)	Number of Shares Purchased	Purchase Price Per Share	Total Purchase Price (excluding any taxes, commissions, and fees)	Confirm Proof of Purchase Enclosed
/ /		$	$	☐
/ /		$	$	☐
/ /		$	$	☐
/ /		$	$	☐

3. PURCHASES/ACQUISITIONS FROM MAY 7, 2021 THROUGH AUGUST 4, 2021, INCLUSIVE – State the total number of shares of ChemoCentryx common stock purchased or acquired (including free receipts) from May 7, 2021 through the close of trading on August 4, 2021. If none, write "zero" or "0." ______

4. SALES FROM NOVEMBER 26, 2019 THROUGH AUGUST 4, 2021 – Separately list each and every sale or disposition (including free deliveries) of ChemoCentryx common stock from November 26, 2019 through the close of trading on August 4, 2021. (Must be documented.)	**IF NONE, CHECK HERE** ☐

Date of Sale (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Sale Price Per Share	Total Sale Price (not deducting any taxes, commissions, and fees)	Confirm Proof of Sale Enclosed
/ /		$	$	☐
/ /		$	$	☐
/ /		$	$	☐
/ /		$	$	☐

5. HOLDINGS AS OF AUGUST 4, 2021 – State the total number of shares of ChemoCentryx common stock held as of the close of trading on August 4, 2021. (Must be documented.) If none, write "zero" or "0." ______	Confirm Proof of Position Enclosed ☐

IF YOU REQUIRE ADDITIONAL SPACE FOR THE SCHEDULE ABOVE, ATTACH EXTRA SCHEDULES IN THE SAME FORMAT. PRINT THE BENEFICIAL OWNER'S FULL NAME AND LAST FOUR DIGITS OF SOCIAL SECURITY/TAXPAYER IDENTIFICATION NUMBER ON EACH ADDITIONAL PAGE. IF YOU DO ATTACH EXTRA SCHEDULES, CHECK THIS BOX. ☐

PART IV – RELEASE OF CLAIMS, CERTIFICATION, AND SIGNATURE

YOU MUST ALSO READ THE RELEASE AND CERTIFICATION BELOW AND SIGN ON PAGE 8 OF THIS CLAIM FORM.

I (We) hereby acknowledge that, pursuant to the terms set forth in the Stipulation, without further action by anyone, upon the Effective Date of the Settlement, I (we), on behalf of myself (ourselves) and my (our) (the claimant(s)') respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, shall be deemed to have, and by operation of law and of the Judgment or the Alternate Judgment, if applicable, shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Plaintiff's Claim (including, without limitation, Unknown Claims) against Defendants and the other Defendants' Releasees, and shall forever be barred and enjoined from prosecuting any and all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants' Releasees.

CERTIFICATION

By signing and submitting this Claim Form, the claimant(s) or the person(s) who represent(s) the claimant(s) agree(s) to the release above and certifies (certify) as follows:

1. that I (we) have read and understand the contents of the Settlement Notice and this Claim Form, including the releases provided for in the Settlement and the terms of the Plan of Allocation;

2. that the claimant(s) is a (are) Class Member(s), as defined in the Settlement Notice, and is (are) not excluded by definition from the Class as set forth in the Settlement Notice;

3. that the claimant(s) did ***not*** submit a request for exclusion from the Class;

4. that I (we) owned the ChemoCentryx common stock identified in the Claim Form and have not assigned the claim against any of the Defendants or any of the other Defendants' Releasees to another, or that, in signing and submitting this Claim Form, I (we) have the authority to act on behalf of the owner(s) thereof;

5. that the claimant(s) has (have) not submitted any other claim covering the same purchases of ChemoCentryx common stock and knows (know) of no other person having done so on the claimant's (claimants') behalf;

6. that the claimant(s) has (have) not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any Released Plaintiff's Claim against any of the Defendants' Releasees;

7. that the claimant(s) submit(s) to the jurisdiction of the United States District Court for the Northern District of California with respect to claimant's (claimants') claim and for purposes of enforcing the releases set forth herein;

8. that I (we) agree to furnish such additional information with respect to this Claim Form as Class Counsel, the Claims Administrator, or the Court may require;

9. that the claimant(s) waive(s) the right to trial by jury, to the extent it exists, and agree(s) to the determination by the Court of the validity or amount of this Claim, and waive(s) any right of appeal or review with respect to such determination;

10. that I (we) acknowledge that the claimant(s) will be bound by and subject to the terms of any judgment(s) that may be entered in the Action; and

11. that the claimant(s) is (are) NOT subject to backup withholding under the provisions of Section 3406(a)(1)(C) of the Internal Revenue Code because (i) the claimant(s) is (are) exempt from backup withholding or (ii) the claimant(s) has (have) not been notified by the IRS that he, she, or it is subject to backup withholding as a result of a failure to report all interest or dividends or (iii) the IRS has notified the claimant(s) that he, she, or it is no longer subject to backup withholding. **If the IRS has notified the claimant(s) that he, she, it, or they is (are) subject to backup withholding, please strike out the language in the preceding sentence indicating that the claim is not subject to backup withholding in the certification above.**

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES OF AMERICA, I (WE) CERTIFY THAT ALL OF THE INFORMATION PROVIDED BY ME (US) ON THIS CLAIM FORM IS TRUE, CORRECT, AND COMPLETE, AND THAT THE DOCUMENTS SUBMITTED HEREWITH ARE TRUE AND CORRECT COPIES OF WHAT THEY PURPORT TO BE.

Signature of claimant Date

Print claimant name here

Signature of joint claimant, if any Date

Print joint claimant name here

If the claimant is other than an individual, or is not the person completing this form, the following also must be provided:

Signature of person signing on behalf of claimant Date

Print name of person signing on behalf of claimant here

Capacity of person signing on behalf of claimant, if other than an individual, *e.g.*, executor, president, trustee, custodian, etc. (Must provide evidence of authority to act on behalf of Claimant – *see* ¶ 10 on page 4 of this Claim Form.)

REMINDER CHECKLIST

1. Sign the above release and certification. If this Claim Form is being made on behalf of joint claimants, then both must sign.
2. Attach only ***copies*** of acceptable supporting documentation as these documents will not be returned to you.
3. Do not highlight any portion of the Claim Form or any supporting documents.
4. Keep copies of the completed Claim Form and documentation for your own records.
5. The Claims Administrator will acknowledge receipt of your Claim Form by mail, within 60 days. Your claim is not deemed filed until you receive an acknowledgment postcard. **If you do not receive an acknowledgment postcard within 60 days, please call the Claims Administrator toll-free at (833) 522-2606.**
6. If your address changes in the future, or if this Claim Form was sent to an old or incorrect address, you must send the Claims Administrator written notification of your new address. If you change your name, inform the Claims Administrator.
7. If you have any questions or concerns regarding your Claim Form, contact the Claims Administrator at the mailing address below, by email at info@ChemoCentryxSecuritiesLitigation.com, or by toll-free phone at (833) 522-2606, or you may visit www.ChemoCentryxSecuritiesLitigation.com. DO NOT call ChemoCentryx, the other Defendants, or their counsel with questions regarding your Claim Form.

This Claim Form must be mailed to the Claims Administrator by First-Class Mail or submitted online at www.ChemoCentryxSecuritiesLitigation.com, postmarked (or submitted online) no later than October 1, 2026. If mailed, the Claim Form should be addressed as follows:

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5013
New York, NY 10150-5013

Payments to eligible Authorized Claimants will be made only if the Court approves the Settlement, after any appeals are resolved, and after the completion of all claims processing.

You should be aware that it will take a significant amount of time to fully process all of the Claim Forms. Please be patient and notify the Claims Administrator of any change of address.

Exhibit C

ADVERTISEMENT

The Marketplace

To advertise: 800-366-3975 or WSJ.com/classifieds

CLASS ACTION

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN JOSE DIVISION

BIAO WANG, Individually and on Behalf of All Others Similarly Situated, Plaintiff, vs. ZYMERGEN INC., et al., Defendants.	Case No. 5:21-cv-06028-PCP

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION

TO: ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED ZYMERGEN INC. ("ZYMERGEN") COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH ITS APRIL 2021 INITIAL PUBLIC OFFERING ("CLASS" OR "CLASS MEMBERS")

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

YOU ARE HEREBY NOTIFIED that a hearing will be held on October 13, 2026, at 10:00 a.m., before the Honorable P. Casey Pitts at the United States District Court, Northern District of California, Robert F. Peckham Federal Building & United States Courthouse, 280 South 1st Street, San Jose, CA 95113, to determine whether: (1) the proposed settlement (the "Settlement") of the above-captioned action ("Action") as set forth in the Stipulation of Settlement ("Stipulation") for $125,000,000 in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Action with prejudice; (3) to award Lead Counsel attorneys' fees and expenses and awards to Plaintiffs pursuant to 15 U.S.C. §77z-1(a)(4) out of the Settlement Fund (as defined in the Notice of Proposed Settlement of Class Action ("Notice"), which is discussed below), and, if so, in what amounts; and (4) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.

IF YOU ARE A MEMBER OF THE CLASS, YOUR RIGHTS WILL BE AFFECTED BY THE SETTLEMENT OF THIS ACTION, AND YOU MAY BE ENTITLED TO SHARE IN THE NET SETTLEMENT FUND.

To share in the distribution of the Net Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail **(postmarked no later than October 11, 2026)** or electronically via the website **(no later than October 11, 2026)**. Failure to submit your Proof of Claim by October 11, 2026, will subject your claim to rejection and preclude you from receiving any of the recovery in connection with the Settlement of this Action. If you purchased or acquired Zymergen common stock pursuant and/or traceable to the Registration Statement issued in connection with Zymergen's April 2021 initial public offering, you will be bound by the Settlement and any judgment and release entered in the Action, including, but not limited to, the Judgment, whether or not you submit a Proof of Claim.

You may review the Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement), access the Proof of Claim, and find the Stipulation (which, among other things, contains definitions for the defined terms used in this Summary Notice) and other Settlement documents, online at www.ZymergenSecuritiesLitigation.com, or by writing to:

Zymergen Securities Litigation
Claims Administrator
c/o Verita Global
P.O. Box 301135
Los Angeles, CA 90030-1135
Telephone: 1-888-858-5903
info@ZymergenSecurities.com

Inquiries should NOT be directed to Settling Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim, may be made to Lead Counsel:

ROBBINS GELLER RUDMAN & DOWD LLP
Ellen Gusikoff Stewart
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 1-800-449-4900
settlementinfo@rgrdlaw.com

No further exclusion opportunity is being provided under the Settlement. Because no Class Member validly excluded themselves previously when notice was provided, you will be bound by any judgment entered by the Court in this Litigation (including the releases provided for therein) whether or not you submit a Proof of Claim.

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT, THE PLAN OF ALLOCATION, AND/OR THE REQUEST BY LEAD COUNSEL FOR AN AWARD OF ATTORNEYS' FEES NOT TO EXCEED 30% OF THE SETTLEMENT AMOUNT AND EXPENSES NOT TO EXCEED $3,000,000, PLUS INTEREST ON BOTH AMOUNTS, AND/OR THE AWARDS TO PLAINTIFFS PURSUANT TO 15 U.S.C. §77z-1(a)(4) IN CONNECTION WITH THEIR REPRESENTATION OF THE CLASS. ANY OBJECTIONS MUST BE FILED WITH THE COURT **BY SEPTEMBER 22, 2026,** IN THE MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: June 22, 2026

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

CLASS ACTION

Legal Notice
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357

SUMMARY NOTICE OF (I) PROPOSED CLASS ACTION SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES

TO: All persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), and were damaged thereby (the "Class")[1]:

PLEASE READ THIS NOTICE CAREFULLY. YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, that Class Representative Indiana Public Retirement System on behalf of itself and the Court-certified Class, has reached a proposed settlement of the above-captioned securities class action (the "Action") for **$69,000,000** in cash (the "Settlement"). If approved, the Settlement will resolve all claims in the Action.

The Action involves allegations that ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall (together, "Defendants") violated the federal securities laws. Class Representative alleges that Defendants made material misrepresentations during the Class Period regarding ChemoCentryx's ADVOCATE study, the Company's Phase 3 clinical trial of avacopan, and the Company's communications with the FDA related to the approval of avacopan, in violation of Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), that Schall controlled ChemoCentryx when the alleged misstatements were made, in violation of Section 20(a) of the Exchange Act, and that Schall sold ChemoCentryx stock while in possession of material non-public information about avacopan, in violation of Section 20A of the Exchange Act. Defendants deny all allegations in the Action and deny any violations of the federal securities laws.[2]

A hearing (the "Settlement Hearing") will be held on **October 29, 2026, at 2:00 p.m. Pacific time**, before the Honorable Jon S. Tigar of the United States District Court for the Northern District of California, by Zoom videoconference, to determine: (i) whether the proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation (and in the Settlement Notice) should be granted; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Class Counsel's motion for attorneys' fees in an amount not to exceed 22% of the Settlement Fund and payment of expenses in an amount not to exceed $5 million should be approved. **If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.** Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the case website, www.ChemoCentryxSecuritiesLitigation.com.

If you are a member of the Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund. This notice provides only a summary of the information contained in the full Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice"). You may obtain copies of the Settlement Notice and the Claim Form on the case website, www.ChemoCentryxSecuritiesLitigation.com, by contacting the Claims Administrator at: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013; by calling toll free 1-833-522-2606; or by emailing info@ChemoCentryxSecuritiesLitigation.com.

If you are a Class Member, in order to be eligible to receive a payment from the Settlement, you must submit a Claim Form ***postmarked* (if mailed) or online by no later than October 1, 2026.** To submit a claim online, visit www.ChemoCentryxSecuritiesLitigation.com. If you are a Class Member and do not submit a proper Claim Form, you will not be eligible to receive a payment from the Settlement, but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

Any objections to the proposed Settlement, the proposed Plan of Allocation, or Class Counsel's motion for attorneys' fees and expenses must be filed with the Court and delivered to Class Counsel and Defendants' Counsel or emailed to Class Counsel and Defendants' Counsel such that they are ***filed or postmarked*** **no later than September 21, 2026**, in accordance with the instructions set forth in the Settlement Notice. The Class was previously certified and, in connection with class certification, Class Members previously had the opportunity to request exclusion from the Class. There will not be a second opportunity to request exclusion in connection with the Settlement proceedings; however, if you previously requested exclusion, you may opt back into the Class by following the instructions in the Settlement Notice.

Please do not contact the Court, the Office of the Clerk of the Court, Defendants, or their counsel regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Class Counsel.

Requests for the Settlement Notice and Claim Form should be made to:	All other inquiries should be made to Class Counsel:
ChemoCentryx Securities Litigation c/o Kroll Settlement Administration P.O. Box 5090, New York, NY 10150-5090, (833) 754-8921 info@ChemoCentryxSecuritiesLitigation.com www.ChemoCentryxSecuritiesLitigation.com	BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP Jonathan D. Uslaner, Esq. 212 Avenue of the Stars, Suite 2575 Los Angeles, CA 90067 (800) 380-8496, settlements@blbglaw.com

By Order of the Court

[1] Certain persons and entities are excluded from the Class by definition and others are excluded pursuant to their prior request. The full definition of the Class, including a complete description of who is excluded from the Class, is set forth in the full Settlement Notice referred to herein.

[2] Capitalized terms not otherwise defined herein shall have the same meaning as in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 ("Stipulation"). The Stipulation can be viewed at www.ChemoCentryxSecuritiesLitigation.com.

BUSINESS & FINANCE

Individuals Flock to AI Trades

HWA CHENG/AFP/GETTY IMAGES

Individual investors plugged $194 million into Intel so far this month, Vanda's data show.

Continued from page B1

member. Compare that with the $194 million they plugged into **Intel**, and the $56 million to the AI cloud company **Iren**.

For years, ordinary investors were the Mag Seven's most loyal and enthusiastic fans, plowing into the stocks through the early days of the AI race, the DeepSeek scare of early 2025 and the tariff turmoil last spring. But the members of the group have since headed in very different directions. In recent months, individual traders turned their attention away from the trillion-dollar firms funding the AI build-out and toward those making the chips, cooling systems and electric power it requires.

"The Mag Seven for years were the market darlings," said Bret Kenwell, U.S. investment analyst at eToro. Now, he said, individual investors are "following the money, figuratively and literally."

That isn't to say that individual traders are backing away from markets. Retail activity surged to new records in May and June, according to Scott Rubner, head of equity and equity derivatives strategy at Citadel Securities. Average daily stock-trading volumes during those months were more than double the 2024 average.

Even before Friday's drop, the momentum of the AI boom had hit a lull on Wall Street. The semiconductor rally, once red-hot, had chilled. Major U.S. indexes were trading sideways in a typical summer slowdown. Investors were looking ahead to second-quarter earnings reports—with their eyes peeled for evidence that the returns on AI investments would start to show up on corporate balance sheets.

"The market is looking for more signs of AI driving revenue growth or driving productivity gains," said Jonathan Cofsky, portfolio manager on the global technology and innovation team at Janus Henderson. "To continue supporting that level of spend, you need the returns to be pervasive throughout the economy."

AI stocks of all kinds are ultimately subject to similar concerns. On Friday, shares of small-cap chip makers, software companies and the Mag Seven all fell in tandem.

For some traders, the potential payoff is worth the risk. Davis Cantrell, a college student based near Atlanta, has been investing for roughly two years and closely following the biggest AI players over that period. But recently, the 19-year-old trimmed his Microsoft holdings, sold all of his Nvidia shares and rotated the funds into a few corners of the market that he finds more promising: space and quantum computing, two industries he thinks are poised to skyrocket as the AI revolution takes hold.

"I'm looking for aggressive, more high-risk growth stocks," he said. "I just don't see Microsoft and Nvidia fitting into that category anymore."

ADVERTISEMENT

The Marketplace

To advertise: 800-366-3975 or WSJ.com/classifieds

CLASS ACTION

UNITED STATES DISTRICT COURT, SOUTHERN DISTRICT OF NEW YORK

NIZAR SAMI AYOUB, Individually and on Behalf of All Others Similarly Situated, Plaintiff, v. SPECTRUM PHARMACEUTICALS, INC., THOMAS J. RIGA, and FRANCOIS J. LEBEL, Defendants.	Case No. 1:22-cv-10292 (VEC) (Consolidated) SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

TO: ALL PERSONS OR ENTITIES WHO PURCHASED SPECTRUM PHARMACEUTICALS, INC. ("SPECTRUM") COMMON STOCK BETWEEN MAY 12, 2022 AND SEPTEMBER 22, 2022, INCLUSIVE (THE "CLASS PERIOD")

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

THE CUSIP NUMBER FOR SPECTRUM PHARMACEUTICALS, INC. (FORMERLY TRADED AS NASDAQ: SPPI) COMMON STOCK WAS 84763A108.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of New York ("Court"), that the above-captioned action ("Litigation") has been certified as a class action, except for certain Persons and entities who are excluded from the Class by definition as set forth in the Stipulation of Settlement, dated June 1, 2026 ("Stipulation") and the detailed Notice of Pendency and Proposed Settlement of Class Action ("Notice"). The Stipulation and Notice can be viewed at www.strategicclaims.net/AyoubvSpectrum/.

YOU ARE ALSO HEREBY NOTIFIED that Nizar Sami Ayoub ("Lead Plaintiff"), and defendants Spectrum, Francois J. Lebel, and Thomas J. Riga ("Defendants") have reached a proposed settlement of the Litigation on behalf of the Class for $7 million in cash ("Settlement"). If approved by the Court, the Settlement will resolve all claims in the Litigation.

YOU ARE ALSO HEREBY NOTIFIED that a hearing will be held on November 20, 2026, at 10:00 a.m., before the Honorable Valerie E. Caproni at the United States District Court, Southern District of New York, Daniel P. Moynihan United States Courthouse, 500 Pearl Street, New York, NY 10007, to determine whether: (1) the Settlement of the above-captioned Litigation as set forth in the Stipulation for $7 million in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Counsel attorneys' fees and expenses out of the Settlement Fund (as defined in the Notice) and, if so, in what amounts; (4) to award Lead Plaintiff its costs and expenses in representing the Class out of the Settlement Fund and, if so, in what amount; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.

The Court may decide to change the date and/or time of the Settlement Hearing, conduct the hearing by video or telephonic conference, or otherwise allow Class Members to appear at the hearing by telephone or videoconference, without further written notice to the Class. It is important that you check the Settlement website, www.strategicclaims.net/AyoubvSpectrum/, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or telephonic appearances at the hearing, will be posted to the Settlement website. Also, if the Court requires or allows Class Members to participate in the hearing by telephone or videoconference, the access information will be posted to the website.

IF YOU PURCHASED SPECTRUM COMMON STOCK BETWEEN MAY 12, 2022, AND SEPTEMBER 22, 2022, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

To share in the distribution of the Net Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form ("Proof of Claim") to the Claims Administrator by mail **(postmarked no later than October 12, 2026)** or electronically via the Settlement website **(no later than 11:59 p.m. ET on October 12, 2026)**. Failure to submit your Proof of Claim by October 12, 2026, will subject your claim to rejection and preclude you from receiving any of the recovery in connection with the Settlement of this Litigation. If you are a Class Member and do not request exclusion from the Class (as described below), you will be bound by the Settlement and any judgment and release entered in the Litigation, including, but not limited to, the Judgment, whether or not you submit a Proof of Claim.

The Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement); the Proof of Claim; the Stipulation (which, among other things, contains definitions for the capitalized terms used in this Summary Notice); and other important documents may be accessed online at www.strategicclaims.net/AyoubvSpectrum/, or by writing to the Claims Administrator:

Spectrum Pharmaceuticals Securities Settlement
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 205, Media, PA 19063
info@strategicclaims.net

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim, may be made to Lead Counsel:

KAPLAN FOX & KILSHEIMER LLP
Jeffrey P. Campisi
800 Third Avenue, 38th Floor, New York, NY 10022
Telephone: (212) 687-1980
jcampisi@kaplanfox.com

IF YOU DESIRE TO BE EXCLUDED FROM THE CLASS, YOU MUST SUBMIT A REQUEST FOR EXCLUSION SUCH THAT IT IS **POSTMARKED BY OCTOBER 30, 2026**, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE. IF YOU PROPERLY EXCLUDE YOURSELF FROM THE CLASS, YOU WILL NOT BE BOUND BY ANY RELEASES, JUDGMENTS, OR ORDERS ENTERED BY THE COURT IN THE LITIGATION AND YOU WILL NOT RECEIVE ANY BENEFITS FROM THE SETTLEMENT. EXCLUDING YOURSELF FROM THE CLASS IS THE ONLY OPTION THAT MAY ALLOW YOU TO BE PART OF ANY OTHER CURRENT OR FUTURE LAWSUIT AGAINST DEFENDANTS CONCERNING THE CLAIMS BEING RESOLVED BY THE SETTLEMENT.

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT, THE PLAN OF ALLOCATION, THE REQUEST BY LEAD COUNSEL FOR AN AWARD OF ATTORNEYS' FEES NOT TO EXCEED 25% OF THE $7 MILLION SETTLEMENT AMOUNT AND EXPENSES NOT TO EXCEED $250,000, PLUS INTEREST ON BOTH AMOUNTS, AND/OR THE REQUEST FOR AN AWARD TO LEAD PLAINTIFF PURSUANT TO 15 U.S.C. §78u-4(a)(4). ANY OBJECTIONS MUST BE FILED WITH THE COURT AND SENT TO LEAD COUNSEL AND DEFENDANTS' COUNSEL **BY OCTOBER 30, 2026**, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: JUNE 22, 2026

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT, SOUTHERN DISTRICT OF NEW YORK

NOTICE OF SALE

NOTICE OF PUBLIC SALE OF COLLATERAL
UNDER DELAWARE UNIFORM COMMERCIAL CODE

PLEASE TAKE NOTICE that, in accordance with applicable provisions of the Uniform Commercial Code as enacted in Delaware ("Delaware UCC"), notice is hereby given that a public sale shall be conducted of the secured grid promissory notes and related loan documents pledged by Art Finance Funding (IX), LLC ("Borrower") to Century Bank ("Secured Party") pursuant to the Commercial Pledge Agreements, dated as of May 21, 2020, August 31, 2020, November 12, 2020, August 3, 2021, and August 6, 2021, respectively, in each case executed between Secured Party and Borrower, to secure obligations owed under loans made by Secured Party to Borrower pursuant to the master Business Loan Agreement dated as of July 22, 2022, as described in Schedule A (the "Collateral").

The sale will take place at 3:30 p.m. EDT on August 25, 2026, via Zoom, as well as in person at Gibson, Dunn & Crutcher LLP, located at 200 Park Avenue, New York, New York 10166, Attention: Jason Myatt, Esq. Remote log-in credentials will be provided to registered bidders upon request.

The Collateral will be sold to the highest qualified bidder for cash, or the credit against outstanding indebtedness held by the Secured Party. Secured Party reserves the right to bid, assign its bid, and credit bid all or any portion of the secured indebtedness. The Collateral is offered "AS IS, WHERE IS," with all faults, and there is no warranty by the Secured Party relating to title, possession, quiet enjoyment, merchantability, fitness or the like in this disposition.

Under the applicable provisions of the Delaware UCC, Borrower is entitled, at no additional cost to it, to an accounting of all the unpaid indebtedness that is secured by the Collateral. Borrower may request such an accounting by contacting Secured Party's counsel, Jason Myatt, Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, New York 10166; (212) 351-4085; and jmyatt@gibsondunn.com.

Secured Party reserves the right, in accordance with the Delaware UCC, prior to the auction date to cancel the sale in its entirety, or to adjourn the sale to a future date, or to modify, waive or amend any terms or conditions of the auction or impose any other terms or conditions on the auction and, if Secured Party, or an affiliate of Secured Party, deems appropriate, to reject any or all bids or to continue the auction to such time and place as Secured Party, or an affiliate of Secured Party, in its sole and absolute discretion, may deem fit.

To be a qualified bidder, each prospective bidder must, by 3:30 p.m. EDT on August 18, 2026: (1) execute and deliver to Jason Myatt, Esq. (by email at jmyatt@gibsondunn.com), a written certification on the form attached to Terms of Sale; (2) provide to Jason Myatt, Esq. (by email at jmyatt@gibsondunn.com) proof of readily available funds; and (3) register as a prospective bidder at the auction with Mannion Auctions, LLC by email to mdmannion@jpandr.com.

Interested parties that intend to bid on the Collateral should contact Jason Myatt, Esq. at (212) 351-4085 or jmyatt@gibsondunn.com to receive the Terms of Sale and bidding instructions.

Schedule A – Collateral

Collateral in which Borrower granted Secured Party a security interest includes, without limitation, the following assets of Borrower, together with any related loan documents, modifications, amendments, replacements, and extensions: (a) Secured Grid Promissory Note dated May 8, 2020, in the amount of $6,000,000 by and between Rose Petal Commodities, Inc. and Borrower; (b) Secured Grid Promissory Note dated November 14, 2023, in the amount of $5,000,000 by and between Adelson Galleries, Inc. and Borrower, which amended, restated, and replaced the Secured Grid Promissory Note dated July 27, 2020, in the amount of $2,500,000 by and between Adelson Galleries, Inc. and Borrower; (c) Secured Grid Promissory Note dated October 26, 2020, in the amount of $7,500,000 by and between Viana Art, LLC and Borrower; (d) Secured Grid Promissory Note dated March 2, 2019, in the amount of $3,500,000 by and between Carlton Rochell, Jr. and Borrower; (e) Secured Grid Promissory Note dated March 28, 2021, in the amount of $3,500,000 by and between Carlton Rochell, Jr. and Borrower; (f) Secured Grid Promissory Note dated November 1, 2023, in the amount of $7,500,000 by and between Carlton Rochell, Jr. and Borrower; and (g) Secured Grid Promissory Note dated July 29, 2021, in the amount of $4,000,000 by and between Petrarch, LLC d/b/a Electrum, and Tanis Antiquities, Ltd. and Borrower.

NXT Raises $1.8 Billion For Fund

BY ISAAC TAYLOR

Credit-focused NXT Capital raised $1.8 billion at the initial close of its eighth fund to invest through direct-lending.

The unit of Tokyo-listed **Orix's** U.S. arm makes loans from the fund to middle-market companies with adjusted pretax annual earnings of $5 million to $50 million.

The new pool, NXT Capital Senior Loan Fund VIII, marks the company's largest commingled vehicle so far. The amount raised for the initial close exceeds the total amount collected for each of the strategy's previous funds, which have typically wrapped up with roughly $1.5 billion.

The Chicago firm plans to invest from the new fund in U.S. companies that are backed by private-equity sponsors.

Earlier this year, NXT provided a senior credit facility to back CenterOak Partners' acquisition of Grismer Tire & Auto Service. The company operates vehicle service centers that offer tires, mechanical and electrical repair.

The firm in 2024 provided a $202 million senior credit facility to support Kian Capital Partners' recapitalization of Spatco Energy Solutions, a provider of service and maintenance for the fueling infrastructure market.

While NXT's strategy for the fund is sector-agnostic, the firm expects to make minimal investments in software businesses, which have become an area of concern for limited partners in private-credit vehicles.

Many nonbank direct lenders have looked to distance themselves from software investing this year after warnings from Wall Street leaders about the potential for artificial-intelligence disruptions of their business models.

Starting late last year, such alarms acutely affected private-credit focused business-development companies and interval funds, some of which have heavily backed software suppliers with loans. The warnings spooked many individual investors who were drawn to private credit in recent years, triggering a wave of requests to withdraw from evergreen credit funds and to cash in shares of private lenders such as BDCs and other semiliquid vehicles.

NXT gathered the fresh capital after a down year for direct-lending activity generally. The value of U.S. direct lending transactions fell 11% to $247 billion last year from 2024, PitchBook LCD said in December.

Notice of Proposed Settlement of Class Action Announced in ChemoCentryx Securities Litigation

NEWS PROVIDED BY
Kroll Settlement Administration LLC →
Jul 20, 2026, 08:00 ET

PHILADELPHIA, July 20, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Settlement Administration LLC regarding *Homyk v. ChemoCentryx, Inc.*, Case No. 4:21-CV-03343-JST pending in the United States District Court for the Northern District of California.

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357

SUMMARY NOTICE OF (I) PROPOSED CLASS ACTION SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES

TO: All persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), and were damaged thereby (the "Class")[1]:

PLEASE READ THIS NOTICE CAREFULLY. YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, that Class Representative Indiana Public Retirement System on behalf of itself and the Court-certified Class, has reached a proposed settlement of the above-captioned securities class action (the "Action") for **$69,000,000** in cash (the "Settlement"). If approved, the Settlement will resolve all claims in the Action.

The Action involves allegations that ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall (together, "Defendants") violated the federal securities laws. Class Representative alleges that Defendants made material misrepresentations during the Class Period regarding ChemoCentryx's ADVOCATE study, the Company's Phase 3 clinical trial of avacopan, and the Company's communications with the FDA related to the approval of avacopan, in violation of Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), that Schall controlled ChemoCentryx when the alleged misstatements were made, in violation of Section 20(a) of the Exchange Act, and that Schall sold ChemoCentryx stock while in possession of material non-public information about avacopan, in violation of Section 20A of the Exchange Act. Defendants deny all allegations in the Action and deny any violations of the federal securities laws.[2]

A hearing (the "Settlement Hearing") will be held on **October 29, 2026, at 2:00 p.m. Pacific time**, before the Honorable Jon S. Tigar of the United States District Court for the Northern District of California, by Zoom videoconference, to determine: (i) whether the proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation (and in the Settlement Notice) should be granted; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Class Counsel's motion for attorneys' fees in an amount not to exceed 22% of the Settlement Fund and payment of expenses in an amount not to exceed $5 million should be approved. **If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com, to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.** Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the case website, **www.ChemoCentryxSecuritiesLitigation.com**.

If you are a member of the Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund. This notice provides only a summary of the information contained in the full Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice"). You may obtain copies of the Settlement Notice and the Claim Form on the case website,

www.ChemoCentryxSecuritiesLitigation.com, by contacting the Claims Administrator at: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013; by calling toll free 1-833-522-2606; or by emailing **info@ChemoCentryxSecuritiesLitigation.com**.

If you are a Class Member, in order to be eligible to receive a payment from the Settlement, you must submit a Claim Form ***postmarked*** **(if mailed) or online by no later than October 1, 2026**. To submit a claim online, visit **www.ChemoCentryxSecuritiesLitigation.com**. If you are a Class Member and do not submit a proper Claim Form, you will not be eligible to receive a payment from the Settlement, but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

Any objections to the proposed Settlement, the proposed Plan of Allocation, or Class Counsel's motion for attorneys' fees and expenses must be filed with the Court and delivered to Class Counsel and Defendants' Counsel or emailed to Class Counsel and Defendants' Counsel such that they are ***filed or postmarked*** **no later than September 21, 2026**, in accordance with the instructions set forth in the Settlement Notice. The Class was previously certified and, in connection with class certification, Class Members previously had the opportunity to request exclusion from the Class. There will not be a second opportunity to request exclusion in connection with the Settlement proceedings; however, if you previously requested exclusion, you may opt back into the Class by following the instructions in the Settlement Notice.

Please do not contact the Court, the Office of the Clerk of the Court, Defendants, or their counsel regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Class Counsel.

Requests for the Settlement Notice and Claim Form should be made to:

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5013
New York, NY 10150-5013

(833) 522-2606
info@ChemoCentryxSecuritiesLitigation.com
www.ChemoCentryxSecuritiesLitigation.com

All other inquiries should be made to Class Counsel:

BERNSTEIN LITOWITZ
BERGER & GROSSMANN LLP
Jonathan D. Uslaner, Esq.

2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
(800) 380-8496
settlements@blbglaw.com

By Order of the Court

---

[1] Certain persons and entities are excluded from the Class by definition and others are excluded pursuant to their prior request. The full definition of the Class, including a complete description of who is excluded from the Class, is set forth in the full Settlement Notice referred to herein.

[2] Capitalized terms not otherwise defined herein shall have the same meaning as in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 ("Stipulation"). The Stipulation can be viewed at **www.ChemoCentryxSecuritiesLitigation.com**.

SOURCE Kroll Settlement Administration LLC

Exhibit 4

EXHIBIT 4

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Summary Lodestar Chart
Inception - August 31, 2026

Name	Position	Total Hours	Current Rate[1]	Historical Lodestar	Current Lodestar
Abe Alexander	Partner	3,347.25	$1,300	$3,181,081.25	$4,351,425.00
Scott Foglietta	Partner	61.00	$1,500	$50,325.00	$91,500.00
Salvatore Graziano	Partner	354.00	$1,800	$532,150.00	$637,200.00
Robert Kravetz	Partner	405.75	$1,300	$495,625.00	$527,475.00
Hannah Ross	Partner	73.00	$1,800	$83,525.00	$131,400.00
Gerald Silk	Partner	21.00	$1,800	$24,450.00	$37,800.00
Katherine Sinderson	Partner	491.75	$1,600	$644,950.00	$786,800.00
Jorge Tenreiro	Partner	613.25	$1,300	$741,650.00	$797,225.00
Jonathan D. Uslaner	Partner	2,986.00	$1,600	$3,626,900.00	$4,777,600.00
Shane Avidan	Senior Counsel	719.25	$1,100	$724,275.00	$791,175.00
Lauren Cruz	Senior Counsel	2,273.75	$1,000	$1,773,106.25	$2,273,750.00
David L. Duncan	Senior Counsel	153.50	$1,100	$162,143.75	$168,850.00
John Esmay -	Senior Counsel	1,225.50	$1,100	$1,179,043.75	$1,348,050.00
John Mills	Senior Counsel	25.00	$1,100	$26,200.00	$27,500.00
Caitlin Bozman	Associate	869.75	$800	$437,606.25	$695,800.00
James Briggs	Associate	4,599.75	$650	$2,250,000.00	$2,989,837.50
Girolamo Brunetto	Associate	259.25	$875	$136,106.25	$226,843.75
Stephen Boscolo -	Associate	1,104.25	$700	$557,325.00	$772,975.00
Chloe Jasper	Associate	1,747.25	$700	$968,400.00	$1,223,075.00
Yando Peralta	Associate	64.75	$500	$30,787.50	$32,375.00
Lawrence Hosmer	Senior Staff Attorney	260.50	$525	$117,225.00	$136,762.50
Ryan McCurdy	Senior Staff Attorney	2,321.00	$525	$1,110,285.00	$1,218,525.00
Damien Puniello	Senior Staff Attorney	1,104.50	$525	$507,622.50	$579,862.50
Zvi Bar-Kochba	Staff Attorney	790.00	$425	$302,757.50	$335,750.00
Isabelle Bowers	Staff Attorney	2,068.75	$385	$789,516.25	$796,468.75
Daniel Cedrone	Staff Attorney	653.75	$425	$277,843.75	$277,843.75
Jonathan Cohen.	Staff Attorney	2,699.50	$425	$1,103,433.75	$1,147,287.50
Igor Faynshteyn	Staff Attorney	1,165.50	$425	$495,337.50	$495,337.50
Sascha Goergen	Staff Attorney	2,277.00	$425	$967,725.00	$967,725.00
Steffanie Keim	Staff Attorney	378.25	$425	$160,756.25	$160,756.25
Shammari Khan	Staff Attorney	365.00	$425	$155,125.00	$155,125.00
Paul Lim	Staff Attorney	1,441.25	$425	$612,531.25	$612,531.25
Tiffany Michael	Staff Attorney	1,254.50	$425	$533,162.50	$533,162.50
Emily Nalven	Staff Attorney	557.25	$410	$226,822.50	$228,472.50
Yeruchem Neiman	Staff Attorney	1,185.00	$425	$503,625.00	$503,625.00
Rodney Nutt	Staff Attorney	382.75	$425	$162,668.75	$162,668.75
John Pate	Staff Attorney	1,949.00	$410	$786,925.00	$799,090.00
Mark Paul	Staff Attorney	916.25	$400	$366,500.00	$366,500.00
Priscilla Pellecchia	Staff Attorney	4,445.50	$450	$1,828,976.25	$2,000,475.00
Kirstin Peterson	Staff Attorney	2,794.25	$475	$1,192,550.00	$1,327,268.75
Joanna Tarnawsk	Staff Attorney	4,506.50	$450	$1,851,342.50	$2,027,925.00
Adam Weinschel	Financial Analyst	34.50	$650	$19,150.00	$22,425.00
Milana Babic	Financial Analyst	44.00	$425	$17,600.00	$18,700.00
Tanjila Sultana	Financial Analyst	45.00	$550	$19,525.00	$24,750.00
Andrew Thompson	Financial Analyst	44.00	$575	$17,600.00	$25,300.00
Amy Bitkower	Dir. of Investigations	56.25	$650	$33,037.50	$36,562.50

EXHIBIT 4

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Summary Lodestar Chart
Inception - August 31, 2026

Name	Position	Total Hours	Current Rate[1]	Historical Lodestar	Current Lodestar
John Deming	Senior Investigator	148.25	$500	$62,275.00	$74,125.00
Jacob Foster	Investigator	102.25	$400	$32,943.75	$40,900.00
Gary Weston	Dir. of Paralegals	36.25	$475	$15,700.00	$17,218.75
Cindy Bomzer-Stein	Case Manager	878.00	$450	$323,325.00	$395,100.00
Khristine De Leon	Case Manager	50.00	$450	$16,275.00	$22,500.00
Jay Layfield	Case Manager	21.50	$425	$9,137.50	$9,137.50
Matthew Mahady	Case Manager	55.25	$450	$19,387.50	$24,862.50
Toby Saviano	Case Manager	330.75	$450	$134,887.50	$148,837.50
Yulia Tsoy	Case Manager	17.00	$425	$5,525.00	$7,225.00
Melody Yaghoubzadeh	Case Manager	2,181.00	$450	$872,975.00	$981,450.00
Annemarie Eames	Paralegal	1,608.50	$350	$535,200.00	$562,975.00
Ryan McCarthy	Paralegal	60.25	$375	$21,450.00	$22,593.75
Nathan Vickers	Paralegal	18.50	$325	$6,012.50	$6,012.50
Paul Charlotin	Litigation Support	38.25	$475	$15,925.00	$18,168.75
Roberto Santamarina	Litigation Support	353.50	$525	$164,006.25	$185,587.50
Julio Velazquez	Litigation Support	154.75	$475	$66,693.75	$73,506.25
Mahiri Buffong	Managing Clerk	232.25	$500	$105,393.75	$116,125.00
Janielle Lattimore	Asst. Managing Clerk	161.25	$475	$69,193.75	$76,593.75
Jessica Lacon	Docket Clerk	106.25	$450	$42,906.25	$47,812.50
		61,688.50		**$34,304,506.25**	**$40,480,287.50**

1. For timekeepers who are no longer at the firm, the Current Rate used is their rate in their last year at the firm.

Exhibit 5

BLB&G Bernstein Litowitz Berger & Grossmann LLP

Bernstein Litowitz Berger & Grossmann LLP
Attorneys at Law

Firm Resume

Table of Contents

Since our founding in 1983, Bernstein Litowitz Berger & Grossmann LLP has obtained more than $40 billion in recoveries on behalf of investors. The firm has obtained some of the largest settlements ever agreed to by public companies related to securities fraud, including six of the 15 largest in history. Working with our clients, we have also used the litigation process to achieve precedent-setting reforms that have increased market transparency, held wrongdoers accountable, and improved corporate business practices in groundbreaking ways.

Firm Overview

Bernstein Litowitz Berger & Grossmann LLP (BLB&G), a national law firm with offices located in New York, California, Delaware, Louisiana, and Illinois, prosecutes class and private actions on behalf of individual and institutional clients. The firm's litigation practice areas include securities class and direct actions in federal and state courts; corporate governance and shareholder rights litigation, including claims for breach of fiduciary duty and proxy violations; mergers and acquisitions and transactional litigation; alternative dispute resolution; and distressed debt and bankruptcy. We also handle, on behalf of major institutional clients and lenders, more general complex commercial litigation involving allegations of breach of contract, accountants' liability, breach of fiduciary duty, fraud, and negligence.

We are the nation's leading firm representing institutional investors in securities fraud class action litigation. The firm's institutional client base includes U.S. public pension funds the New York State Common Retirement Fund; the California Public Employees' Retirement System (CalPERS); the Los Angeles County Employees Retirement Association; the Chicago Municipal, Police and Labor Retirement Systems; the Teacher Retirement System of Texas; the Arkansas Teacher Retirement System; the Florida State Board of Administration; the Public Employees' Retirement System of Mississippi; the New York State Teachers' Retirement System; the Ohio Public Employees Retirement System; the State Teachers Retirement System of Ohio; the Oregon Public Employees Retirement System; the Virginia Retirement System; the Louisiana School, State, Teachers and Municipal Police Retirement Systems; the Public School Teachers' Pension and Retirement Fund of Chicago; the New Jersey Division of Investment of the Department of the Treasury; TIAA-CREF and other private institutions; as well as numerous other public and Taft-Hartley pension entities. Our European client base includes APG; Aegon AM; ATP; Blue Sky Group; Hermes IM; Robeco; SEB; Handelsbanken; Nykredit; PGB; and PGGM, among others.

More Top Securities Recoveries Than Any Other Firm

Since its founding in 1983, BLB&G has prosecuted some of the most complex cases in history and obtained more than $40 billion on behalf of investors. The firm has negotiated and obtained many of the largest securities recoveries in history, including:

- *In re WorldCom, Inc. Securities Litigation – $6.19 billion recovery*
- *In re Cendant Corporation Securities Litigation – $3.3 billion recovery*
- *In re Bank of America Corp. Securities, Derivative, and Employee Retirement Income Security Act (ERISA) Litigation – $2.43 billion recovery*

- *In re Allianz Global Investors U.S. Litigation – More than $2 billion recovered in a series of direct actions*
- *In re Nortel Networks Corporation Securities Litigation (Nortel II) – $1.07 billion recovery*
- *In re Merck & Co., Inc. Securities Litigation – $1.06 billion recovery*
- *In re McKesson HBOC, Inc. Securities Litigation – $1.05 billion recovery*
- *In re Wells Fargo & Company Securities Litigation – $1.00 billion recovery*

Based on our record of success, BLB&G has been at the top of the rankings by ISS Securities Class Action Services (ISS-SCAS), a leading industry research publication that provides independent and objective third-party analysis and statistics on securities-litigation law firms, since its inception. In its most recent report, *Top 100 U.S. Class Action Settlements of All-Time*, ISS-SCAS once again ranked BLB&G as the top firm in the field for the 14th year in a row. BLB&G has served as lead or co-lead counsel in 38 of the ISS-SCAS's top 100 U.S. securities-fraud settlements—significantly more than any other firm—and recovered over $27 billion for investors in those cases, nearly $9 billion more than any other plaintiffs' securities firm.

Giving Shareholders a Voice and Changing Business Practices for the Better

BLB&G was among the first law firms ever to obtain meaningful corporate governance reforms through litigation. In courts throughout the country, we prosecute shareholder class and derivative actions, asserting claims for breach of fiduciary duty and proxy violations wherever the conduct of corporate officers and/or directors, or M&A transactions, seeks to deprive shareholders of fair value, undermine shareholder voting rights, or allow management to profit at the expense of shareholders.

We have prosecuted seminal cases establishing precedent that has increased market transparency, held wrongdoers accountable, addressed issues in the boardroom and executive suite, challenged unfair deals, and improved corporate business practices in groundbreaking ways. We have confronted a variety of questionable, unethical, and proliferating corporate practices, setting new standards of director independence, restructuring board practices in the wake of persistent illegal conduct, challenging the improper use of defensive measures and deal protections for management's benefit, and confronting stock options backdating abuses and other self-dealing by executives.

Practice Areas

Securities Fraud Litigation

Securities fraud litigation is the cornerstone of the firm's litigation practice. Since its founding, the firm has had the distinction of having tried and prosecuted many of the most high-profile securities fraud class actions in history, recovering billions of dollars and obtaining unprecedented corporate governance reforms on behalf of our clients. BLB&G continues to play a leading role in major securities litigation pending in federal and state courts, and the firm remains one of the nation's leaders in representing institutional investors in securities fraud class litigation.

The firm also pursues direct actions in securities fraud cases, when appropriate. By selectively opting out of certain securities class actions, we seek to resolve our clients' claims efficiently and for substantial multiples of what they might otherwise recover from related class action settlements.

Our attorneys have extensive experience in the laws that regulate the securities markets and in the disclosure requirements of corporations that issue publicly traded securities. Many also have accounting backgrounds. The group has access to state-of-the-art, online financial wire services and databases, which enable it to instantaneously investigate any potential securities fraud action involving a public company's debt and equity securities. Biographies for our attorneys can be accessed on the firm's website by clicking here.

Corporate Governance and Shareholder Rights

Our Corporate Governance and Shareholder Rights attorneys prosecute derivative actions, claims for breach of fiduciary duty, and proxy violations on behalf of individual and institutional investors in state and federal courts throughout the country. We have prosecuted actions challenging numerous highly publicized corporate transactions that violated fair process, fair price, and the applicability of the business judgment rule, and have also addressed issues of corporate waste, shareholder voting rights claims, and executive compensation.

Our attorneys have prosecuted numerous cases regarding the improper "backdating" of executive stock options that resulted in windfall undisclosed compensation to executives at the direct expense of shareholders—and returned hundreds of millions of dollars to company coffers. We also represent institutional clients in lawsuits seeking to enforce fiduciary obligations in connection with mergers and acquisitions and going-private transactions that deprive shareholders of fair value when participants buy companies from their public shareholders "on the cheap." Although enough shareholders accept the consideration offered for the transaction to close, many sophisticated investors correctly recognize and ultimately enjoy the increased returns to be obtained by pursuing appraisal rights and demanding that courts assign a "true value" to the shares taken private in these transactions.

Our attorneys are well versed in changing SEC rules and regulations on corporate governance issues and have a comprehensive understanding of a wide variety of corporate law transactions and both substantive and courtroom expertise in the specific legal areas involved. As a result of the firm's high-profile and widely recognized capabilities, our attorneys are increasingly in demand with institutional investors who are exercising a more assertive voice with corporate boards regarding corporate governance issues and the boards' accountability to shareholders.

Distressed Debt and Bankruptcy

BLB&G has obtained billions of dollars through litigation on behalf of bondholders and creditors of distressed and bankrupt companies, as well as through third-party litigation brought by bankruptcy trustees and creditors' committees against auditors, appraisers, lawyers, officers and directors, and other defendants who may have contributed to client losses. As counsel, we advise institutions and individuals nationwide in developing strategies and tactics to recover assets presumed lost as a result of bankruptcy. Our record in this practice area is characterized by extensive trial experience in addition to successful settlements.

Commercial Litigation

BLB&G provides contingency fee representation in complex business litigation and has obtained substantial recoveries on behalf of investors, corporations, bankruptcy trustees, creditor committees, and other business entities. We have faced down the most powerful and well-funded law firms and defendants in the country—and consistently prevailed. For example, on behalf of the bankruptcy trustee, the firm prosecuted *BFA Liquidation Trust v. Arthur Andersen*, arising from the largest nonprofit bankruptcy in U.S. history. After two years of litigation and a week-long trial, the firm obtained a $217 million recovery from Andersen for the Trust. Combined with other recoveries, the total amounted to more than 70 percent of the Trust's losses.

Having obtained huge recoveries with nominal out-of-pocket expenses and fees of less than 20 percent, we have repeatedly demonstrated that valuable claims are best prosecuted by a first-rate litigation firm on a contingent basis at negotiated percentages. Legal representation need not compound the risk and high cost inherent in today's complex and competitive business environment. We are paid only if we (and our clients) win. The result: the highest quality legal representation at a fair price.

Alternative Dispute Resolution

BLB&G offers clients an accomplished team and a creative venue in which to resolve conflicts outside of the litigation process. We have experience in U.S. and international disputes, and our attorneys have led complex business-to-business arbitrations and mediations domestically and abroad, representing clients before all the major arbitration tribunals, including the American Arbitration Association, FINRA, JAMS, International Chamber of Commerce, and the London Court of International Arbitration.

Our lawyers have successfully arbitrated cases that range from complex business-to-business disputes to individuals' grievances with employers. It is our experience that in some cases, a well-executed arbitration process can resolve disputes faster, with limited appeals and a higher level of confidentiality than public litigation.

In the wake of the credit crisis, for example, we successfully represented numerous former executives of a major financial institution in arbitrations relating to claims for compensation. We have also assisted clients with disputes involving failure to honor compensation commitments, disputes over the purchase of securities, businesses seeking compensation for uncompleted contracts, and unfulfilled financing commitments.

Feedback from the Courts

Throughout the firm's history, many courts have recognized the professional excellence and diligence of the firm and its members. A few examples are set forth below.

In re WorldCom, Inc. Securities Litigation

- The Honorable Denise Cote of the United States District Court for the Southern District of New York

"I have the utmost confidence in plaintiffs' counsel…they have been doing a superb job…The Class is extraordinarily well represented in this litigation."

"The magnitude of this settlement is attributable in significant part to Lead Counsel's advocacy and energy…The quality of the representation given by Lead Counsel…has been superb…and is unsurpassed in this Court's experience with plaintiffs' counsel in securities litigation."

"Lead Counsel has been energetic and creative…Its negotiations with the Citigroup Defendants have resulted in a settlement of historic proportions."

* * *

In re Clarent Corporation Securities Litigation

- The Honorable Charles R. Breyer of the United States District Court for the Northern District of California

"It was the best tried case I've witnessed in my years on the bench…."

"[A]n extraordinarily civilized way of presenting the issues to you [the jury]…We've all been treated to great civility and the highest professional ethics in the presentation of the case…"

"These trial lawyers are some of the best I've ever seen."

* * *

Landry's Restaurants, Inc. Shareholder Litigation

- Vice Chancellor J. Travis Laster of the Delaware Court of Chancery

"I do want to make a comment again about the excellent efforts…put into this case…This case, I think, shows precisely the type of benefits that you can achieve for stockholders and how representative litigation can be a very important part of our corporate governance system…you hold up this case as an example of what to do."

* * *

McCall V. Scott (Columbia/HCA Derivative Litigation)

- The Honorable Thomas A. Higgins of the United States District Court for the Middle District of Tennessee

"Counsel's excellent qualifications and reputations are well documented in the record, and they have litigated this complex case adeptly and tenaciously throughout the six years it has been pending. They assumed an enormous risk and have shown great patience by taking this case on a contingent basis, and despite an early setback they have persevered and brought about not only a large cash settlement but sweeping corporate reforms that may be invaluable to the beneficiaries."

Significant Recoveries

BLB&G has successfully identified, investigated, and prosecuted many of the most significant securities and shareholder actions in history, recovering billions of dollars on behalf of defrauded investors and obtaining groundbreaking corporate-governance reforms. These resolutions include eight recoveries of over $1 billion, more than any other firm in our field. Examples of cases with our most significant recoveries include:

Securities Fraud Litigation

Case: *In re WorldCom, Inc. Securities Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $6.19 billion securities fraud class action recovery—the second largest in history; unprecedented recoveries from Director Defendants.

Case Summary: Investors suffered massive losses in the wake of the financial fraud and subsequent bankruptcy of former telecom giant WorldCom. This litigation alleged that WorldCom and others disseminated false and misleading statements to the investing public regarding its earnings and financial condition in violation of the federal securities and other laws. It further alleged a nefarious relationship between Citigroup subsidiary Salomon Smith Barney and WorldCom, carried out primarily by Salomon employees involved in providing investment banking services to WorldCom, and by WorldCom's former CEO and CFO. As Court-appointed Co-Lead Counsel representing Lead Plaintiff the New York State Common Retirement Fund, we obtained unprecedented settlements totaling more than $6 billion from the Investment Bank Defendants who underwrote WorldCom bonds, including a $2.575 billion cash settlement to settle all claims against the Citigroup Defendants. On the eve of trial, the 13 remaining "Underwriter Defendants," including J.P. Morgan Chase, Deutsche Bank, and Bank of America, agreed to pay settlements totaling nearly $3.5 billion to resolve all claims against them. Additionally, the day before trial was scheduled to begin, the former WorldCom Director Defendants agreed to pay over $60 million to settle the claims against them. An unprecedented first for outside directors, $24.75 million of that amount came out of the pockets of the individuals—20% of their collective net worth. *The Wall Street Journal*, in its coverage, profiled the settlement as having "shaken Wall Street, the audit profession and corporate boardrooms." After four weeks of trial, Arthur Andersen, WorldCom's former auditor, settled for $65 million. Subsequent settlements were reached with the former executives of WorldCom, and then with Andersen, bringing the total obtained for the Class to over $6.19 billion.

Case: *In re Cendant Corporation Securities Litigation*

Court: United States District Court for the District of New Jersey

Highlights: $3.3 billion securities fraud class action recovery—the third largest in history; significant corporate governance reforms obtained.

Summary: The firm was Co-Lead Counsel in this class action against Cendant Corporation, its officers and directors and Ernst & Young (E&Y), its auditors, for their role in disseminating materially false and misleading financial statements concerning the company's revenues, earnings and expenses for its 1997 fiscal year. As a result of companywide accounting irregularities, Cendant restated its financial results for its 1995, 1996, and 1997 fiscal years and all fiscal quarters therein. Cendant agreed to settle the action for $2.8 billion and to adopt some of the most extensive corporate governance changes in history. E&Y settled for $335 million. These settlements remain the largest sums ever recovered from a public company and a public accounting firm through securities class action litigation. BLB&G represented Lead Plaintiffs CalPERS, the New York State Common Retirement Fund, and the New York City Pension Funds, the three largest public pension funds in America, in this action.

Case: *In re Bank of America Corp. Securities, Derivative, and Employee Retirement Income Security Act (ERISA) Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $2.425 billion in cash; significant corporate governance reforms to resolve all claims. This recovery is by far the largest shareholder recovery related to the subprime meltdown and credit crisis; the single largest securities class action settlement ever resolving a Section 14(a) claim—the federal securities provision designed to protect investors against misstatements in connection with a proxy solicitation; the largest ever funded by a single corporate defendant for violations of the federal securities laws; the single largest settlement of a securities class action in which there was neither a financial restatement involved nor a criminal conviction related to the alleged misconduct; and one of the 10 largest securities class action recoveries in history.

Summary: The firm represented Co-Lead Plaintiffs the State Teachers Retirement System of Ohio, the Ohio Public Employees Retirement System, and the Teacher Retirement System of Texas in this securities class action filed on behalf of shareholders of Bank of America Corporation (BAC) arising from BAC's 2009 acquisition of Merrill Lynch & Co. The action alleges that BAC, Merrill Lynch, and certain of the companies' current and former officers and directors violated the federal securities laws by making a series of materially false statements and omissions in connection with the acquisition. These violations included the alleged failure to disclose information regarding billions of dollars of losses Merrill had suffered before the BAC shareholder vote on the proposed acquisition, as well as an undisclosed agreement allowing Merrill to pay billions in bonuses before the acquisition closed despite these losses. Not privy to these material facts, BAC shareholders voted to approve the acquisition.

Case: *In re Allianz Global Investors U.S. Litigation*

Court: Cases primarily filed in the United States District Court for the Southern District of New York

Highlights: Over $2 billion dollars recovered for investors in a series of more than 20 direct actions.

Summary: BLB&G prosecuted claims on behalf of institutional investors that suffered losses in connection with investments in the Allianz Structured Alpha Funds—a suite of investment products developed and overseen by Allianz Global Investors U.S.—due to Allianz's breaches of fiduciary and contractual duties. BLB&G negotiated settlements that returned over $2 billion to investors. Our firm filed a series of direct actions, including the first complaint in this matter on behalf of Arkansas Teacher Retirement System, and subsequently served as liaison counsel in more than 20 related actions.

Allianz's representations concerning the Alpha Funds were also investigated by the SEC and the U.S. Department of Justice. Allianz ultimately set aside over $6 billion to deal with government investigations and lawsuits resulting from the collapse of the Structured Alpha Funds.

Case: *In re Nortel Networks Corporation Securities Litigation (Nortel II)*

Court: United States District Court for the Southern District of New York

Highlights: Over $1.07 billion in cash and common stock recovered for the class.

Summary: This securities fraud class action charged Nortel Networks Corporation and certain of its officers and directors with violations of the Securities Exchange Act of 1934, alleging that the Defendants knowingly or recklessly made false and misleading statements with respect to Nortel's financial results during the relevant period. BLB&G clients the Ontario Teachers' Pension Plan Board and the Treasury of the State of New Jersey and its Division of Investment were appointed as Co-Lead Plaintiffs for the Class in one of two related actions (Nortel II), and BLB&G was appointed Lead Counsel for the Class. In a historic settlement, Nortel agreed to pay $2.4 billion in cash and Nortel common stock to resolve both matters. Nortel later announced that its insurers had agreed to pay $228.5 million toward the settlement, bringing the total amount of the global settlement to approximately $2.7 billion, and the total amount of the Nortel II settlement to over $1.07 billion.

Case: *In re Merck & Co., Inc. Securities Litigation*

Court: United States District Court, District of New Jersey

Highlights: $1.06 billion recovery for the class.

Summary: This case arises out of misrepresentations and omissions concerning life-threatening risks posed by the "blockbuster" COX-2 painkiller Vioxx, which Merck withdrew from the market in 2004. In January 2016, BLB&G achieved a $1.062 billion settlement on the eve of trial after more than 12 years of hard-fought litigation that included a successful decision at the United States Supreme Court. This settlement is the second-largest recovery ever obtained in the Third Circuit and one of the top securities recoveries of all time. BLB&G represented Lead Plaintiff the Public Employees' Retirement System of Mississippi.

Case: *In re McKesson HBOC, Inc. Securities Litigation*

Court: United States District Court for the Northern District of California

Highlights: $1.05 billion recovery for the class.

Summary: This securities fraud litigation was filed on behalf of purchasers of HBOC, McKesson, and McKesson HBOC securities, alleging that Defendants misled the investing public concerning HBOC's and McKesson HBOC's financial results. On behalf of Lead Plaintiff the New York State Common Retirement Fund, BLB&G obtained a $960 million settlement from the company, $72.5 million in cash from Arthur Andersen, and, on the eve of trial, a $10 million settlement from Bear Stearns & Co., with total recoveries reaching more than $1 billion.

Case: *In re Wells Fargo & Company Securities Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $1 billion recovery for the class, the top U.S. securities class action settlement of 2023, among the top six in the past decade, and among the top 17 of all time.

Summary: In 2018, Wells Fargo's regulators imposed unprecedented consent orders on Wells Fargo designed to halt the bank's decades-long, fraudulent banking practices and rectify the severely deficient corporate oversight that allowed those fraudulent practices to develop and endure (the "2018 Consent Orders"). In this action, lead plaintiffs, represented by BLB&G as co-lead counsel, alleged that Wells Fargo and certain of its senior executives issued false and misleading statements to investors regarding the status of Wells Fargo's compliance with the 2018 Consent Orders, claiming that the bank had regulator-approved "plans" and that it was "in compliance" with the Orders. In reality, Wells Fargo had yet to submit to regulators an acceptable plan or schedule for overhauling the bank's compliance and oversight practices and was nowhere near meeting the regulators' requirements that were a predicate to lifting the severe measures imposed on the bank. Wells Fargo investors were harmed after a series of disclosures, including damning congressional hearings and reports, revealed the truth to the market that the bank had blatantly disregarded the basic requirements set forth in the 2018 Consent Orders. The $1 billion settlement was reached after three years of hard-fought litigation and was achieved with the assistance of a respected mediator, former U.S. District Judge Layn R. Phillips.

Case: *HealthSouth Corporation Bondholder Litigation*

Court: United States District Court for the Northern District of Alabama

Highlights: $804.5 million in total recoveries.

Summary: In this litigation, BLB&G was the appointed Co-Lead Counsel for the bond holder class, representing Lead Plaintiff the Retirement Systems of Alabama. This action arose from allegations that Birmingham-based HealthSouth Corporation overstated its earnings at the direction of its founder and former CEO Richard Scrushy. Subsequent revelations disclosed that the overstatement exceeded over $2.4 billion, virtually wiping out all of HealthSouth's reported profits for the prior five years. A total recovery of $804.5 million was obtained in this litigation through a series of settlements, including an approximately $445 million settlement for shareholders and bondholders, a $100 million in cash settlement from UBS AG, UBS Warburg LLC, and individual UBS Defendants, and $33.5 million in cash from the company's auditor. The total settlement for injured HealthSouth bond purchasers exceeded $230 million, recouping over a third of bond purchaser damages.

Case: *In re Washington Public Power Supply System Litigation*

Court: United States District Court for the District of Arizona

Highlights: Over $750 million—the largest securities fraud settlement ever achieved at the time.

***Summary*:** BLB&G was appointed Chair of the Executive Committee responsible for litigating on behalf of the class in this action. The case was litigated for over seven years and involved an estimated 200 million pages of documents produced in discovery; the depositions of 285 fact witnesses and 34 expert witnesses; more than 25,000 introduced exhibits; six published district court opinions; seven appeals or attempted appeals to the Ninth Circuit; and a three-month jury trial, which resulted in a settlement of over $750 million—then the largest securities fraud settlement ever achieved.

Case: *In re Lehman Brothers Equity/Debt Securities Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $735 million in total recoveries.

***Summary*:** Representing the Government of Guam Retirement Fund, BLB&G successfully prosecuted this securities class action arising from Lehman Brothers Holdings' issuance of billions of dollars in offerings of debt and equity securities that were sold using offering materials that contained untrue statements and missing material information.

After four years of intense litigation, Lead Plaintiffs achieved a total of $735 million in recoveries consisting of a $426 million settlement with underwriters of Lehman securities offerings, a $90 million settlement with former Lehman directors and officers, a $99 million settlement that resolves claims against Ernst & Young, Lehman's former auditor (considered one of the top 10 auditor settlements ever achieved), and a $120 million settlement that resolves claims against UBS Financial Services. This recovery is remarkable not only because of the difficulty in recovering assets when the issuer defendant is bankrupt, but also because no financial results were restated, and the auditors never disavowed the statements.

Case: *In re Citigroup, Inc. Bond Action Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $730 million cash recovery, the second largest recovery in a litigation arising from the financial crisis.

Summary: In the years prior to the collapse of the subprime mortgage market, Citigroup issued 48 offerings of preferred stock and bonds. This securities fraud class action was filed on behalf of purchasers of Citigroup bonds and preferred stock alleging that these offerings contained material misrepresentations and omissions regarding Citigroup's exposure to billions of dollars in mortgage-related assets, the loss reserves for its portfolio of high-risk residential mortgage loans, and the credit quality of the risky assets it held in off-balance sheet entities known as "structured investment vehicles." After protracted litigation lasting four years, we obtained a $730 million cash recovery—the second largest securities class action recovery in a litigation arising from the financial crisis, and the second largest recovery ever in a securities class action brought on behalf of purchasers of debt securities. As Lead Bond Counsel for the Class, BLB&G represented Lead Bond Plaintiffs Minneapolis Firefighters' Relief Association, Louisiana Municipal Police Employees' Retirement System, and Louisiana Sheriffs' Pension and Relief Fund.

Case: *In re Schering-Plough Corporation/Enhance Securities Litigation; In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation*

Court: United States District Court for the District of New Jersey

Highlights: $688 million in combined settlements (Schering-Plough settled for $473 million; Merck settled for $215 million) in this coordinated securities fraud litigations filed on behalf of investors in Merck and Schering-Plough.

Summary: After nearly five years of intense litigation, just days before trial, BLB&G resolved the two actions against Merck and Schering-Plough, which stemmed from claims that Merck and Schering artificially inflated their market value by concealing material information and making false and misleading statements regarding their blockbuster anti-cholesterol drugs Zetia and Vytorin. Specifically, we alleged that the companies knew that their "ENHANCE" clinical trial of Vytorin (a combination of Zetia and a generic) demonstrated that Vytorin was no more effective than the cheaper generic at reducing artery thickness. The companies nonetheless championed the "benefits" of their drugs, attracting billions of dollars of capital. When public pressure to release the results of the ENHANCE trial became too great, the companies reluctantly announced these negative results, which we alleged led to sharp declines in the value of the companies' securities, resulting in significant losses to investors. The combined $688 million in settlements (Schering-Plough settled for $473 million; Merck settled for $215 million) is the second largest securities recovery ever in the Third Circuit, among the top 25 settlements of all time, and among the 10 largest recoveries ever in a case where there was no financial restatement. BLB&G represented Lead Plaintiffs Arkansas Teacher Retirement System, the Public Employees' Retirement System of Mississippi, and the Louisiana Municipal Police Employees' Retirement System.

Case: *In re Lucent Technologies, Inc. Securities Litigation*

Court: United States District Court for the District of New Jersey

Highlights: $667 million in total recoveries; the appointment of BLB&G as Co-Lead Counsel is especially noteworthy as it marked the first time since the 1995 passage of the Private Securities Litigation Reform Act that a court reopened the lead plaintiff or lead counsel selection process to account for changed circumstances, new issues, and possible conflicts between new and old allegations.

***Summary*:** BLB&G served as Co-Lead Counsel in this securities class action, representing Lead Plaintiffs the Parnassus Fund, Teamsters Locals 175 & 505 D&P Pension Trust, Anchorage Police and Fire Retirement System, and the Louisiana School Employees' Retirement System. The complaint accused Lucent of making false and misleading statements to the investing public concerning its publicly reported financial results and failing to disclose the serious problems in its optical networking business. When the truth was disclosed, Lucent admitted that it had improperly recognized revenue of nearly $679 million in fiscal 2000. The settlement obtained in this case is valued at approximately $667 million, and is composed of cash, stock, and warrants.

Case: *In re Wachovia Preferred Securities and Bond/Notes Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $627 million recovery—among the largest securities class action recoveries in history; third-largest recovery obtained in an action arising from the subprime mortgage crisis.

***Summary*:** This securities class action was filed on behalf of investors in certain Wachovia bonds and preferred securities against Wachovia Corp., certain former officers and directors, various underwriters, and its auditor, KPMG. The case alleged that Wachovia provided offering materials that misrepresented and omitted material facts concerning the nature and quality of Wachovia's multibillion-dollar option-ARM (adjustable rate mortgage) "Pick-A-Pay" mortgage loan portfolio, and that Wachovia's loan loss reserves were materially inadequate. According to the Complaint, these undisclosed problems threatened the viability of the financial institution, requiring it to be "bailed out" during the financial crisis before it was acquired by Wells Fargo. The combined $627 million recovery obtained in the action is among the 20 largest securities class action recoveries in history, the largest settlement ever in a class action case asserting only claims under the Securities Act of 1933, and one of a handful of securities class action recoveries obtained where there were no parallel civil or criminal actions brought by government authorities. The firm represented Co-Lead Plaintiffs Orange County Employees Retirement System and Louisiana Sheriffs' Pension and Relief Fund in this action.

Case: *In re Fannie Mae/Freddie Mac Senior Preferred Stock Purchase Agreement Class Action Litigations*

Court: United States District Court for the District of Columbia

Highlights: $612.4 million jury award for Fannie Mae and Freddie Mac investors in a unanimous trial verdict.

***Summary*:** BLB&G secured a $612.4 million jury award for Fannie Mae and Freddie Mac investors in a unanimous trial verdict against the Federal Housing Finance Agency (FHFA). The action challenged FHFA's decision to sweep the entire net worth of Fannie Mae and Freddie Mac to the U.S. Treasury, depriving shareholders of significant value. The award came after two trials and 10 years of intense litigation and negotiations. The court also recently approved our request for prejudgment interest, adding approximately $198 million to the recovery for investors (pending entry of judgment).

Case: *Bear Stearns Mortgage Pass-Through Litigation*

Court: United States District Court for the Southern District of New York

Highlights: $500 million recovery—the largest recovery ever on behalf of purchasers of residential mortgage-backed securities.

Summary**:** BLB&G served as Co-Lead Counsel in this securities action, representing Lead Plaintiffs the Public Employees' Retirement System of Mississippi. The case alleged that Bear Stearns & Company sold mortgage pass-through certificates using false and misleading offering documents. The offering documents contained false and misleading statements related to, among other things, the underwriting guidelines used to originate the mortgage loans underlying the certificates and the accuracy of the appraisals for the properties underlying the certificates. After six years of hard-fought litigation and extensive arm's-length negotiations, the $500 million recovery is the largest settlement in a U.S. class action against a bank that packaged and sold mortgage securities at the center of the 2008 financial crisis.

Case: *Gary Hefler et al. v. Wells Fargo & Company et al.*

Court: United States District Court for the Northern District of California

Highlights $480 million recovery—the fourth largest securities settlement ever achieved in the Ninth Circuit.

Summary**:** BLB&G served as Lead Counsel for the Court-appointed Lead Plaintiff Union Asset Management Holding, AG in this action, which alleged that Wells Fargo and certain current and former officers and directors of Wells Fargo made a series of materially false statements and omissions in connection with Wells Fargo's secret creation of fake or unauthorized client accounts in order to hit performance-based compensation goals. After years of presenting a business driven by legitimate growth prospects, U.S. regulators revealed in September 2016 that Wells Fargo employees were secretly opening millions of potentially unauthorized accounts for existing Wells Fargo customers. The Complaint alleged that these accounts were opened in order to hit performance targets and inflate the "cross-sell" metrics that investors used to measure Wells Fargo's financial health and anticipated growth. When the market learned the truth about Wells Fargo's violation of its customers' trust and failure to disclose reliable information to its investors, the price of Wells Fargo's stock dropped, causing substantial investor losses.

Case: *In re Kraft Heinz Securities Litigation*

Court: United States District Court for the Northern District of Illinois

Highlights: $450 million in total recoveries.

***Summary*:** BLB&G litigated claims against Kraft Heinz arising from the defendants' misstatements regarding the company's financial position, including the carrying value of Kraft's assets, the sustainability of Kraft's margins, and the success of recent cost-cutting strategies by the company. After overcoming defendants' motions to dismiss and conducting discovery involving the production of over 14.7 million pages of documents, the parties engaged in mediation and reached a settlement that represented a recovery of $450 million for impacted investors.

Case: *Ohio Public Employees Retirement System v. Freddie Mac*

Court: United States District Court for the Southern District of Ohio

Highlights: $410 million settlement.

***Summary*:** This securities fraud class action was filed on behalf of the Ohio Public Employees Retirement System and the State Teachers Retirement System of Ohio alleging that Freddie Mac and certain of its current and former officers issued false and misleading statements in connection with the company's previously reported financial results. Specifically, the Complaint alleged that the Defendants misrepresented the company's operations and financial results by engaging in numerous improper transactions and accounting machinations that violated fundamental GAAP precepts in order to artificially smooth the company's earnings and hide earnings volatility. In connection with these improprieties, Freddie Mac restated more than $5 billion in earnings. A settlement of $410 million was reached in the case just as deposition discovery had begun and document review was complete.

Case: *In re Refco, Inc. Securities Litigation*

Court: United States District Court for the Southern District of New York

Highlights: Over $407 million in total recoveries.

***Summary*:** The lawsuit arises from the revelation that Refco, a once-prominent brokerage, had for years secreted hundreds of millions of dollars of uncollectible receivables with a related entity controlled by Phillip Bennett, the company's Chairman and Chief Executive Officer. This revelation caused the stunning collapse of the company a mere two months after its initial public offering of common stock. As a result, Refco filed one of the largest bankruptcies in U.S. history. Settlements have been obtained from multiple company and individual defendants, resulting in a total recovery for the class of over $407 million. BLB&G represented Co-Lead Plaintiff RH Capital Associates LLC.

Case: *In re Allergan, Inc. Proxy Violation Securities Litigation*

Court: United States District Court for the Central District of California

Highlights: Recovered over $250 million for investors while challenging an unprecedented insider trading scheme by billionaire hedge fund manager Bill Ackman.

Summary: As alleged in groundbreaking litigation, billionaire hedge fund manager Bill Ackman and his Pershing Square Capital Management fund secretly acquired a near 10% stake in pharmaceutical concern Allergan as part of an unprecedented insider trading scheme by Ackman and Valeant Pharmaceuticals International. What Ackman knew—but investors did not—was that in the ensuing weeks, Valeant would be launching a hostile bid to acquire Allergan shares at a far higher price. Ackman enjoyed a massive instantaneous profit upon public news of the proposed acquisition, and the scheme worked for both parties as he kicked back hundreds of millions of his insider-trading proceeds to Valeant after Allergan agreed to be bought by a rival bidder. After a ferocious three-year legal battle over this attempt to circumvent the spirit of the U.S. securities laws, BLB&G obtained a $250 million settlement for Allergan investors, and created precedent to prevent similar such schemes in the future. The Plaintiffs in this action were the State Teachers Retirement System of Ohio, the Iowa Public Employees Retirement System, and Patrick T. Johnson.

Corporate Governance and Shareholders' Rights

Case: *Tornetta v. Musk*

Court: Delaware Court of Chancery

Highlights: Achieved a historic ruling rescinding Elon Musk's $55 billion compensation package at Tesla—the largest such package in history.

Summary: BLB&G led a headline-grabbing shareholder derivative action against Elon Musk and certain Tesla board members challenging the $55 billion compensation plan granted to Musk—the largest such compensation plan in history. BLB&G served as lead trial counsel in this case on behalf of a Tesla stockholder. The firm litigated for more than four years, examined eight of the most critical witnesses—including Elon Musk himself—and presented a strong factual record to the Court. On January 30, 2024, in a historic decision, the court nullified Musk's entire $55 billion compensation package, finding that Tesla's board of directors had breached their fiduciary duty in structuring Musk's multi-tranched compensation.

Case: *City of Monroe Employees' Retirement System, Derivatively on Behalf of Twenty-First Century Fox, Inc. v. Rupert Murdoch, et al.*

Court: Delaware Court of Chancery

Highlights: Landmark derivative litigation established unprecedented, independent Board-level council to ensure employees are protected from workplace harassment while recouping $90 million for the company's coffers.

Summary: Before the birth of the #metoo movement, BLB&G led the prosecution of an unprecedented shareholder derivative litigation against Fox News parent 21st Century Fox arising from the systemic sexual and workplace harassment at the embattled network. After nearly 18 months of litigation, discovery and negotiation related to the shocking misconduct and the Board's extensive alleged governance failures, the parties unveil a landmark settlement with two key components: 1) the first ever Board-level watchdog of its kind—the "Fox News Workplace Professionalism and Inclusion Council" of experts (WPIC)—majority independent of the Murdochs, the Company and Board; and 2) one of the largest financial recoveries—$90 million—ever obtained in a pure corporate board oversight dispute. The WPIC serves as a model for public companies in all industries. The firm represented 21st Century Fox shareholder the City of Monroe (Michigan) Employees' Retirement System.

Case: *In re McKesson Corporation Derivative Litigation*

Court: United States District Court, Northern District of California, Oakland Division and Delaware Chancery Court

***Highlights*:** Litigation recovered $175 million and achieved substantial corporate governance reforms.

***Summary*:** BLB&G represented the Police & Fire Retirement System City of Detroit and Amalgamated Bank in this derivative class action arising from the company's role in permitting and exacerbating America's ongoing opioid crisis. The complaint, initially filed in Delaware Chancery Court, alleged that defendants breached their fiduciary duties by failing to adequately oversee McKesson's compliance with provisions of the Controlled Substances Act and a series of settlements with the Drug Enforcement Administration intended to regulate the distribution and misuse of controlled substances such as opioids. Even after paying fines and settlements in the hundreds of millions of dollars, McKesson was sued in the National Opioid Multidistrict Litigation. In May 2018, our clients joined a substantially similar action being litigated in California federal court. Acting as co-lead counsel, BLB&G played a major role in litigating the case, opposing a motion to stay the action by a special litigation committee, and engaging in extensive pretrial discovery. Ultimately, $175 million was recovered for the benefit of McKesson's shareholders in a settlement that also created substantial corporate-governance reforms to prevent a recurrence of McKesson's inadequate legal compliance efforts.

Case: *UnitedHealth Group, Inc. Shareholder Derivative Litigation*

Court: United States District Court for the District of Minnesota

Highlights: Recovered over $920 million in ill-gotten compensation directly from former officers for their roles in illegally backdating stock options, while the company agreed to far-reaching reforms aimed at curbing future executive compensation abuses.

Summary: This shareholder derivative action filed against certain current and former executive officers and members of the Board of Directors of UnitedHealth Group alleged that the Defendants obtained, approved and/or acquiesced in the issuance of stock options to senior executives that were unlawfully backdated to provide the recipients with windfall compensation at the direct expense of UnitedHealth and its shareholders. The firm recovered over $920 million in ill-gotten compensation directly from the former officer Defendants—the largest derivative recovery in history. As feature coverage in *The New York Times* indicated, "investors everywhere should applaud [the UnitedHealth settlement]….[T]he recovery sets a standard of behavior for other companies and boards when performance pay is later shown to have been based on ephemeral earnings." The Plaintiffs in this action were the St. Paul Teachers' Retirement Fund Association, the Public Employees' Retirement System of Mississippi, the Jacksonville Police & Fire Pension Fund, the Louisiana Sheriffs' Pension & Relief Fund, the Louisiana Municipal Police Employees' Retirement System and Fire & Police Pension Association of Colorado.

Case: *Caremark Merger Litigation*

Court: Delaware Court of Chancery – New Castle County

Highlights: Landmark Court ruling ordered Caremark's board to disclose previously withheld information, enjoined a shareholder vote on the CVS merger offer, and granted statutory appraisal rights to Caremark shareholders. The litigation ultimately forced CVS to raise its offer by $7.50 per share, equal to more than $3.3 billion in additional consideration to Caremark shareholders.

Summary: Commenced on behalf of the Louisiana Municipal Police Employees' Retirement System and other shareholders of Caremark RX, this shareholder class action accused the company's directors of violating their fiduciary duties by approving and endorsing a proposed merger with CVS Corporation, while refusing to fairly consider an alternative transaction proposed by another bidder. In a landmark decision, the Court ordered the Defendants to disclose material information that had previously been withheld, enjoined the shareholder vote on the CVS transaction until the additional disclosures occurred, and granted statutory appraisal rights to Caremark's shareholders—forcing CVS to increase the consideration offered to shareholders by $7.50 per share in cash (over $3 billion in total).

Case: *In re Pfizer Inc. Shareholder Derivative Litigation*

Court: United States District Court for the Southern District of New York

Highlights: Landmark settlement in which Defendants agreed to create a new Regulatory and Compliance Committee of the Pfizer Board to be supported by a dedicated $75 million fund.

Summary: In the wake of Pfizer's agreement to pay $2.3 billion as part of a settlement with the U.S. Department of Justice to resolve civil and criminal charges relating to the illegal marketing of at least 13 of the company's most important drugs (the largest such fine ever imposed), this shareholder derivative action was filed against Pfizer's senior management and Board alleging they breached their fiduciary duties to Pfizer by, among other things, allowing unlawful promotion of drugs to continue after receiving numerous "red flags" that Pfizer's improper drug marketing was systemic and widespread. The suit was brought by Court-appointed Lead Plaintiffs Louisiana Sheriffs' Pension and Relief Fund and Skandia Life Insurance Company, Ltd. In an unprecedented settlement reached by the parties, the Defendants agreed to create a new Regulatory and Compliance Committee of the Pfizer Board of Directors (the "Regulatory Committee") to oversee and monitor Pfizer's compliance and drug marketing practices and to review the compensation policies for Pfizer's drug sales related employees.

Case: *Miller et al. v. IAC/InterActiveCorp et al.*

Court: Delaware Court of Chancery

Highlights: This litigation shut down efforts by controlling shareholders to obtain "dynastic control" of the company through improper stock class issuances, setting valuable precedent and sending a strong message to boards and management in all sectors that such moves will not go unchallenged.

Summary: BLB&G obtained this landmark victory for shareholder rights against IAC/InterActiveCorp and its controlling shareholder and chairman, Barry Diller. For decades, activist corporate founders and controllers sought ways to entrench their position atop the corporate hierarchy by granting themselves and other insiders "supervoting rights." Diller laid out a proposal to introduce a new class of non-voting stock to entrench "dynastic control" of IAC within the Diller family. BLB&G litigation on behalf of IAC shareholders ended in capitulation with the Defendants effectively conceding the case by abandoning the proposal. This became a critical corporate governance precedent, given the trend of public companies to introduce "low" and "no-vote" share classes, which diminish shareholder rights, insulate management from accountability, and can distort managerial incentives by providing controllers voting power out of line with their actual economic interests in public companies.

Case: *In re News Corp. Shareholder Derivative Litigation*

Court: Delaware Court of Chancery – Kent County

Highlights: An unprecedented settlement in which News Corp. recouped $139 million and enacted significant corporate governance reforms that combat self-dealing in the boardroom.

Summary: Following News Corp.'s 2011 acquisition of a company owned by News Corp. Chairman and CEO Rupert Murdoch's daughter, and the phone-hacking scandal within its British newspaper division, BLB&G filed a derivative litigation on behalf of the company because of institutional shareholder concern with the conduct of News Corp.'s management. BLB&G ultimately obtained an unprecedented settlement in which News Corp. recouped $139 million for the company coffers and agreed to enact corporate governance enhancements to strengthen its compliance structure, the independence and functioning of its board, and the compensation and clawback policies for management.

Clients and Fees

We are firm believers in the contingency fee as a socially useful, productive and satisfying basis of compensation for legal services, particularly in litigation. Wherever appropriate, even with our corporate clients, we encourage retentions in which our fee is contingent on the outcome of the litigation. This way, it is not the number of hours worked that will determine our fee, but rather the result achieved for our client. The firm generally negotiates with our clients a contingent fee schedule specific to each litigation, and all fee proposals are approved by the client prior to commencing litigation, and ultimately by the Court.

Our clients include many large and well-known financial and lending institutions and pension funds, as well as privately held companies that are attracted to our firm because of our reputation, expertise, and fee structure. Most of the firm's clients are referred by other clients, law firms and lawyers, bankers, investors, and accountants. A considerable number of clients have been referred to the firm by former adversaries. We have always maintained a high level of independence and discretion in the cases we decide to prosecute. As a result, the level of personal satisfaction and commitment to our work is high.

In the Public Interest

Bernstein Litowitz Berger & Grossmann LLP is guided by two principles: excellence in legal work and a belief that the law should serve a socially useful and dynamic purpose. Attorneys at the firm are active in academic, community, and pro bono activities and regularly participate as speakers and contributors to professional organizations. In addition, the firm endows a public interest law fellowship and sponsors an academic scholarship at Columbia Law School. Highlights of our community contributions include:

Bernstein Litowitz Berger & Grossmann Public Interest Law Fellows

BLB&G is committed to fighting discrimination and effecting positive social change. In support of this commitment, the firm donates funds to Columbia Law School to create the Bernstein Litowitz Berger & Grossmann Public Interest Law Fellowship. This fund at Columbia Law School provides Fellows with 100% of the funding needed to make payments on their law school tuition loans so long as such graduates remain in the public interest law field. BLB&G Fellows can begin their careers free of any school debt if they make a long-term commitment to public interest law.

Firm Sponsorship of Her Justice

BLB&G is a sponsor of Her Justice, a not-for-profit organization in New York City dedicated to providing pro bono legal representation to indigent women, principally vulnerable women, in connection with the myriad legal problems they face. The organization trains and supports the efforts of New York lawyers who provide pro bono counsel to these women. Several members and associates of the firm volunteer their time to help women who need divorces from abusive spouses or representation on issues such as child support, custody, and visitation. To read more about Her Justice, visit the organization's website at http://www.herjustice.org/.

Firm Sponsorship of City Year New York

BLB&G is an active supporter of City Year New York, a division of AmeriCorps. The program was founded in 1988 as a means of encouraging young people to devote time to public service and unites a diverse group of volunteers for a demanding year of full-time community service, leadership development, and civic engagement. Through their service, corps members experience a rite of passage that can inspire a lifetime of citizenship and build a stronger democracy.

Max W. Berger Pre-Law Program

The Max W. Berger Pre-Law Program was established at Baruch College to encourage outstanding minority undergraduates to pursue a meaningful career in the legal profession. Providing workshops, seminars, counseling, and mentoring to Baruch students, the program facilitates and guides them through the law school research and application process, and places them in appropriate internships and other pre-law working environments.

Exhibit 6

EXHIBIT 6

***Homyk v. ChemoCentryx, Inc.*, Master File No. 4:21-cv-03343-JST**

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP

ATTORNEY BIOGRAPHIES

PARTNERS

Abraham ("Abe") Alexander [Former Partner] practiced out of the New York office, where he focused on securities fraud, corporate governance and shareholder rights litigation.

As a principal member of the trial team prosecuting *In re Merck Vioxx Securities Litigation*, Abe helped recover over $1.06 billion on behalf of injured investors. The case, which asserted claims arising out of the Defendants' alleged misrepresentations concerning the safety profile of Merck's pain-killer, VIOXX, was settled shortly before trial and after more than 10 years of litigation, during which time plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the largest securities recovery ever achieved against a pharmaceutical company and among the 15 largest recoveries of all time.

Abe was also a principal member of the trial team that prosecuted *In re Schering-Plough Corp./ENHANCE Securities Litigation* and *In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation*, which settled on the eve of trial for a combined $688 million. This $688 million settlement represents the second largest securities class action recovery against a pharmaceutical company in history and is among the largest securities class action settlements of any kind.

Abe had also obtained several additional significant recoveries on behalf of investors in pharmaceutical and life sciences companies, including a $142 million recovery in *Medina v. Clovis Oncology, Inc.*, a securities fraud class action arising from Defendants' alleged misstatements about the efficacy and safety of its most important drug; a $77.5 million recovery in *In re Myriad Genetics, Inc. Securities Litigation*, a case arising from alleged misstatements concerning genetic testing products; a $55 million recovery in *In re HeartWare International, Inc. Securities Litigation*, a case arising from Defendants' alleged misstatements about the device-maker's compliance with FDA regulations and the performance of its key heart pump; a $44 million recovery in *In re Adeptus Health Inc. Securities Litigation*, a case arising from alleged misstatements concerning the liquidity and cash flow of the country's largest operator of freestanding emergency rooms; and a $39 million recovery, *BioMarin Pharmaceutical Inc.*, a case arising from alleged misstatements concerning FDA review of a biologic.

Abe secured a $450 million recovery in *In re Kraft Heinz Securities Litigation*, a case arising from alleged misstatements concerning the sustainability of Kraft Heinz's cost-cutting measures and its brand investment and operations. Abe also secured a $149 million recovery on behalf of investors in Equifax, Inc., helping to lead a securities class action arising from one of the largest data breaches in American history. Abe also played a lead role in securing a $150 million settlement of investors' claims against JPMorgan Chase arising from alleged misrepresentations concerning the trading activities of the so-called "London Whale," and in securing a $95 million recovery on behalf of investors in Cognizant Technology Solutions dealing with alleged false statements and illegal payments to Indian governmental officials to secure favorable permits.

He was a member of the team prosecuting *In re The Boeing Company Aircraft Securities Litigation*; *Homyk v. ChemoCentryx, Inc.*; and *In re Seagate Tech. Holdings plc*, among others.

Prior to joining the firm, Abe represented institutional clients in a number of high-profile securities, corporate governance, and antitrust matters.

Abe was an award-winning member of his law school's national moot court team. Following law school, Abe served as a judicial clerk to Chief Justice Michael L. Bender of the Colorado Supreme Court.

He was named a 2022 "Rising Star of the Plaintiff's Bar" by the *National Law Journal,* was named a 2021 "Rising Star" by *Law360,* and chosen by *Benchmark Litigation* for its "40 & Under Hot List." *Super Lawyers* has also regularly selected Abe as a New York "Rising Star" in recognition of his accomplishments.

Education: New York University - The College of Arts and Science, 2003, B.A., *cum laude*, Analytic Philosophy; University of Colorado Law School, 2008, J.D., Order of the Coif

Bar Admissions: New York, Delaware, U.S. District Court for the Southern District of New York, U.S. District Court for the Eastern District of New York, U.S. District Court for the District of Delaware; U.S. Court of Appeals for the First Circuit

Scott Foglietta prosecutes securities fraud, corporate governance, and shareholder rights litigation on behalf of the firm's institutional investor clients. As a member of the firm's case development and client advisory group, Scott advises Taft-Hartley pension funds, public pension funds, and other institutional investors on potential legal claims.

Scott was an integral member of the teams that advised the firm's clients in their prosecution of numerous significant matters, including securities class actions against *Wells Fargo* ($480 million recovery), *Kraft Heinz* ($450 million recovery), *Salix Pharmaceuticals* ($210 million recovery), *Luckin Coffee* ($175 million recovery), and *Equifax* ($149 million recovery). Scott was also key member of the teams that evaluated and developed novel case theories or claims in several matters, including a securities class action against Willis Towers Watson, which arose from misrepresentations made in a proxy statement in connection with the merger between Willis Group and Towers Watson and was resolved for $75 million, and an ongoing securities class action against *Perrigo* arising from misrepresentations made in connection with a tender offer for shares trading in both the United States and Israel. Scott was also a member of the teams that secured our clients' appointments as lead plaintiffs in the ongoing securities class actions against *Boeing, Meta Platforms, Seagate, Silvergate, TD Bank* and *First Horizon*, and *SVB Financial*, among others.

Scott was also a member of the team that advised one of the firm's institutional investor clients in a shareholder derivative action against the board of directors of *FirstEnergy Corp*. arising from the company's role in an egregious public corruption scandal, in which $180 million was recovered and substantial governance reforms were obtained. Scott is routinely recognized for his outstanding legal work, including being named a "Rising Star" by *The National Law Journal* and *Law360*, and to *Benchmark Litigation's* "40 & Under" Hot List. Scott has also been named to numerous Lawdragon lists, including "500 Leading Plaintiff Financial Lawyers," "500 Leading Lawyers in America," and "*Lawdragon 500 X* – The Next Generation."

Before joining the firm, Scott represented institutional and individual clients in a wide variety of complex litigation matters, including securities class actions, commercial litigation, and ERISA litigation. Prior to law school, Scott earned an M.B.A. in finance from Clark University and worked as a capital markets analyst for a boutique investment banking firm.

Education: Brooklyn Law School, 2010, J.D. Clark University, Graduate School of Management, 2007, M.B.A., Finance; Clark University, 2006, B.A., *cum laude*, Management
Bar Admissions: New York; New Jersey; United States District Court for the Southern District of New York; United States District Court for the Eastern District of New York; United States District Court for the District of New Jersey

Salvatore Graziano is a BLB&G partner and member of the firm's Executive Committee. Widely recognized as one of the top securities litigators in the country, he has served as lead trial counsel in several historic securities fraud class actions, recovering billions of dollars on behalf of institutional investors and hedge fund clients. He practices out of the firm's New York office.

Over the course of his distinguished career, Salvatore has successfully litigated many high-profile cases, including: *In re Merck & Co., Inc. Securities Litigation* (Vioxx-Related): Securing a landmark $1.06 billion recovery in this litigation concerning misrepresentations about the safety of Merck's drug Vioxx. Salvatore led the BLB&G team through 10 years of litigation, successfully obtaining a groundbreaking, investor-friendly ruling from the U.S. Supreme Court on the statute of limitations for securities fraud claims. *In re Schering-Plough Corporation/ENHANCE Securities Litigation*: Leading the BLB&G team that prosecuted this case, which settled on the eve of trial for a combined $688 million—the second largest securities class action recovery against a pharmaceutical company in history and among the largest securities class action settlements of any kind.

- *Gary Hefler et al. v. Wells Fargo & Company et al.*: Leading the BLB&G team that prosecuted this securities class action against Wells Fargo arising from the highly publicized scandal concerning Wells Fargo's creation of millions of fake or unauthorized accounts. Salvatore successfully recovered $480 million for investors— the fifth largest securities class action recovery ever in the Ninth Circuit.
- *In re Kraft Heinz Securities Litigation*: Prosecuting securities class action claims arising from Kraft Heinz's $15.4 billion goodwill write-down in 2019—one of the largest goodwill impairment

charges taken by any company since the 2008 financial crisis. Salvatore and the BLB&G team overcame defendants' motions to dismiss and recovered $450 million for impacted investors.

- *New York State Teachers' Retirement System v. General Motors Co.*: Resolving this securities class action against General Motors for $300 million—the second largest recovery of its kind in the Sixth Circuit. This case arose from a series of misrepresentations concerning the quality, safety, and reliability of the company's cars.

Salvatore is consistently recognized by industry observers, peers, and adversaries for his remarkable achievements. He is celebrated as one of the *"Top 100 Trial Lawyers"* in the nation and a *"Litigation Star"* by *Benchmark Litigation* for delivering "top quality work." *Chambers USA* regularly ranks him as a top litigator, with market sources describing him as "a fabulous oral advocate" and having "the vision to view a case like a chess master...always several moves ahead." *The Legal 500* also ranks him highly, quoting sources who commend him as a "highly effective litigator."

Salvatore's accolades from *Law360* include multiple recognitions as one of the few Securities Litigation and Class Action "MVPs" in the nation and as a 2025 "Titan of the Plaintiffs Bar" for his exceptional work in multiple high profile securities litigation cases before the U.S. Supreme Court involving Macquarie, Facebook, and Nvidia. Additionally, he is named a "Litigation Trailblazer" by *The National Law Journal*, featured in *Lawdragon's* "500 Leading Lawyers in America" and "500 Leading Plaintiff Financial Lawyers in America," recognized as a leading mass tort and plaintiff class action litigator by *Best Lawyers®*, and listed among *Thomson Reuters'* "Super Lawyers."

In recognition of his high level of efficacy and countless accomplishments in litigation and trial work, as well as his ethical reputation, Salvatore was named a Fellow of the Litigation Counsel of America ("LCA"). This close-knit, peerselected group embodies the best of the best in trial law, with most members bringing 12 or more years of experience to the table. LCA membership is limited to 3,500 fellows, representing less than one-half of one percent of American lawyers.

A highly esteemed voice on investor rights, regulatory and market issues, in 2008, Salvatore was called upon by the U.S. Securities and Exchange Commission's Advisory Committee on Improvements to Financial Reporting to give testimony as to the state of the industry and potential impacts of proposed regulatory changes being considered. He is the author and co-author of numerous articles on developments in the securities laws, and was chosen, along with several of his BLB&G partners, to author the first chapter, "Plaintiffs' Perspective," of Lexis/Nexis's seminal industry guide Litigating Securities Class Actions. He regularly speaks on securities fraud litigation and shareholder rights and has repeatedly guest lectured at Columbia Law School on these topics.

Salvatore is a Senior Vice President of the Institute for Law and Economic Policy. He previously served as President of the National Association of Shareholder & Consumer Attorneys and has served as a member of the Financial Reporting Committee and the Securities Regulation Committee of the Association of the Bar of the City of New York. Prior to entering private practice, Salvatore served as an Assistant District Attorney in the Manhattan District Attorney's Office.

Education: New York University School of Law, 1991, J.D., *cum laude*; New York University - The College of Arts and Science, 1988, B.A., *cum laude*, Psychology

Bar Admissions: New York; United States District Court for the Southern District of New York; United States District Court for the Eastern District of New York; United States District Court for the Eastern District of Michigan; United States Court of Appeals for the First Circuit; United States Court of Appeals for the Second Circuit; United States Court of Appeals for the Third Circuit; United States Court of Appeals for the Fourth Circuit; United States Court of Appeals for the Sixth Circuit; United States Court of Appeals for the Ninth Circuit; United States Court of Appeals for the Eleventh Circuit; Supreme Court of the United States

Robert "Rocky" Kravetz is a partner out of the firm's New York office. Having served as an Assistant United States Attorney and Chief of Appeals for the United States Attorney's Office for the District of Delaware for over thirteen years, Robert has substantial investigative, litigation, trial, and appellate experience involving a wide array of federal criminal offenses, including financial institution, securities, and health care fraud.

His extensive experience includes leading large-scale investigations of financial institutions and auditing firms, in concert with securities and banking regulators. He has tried multiple cases to verdict as lead counsel, including a recent securities fraud case involving a bank and its senior executives that yielded multiple guilty pleas and resulted in a trial verdict against the remaining defendants. As Chief of Appeals, Robert supervised the Office's written advocacy and conducted oral arguments before the United States Court of Appeals. He has received the Executive Office of United States Attorneys Director's Award, one of the Department of Justice's highest honors, and he was previously named the Federal Bar Association's Younger Attorney of the Year.

Since joining BLB&G, Rocky has been part of case teams responsible for securing over $1 billion in recoveries for investors. In Summer 2023, Rocky was co-lead trial counsel *in In re Fannie Mae/Freddie Mac Senior Preferred Stock Purchase Agreement Class Action Litigations*, Case No. 1:13-mc-1288 (RCL) (D.D.C.), in which Fannie Mae and Freddie Mac investors secured an historic $612 million verdict before a D.C. jury relating to the government takeover of Fannie and Freddie during the 2008 Financial Crisis.

Before becoming an Assistant United States Attorney, Robert served as a law clerk to the Honorable D. Michael Fisher on the United States Court of Appeals for the Third Circuit, and to the Honorable Joy Flowers Conti on the United States District Court for the Western District of Pennsylvania. Prior to joining BLB&G, Robert served as an Assistant Professor of Law at Duquesne University School of Law for two years, teaching courses in advanced criminal law and investigations and torts. He continues to serve as an Adjunct Professor at Duquesne.

Robert is the past president of the Delaware Chapter of the Federal Bar Association and a recipient of the Caleb R. Layton III Service Award, chosen by the Judges of the United States District Court for the District of Delaware.

Education: Duquesne University, 2003, J.D., Editor-in-Chief, Duquesne Law Review; Duquesne University, 2000, B.A., *summa cum laude*
Bar Admissions: Pennsylvania; United States District Court for the Western District of Pennsylvania; United States Court of Appeals for the Third Circuit

Hannah Ross, a BLB&G partner and member of the firm's Executive Committee, has more than 25 years of experience as a civil and criminal litigator. In addition to prosecuting securities fraud, corporate governance, and other forms of shareholder litigation on behalf of BLB&G's institutional investor clients, Hannah dedicates a significant part of her practice to counseling the firm's clients on potential claims in both U.S. and non-U.S. jurisdictions. She practices out of the firm's New York office. A former prosecutor in the Massachusetts Attorney General's Office and Assistant District Attorney in the Middlesex County (Massachusetts) District Attorney's Office, Hannah is a fierce litigator who fights to maximize recoveries for investors injured by corporate fraud and malfeasance. She has been a leader and key member of trial teams that have recovered billions of dollars for BLB&G's clients and other investors through shareholder litigation. Most recently, Hannah was a leader of the BLB&G team that recovered more than $2 billion for 35 institutions that invested in the Allianz Structured Alpha Funds. Among the many highlights of Hannah's career are several cases against some of the largest U.S. banking institutions, including several that collapsed in the wake of the 2008 financial crisis:

- *In re Bank of America Securities Litigation*: Prosecuting the securities fraud class action against Bank of America, which resulted in a landmark settlement shortly before trial of $2.425 billion—one of the largest securities recoveries ever obtained and by far the largest recovery achieved in a litigation arising from the 2008 financial crisis.

- *In re Wells Fargo & Company Securities Litigation*: Co-leading the team that prosecuted the securities class action against Wells Fargo, which resulted in a historic $1 billion recovery for investors—the top U.S. securities class action recovery in 2023.

- *In re MF Global Holdings Limited Securities Litigation*: Serving as a senior member of the trial team that prosecuted the litigation arising from the collapse of former leading brokerage MF Global, recovering $234.3 million for injured investors.

- *In re Washington Mutual, Inc., Securities Litigation:* Leading the prosecution against Washington Mutual and certain of its former officers and directors for alleged fraudulent conduct in the company's home lending operations, an action which settled for $216.75 million—one of the largest recoveries in a case related to the subprime crisis and the largest recovery ever achieved in a securities class action in the Western District of Washington.

- *In re Wilmington Trust Securities Litigation:* Serving as lead partner in the securities class action arising from the failure of major mid-Atlantic bank Wilmington Trust, achieving a $210 million recovery.

Hannah's litigation experience also includes prosecuting the seminal securities fraud class action against *Nortel Networks*, in which the firm obtained a $1.07 billion recovery for investors—among the top 12 U.S. securities class action recoveries of all time. She also prosecuted the securities fraud class action against *Freddie Mac*, securing a $410 million recovery for investors—one of the top 50 U.S. securities class action recoveries ever. Beyond her litigation responsibilities, Hannah is a leader at BLB&G and in the public pension fund community at large. She serves as co-chair of the firm's Forum for Institutional Investors and Women's Forum. She also serves on the Corporate Leadership Committee of the New York Women's Foundation and recently concluded a three-year term on the Council of Institutional Investors' Markets Advisory Council. She is an active member of the National Association of Public Pension Attorneys and has also served as an adjunct faculty member in the trial advocacy program at the Dickinson School of Law of the Pennsylvania State University.

Hannah is widely recognized by industry observers for her professional achievements. *Chambers USA* has recognized Hannah as a "notable practitioner" in the Nationwide Securities Litigation Plaintiff category. She has also been named a "Litigation Star," a "Top U.S. Woman Litigator," and one of the "Top 250 Women in Litigation" in the nation by *Benchmark Litigation*; recognized by *The National Law Journal* as an "Elite Woman of the Plaintiffs' Bar" three times and as a "Litigation & Plaintiffs' Lawyer Trailblazer"; named a New York "Super Lawyer" by *Thomson Reuters' Super Lawyers magazine*; honored as a "Titan of the Plaintiffs Bar" by *Law360*; named one of the top female litigators in the country by *Euromoney/Legal Media Group*; named to an exclusive group of practitioners by *The Legal 500*; and included on *Lawdragon's* "500 Leading Lawyers in America," "500 Leading Plaintiff Financial Lawyers," and "Legends" lists. Hannah received her J.D. from Penn State Dickinson School of Law, where she was a member of the Woolsack Honor Society, received the D. Arthur Magaziner Human Services Award, and served as Comments Editor for the Dickinson Law Review. She received her B.A., *cum laude*, from Cornell University.

Education: Penn State Dickinson School of Law, 1998, J.D., Woolsack Honor Society; Comments Editor, Dickinson Law Review; D. Arthur Magaziner Human Services Award; Cornell University, 1995, B.A., *cum laude*

Bar Admissions: Massachusetts; New York; United States District Court for the Eastern District of Wisconsin; United States District Court for the Southern District of New York; United States Court of Appeals for the Second Circuit of Appeals for the Third Circuit

Jerry Silk is a member of BLB&G's Executive Committee and co-leader of the firm's case development and client advisory group, which performs portfolio monitoring and case evaluation services for the firm's more than 350 institutional investor clients. Recognized as one of the country's leading advisors to institutional investors worldwide, Jerry has nearly 30 years of experience advising and representing institutional investors on matters involving federal and state securities laws, accountants' liability, corporate officers' and directors' fiduciary duties, and the fairness of corporate transactions to shareholders. He also advises creditors on their right to pursue claims against officers and directors, as well as professionals, both inside and outside of bankruptcy.

Jerry practices out of the firm's New York office. Jerry has led BLB&G's representation of some of the most important securities actions of all time, recovering billions of dollars for investors damaged by corporate fraud and misconduct. Highlights of Jerry's litigation experience include: *In re Cendant Corporation Securities Litigation*: Playing a key role in the prosecution of the securities fraud class action against Cendant, which was resolved for $3.3 billion—the third largest U.S. securities class action recovery of all time; *In re Allianz Global Investors U.S. Litigation*: Playing a key role on the BLB&G team that recovered over $2 billion for 35 institutions that invested in the Allianz Structured Alpha Funds; *New York State Teachers' Retirement System v. General Motors Company*: Litigating the securities case against General Motors arising from misrepresentations concerning the safety and reliability of the company's cars, recovering $300 million.

In addition, Jerry is actively involved in the firm's prosecution of highly successful M&A litigation. He was a coleader of the BLB&G team that prosecuted the shareholder class action arising from the proposed acquisition of Caremark Rx by CVS—which led to an increase of approximately $3.5 billion in the consideration offered to shareholders. Jerry also successfully resolved an innovative case on behalf of sellers of Dole Food securities, where plaintiffs alleged that Dole's CEO issued misrepresentations to drive the price of the company down in order to take the company private on the cheap. BLB&G resolved the Dole case for $74 million.

In the wake of the 2008 financial crisis, Jerry advised the firm's institutional investor clients on their rights with respect to claims involving transactions in residential mortgage-backed securities ("RMBS") and collateralized debt obligations. His work representing Cambridge Place Investment Management on claims under Massachusetts state law against numerous investment banks arising from the purchase of billions of dollars of RMBS was featured in the 2010 New York Times article "Mortgage Investors Turn to State Courts for Relief."

Recognized as one of an elite group of notable practitioners by *Chambers USA*, Jerry has also been named a "Litigation Star" by *Benchmark Litigation* and is recommended by *The Legal 500* USA guide for plaintiffs' securities litigation. *Lawdragon* magazine, which has named Jerry one of the "100 Securities Litigators You Need to Know," one of the "500 Leading Plaintiff Financial Lawyers," one of the "500 Leading Lawyers in America," and a "Lawdragon Legend," profiled Jerry as part of its "Lawyer Limelight" special series, discussing subprime litigation and his passion for plaintiffs' work. In 2014, Jerry was recognized by *The National Law Journal* in its inaugural list of "Litigation Trailblazers & Pioneers"—one of 50 lawyers in the country recognized for having changed the practice of litigation through innovative legal strategies. He has also been selected by Thomson Reuters as a New York City "Super Lawyer" several times.

Jerry lectures to institutional investors at conferences throughout the country and is a regular speaker at Practising Law Institute's Annual Institute on Securities Regulation. He has written several articles on developments in securities and corporate law, including in the *New York Times, Financial Times, Bloomberg, The National Law Journal, and the New York Law Journal*. He has also served as a commentator for the business media on television, appearing on NBC's Today, and CNBC's Power Lunch, Morning Call, and Squawkbox, among other programs. Jerry received his J.D., *cum laude*, from Brooklyn Law School, and his B.S. in Economics from the Wharton School of the University of Pennsylvania. Jerry previously served as a law clerk to the Honorable Steven M. Gold in the U.S. District Court for the Eastern District of New York.

Education: Brooklyn Law School, 1995, J.D., *cum laude;* Wharton School of the University of Pennsylvania, 1991, B.S., Economics

Bar Admissions: New York; United States District Court for the Southern District of New York; United States District Court for the Eastern District of New York; United States Court of Appeals for the Second Circuit

Katie Sinderson, a BLB&G partner, focuses her practice on advising and representing the firm's institutional investor clients in securities fraud class actions. With more than 18 years of practice experience, she has led litigation teams that have recovered billions of dollars for investors harmed by corporate fraud and malfeasance. She practices out of the firm's New York office.
Katie played a key role in two of the firm's largest cases, both of which settled near trial for billions of dollars on behalf of investors:

- *In re Bank of America Securities Litigation*: Katie was an integral member of the trial team that prosecuted the securities fraud action against Bank of America related to the company's acquisition of Merrill Lynch & Co., achieving a recovery of $2.425 billion—one of the top seven U.S. securities class action recoveries of all time.

- *In re Merck Securities Litigation*: Katie was a leader of the trial team that achieved a $1.062 billion recovery in the action arising from Merck's marketing of the recalled drug Vioxx—one of the top 13 U.S. securities class action recoveries of all time.

Her recent significant litigation wins include:

- *In re Kraft Heinz Securities Litigation*: Leading the team that recovered $450 million in the securities class action involving Kraft Heinz and Brazilian private equity firm 3G Capital.

- *In re Washington Mutual, Inc., Securities Litigation*: Leading the prosecution against Washington Mutual and certain of its former officers and directors for alleged fraudulent conduct in the company's home lending operations, an action which was resolved for $216.75 million.

- *In re Wilmington Trust Securities Litigation*: Serving as lead partner in the securities class action arising from the failure of major mid-Atlantic bank Wilmington Trust, achieving a $210 million recovery.

- *In re Salix Pharmaceuticals, Ltd. Securities Litigation*: Obtaining a $210 million recovery for investors in the securities fraud class action against Salix Pharmaceuticals arising from misrepresentations concerning the wholesaler inventory levels of several of Salix's most successful products.

- *San Antonio Fire and Police Pension Fund et al. v. Dole Food Co. et al.*: Resolving an innovative case on behalf of sellers of Dole Food securities, where plaintiffs alleged that Dole's CEO issued misrepresentations to drive the price of the company down in order to take the company private on the cheap. BLB&G resolved the Dole case for $74 million.

In addition to her litigation responsibilities, Katie co-chairs the Federal Bar Council Securities Litigation Committee. She is also committed to educating clients and the greater investment and legal communities on topics related to securities litigation and women in law. She has served as a guest lecturer at Columbia University and regularly speaks at Practicing Law Institute's "Expert Witness" programs, among other webinars, seminars, and conferences.

Katie is widely recognized in the market for her litigation work. In 2024, Chambers ranked Katie as one of the top plaintiff securities litigators in New York. She has been named a "Litigation Trailblazer" by *The National Law Journal*, a "Next Generation Partner" by *The Legal 500*, a "Titan of the Plaintiffs Bar" and "Rising Star" by *Law360*, a "Rising Star" by the *New York Law Journal*, and a "Future Star" by *Benchmark Litigation*. For six straight years, Katie was named to *Benchmark Litigation's* "40 & Under List." In 2024, Lawdragon named Katie one of the "500 Leading Lawyers in America," and the publication regularly lists Katie as a "Leading Plaintiff Financial Lawyer." She is regularly selected as a New York "Rising Star" by Thomson Reuters' *Super Lawyers*.

Katie received her J.D., *cum laude*, from the Georgetown University Law Center, where she was a Dean's Scholar Full Scholarship Award recipient and served as Articles Editor for The Georgetown Journal of Gender and the Law. She received her B.A., *cum laude*, from Baylor University, where she received the Regents Full Scholarship Award.

Education: Georgetown University Law Center, 2006, J.D., *cum laude*, Dean's Scholar Full Scholarship Award Recipient; Articles Editor for The Georgetown Journal of Gender and the Law; Baylor University, 2002, B.A., *cum laude*, Regents Full Scholarship Award Recipient

Bar Admissions: New York; United States District Court for the Southern District of New York; United States District Court for the Southern District of Texas; United States District Court for the Western District of Wisconsin; United States Court of Appeals for the Second Circuit; United States Court of Appeals for the Third Circuit; United States Court of Appeals for the Fifth Circuit

Jorge G. Tenreiro is a securities litigation partner in BLB&G's New York office. Having served as Chief Litigation Counsel and Senior Trial Counsel for the Division of Enforcement at the U.S. Securities and Exchange Commission ("SEC"), Jorge is a leading authority in complex federal civil litigations, with an extensive career dedicated to civil litigation and securities enforcement.

At the SEC, Jorge spearheaded a national civil litigation program comprised of over 120 attorneys. His leadership and strategic acumen led to groundbreaking litigations against high-profile entities and individuals such as Sam Bankman-Fried, Terraform Labs, and Binance, earning him recognition as one of the SEC's most formidable litigators. Jorge's tenure at the SEC was marked by significant courtroom successes. These included favorable jury verdicts in multiple cases, such as *SEC v. Terraform* and other securities fraud matters, as well as obtaining favorable rulings in complex, highly contested litigations such as *SEC v. Telegram Group, Inc.,* all resulting in landmark settlements favorable to harmed investors. His role as lead trial counsel in major litigations solidified his expertise in navigating complex legal challenges in emerging sectors and delivering persuasive arguments in high stakes environments.

Jorge also served as Enforcement Counsel to the SEC Chair and held senior management positions in the SEC's Crypto Assets & Cyber Unit. His efforts established critical legal precedents, particularly in the fintech space, and his collaboration with the U.S. Department of Justice strengthened enforcement efforts across federal agencies. Throughout his SEC career, Jorge received multiple accolades and recognitions for his work on behalf of harmed investors, including the SEC Chair's Award for Excellence and Investor Protection and the SEC's New York Regional Office's Award for Outstanding Contributions to Litigation. National publications and commentators have called Jorge one of the most outstanding trial lawyers ever at the SEC and lauded his tenacious skills as a litigator.

In recognition of his exceptional litigation work, Jorge has been named to *Lawdragon's* 2026 "500 Leading Plaintiff Financial Lawyers" list. Beyond the courtroom, he actively participates in several professional associations, including the Hispanic National Bar Association, where he serves on the planning committee, and the LGBT Bar Association of Greater New York, where he serves on the judiciary committee. He is a sought-after speaker and lecturer, sharing insights on government enforcement trends at international conferences and academic institutions, and has contributed to prominent legal publications. In 2020, Jorge was named one of the nation's top 40 LGBTQ+ lawyers under 40 by the National LGBTQ+ Bar Association.

Jorge previously clerked for the Honorable Julio M. Fuentes of the 3rd Circuit Court of Appeals and the Honorable Allyne R. Ross of the U.S. District Court for the Eastern District of New York and was a litigation associate at a prominent law firm in New York City. He received his J.D. from Yale Law School and his B.A., *magna cum laude*, from Yale University.

Education: Yale Law School, 2006, J.D. Yale University, 2003, B.A., *magna cum laude*, with distinction, Economics and Mathematics

Bar Admissions: United States District Court for the Eastern District of New York; United States District Court for the Southern District of New York; United States Court of Appeals for the Second

Circuit; United States Court of Appeals for the Third Circuit; Supreme Court of the United States; United States Tax Court

Jonathan Uslaner is a BLB&G partner and head of the firm's Los Angeles office, prosecutes class and direct actions on behalf of the firm's institutional investor clients. A prolific securities litigator, he has secured billions of dollars in recoveries for investors injured by corporate fraud and misconduct.

Jonathan has litigated many of BLB&G's most high-profile securities fraud actions. Most recently, he co-led the BLB&G team that prosecuted the securities fraud class action challenging Wells Fargo's fraudulent banking practices and the deficient corporate oversight that allowed those practices to develop and endure. Jonathan achieved a recovery of $1 billion for damaged investors—the largest recovery ever in a securities class action not involving a restatement, an SEC action, or DOJ criminal charges litigations.

Other highlights of Jonathan's experience prosecuting securities class actions include:

- *In re Bank of America Securities Litigation*: Co-leading the BLB&G team that prosecuted the securities class action against Bank of America, which resulted in a historic recovery shortly before trial of $2.425 billion— one of the largest shareholder recoveries ever obtained.

- *In re Cobalt International Energy, Inc. Securities Litigation*: Co-leading the securities class action against Cobalt, which resulted in recoveries totaling up to $335.3 million after years of hard-fought litigation.

- *In re Genworth Financial, Inc. Securities Litigation*: Achieving a $219 million recovery in the securities fraud class action against Genworth—the largest recovery ever obtained in a securities class action in Virginia.

- *In re JPMorgan Chase & Co. Securities Litigation*: Serving as a leader of the team that recovered $150 million for investors in the securities fraud class action arising out of the trading activities of the "London Whale."

- *In re Wells Fargo Mortgage-Backed Certificates Litigation*: Leading the securities class action against Wells Fargo and certain defendants related to the issuance of mortgage pass-through certificates, which was resolved for $125 million.

Jonathan is also actively involved in the firm's direct-action opt-out practice. He represented numerous clients in opt-out actions brought against American Realty Capital Properties, which resulted in recoveries totaling $85 million, and more recently represented 18 institutional clients in opt-out actions brought against Valeant Pharmaceuticals, which resulted in confidential settlements.

A respected and prolific thought leader in his field, Jonathan serves as editor of the American Bar Association's *Class Actions and Derivative Suits Committee's Newsletter*. He has authored numerous articles relating to class actions and the federal securities laws, which have appeared in *Pensions & Investments* and *SACRS Magazine*, and has a recurring column with Reuters. Jonathan is also a member of the Board of Governors of the Association of Business Trial Lawyers, a professional group dedicated to advancing discussions on business litigation issues.

For his achievements, Jonathan has been recognized as a top securities litigation attorney in California by Chambers USA, which describes Jonathan as "an excellent lawyer and a strong advocate for his clients" and "a fierce advocate for his clients and tough opponent." In 2024, he was named to the Daily Journal's "Top 100 Lawyers" list honoring the top attorneys in California. Jonathan has also been recognized by Benchmark Litigation as a "Litigation Star" and among Lawdragon's "500 Leading Plaintiff Financial Lawyers" and "500 Leading Lawyers in America."

Jonathan has served as a board member of UCPLA, a non-profit organization dedicated to advancing the independence, productivity, and full citizenship of individuals with developmental and intellectual disabilities. He has also been a board member of Home of Guiding Hands, a non-profit organization that serves individuals with developmental disabilities and their families. For his work and contributions to the organization, he was named "Volunteer of the Year."

Prior to joining BLB&G, Jonathan was a senior litigation associate at Skadden, Arps, Slate, Meagher & Flom LLP, where he successfully prosecuted and defended claims from the discovery stage through trial. He also gained significant trial experience as a volunteer prosecutor for the City of Inglewood, California, and as a judicial extern for Justice Steven Wayne Smith of the Supreme Court of Texas.

Jonathan received his J.D. from The University of Texas School of Law, where he served as Articles Editor for the *Texas Journal of Business Law*. He received his B.A., *magna cum laude*, from Duke University, where he received the William J. Griffith Award for Leadership and served as chairperson of the Duke University Undergraduate Publications Board.

Education: The University of Texas School of Law, 2005, J.D., University of Texas Presidential Academic Merit Fellowship; Articles Editor, Texas Journal of Business Law; Duke University, 2001, B.A., magna *cum laude*, William J. Griffith Award for Leadership; Chairperson, Duke University Undergraduate Publications Board

Bar Admissions: California; United States District Court for the Central District of California; United States District Court for the Northern District of California; New York; United States District Court for the Southern District of New York

SENIOR COUNSEL

Shane Avidan, senior counsel of the firm, prosecutes securities fraud and shareholder rights litigation on behalf of BLB&G's institutional investor clients. With more than a decade of legal experience, Shane leverages his experience to provide BLB&G's plaintiff clients with top-notch representation and advice. He practices out of the firm's New York office.

Shane has been an integral member of the BLB&G teams that prosecuted several notable securities matters, including:

- *In re Silvergate Capital Corporation Securities Litigation*: Shane was actively involved in this securities class action against Silvergate, one of the major banks that failed amid the 2023 U.S. banking collapse, achieving a proposed $37.5 million settlement, pending court approval.

- *In re EQT Corporation Securities Litigation*: Shane was a core member of the team prosecuting this securities class action against EQT Corporation, the largest gas producer in the United States, related to the company's $6.7 billion acquisition of rival gas producer Rice, securing a proposed $167.5 million settlement, pending court approval.

- *Camelot Event Driven Fund v. Morgan Stanley*: Shane was a key member of the team prosecuting this Securities Act lawsuit against three underwriter defendants related to $3 billion of public offerings of Viacom stock in March 2021 and the concurrent implosion of family fund Archegos Capital Management. This case was settled for $120 million, pending court approval.

Shane is currently a key member of the litigation teams prosecuting many of the firm's ongoing cases, including:

- *City of Hollywood Police Officers' Retirement System v. First Republic Bank*: Shane is litigating the high-profile case against First Republic Bank, which has since closed and been sold to JPMorgan Chase, coming out of the 2023 U.S. banking collapse.

- *Homyk v. ChemoCentryx, Inc. et al.:* Shane is actively involved in this securities fraud class action against ChemoCentryx and its CEO, alleging false and misleading statements and omissions about the company's proprietary vasculitis drug, avacopan.

- *In re Dentsply Sirona, Inc. Securities Litigation*: Shane plays a key role in this class action against Dentsply and its executives, alleging false and misleading statements made about the company's direct-to-consumer sales.

- *Roofers Local No. 149 Pension Fund v. GSK plc:* Shane plays a key role in the high-profile lawsuit against GSK for allegedly misleading investors about Zantac's cancer risks and concealing decades of internal knowledge about known carcinogens in its product.

Prior to joining BLB&G, Shane was a litigation associate at Paul Weiss, where he represented clients in securities class actions, criminal and regulatory securities matters, bankruptcy and insolvency litigation, and complex commercial litigation.

Shane received his J.D. from Columbia Law School, where he served as Managing Editor of the *Columbia Law Review* and was a James Kent Scholar and a Harlan Fiske Stone Scholar. During this time, he also worked as an extern for the Honorable Denny Chin of the U.S. Court of Appeals for the Second Circuit. He graduated *cum laude* from Dartmouth College with a B.A. in both Economics and Geography.

Education: Columbia Law School, 2012, J.D., James Kent Scholar, Harlan Fiske Stone Scholar; Dartmouth College, 2009, B.A., *cum laude*, Economics, Geography

Bar Admissions: New York; U.S. District Court for the Southern District of New York; U.S. District Court for the Eastern District of New York; U.S. Court of Appeals for the Second Circuit; U.S. Court of Appeals for the Ninth Circuit

Lauren Cruz [Former Senior Counsel] practiced out of the firm's Los Angeles office, where she prosecuted corporate governance and shareholder rights litigation as well as securities fraud on behalf of the firm's investor clients.

With over a decade of experience, Lauren was a key member of the teams that prosecuted and secured over $1.2 billion in recoveries for investors, including a landmark $1 billion settlement in *In re Wells Fargo & Company Securities Litigation.*

Lauren also serves as the Board President and has served as a board member since 2019 of Mental Health Advocacy Services, a non-profit organization that provides free legal services to people with mental health disabilities in Los Angeles.

Prior to joining BLB&G, Lauren was a litigation associate at Sullivan & Cromwell LLP, where she represented domestic and international clients in complex civil litigation and alternative dispute resolution. She also gained considerable experience advising company boards following internal investigations of shareholder demands. In addition, Lauren's practice included substantial pro bono civil rights class action litigation on behalf of immigration detainees with indicia of mental health disabilities.

Education: New York University School of Law, 2014, J.D., Senior Articles Editor, *Journal of Law and Liberty*; Staff Editor, *Environmental Law Journal*. California State University Channel Islands, 2008, B.S., *summa cum laude*, Business

Bar Admissions: California; U.S. District Court for the Central District of California; U.S. District Court for the Eastern District of California; U.S. District Court for the Northern District of California; U.S. District Court for the Southern District of California; U.S. Court of Appeals for the Ninth Circuit

David Duncan's practice concentrates on the settlement of class actions and other complex litigation and the administration of class action settlements.

Prior to joining BLB&G, David worked as a litigation associate at Debevoise & Plimpton, where he represented clients in a wide variety of commercial litigation, including contract disputes, antitrust and products liability litigation, and in international arbitration. In addition, he has represented criminal defendants on appeal in New York State courts and has successfully litigated on behalf of victims of torture and political persecution from Sudan, Côte d'Ivoire and Serbia in seeking asylum in the United States.

While in law school, David served as an editor of the *Harvard Law Review*. After law school, he clerked for Judge Amalya L. Kearse of the U.S. Court of Appeals for the Second Circuit.

Education: Harvard Law School, 1997, J.D; *magna cum laude;* Harvard College, 1993, A.B., *magna cum laude*, Social Studies

Bar Admissions: New York; Connecticut; United States District Court for the Southern District of New York

John Esmay prosecutes securities fraud and shareholder rights litigation on behalf of the firm's institutional clients. John has worked on federal securities litigations that have returned more than $3 billion to defrauded investors. He has deep experience with complex litigation and has prepared and participated in trials and hearings in federal and state courtrooms around the country from California to New York. He has also taken part in private arbitration proceedings as well as disciplinary hearings before securities regulatory organizations such as the SEC and FINRA. John graduated *magna cum laude* from Brooklyn Law School, where he served on the Journal of Law and Policy. He received his Bachelor of Science degree in physics from Pomona College. While attending Brooklyn Law School, John interned for the Honorable Edward R. Korman, and later clerked for the Honorable William H. Pauley III. Prior to attending law school, John worked as a securities broker at the investment banking subsidiary of a prominent bank.

Education: Brooklyn Law School, 2007, J.D., *magna cum laude*; Pomona College, 1998, B.A., Physics

Bar Admissions: New York; United States District Court for the Southern District of New York; United States District Court for the Eastern District of New York

John MIlls' practice focuses on negotiating, documenting, and obtaining court approval of the firm's securities, merger, and derivative settlements.

Over the past decade, John was actively involved in finalizing the following settlements, among others: *In re Wachovia Preferred Sec. and Bond/Notes Litig.* (S.D.N.Y.) ($627 million settlement); *In re Wilmington Trust Sec. Litig.* (D. Del.) ($210 million settlement); *In re Freeport-McMoRan Copper & Gold Inc. Derivative Litig.* (Del. Ch.) ($153.75 million settlement); *Medina, et al. v. Clovis Oncology, Inc., et al.* (D. Colo.) ($142 million settlement); *In re News Corp. S'holder Litig.* (Del. Ch.)

($139 million recovery and corporate governance enhancements); *In re Mut. Funds Invest. Litig. (MFS, Invesco, and Pilgrim Baxter Sub-Tracks)* (D. Md.) ($127.036 million total recovery); *Fresno County Employees' Ret. Ass'n, et al. v. comScore, Inc., et al.* (S.D.N.Y.) ($110 million settlement); *In re El Paso Corp. S'holder Litig.* (Del. Ch.) ($110 million settlement); *In re Starz Stockholder Litig.* (Del. Ch.) ($92.5 million settlement); *The Dep't of the Treasury of the State of New Jersey and its Div. of Invest. v. Cliffs Natural Res. Inc., et al.* (N.D. Ohio) ($85 million settlement).

John received his J.D. from Brooklyn Law School, *cum laude*, where he was a Carswell Merit Scholar recipient and a member of *The Brooklyn Journal of International Law*. He received his B.A. from Duke University.

Education: Brooklyn Law School, 2000, J.D., *cum laude*, *Member of The Brooklyn Journal of International Law*; Carswell Merit Scholar recipient; Duke University, 1997, B.A.

Bar Admissions: New York; United States District Court for the Southern District of New York; United States District Court for the Eastern District of New York

ASSOCIATES

Caitlin Bozman [Former Associate] practiced out of the firm's Los Angeles office and prosecuted securities fraud, corporate governance, and shareholder rights litigation on behalf of the firm's institutional investor clients.

Prior to joining the firm, Caitlin was an associate at Hueston Hennigan LLP, where she practiced complex commercial litigation, managing all aspects of a case for a variety of clients. Upon graduation from law school, she clerked for the Honorable Vice Chancellor J. Travis Laster of the Delaware Court of Chancery. Prior to entering law school, Caitlin was a Foreign Exchange Operations Analyst for Morgan Stanley, where she confirmed, settled, and reconciled foreign exchange cash and derivative trades for institutional clients.

Caitlin graduated *magna cum laude* from Georgetown University Law Center, where she was an Executive Articles Editor for *The Georgetown Law Journal* and co-director and competing member of the Trial Advocacy Division of the Barristers' Council. She authored the student note, "Holding the Line or Changing Tides? The Future of 'Too Big to Fail' Regulation." During law school, she also served as a legal intern for the Division of Trading and Markets of the U.S. Securities and Exchange Commission. Caitlin graduated *cum laude* from University of Maryland, Baltimore County ("UMBC") with her B.A. in sociology and political science, with a minor in legal policy. During her undergrad, she was the Vice President and a founding member of the UMBC Mock Trial Team.

Education: University of Maryland, Baltimore County, 2014, B.A., *cum laude*, Sociology and Political Science; Georgetown University Law Center, 2019, J.D., *magna cum laude*, Order of the Coif

Bar Admissions: New York, California, U.S. District Court for the Northern District of California, U.S. District Court for the Southern District of California, U.S. Court of Appeals for the Fifth Circuit

James ("Jim") Briggs [Former Associate] focused on securities litigation on behalf of the firm's institutional investor clients. He practiced out of the firm's New York office.

Jim contributed to numerous matters at BLB&G, including litigation involving Willis Towers Watson, Tile Shop Holdings, Equifax, Adeptus Health, HeartWare International, Wells Fargo & Company, comScore, Clovis Oncology, Salix Pharmaceuticals, JPMorgan Chase & Co., and Merck & Co. Most recently, Jim was a member of the team litigating *Homyk v. ChemoCentryx, Inc. et al.*, a case against ChemoCentryx and its CEO alleging fraud related to the safety, efficacy, and application for FDA approval of ChemoCentryx's proprietary vasculitis drug, avacopan.

Beyond his litigation practice, Jim has authored articles in leading scientific journals, including *Conservation Genetics* and *Emerging Infectious Diseases*.

Prior to becoming an associate, Jim served as both a staff attorney and senior staff attorney at BLB&G.

Jim earned his J.D. from Fordham University School of Law and his B.S. from Cornell University in Biological Sciences, graduating *cum laude*.

Education: Cornell University, 2007, B.S., *cum laude*, Biological Science; Fordham University School of Law, J.D., 2010

Bar Admissions: New York

Jimmy Brunetto is a BLB&G associate prosecuting securities fraud, corporate governance, and shareholder rights litigation on behalf of the firm's institutional investor clients. He practices out of the firm's New York office.

As a member of the firm's case development and client advisory group, Jimmy works as part of a team of attorneys, financial analysts, and investigators to counsel public pension funds and other institutional investors on potential legal claims.

Jimmy contributes to ongoing legal discourse on topics related to his practice areas. Most recently, he co-authored "The SEC's New Cybersecurity Disclosure Rules Decoded: What They Mean for Investors," published in *Reuters*.

Prior to joining the firm, Jimmy investigated and prosecuted securities fraud at the New York State Office of the Attorney General's Investor Protection Bureau, where he worked on several high-profile matters. In recognition for his contributions as part of a federal and state working group that investigated and prosecuted securities fraud in connection with the issuance and sale of residential mortgage-backed securities, Jimmy was awarded the Louis J. Lefkowitz Award for outstanding performance.

Jimmy received his J.D. from New York Law School, where he was honored as a John Marshall Harlan Scholar and served as a Staff Editor of the *New York Law School Law Review*. He holds both a B.S. in Finance and a B.A. in Political Science from the University of Florida.

Education: New York Law School, 2011, J.D., *cum laude*, John Marshall Harlan Scholar; Staff Editor, New York Law School Law Review; University of Florida, 2007, B.A., *cum laude*, Political Science; University of Florida, 2007, B.S.B.A, Finance

Bar Admissions: New York; U.S. District Court for the Eastern District of New York; U.S. District Court for the Southern District of New York

Stephen Boscolo [Former Associate] practiced out of the firm's New York office and prosecuted securities fraud, corporate governance, and shareholder rights litigation on behalf of the firm's institutional investor clients.

Stephen received his J.D. from Georgetown University Law Center, graduating *magna cum laude* and serving as Managing Editor for the *Food and Drug Law Journal*. While in law school, Stephen interned for the Disability Rights Section of the Civil Rights Division of the U.S. Department of Justice and for the Honorable Peter J. Messitte of the U.S. District Court for the District of Maryland. He also worked as a summer associate for Carlton Fields, P.A.

After law school, Stephen clerked for the Honorable Matthew J. Fader of the Maryland Court of Special Appeals and the Honorable David Nuffer of the U.S. District Court for the District of Utah.

He received his B.A. in both Government and Biology from The College of William & Mary.

Education: The College of William & Mary, 2017, B.A., *magna cum laude*, Government, Biology; Georgetown University Law Center, 2020, J.D., *magna cum laude*, Order of the Coif

Bar Admissions: New York, Maryland

Chloe Jasper [Former Associate] practiced out of the firm's Los Angeles office and prosecuted securities fraud, corporate governance, and shareholder rights litigation on behalf of the firm's institutional investor clients.

Prior to joining the firm, Chloe was an associate at a premier international law firm, specializing in litigation and arbitration. As a law student, Chloe clerked for the Civil Division of the U.S. Attorney's Office for the Southern District of California.

Chloe received her J.D. from the University of Michigan Law School, during which time she served as Associate Editor for the *Michigan Journal of Law Reform* and worked as a student attorney and supervisor for the Michigan Law Workers' Rights Clinic, representing Michigan workers denied unemployment benefits in administrative hearings and on appeal. She also served as a student attorney for the Child Advocacy Clinic and studied international law at the University of Amsterdam while conducting research on Dutch and European neonaticide laws. She graduated with a B.A. in Government from Wesleyan University.

Education: Wesleyan University, 2015, B.A., Government; University of Michigan Law School, 2020, J.D.

Bar Admissions: California; U.S. District Court for the District of Columbia.

Yando Peralta [Former Associate] practiced out of the firm's New York office and prosecuted securities fraud and shareholder rights litigation on behalf of the firm's institutional investor clients.

Prior to joining the firm, Yando worked as a litigation associate at Dechert and at a legal nonprofit as a non-attorney advocate, representing individuals seeking public benefits in state administrative hearings.

While at law school, Yando was an intern to the Honorable Ronald L. Ellis, Magistrate Judge, United States District Court for the Southern District of New York. In addition, he served as the Mulligan Competition Editor for the Fordham Moot Court Board.

Education: Fordham University School of Law, 2017, J.D., Editor, Moot Court Board; Member, *Fordham Intellectual Property, Media & Entertainment Law Journal*; Bowdoin College, 2011, B.A., Classics, Dean's List

Bar Admissions: New York, U.S. District Courts for the Eastern and Southern Districts of New York

SENIOR STAFF ATTORNEYS

Larry Hosmer is a senior staff attorney in the New York* office, and primarily provides electronic discovery assistance and support in the litigation of securities fraud-related matters.

Prior to joining the firm, Larry had a private litigation practice in Dallas, Texas, and from there went on to focus in the growing electronic discovery field. Larry is a graduate of the SMU School of Law, where he was an Articles Editor of the International Lawyer law review. He was a National Merit Scholar at the University of Texas at Austin, where he graduated with a Bachelor of Arts degree in history.

**Not admitted to practice in New York.*

Education: Southern Methodist University School of Law, 1996, J.D.; University of Texas at Austin, 1993, B.A.

Bar Admissions: Texas

Ryan McCurdy is a senior staff attorney in the Los Angeles office, where he assists with securities fraud class actions. Since joining the firm, Ryan has worked on several matters, including *Impinj, Merit Medical Systems, Allianz, Symantec, Valeant Pharmaceuticals*, and *EQT*. Prior to joining the firm, Ryan worked with a small aircraft products liability boutique, a large firm in mortgagebacked securities, and with a major eDiscovery vendor. Ryan received his J.D. from UCLA, School of Law and he received his B.A. in political science from Emory University.

Education: University of California, Los Angeles, 2003, J.D.; Emory University, 1999, B.A., Political Science

Bar Admissions: California

Damian Puniello practices out of the firm's New York office, where he prosecutes securities fraud, corporate governance and shareholder rights litigation on behalf of the firm's institutional clients.

Before joining the firm, Damian was an attorney at a smaller plaintiffs' firm, where he represented plaintiffs in complex securities class actions. Prior to joining his previous firm, he worked at the New York County District and Kings County District Attorney's Offices, as well as interned at the New York State Attorney General's Office, Antitrust Division. While at BLB&G, Damian has worked on both securities fraud and Department of Governance cases, which have successfully recovered hundreds of millions of dollars for investors. Some cases of note are *Wilmington Trust*, *Allergan Proxy Violation Litigation*,, *Wells Fargo & Company*, *In re Genworth Financial Inc*, *ComScore Inc*., *Qualcomm*, *Inc., Cummings v. Edens (New Senior InvestmentGroup), and In re Xerox Corporation.*

Damian obtained his B.A. from Rutgers University, majoring in History and Art History, graduating with honors, and his J.D. from Brooklyn Law School.

Education: Brooklyn Law School, 2009, J.D.; Rutgers University, 2000, B.A.

Bar Admissions: New York; New Jersey; Pennsylvania; United States District Court for the District of New Jersey

SENIOR STAFF ATTORNEYS

Zvi Bar-Kochba has worked on several matters at BLB&G, including *In re SVB Financial Group Securities Litigation*; *In re Turquoise Hill Resources Ltd. Securities Litigation*; *In re Wells Fargo & Company Securities Litigation; In re Allianz Global Investors U.S. LLC Alpha Series Litigation;* and *Homyk, et al. v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Zvi worked as an e-discovery contract attorney for several law firms. Previously, Zvi was an Associate with London Fischer and a Trust Administrator & Advisor with Merrill Lynch Wealth Management.

Education: University of Chicago, B.A., 1998. Hofstra University School of Law, J.D., 2008

Bar Admissions: New York

Isabelle Bowers [Former Staff Attorney] worked on several matters at BLB&G, including *In re Allianz Global Investors U.S. LLC Alpha Series Litigation*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Isabelle worked as an E-discovery contract attorney for several law firms.

Education: Ohio State University, B.A., 2015; University of Richmond School of Law, J.D., 2018; Virginia Commonwealth University, MPA, 2019

Bar Admissions: Virginia

Daniel G. Cedrone [Former Staff Attorney] worked on *In re The Boeing Company Aircraft Securities Litigation*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Daniel worked as an e-discovery contract attorney for several law firms. Previously, Daniel was an attorney with Bottomline Technologies and Nelson Levine DeLuca & Horst LLC focused on insurance litigation cases.

Education: University of Pennsylvania, B.A.,(Biology) 1983; Villanova University, M.A. (Bus. Admin),1998; Temple University School of Law, J.D., 2002

Bar Admission: New York. Pennsylvania

Jonathan Cohen [Former Staff Attorney] worked on several matters at BLB&G, including *In re EQT Corporation Securities Litigation*; *Homyk v. ChemoCentryx, Inc. et al.*; and *In re Facebook, Inc. Securities Litigation*.

Prior to joining the firm, Jonathan worked as an e-discovery contract attorney for several law firms. Previously, Jonathan was in private practice focused on civil litigation.

Education: Long Island University, B.A., 1987; University of Washington Law School, J.D., 1991

Bar Admissions: New York

Igor Faynshteyn has worked on several matters at BLB&G, including *In re SVB Financial Group Securities Litigation; Fresno County Employees' Retirement Association v. comScore, Inc.*; *Hefler, et al. v. Wells Fargo & Company et al.*; *In re Signet Jewelers Limited Securities Litigation*; *Medina et al v. Clovis Oncology, Inc., et al.; In re Celgene Corporation Securities Litigation; In re Synchrony Financial Securities Litigation; In re Tile Shop Holdings Inc. Litigation; Fishel v. Liberty Media, et al.; Public Employees' Retirement System of Mississippi v. Mohawk Industries, Inc.;* and *Homyk, et al. v. ChemoCentryx, Inc. et al.* Igor also worked with BLB&G on behalf of co-counsel on *In re Merck & Co., Inc., Securities Litigation (VIOXX-related).*

Prior to joining the firm, Igor was a contract attorney at several New York law firms.

Education: City University of New York, Hunter College, B.A., M.A., Biological Science, 2006. Brooklyn Law School, J.D., 2011

Bar Admissions: New York. US Patent and Trademark Office (USPTO)

Sascha Goergen [Former Staff Attorney] was on the BLB&G German review team and had worked on several matters, including *In re Kraft Heinz Securities Litigation; In re Bumble, Inc. Securities Litigation*; *Homyk v. ChemoCentryx, Inc. et al.*; and *In re Edwards Lifesciences*.

Prior to joining the firm, Sascha worked as a contract attorney in various industries including shareholder litigations and securities fraud class action suits. Previously, Sascha was an Associate Attorney with Heimeshoff Riese Linnkamp in Germany.

Education: Ruhr-University of Bochum School of Law, Bochum, Germany, (J.D. equivalent), 1998; Fordham University School of Law, LL.M 2008

Bar Admissions: New York

Steffanie Keim [Former Staff Attorney] worked on numerous matters at BLB&G, including *In re McKesson Corporation Derivative Litigation; In re SunEdison, Inc. Securities Litigation; Hefler et al. v. Wells Fargo & Company et al.; In re Volkswagen AG Securities Litigation; 3-Sigma Value Financial Opportunities LP et al. v. Jones et al. ("CertusHoldings, Inc."); In re Allergan, Inc. Proxy Violation Securities Litigation;* and *In re Altisource Portfolio Solutions, S.A. Securities Litigation*.

Prior to joining the firm in 2016, Steffanie was a senior associate at Ernst & Linder LLC and corporate associate at Dewey & LeBoeuf LLP.

Education: Ruprecht-Karls-University of Heidelberg Law School, First Juristic Examination, Germany, (J.D. equivalent), 1999. Fordham University School of Law, LL.M., *cum laude*, 2007

Bar Admissions: New York; Germany

Steffanie Keim [Former Staff Attorney] worked on numerous matters at BLB&G, including *In re McKesson Corporation Derivative Litigation; In re SunEdison, Inc. Securities Litigation; Hefler et al. v. Wells Fargo & Company et al.; In re Volkswagen AG Securities Litigation; 3-Sigma Value Financial Opportunities LP et al. v. Jones et al. ("CertusHoldings, Inc."); In re Allergan, Inc. Proxy Violation Securities Litigation;* and *In re Altisource Portfolio Solutions, S.A. Securities Litigation*.

Prior to joining the firm in 2016, Steffanie was a senior associate at Ernst & Linder LLC and corporate associate at Dewey & LeBoeuf LLP.

Education: Ruprecht-Karls-University of Heidelberg Law School, First Juristic Examination, Germany, (J.D. equivalent), 1999. Fordham University School of Law, LL.M., *cum laude*, 2007

Bar Admissions: New York; Germany

Shammari Khan [Former Staff Attorney] worked on *In re The Boeing Company Aircraft Securities Litigation.*

Prior to joining the firm, Shammari worked as an e-discovery contract attorney for several law firms. Previously, Shammari was a co-founder of Labyrinthus LLC offering consulting services in virtual currencies.

Education: University of Toronto, Canada, B.Sc. (Genetics & Biotech), 2003; Benjamin N. Cardozo School of Law, J.D., 2007

Bar Admissions: New York. California

Paul Lim [Former Staff Attorney] worked on several matters at BLB&G, including *In re Signet Jewelers Limited Securities Litigation; In Re Wells Fargo & Company Securities Litigation*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Paul worked as a contract attorney at various law firms, including Milbank Tweed, Hadley & McCloy, O'Melveny & Myers & Cravath, Swaine & Moore. Previously, Paul worked as a patent attorney with Cooper Dunham LLP and Norris McLaughlin & Marcus.

Education: Boston University, MA, BA International Relations, 1995. Harvard University, Cambridge, MA Biology, 2005 (completed all courses). Boston University School of Law, MA, J.D. 2001

Bar Admission: New York

Tiffany R. Michael [Former Staff Attorney] worked on *In re The Boeing Company Aircraft Securities Litigation*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Tiffany worked as an e-discovery contract attorney for several law firms. Previously, Tiffany was an Associate Attorney with Aceto Bonner & Prager, and Harvey Kleger & Thomas focused on civil litigation.

Education: Stony Brook University (SUNY), B.A.,2006; Suffolk University Law School, MA, J.D., 2010

Bar Admissions: New York. Massachusetts

Emily Nalven [Former Staff Attorney] worked on *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Emily worked as a Director with Crafty Counsel Limited focused on patents and trademarks' compliance for UK and European based-companies doing business in the United States. Previously, Emily was Chief Legal Officer with Firehouse Horology and an attorney with Berquist, Jackson & Gowdey engaged in the practice of intellectual property. Emily is also a registered U.S. Patent Attorney and Agent and was a Patent Examiner with the United States Patent & Trademark Office.

Education: John Hopkins University, B.Sc., Mechanical Engineering & Mathematics, 2005. Catholic University of America, Columbus School of Law, J.D., 2012

Bar Admissions: New York. D.C. Massachusetts

Yeruchem Neiman [Former Staff Attorney] worked on *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Yeruchem ("Jerry") was a staff attorney with various law firms working on financial class actions, oil and gas, pharmaceutical and biotech litigations including foreign language reviews in German, Dutch and the Nordic languages. Previously, Jerry was a financial analyst with B&W Equities and UBS Paine Webber.

Education: Brooklyn College of CUNY, NY, B.A. (Pre-Med & Economics), 2000. Fordham University School of Law, J.D., 2009

Bar Admissions: New York, New Jersey

Rodney V. Nutt [Former Staff Attorney] worked on *The Liverpool Limited Partnership v. Santander Holdings USA, Inc.*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, Rodney worked as an e-discovery contract attorney for several e-discovery vendors. Previously, Rodney worked in the fields of Investment Banking and the Energy & Capital markets with Industrial Power Generating Company and Customized Energy Solutions.

Education: University of Pennsylvania, B.A., 1987; Western New England College School of Law J.D., 1992; New York University Leonard N. Stern School of Business, M.B.A. (Finance) 1994.

Bar Admissions: New York

John J. Pate [Former Staff Attorney] worked on several matters at BLB&G, including *In re Allianz Global Investors U.S. LLC Alpha Series Litigation*; *In re Wells Fargo & Company Securities Litigation*; and *Homyk v. ChemoCentryx, Inc. et al.*

Prior to joining the firm, John worked as an E-discovery contract attorney.

Education: New York University B.Sc., 2007; University of Miami School of Law, J.D., 2012

Bar Admissions: New York

Mark T. Paul [Former Staff Attorney] worked on several matters at BLB&G, including *In re Allianz Global Investors U.S. LLC Alpha Series Litigation.*

Prior to joining the firm, Mark worked as an E-discovery contract attorney with several law firms. Previously, Mark was Of Counsel with Slater & Cole focused in intellectual property practice.

Education: Rutgers University B.Sc. (Computer Science), B.A. (Economics), 1985; Tulane University Law School, J.D., 2004

Bar Admissions: New York

Priscilla Pellecchia has worked on several matters at BLB&G, including *Schmidlin et al. v. Raymond James Financial, Inc., et al.; In re Seagate Technology Holdings plc Securities Litigation; Homyk, et al. v. ChemoCentryx, Inc. et al.*; *Oklahoma Firefighters Pension and Retirement System v. Musk et al.; In re Myriad Genetics, Inc. Securities Litigation; In re Venator Materials PLC Securities Litigation; In re Celgene Corporation Securities Litigation; In re Fannie Mae/Freddie Mac Senior Preferred Stock Purchase Agreement Class Action Litigations;* and *In re Equifax Inc. Securities Litigation*.

Prior to joining the firm, Priscilla was a contract attorney at Selendy & Gay PLLC. Previously, Priscilla was an Associate at Caruso Smith Edell Picini, PC.

Education: Georgetown University, B.A., 2002. Brooklyn Law School, J.D., 2008

Bar Admissions: New York; New Jersey

Kirstin Peterson has worked on several matters at BLB&G, including *In re LPL Financial Cash Sweep Litigation*; *Dhimant Patel, et al. v. Edwards Lifesciences Corporation, Bernard J. Zovighian, Larry L. Wood and Scott B. Ullem*; *In re SVB Financial Group Securities Litigation; In re Meta Platforms, Inc. Securities Litigation; In re Facebook, Inc. Securities Litigation; Homyk, et al. v. ChemoCentryx, Inc. et al.*; *In re Bumble, Inc. Securities Litigation; In re Boston Scientific Corporation Securities Litigation; In re Wells Fargo & Company Securities Litigation; In re Kraft Heinz Securities Litigation; In re Oracle Corporation Securities Litigation; Cambridge Retirement System v. Amneal Pharmaceuticals Inc.; In re Allergan Generic Drug Pricing Securities Litigation; In re Novo Nordisk Securities Litigation.; In re Equifax Inc. Securities Litigation; In re: Volkswagen "Clean Diesel" Marketing, Sales Practices, and Products Liability Litigation* ; *and In re Merck & Co., Inc. Securities Litigation (VIOXX-related).*

Prior to joining the firm in 2011, Kirstin was an Associate at Davis Polk & Wardell, Richards & O'Neil, LLP, and Wollmuth Maher & Deutsch, LLP.

Education: Northwestern University, B.A., 1985; Phi Beta Kappa. Yale University, M.A., 1989. Northwestern University Medical School, M.D., 1990. Harvard Law School, J.D., *cum laude,* 1993

Bar Admissions: New York

Joanna Tarnawski has worked on numerous matters at BLB&G, including *In re Wells Fargo Cash Sweep Litigation*; *In re Seagate Technology Holdings plc Securities Litigation; Oklahoma Firefighters Pension and Retirement System v. Musk et al.; Homyk, et al. v. ChemoCentryx, Inc. et al.*; *In re Celgene Corporation Securities Litigation; In re Henry Schein, Inc. Securities Litigation; Hefler et al. v. Wells Fargo & Company et al.*; *Fresno County Employees' Retirement Association v. comScore, Inc.*; *Medina et al v. Clovis Oncology, Inc., et al*. and *San Antonio Fire and Police Pension Fund et al. v. Dole Food Company, Inc., et al*.

Prior to joining the firm in 2016, Joanna worked as a contract attorney on complex litigations. Prior to attending law school, she was a Research Scientist at the Institute for Basic Research in Developmental Disabilities.

Education: University of Gdansk, M.S. Polish Academy of Sciences, Poland, Ph.D., 2003. Seton Hall University School of Law, J.D., 2008

Bar Admissions: New York; New Jersey. US Patent and Trademark Office (USPTO)

Exhibit 7

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
Abe Alexander - Partner																		**3,347.25**		**$3,181,081.25**	**$1,300**	**$4,351,425.00**
July 2021	18.75		18.75															37.50	$825	$30,937.50	$1,300	$48,750.00
August 2021	23.25		26.50						2.50									52.25	$825	$43,106.25	$1,300	$67,925.00
September 2021	1.75		7.50															9.25	$825	$7,631.25	$1,300	$12,025.00
October 2021	0.75		17.00															17.75	$825	$14,643.75	$1,300	$23,075.00
November 2021			12.25															12.25	$825	$10,106.25	$1,300	$15,925.00
December 2021			6.75															6.75	$825	$5,568.75	$1,300	$8,775.00
January 2022	1.00		19.50															20.50	$850	$17,425.00	$1,300	$26,650.00
May 2022				9.50													1.00	10.50	$850	$8,925.00	$1,300	$13,650.00
June 2022				70.50													1.75	72.25	$850	$61,412.50	$1,300	$93,925.00
July 2022				24.50														24.50	$850	$20,825.00	$1,300	$31,850.00
August 2022				5.00														5.00	$850	$4,250.00	$1,300	$6,500.00
September 2022				5.50														5.50	$850	$4,675.00	$1,300	$7,150.00
February 2023						8.25									2.00		2.00	12.25	$900	$11,025.00	$1,300	$15,925.00
June 2023						23.50	2.25											25.75	$900	$23,175.00	$1,300	$33,475.00
July 2023					13.75	54.00	2.50											70.25	$900	$63,225.00	$1,300	$91,325.00
August 2023					36.25	43.75	7.50											87.50	$900	$78,750.00	$1,300	$113,750.00
September 2023						71.75	19.25	9.75	5.25								0.75	106.75	$900	$96,075.00	$1,300	$138,775.00
October 2023						47.50	18.75		13.75									80.00	$900	$72,000.00	$1,300	$104,000.00
November 2023						26.00	7.75	127.25	2.00									163.00	$900	$146,700.00	$1,300	$211,900.00
December 2023					2.50	25.25		124.75	9.75				10.75				0.75	173.75	$900	$156,375.00	$1,300	$225,875.00
January 2024					35.75	27.75		104.50					40.50					208.50	$975	$203,287.50	$1,300	$271,050.00
February 2024					15.00	40.25		71.50					28.25					155.00	$975	$151,125.00	$1,300	$201,500.00
March 2024					19.75	28.25	7.75	119.75										175.50	$975	$171,112.50	$1,300	$228,150.00
April 2024					7.00	50.75	9.75	115.25	5.75					5.25				193.75	$975	$188,906.25	$1,300	$251,875.00
May 2024						24.25	2.25	126.75	17.00									170.25	$975	$165,993.75	$1,300	$221,325.00
June 2024						33.75	9.00	29.00	69.00		1.75							142.50	$975	$138,937.50	$1,300	$185,250.00
July 2024					3.00	31.00	6.75	151.50	47.25									239.50	$975	$233,512.50	$1,300	$311,350.00
August 2024						46.75		15.75	164.50									227.00	$975	$221,325.00	$1,300	$295,100.00
September 2024						14.00			250.00		28.00							292.00	$975	$284,700.00	$1,300	$379,600.00
October 2024									26.00		230.00							256.00	$975	$249,600.00	$1,300	$332,800.00
November 2024									229.00									229.00	$975	$223,275.00	$1,300	$297,700.00
December 2024									37.00									37.00	$975	$36,075.00	$1,300	$48,100.00
January 2025									28.00									28.00	$1,300	$36,400.00	$1,300	$36,400.00
Scott Foglietta - Partner																		**61.00**		**$50,325.00**	**$1,500**	**$91,500.00**
May 2021	5.00																	5.00	$825	$4,125.00	$1,500	$7,500.00
June 2021	2.00	1.00															12.00	15.00	$825	$12,375.00	$1,500	$22,500.00
July 2021		40.25															0.75	41.00	$825	$33,825.00	$1,500	$61,500.00
Salvatore Graziano - Partner																		**354.00**		**$532,150.00**	**$1,800**	**$637,200.00**
December 2021	1.00																	1.00	$1,150	$1,150.00	$1,800	$1,800.00
February 2022			0.50															0.50	$1,200	$600.00	$1,800	$900.00
March 2022			23.75															23.75	$1,200	$28,500.00	$1,800	$42,750.00
May 2022				0.50														0.50	$1,200	$600.00	$1,800	$900.00
June 2022				0.50														0.50	$1,200	$600.00	$1,800	$900.00
July 2022				3.50														3.50	$1,200	$4,200.00	$1,800	$6,300.00
August 2022				0.50											0.50			1.00	$1,200	$1,200.00	$1,800	$1,800.00
September 2022				3.50														3.50	$1,200	$4,200.00	$1,800	$6,300.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
January 2023				0.75														0.75	$1,250	$937.50	$1,800	$1,350.00
February 2023														0.75	0.75			1.50	$1,250	$1,875.00	$1,800	$2,700.00
June 2023													0.75					0.75	$1,250	$937.50	$1,800	$1,350.00
August 2023					1.50													1.50	$1,250	$1,875.00	$1,800	$2,700.00
September 2023													1.00					1.00	$1,250	$1,250.00	$1,800	$1,800.00
November 2023													2.50	0.50				3.00	$1,250	$3,750.00	$1,800	$5,400.00
December 2023						0.75												0.75	$1,250	$937.50	$1,800	$1,350.00
January 2024								1.00					3.50					4.50	$1,350	$6,075.00	$1,800	$8,100.00
February 2024					2.00								9.75	1.00				12.75	$1,350	$17,212.50	$1,800	$22,950.00
March 2024					0.50	0.75							1.00					2.25	$1,350	$3,037.50	$1,800	$4,050.00
April 2024					0.75								1.00					1.75	$1,350	$2,362.50	$1,800	$3,150.00
May 2024					0.50								2.50					3.00	$1,350	$4,050.00	$1,800	$5,400.00
July 2024											0.75							0.75	$1,350	$1,012.50	$1,800	$1,350.00
August 2024						1.50									1.00			2.50	$1,350	$3,375.00	$1,800	$4,500.00
September 2024											1.25		1.25					2.50	$1,350	$3,375.00	$1,800	$4,500.00
October 2024											18.25							18.25	$1,350	$24,637.50	$1,800	$32,850.00
November 2024									1.00		1.25							2.25	$1,350	$3,037.50	$1,800	$4,050.00
December 2024						0.50			96.25						0.50			97.25	$1,350	$131,287.50	$1,800	$175,050.00
January 2025									48.00		0.50		6.75					55.25	$1,700	$93,925.00	$1,800	$99,450.00
February 2025									15.50		0.50		2.50					18.50	$1,700	$31,450.00	$1,800	$33,300.00
March 2025									9.25		1.00							10.25	$1,700	$17,425.00	$1,800	$18,450.00
April 2025									9.25				0.50	1.00				10.75	$1,700	$18,275.00	$1,800	$19,350.00
May 2025										4.00	0.75		2.50		1.00			8.25	$1,700	$14,025.00	$1,800	$14,850.00
June 2025										6.75	6.00		2.50					15.25	$1,700	$25,925.00	$1,800	$27,450.00
July 2025											1.50							1.50	$1,700	$2,550.00	$1,800	$2,700.00
August 2025										3.50		2.25	0.50		1.00			7.25	$1,700	$12,325.00	$1,800	$13,050.00
September 2025												0.75	1.00					1.75	$1,700	$2,975.00	$1,800	$3,150.00
January 2026													3.50		0.50			4.00	$1,800	$7,200.00	$1,800	$7,200.00
February 2026															0.50		0.50	1.00	$1,800	$1,800.00	$1,800	$1,800.00
March 2026													1.00		0.50			1.50	$1,800	$2,700.00	$1,800	$2,700.00
April 2026													3.50	0.50	1.50			5.50	$1,800	$9,900.00	$1,800	$9,900.00
May 2026													17.25		1.00			18.25	$1,800	$32,850.00	$1,800	$32,850.00
June 2026													2.75					2.75	$1,800	$4,950.00	$1,800	$4,950.00
August 2026													1.00					1.00	$1,800	$1,800.00	$1,800	$1,800.00
Robert Kravetz - Partner																		**405.75**		**$495,625.00**	**$1,300**	**$527,475.00**
February 2025									17.75						1.75			19.50	$1,200	$23,400.00	$1,300	$25,350.00
March 2025									22.00		7.00				0.75			29.75	$1,200	$35,700.00	$1,300	$38,675.00
April 2025									15.50									15.50	$1,200	$18,600.00	$1,300	$20,150.00
June 2025										1.00	21.25			0.25				22.50	$1,200	$27,000.00	$1,300	$29,250.00
July 2025											11.25							11.25	$1,200	$13,500.00	$1,300	$14,625.00
August 2025										14.00	26.00	1.25						41.25	$1,200	$49,500.00	$1,300	$53,625.00
September 2025												6.25						6.25	$1,200	$7,500.00	$1,300	$8,125.00
October 2025												13.25						13.25	$1,200	$15,900.00	$1,300	$17,225.00
November 2025												31.25						31.25	$1,200	$37,500.00	$1,300	$40,625.00
December 2025												128.00						128.00	$1,200	$153,600.00	$1,300	$166,400.00
January 2026												2.50						2.50	$1,300	$3,250.00	$1,300	$3,250.00
April 2026															8.75			8.75	$1,300	$11,375.00	$1,300	$11,375.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
May 2026													50.75		25.25			76.00	$1,300	$98,800.00	$1,300	$98,800.00
Hannah Ross - Partner																		**73.00**		**$83,525.00**	**$1,800**	**$131,400.00**
July 2021		2.50															0.50	3.00	$1,050	$3,150.00	$1,800	$5,400.00
May 2022				2.00													1.00	3.00	$1,100	$3,300.00	$1,800	$5,400.00
June 2022				1.50													2.00	3.50	$1,100	$3,850.00	$1,800	$6,300.00
February 2023						2.50									1.25		1.25	5.00	$1,150	$5,750.00	$1,800	$9,000.00
March 2023						4.00											1.00	5.00	$1,150	$5,750.00	$1,800	$9,000.00
April 2023						4.50												4.50	$1,150	$5,175.00	$1,800	$8,100.00
May 2023						3.00	0.50										0.50	4.00	$1,150	$4,600.00	$1,800	$7,200.00
June 2023					0.75	2.25	3.50								1.00		0.50	8.00	$1,150	$9,200.00	$1,800	$14,400.00
July 2023						5.50	1.00											6.50	$1,150	$7,475.00	$1,800	$11,700.00
August 2023					3.50	0.50	0.50										1.00	5.50	$1,150	$6,325.00	$1,800	$9,900.00
September 2023						2.50		15.00									0.50	18.00	$1,150	$20,700.00	$1,800	$32,400.00
November 2023						2.00											1.00	3.00	$1,150	$3,450.00	$1,800	$5,400.00
December 2023						1.00							1.00					2.00	$1,150	$2,300.00	$1,800	$3,600.00
January 2024													2.00					2.00	$1,250	$2,500.00	$1,800	$3,600.00
Gerald Silk - Partner																		**21.00**		**$24,200.00**	**$1,800**	**$37,800.00**
May 2021	3.00																	3.00	$1,150	$3,450.00	$1,800	$5,400.00
July 2021		12.00																12.00	$1,150	$13,800.00	$1,800	$21,600.00
June 2022				5.00														5.00	$1,150	$5,750.00	$1,800	$9,000.00
September 2022															1.00			1.00	$1,200	$1,200.00	$1,800	$1,800.00
Katherine Sinderson - Partner																		**491.75**		**$644,950.00**	**$1,600**	**$786,800.00**
December 2024									117.25						7.75			125.00	$1,050	$131,250.00	$1,600	$200,000.00
January 2025									148.75				1.00					149.75	$1,400	$209,650.00	$1,600	$239,600.00
February 2025									45.50									45.50	$1,400	$63,700.00	$1,600	$72,800.00
March 2025									133.00									133.00	$1,400	$186,200.00	$1,600	$212,800.00
April 2025									6.75									6.75	$1,400	$9,450.00	$1,600	$10,800.00
May 2025										5.75			1.50		4.75			12.00	$1,400	$16,800.00	$1,600	$19,200.00
June 2025										16.50	1.50			0.50				18.50	$1,400	$25,900.00	$1,600	$29,600.00
April 2026													0.25					0.25	$1,600	$400.00	$1,600	$400.00
July 2026													1.00					1.00	$1,600	$1,600.00	$1,600	$1,600.00
Jorge Tenreiro - Partner																		**613.25**		**$741,650.00**	**$1,300**	**$797,225.00**
June 2025										2.75	48.75				2.50			54.00	$1,200	$64,800.00	$1,300	$70,200.00
July 2025										11.50	121.50				2.25			135.25	$1,200	$162,300.00	$1,300	$175,825.00
August 2025									2.75	13.00	42.25	57.25			4.75			120.00	$1,200	$144,000.00	$1,300	$156,000.00
September 2025												22.00						22.00	$1,200	$26,400.00	$1,300	$28,600.00
October 2025												38.25						38.25	$1,200	$45,900.00	$1,300	$49,725.00
November 2025												52.50						52.50	$1,200	$63,000.00	$1,300	$68,250.00
December 2025												133.75						133.75	$1,200	$160,500.00	$1,300	$173,875.00
January 2026												27.50	1.25					28.75	$1,300	$37,375.00	$1,300	$37,375.00
April 2026													2.00		6.00			8.00	$1,300	$10,400.00	$1,300	$10,400.00
May 2026													18.75		2.00			20.75	$1,300	$26,975.00	$1,300	$26,975.00
Jonathan D. Uslaner - Partner																		**2,986.00**		**$3,626,900.00**	**$1,600**	**$4,777,600.00**
February 2023						3.50	14.50										1.50	19.50	$975	$19,012.50	$1,600	$31,200.00
March 2023						9.00	13.50											22.50	$975	$21,937.50	$1,600	$36,000.00
April 2023						8.75	7.00		1.25									17.00	$975	$16,575.00	$1,600	$27,200.00
May 2023						5.25	6.50											11.75	$975	$11,456.25	$1,600	$18,800.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
June 2023						8.50	7.50						2.75					18.75	$975	$18,281.25	$1,600	$30,000.00
July 2023					3.25	11.75	4.75										1.50	21.25	$975	$20,718.75	$1,600	$34,000.00
August 2023					4.25	1.50	1.50											7.25	$975	$7,068.75	$1,600	$11,600.00
September 2023						15.00	21.50	43.25	1.50				0.75		1.25		6.50	89.75	$975	$87,506.25	$1,600	$143,600.00
October 2023					0.50	28.50	27.00	57.25						1.25	3.25		1.50	119.25	$975	$116,268.75	$1,600	$190,800.00
November 2023					1.75	17.25	6.75	36.75							1.75		1.00	65.25	$975	$63,618.75	$1,600	$104,400.00
December 2023					9.00	13.25	7.75		7.50				1.25					38.75	$975	$37,781.25	$1,600	$62,000.00
January 2024					40.50	10.75	1.00	1.50	76.00				37.25		3.25			170.25	$1,050	$178,762.50	$1,600	$272,400.00
February 2024					37.50	11.25		3.50	2.00				33.75	1.25			6.50	95.75	$1,050	$100,537.50	$1,600	$153,200.00
March 2024					17.00	11.50	1.25	89.25						3.25			0.50	122.75	$1,050	$128,887.50	$1,600	$196,400.00
April 2024					1.75	12.25	7.25	61.00						6.75				89.00	$1,050	$93,450.00	$1,600	$142,400.00
May 2024						5.50	6.50	23.75	9.25				1.75		3.25		0.50	50.50	$1,050	$53,025.00	$1,600	$80,800.00
June 2024						25.00		2.25	9.00				1.75		1.75		0.75	40.50	$1,050	$42,525.00	$1,600	$64,800.00
July 2024						26.75	1.00	87.25	1.25									116.25	$1,050	$122,062.50	$1,600	$186,000.00
August 2024						13.50		185.00	2.25									200.75	$1,050	$210,787.50	$1,600	$321,200.00
September 2024						5.75	10.25	34.25	6.50		9.75			2.75	1.25		2.25	72.75	$1,050	$76,387.50	$1,600	$116,400.00
October 2024						4.50	3.25		15.00		130.25							153.00	$1,050	$160,650.00	$1,600	$244,800.00
November 2024									166.25									166.25	$1,050	$174,562.50	$1,600	$266,000.00
December 2024									137.75									137.75	$1,050	$144,637.50	$1,600	$220,400.00
January 2025									124.50									124.50	$1,500	$186,750.00	$1,600	$199,200.00
February 2025									142.25									142.25	$1,500	$213,375.00	$1,600	$227,600.00
March 2025									153.00									153.00	$1,500	$229,500.00	$1,600	$244,800.00
April 2025									92.00	14.25			1.00					107.25	$1,500	$160,875.00	$1,600	$171,600.00
May 2025									0.75	40.00			3.25		1.25			45.25	$1,500	$67,875.00	$1,600	$72,400.00
June 2025										178.25	91.50				1.75			271.50	$1,500	$407,250.00	$1,600	$434,400.00
July 2025										75.50	10.00			1.75				87.25	$1,500	$130,875.00	$1,600	$139,600.00
August 2025										46.25	3.00	12.25			0.50		1.75	63.75	$1,500	$95,625.00	$1,600	$102,000.00
September 2025												3.25						3.25	$1,500	$4,875.00	$1,600	$5,200.00
December 2025												29.50					0.50	30.00	$1,500	$45,000.00	$1,600	$48,000.00
January 2026												13.75	10.25					24.00	$1,600	$38,400.00	$1,600	$38,400.00
February 2026													2.50					2.50	$1,600	$4,000.00	$1,600	$4,000.00
March 2026													3.50					3.50	$1,600	$5,600.00	$1,600	$5,600.00
May 2026													66.50		14.25			80.75	$1,600	$129,200.00	$1,600	$129,200.00
August 2026													0.75					0.75	$1,600	$1,200.00	$1,600	$1,200.00
Shane Avidan - Senior Counsel																		**719.25**		**$724,275.00**	**$1,100**	**$791,175.00**
February 2025									2.50									2.50	$1,000	$2,500.00	$1,100	$2,750.00
March 2025									92.00									92.00	$1,000	$92,000.00	$1,100	$101,200.00
April 2025									15.50									15.50	$1,000	$15,500.00	$1,100	$17,050.00
May 2025										37.50	1.25							38.75	$1,000	$38,750.00	$1,100	$42,625.00
June 2025										99.50	65.25							164.75	$1,000	$164,750.00	$1,100	$181,225.00
July 2025										3.25	47.50							50.75	$1,000	$50,750.00	$1,100	$55,825.00
August 2025										3.00	74.00	33.50			0.50			111.00	$1,000	$111,000.00	$1,100	$122,100.00
September 2025												6.50						6.50	$1,000	$6,500.00	$1,100	$7,150.00
October 2025												22.75						22.75	$1,000	$22,750.00	$1,100	$25,025.00
November 2025												68.75						68.75	$1,000	$68,750.00	$1,100	$75,625.00
December 2025												95.75						95.75	$1,000	$95,750.00	$1,100	$105,325.00
January 2026												13.00	0.25					13.25	$1,100	$14,575.00	$1,100	$14,575.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
February 2026													3.00					3.00	$1,100	$3,300.00	$1,100	$3,300.00
April 2026															4.00			4.00	$1,100	$4,400.00	$1,100	$4,400.00
May 2026													3.50		26.50			30.00	$1,100	$33,000.00	$1,100	$33,000.00
Lauren Cruz - Senior Counsel																		**2,273.75**		**$1,773,106.25**	**$1,000**	**$2,273,750.00**
September 2021			9.75															9.75	$550	$5,362.50	$1,000	$9,750.00
October 2021	3.25		4.50															7.75	$550	$4,262.50	$1,000	$7,750.00
November 2021			13.25															13.25	$550	$7,287.50	$1,000	$13,250.00
December 2021	0.25		4.50															4.75	$550	$2,612.50	$1,000	$4,750.00
January 2022	3.00		23.25															26.25	$575	$15,093.75	$1,000	$26,250.00
February 2022	1.50		26.00															27.50	$575	$15,812.50	$1,000	$27,500.00
March 2022	3.50		68.25															71.75	$575	$41,256.25	$1,000	$71,750.00
April 2022				0.25														0.25	$575	$143.75	$1,000	$250.00
May 2022				42.50											0.75		0.75	44.00	$575	$25,300.00	$1,000	$44,000.00
June 2022				91.50														91.50	$575	$52,612.50	$1,000	$91,500.00
July 2022				23.00														23.00	$575	$13,225.00	$1,000	$23,000.00
August 2022				2.50														2.50	$575	$1,437.50	$1,000	$2,500.00
September 2022				6.75														6.75	$575	$3,881.25	$1,000	$6,750.00
January 2023				2.25														2.25	$650	$1,462.50	$1,000	$2,250.00
February 2023				4.50		2.50	1.00								0.75		1.25	10.00	$650	$6,500.00	$1,000	$10,000.00
March 2023						12.00	7.25											19.25	$650	$12,512.50	$1,000	$19,250.00
April 2023						9.50	10.75											20.25	$650	$13,162.50	$1,000	$20,250.00
May 2023						7.00	19.75		1.00								1.00	28.75	$650	$18,687.50	$1,000	$28,750.00
June 2023						2.75	7.00		1.25									11.00	$650	$7,150.00	$1,000	$11,000.00
July 2023						14.50	11.25										0.75	26.50	$650	$17,225.00	$1,000	$26,500.00
August 2023					14.25	13.00	11.25											38.50	$650	$25,025.00	$1,000	$38,500.00
September 2023						34.25	19.25	38.75	1.25						2.00			95.50	$650	$62,075.00	$1,000	$95,500.00
October 2023						8.50	27.50	75.00	2.25									113.25	$650	$73,612.50	$1,000	$113,250.00
November 2023						36.75	0.50	38.75										76.00	$650	$49,400.00	$1,000	$76,000.00
December 2023					4.75	7.75	8.25	3.00	53.25				2.00					79.00	$650	$51,350.00	$1,000	$79,000.00
January 2024					55.75	36.25	1.50	8.75	67.75				23.50				2.25	195.75	$875	$171,281.25	$1,000	$195,750.00
February 2024					42.75	16.50	2.50	2.00					16.25	1.50			9.25	90.75	$875	$79,406.25	$1,000	$90,750.00
March 2024					3.25	3.75	0.75	1.75	4.00	5.00								18.50	$875	$16,187.50	$1,000	$18,500.00
April 2024					3.25	2.75	0.75											6.75	$875	$5,906.25	$1,000	$6,750.00
May 2024						2.50	5.75		10.75									19.00	$875	$16,625.00	$1,000	$19,000.00
June 2024						11.25	16.50		21.50									49.25	$875	$43,093.75	$1,000	$49,250.00
July 2024						1.75	32.75	133.00	32.00									199.50	$875	$174,562.50	$1,000	$199,500.00
August 2024						9.25	42.75	189.75	29.25									271.00	$875	$237,125.00	$1,000	$271,000.00
September 2024							27.25	4.50	120.00		14.25						0.25	166.25	$875	$145,468.75	$1,000	$166,250.00
October 2024							9.50		24.25		147.25							181.00	$875	$158,375.00	$1,000	$181,000.00
November 2024									137.75									137.75	$875	$120,531.25	$1,000	$137,750.00
December 2024									87.25									87.25	$875	$76,343.75	$1,000	$87,250.00
April 2025									1.00									1.00	$1,000.00	$1,000.00	$1,000	$1,000.00
June 2025											0.75							0.75	$1,000.00	$750.00	$1,000	$750.00
David L. Duncan - Senior Counsel																		**153.50**		**$162,143.75**	**$1,100**	**$168,850.00**
June 2024					8.00													8.00	$875	$7,000.00	$1,100	$8,800.00
July 2024					4.50													4.50	$875	$3,937.50	$1,100	$4,950.00
August 2024					1.00													1.00	$875	$875.00	$1,100	$1,100.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
September 2024					3.00													3.00	$875	$2,625.00	$1,100	$3,300.00
October 2024					6.00													6.00	$875	$5,250.00	$1,100	$6,600.00
November 2024					1.00													1.00	$875	$875.00	$1,100	$1,100.00
December 2024					0.75													0.75	$875	$656.25	$1,100	$825.00
January 2025					4.75													4.75	$1,000.00	$4,750.00	$1,100	$5,225.00
February 2025					1.50													1.50	$1,000.00	$1,500.00	$1,100	$1,650.00
May 2025					0.25													0.25	$1,000.00	$250.00	$1,100	$275.00
June 2025													5.75					5.75	$1,000.00	$5,750.00	$1,100	$6,325.00
August 2025															0.25			0.25	$1,000.00	$250.00	$1,100	$275.00
January 2026													11.25					11.25	$1,100.00	$12,375.00	$1,100	$12,375.00
February 2026													23.25					23.25	$1,100.00	$25,575.00	$1,100	$25,575.00
March 2026													28.75					28.75	$1,100.00	$31,625.00	$1,100	$31,625.00
April 2026													7.75		2.75			10.50	$1,100.00	$11,550.00	$1,100	$11,550.00
May 2026													2.25					2.25	$1,100.00	$2,475.00	$1,100	$2,475.00
June 2026													12.75					12.75	$1,100.00	$14,025.00	$1,100	$14,025.00
July 2026													2.75					2.75	$1,100.00	$3,025.00	$1,100	$3,025.00
August 2026													25.25					25.25	$1,100.00	$27,775.00	$1,100	$27,775.00
John Esmay - Senior Counsel																		**1,225.50**		**$1,179,043.75**	**$1,100**	**$1,348,050.00**
September 2024											1.50							1.50	$875	$1,312.50	$1,100	$1,650.00
October 2024									41.50		82.50				10.25			134.25	$875	$117,468.75	$1,100	$147,675.00
November 2024									145.25		1.75							147.00	$875	$128,625.00	$1,100	$161,700.00
December 2024									104.50									104.50	$875	$91,437.50	$1,100	$114,950.00
January 2025			-						142.25									142.25	$1,000.00	$142,250.00	$1,100	$156,475.00
February 2025									135.25									135.25	$1,000.00	$135,250.00	$1,100	$148,775.00
March 2025									154.75	0.50	0.50							155.75	$1,000.00	$155,750.00	$1,100	$171,325.00
April 2025									20.25	3.75								24.00	$1,000.00	$24,000.00	$1,100	$26,400.00
May 2025										27.25	2.00			1.00				30.25	$1,000.00	$30,250.00	$1,100	$33,275.00
June 2025										117.75	60.25							178.00	$1,000.00	$178,000.00	$1,100	$195,800.00
July 2025										8.25	14.00			1.25				23.50	$1,000.00	$23,500.00	$1,100	$25,850.00
August 2025											15.00				1.50			16.50	$1,000.00	$16,500.00	$1,100	$18,150.00
September 2025												8.00						8.00	$1,000.00	$8,000.00	$1,100	$8,800.00
October 2025												16.75						16.75	$1,000.00	$16,750.00	$1,100	$18,425.00
November 2025												41.50						41.50	$1,000.00	$41,500.00	$1,100	$45,650.00
December 2025												47.00						47.00	$1,000.00	$47,000.00	$1,100	$51,700.00
January 2026												4.75	1.50					6.25	$1,100.00	$6,875.00	$1,100	$6,875.00
February 2026													13.25					13.25	$1,100.00	$14,575.00	$1,100	$14,575.00
John Mills - Senior Counsel																		**25.00**		**$26,200.00**	**$1,100**	**$27,500.00**
June 2025													13.00					13.00	$1,000.00	$13,000.00	$1,100	$14,300.00
May 2026													12.00					12.00	$1,100.00	$13,200.00	$1,100	$13,200.00
Caitlin Bozman - Associate																		**869.75**		**$437,606.25**	**$800**	**$695,800.00**
April 2022				28.50														28.50	$450	$12,825.00	$800	$22,800.00
May 2022				29.50														29.50	$450	$13,275.00	$800	$23,600.00
January 2023				17.00														17.00	$475	$8,075.00	$800	$13,600.00
February 2023				13.50		1.00									0.50			15.00	$475	$7,125.00	$800	$12,000.00
March 2023						4.50	25.50							3.00				33.00	$475	$15,675.00	$800	$26,400.00
April 2023						10.75												10.75	$475	$5,106.25	$800	$8,600.00
May 2023						1.25	34.00											35.25	$475	$16,743.75	$800	$28,200.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
June 2023						5.00	30.50											35.50	$475	$16,862.50	$800	$28,400.00
July 2023						1.00												1.00	$475	$475.00	$800	$800.00
October 2023						6.25												6.25	$475	$2,968.75	$800	$5,000.00
December 2023					66.25	65.50	2.75		5.00									139.50	$475	$66,262.50	$800	$111,600.00
January 2024					111.00	21.75							59.75					192.50	$525	$101,062.50	$800	$154,000.00
February 2024					30.25	13.25							4.50					48.00	$525	$25,200.00	$800	$38,400.00
March 2024					4.25	15.00	2.00											21.25	$525	$11,156.25	$800	$17,000.00
April 2024					4.00													4.00	$525	$2,100.00	$800	$3,200.00
May 2024							2.75											2.75	$525	$1,443.75	$800	$2,200.00
June 2024						5.75	12.50		10.25									28.50	$525	$14,962.50	$800	$22,800.00
July 2024						36.50	9.25	26.50	39.25									111.50	$525	$58,537.50	$800	$89,200.00
August 2024						28.00	13.00		19.00									60.00	$525	$31,500.00	$800	$48,000.00
September 2024						44.75			5.25									50.00	$525	$26,250.00	$800	$40,000.00
James Briggs - Associate																		**4,599.75**		**$2,250,000.00**	**$650**	**$2,989,837.50**
June 2022				21.00														21.00	$450	$9,450.00	$650	$13,650.00
February 2023						0.50												0.50	$450	$225.00	$650	$325.00
April 2023						5.00	3.50											8.50	$450	$3,825.00	$650	$5,525.00
May 2023							26.50											26.50	$450	$11,925.00	$650	$17,225.00
June 2023							74.00											74.00	$450	$33,300.00	$650	$48,100.00
July 2023							94.75											94.75	$450	$42,637.50	$650	$61,587.50
August 2023						9.25	191.00		0.75									201.00	$450	$90,450.00	$650	$130,650.00
September 2023							133.50	36.00	3.00									172.50	$450	$77,625.00	$650	$112,125.00
October 2023						16.50	91.75	93.75	0.50									202.50	$450	$91,125.00	$650	$131,625.00
November 2023							87.00	89.25										176.25	$450	$79,312.50	$650	$114,562.50
December 2023							73.50	101.50	11.50									186.50	$450	$83,925.00	$650	$121,225.00
January 2024							36.75	90.25	17.75				48.25					193.00	$450	$86,850.00	$650	$125,450.00
February 2024							30.25	125.25					22.50					178.00	$450	$80,100.00	$650	$115,700.00
March 2024							19.75	184.50										204.25	$450	$91,912.50	$650	$132,762.50
April 2024							21.25	181.00										202.25	$450	$91,012.50	$650	$131,462.50
May 2024							6.00	193.75										199.75	$450	$89,887.50	$650	$129,837.50
June 2024								151.75										151.75	$450	$68,287.50	$650	$98,637.50
July 2024								179.50										179.50	$450	$80,775.00	$650	$116,675.00
August 2024								130.75	28.75									159.50	$450	$71,775.00	$650	$103,675.00
September 2024							4.25		149.75		23.75							177.75	$450	$79,987.50	$650	$115,537.50
October 2024									51.50		146.75							198.25	$450	$89,212.50	$650	$128,862.50
November 2024									192.00									192.00	$450	$86,400.00	$650	$124,800.00
December 2024									208.50									208.50	$450	$93,825.00	$650	$135,525.00
January 2025									253.75									253.75	$600	$152,250.00	$650	$164,937.50
February 2025									167.00									167.00	$600	$100,200.00	$650	$108,550.00
March 2025									130.75									130.75	$600	$78,450.00	$650	$84,987.50
April 2025									41.75		1.50							43.25	$600	$25,950.00	$650	$28,112.50
May 2025										73.00								73.00	$600	$43,800.00	$650	$47,450.00
June 2025										159.25	68.50							227.75	$600	$136,650.00	$650	$148,037.50
July 2025										49.50	90.25							139.75	$600	$83,850.00	$650	$90,837.50
August 2025										23.50	12.25				2.75			38.50	$600	$23,100.00	$650	$25,025.00
September 2025												6.25						6.25	$600	$3,750.00	$650	$4,062.50
October 2025												25.25						25.25	$600	$15,150.00	$650	$16,412.50

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
November 2025												21.75						21.75	$600	$13,050.00	$650	$14,137.50
December 2025												35.75						35.75	$600	$21,450.00	$650	$23,237.50
January 2026													5.25					5.25	$650	$3,412.50	$650	$3,412.50
April 2026															1.00			1.00	$650	$650.00	$650	$650.00
May 2026													11.00		11.25			22.25	$650	$14,462.50	$650	$14,462.50
Girolamo Brunetto - Associate																		**259.25**		**$136,106.25**	**$875**	**$226,843.75**
May 2021																	102.00	102.00	$525	$53,550.00	$875	$89,250.00
June 2021	1.25	24.75															14.75	40.75	$525	$21,393.75	$875	$35,656.25
July 2021	6.00	108.00															1.00	115.00	$525	$60,375.00	$875	$100,625.00
October 2021		1.50																1.50	$525	$787.50	$875	$1,312.50
Stephen Boscolo - Associate																		**1,104.25**		**$557,325.00**	**$700**	**$772,975.00**
February 2023						4.00												4.00	$450	$1,800.00	$700	$2,800.00
March 2023						13.00	5.25							0.25				18.50	$450	$8,325.00	$700	$12,950.00
April 2023						11.50	4.25											15.75	$450	$7,087.50	$700	$11,025.00
May 2023						8.25	7.00		1.75						1.75			18.75	$450	$8,437.50	$700	$13,125.00
June 2023					19.25	6.00	20.50											45.75	$450	$20,587.50	$700	$32,025.00
July 2023					13.75	17.75	14.00		2.00									47.50	$450	$21,375.00	$700	$33,250.00
August 2023					21.50	14.50	9.50		0.25						0.50		1.00	47.25	$450	$21,262.50	$700	$33,075.00
September 2023						21.75	13.00	2.25									0.50	37.50	$450	$16,875.00	$700	$26,250.00
October 2023						43.50	11.75	0.75	6.75									62.75	$450	$28,237.50	$700	$43,925.00
November 2023					0.50	38.75	9.25	3.00									0.50	52.00	$450	$23,400.00	$700	$36,400.00
December 2023					6.50	32.25	7.25	1.75	0.50				1.25		0.75			50.25	$450	$22,612.50	$700	$35,175.00
January 2024					15.00	43.00	12.25	8.75	2.50				10.50		1.25			93.25	$500	$46,625.00	$700	$65,275.00
February 2024					4.00	30.00	16.25	3.00	5.25				4.00					62.50	$500	$31,250.00	$700	$43,750.00
March 2024					17.75	5.25	11.00	14.75										48.75	$500	$24,375.00	$700	$34,125.00
April 2024					0.25	16.75	9.25	0.75	0.25									27.25	$500	$13,625.00	$700	$19,075.00
May 2024						18.25	20.00	2.25	2.25									42.75	$500	$21,375.00	$700	$29,925.00
June 2024						34.50	9.25	0.25	19.75									63.75	$500	$31,875.00	$700	$44,625.00
July 2024						47.00	12.75	3.75	8.75									72.25	$500	$36,125.00	$700	$50,575.00
August 2024						16.25	26.50	9.75										52.50	$500	$26,250.00	$700	$36,750.00
September 2024						6.75	1.25		5.75		1.75			3.50	0.25			19.25	$500	$9,625.00	$700	$13,475.00
October 2024						1.25	7.25		14.00		20.25							42.75	$500	$21,375.00	$700	$29,925.00
November 2024						0.50	1.75		14.50									16.75	$500	$8,375.00	$700	$11,725.00
December 2024									36.50									36.50	$500	$18,250.00	$700	$25,550.00
January 2025						2.50			83.50									86.00	$700	$60,200.00	$700	$60,200.00
February 2025									40.00									40.00	$700	$28,000.00	$700	$28,000.00
Chloe Jasper - Associate																		**1,747.25**		**$968,400.00**	**$700**	**$1,223,075.00**
December 2023					2.75	6.00	3.50		44.25									56.50	$450	$25,425.00	$700	$39,550.00
January 2024					33.75	7.75	11.25	3.50	114.50				6.75					177.50	$500	$88,750.00	$700	$124,250.00
February 2024					20.25	48.75	8.50	0.75			2.00		11.00				1.50	92.75	$500	$46,375.00	$700	$64,925.00
March 2024					62.75	18.75	45.00								15.00			141.50	$500	$70,750.00	$700	$99,050.00
April 2024					9.00	18.50	34.25	7.50									0.50	69.75	$500	$34,875.00	$700	$48,825.00
May 2024						22.75	13.75	14.75						2.00	3.50			56.75	$500	$28,375.00	$700	$39,725.00
June 2024						1.25	3.00		32.50									36.75	$500	$18,375.00	$700	$25,725.00
July 2024						16.00	5.25	65.50	25.25									112.00	$500	$56,000.00	$700	$78,400.00
August 2024						0.75	2.25		10.00									13.00	$500	$6,500.00	$700	$9,100.00
September 2024						1.00	24.75	3.75	1.00		13.00							43.50	$500	$21,750.00	$700	$30,450.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
October 2024						0.75	10.25		24.50		161.75							197.25	$500	$98,625.00	$700	$138,075.00
November 2024									139.75		2.00							141.75	$500	$70,875.00	$700	$99,225.00
December 2024									120.25									120.25	$500	$60,125.00	$700	$84,175.00
January 2025									140.00									140.00	$700	$98,000.00	$700	$98,000.00
February 2025									104.75									104.75	$700	$73,325.00	$700	$73,325.00
March 2025									116.75									116.75	$700	$81,725.00	$700	$81,725.00
April 2025									51.75	44.50								96.25	$700	$67,375.00	$700	$67,375.00
May 2025										25.50	3.00			1.75				30.25	$700	$21,175.00	$700	$21,175.00
Yando Peralta - Associate																		**64.75**		**$30,787.50**	**$500**	**$32,375.00**
August 2021			9.50															9.50	$475	$4,512.50	$500	$4,750.00
September 2021			25.25															25.25	$475	$11,993.75	$500	$12,625.00
October 2021			4.50															4.50	$475	$2,137.50	$500	$2,250.00
November 2021			23.25															23.25	$475	$11,043.75	$500	$11,625.00
December 2021			1.00															1.00	$475	$475.00	$500	$500.00
January 2022			1.25															1.25	$500	$625.00	$500	$625.00
Lawrence Hosmer - Sr. Staff Atty.																		**260.50**		**$117,225.00**	**$525**	**$136,762.50**
December 2023						1.25	25.25	7.00										33.50	$450	$15,075.00	$525	$17,587.50
January 2024						1.00	36.75	4.50	3.25									45.50	$450	$20,475.00	$525	$23,887.50
February 2024							21.50	4.00										25.50	$450	$11,475.00	$525	$13,387.50
March 2024						1.50	19.25	0.75										21.50	$450	$9,675.00	$525	$11,287.50
April 2024							21.25											21.25	$450	$9,562.50	$525	$11,156.25
May 2024							5.25											5.25	$450	$2,362.50	$525	$2,756.25
June 2024							11.75											11.75	$450	$5,287.50	$525	$6,168.75
July 2024							27.75											27.75	$450	$12,487.50	$525	$14,568.75
August 2024							62.75											62.75	$450	$28,237.50	$525	$32,943.75
September 2024							1.75	4.00										5.75	$450	$2,587.50	$525	$3,018.75
Ryan McCurdy - Sr. Staff Atty.																		**2,321.00**		**$1,110,285.00**	**$525**	**$1,218,525.00**
August 2024							15.00		15.25									30.25	$450	$13,612.50	$525	$15,881.25
September 2024						0.75	30.00	41.50	75.75		22.50							170.50	$450	$76,725.00	$525	$89,512.50
October 2024							43.00	42.00	28.75		113.25							227.00	$450	$102,150.00	$525	$119,175.00
November 2024									259.00									259.00	$450	$116,550.00	$525	$135,975.00
December 2024									171.25									171.25	$450	$77,062.50	$525	$89,906.25
January 2025									195.75		35.00							230.75	$495	$114,221.25	$525	$121,143.75
February 2025									105.75		52.50				0.75			159.00	$495	$78,705.00	$525	$83,475.00
March 2025									117.50	49.75	31.00							198.25	$495	$98,133.75	$525	$104,081.25
April 2025									48.75	13.00	116.25							178.00	$495	$88,110.00	$525	$93,450.00
May 2025							1.75			116.25	59.25							177.25	$495	$87,738.75	$525	$93,056.25
June 2025										179.50	58.25							237.75	$495	$117,686.25	$525	$124,818.75
July 2025										89.25	88.75							178.00	$495	$88,110.00	$525	$93,450.00
August 2025										48.75	40.50	1.75			2.75			93.75	$495	$46,406.25	$525	$49,218.75
September 2025												5.75						5.75	$495	$2,846.25	$525	$3,018.75
October 2025												3.00						3.00	$495	$1,485.00	$525	$1,575.00
November 2025												1.50						1.50	$495	$742.50	$525	$787.50
Damien Puniello - Sr. Staff Atty.																		**1,104.50**		**$507,622.50**	**$525**	**$579,862.50**
August 2024							14.00	3.00	16.00									33.00	$450	$14,850.00	$525	$17,325.00
September 2024						18.75	13.50	16.25	98.50		35.00							182.00	$450	$81,900.00	$525	$95,550.00
October 2024							11.75		60.75		141.25							213.75	$450	$96,187.50	$525	$112,218.75

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
November 2024									247.75									247.75	$450	$111,487.50	$525	$130,068.75
December 2024						0.50			192.00									192.50	$450	$86,625.00	$525	$101,062.50
January 2025									233.50									233.50	$495	$115,582.50	$525	$122,587.50
February 2025											2.00							2.00	$495	$990.00	$525	$1,050.00
Zvi Bar-Kochba - Staff Atty.																		**790.00**		**$302,757.50**	**$425**	**$335,750.00**
December 2023							138.50	0.75										139.25	$375	$52,218.75	$425	$59,181.25
January 2024						1.00	167.00		30.50									198.50	$385	$76,422.50	$425	$84,362.50
February 2024							167.25											167.25	$385	$64,391.25	$425	$71,081.25
March 2024							153.75	11.25										165.00	$385	$63,525.00	$425	$70,125.00
April 2024							120.00											120.00	$385	$46,200.00	$425	$51,000.00
Isabelle Bowers - Staff Atty.																		**2,068.75**		**$789,516.25**	**$385**	**$796,468.75**
August 2023							40.00											40.00	$375	$15,000.00	$385	$15,400.00
September 2023							147.50											147.50	$375	$55,312.50	$385	$56,787.50
October 2023							157.00	16.25										173.25	$375	$64,968.75	$385	$66,701.25
November 2023							144.25	2.00										146.25	$375	$54,843.75	$385	$56,306.25
December 2023							187.75	0.50										188.25	$375	$70,593.75	$385	$72,476.25
January 2024							192.75		10.25									203.00	$385	$78,155.00	$385	$78,155.00
February 2024							177.75											177.75	$385	$68,433.75	$385	$68,433.75
March 2024							185.25											185.25	$385	$71,321.25	$385	$71,321.25
April 2024							155.75											155.75	$385	$59,963.75	$385	$59,963.75
May 2024							175.25											175.25	$385	$67,471.25	$385	$67,471.25
June 2024							119.25											119.25	$385	$45,911.25	$385	$45,911.25
July 2024							109.50	60.50										170.00	$385	$65,450.00	$385	$65,450.00
August 2024							60.75	84.75										145.50	$385	$56,017.50	$385	$56,017.50
September 2024							22.25	2.50	17.00									41.75	$385	$16,073.75	$385	$16,073.75
Daniel Cedrone - Staff Atty.																		**653.75**		**$277,843.75**	**$425**	**$277,843.75**
December 2023							125.75											125.75	$425	$53,443.75	$425	$53,443.75
January 2024							136.00											136.00	$425	$57,800.00	$425	$57,800.00
February 2024							160.00											160.00	$425	$68,000.00	$425	$68,000.00
March 2024							120.00											120.00	$425	$51,000.00	$425	$51,000.00
April 2024							112.00											112.00	$425	$47,600.00	$425	$47,600.00
Jonathan Cohen - Staff Atty.																		**2,699.50**		**$1,103,433.75**	**$425**	**$1,147,287.50**
September 2023							77.00											77.00	$400	$30,800.00	$425	$32,725.00
October 2023							169.75											169.75	$400	$67,900.00	$425	$72,143.75
November 2023							164.75											164.75	$400	$65,900.00	$425	$70,018.75
December 2023							130.50	11.25	15.75									157.50	$400	$63,000.00	$425	$66,937.50
January 2024							163.25	13.50					16.75					193.50	$410	$79,335.00	$425	$82,237.50
February 2024							177.00											177.00	$410	$72,570.00	$425	$75,225.00
March 2024							189.25											189.25	$410	$77,592.50	$425	$80,431.25
April 2024							129.00											129.00	$410	$52,890.00	$425	$54,825.00
May 2024							171.00	5.25										176.25	$410	$72,262.50	$425	$74,906.25
June 2024							142.25		5.50									147.75	$410	$60,577.50	$425	$62,793.75
July 2024						3.75	63.00	64.50	34.50									165.75	$410	$67,957.50	$425	$70,443.75
August 2024							57.75	69.00	55.25									182.00	$410	$74,620.00	$425	$77,350.00
September 2024							3.25	8.25	53.50		60.00							125.00	$410	$51,250.00	$425	$53,125.00
October 2024									124.50		52.75							177.25	$410	$72,672.50	$425	$75,331.25
November 2024							6.00		166.00									172.00	$410	$70,520.00	$425	$73,100.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
December 2024							7.75		132.75									140.50	$410	$57,605.00	$425	$59,712.50
January 2025									155.25									155.25	$425	$65,981.25	$425	$65,981.25
Igor Faynshteyn - Staff Atty.																		**1,165.50**		**$495,337.50**	**$425**	**$495,337.50**
February 2024							14.00											14.00	$425	$5,950.00	$425	$5,950.00
March 2024							164.75	1.00										165.75	$425	$70,443.75	$425	$70,443.75
April 2024							177.00											177.00	$425	$75,225.00	$425	$75,225.00
May 2024							62.00	117.00										179.00	$425	$76,075.00	$425	$76,075.00
June 2024							129.00	27.00										156.00	$425	$66,300.00	$425	$66,300.00
July 2024							129.00	53.00										182.00	$425	$77,350.00	$425	$77,350.00
August 2024							4.50	159.25	26.00									189.75	$425	$80,643.75	$425	$80,643.75
September 2024								40.00	40.00									80.00	$425	$34,000.00	$425	$34,000.00
October 2024								22.00										22.00	$425	$9,350.00	$425	$9,350.00
Sascha Goergen - Staff Atty.																		**2,277.00**		**$967,725.00**	**$425**	**$967,725.00**
September 2023							94.00											94.00	$425	$39,950.00	$425	$39,950.00
October 2023							191.00											191.00	$425	$81,175.00	$425	$81,175.00
November 2023							165.25											165.25	$425	$70,231.25	$425	$70,231.25
December 2023							206.50											206.50	$425	$87,762.50	$425	$87,762.50
January 2024							230.50											230.50	$425	$97,962.50	$425	$97,962.50
February 2024							212.00											212.00	$425	$90,100.00	$425	$90,100.00
March 2024							207.00											207.00	$425	$87,975.00	$425	$87,975.00
April 2024							202.00											202.00	$425	$85,850.00	$425	$85,850.00
May 2024							178.00											178.00	$425	$75,650.00	$425	$75,650.00
June 2024							159.00											159.00	$425	$67,575.00	$425	$67,575.00
July 2024							189.00											189.00	$425	$80,325.00	$425	$80,325.00
August 2024							182.75	10.00										192.75	$425	$81,918.75	$425	$81,918.75
September 2024						10.00	20.00		20.00									50.00	$425	$21,250.00	$425	$21,250.00
Steffanie Keim - Staff Atty.																		**378.25**		**$160,756.25**	**$425**	**$160,756.25**
September 2023							59.75											59.75	$425	$25,393.75	$425	$25,393.75
October 2023							95.75											95.75	$425	$40,693.75	$425	$40,693.75
November 2023							145.00	9.50										154.50	$425	$65,662.50	$425	$65,662.50
December 2023							68.25											68.25	$425	$29,006.25	$425	$29,006.25
Shammari Khan - Staff Atty.																		**365.00**		**$155,125.00**	**$425**	**$155,125.00**
December 2023							111.00		27.00									138.00	$425	$58,650.00	$425	$58,650.00
January 2024							174.00											174.00	$425	$73,950.00	$425	$73,950.00
February 2024							53.00											53.00	$425	$22,525.00	$425	$22,525.00
Paul Lim - Staff Atty.																		**1,441.25**		**$612,531.25**	**$425**	**$612,531.25**
November 2023							162.00											162.00	$425	$68,850.00	$425	$68,850.00
December 2023							162.00											162.00	$425	$68,850.00	$425	$68,850.00
January 2024							190.50											190.50	$425	$80,962.50	$425	$80,962.50
February 2024							167.25											167.25	$425	$71,081.25	$425	$71,081.25
March 2024							162.00											162.00	$425	$68,850.00	$425	$68,850.00
April 2024							180.50											180.50	$425	$76,712.50	$425	$76,712.50
May 2024							179.00											179.00	$425	$76,075.00	$425	$76,075.00
June 2024							160.00											160.00	$425	$68,000.00	$425	$68,000.00
July 2024							78.00											78.00	$425	$33,150.00	$425	$33,150.00
Tiffany Michael - Staff Atty.																		**1,254.50**		**$533,162.50**	**$425**	**$533,162.50**
September 2023							75.00	7.50										82.50	$425	$35,062.50	$425	$35,062.50
October 2023							117.75	1.00										118.75	$425	$50,468.75	$425	$50,468.75

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
November 2023							137.50											137.50	$425	$58,437.50	$425	$58,437.50
December 2023							139.50	4.50										144.00	$425	$61,200.00	$425	$61,200.00
January 2024							173.75											173.75	$425	$73,843.75	$425	$73,843.75
February 2024							161.25						1.00					162.25	$425	$68,956.25	$425	$68,956.25
March 2024							43.00											43.00	$425	$18,275.00	$425	$18,275.00
April 2024							62.75											62.75	$425	$26,668.75	$425	$26,668.75
May 2024							151.00											151.00	$425	$64,175.00	$425	$64,175.00
June 2024							135.00											135.00	$425	$57,375.00	$425	$57,375.00
July 2024							44.00											44.00	$425	$18,700.00	$425	$18,700.00
Emily Nalven - Staff Atty.																		**557.25**		**$226,822.50**	**$410**	**$228,472.50**
December 2023							132.50	24.50	8.00									165.00	$400	$66,000.00	$410	$67,650.00
January 2024					16.25		83.00	85.50										184.75	$410	$75,747.50	$410	$75,747.50
February 2024							149.50	24.00										173.50	$410	$71,135.00	$410	$71,135.00
March 2024							34.00											34.00	$410	$13,940.00	$410	$13,940.00
Yeruchem Neiman - Staff Atty.																		**1,185.00**		**$503,625.00**	**$425**	**$503,625.00**
September 2023							64.00											64.00	$425	$27,200.00	$425	$27,200.00
October 2023							174.00											174.00	$425	$73,950.00	$425	$73,950.00
November 2023							176.00											176.00	$425	$74,800.00	$425	$74,800.00
December 2023							131.00											131.00	$425	$55,675.00	$425	$55,675.00
January 2024							186.00											186.00	$425	$79,050.00	$425	$79,050.00
February 2024							170.00											170.00	$425	$72,250.00	$425	$72,250.00
March 2024							164.00											164.00	$425	$69,700.00	$425	$69,700.00
April 2024							120.00											120.00	$425	$51,000.00	$425	$51,000.00
Rodney Nutt - Staff Atty.																		**382.75**		**$162,668.75**	**$425**	**$162,668.75**
February 2024							108.25											108.25	$425	$46,006.25	$425	$46,006.25
March 2024							163.00											163.00	$425	$69,275.00	$425	$69,275.00
April 2024							111.50											111.50	$425	$47,387.50	$425	$47,387.50
John Pate - Staff Atty.																		**1,949.00**		**$786,925.00**	**$410**	**$799,090.00**
May 2023							114.25											114.25	$400	$45,700.00	$410	$46,842.50
June 2023							146.25											146.25	$400	$58,500.00	$410	$59,962.50
July 2023							126.25											126.25	$400	$50,500.00	$410	$51,762.50
August 2023							177.25											177.25	$400	$70,900.00	$410	$72,672.50
September 2023							157.50											157.50	$400	$63,000.00	$410	$64,575.00
October 2023							174.25											174.25	$400	$69,700.00	$410	$71,442.50
November 2023							160.25											160.25	$400	$64,100.00	$410	$65,702.50
December 2023							160.00	0.50										160.50	$400	$64,200.00	$410	$65,805.00
January 2024							162.00		4.00				4.00					170.00	$410	$69,700.00	$410	$69,700.00
February 2024							138.00											138.00	$410	$56,580.00	$410	$56,580.00
March 2024							201.00	0.50										201.50	$410	$82,615.00	$410	$82,615.00
April 2024							140.25	24.25										164.50	$410	$67,445.00	$410	$67,445.00
May 2024							58.50											58.50	$410	$23,985.00	$410	$23,985.00
Mark Paul - Staff Atty.																		**916.25**		**$366,500.00**	**$400**	**$366,500.00**
May 2023							134.50											134.50	$400	$53,800.00	$400	$53,800.00
June 2023							166.00											166.00	$400	$66,400.00	$400	$66,400.00
July 2023							128.00											128.00	$400	$51,200.00	$400	$51,200.00
August 2023							184.50											184.50	$400	$73,800.00	$400	$73,800.00
September 2023							155.00											155.00	$400	$62,000.00	$400	$62,000.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
October 2023							148.25											148.25	$400	$59,300.00	$400	$59,300.00
Priscilla Pellecchia - Staff Atty.																		**4,445.50**		**$1,828,976.25**	**$450**	**$2,000,475.00**
July 2023							87.75											87.75	$400	$35,100.00	$450	$39,487.50
August 2023							184.50											184.50	$400	$73,800.00	$450	$83,025.00
September 2023							83.00	83.50										166.50	$400	$66,600.00	$450	$74,925.00
October 2023							3.25	191.00										194.25	$400	$77,700.00	$450	$87,412.50
November 2023							86.25	127.25										213.50	$400	$85,400.00	$450	$96,075.00
December 2023							122.25	28.75	58.25									209.25	$400	$83,700.00	$450	$94,162.50
January 2024							50.50	132.00	10.00				49.00					241.50	$410	$99,015.00	$450	$108,675.00
February 2024							209.50	2.00										211.50	$410	$86,715.00	$450	$95,175.00
March 2024							10.00	159.00										169.00	$410	$69,290.00	$450	$76,050.00
April 2024								197.75										197.75	$410	$81,077.50	$450	$88,987.50
May 2024							129.00	32.00	21.00									182.00	$410	$74,620.00	$450	$81,900.00
June 2024							78.50	17.00	64.50									160.00	$410	$65,600.00	$450	$72,000.00
July 2024							39.75	69.00	80.00									188.75	$410	$77,387.50	$450	$84,937.50
August 2024								103.00	81.25									184.25	$410	$75,542.50	$450	$82,912.50
September 2024									79.00		87.50							166.50	$410	$68,265.00	$450	$74,925.00
October 2024							7.00		67.25		115.50							189.75	$410	$77,797.50	$450	$85,387.50
November 2024									185.50									185.50	$410	$76,055.00	$450	$83,475.00
December 2024									188.00									188.00	$410	$77,080.00	$450	$84,600.00
January 2025									147.00		32.00							179.00	$425	$76,075.00	$450	$80,550.00
February 2025							13.00		46.75		107.25							167.00	$425	$70,975.00	$450	$75,150.00
March 2025									47.75		120.00							167.75	$425	$71,293.75	$450	$75,487.50
April 2025									37.50	64.00	74.50							176.00	$425	$74,800.00	$450	$79,200.00
May 2025										55.75	8.00							63.75	$425	$27,093.75	$450	$28,687.50
June 2025										86.50	26.25							112.75	$425	$47,918.75	$450	$50,737.50
July 2025										75.50	103.50							179.00	$425	$76,075.00	$450	$80,550.00
August 2025									3.25	36.75	39.00				1.00			80.00	$425	$34,000.00	$450	$36,000.00
Kirstin Peterson - Staff Atty.																		**2,794.25**		**$1,192,550.00**	**$475**	**$1,327,268.75**
September 2023							80.00											80.00	$425	$34,000.00	$475	$38,000.00
October 2023							158.25											158.25	$425	$67,256.25	$475	$75,168.75
November 2023							161.75											161.75	$425	$68,743.75	$475	$76,831.25
December 2023							178.00											178.00	$425	$75,650.00	$475	$84,550.00
January 2024							165.25		28.00									193.25	$425	$82,131.25	$475	$91,793.75
February 2024							142.75											142.75	$425	$60,668.75	$475	$67,806.25
March 2024							174.00											174.00	$425	$73,950.00	$475	$82,650.00
April 2024							164.00											164.00	$425	$69,700.00	$475	$77,900.00
May 2024							140.50											140.50	$425	$59,712.50	$475	$66,737.50
June 2024						15.00	111.00	17.50										143.50	$425	$60,987.50	$475	$68,162.50
July 2024							59.25	32.50	40.75									132.50	$425	$56,312.50	$475	$62,937.50
August 2024							38.75	74.25	76.00									189.00	$425	$80,325.00	$475	$89,775.00
September 2024							19.50		58.50		94.50							172.50	$425	$73,312.50	$475	$81,937.50
October 2024							5.00		69.50		116.50							191.00	$425	$81,175.00	$475	$90,725.00
November 2024									186.50									186.50	$425	$79,262.50	$475	$88,587.50
December 2024									187.00									187.00	$425	$79,475.00	$475	$88,825.00
January 2025									183.50		16.25							199.75	$450	$89,887.50	$475	$94,881.25
Joanna Tarnawski - Staff Atty.																		**4,506.50**		**$1,851,342.50**	**$450**	**$2,027,925.00**

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
June 2023							73.50											73.50	$400	$29,400.00	$450	$33,075.00
July 2023							130.25											130.25	$400	$52,100.00	$450	$58,612.50
August 2023							185.50											185.50	$400	$74,200.00	$450	$83,475.00
September 2023							163.50											163.50	$400	$65,400.00	$450	$73,575.00
October 2023							63.75	110.50										174.25	$400	$69,700.00	$450	$78,412.50
November 2023							178.50	36.75										215.25	$400	$86,100.00	$450	$96,862.50
December 2023							197.50	2.50	7.25									207.25	$400	$82,900.00	$450	$93,262.50
January 2024							78.25	116.75					52.00					247.00	$410	$101,270.00	$450	$111,150.00
February 2024							29.75	164.00										193.75	$410	$79,437.50	$450	$87,187.50
March 2024							65.00	143.25										208.25	$410	$85,382.50	$450	$93,712.50
April 2024							199.50											199.50	$410	$81,795.00	$450	$89,775.00
May 2024							116.75	55.00										171.75	$410	$70,417.50	$450	$77,287.50
June 2024							74.75	55.25	29.25									159.25	$410	$65,292.50	$450	$71,662.50
July 2024							30.00	96.00	57.75									183.75	$410	$75,337.50	$450	$82,687.50
August 2024								109.25	99.25									208.50	$410	$85,485.00	$450	$93,825.00
September 2024									167.75									167.75	$410	$68,777.50	$450	$75,487.50
October 2024								25.75	150.00		14.00							189.75	$410	$77,797.50	$450	$85,387.50
November 2024									229.00									229.00	$410	$93,890.00	$450	$103,050.00
December 2024								9.00	178.25									187.25	$410	$76,772.50	$450	$84,262.50
January 2025									195.00									195.00	$425	$82,875.00	$450	$87,750.00
February 2025									156.00									156.00	$425	$66,300.00	$450	$70,200.00
March 2025									157.75		10.00							167.75	$425	$71,293.75	$450	$75,487.50
April 2025									40.00		136.00							176.00	$425	$74,800.00	$450	$79,200.00
May 2025											24.00							24.00	$425	$10,200.00	$450	$10,800.00
June 2025											35.25							35.25	$425	$14,981.25	$450	$15,862.50
July 2025										106.50	68.75							175.25	$425	$74,481.25	$450	$78,862.50
August 2025										40.75	41.50							82.25	$425	$34,956.25	$450	$37,012.50
Adam Weinschel - Fin. Analyst																		**34.50**		**$19,150.00**	**$650**	**$22,425.00**
May 2021	5.00																	5.00	$550	$2,750.00	$650	$3,250.00
June 2021	7.00	7.00																14.00	$550	$7,700.00	$650	$9,100.00
July 2021	1.00	11.00																12.00	$550	$6,600.00	$650	$7,800.00
February 2023						0.50												0.50	$600	$300.00	$650	$325.00
May 2023							1.00											1.00	$600	$600.00	$650	$650.00
June 2023							1.00											1.00	$600	$600.00	$650	$650.00
October 2023								1.00										1.00	$600	$600.00	$650	$650.00
Milana Babic - Fin. Analyst																		**44.00**		**$17,600.00**	**$425**	**$18,700.00**
May 2021	6.00																	6.00	$400	$2,400.00	$425	$2,550.00
June 2021	12.00	4.00																16.00	$400	$6,400.00	$425	$6,800.00
July 2021	22.00																	22.00	$400	$8,800.00	$425	$9,350.00
Tanjila Sultana - Fin. Analyst																		**45.00**		**$19,525.00**	**$550**	**$24,750.00**
May 2021	10.00																	10.00	$425	$4,250.00	$550	$5,500.00
June 2021	10.50																	10.50	$425	$4,462.50	$550	$5,775.00
July 2021	15.75																	15.75	$425	$6,693.75	$550	$8,662.50
March 2022	1.50																	1.50	$450	$675.00	$550	$825.00
May 2023							1.00											1.00	$475	$475.00	$550	$550.00
June 2023	1.25																	1.25	$475	$593.75	$550	$687.50
July 2023	5.00																	5.00	$475	$2,375.00	$550	$2,750.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
Andrew Thompson - Fin. Analyst																		**44.00**		**$17,600.00**	**$575**	**$25,300.00**
June 2021	40.00																	40.00	$400	$16,000.00	$575	$23,000.00
July 2021	4.00																	4.00	$400	$1,600.00	$575	$2,300.00
Amy Bitkower - Dir. of Investigations																		**56.25**		**$33,037.50**	**$650**	**$36,562.50**
June 2021	22.25																	22.25	$575	$12,793.75	$650	$14,462.50
July 2021	1.75																	1.75	$575	$1,006.25	$650	$1,137.50
August 2021	0.25																	0.25	$575	$143.75	$650	$162.50
October 2021	1.50																	1.50	$575	$862.50	$650	$975.00
November 2021	0.25																	0.25	$575	$143.75	$650	$162.50
December 2021	5.00																	5.00	$575	$2,875.00	$650	$3,250.00
January 2022	2.50																	2.50	$600	$1,500.00	$650	$1,625.00
February 2022	5.75																	5.75	$600	$3,450.00	$650	$3,737.50
March 2022	2.25																	2.25	$600	$1,350.00	$650	$1,462.50
April 2022	0.25																	0.25	$600	$150.00	$650	$162.50
March 2023	4.50																	4.50	$600	$2,700.00	$650	$2,925.00
April 2023	0.25																	0.25	$600	$150.00	$650	$162.50
May 2023	6.00																	6.00	$600	$3,600.00	$650	$3,900.00
July 2023	0.25									0.25								0.50	$600	$300.00	$650	$325.00
August 2023	0.75																	0.75	$600	$450.00	$650	$487.50
September 2023	0.25																	0.25	$600	$150.00	$650	$162.50
May 2024	1.50																	1.50	$625	$937.50	$650	$975.00
July 2024	0.25																	0.25	$625	$156.25	$650	$162.50
November 2024	0.25																	0.25	$625	$156.25	$650	$162.50
July 2025	0.25																	0.25	$650	$162.50	$650	$162.50
John Deming - Senior Investigator																		**148.25**		**$62,275.00**	**$500**	**$74,125.00**
October 2021	12.75																	12.75	$400	$5,100.00	$500	$6,375.00
November 2021	13.75																	13.75	$400	$5,500.00	$500	$6,875.00
December 2021	2.75																	2.75	$400	$1,100.00	$500	$1,375.00
January 2022	54.75																	54.75	$425	$23,268.75	$500	$27,375.00
February 2022	63.50																	63.50	$425	$26,987.50	$500	$31,750.00
March 2023	0.50																	0.50	$425	$212.50	$500	$250.00
December 2023	0.25																	0.25	$425	$106.25	$500	$125.00
Jacob Foster - Investigator																		**102.25**		**$32,943.75**	**$400**	**$40,900.00**
June 2021	9.50																	9.50	$300	$2,850.00	$400	$3,800.00
July 2021	1.00																	1.00	$300	$300.00	$400	$400.00
August 2021	8.50																	8.50	$300	$2,550.00	$400	$3,400.00
October 2021	6.00																	6.00	$300	$1,800.00	$400	$2,400.00
March 2023	10.50																	10.50	$325	$3,412.50	$400	$4,200.00
June 2023	1.50																	1.50	$325	$487.50	$400	$600.00
July 2023	28.00																	28.00	$325	$9,100.00	$400	$11,200.00
August 2023	1.50																	1.50	$325	$487.50	$400	$600.00
September 2023	3.50																	3.50	$325	$1,137.50	$400	$1,400.00
October 2023	7.50																	7.50	$325	$2,437.50	$400	$3,000.00
November 2023	0.25																	0.25	$325	$81.25	$400	$100.00
December 2023	11.00																	11.00	$325	$3,575.00	$400	$4,400.00
January 2024	0.25																	0.25	$350	$87.50	$400	$100.00
February 2024	8.25																	8.25	$350	$2,887.50	$400	$3,300.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
April 2024	0.50																	0.50	$350	$175.00	$400	$200.00
June 2024	4.50																	4.50	$350	$1,575.00	$400	$1,800.00
Gary Weston - Dir. of Paralegals																		**36.25**		**$15,700.00**	**$475**	**$17,218.75**
July 2021	0.25													0.50				0.75	$375	$281.25	$475	$356.25
August 2021	0.25																	0.25	$375	$93.75	$475	$118.75
January 2022														1.00				1.00	$400	$400.00	$475	$475.00
March 2022	0.25																	0.25	$400	$100.00	$475	$118.75
May 2022	0.50			0.25														0.75	$400	$300.00	$475	$356.25
June 2022	0.25																	0.25	$400	$100.00	$475	$118.75
July 2022				0.25														0.25	$400	$100.00	$475	$118.75
October 2022														0.50				0.50	$400	$200.00	$475	$237.50
February 2023														0.25				0.25	$400	$100.00	$475	$118.75
March 2023							0.75							0.25				1.00	$400	$400.00	$475	$475.00
April 2023						0.25												0.25	$400	$100.00	$475	$118.75
June 2023							1.50											1.50	$400	$600.00	$475	$712.50
July 2023							0.25											0.25	$400	$100.00	$475	$118.75
August 2023						0.25		0.25										0.50	$400	$200.00	$475	$237.50
September 2023								0.25										0.25	$400	$100.00	$475	$118.75
October 2023							0.25							0.25				0.50	$400	$200.00	$475	$237.50
November 2023														0.25				0.25	$400	$100.00	$475	$118.75
January 2024					0.75			1.00	0.50									2.25	$425	$956.25	$475	$1,068.75
February 2024					2.00													2.00	$425	$850.00	$475	$950.00
May 2024									0.50									0.50	$425	$212.50	$475	$237.50
July 2024							0.25	0.25										0.50	$425	$212.50	$475	$237.50
August 2024								1.25						0.50				1.75	$425	$743.75	$475	$831.25
September 2024					0.25				0.25									0.50	$425	$212.50	$475	$237.50
October 2024									1.00									1.00	$425	$425.00	$475	$475.00
November 2024									0.50									0.50	$425	$212.50	$475	$237.50
December 2024														0.25				0.25	$425	$106.25	$475	$118.75
January 2025									1.50									1.50	$450	$675.00	$475	$712.50
February 2025									2.25									2.25	$450	$1,012.50	$475	$1,068.75
March 2025									2.00									2.00	$450	$900.00	$475	$950.00
April 2025														0.50				0.50	$450	$225.00	$475	$237.50
June 2025										1.25				2.25				3.50	$450	$1,575.00	$475	$1,662.50
July 2025														0.25				0.25	$450	$112.50	$475	$118.75
August 2025											1.00	0.50						1.50	$450	$675.00	$475	$712.50
September 2025												0.25		0.75				1.00	$450	$450.00	$475	$475.00
November 2025												2.00						2.00	$450	$900.00	$475	$950.00
December 2025												0.25		0.25				0.50	$450	$225.00	$475	$237.50
January 2026												0.50						0.50	$475	$237.50	$475	$237.50
February 2026													0.25					0.25	$475	$118.75	$475	$118.75
March 2026													0.50					0.50	$475	$237.50	$475	$237.50
April 2026													0.25					0.25	$475	$118.75	$475	$118.75
May 2026													1.00					1.00	$475	$475.00	$475	$475.00
July 2026													0.25					0.25	$475	$118.75	$475	$118.75
August 2026													0.50					0.50	$475	$237.50	$475	$237.50
Cindy Bomzer-Stein - Case Manager																		**878.00**		**$323,325.00**	**$450**	**$395,100.00**

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
January 2022	2.00													2.50				4.50	$325	$1,462.50	$450	$2,025.00
February 2022	18.75		8.75											9.00				36.50	$325	$11,862.50	$450	$16,425.00
March 2022			109.25															109.25	$325	$35,506.25	$450	$49,162.50
April 2022																2.00		2.00	$325	$650.00	$450	$900.00
May 2022																1.00		1.00	$325	$325.00	$450	$450.00
June 2022				2.00												2.00		4.00	$325	$1,300.00	$450	$1,800.00
July 2022				13.00												0.50		13.50	$325	$4,387.50	$450	$6,075.00
August 2022																0.75		0.75	$325	$243.75	$450	$337.50
September 2022																2.00		2.00	$325	$650.00	$450	$900.00
October 2022																2.25		2.25	$325	$731.25	$450	$1,012.50
November 2022																0.50		0.50	$325	$162.50	$450	$225.00
March 2023														2.00				2.00	$325	$650.00	$450	$900.00
May 2023							0.50		23.00									23.50	$325	$7,637.50	$450	$10,575.00
July 2023							6.75											6.75	$325	$2,193.75	$450	$3,037.50
August 2023					0.50		17.00											17.50	$325	$5,687.50	$450	$7,875.00
September 2023							11.25											11.25	$325	$3,656.25	$450	$5,062.50
October 2023							6.50	1.25										7.75	$325	$2,518.75	$450	$3,487.50
November 2023						14.75	10.50	14.25										39.50	$325	$12,837.50	$450	$17,775.00
December 2023					0.50	0.50	7.00	4.25	6.00									18.25	$325	$5,931.25	$450	$8,212.50
January 2024					13.50		7.00	0.25										20.75	$325	$6,743.75	$450	$9,337.50
February 2024						2.00	10.00						3.25					15.25	$325	$4,956.25	$450	$6,862.50
March 2024					1.25	0.25	9.25	3.75										14.50	$325	$4,712.50	$450	$6,525.00
April 2024					3.50		8.00							0.25				11.75	$325	$3,818.75	$450	$5,287.50
May 2024							11.00	5.75						2.00				18.75	$325	$6,093.75	$450	$8,437.50
June 2024							5.00											5.00	$325	$1,625.00	$450	$2,250.00
July 2024							5.00	5.25										10.25	$325	$3,331.25	$450	$4,612.50
August 2024							5.00	15.75										20.75	$325	$6,743.75	$450	$9,337.50
September 2024							3.25											3.25	$325	$1,056.25	$450	$1,462.50
October 2024							0.25		30.00		1.00							31.25	$325	$10,156.25	$450	$14,062.50
November 2024						0.75	1.00		43.00									44.75	$325	$14,543.75	$450	$20,137.50
December 2024							1.00	0.25	6.00									7.25	$325	$2,356.25	$450	$3,262.50
January 2025								1.25	8.25									9.50	$425	$4,037.50	$450	$4,275.00
February 2025									26.25									26.25	$425	$11,156.25	$450	$11,812.50
March 2025									57.75									57.75	$425	$24,543.75	$450	$25,987.50
April 2025									22.50									22.50	$425	$9,562.50	$450	$10,125.00
May 2025										15.50								15.50	$425	$6,587.50	$450	$6,975.00
June 2025										31.25	17.75			0.75				49.75	$425	$21,143.75	$450	$22,387.50
July 2025										28.50	28.25			1.00				57.75	$425	$24,543.75	$450	$25,987.50
August 2025												1.50						1.50	$425	$637.50	$450	$675.00
September 2025												12.50						12.50	$425	$5,312.50	$450	$5,625.00
October 2025												12.75						12.75	$425	$5,418.75	$450	$5,737.50
November 2025												17.50						17.50	$425	$7,437.50	$450	$7,875.00
December 2025												56.50						56.50	$425	$24,012.50	$450	$25,425.00
January 2026												24.25						24.25	$450	$10,912.50	$450	$10,912.50
February 2026													0.25					0.25	$450	$112.50	$450	$112.50
April 2026													3.25					3.25	$450	$1,462.50	$450	$1,462.50
May 2026													3.75		0.50			4.25	$450	$1,912.50	$450	$1,912.50

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
Khristine De Leon - Case Manager																		**50.00**		**$16,275.00**	**$450**	**$22,500.00**
June 2021		5.50															5.75	11.25	$325	$3,656.25	$450	$5,062.50
July 2021		37.50												0.25				37.75	$325	$12,268.75	$450	$16,987.50
August 2021		0.50																0.50	$325	$162.50	$450	$225.00
September 2023								0.50										0.50	$375	$187.50	$450	$225.00
Jay Layfield - Case Manager																		**21.50**		**$9,137.50**	**$425**	**$9,137.50**
June 2025											9.00							9.00	$425	$3,825.00	$425	$3,825.00
July 2025											11.00							11.00	$425	$4,675.00	$425	$4,675.00
August 2025											1.50							1.50	$425	$637.50	$425	$637.50
Matthew Mahady - Case Manager																		**55.25**		**$19,387.50**	**$450**	**$24,862.50**
May 2021	0.25																	0.25	$350	$87.50	$450	$112.50
June 2021	2.50	8.25															4.25	15.00	$350	$5,250.00	$450	$6,750.00
July 2021	0.50	37.25																37.75	$350	$13,212.50	$450	$16,987.50
August 2021		0.25																0.25	$350	$87.50	$450	$112.50
May 2023															1.50			1.50	$375	$562.50	$450	$675.00
August 2023					0.50													0.50	$375	$187.50	$450	$225.00
Toby Saviano - Case Manager																		**330.75**		**$134,887.50**	**$450**	**$148,837.50**
June 2022				0.75														0.75	$375	$281.25	$450	$337.50
July 2022				16.75														16.75	$375	$6,281.25	$450	$7,537.50
March 2023							5.25											5.25	$375	$1,968.75	$450	$2,362.50
May 2023							1.00											1.00	$375	$375.00	$450	$450.00
October 2023								3.00										3.00	$375	$1,125.00	$450	$1,350.00
November 2023								13.50										13.50	$375	$5,062.50	$450	$6,075.00
December 2023									5.00									5.00	$375	$1,875.00	$450	$2,250.00
January 2024								3.25	10.50									13.75	$400	$5,500.00	$450	$6,187.50
February 2024						1.00												1.00	$400	$400.00	$450	$450.00
March 2024						1.00		5.00										6.00	$400	$2,400.00	$450	$2,700.00
April 2024					4.00			3.00										7.00	$400	$2,800.00	$450	$3,150.00
July 2024							1.00	1.00										2.00	$400	$800.00	$450	$900.00
August 2024								8.00										8.00	$400	$3,200.00	$450	$3,600.00
September 2024								4.00	11.25									15.25	$400	$6,100.00	$450	$6,862.50
October 2024								2.00	3.00		1.00							6.00	$400	$2,400.00	$450	$2,700.00
November 2024									67.50									67.50	$400	$27,000.00	$450	$30,375.00
December 2024								2.00	14.50									16.50	$400	$6,600.00	$450	$7,425.00
January 2025									8.75									8.75	$425	$3,718.75	$450	$3,937.50
February 2025									8.50		13.50							22.00	$425	$9,350.00	$450	$9,900.00
March 2025									2.00		12.75							14.75	$425	$6,268.75	$450	$6,637.50
April 2025									0.75	0.50				1.25				2.50	$425	$1,062.50	$450	$1,125.00
May 2025										28.25								28.25	$425	$12,006.25	$450	$12,712.50
June 2025										39.75	1.50							41.25	$425	$17,531.25	$450	$18,562.50
July 2025										2.50	3.75			1.50				7.75	$425	$3,293.75	$450	$3,487.50
August 2025											4.50							4.50	$425	$1,912.50	$450	$2,025.00
September 2025												2.00						2.00	$425	$850.00	$450	$900.00
November 2025												3.75						3.75	$425	$1,593.75	$450	$1,687.50
December 2025												0.75						0.75	$425	$318.75	$450	$337.50
May 2026													3.75		2.50			6.25	$450	$2,812.50	$450	$2,812.50
Yulia Tsoy - Case Manager																		**17.00**		**$5,525.00**	**$425**	**$7,225.00**

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
November 2024									17.00									17.00	$325	$5,525.00	$425	$7,225.00
Melody Yaghoubzadeh - Case Manager																		**2,181.00**		**$872,975.00**	**$450**	**$981,450.00**
July 2021	21.50																	21.50	$350	$7,525.00	$450	$9,675.00
August 2021	21.00		0.50															21.50	$350	$7,525.00	$450	$9,675.00
September 2021	7.75																	7.75	$350	$2,712.50	$450	$3,487.50
October 2021	13.25		0.50															13.75	$350	$4,812.50	$450	$6,187.50
November 2021	6.25		1.25															7.50	$350	$2,625.00	$450	$3,375.00
December 2021	2.50																	2.50	$350	$875.00	$450	$1,125.00
January 2022	7.50																	7.50	$375	$2,812.50	$450	$3,375.00
February 2022	6.00		18.00											5.25				29.25	$375	$10,968.75	$450	$13,162.50
March 2022	2.00		77.00															79.00	$375	$29,625.00	$450	$35,550.00
April 2022				2.00												0.25		2.25	$375	$843.75	$450	$1,012.50
May 2022	0.25			2.50										0.75				3.50	$375	$1,312.50	$450	$1,575.00
June 2022	0.50			5.25												0.25		6.00	$375	$2,250.00	$450	$2,700.00
July 2022				9.00												0.50		9.50	$375	$3,562.50	$450	$4,275.00
August 2022				0.25														0.25	$375	$93.75	$450	$112.50
September 2022				7.50														7.50	$375	$2,812.50	$450	$3,375.00
December 2022																0.25		0.25	$375	$93.75	$450	$112.50
January 2023				1.25										0.25				1.50	$375	$562.50	$450	$675.00
February 2023				5.75		5.50	1.50								0.25	0.25		13.25	$375	$4,968.75	$450	$5,962.50
March 2023						9.25	16.25							4.00		1.00		30.50	$375	$11,437.50	$450	$13,725.00
April 2023						8.00	8.50											16.50	$375	$6,187.50	$450	$7,425.00
May 2023						1.50	15.00		1.00					0.25		0.75		18.50	$375	$6,937.50	$450	$8,325.00
June 2023					2.75	1.50	15.75		0.50									20.50	$375	$7,687.50	$450	$9,225.00
July 2023					0.50	0.50	10.50								2.25			13.75	$375	$5,156.25	$450	$6,187.50
August 2023					29.50	0.75	15.75	1.75								0.75		48.50	$375	$18,187.50	$450	$21,825.00
September 2023						2.25	24.25	12.25										38.75	$375	$14,531.25	$450	$17,437.50
October 2023					0.25		20.25	21.00	7.50							0.25		49.25	$375	$18,468.75	$450	$22,162.50
November 2023					0.25	24.00	13.00	14.25	0.50					1.00		0.25		53.25	$375	$19,968.75	$450	$23,962.50
December 2023					0.25	12.50	6.00	10.75	23.75				1.25	2.00		0.25		56.75	$375	$21,281.25	$450	$25,537.50
January 2024					64.75	19.75	5.00	7.25	28.50				16.00	0.50				141.75	$400	$56,700.00	$450	$63,787.50
February 2024					14.25	15.75	5.50	8.00					8.50	2.75		0.50		55.25	$400	$22,100.00	$450	$24,862.50
March 2024					4.75	5.50	12.00	24.75								0.25		47.25	$400	$18,900.00	$450	$21,262.50
April 2024					4.25		20.00	11.75						4.75		0.50		41.25	$400	$16,500.00	$450	$18,562.50
May 2024					0.25		11.25	13.75	3.25					0.75		1.00		30.25	$400	$12,100.00	$450	$13,612.50
June 2024						0.50	13.00	9.50	6.50					0.25		0.25		30.00	$400	$12,000.00	$450	$13,500.00
July 2024						3.25	10.75	67.00	8.75							0.25		90.00	$400	$36,000.00	$450	$40,500.00
August 2024						10.50	16.25	96.50	10.50					0.50		0.25		134.50	$400	$53,800.00	$450	$60,525.00
September 2024							12.25	15.75	64.25		7.00			5.75				105.00	$400	$42,000.00	$450	$47,250.00
October 2024						0.50	1.25	2.75	38.50		27.75			0.25		0.50		71.50	$400	$28,600.00	$450	$32,175.00
November 2024									127.75									127.75	$400	$51,100.00	$450	$57,487.50
December 2024									94.00		0.25			4.75				99.00	$400	$39,600.00	$450	$44,550.00
January 2025									63.75					0.25		0.25		64.25	$425	$27,306.25	$450	$28,912.50
February 2025					0.25				63.50	0.50								64.25	$425	$27,306.25	$450	$28,912.50
March 2025								0.75	78.25	6.25	0.50			1.75				87.50	$425	$37,187.50	$450	$39,375.00
April 2025									17.75	10.00	16.50			1.00				45.25	$425	$19,231.25	$450	$20,362.50
May 2025										15.25				1.50				16.75	$425	$7,118.75	$450	$7,537.50

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
June 2025										85.50	26.50							112.00	$425	$47,600.00	$450	$50,400.00
July 2025										12.50	25.75							38.25	$425	$16,256.25	$450	$17,212.50
August 2025										9.25	23.75	6.00		1.75	1.00			41.75	$425	$17,743.75	$450	$18,787.50
September 2025												22.00		0.25				22.25	$425	$9,456.25	$450	$10,012.50
October 2025												14.00						14.00	$425	$5,950.00	$450	$6,300.00
November 2025												18.00						18.00	$425	$7,650.00	$450	$8,100.00
December 2025												51.75						51.75	$425	$21,993.75	$450	$23,287.50
January 2026												21.50	1.00					22.50	$450	$10,125.00	$450	$10,125.00
February 2026													0.50					0.50	$450	$225.00	$450	$225.00
March 2026													7.75	0.50				8.25	$450	$3,712.50	$450	$3,712.50
April 2026													0.75					0.75	$450	$337.50	$450	$337.50
May 2026													15.75	1.00				16.75	$450	$7,537.50	$450	$7,537.50
June 2026													0.50		0.50			1.00	$450	$450.00	$450	$450.00
July 2026													0.25					0.25	$450	$112.50	$450	$112.50
August 2026													1.00					1.00	$450	$450.00	$450	$450.00
Annemarie Eames - Paralegal																		**1,608.50**		**$535,200.00**	**$350**	**$562,975.00**
February 2023				3.00			3.00											6.00	$325	$1,950.00	$350	$2,100.00
March 2023						1.00	23.00							6.50				30.50	$325	$9,912.50	$350	$10,675.00
April 2023						6.00												6.00	$325	$1,950.00	$350	$2,100.00
May 2023							6.25											6.25	$325	$2,031.25	$350	$2,187.50
June 2023							14.25											14.25	$325	$4,631.25	$350	$4,987.50
July 2023							19.00								2.00			21.00	$325	$6,825.00	$350	$7,350.00
August 2023					4.25	1.50	8.00	1.00										14.75	$325	$4,793.75	$350	$5,162.50
September 2023							7.25	3.50	2.00									12.75	$325	$4,143.75	$350	$4,462.50
October 2023							20.00	24.00	11.50									55.50	$325	$18,037.50	$350	$19,425.00
November 2023						5.00	8.50	12.00						5.00				30.50	$325	$9,912.50	$350	$10,675.00
December 2023						1.00	1.75	3.25	37.00					1.75				44.75	$325	$14,543.75	$350	$15,662.50
January 2024					35.50	13.75	10.00	8.00	41.25					3.50		2.50		114.50	$325	$37,212.50	$350	$40,075.00
February 2024					17.75	0.75	1.00						1.25					20.75	$325	$6,743.75	$350	$7,262.50
March 2024								25.25										25.25	$325	$8,206.25	$350	$8,837.50
April 2024						2.00	4.25	9.00						1.25				16.50	$325	$5,362.50	$350	$5,775.00
May 2024						1.00	1.00	6.00	11.00									19.00	$325	$6,175.00	$350	$6,650.00
June 2024						4.25	5.25	8.25	7.50									25.25	$325	$8,206.25	$350	$8,837.50
July 2024						5.00	12.00	37.50	25.00									79.50	$325	$25,837.50	$350	$27,825.00
August 2024						0.50		92.75	15.25									108.50	$325	$35,262.50	$350	$37,975.00
September 2024					1.50		3.50	9.00	121.00		18.00							153.00	$325	$49,725.00	$350	$53,550.00
October 2024						6.00			43.50		48.50			1.00				99.00	$325	$32,175.00	$350	$34,650.00
November 2024									65.50									65.50	$325	$21,287.50	$350	$22,925.00
December 2024								7.00	135.00									142.00	$325	$46,150.00	$350	$49,700.00
January 2025									138.50									138.50	$350	$48,475.00	$350	$48,475.00
February 2025									94.00	2.00								96.00	$350	$33,600.00	$350	$33,600.00
March 2025									90.00									90.00	$350	$31,500.00	$350	$31,500.00
April 2025									15.00	14.00				1.00				30.00	$350	$10,500.00	$350	$10,500.00
May 2025										29.50	3.50			1.50				34.50	$350	$12,075.00	$350	$12,075.00
June 2025										51.50	36.00							87.50	$350	$30,625.00	$350	$30,625.00
July 2025											21.00							21.00	$350	$7,350.00	$350	$7,350.00
Ryan McCarthy - Paralegal																		**60.25**		**$21,450.00**	**$375**	**$22,593.75**

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
September 2025												1.50						1.50	$350	$525.00	$375	$562.50
October 2025												2.50						2.50	$350	$875.00	$375	$937.50
November 2025												7.25						7.25	$350	$2,537.50	$375	$2,718.75
December 2025												34.50						34.50	$350	$12,075.00	$375	$12,937.50
January 2026												13.50	0.25					13.75	$375	$5,156.25	$375	$5,156.25
April 2026													0.25					0.25	$375	$93.75	$375	$93.75
August 2026													0.50					0.50	$375	$187.50	$375	$187.50
Nathan Vickers - Paralegal																		**18.50**		**$6,012.50**	**$325**	**$6,012.50**
March 2022	18.50																	18.50	$325	$6,012.50	$325	$6,012.50
Paul Charlotin - Lit. Support																		**38.25**		**$15,925.00**	**$475**	**$18,168.75**
July 2021	7.50																	7.50	$350	$2,625.00	$475	$3,562.50
February 2024							3.25											3.25	$425	$1,381.25	$475	$1,543.75
June 2024							6.25											6.25	$425	$2,656.25	$475	$2,968.75
July 2024							0.75											0.75	$425	$318.75	$475	$356.25
August 2024							1.00	2.50										3.50	$425	$1,487.50	$475	$1,662.50
October 2024							0.50											0.50	$425	$212.50	$475	$237.50
November 2024									0.50									0.50	$425	$212.50	$475	$237.50
December 2024							4.00		2.75									6.75	$425	$2,868.75	$475	$3,206.25
January 2025							4.00											4.00	$450	$1,800.00	$475	$1,900.00
June 2025							1.25				4.00							5.25	$450	$2,362.50	$475	$2,493.75
Roberto Santamarina - Lit. Support																		**353.50**		**$164,006.25**	**$525**	**$185,587.50**
August 2021	1.00																	1.00	$400	$400.00	$525	$525.00
April 2023							2.75											2.75	$450	$1,237.50	$525	$1,443.75
May 2023							11.50											11.50	$450	$5,175.00	$525	$6,037.50
June 2023							3.50											3.50	$450	$1,575.00	$525	$1,837.50
July 2023							32.25											32.25	$450	$14,512.50	$525	$16,931.25
August 2023							40.50											40.50	$450	$18,225.00	$525	$21,262.50
September 2023							15.00	0.75										15.75	$450	$7,087.50	$525	$8,268.75
October 2023							36.50											36.50	$450	$16,425.00	$525	$19,162.50
November 2023							17.25											17.25	$450	$7,762.50	$525	$9,056.25
December 2023							8.50											8.50	$450	$3,825.00	$525	$4,462.50
January 2024							8.50											8.50	$475	$4,037.50	$525	$4,462.50
February 2024							6.50	1.00										7.50	$475	$3,562.50	$525	$3,937.50
March 2024							7.75											7.75	$475	$3,681.25	$525	$4,068.75
April 2024							2.75	0.75										3.50	$475	$1,662.50	$525	$1,837.50
May 2024							8.50											8.50	$475	$4,037.50	$525	$4,462.50
June 2024							10.00											10.00	$475	$4,750.00	$525	$5,250.00
July 2024							23.50											23.50	$475	$11,162.50	$525	$12,337.50
August 2024							16.50	4.00	0.50									21.00	$475	$9,975.00	$525	$11,025.00
September 2024							16.50	5.25	5.75									27.50	$475	$13,062.50	$525	$14,437.50
October 2024							4.50	1.00	7.25		3.00							15.75	$475	$7,481.25	$525	$8,268.75
November 2024							7.75		17.50									25.25	$475	$11,993.75	$525	$13,256.25
December 2024							1.00		9.00									10.00	$475	$4,750.00	$525	$5,250.00
January 2025							1.00		10.25									11.25	$500	$5,625.00	$525	$5,906.25
February 2025							2.00											2.00	$500	$1,000.00	$525	$1,050.00
June 2025							1.00											1.00	$500	$500.00	$525	$525.00
July 2025											1.00							1.00	$500	$500.00	$525	$525.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
Julio Velazquez - Lit. Support																		**154.75**		**$66,693.75**	**$475**	**$73,506.25**
August 2023							2.00											2.00	$400	$800.00	$475	$950.00
October 2023							2.00											2.00	$400	$800.00	$475	$950.00
November 2023							3.50											3.50	$400	$1,400.00	$475	$1,662.50
December 2023							0.75	4.50										5.25	$400	$2,100.00	$475	$2,493.75
January 2024							0.25		2.25									2.50	$425	$1,062.50	$475	$1,187.50
February 2024								2.50	2.75									5.25	$425	$2,231.25	$475	$2,493.75
March 2024							0.50	1.50										2.00	$425	$850.00	$475	$950.00
April 2024								5.50										5.50	$425	$2,337.50	$475	$2,612.50
May 2024							0.25	4.25										4.50	$425	$1,912.50	$475	$2,137.50
June 2024							2.75	0.50										3.25	$425	$1,381.25	$475	$1,543.75
July 2024							8.75	3.75										12.50	$425	$5,312.50	$475	$5,937.50
August 2024								6.25										6.25	$425	$2,656.25	$475	$2,968.75
September 2024								13.50	0.75									14.25	$425	$6,056.25	$475	$6,768.75
October 2024							1.25	8.00										9.25	$425	$3,931.25	$475	$4,393.75
November 2024									0.75									0.75	$425	$318.75	$475	$356.25
December 2024									26.25									26.25	$425	$11,156.25	$475	$12,468.75
January 2025									32.75									32.75	$450	$14,737.50	$475	$15,556.25
February 2025									7.75									7.75	$450	$3,487.50	$475	$3,681.25
March 2025									0.25		0.50							0.75	$450	$337.50	$475	$356.25
April 2025										0.50	0.25							0.75	$450	$337.50	$475	$356.25
June 2025										1.50	2.75							4.25	$450	$1,912.50	$475	$2,018.75
July 2025											3.25							3.25	$450	$1,462.50	$475	$1,543.75
September 2025														0.25				0.25	$450	$112.50	$475	$118.75
Mahiri Buffong - Managing Clerk																		**232.25**		**$105,393.75**	**$500**	**$116,125.00**
February 2022			1.00											2.75				3.75	$400	$1,500.00	$500	$1,875.00
March 2022			3.50											0.25				3.75	$400	$1,500.00	$500	$1,875.00
May 2022														3.25				3.25	$400	$1,300.00	$500	$1,625.00
June 2022				1.25														1.25	$400	$500.00	$500	$625.00
July 2022				0.25														0.25	$400	$100.00	$500	$125.00
August 2022														0.25				0.25	$400	$100.00	$500	$125.00
September 2022														0.50				0.50	$400	$200.00	$500	$250.00
February 2023				0.50										1.50				2.00	$425	$850.00	$500	$1,000.00
March 2023														3.00				3.00	$425	$1,275.00	$500	$1,500.00
April 2023						2.25	0.50							3.25				6.00	$425	$2,550.00	$500	$3,000.00
May 2023							0.75							1.00				1.75	$425	$743.75	$500	$875.00
June 2023														0.50				0.50	$425	$212.50	$500	$250.00
July 2023														0.75				0.75	$425	$318.75	$500	$375.00
August 2023					1.25		0.50							0.75				2.50	$425	$1,062.50	$500	$1,250.00
September 2023								0.50						2.50				3.00	$425	$1,275.00	$500	$1,500.00
October 2023														2.25				2.25	$425	$956.25	$500	$1,125.00
November 2023														3.00				3.00	$425	$1,275.00	$500	$1,500.00
December 2023							1.25							6.25				7.50	$425	$3,187.50	$500	$3,750.00
January 2024					4.75		0.75							10.50				16.00	$450	$7,200.00	$500	$8,000.00
February 2024						6.75								14.25				21.00	$450	$9,450.00	$500	$10,500.00
March 2024					3.00									9.50				12.50	$450	$5,625.00	$500	$6,250.00
April 2024														6.75				6.75	$450	$3,037.50	$500	$3,375.00

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
May 2024							1.75							5.25				7.00	$450	$3,150.00	$500	$3,500.00
June 2024							1.50							3.50				5.00	$450	$2,250.00	$500	$2,500.00
July 2024							1.75							8.25				10.00	$450	$4,500.00	$500	$5,000.00
August 2024						2.75								6.50				9.25	$450	$4,162.50	$500	$4,625.00
September 2024						0.75								6.75				7.50	$450	$3,375.00	$500	$3,750.00
October 2024														3.00				3.00	$450	$1,350.00	$500	$1,500.00
November 2024														2.00				2.00	$450	$900.00	$500	$1,000.00
December 2024									1.00					7.50				8.50	$450	$3,825.00	$500	$4,250.00
January 2025														4.75				4.75	$475	$2,256.25	$500	$2,375.00
March 2025									1.25					4.25				5.50	$475	$2,612.50	$500	$2,750.00
April 2025														2.75				2.75	$475	$1,306.25	$500	$1,375.00
May 2025										5.25				3.00				8.25	$475	$3,918.75	$500	$4,125.00
June 2025										18.00				7.00				25.00	$475	$11,875.00	$500	$12,500.00
July 2025										0.50	0.75			6.75				8.00	$475	$3,800.00	$500	$4,000.00
August 2025												1.00		1.00				2.00	$475	$950.00	$500	$1,000.00
September 2025												0.50		3.25				3.75	$475	$1,781.25	$500	$1,875.00
November 2025														0.75				0.75	$475	$356.25	$500	$375.00
December 2025												1.00		1.75				2.75	$475	$1,306.25	$500	$1,375.00
January 2026												2.25		2.00				4.25	$500	$2,125.00	$500	$2,125.00
February 2026														1.00				1.00	$500	$500.00	$500	$500.00
March 2026													0.75	1.00				1.75	$500	$875.00	$500	$875.00
April 2026														1.75				1.75	$500	$875.00	$500	$875.00
May 2026													1.75	1.50				3.25	$500	$1,625.00	$500	$1,625.00
June 2026														1.75				1.75	$500	$875.00	$500	$875.00
July 2026														0.50				0.50	$500	$250.00	$500	$250.00
August 2026													0.50	0.25				0.75	$500	$375.00	$500	$375.00
Janielle Lattimore - Asst. Man. Clerk																		**161.25**		**$69,193.75**	**$475**	**$76,593.75**
June 2021	0.75													0.75				1.50	$350	$525.00	$475	$712.50
June 2022				3.50														3.50	$375	$1,312.50	$475	$1,662.50
July 2022				4.25														4.25	$375	$1,593.75	$475	$2,018.75
September 2022				0.50														0.50	$375	$187.50	$475	$237.50
January 2023														0.75				0.75	$400	$300.00	$475	$356.25
February 2023				0.25														0.25	$400	$100.00	$475	$118.75
March 2023						0.50								1.75				2.25	$400	$900.00	$475	$1,068.75
April 2023						5.25												5.25	$400	$2,100.00	$475	$2,493.75
June 2023							1.75											1.75	$400	$700.00	$475	$831.25
July 2023							0.50											0.50	$400	$200.00	$475	$237.50
August 2023							0.75											0.75	$400	$300.00	$475	$356.25
September 2023							5.25											5.25	$400	$2,100.00	$475	$2,493.75
October 2023							4.75											4.75	$400	$1,900.00	$475	$2,256.25
December 2023						5.25								0.75				6.00	$400	$2,400.00	$475	$2,850.00
January 2024					8.50	9.75								0.25				18.50	$425	$7,862.50	$475	$8,787.50
February 2024						3.25								1.00				4.25	$425	$1,806.25	$475	$2,018.75
March 2024					5.25	1.00								4.50				10.75	$425	$4,568.75	$475	$5,106.25
April 2024					1.50	0.50	4.50							2.75				9.25	$425	$3,931.25	$475	$4,393.75
May 2024							2.75							1.00				3.75	$425	$1,593.75	$475	$1,781.25
July 2024						4.25	0.50							1.00				5.75	$425	$2,443.75	$475	$2,731.25

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:
1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
August 2024					2.75	0.75		0.50						0.25				4.25	$425	$1,806.25	$475	$2,018.75
September 2024														0.75				0.75	$425	$318.75	$475	$356.25
October 2024					0.25									0.50				0.75	$425	$318.75	$475	$356.25
November 2024														0.50				0.50	$425	$212.50	$475	$237.50
December 2024														0.75				0.75	$425	$318.75	$475	$356.25
January 2025														0.50				0.50	$450	$225.00	$475	$237.50
February 2025					0.25				11.75									12.00	$450	$5,400.00	$475	$5,700.00
March 2025									8.75					1.75				10.50	$450	$4,725.00	$475	$4,987.50
April 2025										0.50								0.50	$450	$225.00	$475	$237.50
May 2025										11.25				4.25				15.50	$450	$6,975.00	$475	$7,362.50
June 2025										8.50	4.00			1.00				13.50	$450	$6,075.00	$475	$6,412.50
July 2025										0.75								0.75	$450	$337.50	$475	$356.25
August 2025												0.25		1.00				1.25	$450	$562.50	$475	$593.75
March 2026													3.25	0.25				3.50	$475	$1,662.50	$475	$1,662.50
April 2026													1.00	1.50				2.50	$475	$1,187.50	$475	$1,187.50
May 2026													2.75		0.25			3.00	$475	$1,425.00	$475	$1,425.00
June 2026													0.50					0.50	$475	$237.50	$475	$237.50
August 2026													0.50	0.25				0.75	$475	$356.25	$475	$356.25
Jessica Lacon - Docket Clerk																		**106.25**		**$42,906.25**	**$540**	**$47,812.50**
October 2023							2.50							3.75				6.25	$375	$2,343.75	$450	$2,812.50
November 2023						1.00								4.50				5.50	$375	$2,062.50	$450	$2,475.00
December 2023						0.50	0.75							7.25				8.50	$375	$3,187.50	$450	$3,825.00
January 2024														6.25				6.25	$400	$2,500.00	$450	$2,812.50
February 2024														7.75				7.75	$400	$3,100.00	$450	$3,487.50
March 2024														9.25				9.25	$400	$3,700.00	$450	$4,162.50
April 2024							0.75							7.50				8.25	$400	$3,300.00	$450	$3,712.50
May 2024														3.25				3.25	$400	$1,300.00	$450	$1,462.50
June 2024														1.25				1.25	$400	$500.00	$450	$562.50
July 2024														5.75				5.75	$400	$2,300.00	$450	$2,587.50
August 2024														1.75				1.75	$400	$700.00	$450	$787.50
September 2024														3.25				3.25	$400	$1,300.00	$450	$1,462.50
October 2024														2.00				2.00	$400	$800.00	$450	$900.00
November 2024														1.75				1.75	$400	$700.00	$450	$787.50
December 2024														3.50				3.50	$400	$1,400.00	$450	$1,575.00
January 2025														4.25				4.25	$425	$1,806.25	$450	$1,912.50
February 2025									0.75					1.25				2.00	$425	$850.00	$450	$900.00
March 2025														3.00				3.00	$425	$1,275.00	$450	$1,350.00
April 2025														2.50				2.50	$425	$1,062.50	$450	$1,125.00
May 2025														2.75				2.75	$425	$1,168.75	$450	$1,237.50
June 2025										1.00	0.50			3.25				4.75	$425	$2,018.75	$450	$2,137.50
July 2025														2.00				2.00	$425	$850.00	$450	$900.00
August 2025														2.00				2.00	$425	$850.00	$450	$900.00
September 2025														2.75				2.75	$425	$1,168.75	$450	$1,237.50
October 2025														0.25				0.25	$425	$106.25	$450	$112.50
November 2025														1.00				1.00	$425	$425.00	$450	$450.00
December 2025														0.25				0.25	$425	$106.25	$450	$112.50
January 2026												2.25		1.50				3.75	$450	$1,687.50	$450	$1,687.50

EXHIBIT 7

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Lodestar Chart by Timekeeper & Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	HISTORIC RATE	LODESTAR AT HISTORIC RATE	CURRENT RATE	LODESTAR AT CURRENT RATE
February 2026														0.25				0.25	$450	$112.50	$450	$112.50
March 2026													0.50					0.50	$450	$225.00	$450	$225.00
TOTAL	**664.50**	**301.25**	**566.50**	**495.50**	**1,107.00**	**2,265.00**	**23,513.25**	**7,869.25**	**14,728.25**	**2,508.00**	**4,450.00**	**1,369.50**	**994.00**	**416.75**	**217.00**	**22.00**	**200.75**	**61,688.50**		**$34,304,256.25**		**$40,480,287.50**

Exhibit 8

EXHIBIT 8

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Category Lodestar Chart by Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

MONTH	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	LODESTAR AT HISTORIC RATE	LODESTAR AT CURRENT RATE
May 2021	29.25																102.00	131.25	$70,612.50	$113,562.50
June 2021	107.75	50.50												0.75			36.75	195.75	$93,406.25	$133,618.75
July 2021	100.00	248.50	18.75											0.75			2.25	370.25	$203,000.00	$315,093.75
August 2021	54.25	0.75	36.50						2.50									94.00	$58,581.25	$86,893.75
September 2021	9.50		42.50															52.00	$27,700.00	$37,887.50
October 2021	37.50	1.50	26.50															65.50	$34,406.25	$50,325.00
November 2021	20.25		50.00															70.25	$36,706.25	$51,212.50
December 2021	11.50		12.25															23.75	$14,656.25	$21,575.00
January 2022	70.75		44.00											3.50				118.25	$62,587.50	$88,400.00
February 2022	95.50		54.25											17.00				166.75	$71,181.25	$95,350.00
March 2022	28.00		281.75											0.25				310.00	$144,525.00	$209,506.25
April 2022	0.25			30.75												2.25		33.25	$14,612.50	$25,125.00
May 2022	0.75			86.75										4.00	0.75	1.00	2.75	96.00	$54,637.50	$91,556.25
June 2022	0.75			202.75												2.25	3.75	209.50	$139,668.75	$222,518.75
July 2022				94.50												1.00		95.50	$54,275.00	$81,300.00
August 2022				8.25										0.25	0.50	0.75		9.75	$7,325.00	$11,375.00
September 2022				23.75										0.50	1.00	2.00		27.25	$17,806.25	$26,762.50
October 2022														0.50		2.25		2.75	$931.25	$1,250.00
November 2022																0.50		0.50	$162.50	$225.00
December 2022																0.25		0.25	$93.75	$112.50
January 2023				21.25										1.00				22.25	$11,337.50	$18,231.25
February 2023				27.50		28.25	20.00							2.50	5.50	0.25	6.00	90.00	$61,581.25	$93,575.00
March 2023	15.50					53.25	96.75							20.75		1.00	1.00	188.25	$97,068.75	$141,681.25
April 2023	0.25					71.75	37.25		1.25					3.25				113.75	$65,206.25	$97,443.75
May 2023	6.00					26.25	380.00		26.75					1.25	3.25	0.75	1.50	445.75	$199,487.50	$248,167.50
June 2023	2.75				22.75	49.50	568.75		1.75				3.50	0.50	1.00		0.50	651.00	$300,881.25	$377,968.75
July 2023	33.25				31.25	105.00	669.75		2.00		0.25			0.75	4.25		2.25	848.75	$403,112.50	$508,737.50
August 2023	2.25				117.25	85.00	1,077.50	3.00	1.00					0.75	0.50	0.75	2.00	1,290.00	$588,837.50	$728,778.75
September 2023	3.75					147.50	1,425.75	253.75	13.00				1.75	2.50	3.25		8.25	1,859.50	$901,193.75	$1,121,775.00
October 2023	7.50				0.75	150.75	1,722.50	595.75	42.25					7.50	3.25	0.25	1.50	2,532.00	$1,172,837.50	$1,422,087.50
November 2023	0.25				2.50	165.50	1,845.50	524.50	2.50				2.50	14.25	1.75	0.25	2.50	2,562.00	$1,193,162.50	$1,427,240.00
December 2023	11.25				92.50	172.75	2,345.25	334.00	319.75				17.50	18.00	0.75	0.25	0.75	3,312.75	$1,496,906.25	$1,789,143.75
January 2024	0.25				435.75	192.50	2,283.75	590.25	447.50				369.75	21.00	4.50	2.50	2.25	4,350.00	$2,160,876.25	$2,554,958.75
February 2024	8.25				185.75	189.50	2,342.50	411.50	10.00		2.00		144.00	29.50		0.50	17.25	3,340.75	$1,606,950.00	$1,849,723.75
March 2024					139.50	92.50	2,172.25	786.00	4.00	5.00			1.00	26.50	15.00	0.25	0.50	3,242.50	$1,552,872.50	$1,807,551.25
April 2024	0.50				39.25	103.50	2,018.25	617.50	6.00				1.00	35.25		0.50	0.50	2,822.25	$1,354,240.00	$1,567,140.00
May 2024	1.50				0.75	74.25	1,459.75	600.25	75.00				4.25	14.25	6.75	1.00	0.50	2,238.25	$1,081,093.75	$1,258,487.50
June 2024	4.50				8.00	131.25	1,214.50	318.25	275.25		1.75		1.75	5.00	1.75	0.25	0.75	1,963.00	$962,906.25	$1,125,048.75
July 2024	0.25				7.50	175.25	901.25	1,137.25	400.50		0.75			15.00		0.25		2,638.00	$1,423,357.50	$1,731,737.50
August 2024					3.75	130.50	559.50	1,371.00	649.00					9.50	1.00	0.25		2,724.50	$1,521,302.50	$1,854,373.75
September 2024					4.75	102.50	213.50	202.50	1,351.50		417.75		1.25	22.75	1.50		2.50	2,320.50	$1,268,828.75	$1,552,180.00

EXHIBIT 8

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Category Lodestar Chart by Month
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

MONTH	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	LODESTAR AT HISTORIC RATE	LODESTAR AT CURRENT RATE
October 2024					6.25	13.00	104.75	103.50	820.75		1,571.50			6.75	10.25	0.50		2,637.25	$1,530,173.75	$1,919,881.25
November 2024	0.25				1.00	1.25	16.50		2,639.25		5.00			4.25				2,667.50	$1,498,483.75	$1,872,731.25
December 2024					0.75	1.00	13.75	18.25	2,283.00		0.25			16.75	8.25			2,342.00	$1,357,638.75	$1,732,356.25
January 2025					4.75	2.50	5.00	1.25	2,342.50		83.75		7.75	9.75		0.25		2,457.50	$1,639,460.00	$1,746,581.25
February 2025					2.00		15.00		1,193.75	2.50	175.75		2.50	1.25	2.50			1,395.25	$982,832.50	$1,048,600.00
March 2025								0.75	1,374.75	56.50	183.25			10.75	0.75			1,626.75	$1,226,821.25	$1,322,912.50
April 2025									436.00	165.00	345.00		1.50	10.00				957.50	$622,247.50	$659,131.25
May 2025					0.25		1.75		0.75	490.00	101.75		7.25	15.75	7.00			624.50	$407,807.50	$435,818.75
June 2025							2.25			1,086.00	585.50		21.25	15.00	4.25			1,714.25	$1,377,405.00	$1,482,306.25
July 2025	0.25									464.00	651.75			14.50	2.25			1,132.75	$769,335.00	$824,443.75
August 2025									6.00	238.75	324.25	117.50	0.50	5.75	16.00		1.75	710.50	$591,631.25	$637,787.50
September 2025												97.50	1.00	7.25				105.75	$82,502.50	$88,912.50
October 2025												148.50		0.25				148.75	$130,285.00	$141,475.00
November 2025												265.75		1.75				267.50	$245,442.50	$267,231.25
December 2025												614.50		2.25			0.50	617.25	$583,337.50	$632,250.00
January 2026												125.75	34.50	3.50	0.50			164.25	$153,706.25	$153,706.25
February 2026													43.00	1.25	0.50		0.50	45.25	$50,318.75	$50,318.75
March 2026													46.00	1.75	0.50			48.25	$46,637.50	$46,637.50
April 2026													19.00	3.75	24.00			46.75	$52,750.00	$52,750.00
May 2026													210.75	2.50	83.50			296.75	$366,750.00	$366,750.00
June 2026													16.50	1.75	0.50			18.75	$20,537.50	$20,537.50
July 2026													4.25	0.50				4.75	$5,106.25	$5,106.25
August 2026													30.00	0.50				30.50	$32,381.25	$32,381.25
TOTAL	**664.50**	**301.25**	**566.50**	**495.50**	**1,107.00**	**2,265.00**	**23,513.25**	**7,869.25**	**14,728.25**	**2,507.75**	**4,450.25**	**1,369.50**	**994.00**	**416.75**	**217.00**	**22.00**	**200.75**	**61,688.50**	**$34,304,506.25**	**$40,480,287.50**

Exhibit 9

EXHIBIT 9

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Category Lodestar Chart by Timekeeper
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	LODESTAR AT HISTORIC RATE	LODESTAR AT CURRENT RATE
Abe Alexander - Partner	45.50		108.25	115.00	133.00	596.75	93.50	995.75	906.75		259.75		79.50	5.25	2.00		6.25	3,347.25	$3,181,081.25	$4,351,425.00
Scott Foglietta - Partner	7.00	41.25															12.75	61.00	$50,325.00	$91,500.00
Salvatore Graziano - Partner	1.00		24.25	9.25	5.25	3.50		1.00	179.25	14.25	31.75	3.00	68.50	3.75	8.75		0.50	354.00	$532,150.00	$637,200.00
Robert Kravetz - Partner									55.25	15.00	65.50	182.50	50.75	0.25	36.50			405.75	$495,625.00	$527,475.00
Hannah Ross - Partner		2.50		3.50	4.25	27.75	5.50	15.00					3.00		2.25		9.25	73.00	$83,525.00	$131,400.00
Gerald Silk - Partner	3.00	12.00		5.00											1.00			21.00	$24,450.00	$37,800.00
Katherine Sinderson - Partner									451.25	22.25	1.50		3.75	0.50	12.50			491.75	$644,950.00	$786,800.00
Jorge Tenreiro - Partner									2.75	27.25	212.50	331.25	22.00		17.50			613.25	$741,650.00	$797,225.00
Jonathan D. Uslaner - Partner					115.50	249.00	148.75	625.00	948.00	354.25	244.50	58.75	167.00	17.00	33.50		24.75	2,986.00	$3,626,900.00	$4,777,600.00
Shane Avidan - Senior Counsel									110.00	143.25	188.00	240.25	6.75		31.00			719.25	$724,275.00	$791,175.00
Lauren Cruz - Senior Counsel	11.50		149.50	173.25	124.00	232.50	263.75	495.25	594.50	5.00	162.25		41.75	1.50	3.50		15.50	2,273.75	$1,773,106.25	$2,273,750.00
David L. Duncan - Senior Counsel					30.75								119.75		3.00			153.50	$162,143.75	$168,850.00
John Esmay - Senior Counsel									743.75	157.50	177.50	118.00	14.75	2.25	11.75			1,225.50	$1,179,043.75	$1,348,050.00
John Mills - Senior Counsel													25.00					25.00	$26,200.00	$27,500.00
Caitlin Bozman - Associate				88.50	215.75	260.25	132.25	26.50	78.75				64.25	3.00	0.50			869.75	$437,606.25	$695,800.00
James Briggs - Associate				21.00		31.25	893.75	1,557.25	1,257.25	305.25	343.00	89.00	87.00		15.00			4,599.75	$2,250,000.00	$2,989,837.50
Girolamo Brunetto - Associate	7.25	134.25															117.75	259.25	$136,106.25	$226,843.75
Stephen Boscolo - Associate					98.50	433.25	229.25	51.00	244.25		22.00		15.75	3.75	4.50		2.00	1,104.25	$557,325.00	$772,975.00
Chloe Jasper - Associate					128.50	142.25	161.75	95.75	925.25	70.00	181.75		17.75	3.75	18.50		2.00	1,747.25	$968,400.00	$1,223,075.00
Yando Peralta - Associate			64.75															64.75	$30,787.50	$32,375.00
Lawrence Hosmer - Sr. Staff Atty.						3.75	233.25	20.25	3.25									260.50	$117,225.00	$136,762.50
Ryan McCurdy - Sr. Staff Atty.						0.75	89.75	83.50	1,017.75	496.50	617.25	12.00			3.50			2,321.00	$1,110,285.00	$1,218,525.00
Damien Puniello - Sr. Staff Atty.						19.25	39.25	19.25	848.50		178.25							1,104.50	$507,622.50	$579,862.50
Zvi Bar-Kochba - Staff Atty.						1.00	746.50	12.00	30.50									790.00	$302,757.50	$335,750.00
Isabelle Bowers - Staff Atty.							1,875.00	166.50	27.25									2,068.75	$789,516.25	$796,468.75
Daniel Cedrone - Staff Atty.							653.75											653.75	$277,843.75	$277,843.75
Jonathan Cohen - Staff Atty.						3.75	1,651.50	171.75	743.00		112.75		16.75					2,699.50	$1,103,433.75	$1,147,287.50
Igor Faynshteyn - Staff Atty.							680.25	419.25	66.00									1,165.50	$495,337.50	$495,337.50
Sascha Goergen - Staff Atty.						10.00	2,237.00	10.00	20.00									2,277.00	$967,725.00	$967,725.00
Steffanie Keim - Staff Atty.							368.75	9.50										378.25	$160,756.25	$160,756.25
Shammari Khan - Staff Atty.							338.00		27.00									365.00	$155,125.00	$155,125.00
Paul Lim - Staff Atty.							1,441.25											1,441.25	$612,531.25	$612,531.25
Tiffany Michael - Staff Atty.							1,240.50	13.00					1.00					1,254.50	$533,162.50	$533,162.50
Emily Nalven - Staff Atty.					16.25		399.00	134.00	8.00									557.25	$226,822.50	$228,472.50
Yeruchem Neiman - Staff Atty.							1,185.00											1,185.00	$503,625.00	$503,625.00
Rodney Nutt - Staff Atty.							382.75											382.75	$162,668.75	$162,668.75
John Pate - Staff Atty.							1,915.75	25.25	4.00				4.00					1,949.00	$786,925.00	$799,090.00
Mark Paul - Staff Atty.							916.25											916.25	$366,500.00	$366,500.00
Priscilla Pellecchia - Staff Atty.							1,104.25	1,142.25	1,117.00	318.50	713.50		49.00		1.00			4,445.50	$1,828,976.25	$2,000,475.00
Kirstin Peterson - Staff Atty.						15.00	1,598.00	124.25	829.75		227.25							2,794.25	$1,192,550.00	$1,327,268.75
Joanna Tarnawski - Staff Atty.							1,586.50	924.00	1,467.25	147.25	329.50		52.00					4,506.50	$1,851,342.50	$2,027,925.00

EXHIBIT 9

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

Bernstein Litowitz Berger & Grossmann LLP
Category Lodestar Chart by Timekeeper
Inception - August 31, 2026

Category Codes:

1. Invesgiation & Pre-Filing Case Analysis
2. Lead Plaintiff Motion
3. Complaint
4. Motion to Dismiss Opposition
5. Class Certification
6. Discovery - General, Commc'ns & Disputes
7. Written/Document Discovery
8. Fact Depositions
9. Experts
10. Summary Judgment Motions
11. Pre-Trial Motions & Trial Prep
12. Appeal
13. Mediation & Settlement
14. Case Management
15. Strategy & Analysis
16. Docket/News Monitoring
17. Client Communications

TIMEKEEPER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	TOTAL SUM OF HOURS	LODESTAR AT HISTORIC RATE	LODESTAR AT CURRENT RATE
Adam Weinschel - Fin. Analyst	13.00	18.00				0.50	2.00	1.00										34.50	$19,150.00	$22,425.00
Milana Babic - Fin. Analyst	40.00	4.00																44.00	$17,600.00	$18,700.00
Tanjila Sultana - Fin. Analyst	44.00						1.00											45.00	$19,525.00	$24,750.00
Andrew Thompson - Fin. Analyst	44.00																	44.00	$17,600.00	$25,300.00
Amy Bitkower - Dir. of Investigations	56.00										0.25							56.25	$33,037.50	$36,562.50
John Deming - Senior Investigator	148.25																	148.25	$62,275.00	$74,125.00
Jacob Foster - Investigator	102.25																	102.25	$32,943.75	$40,900.00
Gary Weston - Dir. of Paralegals	1.50			0.50	3.00	0.50	3.00	3.00	8.50	1.25	1.00	3.50	2.75	7.75				36.25	$15,700.00	$17,218.75
Cindy Bomzer-Stein - Case Manager	20.75		118.00	15.00	19.25	18.25	125.25	52.00	222.75	75.25	47.00	125.00	10.50	17.50	0.50	11.00		878.00	$323,325.00	$395,100.00
Khristine De Leon - Case Manager		43.50						0.50						0.25			5.75	50.00	$16,275.00	$22,500.00
Jay Layfield - Case Manager											21.50							21.50	$9,137.50	$9,137.50
Matthew Mahady - Case Manager	3.25	45.75			0.50										1.50		4.25	55.25	$19,387.50	$24,862.50
Toby Saviano - Case Manager				17.50	4.00	2.00	7.25	44.75	131.75	71.00	37.00	6.50	3.75	2.75	2.50			330.75	$134,887.50	$148,837.50
Yulia Tsoy - Case Manager									17.00									17.00	$5,525.00	$7,225.00
Melody Yaghoubzadeh - Case Manager	88.50		97.25	33.50	122.00	121.50	254.00	317.75	638.50	139.25	128.00	133.25	53.25	41.75	4.00	8.50		2,181.00	$872,975.00	$981,450.00
Annemarie Eames - Paralegal				3.00	59.00	47.75	148.00	246.50	853.00	97.00	127.00		1.25	21.50	2.00	2.50		1,608.50	$535,200.00	$562,975.00
Ryan McCarthy - Paralegal												59.25	1.00					60.25	$21,450.00	$22,593.75
Nathan Vickers - Paralegal	18.50																	18.50	$6,012.50	$6,012.50
Paul Charlotin - Lit. Support	7.50						21.00	2.50	3.25		4.00							38.25	$15,925.00	$18,168.75
Roberto Santamarina - Lit. Support	1.00						285.50	12.75	50.25		4.00							353.50	$164,006.25	$185,587.50
Julio Velazquez - Lit. Support							22.00	50.25	73.50	2.00	6.75			0.25				154.75	$66,693.75	$73,506.25
Mahiri Buffong - Managing Clerk			4.50	2.00	9.00	12.50	8.75	0.50	2.25	23.75	0.75	4.75	3.00	160.50				232.25	$105,393.75	$116,125.00
Janielle Lattimore - Asst. Man. Clerk	0.75			8.50	18.50	30.50	20.75	0.50	20.50	21.00	4.00	0.25	8.00	27.75	0.25			161.25	$69,193.75	$76,593.75
Jessica Lacon - Docket Clerk						1.50	4.00		0.75	1.00	0.50	2.25	0.50	95.75				106.25	$42,906.25	$47,812.50
TOTAL	**664.50**	**301.25**	**566.50**	**495.50**	**1,107.00**	**2,265.00**	**23,513.25**	**7,869.25**	**14,728.25**	**2,507.75**	**4,450.25**	**1,369.50**	**994.00**	**416.75**	**217.00**	**22.00**	**200.75**	**61,688.50**	**$34,304,506.25**	**$40,480,287.50**

Exhibit 10

EXHIBIT 10

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP

SUMMARY OF EXPENSES BY CATEGORY

CATEGORY	AMOUNT
Court Fees	$3,927.00
Service of Process	$9,389.84
Factual Research	$83,545.56
Legal Research	$266,493.68
Telephone & Faxes	$888.34
Postage & Express Mail	$7,250.30
Hand Delivery Charges	$1,369.25
Document Hosting & Management	$179,994.60
Local Transportation	$12,383.20
Outside Copying & Printing	$55,865.01
Discovery Costs	$20,000.00
Out-of-Town Travel	$149,712.13
Working Meals	$5,866.86
Court Reporting & Transcripts	$200,378.42
Software	$1,075.00
Experts & Consultants	$3,571,480.31
Independent Witness Counsel	$168,021.39
Rule 54(d)(1) Taxable Costs	$139,246.01
Mediation Fees	$21,250.00
TOTAL:	**$4,898,136.90**

Exhibit 11

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Expense	Date	Expense Amount
Type of Expense - Court Fees		
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; 2022-02-02 (2369-001) Motion For Leave To Appear In Pro Hac Vice - A. Alexander	2/2/2022	$317.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; 2022-02-02 (2369-001) Motion For Leave To Appear In Pro Hac Vice - S. Graziano	2/2/2022	$317.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; 2022-02-02 (2369-001) Motion For Leave To Appear In Pro Hac Vice - Y. Peralta	2/2/2022	$317.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; 2023-03-10 (2369-001) MOTION for leave to appear in Pro Hac Vice - S. Boscolo	3/10/2023	$317.00
Supreme Court of California Check No. 1151	12/4/2023	$1.00
AMEX. U.S. COURT OF APPEA SAN FRANCISCO CA; Professional Membership Dues; U.S. Court of Appeals – 9th Circuit admission	3/28/2024	$230.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; US DISTRICT COURT ND - Motion for Leave to Appear in Pro Hac Vice	12/10/2024	$328.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; Pro hac vice admission	12/10/2024	$328.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; US DISTRICT COURT ND - Motion for Leave to Appear in Pro Hac Vice	5/20/2025	$328.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; Pro Hac Vice application fee	6/30/2025	$328.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; US DISTRICT COURT ND - PHV for Jorge Teniero	6/23/2025	$328.00
AMEX. US DISTRICT COURT ND SAN FRANCISCO CA; Court Fees; Motion to appear pro hac vice	5/20/2025	$328.00
AMEX. U.S. COURT OF APPEA SAN FRANCISCO CA; Court Fees; Court Fee - Admission application	1/5/2026	$230.00
AMEX. U.S. COURT OF APPEA SAN FRANCISCO CA; Court Fees; U.S. COURT OF APPEA - admission application	1/5/2026	$230.00
Total Court Fees		**$3,927.00**

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Type of Expense - Service of Process		
Nationwide Legal, LLC Check No. 33859	8/4/2021	$142.75
AMEX. PAYPAL *CSA 4029357733 OH; Subpoena Service	6/5/2023	$125.00
AMEX. STAX *KAUNDRE JUDI BOWIE MD; Subpoena Service - LVM Pharma	6/21/2023	$80.00
AMEX. ATTORNEY SUPPORT GRO Boston MA; Subpoena service on Lee S. Simon	6/26/2023	$135.00
AMEX. MIDDLESEX CONSTABLE Nashua NH; Subpoena service (J. Niles & J. Stone) Invoice (No. 2023-18372) from MIDDLESEX	6/28/2023	$158.40
AMEX. INTERCEPTOR LEGAL SU OAKLAND CA; Subpoena Service - Curtis Scribner	6/30/2023	$119.03
AMEX. SWIFT ATTORNEY SERVI REDWOOD CITY CA; Service of Process - C. Wang	7/13/2023	$133.90
AMEX. NATIONWIDE-INVESTIGA CHICAGO IL; Court Fees; (2369-001) Subpoena service to Katie Deering	7/17/2023	$110.00
AMEX. AMERISERVE, LLC Brick NJ; Subpoena Service	7/21/2023	$75.00
Nationwide Legal, LLC Check No. 38199	8/8/2023	$105.30
Snappy Process Services Check No. 38281	8/16/2023	$125.00
Official Serves LLC Check No. 38301	8/29/2023	$125.00
Nationwide Legal, LLC Check No. 38368	9/13/2023	$124.55
The Legal Rush LLC Check No. 38365	9/13/2023	$360.00
Middlesex Constable Service Check No. 38583	10/25/2023	$158.40
Nationwide Legal, LLC Check No. 38712	11/15/2023	$471.60
AMEX. DE NOVO ATTORNEY SER BALTIMORE MD; Subpoena Service	12/14/2023	$85.00
Aqua Legal, LLC Check No. 38907	12/20/2023	$364.58
Nationwide Legal, LLC Check No. 38973	1/3/2024	$2,056.35
Court Support Inc. Check No. 39000	1/10/2024	$934.00
Court Support Inc. Check No. 39000	1/10/2024	$293.80
Lightning Legal Process Service LLC Check No. 39055	1/18/2024	$165.00
The Legal Rush LLC Check Nos. 39079, 39080	1/18/2024	$85.00
Nationwide Legal, LLC Check No. 39441	3/20/2024	$463.20
Nationwide Legal, LLC Check No. 39441	3/20/2024	$637.70
Nationwide Legal, LLC Check No. 39441	3/20/2024	$393.40
AMEX. WWW.ACCURATESERVEPLA FORT MYERS FL; Subpoena Service to Raymond James Financial	4/30/2024	$169.00
Wally Enterprises, Inc. HPS Process Service & Investigations Check No. 39702	5/8/2024	$112.00
Court Support Inc. Check No. 39931	6/18/2024	$190.80
Court Support Inc. Check No. 40136	7/31/2024	$251.08
The Legal Rush LLC Check No. 40148	7/31/2024	$320.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

The Legal Rush LLC Check No. 40196	8/13/2024	$95.00
The Legal Rush LLC Check No. 40196	8/13/2024	$225.00
Total Service of Process		**$9,389.84**
Type of Expense - Factual Research		
Refinitiv US LLC Check No. 33722	6/30/2021	$7,422.09
Refinitiv US LLC Check No. 33967	9/8/2021	$2,136.98
Refinitiv US LLC Check No. 34067	9/29/2021	$464.56
PACER Service Center Check No. 34157	10/20/2021	$70.60
Refinitiv US LLC Check No. 34212	11/3/2021	$3,635.43
LexisNexis Risk Data Management Inc Check No. 34238	11/10/2021	$11.43
Refinitiv US LLC Check No. 34323	12/8/2021	$622.80
LexisNexis Risk Data Management Inc Check No. 34382	12/15/2021	$22.86
PACER Service Center Check No. 34569	1/19/2022	$0.40
AMEX. FOOD & DRUG AMIN-FIN ROCKVILLE MD; Transcripts; Documents provided under the FOIA request for ChemoCentryx	1/25/2022	$69.00
Refinitiv US LLC Check No. 34600	1/26/2022	$240.15
LexisNexis Risk Data Management Inc Check No. 34653	2/16/2022	$25.34
AMEX. FOOD & DRUG AMIN-FIN ROCKVILLE MD; Transcripts; FOIA Request for documents	2/22/2022	$74.75
LexisNexis Risk Data Management Inc Check Nos. 34806, 34835	3/16/2022	$45.73
PACER Service Center Check No. 35088	3/31/2022	$15.30
PACER Service Center Check No. 35088	3/31/2022	$45.80
AMEX. FOOD & DRUG AMIN-FIN ROCKVILLE MD; Transcripts; Request for documents from FDA	4/13/2022	$26.50
AMEX. BT*HEALTH AFFAIRS WASHINGTON DC; Online Report Order	6/21/2022	$21.00
CalendarRules.com LLC Check No. 35354	6/22/2022	$45.00
Court Alert.com Inc Check No. 35375	6/29/2022	$173.26
Bureau of National Affairs Check No. 35504	7/27/2022	$1,201.26
PACER Service Center Check No. 35518	7/27/2022	$31.50
Refinitiv US LLC Check No. 35519	7/27/2022	$46.84
Refinitiv US LLC Check No. 35519	7/27/2022	$1,494.95
Refinitiv US LLC Check No. 35519	7/27/2022	$231.16
Refinitiv US LLC Check No. 35550	8/3/2022	$91.48
Refinitiv US LLC Check No. 35550	8/3/2022	$15.41
CourtAlert.com Inc. Check No. 35569	8/10/2022	$3.13
PACER Service Center Check No. 35917	10/19/2022	$6.30
Bureau of National Affairs Check Nos. 35973, 35974	10/26/2022	$1,201.26
AMEX. FOOD & DRUG AMIN-FIN ROCKVILLE MD; payment to FDA for FOIA request	2/6/2023	$136.00
Bureau of National Affairs Check No. 36617	3/8/2023	$1,201.26

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Bureau of National Affairs Check No. 36840	4/19/2023	$1,201.26
PACER Service Center Check No. 36910	4/26/2023	$45.60
Refinitiv US LLC Check No. 37080	5/31/2023	$993.45
Court Alert.com Inc Check No. 37156 Date: 06/14/23	6/14/2023	$9.68
Court Alert.com Inc Check No. 38072 Date: 07/19/23	7/12/2023	$41.87
Bureau of National Affairs Check No. 38069	7/19/2023	$1,201.26
PACER Service Center Check No. 38125	7/26/2023	$44.50
AMEX. NJ BUSINES SERVICES TRENTON NJ - Business Records Service	8/8/2023	$6.25
Court Alert.com Inc Check No. 38226	8/16/2023	$20.35
LexisNexis Risk Data Management Inc Check No. 38366	9/13/2023	$6.51
AMEX. TEXAS SECRETARY OF STATE SVC HAGERSTOWN MD - Online Research	9/19/2023	$0.16
AMEX. TEXAS SECRETARY OF STATE, AUSTIN TX - Online Research	9/19/2023	$6.00
PACER Service Center Check No. 38546	10/18/2023	$269.20
Bureau of National Affairs Check No. 38644	11/8/2023	$1,201.26
Court Alert.com Inc Check No. 38740	11/28/2023	$57.51
Court Alert.com Inc Check No. 38874	12/13/2023	$393.07
AMEX. CHESS DIGITAL Chess LONDON - journal article for discovery research	12/20/2023	$56.62
Bureau of National Affairs Check No. 39037	1/17/2024	$1,236.89
PACER Service Center Check No. 39106	1/24/2024	$237.60
Court Alert.com Inc Check No. 39196	2/14/2024	$276.19
AMEX. CHESS DIGITAL Chess LONDON - scientific article for use in discovery	3/13/2024	$59.88
CalendarRules.com LLC Check No. 39538	4/10/2024	$139.72
Court Alert.com Inc Check No. 39592	4/17/2024	$136.06
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Scientific article pulling	4/17/2024	$39.95
The Bureau of National Affairs Check No. 39645	4/23/2024	$1,236.89
PACER Service Center Check No. 39662	4/23/2024	$143.50
Court Alert.com Inc Check No. 39774	5/22/2024	$65.31
Refinitiv US LLC Check No. 39795	5/22/2024	$2,418.39
Refinitiv US LLC Check No. 39795	5/22/2024	$536.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - bought a scientific journal for discovery	5/28/2024	$59.28
Bureau of National Affairs Check No. 39923	6/18/2024	$130.65
Refinitiv US LLC Check No. 40012	7/3/2024	$252.19
Refinitiv US LLC Check No. 40012	7/3/2024	$267.00
Refinitiv US LLC Check No. 40043	7/10/2024	$309.21
PACER Service Center Check Nos. 40113, 40123	7/24/2024	$95.00
Refinitiv US LLC Check Nos. 40115, 40125	7/24/2024	$16.83
The Bureau of National Affairs Check No. 40167	8/13/2024	$1,236.89
Court Alert.com Inc Check No. 40225	8/20/2024	$44.13

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Court Alert.com Inc Check No. 40341	9/18/2024	$73.49
PACER Service Center Check No. 40536	10/23/2024	$86.70
AMEX. AMERICAN COLLEGE OF PHILADELPHIA PA; Book - publication	10/29/2024	$35.00
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/29/2024	$39.95
AMEX. MARY ANN LIEBERT INC NEW ROCHELLE NY; Book - publication	10/29/2024	$51.00
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Books / Publications; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/29/2024	$59.28
AMEX. ELSEVIER ST LOUIS US - purchased online article for expert	10/30/2024	$106.59
AMEX. AMERICAN SOCIETY-PHA ROCKVILLE MD - purchased online article for expert	10/30/2024	$35.00
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US - purchased online article for expert	10/30/2024	$39.95
AMEX. SAGE PUBLICATIONS 805-499-9774 CA - purchased online article for expert	10/30/2024	$41.50
AMEX. MARY ANN LIEBERT INC NEW ROCHELLE NY - purchased online article	10/30/2024	$51.00
AMEX. ELSEVIER ST LOUIS US; Book - publication	10/30/2024	$24.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	10/30/2024	$24.95
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/30/2024	$29.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	10/30/2024	$34.30
AMEX. ELSEVIER ST LOUIS US; Book - publication	10/30/2024	$39.14
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/30/2024	$39.95
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/30/2024	$39.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/30/2024	$39.95
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	10/30/2024	$39.95
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$48.88
AMEX. Wiley Hoboken US; Books / Publications; Book - publication	10/30/2024	$49.00
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/30/2024	$65.52
AMEX. ELSEVIER ST LOUIS US; Book-publication	10/30/2024	$27.95
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - purchased online journal article	10/31/2024	$48.88
AMEX. Wiley Hoboken US - purchased online article	10/31/2024	$59.00
AMEX. INFORMA UK (DBA TAYL SARASOTA FL - purchased online article	10/31/2024	$70.77
AMEX. Spinger Nature - expert report materials for Chem	10/31/2024	$29.95
AMEX. Wiley Hoboken US - expert report materials for ChemoCentryx	10/31/2024	$49.00
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	10/31/2024	$27.16
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	10/31/2024	$34.30
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	10/31/2024	$34.30
AMEX. ELSEVIER ST LOUIS US; Book - publication	10/31/2024	$34.30
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	10/31/2024	$34.30
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. WWW.SPRINGER.COM US; Book - publication	10/31/2024	$39.95
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	10/31/2024	$43.50
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. ELSEVIER INC NEW YORK NY; Book-publication	10/31/2024	$24.95
AMEX. ELSEVIER ST LOUIS US; Book-publication	10/31/2024	$31.50
AMEX. ELSEVIER INC NEW YORK NY; Book-publication	10/31/2024	$31.50
AMEX. ELSEVIER INC NEW YORK NY; Book-publication	10/31/2024	$34.30
AMEX. ELSEVIER INC NEW YORK NY; Book-publication	10/31/2024	$34.30
AMEX. ELSEVIER ST LOUIS US; Book-publication	10/31/2024	$34.30
AMEX. WOLTERS KLUWERHEALTH 301-223-2300 MD; Book - publication	10/31/2024	$35.00
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book-publication	10/31/2024	$48.88
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	10/31/2024	$65.52
AMEX. ELSEVIER ST LOUIS US - expert report materials for ChemoCentryx	11/1/2024	$34.30
AMEX. Spinger Nature - expert report materials for Chem	11/1/2024	$39.95
AMEX. PAYPAL *ITHAKAHARBO 2123586488 NY; Book - publication	11/1/2024	$14.00
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/1/2024	$27.95
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	11/1/2024	$30.43
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	11/1/2024	$30.43
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/1/2024	$35.95
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	11/1/2024	$39.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication	11/1/2024	$39.95
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$40.00
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$42.00
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$43.55
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$43.55
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$43.55
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	11/1/2024	$48.88
AMEX. Wiley Hoboken US; Books / Publications; Book - publication	11/1/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$59.00
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	11/1/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	11/1/2024	$59.28
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$130.65
AMEX. ELSEVIER INC NEW YORK NY; Book - publication	11/1/2024	$39.14
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$43.55
AMEX. JOURNALS 800-621-8335 IL; Book - publication	11/1/2024	$43.55
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/1/2024	$45.18
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/1/2024	$59.00
AMEX. ACS ARTICLES ON COMM WASHINGTON DC; ACS ARTICLES - expert report materials for ChemoCentryx	11/2/2024	$48.00
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$27.16
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$27.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$31.50
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$39.14
AMEX. WWW.PSYCHIATRIST.COM MEMPHIS TN; Book - publication	11/2/2024	$80.00
AMEX. ELSEVIER ST LOUIS US; Book-publication	11/2/2024	$24.95
AMEX. ELSEVIER ST LOUIS US; Book-publication	11/2/2024	$27.95
AMEX. ELSEVIER ST LOUIS US; Book-publication	11/2/2024	$30.43
AMEX. ELSEVIER ST LOUIS US; Book-publication	11/2/2024	$31.50

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$35.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/2/2024	$35.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/3/2024	$109.92
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US - pay-per-view articles	11/3/2024	$239.70
AMEX. Wiley Hoboken US - expert report materials for ChemoCentryx	11/4/2024	$10.00
AMEX. Spinger Nature - expert report materials for Chem	11/4/2024	$39.95
AMEX. ELSEVIER ST LOUIS US - expert report materials for ChemoCentryx	11/4/2024	$43.50
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book-publication	11/4/2024	$101.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$42.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$42.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$49.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/4/2024	$59.00
AMEX. ELSEVIER INC NEW YORK NY - purchased online journal article related to an expert	11/5/2024	$39.14
AMEX. ELSEVIER INC NEW YORK NY - purchased online journal article related to an expert	11/5/2024	$41.32
Bureau of National Affairs, Invoice 6888464136	11/6/2024	$1,236.89
AMEX. RPRNTS DESK 3104770354 NV - Article related to an expert	11/6/2024	$100.95
AMEX. RPRNTS DESK 3104770354 NV; - Article related to an expert	11/6/2024	$100.95
AMEX. RPRNTS DESK 3104770354 NV - Article related to an expert	11/6/2024	$100.95
AMEX. ELSEVIER ST LOUIS US - Article related to an expert	11/6/2024	$30.43
AMEX. ELSEVIER ST LOUIS US - Article related to an expert	11/6/2024	$30.43
AMEX. ELSEVIER ST LOUIS US - Article related to an expert	11/6/2024	$30.43
AMEX. ELSEVIER ST LOUIS US - purchased online journal article related to an expert	11/6/2024	$30.43
AMEX. ELSEVIER ST LOUIS US - purchased online journal article related to an expert	11/6/2024	$38.05
AMEX. WWW.SPRINGER.COM US - Article related to an expert	11/6/2024	$39.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. WWW.SPRINGER.COM WWW US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. WWW.SPRINGER.COM US - purchased online journal article related to an expert	11/6/2024	$39.95
AMEX. ELSEVIER ST LOUIS US - purchased online journal article related to an expert	11/6/2024	$41.32
AMEX. ELSEVIER ST LOUIS US - purchased online journal article related to an expert	11/6/2024	$41.32
AMEX. Wiley Hoboken US - Article related to an expert	11/6/2024	$42.00
AMEX. Wiley Hoboken US; On-Line Research Services; Wiley Hoboken - Article related to an expert	11/6/2024	$42.00
AMEX. Wiley Hoboken US - Article related to an expert	11/6/2024	$59.00
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/6/2024	$59.00
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/6/2024	$59.00
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/6/2024	$59.00
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/6/2024	$59.00
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/6/2024	$59.00
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$59.28
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$65.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - Article related to an expert	11/6/2024	$65.52
AMEX. VITALSOURCE RALEIGH NC - online article purchased for expert	11/6/2024	$56.39
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA; Book - publication	11/6/2024	$59.28
AMEX. Wiley Hoboken US - purchased online journal article related to an expert	11/7/2024	$42.00
Court Alert.com Inc Check No. 40629	11/13/2024	$15.55
AMEX. CHESS DIGITAL Chess LONDON; CHESS DIGITAL - expert report materials for ChemoCentryx	11/20/2024	$89.28
AMEX. AMAZON.COM*FT0YM5X53 AMZN.COM/BILL WA; Book - publication	11/23/2024	$54.59
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - expert report materials for ChemoCentryx	11/25/2024	$59.28
AMEX. WWW.SPRINGER.COM WWW UNITED STATES US; Book - publication - Current Hypertension Reports	11/25/2024	$39.95
AMEX. ELSEVIER ST LOUIS US; Book - publication	11/27/2024	$35.95
AMEX. JOURNALS 800-621-8335 IL; Book-publication	11/27/2024	$40.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
AMEX. Wiley Hoboken US; Book - publication	11/27/2024	$59.00
Check issued to AnneMarie Eames Check No. 100695 - Articles needed to support expert Alan Bonder	11/29/2024	$139.00
AMEX. AMERICAN COLLEGE OF PHILADELPHIA PA - Purchase Article from Annals for expert	12/3/2024	$35.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. AMZN MKTP US*ZL2BV6P AMZN.COM/BILL WA; Books / Publications; AMZN MKTP - book for CCXI (Primary Care: A Collaborative Practice, Buttaro PhD AGPCNP-BC FAANP FNAP,	12/3/2024	$29.90
AMEX. AMAZON MKTPL*ZL1374P AMZN.COM/BILL WA; Books / Publications; AMZN MKTP -Primary Care: A Collaborative Practice, Buttaro PhD AGPCNP-BC FAANP FNAP, Terry Mahan	12/4/2024	$13.52
AMEX. OVID LWW PPV JOURNAL 800-343-0064 MA - expert report materials	12/10/2024	$48.88
AMEX. UPTODATE SUBSCRPTION 781-392-2000 MA; Subscriptions; UPTODATE SUBSCRPTION	12/10/2024	$20.00
AMEX. ELSEVIER ST LOUIS US - expert report materials	12/12/2024	$45.18
AMEX. CHESS DIGITAL Chess LONDON - expert report materials	12/12/2024	$59.88
Check issued to AnneMarie Eames Check No. 100702 - Reimbursement for purchase of ChemoCentryx article	12/13/2024	$40.00
AMEX. ELSEVIER ST LOUIS US - expert report materials	12/13/2024	$34.30
AMEX. CHESS DIGITAL Chess LONDON - expert report materials	12/15/2024	$59.88
Court Alert.com Inc Check No. 40827	12/18/2024	$37.86
Refinitiv US LLC Check No. 40850	12/18/2024	$2,433.27
AMEX. WWW.SPRINGER.COM US - expert materials of Alan Bonder	12/20/2024	$39.95
AMEX. WWW.SPRINGER.COM US - expert materials of Alan Bonder	12/20/2024	$39.95
AMEX. WWW.SPRINGER.COM US - expert materials	12/23/2024	$39.95
AMEX. ELSEVIER INC NEW YORK NY - expert materials	12/24/2024	$50.03
AMEX. ELSEVIER INC NEW YORK NY - expert materials	12/24/2024	$50.03
AMEX. ELSEVIER INC NEW YORK NY - expert materials	12/27/2024	$45.18
Check issued to AnneMarie Eames Check No. 100706 Original Transaction 3379291	12/27/2024	$271.00
AMEX. INFORMA UK (DBA TAYL SARASOTA FL - purchase of plaintiff expert Marc Walton's published articles.	12/31/2024	$70.77
AMEX. AMERICAN COLLEGE OF PHILADELPHIA PA - materials for expert	1/2/2025	$35.00
AlphaSense Inc, Invoice #INV-226187	1/8/2025	$7.62
AMEX. Wiley Hoboken US - expert materials for Alan Bonder	1/14/2025	$62.00
PACER Service Center Check No. 40954	1/15/2025	$255.60
AMEX. ELSEVIER ST LOUIS US - expert deposition prep	1/15/2025	$38.05
AMEX. GOOGLE *PLAY BOOKS G.CO/HELPPAY# CA; Books / Publications; GOOGLE *PLAY BOOKS - Google play book for expert Bonder	1/15/2025	$51.99
AMEX. ELSEVIER ST LOUIS US -article for expert	1/17/2025	$31.50

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Court Alert.com Inc Check No. 40977	1/22/2025	$12.73
AMEX. WWW.SPRINGER.COM US - expert deposition prep	1/23/2025	$39.95
Check issued to AnneMarie Eames Check No. 100721 - Reimbursement for order of article from Official Journal of the American College of Gastroenterology for expert deposition of Naga Chalasani.	2/14/2025	$57.00
Refinitiv US LLC Check No. 41145	2/26/2025	$18,660.05
AMEX. ELSEVIER ST LOUIS US - purchased article for Chemocentryx	3/11/2025	$27.16
Court Alert.com Inc Check No. 41266	3/26/2025	$70.88
Court Alert.com Inc Check No. 41304	4/2/2025	$62.28
Court Alert.com Inc Check No. 41417	4/23/2025	$36.74
Bureau of National Affairs Check No. 41413	4/23/2025	$1,236.89
PACER Service Center Check No. 41471	4/30/2025	$166.10
Court Alert.com Inc Check No. 41563	5/21/2025	$102.23
Themis Solutions (USA) Inc. Check No. 41589	5/21/2025	$107.85
Court Alert.com Inc Check No. 41810	7/9/2025	$158.35
Bureau of National Affairs Check No. 41872	7/16/2025	$1,236.89
Court Alert.com Inc Check No. 41883	7/23/2025	$179.81
PACER Service Center Check No. 41932	7/30/2025	$1,325.30
Court Alert.com Inc Check Nos. 41992, 41994	8/20/2025	$57.87
Court Alert.com Inc Check No. 42132	9/17/2025	$82.27
Check issued to Jorge Tenreiro Check Nos. 42259, 42260 - reimbursement for article purchases	10/8/2025	$605.00
Bloomberg Finance LP Check No. 42296	10/15/2025	$1,236.89
Court Alert.com Inc Check No. 42340	10/22/2025	$48.56
PACER Service Center Check No. 42396	10/29/2025	$200.50
Court Alert.com Inc Check No. 42478	11/19/2025	$22.46
Court Alert.com Inc Check No. 42478	11/19/2025	$231.25
Court Alert.com Inc Check No. 42627	1/7/2026	$24.60
Court Alert.com Inc Check No. 42666	1/21/2026	$98.95
Bureau of National Affairs Check Nos. ACH-20260209-218, ACH-2026121-4A	1/21/2026	$1,536.89
PACER Service Center Check No. 42689	1/28/2026	$20.20
Court Alert.com Inc Check No. 42742	2/3/2026	$95.19
Court Alert.com Inc Check No. 42803	3/18/2026	$7.92
Court Alert.com Inc Check No. ACH-20260422-41	4/22/2026	$24.22
Bureau of National Affairs Check No. ACH-20260429-27	4/29/2026	$1,536.89
PACER Service Center Check No. 42868	4/29/2026	$89.80
Court Alert.com Inc Check No. ACH-20260506-38	5/6/2026	$72.93
Themis Solutions (USA) Inc. Check No. ACH-20260617-28	6/17/2026	$216.60
Bureau of National Affairs Check No. ACH-20260722-5	7/22/2026	$1,536.89

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Court Alert.com Inc Check No. ACH-20260722-17	7/26/2026	$10.74
PACER Service Center Check No. 42957	7/29/2026	$34.50
Court Alert.com Inc Check No. ACH-20260902-20	9/2/2026	$6.69
Total Factual Research		**$83,545.56**
Type of Expense - Legal Research		
Thomson Reuters Check No. 33778	7/14/2021	$171.48
Relx Inc DBA LexisNexis Check No. 33813	7/21/2021	$1,459.44
Relx Inc DBA LexisNexis Check No. 33888	8/11/2021	$17.81
Relx Inc DBA LexisNexis Check No. 33888	8/11/2021	$2.02
Thomson Reuters Check No. 33911	8/18/2021	$2.22
Thomson Reuters Check No. 33911	8/18/2021	$82.66
Thomson Reuters Check No. 33911	8/18/2021	$1,212.63
Relx Inc DBA LexisNexis Check No. 34014	9/15/2021	$64.51
Thomson Reuters Check No. 34041	9/22/2021	$315.62
Relx Inc DBA LexisNexis Check No. 34130	10/13/2021	$6.07
Relx Inc DBA LexisNexis Check No. 34130	10/13/2021	$19.26
Relx Inc DBA LexisNexis Check No. 34883	2/15/2022	$22.66
Relx Inc DBA LexisNexis Check No. 34883	2/15/2022	$4.12
Relx Inc DBA LexisNexis Check No. 35003	3/15/2022	$18.45
Relx Inc DBA LexisNexis Check No. 35003	3/15/2022	$1.42
Thomson Reuters Check No. 35102	2/15/2022	$8.37
Relx Inc DBA LexisNexis Check No. 35171	4/15/2022	$7.63
Relx Inc DBA LexisNexis Check No. 35337	6/22/2022	$25.17
Thomson Reuters Check No. 35336	6/22/2022	$1,225.63
Relx Inc DBA LexisNexis Check No. 35452	7/13/2022	$20.67
Thomson Reuters Check No. 35494	7/20/2022	$1,238.44
Relx Inc DBA LexisNexis Check No. 35598	8/10/2022	$26.78
Thomson Reuters Check No. 35861	10/5/2022	$2,826.68
Thomson Reuters Check No. 36106	11/22/2022	$742.99
Thomson Reuters Check No. 36441	2/1/2023	$0.08
Thomson Reuters Check No. 36601	3/1/2023	$552.26
Thomson Reuters Check No. 36748	3/29/2023	$325.35
Relx Inc DBA LexisNexis Check No. 36797	4/12/2023	$1,005.79
Thomson Reuters Check No. 36917	4/26/2023	$124.06
Relx Inc DBA LexisNexis Check No. 36978	5/10/2023	$1.94
Thomson Reuters Check No. 37079	5/31/2023	$451.17
Relx Inc DBA LexisNexis Check Nos. 37132, 37133	6/7/2023	$6.26
Relx Inc DBA LexisNexis Check No. 38093	6/30/2023	$184.98
Relx Inc DBA LexisNexis Check Nos. 38249, 38250	8/16/2023	$13.74
Thomson Reuters Check No. 38284	8/22/2023	$2,020.31
Relx Inc DBA LexisNexis Check No. 38408	9/13/2023	$16.74
Thomson Reuters Check No. 38344	11/1/2023	$1,596.79

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Thomson Reuters Check No. 38410	9/20/2023	$2,991.13
Relx Inc DBA LexisNexis Check No. 38586	10/19/2023	$45.95
Thomson Reuters Check No. 38557	10/18/2023	$703.08
Relx Inc DBA LexisNexis Check No. 38795	11/22/2023	$336.08
Thomson Reuters Check No. 38727	11/15/2023	$1,118.09
Relx Inc DBA LexisNexis Check No. 38936	12/20/2023	$16.15
Thomson Reuters Check No. 38940	12/20/2023	$4,495.01
Relx Inc DBA LexisNexis Check No. 39066	1/17/2023	$165.72
Thomson Reuters Check No. 39112	1/24/2024	$3,656.53
Relx Inc DBA LexisNexis Check No. 39225	2/14/2024	$121.34
Thomson Reuters Check No. 39269	2/21/2024	$8,471.72
Thomson Reuters Check No. 39450	3/13/2024	$22,319.68
Thomson Reuters Check No. 39672	4/23/2024	$3,396.18
Relx Inc DBA LexisNexis Check No. 39798	5/22/2024	$22.49
Thomson Reuters Check No. 39885	6/5/2024	$3,795.08
Relx Inc DBA LexisNexis Check No. 39982	6/26/2024	$839.50
Thomson Reuters Check No. 40085	7/17/2024	$3,795.08
Thomson Reuters Check No. 40158	7/24/2024	$3,209.48
Relx Inc DBA LexisNexis Check Nos. 40116, 40126	7/24/2024	$13.15
Thomson Reuters Check No. 40242	8/20/2024	$5,821.06
Relx Inc DBA LexisNexis Check No. 40290	9/4/2024	$46.42
Thomson Reuters Check No. 40377	9/18/2024	$4,573.40
Relx Inc DBA LexisNexis Check No. 40373	9/18/2024	$39.41
Thomson Reuters Check No. 40543	10/23/2024	$2,247.31
Relx Inc DBA LexisNexis Check No. 40538	10/23/2024	$17.46
Thomson Reuters Check No. 40710	11/20/2024	$2,157.95
Relx Inc DBA LexisNexis Check No. 40704	11/20/2024	$485.68
Bloomberg Finance LP Check No. 40816	12/18/2024	$43.55
Relx Inc DBA LexisNexis Check No. 40853	12/18/2024	$246.26
Thomson Reuters Check No. 40856	12/18/2024	$2,275.57
Relx Inc DBA LexisNexis Check No. 41053	2/5/2025	$144.92
Thomson Reuters Check No. 41122	2/12/2025	$928.01
Relx Inc DBA LexisNexis Check No. 41121	2/19/2025	$147.25
Relx Inc DBA LexisNexis Check No. 41253	3/19/2025	$34.35
Thomson Reuters Check No. 41254	3/19/2025	$18,900.79
Thomson Reuters Check No. 41447	4/23/2025	$33,263.57
Relx Inc DBA LexisNexis Check No. 41440	4/23/2025	$11.35
Thomson Reuters Check No. 41590	5/21/2025	$10,377.80
Relx Inc DBA LexisNexis Check No. 41752	6/18/2025	$68.97
Thomson Reuters Check No. 41756	6/18/2025	$5,592.43
Thomson Reuters Check No. 41015	1/29/2025	$5,933.15
Thomson Reuters Check No. 41015	1/29/2025	$7.32
Thomson Reuters Check No. 41909	7/23/2025	$16,596.33

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Relx Inc DBA LexisNexis Check No. 41938	7/30/2025	$89.86
Thomson Reuters Check Nos. 42024, 42037	8/20/2025	$5,459.87
Relx Inc DBA LexisNexis Check Nos. 42030, 42020A	8/20/2025	$100.92
Relx Inc DBA LexisNexis Check No. 42157	9/17/2025	$5.89
Thomson Reuters Check No. 42161	9/17/2025	$8,212.41
Relx Inc DBA LexisNexis Check No. 42360	10/22/2025	$0.61
Thomson Reuters Check No. 42366	10/22/2025	$5,323.08
Thomson Reuters Check No. 42515	11/19/2025	$2,904.99
Relx Inc DBA LexisNexis Check No. 42596	12/17/2025	$34.89
Thomson Reuters Check No. 42598	12/17/2025	$1,665.57
Thomson Reuters Check No. 42674	1/21/2026	$13,485.43
Relx Inc DBA LexisNexis Check No. 42670	1/21/2026	$0.24
Thomson Reuters Check No. ACH-20260225-32	2/18/2026	$1,285.39
Relx Inc DBA LexisNexis Check No. ACH-20260325-321	3/25/2026	$5.42
Thomson Reuters Check No. ACH-20260325-328	3/25/2026	$1,209.51
Relx Inc DBA LexisNexis Check No. ACH-20260422-42	4/22/2026	$0.23
Thomson Reuters Check No. ACH-20260422-40	4/22/2026	$34,261.08
Thomson Reuters Check No. ACH-20260527-6	5/27/2026	$2,384.12
Thomson Reuters Check No. ACH-20260624-52	6/24/2026	$4,687.46
Relx Inc DBA LexisNexis Check No. ACH-20260729-44	7/29/2026	$0.53
Thomson Reuters Check No. ACH-20260729-45	7/29/2026	$72.29
Thomson Reuters Check No. ACH-20260826-45	8/26/2026	$9.92
Total Legal Research		**$266,493.68**
Type of Expense - Telephone & Faxes		
LoopUp LLC. Check No. 37168	6/14/2023	$18.78
LoopUp LLC. Check No. 38084	7/19/2023	$22.42
LoopUp LLC. Check No. 38239	8/16/2023	$17.23
LoopUp LLC. Check No. 38440	9/27/2023	$43.33
LoopUp LLC. Check No. 38545	10/18/2023	$27.86
LoopUp LLC. Check No. 38708	11/15/2023	$120.34
AMEX. WIFIONBOARD CHICAGO IL; Mobile / Cellular; Wifi on flight	1/5/2024	$39.95
LoopUp LLC. Check No. 39056	1/17/2024	$53.42
LoopUp LLC. Check No. 39215	2/14/2024	$18.53
LoopUp LLC. Check No. 39389	3/13/2024	$15.93
LoopUp LLC. Check No. 39611	4/17/2024	$75.08
Check issued to David Ortiz Check No. 100604 Date: 05/15/24 Check No. 100605 Date: 05/22/24 - Fee for fax at FedEx location	5/15/2024	$29.82
LoopUp LLC. Check Nos. 40112, 40122	7/24/2024	$83.75
LoopUp LLC. Check No. 40233	8/20/2024	$102.23
LoopUp LLC. Check No. 40364	9/18/2024	$93.09

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

LoopUp LLC. Check No. 40532	10/23/2024	$126.59
Total Telephone & Faxes		**$888.34**
Type of Expense - Postage & Express Mail		
FedEx Check No. 38431	9/27/2023	$381.02
AMEX. FEDEX591226149 FedEx MEMPHIS TN; Shpping binders for ChemoCentryx	11/15/2023	$111.62
Check issued to Jim Briggs Check No. 100480	12/15/2023	$35.00
AMEX. FEDEX594165425 FedEx MEMPHIS TN; Shipping binders to Jim Briggs	12/16/2023	$71.58
AMEX. PAYPAL *ILEFTMYSTUF 8778776727; MShipping fee to have documents and laptop mailed to the office	12/16/2023	$134.94
FedEx Check No. 38922	12/20/2023	$312.67
FedEx Check No. 38922	12/20/2023	$667.18
FedEx Check No. 38922	12/20/2023	$291.78
FedEx Check No. 39097	1/24/2024	$82.41
FedEx Check No. 39128	1/31/2024	$355.69
FedEx Check No. 39203	2/14/2024	$261.53
FedEx Check No. 39203	2/14/2024	$47.81
AMEX. FEDEX600295927 FedEx MEMPHIS TN; Shipping depo binders to Aasiya	2/15/2024	$406.34
FedEx Check Nos. 39456, 39467	3/26/2024	$385.58
AMEX. FEDEX605053471 FedEx MEMPHIS TN; FedEx hearing boxes to Cindy in NY	4/6/2024	$50.42
AMEX. FEDEX605231906 FedEx MEMPHIS TN; FedEx to Cindy	4/8/2024	$3.47
FedEx Check No. 39695	5/8/2024	$142.89
FedEx Check No. 39695	5/8/2024	$347.18
FedEx Check No. 39779	5/22/2024	$492.99
FedEx Check No. 39820	5/29/2024	$51.98
FedEx Check No. 40063	7/17/2024	$225.88
FedEx Check No. 40141	7/31/2024	$153.14
FedEx Check No. 40141	7/31/2024	$22.11
FedEx Check No. 40141	7/31/2024	$93.17
FedEx Check No. 40267	9/4/2024	$90.38
FedEx Check No. 40267	9/4/2024	$122.78
FedEx Check No. 40267	9/4/2024	$87.71
FedEx Check No. 40732	12/4/2024	$124.84
FedEx Check No. 40831	12/18/2024	$250.86
FedEx Check No. 40895	1/8/2025	$297.18
FedEx Check No. 40895	1/8/2025	$225.75
FedEx Check No. 40983	1/22/2025	$483.96
FedEx Check No. 41005	1/29/2025	$232.91
FedEx Check No. 41137	2/26/2025	$141.12
FedEx Check No. 42644	1/14/2026	$25.35
FedEx Check No. 42902	5/20/2026	$39.08

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Total Postage & Express Mail		**$7,250.30**
Type of Expense - Hand Delivery Charges		
Express Transport Worldwide LLC Check No. 38770	11/29/2023	$102.50
Express Transport Worldwide LLC Check No. 39256	2/21/2024	$165.00
Express Transport Worldwide LLC Check No. 39859	6/5/2024	$167.50
Express Transport Worldwide LLC Check No. 39937	6/18/2024	$165.00
Express Transport Worldwide LLC Check No. 40348	9/18/2024	$217.00
Express Transport Worldwide LLC Check No. 41200	3/12/2025	$200.00
NPD Logistics, LLC Check No. 41686	6/11/2025	$167.64
NPD Logistics, LLC Check No. 41894	7/16/2025	$90.36
NPD Logistics, LLC Check Nos. ACH-20260107-16, ACH-20260209-523	1/7/2026	$94.25
Total Hand Delivery Charges		**$1,369.25**
Type of Expense - Document Management		
Relativity Document Management - Data & User Costs	4/30/2023	$336.10
Relativity Document Management - Data & User Costs	5/31/2023	$423.66
Relativity Document Management - Data & User Costs	6/20/2023	$476.96
Relativity Document Management - Data & User Costs	7/31/2023	$836.12
Relativity Document Management - Data & User Costs	8/21/2023	$2,047.54
Relativity Document Management - Data & User Costs	9/30/2023	$2,379.53
Relativity Document Management - Data & User Costs	10/31/2023	$3,459.55
Relativity Document Management - Data & User Costs	11/20/2023	$3,822.62
Relativity Document Management - Data & User Costs	12/31/2023	$3,940.81
Relativity Document Management - Data & User Costs	1/31/2024	$3,969.56
Relativity Document Management - Data & User Costs	2/29/2024	$4,130.67
Relativity Document Management - Data & User Costs	3/31/2024	$4,135.28
Relativity Document Management - Data & User Costs	4/30/2024	$4,127.02
Relativity Document Management - Data & User Costs	5/31/2024	$4,064.66
Relativity Document Management - Data & User Costs	6/20/2024	$4,155.34

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Relativity Document Management - Data & User Costs	7/31/2024	$4,614.92
Relativity Document Management - Data & User Costs	8/31/2024	$4,741.15
Relativity Document Management - Data & User Costs	9/30/2024	$4,940.78
Relativity Document Management - Data & User Costs	10/31/2024	$4,908.40
Relativity Document Management - Data & User Costs	11/30/2024	$4,994.85
Relativity Document Management - Data & User Costs	12/31/2024	$5,029.10
Relativity Document Management - Data & User Costs	1/31/2025	$5,408.04
Relativity Document Management - Data & User Costs	2/28/2025	$5,318.60
Relativity Document Management - Data & User Costs	3/31/2025	$5,386.60
Relativity Document Management - Data & User Costs	4/20/2025	$5,097.60
Relativity Document Management - Data & User Costs	5/31/2025	$5,097.60
Relativity Document Management - Data & User Costs	6/30/2025	$5,097.60
Relativity Document Management - Data & User Costs	7/31/2025	$5,114.60
Relativity Document Management - Data & User Costs	8/31/2025	$5,063.60
Relativity Document Management - Data & User Costs	9/30/2025	$5,046.60
Relativity Document Management - Data & User Costs	10/31/2025	$5,050.32
Relativity Document Management - Data & User Costs	11/30/2025	$5,050.32
Relativity Document Management - Data & User Costs	12/31/2025	$5,050.32
Relativity Document Management - Data & User Costs	1/31/2026	$5,050.32
Relativity Document Management - Data Only	2/28/2025	$4,625.32
Relativity Document Management - Data Only	3/31/2026	$4,625.32
Relativity Document Management - Data Only	4/30/2026	$4,625.32
Relativity Document Management - Data Only	5/31/2026	$4,625.32
Relativity Document Management - Data Only	6/30/2025	$4,625.32
Relativity Document Management - Data Only	7/31/2026	$4,625.32
Relativity Document Management - Data Only	8/31/2026	$4,625.32
Relativity Document Management - Data Only	9/30/2026	$4,625.32
Relativity Document Management - Data Only	10/31/2026	$4,625.32
Total Document Managament		**$179,994.60**
Type of Expense - Local Transportaton		
Uber Technologies Inc Check No. W101123A	10/11/2023	$108.55
Uber Technologies Inc Check No. W111523E	11/15/2023	$18.96

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W111523E	11/15/2023	$82.95
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service	11/15/2023	$76.77
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service	11/16/2023	$12.39
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service	11/16/2023	$51.88
AMEX. NYC TAXI 1246 460010 LONG ISLAND C NY; Taxi / Car Service; Car service	11/17/2023	$54.04
Uber Technologies Inc Check No. W120623A1	12/6/2023	$54.24
Uber Technologies Inc Check No. W120623A1	12/6/2023	$22.25
Uber Technologies Inc Check No. W120623A1	12/6/2023	$77.94
Uber Technologies Inc Check No. W120623A1	12/6/2023	$57.96
Uber Technologies Inc Check No. W120623A1	12/6/2023	$93.00
Uber Technologies Inc Check No. W120623A1	12/6/2023	$122.71
Uber Technologies Inc Check No. W120623A1	12/6/2023	$109.77
Uber Technologies Inc Check No. W120623A1	12/6/2023	$10.97
Uber Technologies Inc Check No. W120623A1	12/6/2023	$91.29
Uber Technologies Inc Check No. W120623A1	12/6/2023	$13.69
Uber Technologies Inc Check No. W011824C1	1/18/2024	$67.93
Uber Technologies Inc Check No. W011824C1	1/18/2024	$86.74
Uber Technologies Inc Check No. W011824C1	1/18/2024	$6.79
Uber Technologies Inc Check No. W011824C1	1/18/2024	$24.43
Uber Technologies Inc Check No. W011824C1	1/18/2024	$33.71
Uber Technologies Inc Check No. W011824C1	1/18/2024	$64.94
Uber Technologies Inc Check No. W011824C1	1/18/2024	$98.89
Uber Technologies Inc Check No. W011824C1	1/18/2024	$9.74
Uber Technologies Inc Check No. W011824C1	1/18/2024	$52.90
Uber Technologies Inc Check No. W011824C1	1/18/2024	$81.29
Uber Technologies Inc Check No. W011824C1	1/18/2024	$16.25
AMEX. P6 LAX SMARTPARKING LOS ANGELES CA; Parking; P6 LAX SMARTPARKING -	2/8/2024	$16.00
AMEX. WALDORF ASTORIA BEVE BEVERLY HILLS CA; Parking	2/9/2024	$26.00
AMEX. LAZ PARKING M17555-F LOS ANGELES CA; Parking; LAZ Parking	2/9/2024	$42.00
AMEX. LAZ PARKING M17555-F LOS ANGELES CA; Parking; LAZ PARKING - parking with client for mediation	2/9/2024	$42.00
Uber Technologies Inc Check No. W021524A	2/14/2024	$19.05
Uber Technologies Inc Check No. W021524A	2/14/2024	$97.86
Uber Technologies Inc Check No. W021524A	2/14/2024	$9.78
Uber Technologies Inc Check No. W021524A	2/14/2024	$19.45
Uber Technologies Inc Check No. W021524A	2/14/2024	$68.15
Uber Technologies Inc Check No. W021524A	2/14/2024	$88.33
Uber Technologies Inc Check No. W021524A	2/14/2024	$101.66
Uber Technologies Inc Check No. W021524A	2/14/2024	$123.73

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W021524A	2/14/2024	$12.37
Uber Technologies Inc Check No. W021524A	2/14/2024	$86.91
Uber Technologies Inc Check No. W021524A	2/14/2024	$17.38
Uber Technologies Inc Check No. W021524A	2/14/2024	$91.53
Uber Technologies Inc Check No. W021524A	2/14/2024	$129.79
Uber Technologies Inc Check No. W021524A	2/14/2024	$18.94
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$103.54
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$15.53
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$18.30
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$156.67
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$31.33
Uber Technologies Inc Check Nos. W031424B, W031424B1	3/13/2024	$93.05
Uber Technologies Inc Check No. W041024F1	4/10/2024	$27.93
Uber Technologies Inc Check No. W041024F1	4/10/2024	$170.56
Uber Technologies Inc Check No. W041024F1	4/10/2024	$33.92
Uber Technologies Inc Check No. W041024F1	4/10/2024	$98.91
Uber Technologies Inc Check No. W041024F1	4/10/2024	$19.78
Uber Technologies Inc Check No. W041024F1	4/10/2024	$98.99
Uber Technologies Inc Check No. W041024F1	4/10/2024	$89.01
Uber Technologies Inc Check No. W041024F1	4/10/2024	$17.80
Uber Technologies Inc Check No. W051524B	5/15/2024	$93.65
Uber Technologies Inc Check No. W051524B	5/15/2024	$121.10
Uber Technologies Inc Check No. W051524B	5/15/2024	$23.92
Uber Technologies Inc Check No. W051524B	5/15/2024	$45.24
Uber Technologies Inc Check No. W051524B	5/15/2024	$10.96
Uber Technologies Inc Check No. W051524B	5/15/2024	$1.00
Uber Technologies Inc Check No. W051524B	5/15/2024	$11.97
Uber Technologies Inc Check No. W051524B	5/15/2024	$11.97
Uber Technologies Inc Check No. W051524B	5/15/2024	$42.96
Uber Technologies Inc Check No. W051524B	5/15/2024	$143.45
Uber Technologies Inc Check No. W051524B	5/15/2024	$82.91
Uber Technologies Inc Check No. W051524B	5/15/2024	$16.58
Uber Technologies Inc Check No. W051524B	5/15/2024	$83.93
Uber Technologies Inc Check No. W051524B	5/15/2024	$98.66
Uber Technologies Inc Check No. W051524B	5/15/2024	$14.79
Uber Technologies Inc Check No. W051524B	5/15/2024	$16.78
Uber Technologies Inc Check No. W061324	6/12/2024	$146.38
Uber Technologies Inc Check No. W061324	6/12/2024	$83.99
Uber Technologies Inc Check No. W061324	6/12/2024	$12.59
Uber Technologies Inc Check No. W061324	6/12/2024	$134.98

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W061324	6/12/2024	$132.62
Uber Technologies Inc Check No. W061324	6/12/2024	$59.90
Uber Technologies Inc Check No. W061324	6/12/2024	$84.31
Uber Technologies Inc Check No. W061324	6/12/2024	$12.64
Uber Technologies Inc Check No. W061324	6/12/2024	$72.90
Uber Technologies Inc Check No. W061324	6/12/2024	$14.58
Uber Technologies Inc Check No. W061324	6/12/2024	$71.99
Uber Technologies Inc Check No. W061324	6/12/2024	$14.39
Uber Technologies Inc Check No. W061324	6/12/2024	$59.14
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$120.15
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$67.19
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$137.86
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$124.17
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$92.59
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$104.48
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$10.44
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$127.43
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$117.73
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$113.94
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$114.54
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$93.93
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$14.08
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$82.99
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$12.44
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$77.17
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$11.57
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$75.13
Uber Technologies Inc Check Nos. W080824C, W080824C1	8/7/2024	$11.26
Uber Technologies Inc Check No. A091224E	9/11/2024	$43.96
Uber Technologies Inc Check No. W101624K	10/16/2024	$62.64
Uber Technologies Inc Check No. W101624K	10/16/2024	$30.87
Uber Technologies Inc Check No. W101624K	10/16/2024	$25.44
Uber Technologies Inc Check No. W101624K	10/16/2024	$19.69

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W101624K	10/16/2024	$61.95
Uber Technologies Inc Check No. W110724D1	11/6/2024	$84.67
Uber Technologies Inc Check No. W110724D1	11/6/2024	$145.12
Uber Technologies Inc Check No. W110724D1	11/6/2024	$61.94
Uber Technologies Inc Check No. W110724D1	11/6/2024	$9.29
Uber Technologies Inc Check No. W110724D1	11/6/2024	$400.74
Uber Technologies Inc Check No. W110724D1	11/6/2024	$57.20
Uber Technologies Inc Check No. W120524B1	12/4/2024	$79.83
Uber Technologies Inc Check No. W120524B1	12/4/2024	$156.67
Uber Technologies Inc Check No. W120524B1	12/4/2024	$31.33
Uber Technologies Inc Check No. W120524B1	12/4/2024	$134.71
Uber Technologies Inc Check No. W120524B1	12/4/2024	$23.97
Uber Technologies Inc Check No. W120524B1	12/4/2024	$120.97
Uber Technologies Inc Check No. W120524B1	12/4/2024	$161.16
Uber Technologies Inc Check No. W120524B1	12/4/2024	$32.23
Uber Technologies Inc Check No. W120524B1	12/4/2024	$152.85
Uber Technologies Inc Check No. W120524B1	12/4/2024	$122.30
Uber Technologies Inc Check No. W120524B1	12/4/2024	$89.03
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP	12/16/2024	$125.75
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP	12/18/2024	$18.86
Uber Technologies Inc Check No. W010925F	1/8/2025	$125.17
Uber Technologies Inc Check No. W010925F	1/8/2025	$31.12
Uber Technologies Inc Check No. W010925F	1/8/2025	$4.34
Uber Technologies Inc Check No. W010925F	1/8/2025	$66.91
Uber Technologies Inc Check No. W010925F	1/8/2025	$25.03
Uber Technologies Inc Check No. W010925F	1/8/2025	$17.55
Uber Technologies Inc Check No. W010925F	1/8/2025	$3.00
Uber Technologies Inc Check No. W010925F	1/8/2025	$154.09
Uber Technologies Inc Check No. W010925F	1/8/2025	$213.92
Uber Technologies Inc Check No. W010925F	1/8/2025	$73.00
Uber Technologies Inc Check No. W010925F	1/8/2025	$10.95
Uber Technologies Inc Check No. W010925F	1/8/2025	$50.60
Uber Technologies Inc Check No. W010925F	1/8/2025	$8.00
Uber Technologies Inc Check No. W010925F	1/8/2025	$80.40
Uber Technologies Inc Check No. W010925F	1/8/2025	$16.08
Uber Technologies Inc Check No. W010925F	1/8/2025	$87.22
Uber Technologies Inc Check No. W010925F	1/8/2025	$73.06
Uber Technologies Inc Check No. W010925F	1/8/2025	$155.93
Uber Technologies Inc Check No. W010925F	1/8/2025	$149.44
Uber Technologies Inc Check No. W010925F	1/8/2025	$13.08
Uber Technologies Inc Check No. W010925F	1/8/2025	$87.96
Uber Technologies Inc Check No. W010925F	1/8/2025	$70.26
Uber Technologies Inc Check No. W010925F	1/8/2025	$25.98

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. NYC TAXI 1246 460010 LONG ISLAND C NY; Taxi / Car Service; Car service	1/8/2025	$45.80
Uber Technologies Inc Check No. W020525F1	2/5/2025	$30.81
Uber Technologies Inc Check No. W020525F1	2/5/2025	$63.90
Uber Technologies Inc Check No. W020525F1	2/5/2025	$67.98
Uber Technologies Inc Check No. W020525F1	2/5/2025	$10.19
Uber Technologies Inc Check No. W020525F1	2/5/2025	$58.05
Uber Technologies Inc Check No. W020525F1	2/5/2025	$8.70
Uber Technologies Inc Check No. W020525F1	2/5/2025	$53.55
Uber Technologies Inc Check No. W020525F1	2/5/2025	$8.03
Uber Technologies Inc Check No. W020525F1	2/5/2025	$59.12
Uber Technologies Inc Check No. W020525F1	2/5/2025	$8.86
Uber Technologies Inc Check No. W020525F1	2/5/2025	$50.05
Uber Technologies Inc Check No. W020525F1	2/5/2025	$10.01
Uber Technologies Inc Check No. W020525F1	2/5/2025	$134.38
Uber Technologies Inc Check No. W020525F1	2/5/2025	$64.99
Uber Technologies Inc Check No. W020525F1	2/5/2025	$12.99
Uber Technologies Inc Check No. W020525F1	2/5/2025	$64.47
Uber Technologies Inc Check No. W020525F1	2/5/2025	$12.89
Uber Technologies Inc Check No. W020525F1	2/5/2025	$82.97
Uber Technologies Inc Check No. W020525F1	2/5/2025	$16.59
Uber Technologies Inc Check No. W020525F1	2/5/2025	$88.78
Uber Technologies Inc Check No. W020525F1	2/5/2025	$17.75
Uber Technologies Inc Check No. W020525F1	2/5/2025	$68.81
Uber Technologies Inc Check No. W020525F1	2/5/2025	$13.76
Uber Technologies Inc Check No. W020525F1	2/5/2025	$67.30
Uber Technologies Inc Check No. W020525F1	2/5/2025	$13.46
Uber Technologies Inc Check No. W020525F1	2/5/2025	$53.41
Uber Technologies Inc Check No. W020525F1	2/5/2025	$57.95
Uber Technologies Inc Check No. W040925F	4/9/2025	$185.20
Uber Technologies Inc Check No. W050725E	5/7/2025	$27.78
Uber Technologies Inc Check No. W070925D3	7/9/2025	$36.92
Uber Technologies Inc Check No. W080725F1	8/6/2025	$5.53
Uber Technologies Inc Check No. W080725F1	8/6/2025	$84.93
Uber Technologies Inc Check No. W091025J1	9/10/2025	$8.49
Uber Technologies Inc Check No. W120325D1	12/3/2025	$85.13
Uber Technologies Inc Check No. W010726H1	1/7/2026	$26.84
Uber Technologies Inc Check No. W031126D1	3/11/2026	$53.90
Uber Technologies Inc Check No. W031126D1	3/11/2026	$8.08
Total Local Transportation		**$12,383.20**
Type of Expense - Outside Copying & Printing		
Check issued to Jeffrey Yourish Check No. 38122 - For copying	7/26/2023	$142.24
iDiscover Check No. 39051	1/18/2024	$676.97

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

iDiscover Check No. 39051	1/18/2024	$206.07
Consilio Inc. Check No. 39149	2/7/2024	$130.00
Consilio Inc. Check No. 39247	2/21/2024	$882.78
AMEX. SIR SPEEDY 286000000 MARBLEHEAD MA; Copies for Ferrell Deposition	1/5/2024	$412.25
iDiscover Check No. 39295	2/28/2024	$262.69
iDiscover Check No. 39295	2/28/2024	$330.78
AMEX. FEDEX Office 5514 15 WASHINGTON DC; Printing for depo	1/12/2024	$4.66
Millnet US LLC Check No. W041924	4/19/2024	$1,562.80
iDiscover Check No. 39704	5/8/2024	$228.20
AMEX. THE UPS STORE 7463 0 REDWOOD CITY CA - copies for a Chemocentryx deposition (witness was Kanagala)	4/18/2024	$81.09
iDiscover Check No. 40143	7/31/2024	$1,279.22
iDiscover Check No. 40189	8/13/2024	$79.50
iDiscover Check No. 40143	7/31/2024	$169.23
Outside Copying - Sales & Use tax paid to California Dept of Taxation period April-June 2024 (Millnet Bills 119479 / 119554)	7/30/2024	$156.13
iDiscover Check No. 40230	8/20/2024	$230.74
iDiscover Check No. 40230	8/20/2024	$5.72
iDiscover Check No. 40230	8/20/2024	$619.49
iDiscover Check No. 40230	8/20/2024	$33.20
iDiscover Check No. 40230	8/20/2024	$237.62
iDiscover Check No. 40230	8/20/2024	$58.21
iDiscover Check No. 40271	9/4/2024	$132.81
iDiscover Check No. 40311	9/11/2024	$245.64
iDiscover Check No. 40311	9/11/2024	$135.88
Millnet US LLC Check No. 40366	9/19/2024	$918.44
Millnet US LLC Check No. 40283	9/4/2024	$737.89
United Litigation Discovery Inc. Check No. 40379	9/18/2024	$4,526.34
United Litigation Discovery Inc. Check No. 40652	11/13/2024	$374.21
United Litigation Discovery Inc. Check No. 40652	11/13/2024	$65.75
AMEX. BUFFALO DESIGN AND P KENMORE NY - printing deposition documents	9/23/2024	$950.60
AMEX. FSP*BOSTON BUSINESS BOSTON MA - materials for deposition	12/3/2024	$1,474.38
iDiscover Check No. 40898	1/8/2025	$375.14
iDiscover Check No. 40898	1/8/2025	$375.29
iDiscover Check No. 40898	1/8/2025	$106.02
Key Discovery Check No. 40902	1/8/2025	$528.90
Key Discovery Check No. 40902	1/8/2025	$157.11
Avalon Document Services Check Nos. 40871, 40879	1/8/2025	$1,112.04
Millnet US LLC Check No. 41082	2/12/2025	$3,089.56
Millnet US LLC Check No. 41082	2/12/2025	$1,389.58

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Van Ausdall and Farrar, Inc. Check No. 41092	2/12/2025	$292.80
Van Ausdall and Farrar, Inc. Check No. 41092	2/12/2025	$897.24
Van Ausdall and Farrar, Inc. Check No. 41092	2/12/2025	$804.49
AMEX. FedEx Office 0083 Plano TX - printed deposition materials	1/4/2025	$247.14
iDiscover Check No. 41109	2/19/2025	$411.05
iDiscover Check No. 41109	2/19/2025	$121.44
iDiscover Check No. 41203	3/12/2025	$102.23
iDiscover Check No. 41203	3/12/2025	$62.72
AMEX. RELIABLE COPY SERVIC PHILADELPHIA PA; Copies / Printing; RELIABLE COPY - materials for deposition	1/15/2025	$723.60
iDiscover Check No. 41347	4/9/2025	$142.49
iDiscover Check No. 41677	6/11/2025	$1,135.93
iDiscover Invoice 102491	7/16/2025	$283.02
Key Discovery Invoice 2412031	1/8/2025	$3,396.79
Key Discovery Invoice 2412064	1/8/2025	$6,423.64
Key Discovery Invoice 2412081	1/8/2025	$175.06
Counsel Press Inc Check No. ACH-20260225-9 - Printing of appeal brief & appendix	2/25/2026	$16,160.20
Total Outside Copying & Printing		**$55,865.01**
Type of Expense - Discovery Costs		
Troutman Pepper Hamilton Sanders LLP Check No. 40579 - Costs to respond to subpoena	10/30/2024	$20,000.00
Total Outside Copying & Printing		**$20,000.00**
Type of Expense - Out of Town Travel		
AMEX. SWA INFLIGHT WIFI 800-435-9792 CA; Air WiFi; purchased in-flight WiFi to research updates in case law relevant to M2D	1/12/2023	$8.00
AMEX. Delta; Airfare; Airfare Boston to New York (coach fare $228)	9/11/2023	$228.00
AMEX. JetBlue; Airfare; Airfare New York to Boston	9/11/2023	$239.70
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare New York to Boston - agency fee	9/11/2023	$45.00
AMEX. 6331113 - SPIRIT AND QUEENS NY; Breakfast; Breakfast	9/19/2023	$20.00
AMEX. PAR*LIFE ALIVE CAFE BOSTON MA; Lunch; Lunch	9/19/2023	$25.00
AMEX. THE NEWBURY BOSTON H BOSTON MA; Hotel - Meals - Other; Water from hotel bar	9/20/2023	$12.50
AMEX. THE NEWBURY BOSTON H BOSTON MA; Hotel - Lodging; Lodging	9/20/2023	$350.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare Boston to New York - agency fee (changed flight)	9/20/2023	$45.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare Boston to New York - agency fee (update profile to reflect TSA number)	9/20/2023	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel to Boston - agency fee - DUPLICATE - TO BE CREDITED	9/20/2023	$45.00
AMEX. DELTA SKY BOS SAT EAST BOSTON MA; Meals - Other; Snacks	9/20/2023	$9.97
AMEX. DELTA SKY BOS SAT EAST BOSTON MA; Meals - Other; Snacks	9/20/2023	$9.97
AMEX. American; Airfare; First class nonrefundable to Indiana	9/22/2023	$276.00
AMEX. Delta; Airfare; IND-LAX Delta	9/22/2023	$343.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel agency fee to book flights	9/22/2023	$45.00
AMEX. American; Airfare; Roundtrip LAX-IND	9/25/2023	$1,087.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fee to switch hotels	9/25/2023	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; After hours call fee	9/26/2023	$24.95
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; Air wifi - no receipt	9/26/2023	$25.00
AMEX. BT*DD *DOORDASH THER SAN FRANCISCO CA; Dinner; Dinner charge doordash	9/26/2023	$31.23
AMEX. American Airlines FT WORTH TX; Seat Upgrade Fee; Seat upgrade fee	9/26/2023	$31.82
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; after hours plus hotel only agency fee	9/26/2023	$34.95
AMEX. United; Airfare; Indianapolis trip	9/26/2023	$98.00
AMEX. HYDE PARK INDIANAPOL INDIANAPOLIS IN; Dinner; Dinner with case team	9/26/2023	$150.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; In-flight wifi	9/26/2023	$25.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel fee to change travel	9/26/2023	$45.00
AMEX. American; Airfare; Flights to and from NY	9/26/2023	$482.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Indianapolis trip	9/27/2023	$148.21
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Indianapolis trip	9/27/2023	$65.30
AMEX. UAL INFLT WIFIONBOAR 877-350-0038 IL; Air WiFi; Indianapolis Trip	9/27/2023	$8.00
AMEX. FIRST CITYCAB CORP. QUEENS NY; Taxi / Car Service; Indianapolis trip	9/27/2023	$80.17
AMEX. American; Airfare; Indianapolis trip	9/27/2023	$98.00
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Other; hotel stay sep 26-28 taxes	9/28/2023	$107.35
AMEX. TST* PATACHOU ON THE INDIANAPOLIS IN; Dinner; Dinner	9/28/2023	$149.20
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Dinner; hotel stay sep 26-28 in room dining	9/28/2023	$42.50

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. CUPS COFFEE AT 1 N C Indianapolis IN; Breakfast; Coffee	9/28/2023	$6.21
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Lodging; hotel stay sep 26-28	9/28/2023	$631.47
AMEX. BT*DD *DOORDASH CAFE SAN FRANCISCO CA; Dinner; Dinner charge	9/28/2023	$50.00
AMEX. HILTON INDIANAPOLIS INDIANAPOLIS IN; Hotel - Dinner; Hilton Indianapolis stay two nights dinner charge	9/28/2023	$41.80
AMEX. HILTON INDIANAPOLIS INDIANAPOLIS IN; Hotel - Lodging; Hilton Indianapolis stay two nights	9/28/2023	$544.00
AMEX. HILTON INDIANAPOLIS INDIANAPOLIS IN; Hotel - Other; Hilton Indianapolis stay two nights taxes	9/28/2023	$92.48
AMEX. OCEANAIRE INDIANAPOL INDIANAPOLIS IN; Dinner; Dinner with case team	9/28/2023	$150.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; Flight wifi	9/29/2023	$29.00
AMEX. DELTA AIR LINES ATLANTA US; Meals - Other; Snack on plane	9/29/2023	$10.00
AMEX. 1060 M&S INDIANAPOLI INDIANAPOLIS IN; Dinner; Dinner charge	9/29/2023	$41.61
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel fee to change travel	10/6/2023	$45.00
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$46.60
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$21.89
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$57.51
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$28.93
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$80.78
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$4.33
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$31.27
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$13.42
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$16.15
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$7.04

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$3.00
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$36.75
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$7.35
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$27.97
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$4.19
Uber Technologies Inc Check No. W101123C Date: 10/11/23 Check No. W101123A3 Date: 10/11/23	10/11/2023	$77.77
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel fee to change travel	10/15/2023	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	10/25/2023	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - round trip flight LAX to JFK	10/25/2023	$836.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	10/25/2023	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - round trip LA to NY	10/25/2023	$836.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	10/30/2023	$45.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; VIASAT IN-FLIGHT WI-FI	10/31/2023	$29.00
AMEX. TST* GREGORY"S COFFE NEW YORK NY; Meals - Other; TST* GREGORY'S COFFE - snack	11/1/2023	$10.89
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Meals - Other; MICHELANGELO HOTEL - Minibar food, sodas, & water	11/1/2023	$11.00
AMEX. STARBUCKS STORE 1027 NEW YORK NY; Breakfast; STARBUCKS STORE - breakfast/coffee	11/1/2023	$9.11
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Dinner; MICHELANGELO HOTEL - minibar snacks, soda, & water	11/2/2023	$24.00
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Breakfast; MICHELANGELO HOTEL - hotel breakfast	11/2/2023	$6.53
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Lodging; MICHELANGELO HOTEL	11/2/2023	$700.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; VIASAT IN-FLIGHT WI-FI	11/3/2023	$29.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; VIASAT IN-FLIGHT WI- in flight Wi-Fi	11/5/2023	$20.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Lodging; MICHELANGELO HOTEL - hotel stay	11/6/2023	$350.00
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Breakfast; MICHELANGELO HOTEL - hotel breakfast	11/6/2023	$52.64
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; VIASAT IN-FLIGHT WI-	11/7/2023	$29.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Santa Ana, CA - agency fee	11/14/2023	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Santa Ana, CA - JIM BRIGGS - agency fee	11/14/2023	$45.00
AMEX. AMERICAN AIRLINES NEW YORK NY; Airfare; Airfare to Santa Ana, CA - JIM BRIGGS (outbound coach flight $368; return flight coach fare $363)	11/14/2023	$731.00
AMEX. AMERICAN AIRLINES NEW YORK NY; Airfare; Airfare to Santa Ana, CA (Coach $987)	11/14/2023	$987.00
AMEX. WESTIN SO COAST PLAZ COSTA MESA CA; Hotel - Lodging; Lodging - JIM BRIGGS	11/16/2023	$254.79
AMEX. TST* GREENLEAF- SOCO COSTA MESA CA; Meals - Other; Food - catering for deposition	11/23/2023	$207.02
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; Inflight wifi	11/29/2023	$25.00
AMEX. WATER GRILL SOUTH CO COSTA MESA CA; Dinner; Dinner after deposition with Adam Hollander and Jim Briggs	11/30/2023	$150.00
AMEX. American; Airfare; Airfare - changed return flight to New York	12/1/2023	$150.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change return flight - agency fee	12/1/2023	$45.00
AMEX. WESTIN SC PLAZA DINI COSTA MESA CA; Lunch; Lunch	12/1/2023	$20.74
AMEX. WESTIN SC PLAZA DINI COSTA MESA CA; Hotel - Dinner; Dinner with Jim Briggs	12/2/2023	$100.00
AMEX. Delta; Airfare; Change return flight (Coach fare $1248)	12/2/2023	$1,198.91
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; Inflight wifi	12/2/2023	$39.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change return flight - agency fee	12/2/2023	$45.00
AMEX. WESTIN SO COAST PLAZ COSTA MESA CA; Hotel - Dinner; Dinner	12/2/2023	$50.00
AMEX. WESTIN SO COAST PLAZ COSTA MESA CA; Hotel - Lodging; Lodging	12/2/2023	$676.08
AMEX. TST* VACA 00001020 COSTA MESA CA; Dinner; Dinner with Adam Hollander and Jim Briggs	12/2/2023	$150.00
AMEX. WESTIN SO COAST PLAZ COSTA MESA CA; Hotel - Lodging; Lodging - stayed extra night	12/3/2023	$241.99

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare - changed return flight to New York - after-hours agency fee	12/4/2023	$34.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Dallas, TX (Coach fare $637.00) - agency fee	12/5/2023	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Dallas, TX (Coach fare $637.00) - JIM BRIGGS - agency fee	12/5/2023	$45.00
AMEX. American; Airfare; Airfare to Dallas, TX (Coach fare $637.00) - JIM BRIGGS	12/5/2023	$637.00
AMEX. American; Airfare; Airfare to Dallas, TX (Coach fare $637.00)	12/5/2023	$637.00
Uber Technologies Inc Check No. W120623A3 Date: 12/06/23	12/6/2023	$17.99
Uber Technologies Inc Check No. W120623A3 Date: 12/06/23	12/6/2023	$132.93
Uber Technologies Inc Check No. W120623A3 Date: 12/06/23	12/6/2023	$45.50
Uber Technologies Inc Check No. W120623A3 Date: 12/06/23	12/6/2023	$14.95
Uber Technologies Inc Check No. W120623A3 Date: 12/06/23	12/6/2023	$3.00
AMEX. SEAMLSS*MODERNMARKET NEW YORK NY; Meals - Other; Food order for deposition in Texas	12/12/2023	$270.04
AMEX. Delta; Airfare; Flight to LAX from JFK (coach fare $208)	12/14/2023	$208.00
AMEX. American; Airfare; Flight from LAX to JFK (coach fare $373)	12/14/2023	$373.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight to LAX from JFK - agency fee	12/14/2023	$45.00
AMEX. Delta; Airfare; Airfare to LAX (Coach fare $422)	12/14/2023	$422.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fkight to LAX - agency fee	12/14/2023	$45.00
AMEX. Dallas Marriott Down Dallas TX; Lunch; Lunch at hotel	12/14/2023	$25.00
AMEX. Dallas Marriott Down Dallas TX; Hotel - Internet / WiFi; Internet at hotel	12/14/2023	$5.87
AMEX. Dallas Marriott Down Dallas TX; Hotel - Dinner; Dinner at hotel	12/14/2023	$50.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - agency fee - JIM BRIGGS	12/15/2023	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - agency fee	12/15/2023	$45.00
AMEX. Dallas Marriott Down Dallas TX; Hotel - Breakfast; Breakfast	12/15/2023	$13.37
AMEX. Dallas Marriott Down Dallas TX; Hotel - Meals - Other; Beverage	12/15/2023	$7.03
AMEX. Dallas Marriott Down Dallas TX; Hotel - Internet / WiFi; High speed internet access	12/16/2023	$17.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. Dallas Marriott Down Dallas TX; Hotel - Internet / WiFi; High speed internet access	12/16/2023	$17.95
AMEX. Dallas Marriott Down Dallas TX; Hotel - Breakfast; Breakfast	12/16/2023	$20.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - after-hours agency fee	12/16/2023	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - after-hours agency fee	12/16/2023	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - after-hours agency fee - JIM BRIGGS	12/16/2023	$34.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Change flight - after-hours agency fee	12/16/2023	$34.95
AMEX. Dallas Marriott Down Dallas TX; Hotel - Lodging; Lodging	12/16/2023	$350.00
AMEX. Dallas Marriott Down Dallas TX; Hotel - Lodging; Lodging	12/16/2023	$350.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fee to book flights	12/22/2023	$45.00
AMEX. JetBlue; Airfare; Flight BOS-LAX	12/22/2023	$491.00
AMEX. Delta; Airfare; Flight to Boston	12/22/2023	$832.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	12/22/2023	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight LA to Boston for Dr. Ferrell deposition	12/22/2023	$924.00
AMEX. JetBlue; Airfare; JETBLUE - flight Boston to LA	12/22/2023	$924.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	12/22/2023	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight LA to DC	12/22/2023	$798.00
AMEX. United; Airfare; Airfare from New York to Seattle (coach fare $288.10)	1/2/2024	$288.10
AMEX. United; Airfare; Airfare from New York to Seattle (coach fare $288.10) Jim Briggs	1/2/2024	$288.10
AMEX. Delta; Airfare; Airfare from Seattle to New York (coach fare $298.10) - Jim Briggs	1/2/2024	$298.10
AMEX. Delta; Airfare; Airfare from Seattle to New York (coach fare $298.10)	1/2/2024	$298.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee;Flight from New York to Seattle - agency fee	1/2/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight rom New York to Seattle, Jim Briggs - agency fee	1/2/2024	$45.00
AMEX. FLY WITH BREEZE EL SEGUNDO CA; Lunch; Lunch charge at airport	1/5/2024	$23.22
AMEX. BOSTON TAXI VTS BOST LONG ISLAND CITY NY; Taxi / Car Service; ChemoCentryx - airport to hotel for LMC and JU for deposition	1/5/2024	$31.56

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fee to book flights	1/5/2024	$45.00
AMEX. Delta; Airfare; Chloe's flight to DC and back	1/5/2024	$796.20
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; WIFIONBOARD - in flight Wi-Fi	1/5/2024	$39.95
AMEX. STARBUCKS 66483 STAR BOSTON MA; Breakfast; STARBUCKS - coffee	1/5/2024	$4.66
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	1/5/2024	$45.00
AMEX. JetBlue; Airfare; JETBLUE - flight NY to LA Coach refundable fare: $924	1/5/2024	$924.00
AMEX. HUDSON-DUNKIN ST1916 BOSTON MA; Breakfast; Coffee charge at airport	1/6/2024	$5.30
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fee to switch hotel dates	1/6/2024	$34.95
AMEX. DELAWARE NORTH LOGAN EAST BOSTON MA; Meals - Other; DELAWARE NORTH LOGAN - snack at airport	1/6/2024	$11.63
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Breakfast; WESTIN COPLEY PLACE BOSTON - breakfast	1/6/2024	$16.35
AMEX. 6551400 - WAHLBURGER BOSTON MS; Lunch; 6551400 - WAHLBURGER - lunch with Lauren Cruz	1/6/2024	$50.00
AMEX. YARD HOUSE ZK 010839 BOSTON MA; Dinner; YARD HOUSE - dinner with Lauren Cruz	1/6/2024	$72.23
AMEX. DELAWARE NORTH LOGAN EAST BOSTON MA; Dinner; DELAWARE NORTH LOGAN - dinner with Lauren Cruz	1/6/2024	$85.16
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours charge	1/6/2024	$34.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Fee to book travel	1/7/2024	$45.00
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Lodging; Stay at Westin Copley room charge	1/8/2024	$219.00
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Lunch; Stay at Westin Copley in room dining	1/8/2024	$23.96
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Dinner; Stay at Westin Copley in room dining	1/8/2024	$25.80
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Other; Stay at Westin Copley taxes	1/8/2024	$40.97
AMEX. WESTIN COPLEY PLACE BOSTON MA; Hotel - Lodging; WESTIN COPLEY PLACE BOSTON - hotel stay	1/8/2024	$273.62
AMEX. DELTA AIR LINES ONBO ATLANTA GA; Breakfast; Snack on flight	1/11/2024	$12.00
AMEX. JW Marriott Washingt Washington DC; Dinner; Dinner charge	1/11/2024	$30.80
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; Wifi on flight	1/11/2024	$39.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. LAX AIRP HOMEBOY CAF LOS ANGELES CA; Breakfast; LAX AIRP HOMEBOY CAF - breakfast at airport	1/11/2024	$20.00
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; WIFIONBOARD CHICAGO	1/11/2024	$39.95
AMEX. JW Marriott Washingt Washington DC; Lunch; Lunch charge	1/12/2024	$19.80
AMEX. JW Marriott Washingt Washington DC; Hotel - Breakfast; JW Marriott Washingt - breakfast at hotel	1/12/2024	$15.17
AMEX. JW Marriott Washingt Washington DC; Hotel - Breakfast; JW Marriott Washington - coffee	1/12/2024	$3.30
AMEX. IC WILLARD FB 0000 WASHINGTON DC; Lunch; IC WILLARD FB - lunch with Chloe	1/12/2024	$36.96
AMEX. JW Marriott Washingt Washington DC; Dinner; JW Marriott Washingt - dinner	1/12/2024	$50.00
AMEX. IC WILLARD FB 0000 WASHINGTON DC; Dinner; IC WILLARD FB - dinner with Chloe	1/12/2024	$64.68
AMEX. UVC INC Washington DC; Taxi / Car Service; UVC INC - taxi to train station	1/13/2024	$16.84
AMEX. AMTRAK COM WASHINGTON DC; Train / Rail; AMTRAK COM - train to NY	1/13/2024	$102.00
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; Wifi on flight to work	1/14/2024	$11.00
AMEX. JW Marriott Washingt Washington DC; Hotel - Other; Taxes JW Marriott	1/14/2024	$143.79
AMEX. JW Marriott Washingt Washington DC; Hotel - Lodging; Room charge JW Marriott	1/14/2024	$538.00
AMEX. JW Marriott Washingt Washington DC; Hotel - Meals - Other; JW Marriott Washington - coffee	1/14/2024	$4.18
AMEX. JW Marriott Washingt Washington DC; Hotel - Lodging; JW Marriott Washington - hotel stay	1/14/2024	$647.01
AMEX. Renaissance New York New York NY; Hotel - Dinner; Renaissance New York - dinner at hotel	1/15/2024	$30.35
AMEX. United; Airfare; Airfare to Seattle	1/16/2024	$426.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Seattle - agency fee	1/16/2024	$45.00
AMEX. United; Airfare; Airfare from Seattle - JIM BRIGGS (coach fare $213)	1/17/2024	$213.00
AMEX. JetBlue; Airfare; Airfare to Seattle - JIM BRIGGS (coach fare $429)	1/17/2024	$429.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Seattle - JIM BRIGGS - agency fee	1/17/2024	$45.00
AMEX. Renaissance New York New York NY; Hotel - Lodging; Renaissance New York - hotel stay	1/17/2024	$350.00
Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$14.38
Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$57.96
Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$11.59

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$214.83
Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$42.96
Uber Technologies Inc Check No. W011824C2 Date: 01/18/24	1/18/2024	$141.27
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; Inflight wifi	1/28/2024	$10.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Dinner; Dinner - JIMM BRIGGS with Abe	1/30/2024	$100.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lunch; Lunch	1/30/2024	$25.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Meals - Other; Snacks	1/30/2024	$28.26
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lodging; Lodging - JIM BRIGGS	1/30/2024	$350.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lodging; Lodging	1/30/2024	$700.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; Air wifi to Philly	1/30/2024	$29.00
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; Inflight wifi	1/31/2024	$10.00
AMEX. MENDOCINO FARMS 59ON SEATTLE WA; Dinner; Dinner with Jim Briggs	1/31/2024	$100.00
AMEX. VIASAT IN-FLIGHT WI- CARLSBAD US; Air WiFi; Air wifi	2/2/2024	$29.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service to airport - tip	2/8/2024	$17.07
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; Inflight wifi	2/8/2024	$39.95
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service to airport	2/8/2024	$85.36
AMEX. American Airlines FT WORTH TX; Airfare; Return flight LAX to JFK (Coach $432)	2/10/2024	$432.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Internet / WiFi; In room internet service	2/11/2024	$20.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Lodging; Return flight LAX to JFK (Coach $432)	2/11/2024	$700.00
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$29.16
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$27.02
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$40.46
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$88.73
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$65.91
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$87.40
Uber Technologies Inc Check No. W021524 Date: 02/15/24	2/14/2024	$13.18
AMEX. Delta; Airfare; Airfare from Seattle to JFK - (Coach fare $1248.00)	2/29/2024	$1,028.10

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare from JFK to Seattle - (Coach fare $1008.00) - agency fee	2/29/2024	$45.00
AMEX. Alaska; Airfare; Airfare from JFK to Seattle - (Coach fare $1008.00)	2/29/2024	$678.10
AMEX. Delta; Airfare; Airfare to Seattle (Coach $1248.00)	3/6/2024	$1,038.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Seattle (Coach $1008.00) - agency fee	3/6/2024	$45.00
AMEX. Alaska; Airfare; Airfare to Seattle (Coach $1008.00)	3/6/2024	$748.10
AMEX. Delta; Airfare; DELTA AIR LINES - round trip flight to LA to London	3/11/2024	$1,702.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	3/11/2024	$45.00
Uber Technologies Inc Check No. W031424C Date: 03/13/24 Check No. W031424B1 Date: 03/13/24 Check No. W031424B3 Date: 03/13/24	3/13/2024	$100.27
Uber Technologies Inc Check No. W031424C Date: 03/13/24 Check No. W031424B1 Date: 03/13/24 Check No. W031424B3 Date: 03/13/24	3/13/2024	$20.05
Uber Technologies Inc Check No. W031424C Date: 03/13/24 Check No. W031424B1 Date: 03/13/24 Check No. W031424B3 Date: 03/13/24	3/13/2024	$41.71
Uber Technologies Inc Check No. W031424C Date: 03/13/24 Check No. W031424B1 Date: 03/13/24 Check No. W031424B3 Date: 03/13/24	3/13/2024	$8.34
AMEX. TAXIDRIVER* TAXIDRIV WALTHAM CROSS; Taxi / Car Service; TAXIDRIVER* TAXIDRIV WALTHAM CROSS - taxi from airport to hotel	3/15/2024	$162.67
AMEX. 3CPAYMENT*ANDAZ LOND LONDON; Dinner; 3CPAYMENT*ANDAZ - dinner at hotel	3/15/2024	$29.69
AMEX. Polo Bar London; Lunch; Polo Bar London - lunch	3/16/2024	$19.56
AMEX. 3CPAYMENT*ANDAZ LOND LONDON; Dinner; 3CPAYMENT*ANDAZ - dinner at hotel	3/16/2024	$31.39
AMEX. BOOTS THE CHEMIST LONDON; - office supplies/thumb drives	3/17/2024	$74.05
AMEX. DIRTY DICKS LONDON; Dinner; DIRTY DICKS LONDON - dinner	3/17/2024	$34.86
AMEX. LOH JAPANDI KITCHEN LONDON; Lunch; LOH JAPANDI KITCHEN LONDON - lunch	3/18/2024	$22.17
AMEX. WIFIONBOARD ALASKA 877-350-0038 IL; Air WiFi; Inflight wifi Jim Briggs	3/19/2024	$8.00
AMEX. WIFIONBOARD ALASKA 877-350-0038 IL; Air WiFi; Inflight wifi	3/19/2024	$8.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - service fee	3/19/2024	$45.00
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; WIFIONBOARD CHICAGO - in flight Wi-Fi	3/19/2024	$10.07

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. 3CPAYMENT*ANDAZ LOND GLASGOW; Hotel - Lodging; 3CPAYMENT*ANDAZ LOND GLASGOW	3/19/2024	$1,400.00
Indiana Public Retirement System Check No. 39436 Date: 03/20/24 - Travel to mediation	3/20/2024	$1,401.84
AMEX. SEAMLSS*NYCDELIMARKE NEW YORK NY; Meals - Other; Catered food for deposition	3/20/2024	$294.50
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Dinner; Dinner at hotel with Jim Briggs	3/21/2024	$100.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Dinner; Shuckers - dinner with Jim Briggs	3/21/2024	$100.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Breakfast; Breakfast	3/21/2024	$12.58
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Internet / WiFi; Internet - premium access	3/21/2024	$32.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Meals - Other; Water and snacks	3/21/2024	$44.40
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Dinner; In-room dining - dinner	3/21/2024	$50.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lunch; Lunch with Jim Briggs	3/21/2024	$50.00
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lodging; Lodging - JIM BRIGGS	3/21/2024	$568.76
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Lodging; Lodging	3/21/2024	$568.76
AMEX. FAIRMONT OLYMPIC HOT SEATTLE WA; Hotel - Other; Package handling - Jim Briggs	3/21/2024	$8.00
AMEX. 6356175 - DUNKIN DON JAMAICA NY; Breakfast; Coffee	3/22/2024	$4.67
Uber Technologies Inc Check No. W041024F Date: 04/10/24	4/10/2024	$77.25
Uber Technologies Inc Check No. W041024F Date: 04/10/24	4/10/2024	$121.58
Uber Technologies Inc Check No. W041024F Date: 04/10/24	4/10/2024	$77.98
AMEX. Delta; Airfare; DELTA AIR LINES - San Jose to LA	4/10/2024	$173.00
AMEX. American; Airfare; AMERICAN AIRLINES - flight to San Jose	4/10/2024	$233.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - travel agency after hours charge	4/10/2024	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - air booking fee	4/10/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - air booking fee	4/10/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - travel agency after hours charge	4/11/2024	$34.95
AMEX. Delta; Airfare; Airfare from LAX to New York (coach $308.00) - JIM BRIGGS	4/12/2024	$308.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare from LAX to New York (coach $308.00) - JIM BRIGGS - agency fee	4/12/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Roundtrip airfare to LAX - agency fee	4/12/2024	$45.00
AMEX. American; Airfare; Airfare to LAX (coach $673.00) - JIM BRIGGS	4/12/2024	$673.00
AMEX. Delta; Airfare; Roundtrip airfare to LAX (coach $696.00)	4/12/2024	$696.00
AMEX. PARK JAMES HOTEL 00- MENLO PARK CA; Hotel - Lunch; PARK JAMES HOTEL - lunch at hotel	4/18/2024	$19.41
AMEX. PARK JAMES HOTEL 00- MENLO PARK CA; Hotel - Dinner; PARK JAMES HOTEL - dinner	4/18/2024	$30.16
AMEX. PARK JAMES HOTEL 00- MENLO PARK CA; Hotel - Lodging; PARK JAMES HOTEL	4/18/2024	$350.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC	4/19/2024	$24.95
AMEX. PARK JAMES HOTEL 00- MENLO PARK CA; Hotel - Dinner; PARK JAMES HOTEL - dinner	4/19/2024	$25.33
AMEX. NAYAX VENDING 40 650 HUNT VALLEY MD; Meals - Other; Snack	4/24/2024	$1.50
AMEX. FOUR SEASONS WLAKE V WESTLAKE VILL CA; Hotel - Meals - Other; Private Bar Food - snack	4/24/2024	$10.00
AMEX. FOUR SEASONS WLAKE V WESTLAKE VILL CA; Hotel - Lunch; Lunch	4/24/2024	$14.55
AMEX. FOUR SEASONS WLAKE V WESTLAKE VILL CA; Hotel - Dinner; Dinner for Abe & Jim	4/24/2024	$200.00
AMEX. FOUR SEASONS WLAKE V WESTLAKE VILL CA; Hotel - Lodging; Lodging - Jim Briggs	4/24/2024	$350.00
AMEX. FOUR SEASONS WLAKE V WESTLAKE VILL CA; Hotel - Lodging; Lodging	4/24/2024	$700.00
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Meals - Other; Coffee and water catered for deposition (final invoice not provided)	4/24/2024	$81.34
AMEX. TST* THE STRAND HOUS MANHATTAN BEACH CA; Dinner; Dinner and drinks with Jim Briggs and Jon Uslaner	4/24/2024	$150.00
AMEX. MENDOCINO FARM 09 - THOUSAND OAKS CA; Meals - Other; Catered lunch for deposition	4/25/2024	$272.04
AMEX. Delta; Airfare; Airfare to San Francisco (Coach fare $ 298)	4/26/2024	$298.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to San Francisco - agency fee	4/26/2024	$45.00
AMEX. Delta; Airfare; Airfare from San Francisco (Coach fare $ 298)	4/29/2024	$298.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to San Francisco - agency fee - JIM BRIGGS	4/29/2024	$45.00
AMEX. Delta; Airfare; Airfare to San Francisco (Coach fare $618) - JIM BRIGGS	4/29/2024	$618.00

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Washington, DC - agency fee	5/8/2024	$45.00
AMEX. Delta; Airfare; Airfare to Washington, DC Coach fare 501.20	5/8/2024	$501.20
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Dinner; Dinner	5/10/2024	$100.00
AMEX. HOTEL NIA - PORTA BL MENLO PARK CA; Breakfast; Breakfast	5/10/2024	$17.84
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Internet / WiFi; Internet service	5/10/2024	$19.98
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lunch; Lunch	5/10/2024	$25.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lunch; Lunch	5/10/2024	$25.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lodging; Lodging - Jim Briggs	5/10/2024	$350.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Dinner; Dinner - Jim Briggs	5/10/2024	$48.22
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lodging; Lodging	5/10/2024	$700.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Parking	5/10/2024	$80.00
AMEX. The Ritz-Carlton, Sa San Francisco CA; Hotel - Breakfast; Breakfast	5/11/2024	$20.00
AMEX. The Ritz-Carlton, Sa San Francisco CA; Hotel - Lodging; Lodging	5/11/2024	$350.00
AMEX. The Ritz-Carlton, Sa San Francisco CA; Hotel - Parking; Parking	5/11/2024	$87.00
AMEX. HERTZ CAR RENTAL 800-654-4173 CA; Car Rental; Car rental	5/13/2024	$909.45
AMEX. American; Airfare; Airfare to Washington, DC Coach fare $243 - JIM BRIGGS	5/14/2024	$243.00
AMEX. Delta; Airfare; Airfare from Washington, DC Coach fare $336 - JIM BRIGGS	5/14/2024	$274.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare from Washington, DC Coach fare $336 - JIM BRIGGS - agency fee	5/14/2024	$45.00
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$295.90
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$20.00
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$109.90
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$16.48
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$22.12
Uber Technologies Inc Check No. W051524B1 Date: 05/15/24	5/15/2024	$269.59
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Changed outbound flight date - agency fee	5/21/2024	$45.00
AMEX. Bethesda Marriott 16 Bethesda MD; Hotel - Dinner; Dinner	5/22/2024	$50.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TJ CAFE 848334400213 BETHESDA MD; Lunch; Lunch with Jim Briggs and Adam Hollander	5/22/2024	$75.00
AMEX. DELTA SKY CLUB - DCA ARLINGTON VA; Meals - Other; Food and drinks at airport - Jim Briggs	5/23/2024	$21.50
AMEX. DELTA SKY CLUB - DCA ARLINGTON VA; Meals - Other; Food and drinks at airport	5/23/2024	$28.30
AMEX. CREWS DCA LLC Arlington VA; Lunch; Lunch with Jim Briggs	5/24/2024	$33.00
AMEX. Bethesda Marriott 16 Bethesda MD; Hotel - Lodging; Lodging	5/24/2024	$350.00
AMEX. REGUS REGUS UNITED STATES US; Meeting Room Rental; Room rental for deposition and prep	5/24/2024	$136.89
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$26.31
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$21.91
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$107.65
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$33.20
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$143.37
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$42.92
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$6.43
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$41.90
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$8.38
Uber Technologies Inc Check No. W061324A1 Date: 06/12/24	6/12/2024	$39.91
AMEX. Delta; Airfare; DELTA AIR LINES - Flight LA to San Jose	7/2/2024	$278.48
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - travel booking fee	7/2/2024	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight NY to LA Coach refundable rate: $433	7/2/2024	$433.00
AMEX. United; Airfare; Flight from LA to Newark (Coach $308.48) - JIM BRIGGS	7/2/2024	$308.48
AMEX. United; Airfare; Flight from LA to Newark (Coach $308.48)	7/2/2024	$308.48
AMEX. American; Airfare; Flight to Santa Ana (Coach $598.00)	7/2/2024	$331.47
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight to Santa Ana - agency fee JIM BRIGGS	7/2/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight to Santa Ana (Coach $598.00) agency fee	7/2/2024	$45.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. American; Airfare; Flight to Santa Ana (Coach $598.00) - JIM BRIGGS	7/2/2024	$598.00
AMEX. Southwest; Airfare; SOUTHWEST AIRLINES - flight Burbank to San Jose	7/4/2024	$234.98
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	7/4/2024	$45.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lodging; Hotel Nia, Autograph - hotel stay	7/7/2024	$350.00
AMEX. BURBANK AIRPORT FOOD BURBANK CA; Breakfast; BURBANK AIRPORT FOOD - meal at airport	7/7/2024	$7.50
AMEX. BT*DD *DOORDASH SPRO SAN FRANCISCO CA; Lunch; BT*DD *DOORDASH - lunch via doorash	7/8/2024	$25.00
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lunch; Hotel Nia, Autograph - room service meal	7/8/2024	$42.85
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Dinner; Hotel Nia, Autograph - dinner Porta Blu	7/9/2024	$144.42
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Dinner; Hotel Nia, Autograph - dinner Porta Blu	7/9/2024	$152.27
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lunch; Hotel Nia, Autograph - lunch	7/9/2024	$22.72
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lunch; Hotel Nia, Autograph - lunch at Verve	7/9/2024	$31.09
AMEX. Hotel Nia, Autograph Menlo Park CA; Hotel - Lodging; Hotel Nia, Autograph	7/9/2024	$700.00
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - in flight Wi-Fi	7/9/2024	$10.00
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - in flight WIFI	7/9/2024	$10.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; Inflight wifi	7/9/2024	$25.00
AMEX. SILVER TRUMPET RESTA COSTA MESA CA; Dinner; Dinner with Jim Briggs	7/9/2024	$100.00
AMEX. WATER GRILL SOUTH CO COSTA MESA CA; Dinner; Dinner with Jim Briggs and Adam Hollander	7/10/2024	$150.00
AMEX. CAPITAL GRILLE 01380 COSTA MESA CA; Lunch; Lunch	7/10/2024	$25.00
AMEX. WATER GRILL SOUTH CO COSTA MESA CA; Meals - Other; Drinks with Jim Briggs and Adam Hollander	7/10/2024	$35.02
AMEX. 6351523 - MI CASA T4 JAMAICA NY; Dinner; 6351523 - MI CASA - dinner at airport	7/11/2024	$33.50
AMEX. The Luxury Collectio New York NY; Hotel - Lodging; The Luxury Collection - hotel stay	7/11/2024	$700.00
AMEX. HILTON GARDEN INN NY NEW YORK NY; Hotel - Lodging; HILTON GARDEN INN - hotel stay	7/11/2024	$1,327.48
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from Santa Ana to New York - CHANGED RETURN FLIGHT - agency fee	7/11/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from Santa Ana to New York - CHANGED RETURN FLIGHT - agency fee	7/11/2024	$45.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. American; Airfare; Flight from Santa Ana to New York - CHANGED RETURN FLIGHT - Coach fare $586 - JIM BRIGGS	7/11/2024	$521.48
AMEX. American; Airfare; Flight from Santa Ana to New York - CHANGED RETURN FLIGHT - Coach fare $586	7/11/2024	$586.00
AMEX. Ruby"s Diner SNA 155 Santa Ana CA; Dinner; Dinner with Jim Briggs	7/11/2024	$100.00
AMEX. Costa Mesa Marriott Costa Mesa CA; Hotel - Internet / WiFi; Internet access	7/12/2024	$16.95
AMEX. American Airlines FORT WORTH TX; Air WiFi; Inflight wifi	7/12/2024	$25.00
AMEX. Costa Mesa Marriott Costa Mesa CA; Hotel - Lodging; Lodging	7/12/2024	$350.00
AMEX. Costa Mesa Marriott Costa Mesa CA; Hotel - Internet / WiFi; Premium internet service	7/12/2024	$4.00
AMEX. Costa Mesa Marriott Costa Mesa CA; Hotel - Lodging; Lodging	7/12/2024	$700.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - Wi-Fi charge	7/15/2024	$32.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - Wi-Fi charge	7/15/2024	$32.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - Wi-Fi charge	7/15/2024	$32.00
AMEX. Delta; Airfare; Air fare to LA (Coach fare $654)	7/16/2024	$654.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Air fare to LA - agency fee	7/16/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	7/17/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	7/17/2024	$45.00
AMEX. Delta; Airfare; Air fare to LA (Coach fare - Coach fare $654) - JIM BRIGGS	7/17/2024	$654.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Air fare to LA - agency fee - JIM BRIGGS	7/17/2024	$45.00
AMEX. Delta; Airfare; Air fare to LA (Coach fare $2300) - extended Abe's stay - additional fee for changed flight	7/18/2024	$200.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Air fare to LA - agency fee - extended Abe's stay	7/18/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Reserved hotel stay close to airport when Delta moved Abe from business to coach; transferred to an	7/23/2024	$45.00
AMEX. TWA HOTEL 0688800217 JAMAICA NY; Hotel - Lodging; Last-minute hotel reservation at hotel close to airport when Delta changed planes and moved Abe to c	7/24/2024	$350.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. PKG ONLINE CENTURY C LOS ANGELES CA; Meals - Other; Catered lunch for Pirow Bekker deposition	7/26/2024	$86.51
AMEX. TST* TAMA 00053098 LOS ANGELES CA; Dinner; Dinner with Jim Briggs, Jon Uslaner, Lauren Cruz, Chloe Jasper	7/27/2024	$250.00
AMEX. FAIRMONT CENTURY PLA CENTURY CITY CA; Hotel - Lunch; Lunch with Jim Briggs	7/27/2024	$50.00
AMEX. TST* THE ROSE 001350 VENICE CA; Dinner; Dinner with Jim Briggs, Jon Uslaner, Lauren Cruz, Chloe Jasper	7/28/2024	$250.00
AMEX. FAIRMONT CENTURY PLA CENTURY CITY CA; Hotel - Meals - Other; Beverage	7/28/2024	$7.57
AMEX. FI *CALIFCHICKENCAFE WESTWOOD CA; Meals - Other; Catered lunch for deposition	7/29/2024	$220.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight LA to NYC Delta coach refundable $348	7/31/2024	$348.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - booking fee	7/31/2024	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - flight NYC to LA AA coach refundable $553	7/31/2024	$553.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Snacks - kettle chips	7/31/2024	$10.95
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner with Jim Briggs	7/31/2024	$100.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner with Jim Briggs	7/31/2024	$100.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner with Jim Briggs	7/31/2024	$100.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner with Jim Briggs	7/31/2024	$100.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Lodging; Lodging	7/31/2024	$1,470.42
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Lunch; Lunch	7/31/2024	$25.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Lunch; Lunch	7/31/2024	$25.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Lunch; Lunch	7/31/2024	$25.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Breakfast; Breakfast with Jim Briggs	7/31/2024	$40.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Breakfast; Breakfast with Jim Briggs	7/31/2024	$40.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner	7/31/2024	$45.71
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Dinner; Dinner	7/31/2024	$50.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Beverage - tonic water	7/31/2024	$6.57
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Laundry; Laundry	7/31/2024	$60.00
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Beverage	7/31/2024	$7.57

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Snack - Bahamii Bar	7/31/2024	$9.36
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Beverage - Red Bull	7/31/2024	$9.86
AMEX. FAIRMONT CENTURY PLA LOS ANGELES CA; Hotel - Meals - Other; Snack - chocolate	7/31/2024	$9.86
AMEX. American; Airfare; AMERICAN AIRLINES - flight exchange to stay extra day	8/6/2024	$170.00
AMEX. 6171113 - TAP AND PO HEBRON KY; Dinner; 6171113 - TAP AND PO - meal at airport	8/6/2024	$50.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; CROWNE PLAZA - fee to book additional night at hotel	8/6/2024	$24.95
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$49.06
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$21.73
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$36.53
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$105.20
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$19.99
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$33.12
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$96.80
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$80.35
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$54.38
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$13.59
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$49.15
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$7.37
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$60.84
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$9.12
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$14.97
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$3.00
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$37.97
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$5.69
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$38.11
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$5.71
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$34.46

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$41.47
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$9.94
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$8.91
Uber Technologies Inc Check No. W080824C2 Date: 08/08/24	8/7/2024	$25.99
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA TIMES	8/7/2024	$350.00
AMEX. CURB SVC.- TAXI CURB QUEENS NY; Taxi / Car Service; CURB SVC.- TAXI - JFK to hotel	8/7/2024	$92.69
AMEX. FAMOUS ORIGINAL RAYS NEW YORK NY; Dinner; FAMOUS ORIGINAL RAYS - dinner	8/8/2024	$18.80
AMEX. OCEANA 000000001 NEW YORK NY; Breakfast; OCEANA - breakfast	8/8/2024	$20.00
AMEX. THE HARRISON NEW YORK NY; Dinner; THE HARRISON - dinner	8/8/2024	$50.00
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA	8/8/2024	$350.00
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Breakfast; CROWNE PLAZA - breakfast to go from hotel	8/8/2024	$9.25
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - rebooking/change fee for change to travel home from NY	8/8/2024	$45.00
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Breakfast; CROWNE PLAZA TIMES - hotel breakfast	8/9/2024	$19.87
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA TIMES	8/9/2024	$209.54
AMEX. THE HARRISON NEW YORK NY; Dinner; THE HARRISON- dinner	8/9/2024	$33.97
AMEX. MYSTTIK MASAALA 0000 NEW YORK NY; Lunch; MYSTTIK MASAALA - lunch	8/10/2024	$25.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	8/14/2024	$45.00
AMEX. JETBLUE NEW YORK NY; Seat Upgrade Fee; JETBLUE - seat assignment	8/14/2024	$166.00
AMEX. JETBLUE NEW YORK NY; Seat Upgrade Fee; JETBLUE - seat assignment	8/14/2024	$166.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	8/14/2024	$45.00
AMEX. JetBlue; Airfare; JETBLUE - round trip flight LA to NY	8/14/2024	$721.20
AMEX. AMTRAK WASHINGTON DC; Train / Rail; AMTRAK - train NY to Philadelphia	8/15/2024	$151.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - train booking fee	8/15/2024	$45.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. SEAMLSS*COSICATERING NEW YORK NY; Meals - Other; SEAMLSS*COSICATERING - lunch for deposition	8/16/2024	$12.96
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Lunch; THE WESTIN- room service	8/16/2024	$24.63
AMEX. SEAMLSS*COSICATERING NEW YORK NY; Meals - Other; SEAMLSS*COSICATERING - lunch for deposition	8/16/2024	$304.28
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Breakfast; THE WESTIN- room service	8/16/2024	$31.35
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Lunch; THE WESTIN- room service	8/16/2024	$31.35
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Dinner; THE WESTIN- room service	8/18/2024	$37.10
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Lodging; THE WESTIN PHILADELP	8/18/2024	$700.00
AMEX. LEMONADE LAX Los Angeles CA; Breakfast; LEMONADE LAX - breakfast at airport	8/18/2024	$14.07
AMEX. JFK T5 FC CARIBBEAN QUEENS NY; Dinner; JFK T5 FC CARIBBEAN - dinner at airport	8/18/2024	$25.35
AMEX. The Michelangelo New York Starhotels Collezione; Meals - Other; The Michelangelo - Insieme Lounge, wine	8/18/2024	$19.24
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Meals - Other; MICHELANGELO HOTEL - F&B gratuity	8/19/2024	$11.05
AMEX. LYFT *RIDE SUN 10P SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - JFK to hotel	8/19/2024	$112.60
AMEX. JETBLUE GATE RETAIL RESTON VA; Meals - Other; JETBLUE - coffee on flight	8/19/2024	$13.00
AMEX. JFK T5 EC CIBO EXPRE QUEENS NY; Meals - Other; JFK T5 EC CIBO EXPRE - snacks at airport	8/19/2024	$24.39
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Lodging; MICHELANGELO HOTEL - hotel stay	8/19/2024	$248.64
AMEX. LYFT *RIDE MON 6PM SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - hotel to JFK	8/19/2024	$249.79
AMEX. JFK T5 CC LA VIE 00- QUEENS NY; Dinner; JFK T5 CC LA VIE- dinner at airport	8/19/2024	$50.00
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Breakfast; THE WESTIN PHILADELP - breakfast at hotel	8/20/2024	$27.18
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Lodging; THE WESTIN PHILADELP - hotel stay	8/20/2024	$347.94
AMEX. THE WESTIN PHILADELP PHILADELPHIA PA; Hotel - Dinner; THE WESTIN PHILADELP - dinner at Lea Restaurant	8/20/2024	$47.96
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	8/22/2024	$45.00
AMEX. United; Airfare; UNITED AIRLINES - round trip LA to SF	8/22/2024	$633.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	8/22/2024	$45.00
AMEX. United; Airfare; UNITED AIRLINES - round trip flight DC - SF - LA Coach refundable: $742.96	8/22/2024	$742.96
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - exchange fee	8/26/2024	$45.00
AMEX. Alaska; Airfare; ALASKA AIRLINES - round trip LA to NY for depo coach refundable $1161	8/27/2024	$1,161.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	8/27/2024	$45.00
AMEX. Coffee Bean Tea T8 L Los Angeles CA; Breakfast; Coffee Bean Tea - breakfast at airport	8/29/2024	$17.37
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS - dinner	8/29/2024	$36.17
AMEX. Menlo Tavern; Dinner; STANFORD PARK HOTEL - dinner	8/29/2024	$42.70
AMEX. Menlo Tavern; Meals - Other; Menlo Tavern - coffee	8/29/2024	$7.11
Jim Briggs Check No. 100674 Date: 08/30/24 Check No. 100674 Date: 08/30/24	8/30/2024	$115.22
AMEX. TST* PRONTO - SFO GO SAN FRANCISCO CA; Lunch; TST* PRONTO - lunch	8/30/2024	$15.91
AMEX. LYFT *RIDE THU 1PM SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - airport to hotel	8/30/2024	$60.23
AMEX. MTK; Breakfast; MTK - breakfast at hotel	8/30/2024	$20.00
AMEX. TAXI TRACY CA; Taxi / Car Service; TAXI - taxi airport to hotel	8/30/2024	$135.00
AMEX. STANFORD PARK HOTEL MENLO PARK CA; Hotel - Lodging; STANFORD PARK HOTEL	8/31/2024	$350.00
AMEX. LYFT *RIDE FRI 4PM SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE	8/31/2024	$40.96
AMEX. SFO 6071 The Plant 1 San Francisco CA; Dinner; SFO 6071 The Plant - dinner	8/31/2024	$50.00
AMEX. STANFORD PARK HOTEL MENLO PARK CA; Hotel - Dinner; STANFORD PARK HOTEL MENLO - dinner with Lauren	8/31/2024	$100.00
AMEX. STANFORD PARK HOTEL MENLO PARK CA; Hotel - Lunch; STANFORD PARK HOTEL MENLO - hotel lunch	8/31/2024	$31.70
AMEX. STANFORD PARK HOTEL MENLO PARK CA; Hotel - Lodging; STANFORD PARK HOTEL MENLO	8/31/2024	$700.00
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$24.91
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$7.83
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$8.96
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$9.91
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$60.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$56.87
Uber Technologies Inc Check No. A091224E1 Date: 09/12/24	9/11/2024	$53.84
AMEX. Delta; Airfare; DELTA AIR LINES - round trip flight LA to Buffalo Coach refundable $1427	9/11/2024	$1,427.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - booking fee	9/11/2024	$45.00
AMEX. THE RICHARDSON HOTEL BUFFALO NY; Hotel - Lodging; THE RICHARDSON HOTEL - hotel stay	9/22/2024	$700.00
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight Wi-Fi	9/23/2024	$10.00
AMEX. TST* LOBBY BAR RESTA BUFFALO NY; Dinner; TST* LOBBY BAR RESTA - dinner at hotel	9/23/2024	$41.80
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours fee	9/24/2024	$24.95
AMEX. United; Airfare; UNITED AIRLINES - flight Buffalo to LA Coach refundable: $269.98	9/24/2024	$269.98
AMEX. TST* LOBBY BAR RESTA BUFFALO NY; Dinner; TST* LOBBY BAR RESTA - dinner at hotel	9/24/2024	$28.92
AMEX. THE RICHARDSON HOTEL BUFFALO NY; Hotel - Lodging; THE RICHARDSON HOTEL - additional night at hotel	9/24/2024	$306.54
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	9/24/2024	$45.00
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - in flight Wi-Fi	9/25/2024	$10.00
AMEX. BUFFALO/NIAGARA AIRP CHEEKTOWAGA NY; Breakfast; BUFFALO/NIAGARA AIRP - breakfast at airport	9/25/2024	$18.20
AMEX. TST* LOBBY BAR RESTA BUFFALO NY; Dinner; TST* LOBBY BAR RESTA- dinner at hotel	9/25/2024	$33.73
AMEX. DELTA AIR LINES NEW YORK NY; Airfare; DELTA AIR LINES - partial refund LA to Buffalo	9/25/2024	-$908.98
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel to San Francisco	9/30/2024	$45.00
AMEX. Delta; Airfare; Airfare to San Francisco (Coach fare $716.95)	9/30/2024	$716.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from SFO to New York - agency fee	9/30/2024	$45.00
AMEX. Delta; Airfare; Flight from SFO to New York	9/30/2024	$796.95
Uber Technologies Inc Check No. W101624K1 Date: 10/16/24	10/16/2024	$59.85
Uber Technologies Inc Check No. W101624K1 Date: 10/16/24	10/16/2024	$25.10
AMEX. United; Airfare; UNITED AIRLINES - round trip flight LA to SF Coach refundable is $300	10/16/2024	$300.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	10/16/2024	$40.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. United; Airfare; UNITED AIRLINES - roundtrip flight LA to SF Coach refundable is $300	10/16/2024	$300.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	10/16/2024	$40.00
AMEX. United; Airfare; UNITED AIRLINES - round trip LA to SF coach refundable - $330.94	10/17/2024	$330.94
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	10/17/2024	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - Round trip flights LA to NY PREMIUM REFUNDABLE 2486.95	10/18/2024	$2,486.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; booking fee	10/18/2024	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - roundtrip flight NY to SF for mock jury exercise in ChemoCentryx	10/21/2024	$916.95
AMEX. HUDSONNEWS ST1176 1 JAMAICA NY; Meals - Other; Beverage at airport	10/23/2024	$4.39
AMEX. LAX AIRP ENGINE CO 2 LOS ANGELES CA; Breakfast; LAX AIRP ENGINE - breakfast in airport	10/23/2024	$20.00
AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Lunch; HILTON HERB N KITCHE - lunch at hotel	10/23/2024	$24.71
AMEX. SEAMLSS*MELTSHOP NEW YORK NY; Dinner; SEAMLSS*MELTSHOP - dinner	10/23/2024	$22.14
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; WIFIONBOARD - in flight Wi-Fi	10/23/2024	$39.95
AMEX. TRISARA RESTAURANT 0 SAN FRANCISCO CA; Dinner; TRISARA RESTAURANT - dinner	10/23/2024	$50.00
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - in flight Wi-Fi	10/23/2024	$10.00
AMEX. Starbucks Retail SFO San Francisco CA; Breakfast; Starbucks Retail SFO - breakfast at airport	10/23/2024	$16.04
AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Lunch; HILTON HERB N KITCHE - lunch for Lauren Cruz and Chloe Jasper	10/23/2024	$43.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - ride home to LAX airport	10/23/2024	$58.56
AMEX. LAX AIRP ENGINE CO 2 LOS ANGELES CA; Meals - Other; LAX AIRP ENGINE - coffee at airport	10/23/2024	$7.87
AMEX. WALGREENS #7043 0000 SAN FRANCISCO CA; WALGREENS - food and charger	10/23/2024	$26.47
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; Car service to airport	10/24/2024	$114.40
AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Breakfast; HILTON HERB N KITCHE - breakfast at hotel	10/24/2024	$14.04

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Lunch; HILTON HERB N KITCHE - lunch at hotel	10/24/2024	$18.74
AMEX. UEP*HON"S WUN-TUN HO SAN FRANCISCO CA; Dinner; UEP*HON'S WUN-TUN HO - dinner	10/24/2024	$50.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - pre-tip for Chloe, Jon, and 10/28 my ride from SFO airport to hotel	10/24/2024	$106.38
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS - Jon, Lauren, Chloe dinner at hotel	10/24/2024	$148.60
AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Meals - Other; HILTON HERB N KITCHE - water & soda for Lauren & Chloe	10/24/2024	$16.02
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - tip for Chloe, Jon, and 10/28 my ride from SFO airport to hotel	10/24/2024	$21.27
AMEX. FOUR SEASONS EMBRCDE SAN FRANCISCO CA; Hotel - Lodging; Lodging	10/25/2024	$700.00
AMEX. HILTON HERB N KITCHE SAN FRANCISCO CA; Breakfast; HILTON HERB N KITCHE - coffee at hotel	10/25/2024	$6.52
AMEX. FOUR SEASONS EMB IRD SAN FRANCISCO CA; Dinner; Dinner with Jon Uslaner, Lauren Cruz and Chloe Jasper	10/25/2024	$200.00
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS- dinner for Lauren and Chloe on 10/24 at the hotel	10/25/2024	$93.95
AMEX. Uber EatsY; Dinner; Uber Eats - travel dinner for C. Jasper and L. Cruz	10/25/2024	$57.97
AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Lunch; HILTON SAN FRANCISCO - lunch at hotel	10/26/2024	$16.84
AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Breakfast; HILTON SAN FRANCISCO - breakfast at hotel	10/26/2024	$23.45
AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Dinner; HILTON SAN FRANCISCO - dinner at hotel	10/26/2024	$27.88
AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Lodging; HILTON SAN FRANCISCO - hotel stay	10/26/2024	$663.80
AMEX. FOUR SEASONS EMBRCDE SAN FRANCISCO CA; Hotel - Dinner; Dinner	10/26/2024	$100.00
AMEX. FOUR SEASONS EMBRCDE SAN FRANCISCO CA; Hotel - Lodging; Lodging	10/26/2024	$1,050.00
AMEX. FOUR SEASONS EMBRCDE SAN FRANCISCO CA; Hotel - Lunch; Lunch	10/26/2024	$25.00
AMEX. San Francisco Marrio San Francisco CA; Hotel - Lodging; San Francisco Marriott - hotel stay for mock jury exercise	10/26/2024	$700.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - Jon & Lauren, ride from hotel to airport	10/26/2024	$65.92

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Lodging; HILTON SAN FRANCISCO - hotel stay	10/26/2024	$700.00
AMEX. P7 LAX SMARTPARKING LOS ANGELES CA; Parking; P7 LAX SMARTPARKING -LAX Parking for work trip.	10/26/2024	$180.00
AMEX. HILTON SAN FRANCISCO SAN FRANCISCO CA; Hotel - Lodging; HILTON SAN FRANCISCO	10/26/2024	$700.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight LA to NY	11/4/2024	$915.92
AMEX. American; Airfare; AMERICAN AIRLINES - flight Philadelphia to LA Coach Fare: $790	11/4/2024	$790.00
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$120.34
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$53.88
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$8.08
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$18.59
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$5.00
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$21.33
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$73.87
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$5.33
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$17.52
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$5.00
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$19.92
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$17.84
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$59.22
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$55.97
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$8.39
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$5.00
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$20.86
Uber Technologies Inc Check No. W110724D2 Date: 11/07/24	11/6/2024	$104.13
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	11/11/2024	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight LA to JFK Coach refundable - $458	11/11/2024	$458.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. United; Airfare; UNITED AIRLINES - flight LA to NY Coach refundable UA $348	11/11/2024	$348.48
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	11/11/2024	$45.00
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight Wi-Fi working on CCXI.	11/12/2024	$5.00
AMEX. STARBUCKS STORE 0278 NEW YORK NY; Breakfast; STARBUCKS STORE - breakfast	11/19/2024	$11.78
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours fee	11/19/2024	$24.95
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA TIMES - hotel stay	11/19/2024	$350.00
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA TIMES - hotel stay	11/19/2024	$350.00
AMEX. TST* OBAO - HELLS KI NEW YORK NY; Dinner; TST* OBAO - Dinner for deposition	11/19/2024	$43.82
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - fee to change hotel and flight	11/19/2024	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - flight NY to LA AA refundable coach $463	11/19/2024	$463.00
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight Wi-Fi	11/19/2024	$5.00
AMEX. UNITED AIRLINES NEW YORK NY; Ticket Change Fee; UNITED AIRLINES - ticket exchange	11/19/2024	$104.99
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	11/19/2024	$45.00
AMEX. STARBUCKS STORE 0278 NEW YORK NY; Breakfast; STARBUCKS STORE - breakfast	11/20/2024	$10.78
AMEX. BLUE RIBBON SUSHI BA NEW YORK NY; Dinner; BLUE RIBBON SUSHI - meal with Rebecca Boon	11/20/2024	$100.00
AMEX. CASCATA RESTAURANT & Queens NY; Dinner; CASCATA RESTAURANT - dinner	11/20/2024	$17.41
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - in flight Wi-Fi	11/21/2024	$29.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	11/26/2024	$40.00
AMEX. DELTA AIR LINES NEW YORK NY; Airfare; DELTA AIR LINES - flight LA to NY	11/26/2024	$621.96
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Lodging; CROWNE PLAZA TIMES - hotel stay	12/1/2024	$2,100.00
AMEX. Delta; Airfare; DELTA AIR - flight LA to Boston LAX-BOS coach refundable $378	12/2/2024	$378.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY - booking fee	12/2/2024	$45.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. DELTA AIR LINES NEW YORK NY; Ticket Change Fee; DELTA AIR LINES - flight exchange fee	12/2/2024	$104.99
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - change fee	12/2/2024	$45.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - airport to hotel	12/2/2024	$132.12
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS - dinner	12/2/2024	$25.27
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight WIFI	12/2/2024	$5.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight Boston to NY	12/2/2024	$323.47
AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Dinner; HOTEL AKA BACK BAY - lunch at hotel	12/3/2024	$31.75
AMEX. BOSTON TAXI VTS BOST LONG ISLAND CITY NY; Taxi / Car Service; BOSTON TAXI - taxi airport to hotel	12/3/2024	$32.54
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - airport to hotel tip	12/3/2024	$13.21
AMEX. Delta; Airfare; DELTA AIR LINES - flight NY to LA Coach refundable $388	12/3/2024	$388.00
Uber Technologies Inc Check No. W120524B Date: 12/05/24	12/4/2024	$5.21
Uber Technologies Inc Check No. W120524B Date: 12/05/24	12/4/2024	$39.24
Uber Technologies Inc Check No. W120524B Date: 12/05/24	12/4/2024	$9.81
Uber Technologies Inc Check No. W120524B Date: 12/05/24	12/4/2024	$53.06
Uber Technologies Inc Check No. W120524B Date: 12/05/24	12/4/2024	$7.95
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight Wi-Fi	12/4/2024	$5.00
AMEX. DELTA AIR LINES ATLANTA US; Air WiFi; DELTA AIR LINES - in flight Wi-Fi	12/4/2024	$5.00
AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Dinner; HOTEL AKA BACK BAY - dinner at hotel	12/4/2024	$62.43
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from New York to Boston - American Airlines - CREDIT USED agency fee	12/4/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel to Boston - CREDITS USED	12/4/2024	$45.00
AMEX. TST* CHOPT CREATIVE NEW YORK NY; Lunch; TST* CHOPT CREATIVE - lunch	12/4/2024	$24.57
AMEX. TST* TATTE BAKERY - BOSTON MA; Breakfast; TST* TATTE BAKERY - breakfast	12/5/2024	$13.49
AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Lunch; HOTEL AKA BACK BAY - lunch at hotel	12/5/2024	$31.75

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Dinner; HOTEL AKA BACK BAY - dinner at hotel	12/5/2024	$62.43
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS - dinner	12/5/2024	$32.21
AMEX. American; Airfare; AMERICAN AIRLINES - flight Philadelphia to Boston coach refundable $378	12/5/2024	$378.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	12/5/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee flight change	12/5/2024	$45.00
AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Dinner; HOTEL AKA BACK BAY - dinner at hotel	12/6/2024	$62.43
AMEX. JetBlue; Airfare; Flight from Boston to New York- JIM BRIGGS	12/6/2024	$223.10
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from New York to Boston - JIM BRIGGS - CREDIT USED agency fee	12/6/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel to Boston - JIM BRIGGS - CREDITS USED	12/6/2024	$45.00
AMEX. AMZ*945F0CGB2 LAX NO EAST RUTHERFORD NJ; Breakfast; AMZ*945F0CGB2 LAX - Breakfast at airport traveling to Ragab deposition	12/6/2024	$15.92
AMEX. ALIZ HOTEL TIMES SQ NEW YORK NY; Hotel - Breakfast; ALIZ HOTEL TIMES - breakfast	12/6/2024	$6.53
AMEX. HOTEL AKA BACK BAY 0 BOSTON MA; Hotel - Lodging; HOTEL AKA BACK BAY - hotel stay	12/7/2024	$1,001.52
AMEX. TST* TATTE BAKERY - BOSTON MA; Breakfast; TST* TATTE BAKERY - breakfast	12/7/2024	$13.49
AMEX. LSF LOGAN AIRPORT A BOSTON MA; Breakfast; LSF LOGAN AIRPORT - breakfast at airport (receipt does not show tip)	12/7/2024	$20.00
AMEX. STARBUCKS STORE 6621 NEW YORK NY; Lunch; STARBUCKS STORE - Lunch during Ragab witness prep	12/7/2024	$16.37
AMEX. ALIZ HOTEL TIMES SQ NEW YORK NY; Hotel - Dinner; ALIZ HOTEL TIMES - dinner at hotel	12/7/2024	$36.51
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Dinner; CROWNE PLAZA TIMES - dinner	12/7/2024	$15.07
AMEX. CROWNE PLAZA TIMES S NEW YORK NY; Hotel - Breakfast; CROWNE PLAZA TIMES - breakfast	12/7/2024	$15.07
AMEX. SEAMLSS*DAIHACHISUSH NEW YORK NY; Dinner; SEAMLSS*DAIHACHISUSH - dinner was for me and Chloe Jasper – both working on CCXI	12/7/2024	$81.95
AMEX. CURB SVC.- TAXI CURB QUEENS NY; Taxi / Car Service; CURB SVC. - airport to hotel	12/7/2024	$10.03

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. ALIZ HOTEL TIMES SQ NEW YORK NY; Hotel - Dinner; ALIZ HOTEL TIMES - dinner at hotel	12/8/2024	$9.80
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Dinner; MICHELANGELO HOTEL - dinner	12/8/2024	$13.00
AMEX. MYSTTIK MASAALA 0000 NEW YORK NY; Lunch; MYSTTIK MASAALA	12/8/2024	$18.77
AMEX. DUNKIN #363687 3636 NEW YORK NY; Breakfast; DUNKIN #363687 - breakfast	12/8/2024	$24.01
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Breakfast; MICHELANGELO HOTEL - breakfast	12/8/2024	$7.53
AMEX. MYSTTIK MASAALA 0000 NEW YORK NY; Lunch; MYSTTIK MASAALA - lunch for Jon U, Chloe J, and expert	12/8/2024	$75.00
AMEX. CURB SVC.- TAXI CURB QUEENS NY; Taxi / Car Service; CURB SVC. - hotel to deposition	12/8/2024	$9.46
AMEX. JETBLUE AIRWAYS JETBLUE NY; Seat Upgrade Fee; JETBLUE AIRWAYS - seat assignment fee (both flights)	12/9/2024	$20.00
AMEX. JetBlue; Airfare; JETBLUE AIRWAYS - round trip flight NY to Boston	12/9/2024	$526.21
AMEX. NYCT PAYGO NEW YORK NY; Public Transit; NYCT PAYGO - subway ride	12/9/2024	$2.90
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight from LGA to BOS - agency fee	12/9/2024	$45.00
AMEX. Delta; Airfare; Flight from LGA to BOS	12/9/2024	$528.10
AMEX. American; Airfare; Flight from BOS to LGA	12/9/2024	$685.48
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Lodging; MICHELANGELO HOTEL - hotel stay	12/9/2024	$1,050.00
AMEX. OCEANA 000000001 NEW YORK NY; Dinner; OCEANA - dinner for Jon U, Chloe J, and expert	12/9/2024	$139.22
AMEX. NYC TAXI 1246 460010 LONG ISLAND C NY; Taxi / Car Service; NYC TAXI - deposition to hotel	12/9/2024	$30.60
AMEX. 6353310 - PEETS B26 JAMAICA NY; Breakfast; 6353310 - PEETS -Breakfast traveling home from Ragab deposition	12/10/2024	$13.65
AMEX. TST* GREGORY"S COFFE NEW YORK NY; Breakfast; TST* GREGORY'S COFFE - breakfast	12/10/2024	$11.32
AMEX. JETBLUE AIRWAYS FOREST HILLS OK; Seat Upgrade Fee; JETBLUE AIRWAYS - seat upgrade fee (flight back to LA)	12/10/2024	$159.00
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Breakfast; MICHELANGELO HOTEL - breakfast at hotel	12/10/2024	$28.06
AMEX. JETBLUE AIRWAYS FOREST HILLS OK; Baggage Fee; JETBLUE AIRWAYS - baggage fee	12/10/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee for changed flight	12/10/2024	$45.00
AMEX. JetBlue; Airfare; JETBLUE - changed flight back to LAX	12/10/2024	$573.10

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Breakfast; MICHELANGELO HOTEL - breakfast	12/10/2024	$7.53
AMEX. AMTRAK ACELA CAFE Q WASHINGTON DC; Meals - Other; Snacks on train	12/11/2024	$11.50
AMEX. AMTRAK WASHINGTON DC; Train / Rail; Train Boston to New York - changed from flight due to bad weather	12/11/2024	$288.00
AMEX. TST* PASTRAMI QUEEN NEW YORK NY; Dinner; Dinner	12/11/2024	$32.34
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Train from Boston to New York - outbound flight day before was delayed	12/11/2024	$45.00
AMEX. ALIZ HOTEL TIMES SQ NEW YORK NY; Hotel - Lodging; ALIZ HOTEL TIMES - hotel stay for deposition	12/11/2024	$1,400.00
AMEX. LYFT *RIDE WED 10P SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - airport to hotel	12/11/2024	$58.06
AMEX. LYFT *RIDE WED 7PM SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - ride to airport	12/11/2024	$64.24
AMEX. TST* EL JEFES - BOST BOSTON MA; Dinner; Dinner	12/12/2024	$16.83
AMEX. TST* TASTY BURGER - BOSTON MA; Lunch; TST* TASTY BURGER - lunch	12/12/2024	$21.09
AMEX. The Westin Copley Pl Boston MA; Hotel - Dinner; The Westin Copley - in room dining, dinner	12/12/2024	$50.72
AMEX. JFK T5 FOOD COURT 00 QUEENS NY; Breakfast; JFK T5 FOOD COURT - breakfast at airport	12/12/2024	$6.09
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Meals - Other; Beverage	12/13/2024	$10.00
AMEX. DELAWARE NORTH LOGAN EAST BOSTON MA; Dinner; Dinner	12/13/2024	$13.54
AMEX. JetBlue; Airfare; Airfare from Boston to New York - original flight delayed, changed to earlier flight - JIM BRIGGS	12/13/2024	$320.01
AMEX. Delta; Airfare; Flight delayed - switched to different flight	12/13/2024	$388.48
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Meals - Other; In room dining late night	12/13/2024	$4.98
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight delayed - switched to different flight - agency fee - JIM BRIGGS	12/13/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight delayed - switched to different flight - agency fee	12/13/2024	$45.00
AMEX. CURB SVC.- TAXI CURB QUEENS NY; Taxi / Car Service; Car service	12/13/2024	$64.26
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging	12/13/2024	$700.00
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging	12/13/2024	$700.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. The Westin Copley Pl Boston MA; Hotel - Breakfast; The Westin Copley - in room dining, lunch	12/13/2024	$36.84
AMEX. CREATIVE MOBIL510014 BOSTON MA; Taxi / Car Service; CREATIVE MOBIL510014 - taxi hotel to deposition	12/13/2024	$8.60
AMEX. The Westin Copley Pl Boston MA; Hotel - Dinner; The Westin Copley - in room dining, dinner	12/13/2024	$90.64
AMEX. American; Airfare; AMERICAN AIRLINES - LAX to NY round trip	12/13/2024	$159.94
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	12/13/2024	$45.00
AMEX. POTBELLY #601 BOSTON MA; Dinner; POTBELLY - dinner at airport	12/13/2024	$16.26
AMEX. LYFT *RIDE THU 6PM SAN FRANCISCO CA; Taxi / Car Service; LYFT *RIDE - ride to dinner	12/13/2024	$17.29
AMEX. TST* ESTELLA - 2023 BOSTON MA; Dinner; TST* ESTELLA - bill was split, receipt shows total dinner amount	12/13/2024	$50.00
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; FOUR SEASONS HTL BOS - hotel stay	12/13/2024	$700.00
AMEX. Uber Technologies, Inc.; Taxi / Car Service; Uber Technologies - ride to airport	12/13/2024	$61.56
AMEX. PAYPAL *NATIONALRAI 8008727245 DC; Train / Rail; Rail fare	12/13/2024	$424.00
AMEX. The Westin Copley Pl Boston MA; Hotel - Lodging; Lodging	12/14/2024	$203.21
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - car hotel to airport	12/14/2024	$51.56
AMEX. The Westin Copley Pl Boston MA; Hotel - Lunch; The Westin Copley - Bar Ten, lunch	12/15/2024	$29.61
AMEX. The Westin Copley Pl Boston MA; Hotel - Lodging; The Westin Copley - hotel stay for deposition	12/15/2024	$613.11
AMEX. Delta; Airfare; Roundtrip airfare to Oklahoma City	12/15/2024	$1,767.45
AMEX. Delta; Airfare; Travel to Boston - changed outbound flight - JIM BRIGGS	12/16/2024	$210.01
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Travel to Boston - changed outbound flight JIM BRIGGS - agency fee	12/16/2024	$45.00
AMEX. LAX AIRP SAMMYS PIZZ LOS ANGELES CA; Breakfast; LAX AIRP SAMMYS PIZZ - breakfast at airport	12/16/2024	$20.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - in flight Wi-Fi	12/16/2024	$29.00
AMEX. UBER TRIP HTTPS://HELP.UBER. CA; Taxi / Car Service; UBER TRIP - tip for uber to airport	12/16/2024	$10.00
AMEX. Delta; Airfare; Airfare Ft Myers to Boston - JIM BRIGGS	12/17/2024	$124.28
AMEX. American; Airfare; Airfare to Naples/Ft Myers - JIM BRIGGS	12/17/2024	$138.48

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Naples/Ft Myers - agency fee	12/17/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to Naples/Ft Myers - JIM BRIGGS - agency fee	12/17/2024	$45.00
AMEX. AMERICAN AIRLINES 800-433-7300 TX; Seat Upgrade Fee; Airfare to Naples/Ft Myers - extra legroom	12/17/2024	$72.12
AMEX. AMERICAN AIRLINES 800-433-7300 TX; Seat Upgrade Fee; Airfare to Naples/Ft Myers - extra legroom	12/17/2024	$76.28
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Meals - Other; MICHELANGELO HOTEL - minibar, food, water/soda	12/17/2024	$13.00
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Lodging; MICHELANGELO HOTEL - hotel stay	12/17/2024	$350.00
AMEX. MICHELANGELO HOTEL M NEW YORK NY; Hotel - Dinner; MICHELANGELO HOTEL - dinner	12/17/2024	$50.00
AMEX. MAJESTIC DELICATESSE NEW YORK NY; Breakfast; MAJESTIC DELICATESSE - breakfast and coffee	12/18/2024	$17.90
AMEX. CASCATA RESTAURANT & Jamaica NY; Dinner; CASCATA RESTAURANT - dinner	12/18/2024	$20.02
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - in flight Wi-Fi	12/18/2024	$29.00
AMEX. EATALY BOSTON TERRA BOSTON MA; Dinner; Dinner with Jim Briggs	12/19/2024	$100.00
AMEX. CREATIVE MOBIL510014 BOSTON MA; Taxi / Car Service; Car service in Boston	12/19/2024	$29.15
AMEX. LSF LOGAN AIRPORT A BOSTON MA; Dinner; Dinner with Jim Briggs	12/20/2024	$100.00
AMEX. HERTZ CAR RENTAL EAST BOSTON MA; Car Rental; Car rental at Boston Airport when flight canceled due to bad weather conditions	12/20/2024	$293.53
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging - JIM BRIGGS	12/20/2024	$350.00
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging	12/20/2024	$350.00
AMEX. AMTRAK WASHINGTON DC; Train / Rail; Amtrak from Boston to New York when flight canceled due to bad weather conditions - JIM BRIGGS	12/20/2024	$361.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Amtrak from Boston to New York when flight canceled due to bad weather conditions - JIM BRIGGS - age	12/20/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Request to change flight - JIM BRIGGS - agency fee	12/20/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Request to reserve Amtrak seat when flight canceled - JIM BRIGGS - agency fee	12/20/2024	$45.00

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. BOSTON NEWS CAFE Boston MA; Meals - Other; BOSTON NEWS CAFE - catered lunch for Madigan Deposition Prep in Boston	12/20/2024	$145.40
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	12/20/2024	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee CASE CASE CASE	12/20/2024	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - round trip flight LA-Philadelphia Coach refundable $798	12/20/2024	$798.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Amtrak from Boston to New York when flight canceled due to bad weather conditions - JIM BRIGGS - aft	12/21/2024	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Request to reserve Amtrak seat when flight canceled - JIM BRIGGS - after-hours agency fee	12/21/2024	$24.95
AMEX. BOSTON NEWS CAFE Boston MA; Meals - Other; Breakfast for depo prep group on December 12, 2024	12/23/2024	$157.50
AMEX. BOSTON NEWS CAFE Boston MA; Meals - Other; Lunch for depo prep group on December 12, 2024	12/23/2024	$236.77
AMEX. Delta; Airfare; Flight Cleveland, OH to NY - Coach fare $283.47	12/23/2024	$283.47
AMEX. American; Airfare; Flight NY to Cleveland, OH - Coach fare $358.48	12/23/2024	$358.48
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Flight Cleveland, OH to NY - Coach fare $283.47 - agency fee	12/23/2024	$45.00
AMEX. Delta; Airfare; DELTA AIR LINES - flight Cleveland to LA 358.00 REF COACH	12/23/2024	$121.51
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	12/23/2024	$45.00
AMEX. United; Airfare; UNITED AIRLINES - flight LA to Cleveland REFUNDABLE 528.00 COACH	12/23/2024	$528.00
AMEX. DELTA AIR LINES ATLANTA US; Airfare; Refund for canceled Delta flight BOS to LGA on December 20, 2024 due to inclement weather	12/24/2024	-$288.47
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Meeting Room Rental; Conference room rental - deposit	12/24/2024	$1,485.00
Check issued to Chloe Jasper Check No. 100708 Date: 12/27/24	12/27/2024	$3,512.17
Check issued to Jim Briggs Check No. 100709 Date: 12/27/24	12/27/2024	$156.16
AMEX. DELTA AIR LINES ATLANTA US; Airfare; Refund for flight cancelation - BOS to LGA December 20, 2024 - JIM BRIGGS	12/27/2024	-$263.48

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - Wi-Fi pass for flight to Cleveland for the Cain deposition	1/4/2025	$10.00
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Dinner; The Ritz-Carlton - in room dinner	1/4/2025	$42.38
AMEX. UNITED AIRLINES HOUSTON TX; Air WiFi; UNITED AIRLINES - in flight Wi-Fi	1/4/2025	$8.00
AMEX. Delta; Airfare; Airfare from Cleveland to LGA - changed return flight	1/6/2025	$117.01
AMEX. EUROCAFE ST733 733 CLEVELAND OH; Lunch; Lunch	1/6/2025	$17.00
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Meals - Other; Mini bar snack	1/6/2025	$17.28
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Lodging; Lodging	1/6/2025	$350.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare from Cleveland to LGA - changed return flight - agency fee	1/6/2025	$45.00
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Dinner; Dinner ($100 food and beverage credit used)	1/6/2025	$50.00
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Meeting Room Rental; Balance due from room rental	1/6/2025	$67.05
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Lodging; The Ritz-Carlton - hotel stay - 3 nights	1/7/2025	$1,050.00
AMEX. The Ritz-Carlton, Cl Cleveland OH; Hotel - Dinner; The Ritz-Carlton - dinner/snacks for both me and Katie after the depo.	1/7/2025	$94.02
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$23.01
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$24.26
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$60.42
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$33.27
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$33.24
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$6.65
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$20.66
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$5.00
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$27.34
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$7.00
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$8.20
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$3.00
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$33.04

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$5.00
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$26.12
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$85.78
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$48.99
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$25.06
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$5.01
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$29.01
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$20.45
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$17.84
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$16.39
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$66.06
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$4.09
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$42.03
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$6.30
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$53.41
Uber Technologies Inc Check No. W010925F2 Date: 01/09/25	1/8/2025	$13.35
AMEX. American Airlines FT WORTH TX; Seat Upgrade Fee; Seat to Ft Myers upgrade	1/9/2025	$92.10
AMEX. AMTRAK WASHINGTON DC; Train / Rail; AMTRAK - train NY to Philadelphia	1/10/2025	$122.00
AMEX. CURB NYC TAXI CURB N QUEENS NY; Taxi / Car Service; CURB NYC TAXI - cab office to train station	1/10/2025	$22.38
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	1/10/2025	$45.00
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner at hotel	1/10/2025	$59.82
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - in flight Wi-Fi	1/10/2025	$29.00
AMEX. SWEETGREEN ROCKEFELL NEW YORK NY; Lunch; SWEETGREEN ROCKEFELL - working lunch	1/10/2025	$18.23
AMEX. American Airlines FORT WORTH TX; Air WiFi; Inflight wifi	1/10/2025	$18.00
AMEX. 4220 DOS TOROS 06888 FLUSHING NY; Lunch; Lunch at airport	1/10/2025	$25.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner at hotel	1/11/2025	$47.96
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Meeting Room Rental; HOTEL PALOMAR PHILAD - meeting space for deposition prep	1/11/2025	$337.50
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner, room service	1/11/2025	$48.56
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Meals - Other; HOTEL PALOMAR PHILAD - breakfast, all day beverages, & lunch for prep	1/11/2025	$590.40
AMEX. DEWARS - C RSW Ft. Myers FL; Dinner; Dinner with Jim Briggs	1/11/2025	$100.00
AMEX. STARBUCKS STORE 0970 NAPLES FL; Breakfast; Breakfast - Coffee	1/11/2025	$8.16
AMEX. PARC RESTAURANT PHILADELPHIA PA; Dinner; PARC RESTAURANT - dinner with Chloe evening before deposition	1/12/2025	$100.00
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner at hotel	1/12/2025	$28.76
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Meeting Room Rental; HOTEL PALOMAR PHILAD - meeting space for deposition	1/12/2025	$337.50
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Meals - Other; HOTEL PALOMAR PHILAD - breakfast, all day beverages, & lunch for deposition (rest of payment on seco	1/12/2025	$34.60
AMEX. PANERA BREAD #202118 BOSTON MA; Lunch; Lunch	1/12/2025	$16.57
AMEX. HILTON HOTELS NAPLES NAPLES FL; Hotel - Lodging; Hotel stay - lodging	1/12/2025	$350.00
AMEX. HILTON HOTELS NAPLES NAPLES FL; Hotel - Lodging; Lodging for Jim Briggs	1/12/2025	$350.00
AMEX. HILTON HOTELS NAPLES NAPLES FL; Hotel - Dinner; Dinner	1/12/2025	$38.69
AMEX. HILTON HOTELS NAPLES NAPLES FL; Hotel - Dinner; Dinner	1/12/2025	$49.14
AMEX. EATALY BOSTON SALIDO BOSTON MA; Dinner; Dinner with Jim Briggs	1/12/2025	$95.25
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner at hotel	1/13/2025	$28.76
AMEX. DELAWARE NORTH LOGAN EAST BOSTON MA; Dinner; Dinner with Jim Briggs	1/13/2025	$100.00
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging - Jim Briggs	1/13/2025	$700.00
AMEX. FOUR SEASONS HTL BOS BOSTON MA; Hotel - Lodging; Lodging	1/13/2025	$700.00
AMEX. TST* DAN DAN - RTH 3 PHILADELPHIA PA; Dinner; TST* DAN DAN - dinner w/ Chloe after depo	1/14/2025	$100.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines - in flight Wi-Fi	1/14/2025	$26.00
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Lodging; HOTEL PALOMAR PHILAD - hotel stay	1/14/2025	$881.56
AMEX. LA COLOMBE TERMINAL PHILADELPHIA PA; Breakfast; LA COLOMBE TERMINAL - breakfast at airport	1/14/2025	$21.69
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Dinner; HOTEL PALOMAR PHILAD - dinner, room service	1/14/2025	$50.00
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Meals - Other; HOTEL PALOMAR PHILAD - breakfast, all day beverages, & lunch for deposition (rest of payment)	1/14/2025	$555.80
AMEX. HOTEL PALOMAR PHILAD PHILADELPHIA PA; Hotel - Lodging; HOTEL PALOMAR PHILAD - hotel stay	1/14/2025	$881.56
AMEX. NYC TAXI 1246 460010 LONG ISLAND C NY; Taxi / Car Service; Car service	1/14/2025	$61.70
AMEX. American; Airfare; AMERICAN AIRLINES - round trip flight for Jim Briggs NY to Indianapolis	1/15/2025	$416.97
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee for Jim Briggs flight/hotel	1/15/2025	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee	1/16/2025	$45.00
AMEX. American; Airfare; AMERICAN AIRLINES - round trip flight LA to Indianapolis	1/16/2025	$722.55
AMEX. Einstein Bagels LAS Las Vegas NV; Breakfast; Einstein Bagels - breakfast at airport	1/21/2025	$18.28
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Dinner; CONRAD HOTEL - room service dinner	1/21/2025	$53.20
AMEX. VIASATSWAIRLINES CARLSBAD CA; Air WiFi; VIASATSWAIRLINES - in flight Wi-Fi	1/21/2025	$8.00
AMEX. CAPITAL GRILLE 01380 INDIANAPOLIS IN; Lunch; CAPITAL GRILLE - lunch (receipt shows amount before tip)	1/22/2025	$25.00
AMEX. CAPITAL GRILLE 01380 INDIANAPOLIS IN; Dinner; CAPITAL GRILLE - dinner	1/22/2025	$34.34
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Dinner; CONRAD HOTEL - room service dinner	1/22/2025	$73.40
AMEX. Delta; Airfare; Changed return flight - Coach refundable fare $311	1/22/2025	$254.66
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Changed return flight - agency fee	1/22/2025	$45.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours charge to change flight (for Jim Briggs)	1/23/2025	$24.95

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours charge to change flight (for Jim Briggs)	1/23/2025	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours fee for flight change (for Jon Uslaner)	1/23/2025	$24.95
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - after hours fee for flight change (for Jon Uslaner)	1/23/2025	$24.95
AMEX. INDIANAPOLIS SUBS LL INDIANAPOLIS IN; Lunch; INDIANAPOLIS SUBS - lunch for deposition	1/23/2025	$25.00
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Dinner; CONRAD HOTEL - room service dinner	1/23/2025	$38.60
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; TRAVEL AGENCY SERVIC - booking fee for flight change	1/23/2025	$45.00
AMEX. SEAMLSS*PANERABREAD NEW YORK NY; Meals - Other; SEAMLSS*PANERABREAD - coffee and water for deposition	1/23/2025	$61.86
AMEX. American; Airfare; AMERICAN AIRLINES - rescheduled flight fare for Jim Briggs	1/23/2025	$80.00
AMEX. 6181115 - SUN KING B INDIANAPOLIS IN; Lunch; 6181115 - SUN KING - lunch	1/24/2025	$25.00
AMEX. American Airlines FORT WORTH TX; Air WiFi; American Airlines	1/24/2025	$28.00
AMEX. CAPITAL GRILLE 01380 INDIANAPOLIS IN; Dinner; CAPITAL GRILLE - dinner	1/24/2025	$36.52
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; Hotel - Lodging; CONRAD HOTEL - hotel stay for deposition	1/24/2025	$559.26
AMEX. CONRAD HOTEL INDANAP INDIANAPOLIS IN; - hotel stay for deposition	1/25/2025	$273.85
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Breakfast; Breakfast	1/26/2025	$10.94
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Lunch; Lunch - Jim Briggs	1/26/2025	$25.00
AMEX. WIFIONBOARD CHICAGO IL; Air WiFi; Inflight wifi	1/26/2025	$29.95
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Meals - Other; Minibar snacks and water	1/26/2025	$33.53
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Lodging; Lodging - Jim Briggs	1/26/2025	$350.00
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Lodging; Lodging	1/26/2025	$350.00
AMEX. THE LANGHAM CHICAGO CHICAGO IL; Hotel - Dinner; Dinner	1/26/2025	$50.00
AMEX. LGA ROSSI PIZZERIA 0 FLUSHING NY; Meals - Other; Food at airport with Jim Briggs	1/26/2025	$6.22
AMEX. LGA ROSSI PIZZERIA 0 FLUSHING NY; Meals - Other; Food at airport with Jim Briggs	1/26/2025	$6.49
AMEX. LGA ROSSI PIZZERIA 0 FLUSHING NY; Meals - Other; Food at airport with Jim Briggs	1/26/2025	$7.14

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$45.48
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$10.62
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$34.24
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$8.56
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$59.75
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$14.93
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$36.94
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$20.96
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$3.14
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$28.98
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$39.37
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$7.87
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$24.90
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$9.91
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$21.95
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$21.65
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$20.09
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$30.43
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$34.04
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$7.00
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$36.32
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$7.00
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$69.11
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$13.82
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$45.99
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$9.20
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$68.84

EXHIBIT 11

Homyk v. ChemoCentryx, Inc. **, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$13.77
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$63.52
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$72.63
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$35.78
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$11.92
Uber Technologies Inc Check No. W020525F2 Date: 02/05/25	2/5/2025	$26.13
Check issued to Jim Briggs Check No. 100723 Date: 02/14/25	2/14/2025	$553.48
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; After-hours call made by Sal on January 11th requesting flight information to Boston	2/18/2025	$29.95
Uber Technologies Inc Check No. W030525D2 Date: 03/05/25	3/5/2025	$7.38
AMEX. JFK T5 FOOD COURT 00 QUEENS NY; Lunch; Lunch at airport	4/13/2025	$10.89
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Roundtrip airfare to San Francisco - agency fee	6/3/2025	$45.00
AMEX. Delta; Airfare; Roundtrip airfare to San Francisco - coach $842	6/3/2025	$842.00
AMEX. BLUE RIBBON SUSHI BA NEW YORK NY; Dinner; BLUE RIBBON SUSHI - CHEMOCENTRYX DINNER JORGE AND JON USLANER	7/17/2025	$85.06
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Canceling trip to Seattle on Aug 4, 2025 - after hours agency fee	7/25/2025	$24.95
AMEX. Delta; Airfare; Airfare from SFO to New York (coach fare $910)	5/14/2026	$910.00
AMEX. Delta; Airfare; Airfare to SFO (coach fare $910)	5/14/2026	$910.00
AMEX. TRAVEL AGENCY SERVIC NEW YORK NY; Travel Agency Fee; Airfare to SFO - agency fee	5/14/2026	$45.00
Check issued to Indiana Public Retirement System Check No. 42985 Date: 09/03/26	9/3/2026	$219.36
Total Out of Town Travel		**$149,712.13**
Type of Expense - Working Meals		
Seamless - Working Lunch	3/13/2023	$25.00
Seamless - Working Lunch	3/14/2023	$25.00
Seamless - Working Lunch	3/27/2023	$25.00
Seamless - Working Lunch	4/5/2023	$25.00
Seamless - Working Lunch	5/27/2023	$25.00
Seamless - Working Lunch	5/30/2023	$25.00
Seamless - Working Lunch	6/5/2023	$23.16
Seamless - Working Lunch	6/12/2023	$24.25

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Seamless - Working Lunch	6/23/2023	$25.00
Seamless - Working Lunch	6/27/2023	$25.00
Seamless - Working Lunch	7/19/2023	$24.65
Seamless - Working Lunch	7/26/2023	$25.00
Seamless - Working Lunch	8/24/2023	$17.50
Seamless - Working Lunch	9/14/2023	$15.04
Seamless - Working Lunch	9/20/2023	$25.00
Seamless - Working Lunch	9/20/2023	$25.00
Seamless - Working Lunch	9/20/2023	$25.00
Seamless - Working Lunch	9/25/2023	$23.33
Seamless - Working Lunch	9/25/2023	$23.32
AMEX. I LOVE LA TERMINAL 5 GARDENA CA; Lunch; Lunch charge at airport	9/26/2023	$19.90
Seamless - Working Lunch	9/26/2023	$25.00
Seamless - Working Lunch	9/28/2023	$25.00
Seamless - Working Lunch	9/28/2023	$25.00
Seamless - Working Lunch	10/2/2023	$22.34
Seamless - Working Lunch	10/2/2023	$22.34
Seamless - Working Lunch	10/5/2023	$24.57
Seamless - Working Lunch	10/10/2023	$25.00
Seamless - Working Lunch	10/10/2023	$25.00
Seamless - Working Lunch	10/16/2023	$23.54
Seamless - Working Lunch	10/18/2023	$25.00
Seamless - Working Lunch	10/18/2023	$25.00
Seamless - Working Lunch	10/24/2023	$24.97
Seamless - Working Lunch	10/24/2023	$24.97
Seamless - Working Lunch	10/24/2023	$24.97
Seamless - Working Lunch	10/25/2023	$22.86
Seamless - Working Lunch	10/25/2023	$22.86
Seamless - Working Lunch	10/25/2023	$22.86
Seamless - Working Lunch	10/26/2023	$25.00
Seamless - Working Lunch	10/26/2023	$25.00
Seamless - Working Lunch	10/26/2023	$25.00
Seamless - Working Lunch	10/27/2023	$25.00
Seamless - Working Lunch	10/27/2023	$25.00
Seamless - Working Lunch	11/1/2023	$17.55
Seamless - Working Lunch	11/2/2023	$25.00
Seamless - Working Lunch	11/3/2023	$25.00
AMEX. TEDS MONTANA GRILL 5 NEW YORK NY; Dinner; TEDS MONTANA GRILL	11/5/2023	$47.35
Seamless - Working Lunch	11/8/2023	$25.00
Seamless - Working Lunch	11/8/2023	$25.00
Seamless - Working Lunch	11/10/2023	$20.07

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. #55 OCEAN PRIME NYC NEW YORK NY; Lunch; Lunch with Adam Hollander and Jim Briggs after deposition	11/13/2023	$75.00
Seamless - Working Lunch	12/4/2023	$24.33
Seamless - Working Lunch	12/11/2023	$23.09
Seamless - Working Lunch	12/11/2023	$23.09
Seamless - Working Lunch	12/12/2023	$22.21
Seamless - Working Lunch	12/12/2023	$22.20
Seamless - Working Lunch	12/15/2023	$16.20
Seamless - Working Lunch	12/19/2023	$22.83
Seamless - Working Lunch	12/19/2023	$25.00
Seamless - Working Lunch	12/19/2023	$25.00
Seamless - Working Lunch	12/20/2023	$25.00
Seamless - Working Lunch	12/20/2023	$25.00
Seamless - Working Lunch	12/20/2023	$25.00
Seamless - Working Lunch	12/20/2023	$25.00
Seamless - Working Lunch	12/21/2023	$25.00
Seamless - Working Lunch	12/21/2023	$25.00
Seamless - Working Lunch	1/2/2024	$25.00
Seamless - Working Lunch	1/3/2024	$25.00
Seamless - Working Lunch	1/3/2024	$25.00
Seamless - Working Lunch	1/3/2024	$25.00
Seamless - Working Lunch	1/4/2024	$25.00
Seamless - Working Lunch	1/4/2024	$25.00
Seamless - Working Lunch	1/4/2024	$25.00
Seamless - Working Lunch	1/4/2024	$25.00
Seamless - Working Lunch	1/8/2024	$25.00
Seamless - Working Lunch	1/9/2024	$19.76
Seamless - Working Lunch	1/9/2024	$19.76
Seamless - Working Lunch	1/9/2024	$19.75
Seamless - Working Lunch	1/9/2024	$19.76
Seamless - Working Lunch	1/10/2024	$24.46
Seamless - Working Lunch	1/10/2024	$24.46
Seamless - Working Lunch	1/10/2024	$24.46
Seamless - Working Lunch	1/10/2024	$24.46
Seamless - Working Lunch	1/10/2024	$24.46
Seamless - Working Lunch	1/10/2024	$25.00
Seamless - Working Lunch	1/10/2024	$25.00
Seamless - Working Lunch	1/10/2024	$25.00
Seamless - Working Lunch	1/10/2024	$25.00
Seamless - Working Lunch	1/10/2024	$25.00
Seamless - Working Lunch	1/11/2024	$23.83
Seamless - Working Lunch	1/11/2024	$23.83
Seamless - Working Lunch	1/16/2024	$25.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. CPK OLO #330 0000 CENTURY CITY CA; Lunch; Lunch order for team	1/17/2024	$74.13
Seamless - Working Lunch	1/18/2024	$25.00
Seamless - Working Lunch	1/18/2024	$25.00
Seamless - Working Lunch	1/18/2024	$25.00
Seamless - Working Lunch	1/18/2024	$25.00
Seamless - Working Lunch	1/22/2024	$25.00
Seamless - Working Lunch	1/23/2024	$17.25
Seamless - Working Lunch	1/24/2024	$25.00
Seamless - Working Lunch	1/24/2024	$25.00
Seamless - Working Lunch	1/25/2024	$25.00
Seamless - Working Lunch	1/26/2024	$23.95
Seamless - Working Lunch	1/26/2024	$23.95
Seamless - Working Lunch	1/29/2024	$23.13
Seamless - Working Lunch	1/29/2024	$23.13
Seamless - Working Lunch	1/29/2024	$14.24
Seamless - Working Lunch	1/29/2024	$23.13
Seamless - Working Lunch	1/29/2024	$23.13
Seamless - Working Lunch	1/31/2024	$25.00
Seamless - Working Lunch	2/2/2024	$22.32
AMEX. SUSHI BY MR. LIM 000 NEW YORK NY; Dinner; Working dinner	2/5/2024	$46.82
Seamless - Working Lunch	2/7/2024	$19.49
AMEX. KATSUYA BRENTWOOD LOS ANGELES CA; Meals - Other; Dinner with Caitlin, Chloe and Lauren for CCXI	2/9/2024	$200.00
Seamless - Working Lunch	2/12/2024	$21.24
Seamless - Working Lunch	2/12/2024	$21.24
Seamless - Working Lunch	2/12/2024	$21.25
Seamless - Working Lunch	2/12/2024	$21.25
Seamless - Working Lunch	2/13/2024	$25.00
Seamless - Working Lunch	2/15/2024	$23.51
Seamless - Working Lunch	2/15/2024	$23.51
Seamless - Working Lunch	2/22/2024	$22.84
Seamless - Working Lunch	2/28/2024	$25.00
Seamless - Working Lunch	3/1/2024	$24.94
Seamless - Working Lunch	3/1/2024	$25.00
AMEX. BT*DD *DOORDASH JOET SAN FRANCISCO CA; Lunch	3/5/2024	$21.43
Seamless - Working Lunch	3/6/2024	$18.55
Seamless - Working Lunch	3/11/2024	$25.00
Seamless - Working Lunch	3/11/2024	$25.00
Seamless - Working Lunch	3/13/2024	$24.90
Seamless - Working Lunch	3/13/2024	$24.90
AMEX. SUSHI BY MR. LIM 000 NEW YORK NY; Dinner; Working dinner	3/14/2024	$40.83

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Seamless - Working Lunch	3/14/2024	$17.85
AMEX. TST* FOX PLAZA 00038 LOS ANGELES CA; Lunch; Lunch charge for Jon	3/19/2024	$18.45
AMEX. TST* FOX PLAZA 00038 LOS ANGELES CA; Lunch; Lunch charge for Max, Madeline and AnneMarie	3/20/2024	$28.61
Seamless - Working Lunch	3/20/2024	$25.00
Seamless - Working Lunch	3/20/2024	$25.00
Seamless - Working Lunch	3/27/2024	$25.00
Seamless - Working Lunch	4/4/2024	$25.00
Seamless - Working Lunch	4/4/2024	$25.00
Seamless - Working Lunch	4/9/2024	$13.20
Seamless - Working Lunch	4/10/2024	$24.99
AMEX. TST* FOX PLAZA 00038 LOS ANGELES CA; Lunch; Mel and Jon lunch	4/15/2024	$36.18
Seamless - Working Lunch	4/24/2024	$25.00
Seamless - Working Lunch	5/15/2024	$25.00
AMEX. BT*DD *DOORDASH BARV SAN FRANCISCO CA; Dinner; BT*DD *DOORDASH - working dinner at office	5/29/2024	$26.94
AMEX. SUSHI BY MR. LIM 000 NEW YORK NY; Dinner; Dinner	7/7/2024	$40.83
AMEX. TST* FOX PLAZA 00038 LOS ANGELES CA; Lunch; TST* FOX PLAZA - lunch ordered for Lauren	7/15/2024	$17.23
AMEX. SUSHI BY MR. LIM 000 NEW YORK NY; Dinner; Dinner	7/19/2024	$44.64
Seamless - Working Lunch	7/19/2024	$25.00
AMEX. SEAMLSS*MARMALADECAF NEW YORK NY; Meals - Other; SEAMLSS - Deposition coffee/breakfast	7/23/2024	$116.87
AMEX. SEAMLSS*MARMALADECAF NEW YORK NY; Meals - Other; SEAMLSS - Deposition lunch	7/23/2024	$234.49
Seamless - Working Dinner	8/1/2024	$27.11
AMEX. TOASTIES 49TH ST 000 NEW YORK NY; Lunch; Lunch with Jon Uslaner and Jim Briggs	8/8/2024	$40.57
Seamless - Working Dinner	8/28/2024	$28.92
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS - working dinner for Chemocentryx	10/18/2024	$47.34
AMEX. SHELL SERVICE STATIO EAST ISLIP NY; Meals - Other; Beverage at gas station	10/26/2024	$2.75
AMEX. UBER EATS HTTPS://HELP.UBER. CA; Dinner; UBER EATS -Working dinner	10/31/2024	$26.69
AMEX. TST* FOX PLAZA 00038 LOS ANGELES CA; Lunch; TST* FOX PLAZA - working lunch	12/11/2024	$18.45
AMEX. MELT SHOP - W 50TH S NEW YORK NY; Lunch; Lunch	1/5/2025	$19.89
Check issued to SCNY Cafe Management Inc #2 Check No. 40959 Date:	1/12/2025	$56.16
Seamless - Working Dinner	1/15/2025	$25.88

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Seamless - Working Lunch	1/24/2025	$25.00
Seamless - Working Lunch	3/13/2025	$21.22
Seamless - Working Lunch	3/13/2025	$25.00
Seamless - Working Lunch	3/15/2025	$25.00
Seamless - Working Dinner	3/17/2025	$25.22
Seamless - Working Lunch	3/17/2025	$25.00
Seamless - Working Lunch	3/18/2025	$25.00
Seamless - Working Dinner	3/19/2025	$40.00
Seamless - Working Dinner	3/19/2025	$33.59
Seamless - Working Lunch	3/19/2025	$25.00
Seamless - Working Lunch	3/19/2025	$25.00
Seamless - Working Lunch	3/20/2025	$25.00
Seamless - Working Lunch	4/9/2025	$25.00
Seamless - Working Lunch	6/3/2025	$20.49
Seamless - Working Dinner	6/4/2025	$24.70
Seamless - Working Dinner	6/17/2025	$26.80
Seamless - Working Dinner	6/17/2025	$26.80
Seamless - Working Lunch	6/17/2025	$25.00
Seamless - Working Lunch	6/18/2025	$25.00
Seamless - Working Lunch	6/18/2025	$25.00
Seamless - Working Lunch	6/18/2025	$25.00
Seamless - Working Lunch	6/18/2025	$25.00
Seamless - Working Lunch	6/24/2025	$19.26
Seamless - Working Dinner	6/25/2025	$30.38
Seamless - Working Dinner	7/8/2025	$40.00
Seamless - Working Lunch	7/8/2025	$25.00
Seamless - Working Lunch	7/28/2025	$25.00
Seamless - Working Dinner	7/30/2025	$28.31
Seamless - Working Lunch	8/13/2025	$25.00
Seamless - Working Lunch	9/24/2025	$25.00
Seamless - Working Lunch	10/6/2025	$23.20
Seamless - Working Lunch	10/8/2025	$25.00
Seamless - Working Lunch	11/5/2025	$25.00
Seamless - Working Dinner	11/11/2025	$40.00
Seamless - Working Lunch	11/19/2025	$25.00
Seamless - Working Lunch	12/16/2025	$25.00
Seamless - Working Lunch	12/16/2025	$21.50
Seamless - Working Lunch	12/16/2025	$25.00
Seamless - Working Lunch	12/17/2025	$25.00
Seamless - Working Dinner	12/18/2025	$40.00
Seamless - Working Lunch	12/23/2025	$25.00
Seamless - Working Dinner	12/23/2025	$40.00
AMEX. SEAMLSS*NAYA NEW YORK NY; Lunch; Lunch	12/27/2025	$25.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

AMEX. SEAMLSS*NAYA NEW YORK NY; Lunch; Lunch	12/30/2025	$25.00
Seamless - Working Lunch	1/5/2026	$25.00
Seamless - Working Dinner	3/12/2026	$35.95
Seamless - Working Lunch	5/6/2026	$25.00
AMEX. FAIRMONT CENTURY PLA CENTURY CITY CA; Lunch; FAIRMONT CENTURY PLA - lunch with Melody	5/15/2026	$50.00
Total Working Meals		**$5,866.86**
Type of Expense - Court Reporting & Transcripts		
Vertitext, Invoice 6864935	10/3/2023	$2,052.70
Vertitext, Invoice 6905825	10/18/2023	$1,904.80
Vertitext, Invoice 6950847	11/2/2023	$1,578.75
Vertitext, Invoice 6957374	11/8/2023	$5,296.30
Vertitext, Invoice 6968230	11/13/2023	$4,362.90
Vertitext, Invoice 6999306	11/25/2023	$828.00
Vertitext, Invoice 7020643	12/1/2023	$1,278.00
Vertitext, Invoice 7051572	12/16/2023	$2,527.80
Vertitext, Invoice 7054859	12/18/2023	$978.00
Vertitext, Invoice 7067584	12/21/2023	$1,538.00
Vertitext, Invoice 7054858	12/23/2023	$678.00
Vertitext, Invoice 7054860	12/23/2023	$678.00
Vertitext, Invoice 7075068	12/27/2023	$4,104.30
Vertitext, Invoice 7098605	1/9/2024	$1,038.00
Vertitext, Invoice 7103489	1/10/2024	$2,212.40
Vertitext, Invoice 7122494	1/23/2024	$1,616.20
Vertitext, Invoice 7137627	1/26/2024	$528.00
Vertitext, Invoice 7148126	1/31/2024	$1,220.00
Vertitext, Invoice 7153990	2/2/2024	$4,172.80
Vertitext, Invoice 7173970	2/9/2024	$1,168.00
Vertitext, Invoice 7298877	3/29/2024	$2,324.30
Vertitext, Invoice 7301383	3/31/2024	$5,524.80
Vertitext, Invoice 7307755	4/3/2024	$2,833.00
Vertitext, Invoice 7311425	4/5/2024	$1,048.00
Vertitext, Invoice 7367244	4/25/2024	$275.00
Vertitext, Invoice 7390265	5/6/2024	$1,626.70
Vertitext, Invoice 7391578	5/6/2024	$768.00
Vertitext, Invoice 7403877	5/13/2024	$1,900.00
Vertitext, Invoice 7405675	5/13/2024	$808.00
Vertitext, Invoice 7414141	5/16/2024	$346.50
Vertitext, Invoice 7429385	5/21/2024	$3,649.90
Vertitext, Invoice 7433552	5/21/2024	$1,483.00
Vertitext, Invoice 7471645	6/17/2024	$1,706.30
Vertitext, Invoice 7491549	6/17/2024	$143.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Vertitext, Invoice 7586271	7/25/2024	$1,642.55
Vertitext, Invoice 7591799	7/26/2024	$378.00
Vertitext, Invoice 7574020	7/29/2024	$2,517.25
Vertitext, Invoice 7574905	7/29/2024	$928.00
Vertitext, Invoice 7620647	8/12/2024	$915.60
Vertitext, Invoice 7626296	8/12/2024	$810.00
Vertitext, Invoice 7632197	8/13/2024	$377.30
Vertitext, Invoice 7652323	8/21/2024	$6,638.05
Vertitext, Invoice 7631190	8/23/2024	$2,155.66
Vertitext, Invoice 7631404	8/23/2024	$2,267.90
Vertitext, Invoice 7634319	8/23/2024	$887.50
Vertitext, Invoice 7634321	8/23/2024	$887.50
Check issued to Melody Yaghoubzadeh Check No. 100680 - Reimbursement for payment to Echo Reporting Inc. Transcript for Hearing of 7/30/2024	8/26/2024	$183.15
Vertitext, Invoice 7664979	8/27/2024	$1,854.00
Vertitext, Invoice 7671635	8/28/2024	$125.00
Vertitext, Invoice 7662771	8/28/2024	$8,673.12
Vertitext, Invoice 7700282	9/10/2024	$978.00
Vertitext, Invoice 7697895	9/12/2024	$970.00
Vertitext, Invoice 7707640	9/13/2024	$1,208.00
Vertitext, Invoice 7707638	9/16/2024	$928.00
Vertitext, Invoice 7705371	9/18/2024	$2,629.75
Vertitext, Invoice 7705656	9/18/2024	$2,898.35
Vertitext, Invoice 7767809	10/10/2024	$4,741.15
Vertitext, Invoice 7776770	10/10/2024	$1,128.00
Vertitext, Invoice 7784198	10/14/2024	$1,128.00
Vertitext, Invoice 7913073	12/4/2024	$1,168.00
Vertitext, Invoice 7909809	12/9/2024	$4,974.95
Vertitext, Invoice 7941862	12/13/2024	$2,983.80
Vertitext, Invoice 7938848	12/18/2024	$2,766.40
Vertitext, Invoice 7943817	12/18/2024	$8,569.15
Vertitext, Invoice 7947561	12/18/2024	$7,962.00
Vertitext, Invoice 7952727	12/19/2024	$1,178.00
Vertitext, Invoice 7969386	12/26/2024	$1,128.00
Vertitext, Invoice 7967984	12/27/2024	$4,742.90
Vertitext, Invoice 7969425	12/28/2024	$3,668.00
Vertitext, Invoice 7972671	12/29/2024	$1,048.00
Vertitext, Invoice 7979080	12/31/2024	$1,448.00
Vertitext, Invoice 7980714	1/1/2025	$1,048.00
Vertitext, Invoice 7982020	1/2/2025	$275.00
Vertitext, Invoice 7983347	1/2/2025	$125.00
Vertitext, Invoice 7987056	1/6/2025	$980.00
Vertitext, Invoice 7988671	1/8/2025	$1,395.00
Vertitext, Invoice 7995658	1/9/2025	$4,600.60

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.* , No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Vertitext, Invoice 7998958	1/10/2025	$1,925.00
Vertitext, Invoice 8007201	1/16/2025	$3,706.80
Vertitext, Invoice 8007782	1/16/2025	$1,626.50
Vertitext, Invoice 8011920	1/17/2025	$5,202.44
Vertitext, Invoice 8015700	1/21/2025	$5,378.50
Vertitext, Invoice 8018413	1/21/2025	$2,230.50
Vertitext, Invoice 8012837	1/23/2025	$2,232.50
Vertitext, Invoice 8007888	1/24/2025	$8,310.25
Vertitext, Invoice 8041202	1/30/2025	$2,952.20
Vertitext, Invoice 8050083	2/3/2025	$1,088.00
Vertitext, Invoice 8049538	2/5/2025	$2,078.10
Vertitext, Invoice 8050745	2/5/2025	$986.50
April Wood Brott Check No. 41371	4/16/2025	$89.70
Pamela Batalo Hebel Check No. 41790	7/2/2025	$68.15
Ruth Levine Ekhaus Check No. 42031	8/20/2025	$336.70
AMEX. WWW.REPORTERSUITE.CO MEMPHIS TN; Transcripts	8/21/2025	$58.50
Total Court Reporting & Transcripts		**$200,378.42**
Type of Expense - Software		
AMEX. REV.COM AUSTIN TX; Software; Transcription	11/22/2024	$756.50
AMEX. REV.COM AUSTIN TX; Software; Transcription	12/16/2024	$149.75
AMEX. REV.COM AUSTIN TX; Software; Translation	12/19/2024	$34.50
AMEX. REV.COM AUSTIN TX; Software; Zoom Renewal	1/16/2025	$134.25
Total Software		**$1,075.00**
Type of Expense - Experts & Consultants		
Alan Bonder Invoice 1	9/23/2024	$50,000.00
Alan Bonder Invoice 2	1/21/2025	$78,000.00
Alan Bonder Invoice 3	2/20/2025	$15,000.00
Alan Bonder Invoice 4	3/7/2025	$4,000.00
The Brattle Group Invoice 078814	7/26/2024	$24,500.00
The Brattle Group Invoice 079194	8/26/2024	$445,212.50
The Brattle Group Invoice 079804	10/4/2024	$413,643.75
The Brattle Group Invoice 080291	11/15/2024	$108,162.50
The Brattle Group Invoice 080409	11/26/2024	$54,243.75
The Brattle Group Invoice 080867	12/23/2024	$227,206.25
Matthew D. Cain, Invoice 478	9/6/2023	$37,525.00
Matthew D. Cain, Invoice 499	11/1/2023	$16,921.72
Matthew D. Cain, Invoice 545	2/12/2024	$19,237.50
Matthew D. Cain, Invoice 546	2/12/2024	$16,625.00
Matthew D. Cain, Invoice 572	3/19/2024	$5,462.50

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Matthew D. Cain, Invoice 694	3/13/2025	$132,287.50
Matthew D. Cain, Invoice 716	5/5/2025	$14,487.50
FIDERES USA Inc., Invoice BLBG/2023-01	9/11/2023	$140,808.00
FIDERES USA Inc., Invoice BLBG/2023-02	9/11/2023	$5,000.00
FIDERES USA Inc., Invoice BLBG/2023-03	10/31/2023	$11,889.00
FIDERES USA Inc., Invoice BLBG/2023-04	11/30/2023	$9,362.00
FIDERES USA Inc., Invoice BLBG/2023-05	12/31/2023	$228,994.00
FIDERES USA Inc., Invoice BLBG/2024-01	1/31/2024	$180,012.95
FIDERES USA Inc., Invoice BLBG/2024-02	6/30/2024	$34,296.00
FIDERES USA Inc., Invoice BLBG/2024-03	7/31/2024	$166,614.00
FIDERES USA Inc., Invoice BLBG/2024-04	8/31/2024	$100,079.00
FIDERES USA Inc., Invoice BLBG/2024-05	9/30/2024	$172,462.00
FIDERES USA Inc., Invoice BLBG/2024-06	10/31/2024	$19,694.00
FIDERES USA Inc., Invoice BLBG/2024-07	11/30/2024	$321,475.00
FIDERES USA Inc., Invoice BLBG/2024-08	12/31/2024	$38,496.00
FIDERES USA Inc., Invoice BLBG/2025-01	1/31/2025	$10,640.00
FIDERES USA Inc., Invoice BLBG/2025-03	2/28/2025	$29,000.00
FIDERES USA Inc., Invoice BLBG/2025-05	3/31/2025	$3,910.00
FIDERES USA Inc., Invoice BLBG/2025-06	4/20/2025	$19,100.00
FIDERES USA Inc., Invoice BLBG/2025-08	6/20/2025	$6,000.00
Global Economics Group LLC Check No. W032223A	3/22/2023	$23,502.50
Global Economics Group LLC Check No. W100325	9/12/2025	$872.50
Simon Helfgott	6/22/2024	$13,860.00
Simon Helfgott	9/30/2024	$10,980.00
Simon Helfgott Billing Remit #3	12/5/2024	$19,440.00
Simon Helfgott Billing Remit #4	1/27/2025	$33,930.00
Simon Helfgott Billing Remit #5	3/31/2025	$2,970.00
David Madigan	8/18/2024	$29,600.00
David Madigan	11/24/2024	$35,200.00
David Madigan	2/23/2025	$24,981.20
Peregrine Economics LLC Invoice 1002	2/15/2024	$3,220.00
Peregrine Economics LLC Invoice 1082	3/15/2024	$1,773.75
Peregrine Economics LLC Invoice 1337	9/30/2024	$406.25
David Perrott & Associates LLC Invoice 24031	8/4/2024	$15,750.00
David Perrott & Associates LLC Advance 240302	10/1/2024	$110,000.00
David Perrott & Associates LLC Invoice 240304	12/31/2024	$4,350.00
David Perrott & Associates LLC Invoice 240305	12/31/2024	$60,496.69
David Perrott & Associates LLC Invoice 240306	7/16/2025	$16,200.00
ZnCu Consulting LLC Check No. 39275	2/14/2024	$3,600.00
Total Experts & Consultants		**$3,571,480.31**
Type of Expense - Independent Witness Counsel		
Slarskey LLC Invoice 11924	9/18/2023	$5,282.00

EXHIBIT 11

***Homyk v. ChemoCentryx, Inc.*, No. 4:21-cv-03343-JST**
Bernstein Litowitz Berger & Grossmann LLP
Expense Details

Slarskey LLC Invoice	10/15/2023	$1,459.50
Slarskey LLC Invoice 11376	11/15/2023	$1,459.50
Slarskey LLC Invoice 11438	12/19/2023	$347.50
Slarskey LLC Invoice 11439	12/19/2023	$17,095.30
Slarskey LLC Invoice 11446	1/10/2024	$8,393.33
Slarskey LLC Invoice 11492	2/12/2024	$1,042.50
Slarskey LLC Invoice 11493	2/12/2024	$1,708.00
Slarskey LLC Invoice 11535	3/13/2024	$6,311.25
Slarskey LLC Invoice 1534	3/13/2024	$1,147.50
Slarskey LLC Invoice 11596	4/12/2024	$765.00
Slarskey LLC Invoice 11780	6/10/2024	$18,168.75
Slarskey LLC Invoice 11931	7/15/2024	$659.37
Slarskey LLC Invoice 11932	7/15/2024	$2,486.25
Slarskey LLC Invoice 11982	8/15/2024	$573.75
Slarskey LLC Invoice 11983	8/15/2024	$10,458.95
Slarskey LLC Invoice 12642	7/14/2025	$573.75
Slarskey LLC Invoice 12643	7/14/2025	$2,677.50
Slarskey LLC Invoice 12738	8/15/2025	$956.25
Hach Rose Schirripa & Cheverie LLP	9/8/2025	$86,455.44
Total Independent Witness Counsel		**$168,021.39**
Type of Expense - Rule 54(d)(1) Taxable Costs		
Amgen Inc. Check No. 42291	10/15/2025	$139,246.01
Total Rule 54(d)(1) Taxable Costs		**$139,246.01**
Type of Expense - Mediation Fees		
Phillips ADR Enterprises P.C. Check No. W010324	1/3/2024	$21,250.00
Total Mediation Fees		**$21,250.00**
GRAND TOTAL		**$4,898,136.90**

Exhibit 12A

Dr. Alan Bonder

Alan Bonder M.D.

147 Andrew St. Newton. MA
02461
617 –959- 44 -46
Email: abonder@bidmc.harvard.edu

INVOICE

INVOICE: 1
DATE: 09/23/24

TO:
Abe Alexander at Bernstein Litowitz Berger & Grossman LLP

FOR:
Consultation services

DESCRIPTION	HOURS	RATE/DATE	AMOUNT
Review discovery materials/prepare opening expert report	35	1000 / hr – (May,June,July,Aug 2024)	$35,000.00
Review discovery materials/prepare opening expert report	15	1000/hr – Sept 2024	$15,000.00
		TOTAL	**$50000.00**

Alan Bonder M.D.

INVOICE

147 Andrew St. Newton. MA
02461
617 –959- 44 -46
Email: abonder@bidmc.harvard.edu

INVOICE: 2
DATE: 01/21/25

TO:
Abe Alexander at Bernstein Litowitz Berger & Grossman LLP

FOR:
Consultation services

DESCRIPTION	HOURS	RATE/DATE	AMOUNT
Review materials/prepare rebuttal	35	1000 / hr – (Oct-Nov 2024)	$35,000.00
Review material/prepare for deposition	35	1000/hr – Nov, Dec, jan 2024-2025	$35,000.00
Deposition	8	Jan, 2025	$8,000.00
		TOTAL	**$78000.00**

Alan Bonder M.D.

147 Andrew St. Newton. MA
02461
617 –959- 44 -46
Email: abonder@bidmc.harvard.edu

INVOICE

INVOICE: 3
DATE: 02/20/25

TO:
Abe Alexander at Bernstein Litowitz Berger & Grossman LLP

FOR:
Consultation services

DESCRIPTION	HOURS	RATE/DATE	AMOUNT
Errata review and signature	7.5	1000 / hr – (Feb/2025)	$7500.00
Review motion to exclude	7.5	1000/hr – Feb/2025	$7500.00
		TOTAL	$15000.00

Alan Bonder M.D.

147 Andrew St. Newton. MA
02461
617 –959- 44 -46
Email: abonder@bidmc.harvard.edu

INVOICE

INVOICE: 4
DATE: 03/07/25

TO:
Abe Alexander at Bernstein Litowitz Berger & Grossman LLP

FOR:
Consultation services

DESCRIPTION	HOURS	RATE/DATE	AMOUNT
Motion to exclude witness document	4	1000 / hr – (Mar/2025)	$4000.00
		TOTAL	**$4000.00**

The Brattle Group, Inc.

Brattle

July 26, 2024

In Account With:

Class Action

Invoice Number	078814
ProjectID	CL-09166
Page	1 of 2

For Professional Services Rendered Through June 30, 2024

	Hours	Rate	Amount
Principals			
Benjamin Sacks	1.00	1,075.00	1,075.00
Laurence Freed	5.75	800.00	4,600.00
Outside Consultants			
Ahmed Ragab	6.00	750.00	4,500.00
Marc Walton	2.00	700.00	1,400.00
Senior Associate			
Julia Zhu	9.50	700.00	6,650.00
Associates			
Dean Pender	1.50	575.00	862.50
Angela Golemac	7.50	575.00	4,312.50
Research Analysts			
Abigail Haraburda	2.25	400.00	900.00
Litigation Specialist			
Maryann Capasso	0.50	400.00	200.00
Total Labor			$24,500.00
TOTAL AMOUNT DUE			**$24,500.00**

Brattle

August 26, 2024

In Account With:

Abe Alexander
Bernstein Litowitz Berger & Grossman, LLP
1251 Avenue of the Americas
New York NY 10020
United States

Invoice Number	079194
ProjectID	CL-09166
Page	1 of 3

For Professional Services Rendered Through July 31, 2024

Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343 (N.D. Cal.)

General

	Hours	Rate	Amount
Principals			
Laurence Freed	1.25	800.00	1,000.00
Total Labor			$1,000.00
Related Expenses			
Books & Subscriptions			59.00
Outside/Information Services			47.00
Total Related Expenses			$106.00
General Total			**$1,106.00**

Ragab Report

	Hours	Rate	Amount
Principals			
Laurence Freed	8.25	800.00	6,600.00
Outside Consultants			
Ahmed Ragab	20.00	750.00	15,000.00
Senior Associate			
Julia Zhu	117.00	700.00	81,900.00
Associates			
Dean Pender	15.75	575.00	9,056.25
Angela Golemac	6.50	575.00	3,737.50
Research Analysts			
Catherine Xi	8.75	450.00	3,937.50
Nana Sakyi	28.50	450.00	12,825.00
Abigail Haraburda	63.75	400.00	25,500.00
Sarah Shen	20.75	375.00	7,781.25
Esha Gupta	23.00	375.00	8,625.00
Emily Deng	17.75	350.00	6,212.50
Data Engineer			

	Hours	Rate	Amount
Abhay Kurian	2.00	275.00	550.00
Litigation Specialist			
Maryann Capasso	59.25	400.00	23,700.00
Total Labor			$205,425.00
Ragab Report Total			**$205,425.00**

Walton Report

	Hours	Rate	Amount
Principals			
Laurence Freed	8.75	800.00	7,000.00
Outside Consultants			
Marc Walton	124.17	700.00	86,919.00
Senior Associate			
Julia Zhu	24.50	700.00	17,150.00
Associates			
Dean Pender	15.25	575.00	8,768.75
Angela Golemac	98.25	575.00	56,493.75
Helena Duffee	4.00	575.00	2,300.00
Research Analysts			
Marina Novoa Gomez	40.00	450.00	18,000.00
Maya Bradbury	15.00	400.00	6,000.00
Abigail Haraburda	0.75	400.00	300.00
Sarah Shen	13.50	375.00	5,062.50
Litigation Specialist			
Jared Milazzo	16.50	300.00	4,950.00
Total Labor			$212,944.00
Walton Report Total			**$212,944.00**

Green Report

	Hours	Rate	Amount
Principals			
Laurence Freed	2.50	800.00	2,000.00
Outside Consultants			
Joseph Green	8.00	800.00	6,400.00
Senior Associate			
Julia Zhu	2.50	700.00	1,750.00
Associates			
Dean Pender	0.50	575.00	287.50
Angela Golemac	0.50	575.00	287.50
Helena Duffee	15.25	575.00	8,768.75
Research Analysts			
Tianshu Yang	13.25	450.00	5,962.50

Bernstein Litowitz Berger & Grossman, LLP

Invoice Number	079194
ProjectID	CL-09166
Page	3 of 3

Aiva Smith		0.75	375.00	281.25
	Total Labor			$25,737.50
	Green Report Total			**$25,737.50**

Labor	445,106.50
Related Expenses	106.00
Subtotal	**$445,212.50**
TOTAL AMOUNT DUE	**$445,212.50**

Please note our updated banking information below. For additional information contact accountsreceivable@brattle.com.

Payable upon receipt in US Dollars to: The Brattle Group, Inc. (FID 04-3254813)

Finance Charge of 1.5% per month (18% APR) will be added to overdue invoices.

Please Remit Payment as Follows:

Check Payments:
The Brattle Group, Inc.
One Beacon Street, Suite 2600
Boston, MA 02108

ACH/Wire Payments:
Citibank, N.A. New York
SWIFT No.: CITIUS33
ABA No.: 021000089
Account: BRATTLE GROUP - OPERATING
Account No.: 31240031

Telephone:
+1.617.864.7900

Email: billingdept@brattle.com

Brattle

October 07, 2024

In Account With:

Abe Alexander
Bernstein, Litowitz, Berger & Grossmann LLP
1251 Avenue of the Americas
New York NY 10020
United States

Invoice Number	079804
ProjectID	CL-09166
Page	1 of 3

For Professional Services Rendered Through August 31, 2024

Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343 (N.D. Cal.)

General

	Hours	Rate	Amount
Principals			
Laurence Freed	2.00	800.00	1,600.00
Total Labor			$1,600.00
	General Total		**$1,600.00**

Ragab Report

	Hours	Rate	Amount
Principals			
Laurence Freed	13.25	800.00	10,600.00
Outside Consultants			
Ahmed Ragab	16.00	750.00	12,000.00
Senior Associate			
Julia Zhu	54.00	700.00	37,800.00
Associates			
Dean Pender	23.00	575.00	13,225.00
Angela Golemac	3.50	575.00	2,012.50
Helena Duffee	64.50	575.00	37,087.50
Research Analysts			
Abigail Haraburda	60.00	400.00	24,000.00
Sarah Shen	30.75	375.00	11,531.25
Esha Gupta	12.50	375.00	4,687.50
Litigation Specialist			
Maryann Capasso	17.00	400.00	6,800.00
Total Labor			$159,743.75
	Ragab Report Total		**$159,743.75**

Walton Report

	Hours	Rate	Amount
Principals			

	Hours	Rate	Amount
Laurence Freed	25.25	800.00	20,200.00
Outside Consultants			
Marc Walton	161.50	700.00	113,050.00
Senior Associate			
Julia Zhu	3.00	700.00	2,100.00
Associates			
Dean Pender	19.00	575.00	10,925.00
Angela Golemac	76.50	575.00	43,987.50
Helena Duffee	1.50	575.00	862.50
Research Analysts			
Marina Novoa Gomez	24.00	450.00	10,800.00
Maya Bradbury	22.00	400.00	8,800.00
Litigation Specialist			
Jared Milazzo	49.00	300.00	14,700.00
Total Labor			$225,425.00

Walton Report Total **$225,425.00**

Green Report

	Hours	Rate	Amount
Principals			
Laurence Freed	2.75	800.00	2,200.00
Outside Consultants			
Joseph Green	9.50	800.00	7,600.00
Associates			
Helena Duffee	17.50	575.00	10,062.50
Research Analysts			
Tianshu Yang	14.75	450.00	6,637.50
Aiva Smith	1.00	375.00	375.00
Total Labor			$26,875.00

Green Report Total **$26,875.00**

Labor	413,643.75
Subtotal	**$413,643.75**
TOTAL AMOUNT DUE	**$413,643.75**

Brattle

November 15, 2024

In Account With:

Abe Alexander
Bernstein, Litowitz, Berger & Grossmann LLP
1251 Avenue of the Americas
New York NY 10020
United States

Invoice Number	080291
ProjectID	CL-09166
Page	1 of 2

For Professional Services Rendered Through September 30, 2024

Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343 (N.D. Cal.)

Ragab Report

	Hours	Rate	Amount
Principals			
Laurence Freed	27.25	800.00	21,800.00
Outside Consultants			
Ahmed Ragab	5.75	750.00	4,312.50
Senior Associate			
Julia Zhu	74.00	700.00	51,800.00
Associates			
Dean Pender	28.75	575.00	16,531.25
Helena Duffee	52.50	575.00	30,187.50
Research Analysts			
Abigail Haraburda	39.75	400.00	15,900.00
Sarah Shen	3.75	375.00	1,406.25
Esha Gupta	3.75	375.00	1,406.25
Litigation Specialist			
Maryann Capasso	46.25	400.00	18,500.00
Jared Milazzo	12.50	300.00	3,750.00
Total Labor			$165,593.75
Ragab Report Total			**$165,593.75**

Walton Report

	Hours	Rate	Amount
Principals			
Laurence Freed	25.75	800.00	20,600.00
Outside Consultants			

Bernstein, Litowitz, Berger & Grossmann LLP	Invoice Number	080291
	ProjectID	CL-09166
	Page	2 of 2

Marc Walton	73.50	700.00	51,450.00
Senior Associate			
Julia Zhu	2.00	700.00	1,400.00
Associates			
Angela Golemac	57.75	575.00	33,206.25
Research Analysts			
Marina Novoa Gomez	5.00	450.00	2,250.00
Maya Bradbury	33.25	400.00	13,300.00
Sarah Shen	12.50	375.00	4,687.50
Litigation Specialist			
Jared Milazzo	52.25	300.00	15,675.00
Total Labor			$142,568.75

Less credit given by Marc Walton		-125,000.00
	Walton Report Total	**$17,568.75**
Less Brattle Group courtesy discount		-75,000.00

Labor	308,162.50
Related Credits	-200,000.00
Subtotal	**$108,162.50**
TOTAL AMOUNT DUE	**$108,162.50**

Please note our updated banking information below. For additional information contact accountsreceivable@brattle.com.

Payable in net 45 days in US Dollars to: The Brattle Group, Inc. (FID 04-3254813)

Finance Charge of 1.5% per month (18% APR) will be added to overdue invoices.

Please Remit Payment as Follows:

Check Payments:
The Brattle Group, Inc.
One Beacon Street, Suite 2600
Boston, MA 02108

ACH/Wire Payments:
Citibank, N.A. New York
SWIFT No.: CITIUS33
ABA No.: 021000089
Account: BRATTLE GROUP - OPERATING
Account No.: 31240031

Telephone:
+1.617.864.7900

Email: billingdept@brattle.com

Brattle

November 26, 2024

In Account With:

Abe Alexander
Bernstein, Litowitz, Berger & Grossmann LLP
1251 Avenue of the Americas
New York NY 10020
United States

Invoice Number	080409
ProjectID	CL-09166
Page	1 of 2

For Professional Services Rendered Through October 31, 2024

Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343 (N.D. Cal.)

General

	Hours	Rate	Amount
Data Engineer			
Abhay Kurian	2.50	275.00	687.50
Total Labor			$687.50
	General Total		**$687.50**

Ragab Report

	Hours	Rate	Amount
Principals			
Laurence Freed	3.25	800.00	2,600.00
Senior Associate			
Julia Zhu	3.00	700.00	2,100.00
Associates			
Dean Pender	4.75	575.00	2,731.25
Research Analysts			
Esha Gupta	1.75	375.00	656.25
Litigation Specialist			
Maryann Capasso	23.00	400.00	9,200.00
Total Labor			$17,287.50
	Ragab Report Total		**$17,287.50**

Walton Report

	Hours	Rate	Amount
Principals			
Laurence Freed	4.00	800.00	3,200.00
Senior Associate			
Chi Cheng	2.50	700.00	1,750.00
Associates			
Dean Pender	0.75	575.00	431.25
Angela Golemac	7.50	575.00	4,312.50

		Hours	Rate	Amount
Research Analysts				
	Maya Bradbury	5.25	400.00	2,100.00
	Sarah Shen	15.25	375.00	5,718.75
	Esha Gupta	15.50	375.00	5,812.50
Litigation Specialist				
	Jared Milazzo	0.75	300.00	225.00
	Total Labor			$23,550.00
	Walton Report Total			**$23,550.00**

Green Report

		Hours	Rate	Amount
Principals				
	Laurence Freed	3.50	800.00	2,800.00
Associates				
	Helena Duffee	17.25	575.00	9,918.75
	Total Labor			$12,718.75
	Green Report Total			**$12,718.75**

Labor	54,243.75
Subtotal	**$54,243.75**
TOTAL AMOUNT DUE	**$54,243.75**

Please note our updated banking information below. For additional information contact accountsreceivable@brattle.com.

Payable in net 45 days in US Dollars to: The Brattle Group, Inc. (FID 04-3254813)

Finance Charge of 1.5% per month (18% APR) will be added to overdue invoices.

Please Remit Payment as Follows:

Check Payments:
The Brattle Group, Inc.
One Beacon Street, Suite 2600
Boston, MA 02108

ACH/Wire Payments:
Citibank, N.A. New York
SWIFT No.: CITIUS33
ABA No.: 021000089
Account: BRATTLE GROUP - OPERATING
Account No.: 31240031

Telephone:
+1.617.864.7900

Email: billingdept@brattle.com

Brattle

December 23, 2024

In Account With:

Abe Alexander
Bernstein, Litowitz, Berger & Grossmann LLP
1251 Avenue of the Americas
New York NY 10020
United States

Invoice Number	080867
ProjectID	CL-09166
Page	1 of 2

For Professional Services Rendered Through November 30, 2024

Homyk v. ChemoCentryx, Inc., No. 4:21-cv-03343 (N.D. Cal.)

Ragab Report

	Hours	Rate	Amount
Principals			
Laurence Freed	0.50	800.00	400.00
Outside Consultants			
Ahmed Ragab	33.50	750.00	25,125.00
Senior Associate			
Julia Zhu	27.50	700.00	19,250.00
Associates			
Dean Pender	13.25	575.00	7,618.75
Helena Duffee	47.75	575.00	27,456.25
Research Analysts			
Abigail Haraburda	20.00	400.00	8,000.00
Sarah Shen	14.50	375.00	5,437.50
Esha Gupta	40.25	375.00	15,093.75
Aiva Smith	20.00	375.00	7,500.00
Litigation Specialist			
Maryann Capasso	27.00	400.00	10,800.00
Total Labor			$126,681.25

Ragab Report Total **$126,681.25**

Walton Report

	Hours	Rate	Amount
Principals			
Laurence Freed	2.00	800.00	1,600.00
Outside Consultants			
Marc Walton	30.00	700.00	21,000.00
Associates			
Dean Pender	6.25	575.00	3,593.75
Angela Golemac	25.25	575.00	14,518.75
Research Analysts			

Bernstein, Litowitz, Berger & Grossmann LLP

Invoice Number 080867
ProjectID CL-09166
Page 2 of 2

Maya Bradbury	27.25	400.00	10,900.00
Sarah Shen	22.50	375.00	8,437.50
Esha Gupta	13.00	375.00	4,875.00
Litigation Specialist			
Jared Milazzo	11.50	300.00	3,450.00
Total Labor			$68,375.00
Walton Report Total			**$68,375.00**

Green Report

	Hours	Rate	Amount
Principals			
Laurence Freed	2.00	800.00	1,600.00
Outside Consultants			
Joseph Green	31.00	800.00	24,800.00
Associates			
Helena Duffee	10.00	575.00	5,750.00
Total Labor			$32,150.00
Green Report Total			**$32,150.00**

Labor	227,206.25
Subtotal	**$227,206.25**
TOTAL AMOUNT DUE	**$227,206.25**

Please note our updated banking information below. For additional information contact accountsreceivable@brattle.com.
Payable in net 45 days in US Dollars to: The Brattle Group, Inc. (FID 04-3254813)
Finance Charge of 1.5% per month (18% APR) will be added to overdue invoices.

Please Remit Payment as Follows:

Check Payments:
The Brattle Group, Inc.
One Beacon Street, Suite 2600
Boston, MA 02108

ACH/Wire Payments:
Citibank, N.A. New York
SWIFT No.: CITIUS33
ABA No.: 021000089
Account: BRATTLE GROUP - OPERATING
Account No.: 31240031

Telephone:
+1.617.864.7900

Email: billingdept@brattle.com

Matthew D. Cain

Matthew D. Cain Invoice

Sep. 6, 2023 **Invoice #:** *478*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours	Amount
6/4/2023	Data Analysis	1.00	$ 950.00
6/20/2023	Call w/ Fideres; Data Analysis	1.00	$ 950.00
6/30/2023	Report Drafting; Data Analysis; Call w/ Fideres	3.00	$ 2,850.00
7/3/2023	Data Analysis; Report Drafting	3.00	$ 2,850.00
7/5/2023	Data Analysis; Report Drafting	2.00	$ 1,900.00
7/12/2023	Data Analysis; Report Drafting	1.25	$ 1,187.50
7/18/2023	Report Drafting; Call w/ Counsel	0.75	$ 712.50
7/20/2023	Call w/ Fideres; Report Drafting; Research	4.50	$ 4,275.00
7/27/2023	Call w/ Fideres; Report Drafting; Research	4.00	$ 3,800.00
7/31/2023	Call w/ Fideres; Report Drafting; Research	2.50	$ 2,375.00
8/1/2023	Call w/ Counsel; Report Drafting	0.75	$ 712.50
8/7/2023	Call w/ Fideres; Document Review	0.75	$ 712.50
8/17/2023	Report Drafting	3.25	$ 3,087.50
8/18/2023	Report Drafting	4.50	$ 4,275.00
8/20/2023	Report Drafting	0.75	$ 712.50
8/21/2023	Report Drafting; Call w/ Fideres	3.25	$ 3,087.50
8/22/2023	Report Drafting	1.50	$ 1,425.00
8/23/2023	Report Drafting	0.75	$ 712.50
8/24/2023	Report Drafting	0.50	$ 475.00
8/25/2023	Report Drafting	0.50	$ 475.00
Total		**39.50**	**$ 37,525.00**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain Invoice

Nov. 1, 2023 **Invoice #:** *499*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours	Amount
10/11/2023	Document Review	2.75	$ 2,612.50
10/12/2023	Call w/ Counsel; Document Review	2.25	$ 2,137.50
10/17/2023	Call w/ Fideres; Document Review	2.25	$ 2,137.50
10/18/2023	Depo Prep; Document Review	3.00	$ 2,850.00
10/19/2023	Deposition	4.50	$ 4,275.00
	Travel Expenses	N/A	$ 2,909.22
Total		**14.75**	**$ 16,921.72**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain

Invoice

Feb. 12, 2024 **Invoice #:** *545*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours	Amount
12/4/2023	Call w/ Counsel; Document Review	2.50	$ 2,375.00
12/5/2023	Call w/ Fideres; Research	2.75	$ 2,612.50
12/8/2023	Research; Document Review	1.75	$ 1,662.50
12/13/2023	Document Review; Call w/ Fideres	3.75	$ 3,562.50
12/18/2023	Document Review; Call w/ Counsel	2.25	$ 2,137.50
12/27/2023	Report Drafting; Calls w/ Fideres	3.25	$ 3,087.50
12/28/2023	Report Drafting	3.00	$ 2,850.00
12/29/2023	Document Review; Call w/ Counsel	1.00	$ 950.00
Total		**20.25**	**$ 19,237.50**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain | Invoice

Feb. 12, 2024 **Invoice #:** *546*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours	Amount
1/3/2024	Call w/ Counsel; Report Drafting	1.00	$ 950.00
1/8/2024	Report Drafting; Meeting w/ Fideres	1.00	$ 950.00
1/12/2024	Report Drafting; Call w/ Counsel	2.25	$ 2,137.50
1/16/2024	Call w/ Fideres; Report Drafting	2.75	$ 2,612.50
1/17/2024	Document Review	1.75	$ 1,662.50
1/18/2024	Doc Review; Drafting; Calls w/ Fideres	2.25	$ 2,137.50
1/19/2024	Report Drafting; Call w/ Counsel	2.50	$ 2,375.00
1/22/2024	Calls w/ Fideres; Document Review	1.50	$ 1,425.00
1/23/2024	Calls w/ Fideres; Report Drafting	2.50	$ 2,375.00
Total		**17.50**	**$ 16,625.00**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain | Invoice

Mar. 19, 2024 | **Invoice #:** *572*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours	Amount
2/14/2024	Document Review	2.25	$ 2,137.50
2/15/2024	Document Review; Hearing Stand-By	3.50	$ 3,325.00
Total		**5.75**	**$ 5,462.50**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain Invoice

Mar. 13, 2025 **Invoice #:** *694*

Bill to:

Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours		Amount
6/4/2024	Call w/ Counsel; Research	1.50	$	1,425.00
6/21/2024	Call w/ Counsel; Research	1.75	$	1,662.50
6/24/2024	Call w/ Fideres; Report Drafting	0.75	$	712.50
7/8/2024	Call w/ Fideres; Report Drafting	1.00	$	950.00
7/11/2024	Call w/ Fideres; Research	1.25	$	1,187.50
7/12/2024	Report Drafting	1.50	$	1,425.00
7/17/2024	Call w/ Fideres; Document Review	2.50	$	2,375.00
7/29/2024	Call w/ Fideres; Document Review	1.00	$	950.00
7/31/2024	Call w/ Fideres; Research	0.75	$	712.50
8/1/2024	Report Drafting; Call w/ Fideres	1.25	$	1,187.50
8/9/2024	Report Drafting	0.75	$	712.50
8/12/2024	Calls w/ Counsel, Fideres; Report Drafting	1.50	$	1,425.00
8/14/2024	Data Analysis; Calls w/ Counsel, Fideres	1.75	$	1,662.50
8/15/2024	Calls w/ Counsel, Fideres; Data Analysis	1.50	$	1,425.00
8/16/2024	Call w/ Counsel; Report Drafting	1.75	$	1,662.50
8/20/2024	Call w/ Fideres; Report Drafting	2.25	$	2,137.50
9/3/2024	Document Review; Report Drafting	1.50	$	1,425.00
9/4/2024	Report Drafting; Call w/ Fideres	1.75	$	1,662.50
9/6/2024	Report Drafting; Call w/ Fideres	2.25	$	2,137.50
9/18/2024	Report Drafting; Document Review	5.25	$	4,987.50
9/20/2024	Call w/ Counsel; Report Drafting	1.50	$	1,425.00
9/22/2024	Report Drafting	3.75	$	3,562.50
9/23/2024	Report Drafting	0.75	$	712.50
9/24/2024	Report Drafting	1.00	$	950.00
10/30/2024	Document Review	3.25	$	3,087.50
10/31/2024	Call w/ Counsel; Report Drafting	1.75	$	1,662.50
11/12/2024	Document Review; Report Drafting	2.50	$	2,375.00
11/17/2024	Report Drafting; Document Review	3.25	$	3,087.50

Date	*Description*	Hours	Amount
11/20/2024	Call w/ Fideres; Document Review	4.00	$ 3,800.00
11/21/2024	Report Drafting; Document Review	3.25	$ 3,087.50
11/23/2024	Report Drafting; Call w/ Counsel	4.75	$ 4,512.50
11/24/2024	Report Drafting; Document Review	1.25	$ 1,187.50
12/5/2024	Call w/ Fideres; Document Review	2.25	$ 2,137.50
12/18/2024	Document Review	2.75	$ 2,612.50
12/19/2024	Document Review	2.00	$ 1,900.00
12/20/2024	Call w/ Counsel; Document Review	5.50	$ 5,225.00
12/30/2024	Document Review	3.75	$ 3,562.50
12/31/2024	Document Review	4.50	$ 4,275.00
1/1/2025	Document Review	4.00	$ 3,800.00
1/2/2025	Document Review	8.00	$ 7,600.00
1/3/2025	Call w/ Counsel; Document Review	8.00	$ 7,600.00
1/4/2025	Document Review	8.00	$ 7,600.00
1/5/2025	Meeting w/ Counsel; Document Review	8.50	$ 8,075.00
1/6/2025	Doc. Review; Deposition	9.00	$ 8,550.00
1/29/2025	Deposition Transcript Review	2.50	$ 2,375.00
2/15/2025	Document Review	0.50	$ 475.00
2/21/2025	Call w/ Counsel; Document Review	1.50	$ 1,425.00
2/22/2025	Document Review; Research	1.75	$ 1,662.50
2/24/2025	Document Review; Call w/ Counsel	0.50	$ 475.00
2/26/2025	Document Review; Drafting	1.00	$ 950.00
2/27/2025	Call w/ Counsel; Document Review	0.75	$ 712.50
Total		**139.25**	**$ 132,287.50**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392

Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037

Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

Matthew D. Cain

Invoice

May 5, 2025 **Invoice #:** *716*

Bill to:

Katie Sinderson & Jon Uslaner
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020

Project: ChemoCentryx, Expert Services

Date	*Description*	Hours		Amount
3/31/25	Document Review	0.50	$	475.00
4/1/25	Call w/ Fideres; Document Review	0.50	$	475.00
4/2/25	Calls w/ Counsel; Document Review	1.50	$	1,425.00
4/3/25	Document Review	1.50	$	1,425.00
4/4/25	Call w/ Counsel; Document Review; Drafting	3.25	$	3,087.50
4/5/25	Document Review; Research	2.00	$	1,900.00
4/7/25	Call w/ Counsel; Document Review; Drafting	1.75	$	1,662.50
4/8/25	Call w/ Counsel; Document Review	1.75	$	1,662.50
4/10/25	Calls w/ Counsel; Doc. Review; Hearing Standby	2.50	$	2,375.00
Total		**15.25**	**$**	**14,487.50**

ACH / Wire Payments: Chase Bank, 34 N Main St., Chagrin Falls, OH 44022, (440) 264-2392
Account Name: Cleveland Analytics, LLC; Account # 895709092; ABA Routing # 044000037
Mailing Address: Cleveland Analytics, LLC, 495 N Main St, Chagrin Falls, OH 44022

FIDERES USA Inc.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2023-01

11th September 2023

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 140,808.00
	Total	USD 140,808.00

<u>Payment Terms:</u>

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2023-02

11th September 2023

DESCRIPTION	VAT RATE	AMOUNT
Expert work – economic consulting services in relation to a securities litigation class action against ChemoCentryx		
- Data set up fee	N/A	USD 5,000.00
	Sub-Total	USD 5,000.00
	VAT	N/A
	Total	USD 5,000.00

<u>Payment Terms:</u>

Payable by electronic wire transfer within 14 days from receipt according to the following payment instructions:

Account bank: Metropolitan Commercial Bank
ACH Routing Number: 026014928
Wire Routing Number: 026013356
Account name: Fideres USA Inc
Account number: 253240633224
Reference: BLBG/2023-02

Please Note: We do NOT accept cheques.
All payments must be made in US Dollars and free of all bank and other charges.

Beneficiary Address:	Bank Address:
Revolut Ltd	99 Park Ave
7 Westferry Circus	New York
London	NY10016
E14 4HD	United States

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2023-03

31st October 2023

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 11,889.00
	Total	USD 11,889.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2023-04

30th November 2023

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 9,362.00
	Total	USD 9,362.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2023-05

31st December 2023

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 228,994.00
	Total	USD 228,994.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-01

31st January 2024

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 178,286.00
- Data recharges	N/A	USD 1,726.95
	Total	USD 180,012.95

<u>Payment Terms:</u>

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-02

30th June 2024

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 34,296.00
	Total	USD 34,296.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-03

31st July 2024

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 166,614.00
	Total	USD 166,614.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-04

31st August 2024

DESCRIPTION	VAT RATE	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	N/A	USD 100,079.00
	Total	USD 100,079.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-05

30th September 2024

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 172,462.00
Total	USD 172,462.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2624
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-06

31st October 2024

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 19,694.00
Total	USD 19,694.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2612
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-07

30th November 2024

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 321,475.00
Total	USD 321,475.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2612
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2024-08

31st December 2024

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 38,496.00
Total	USD 38,496.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2612
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2025-01

31st January 2025

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 10,640.00
Total	USD 10,640.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

FIDERES
USE KNOWLEDGE. TAKE ACTION.

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2612
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2025-03

28th February 2025

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 29,000.00
Total	USD 29,000.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2612
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Jonathan D. Uslaner
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2025-05

31st March 2025

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 3,910.00
Total	USD 3,910.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2632
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Jonathan D. Uslaner
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2025-06

30th April 2025

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 19,100.00
Total	USD 19,100.00

<u>Payment Terms:</u>

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

INVOICE

Fideres USA Inc
405 Lexington Ave
Fl 26 Suite 2632
New York
NY 10174
United States

INVOICE DETAILS

Bill to:
Bernstein Litowitz Berger & Grossmann LLP
Att.: Jonathan D. Uslaner
1251 Avenue of the Americas
New York, NY 10020
United States

Invoice no.: BLBG/2025-08

30th June 2025

DESCRIPTION	AMOUNT
Expert work - economic consulting services in relation to a securities litigation class action against ChemoCentryx	USD 6,000.00
Total	USD 6,000.00

Payment Terms:

Payable by electronic wire transfer within payment date set force in letter of engagement.

Payment instructions will be communicated closer to invoice due date.

Global Economics Group LLC

Global Economics GROUP

Suite 1000
Chicago, IL 60603

Invoice

Invoice #:	Invoice Date:	Due Date:
8360	12/31/2023	1/30/2024

Case Name	ChemoCentryx
Account #	1443
Bill To:	

Bernstein Litowitz Berger & Grossmann LLP
Abe Alexander
1285 Avenue of the Americas
New York, NY 10019

Serviced	Description	Hours/Qty	Rate	Amount
12/27/2023	Peters Analyzed data and documents.	0.5	320.00	160.00
12/27/2023	Hedstrom Analyzed date and documents.	0.5	475.00	237.50
12/27/2023	Coffman Expert analysis.	0.5	950.00	475.00

REMIT TO:
Global Economics Group
140 S Dearborn Street
Suite 1000
Chicago, IL 60603

WIRE/ACH INSTRUCTIONS:
Account Name: Global Economics Group LLC
Account No.: 839600662
ABA Routing No.: 071000013
SWIFT Code: CHASUS33
Bank Info: JP Morgan Chase, 10 S Dearborn
Chicago, IL 60603

Total	$872.50
Payments/Credits	$0.00
Balance Due	$872.50
Customer Balance Total	$872.50

Dr. Simon Helfgott

To: Bernstein, Litowitz, Berger & Grossmann LLP
Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
Abe.Alexander@blbglaw.com

Re: Expert Review
Expert Fees: Simon Helfgott MD

2023

July 1	Review of Documents.	2.0 hr
August 5	Review of Documents.	1.0 hr
Sept. 15	Conference Call with attorneys	1.1 hr
Total for 2023		4.1 hr

2024. Jan 1- June 27

June 7	Call with Abe Alexander, Jim Briggs.	0.75
June 11	Review of Glassock deposition	4.00
June 13	Review of FDA comm. Vote	1.30
June 21	Review of Maddrey deposition-1.	3.25
June 22	Review of Maddrey deposition-2.	2.00

Total to date (2023 to June 22, 2024) 15.4 hours @900/hr = $ 13,860

June 28-Sept 30 2024

June 28	Zoom call with attorneys	0.6 hr
July 11.	Review of Chao Wang docs.	0.8 hr
Sept 2	Review of Expert Report.	3.0 hr
Sept 3.	Review of Expert Report	2.5 hr
Sept 4.	Review of Expert Report	2.0 hr
Sept 6.	Zoom call with attorneys	0.5 hr
Sept 6	Review and analyze data Re pts who were reassigned	0.3
Sept 10	Review and collate CV	0.2
Sept 22.	Edits to final Draft expert report.	0.8
Sept 24	Edits to final Draft expert report.	0.9
Sept 25	Edits to final Draft expert report.	0.6

12.2. =10980

Dec 5, 2024

To: Bernstein, Litowitz, Berger & Grossmann LLP
Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
Abe.Alexander@blbglaw.com

Re: Expert Review
Expert Fees: Simon Helfgott MD
Billing Remit # 3

Oct 30 Review of Dua and Lally Reports	1.5
Oct 31 Call with Attorneys	1.0
Nov 1. Review of Dua and Lally Reports	1.5
Nov 3. Review of Dua and Lally Reports	3.0
Nov 5 Call with Attorneys	1.0
Nov 6. Review of LOVAS study data	0.4
Nov 7. Review-critique Lally report	1.3
Nov. 11 Review of FDA panel qualifications.	0.3
Nov 13. Angioedema data review +reply	1.0
Nov 14. Review of my rebuttal report	0.4
Nov 15. Review of my rebuttal report	1.4
Nov 19. Review of my rebuttal report	2.5
Nov 23 Review of my rebuttal report	4.0
Nov 24. Call with attorneys	0.7
Nov 27. Review of my CV for potential Conflicts	0.5
Nov 30 Review of materials for deposition	1.1

TOTAL 21.6 HR @ 900/hr = $19,440

Payment Info:
Simon Helfgott MD
11 Hamlin Road
Newton MA 02459

January 27, 2025

To: Bernstein, Litowitz, Berger & Grossmann LLP
Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
Abe.Alexander@blbglaw.com

Re: **Expert Review Avacopan**
Expert Fees: Simon Helfgott MD

Billing Remit # 4

Dec 2024-January 2025

Dec 2	email correspondence with attorneys.	0.2
Dec 4.	Review Lally deposition	1.1
Dec 6	Review of Dua deposition	4.7
Dec 8	Review of deposition materials	2.6
Dec 9	Review of deposition materials	1.5
Dec 10	Zoom Call with attorneys	4.0
	Review of documents	1.5
Dec 11.	Review of materials.	1.9
Dec 12	Practice deposition with attorneys	7.7
	Final review of materials	2.0
Dec 13.	Deposition	9.8
Jan 24.	Meet with Attorneys re Dua depo.	0.7
TOTAL		**37.7 hrs = $ 33,930**

Payment Info:

Simon Helfgott MD

11 Hamlin Road

Newton MA 02459

To: Bernstein, Litowitz, Berger & Grossmann LLP
Abe Alexander
1251 Avenue of the Americas
New York, NY 10020
Abe.Alexander@blbglaw.com

Re: Expert Review
Expert Fees: Simon Helfgott MD

Billing Remit # 5

FEB 18 Review of Motion to exclude testimony	1.0 hr
Feb.20 Conference Call with Attorneys	0.5 hr
Mar 4. Review of memorandum of points. .	1.8 hr

Total 3.3hr @900/hr = $2970

Payment Info:
Simon Helfgott MD
11 Hamlin Road
Newton MA 02459

Dr. David Madigan

INVOICE

NAME: David Madigan
SS # (or TIN): [redacted]
Address: 27 Colchester Street, Brookline, MA 02446
Phone #: 862-812-3690
Invoice date: August 18, 2024

Bill to: Abe Alexander, BLBG

Summary

LABOR (at $800/hour)
Total Hours: 37
Subtotal $29,600

EXPENSES
Subtotal $0

Subtotal (Labor) **$29,600.00**
Subtotal (Expenses) **$**

TOTAL AMOUNT DUE	**$29,600.00**

Please make check payable to: David Madigan

Detail

8/5/23	2	Review
10/28/23	2	Review SAS
11/25/23	1	Review files
12/2/23	3	Coding for efficacy analysis
12/10/23	1	Coding + analysis
12/22/23	1	Consult
3/2/24	1.5	Analysis

3/24/24	0.5	Analysis
5/10/24	1	Yue deposition
6/2/24	2	Review depositions
6/16/24	2	Review docs etc.
7/5/24	3	Analysis
7/6/24	3	Analysis
7/10/24	1	Analysis
7/20/24	2	Analysis + Report
7/22/24	1	Analysis
7/24/24	1	Analysis
8/5/25	1	Analysis
8/10/24	2.5	Report
8/11/24	3.5	Report
8/18/24	2	Report

INVOICE

NAME: David Madigan
SS # (or TIN): [redacted]
Address: 27 Colchester Street, Brookline, MA 02446
Phone #: 862-812-3690
Invoice date: November 24, 2024

Bill to: Abe Alexander, BLBG

Summary

LABOR (at $800/hour)
Total Hours: 44
Subtotal $35,200

EXPENSES
Subtotal $0

Subtotal (Labor) **$35,200.00**
Subtotal (Expenses) **$**

TOTAL AMOUNT DUE	**$35,200.00**

Please make check payable to: David Madigan

Detail

8/20/24	0.5	Call
9/2/24	2	Report
9/5/24	0.5	Call
9/7/24	2	Analysis
9/15/24	3	Report
9/21/24	2	Report
9/22/24	4	Report

9/23/24	1	Report
11/2/23	4	Call plus analysis
11/3/24	2	Analysis
11/9/24	3	Analysis, rebuttal
11/10/24	3	Rebuttal
11/11/24	2	Analysis
11/17/24	6	Rebuttal
11/18/24	3	Rebuttal
11/19/24	2	Analysis
11/20/24	1	Analysis
11/23/24	3	Rebuttal

INVOICE

NAME:	David Madigan
SS # (or TIN):	539-19-3793
Address:	27 Colchester Street, Brookline, MA 02446
Phone #:	862-812-3690
Invoice date:	February 23, 2025

Bill to: Abe Alexander, BLBG

Summary

LABOR (at $800/hour)

Total Hours:	30.5
Subtotal	$24,400

EXPENSES

Flight BOS – RSW	$581.20
Subtotal	$0

TOTAL AMOUNT DUE	**$24,981.20**

Please make check payable to: David Madigan

Detail

12/14/24	2	Depo prep call
12/14/24	4	Depo prep
12/19/24	3	Depo prep session
12/19/24	2	Depo prep
12/20/24	2	Depo prep
12/20/24	5.5	Depo
12/24/24	1	Review transcript
12/27/24	1	Further analysis
1/5/25	1	Call
1/10/25	1	Prep

1/11/25	7	Gibbons depo
2/15/25	1	Review motion

Peregrine Economics LLC

Peregrine ECONOMICS

Invoice

125 S Wacker Drive
Suite 2610
IL 60606

Invoice #	Invoice Date	Due Date
1005	2/15/2024	3/16/2024

Case Name	ChemoCentryx
Account #	2113

Bill To

Bernstein Litowitz Berger & Grossmann LLP
Abe Alexander
1285 Avenue of the Americas
New York, NY 10019

Serviced	Description	Hours/Qty	Rate	Amount
1/4/2024	Hedstrom Analyzed data and documents.	0.5	475.00	237.50
1/11/2024	Peters Analyzed data and documents.	3	355.00	1,065.00
1/11/2024	Kubik Analyzed data and documents.	6	280.00	1,680.00
1/11/2024	Hedstrom Analyzed data and documents.	0.5	475.00	237.50

WIRE/ACH INSTRUCTIONS
Account Name: Peregrine Economics LLC
Account No.: 957219121
ABA Routing No.: 071000013
SWIFT Code: CHASUS33
Bank Info: JP Morgan Chase, 10 S Dearborn, Chicago, IL 60603

Total $3,220.00

Peregrine ECONOMICS

125 S Wacker Drive
Suite 2610
IL 60606

Invoice

Invoice #	Invoice Date	Due Date
1082	3/15/2024	4/14/2024

Case Name	ChemoCentryx
Account #	2113
Bill To	

Bernstein Litowitz Berger & Grossmann LLP
Abe Alexander
1285 Avenue of the Americas
New York, NY 10019

Serviced	Description	Hours/Qty	Rate	Amount
2/5/2024	Hedstrom Analyzed data and documents.	0.5	475.00	237.50
2/5/2024	Kubik Analyzed data and documents.	2	280.00	560.00
2/5/2024	Peters Analyzed data and documents.	1.25	355.00	443.75
2/7/2024	Peters Analyzed data and documents.	1.5	355.00	532.50

WIRE/ACH INSTRUCTIONS
Account Name: Peregrine Economics LLC
Account No.: 957219121
ABA Routing No.: 071000013
SWIFT Code: CHASUS33
Bank Info: JP Morgan Chase, 10 S Dearborn, Chicago, IL 60603

Total $1,773.75

Peregrine
ECONOMICS
125 S Wacker Drive
Suite 2610
IL 60606

Invoice

Invoice #	Invoice Date	Due Date
1337	9/30/2024	10/30/2024

Case Name	ChemoCentryx
Account #	2113

Bill To

Bernstein Litowitz Berger & Grossmann LLP
Abe Alexander
1285 Avenue of the Americas
New York, NY 10019

Serviced	Description	Hours/Qty	Rate	Amount
8/16/2024	Peters Analyzed data and documents.	0.75	355.00	266.25
8/16/2024	Kubik Analyzed data and documents.	0.5	280.00	140.00

WIRE/ACH INSTRUCTIONS

Account Name: Peregrine Economics LLC
Account No.: 957219121
ABA Routing No.: 071000013
SWIFT Code: CHASUS33
Bank Info: JP Morgan Chase, 10 S Dearborn, Chicago, IL 60603

Total	$406.25
Payments/Credits	$0.00
Balance Due	$406.25
Customer Total Balance	$5,400.00

David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
(917) 745-7279
accounting@davidperrott.com

Invoice 240301

DAVID PERROTT
& ASSOCIATES LLC

BILL TO
Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020 USA

DATE	PLEASE PAY	DUE DATE
08/04/2024	$15,750.00	08/04/2024

DATE	ACTIVITY	AMOUNT
06/13/2024	**Hourly Consulting** Review Amended CAC (201 pages but skimmed over repetition re: statements at issue) and take notes re: case strengths, risks, potential themes, 4 hrs @ $900.00/hr	3,600.00
07/08/2024	**Hourly Consulting** [cont] Review Amended CAC (201 pages but skimmed over repetition re: statements at issue) and take notes re: case strengths, risks, potential themes, 4 hrs 15 mins @ $900.00/hr	3,825.00
07/10/2024	**Hourly Consulting** Review Def MTD brief and take notes re: case strengths, risks, potential themes, 2 hrs @ $900.00/hr	1,800.00
07/10/2024	**Hourly Consulting** Review Pl Opp to MTD brief and take notes re: case strengths, risks, potential themes, 2 hrs 15 mins @ $900.00/hr	2,025.00
07/10/2024	**Hourly Consulting** Review Def Reply to Pl Opp to MTD brief and take notes re: case strengths, risks, potential themes, 45 mins @ $900.00/hr	675.00
07/11/2024	**Hourly Consulting** Skim/review select exhibits from set provided by counsel, 1 hr 30 mins @ $900.00/hr	1,350.00
07/11/2024	**Hourly Consulting** Review Court’s MTD Opinion and take notes re: case strengths, risks, potential themes, 1 hr @ $900.00/hr	900.00
07/11/2024	**Hourly Consulting** Review Court’s Class Cert. Opinion and take notes re: case strengths, risks, potential themes -, 30 mins @ $900.00/hr	450.00
07/12/2024	**Hourly Consulting** Review notes and organize thoughts in advance of call with counsel and participate in Zoom strategy call with counsel to convey impressions and receive case update, 1 hr 15 mins @ $900.00/hr	1,125.00

Expert consultation re: Homyk v. ChemoCentryx, Inc. et al.,
June-July 2024

TOTAL DUE	$15,750.00

THANK YOU.

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
(917) 745-7279
accounting@davidperrott.com

ADVANCE INVOICE

BILL TO
Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020 USA

ADVANCE # 240302
DATE 10/01/2024

DATE	ACTIVITY	AMOUNT
10/01/2024	**Advance** Retainer for 2-day 3-panel mock jury exercise	110,000.00

re: Homyk v. ChemoCentryx, Inc. et al.
Retainer for 2-day 3-panel mock jury exercise (aprrox. 100% estimated expenses + 50% of flat professional fee)

Balance due by Fri, Oct 11, 2024 **$110,000.00**

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
+19177457279
accounting@davidperrott.com

Invoice 240303

DAVID PERROTT
& ASSOCIATES LLC

BILL TO
Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020 USA

DATE	PLEASE PAY	DUE DATE
12/31/2024	$0.00	12/31/2024

DATE	ACTIVITY	AMOUNT
10/02/2024	**Hourly Consulting** Review Pl and Def mediation statements and reply briefs and take notes, 3 hrs 45 mins @ $900.00/hr	3,375.00
10/03/2024	**Hourly Consulting** Review/skim Pl expert reports (Bonder, Cain, Helfgott), 6 hrs 45 mins @ $900.00/hr	6,075.00
10/04/2024	**Hourly Consulting** Review/skim Pl expert reports (Madigan, Ragab, Walton), 6 hrs 15 mins @ $900.00/hr	5,625.00
10/05/2024	**Hourly Consulting** Review/skim select deposition transcripts (Glassock, Maddrey, Goodkin, Bekker, Schall), 4 hrs 45 mins @ $900.00/hr	4,275.00
	Advance LESS: retainer applied per invoice #240302	-19,350.00

PAID

Expert consultation re: Homyk v. ChemoCentryx, Inc. et al., October 2024

TOTAL DUE **$0.00**

THANK YOU.

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
+19177457279
accounting@davidperrott.com

Invoice 240304

DAVID PERROTT
& ASSOCIATES LLC

BILL TO
Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020 USA

DATE	PLEASE PAY	DUE DATE
12/31/2024	**$4,350.00**	12/31/2024

DATE	ACTIVITY	AMOUNT
	Flat Fee Jury Research Exercise Two-day three-panel mock jury exercise flat professional fee	95,000.00
	Advance LESS: balance from retainer invoice #240302	-90,650.00

re: Homyk v. ChemoCentryx, Inc. et al.
Flat prof. fee for 2-day 3-panel mock jury exercise

TOTAL DUE $4,350.00

THANK YOU.

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
+19177457279
accounting@davidperrott.com

Invoice 240305

DAVID PERROTT
& ASSOCIATES LLC

BILL TO
Abe Alexander
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
New York, NY 10020 USA

DATE	PLEASE PAY	DUE DATE
12/31/2024	$60,496.69	12/31/2024

DATE	ACTIVITY	AMOUNT
10/08/2024	Nichols Research - Advance for mock juror recruit	34,340.00
10/16/2024	Alchemer - online survey platform	299.41
10/16/2024	UPS - ship data collection kiosks to Nichols Research	526.82
10/16/2024	D. Perrott - airfare SFO-JFK	348.48
10/16/2024	D. Perrott - airfare JFK-SFO	348.48
10/23/2024	D. Perrott - ground transport home to JFK	77.06
10/23/2024	D. Perrott - meal expense	15.18
10/23/2024	D. Perrott - meal expense	4.99
10/24/2024	D. Perrott - ground transport - SFO - downtown SF	50.54
10/24/2024	D. Perrott - meal expense	15.91
10/24/2024	D. Perrott - meal expense	13.71
10/24/2024	D. Perrott - meal expense	4.99
10/24/2024	DPA team dinner	185.21
10/24/2024	DPA team dinner	255.00
10/25/2024	UPS - return shipping of data collection kiosks	395.35
10/25/2024	D. Perrott - meal expense	4.99
10/25/2024	D. Perrott - meal expense	4.99
10/25/2024	D. Perrott - meal expense	98.06
10/25/2024	D. Perrott - meal expense	27.66
10/26/2024	D. Perrott - ground transport - SFO - downtown SF (tip)	5.00
10/26/2024	D. Perrott - ground transport - hotel to SFO	51.42
10/26/2024	D. Perrott - ground transport (subway)	2.90

DATE	ACTIVITY	AMOUNT
10/26/2024	D. Perrott - ground transport - JFK Airtrain (no receipt)	8.50
10/26/2024	D. Perrott - ground transport (LIRR)	5.00
10/26/2024	D. Perrott- hotel expense Oct 23-25	1,168.92
10/26/2024	D. Perrott- hotel expense Oct 25-26	362.74
10/31/2024	Nichols Research - Final invoice for facility charges and mock jurors	11,229.23
11/18/2024	C. Mondell - other travel expenses	657.21
11/20/2024	E. Shepherd - travel expenses	1,820.02
10/25/2024	Amazon Fire HD Tablet wireless data collection service Two-day rental	7,000.00
11/18/2024	C. Mondell - hotel expense	1,168.92

re: Homyk v. ChemoCentryx, Inc. et al.
Pass-through expenses for 2-day 3-panel mock jury exercise

TOTAL DUE $60,496.69

THANK YOU.

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC

David Perrott & Associates LLC
511 Ave. of the Americas #108
New York, NY 10011
+19177457279
accounting@davidperrott.com

Invoice 240306

DAVID PERROTT
& ASSOCIATES LLC

BILL TO
Jon Uslaner
Bernstein Litowitz Berger & Grossmann LLP
2121 Avenue of the Stars Suite 2575
Los Angeles, CA 90067 USA

DATE	PLEASE PAY	DUE DATE
07/16/2025	$16,200.00	07/16/2025

DATE	ACTIVITY	AMOUNT
05/22/2025	**Hourly Consulting** Review court opinion re: Daubert motions and make notes, 1 hr 15 mins @ $900.00/hr	1,125.00
06/26/2025	**Hourly Consulting** Review Pl MPSJ noting key points, 15 mins @ $900.00/hr	225.00
06/26/2025	**Hourly Consulting** Review Def MSJ noting key points, 3 hrs 15 mins @ $900.00/hr	2,925.00
06/26/2025	**Hourly Consulting** Review Pl Opp to Def Cross-MSJ noting key points, 2 hrs @ $900.00/hr	1,800.00
06/26/2025	**Hourly Consulting** Review Uslaner Dec noting key points, 45 mins @ $900.00/hr	675.00
06/27/2025	**Hourly Consulting** Peruse Pl exhibits in support of SJ, incl. full review of Helfgott, noting key strategic thoughts/recs for trial, 5 hrs 45 mins @ $900.00/hr	5,175.00
07/07/2025	**Hourly Consulting** Peruse Def exhibits in support of SJ, incl. full review of NEJM article, noting key strategic thoughts/recs for trial, 3 hrs 15 mins @ $900.00/hr	2,925.00
07/15/2025	**Hourly Consulting** Organize notes from review of SJ materials and prepare as strategic memo to counsel, 1 hr 30 mins @ $900.00/hr	1,350.00

Expert consultation re: Homyk v. ChemoCentryx, Inc. et al.
May-July 2025

TOTAL DUE $16,200.00

THANK YOU.

David Perrott & Associates LLC
511 Avenue of the Americas #108
New York NY 10011
Tax ID: 47-5211823

Wire Transfer Routing Number: 026009593
ACH Routing Number: 021000322
Account Number: 483061806161
Account Name: David Perrott & Associates LLC
Bank of America, 127 8th Avenue, New York, NY 10011

ZnCu Consulting LLC

INVOICE #: BLBGLaw020124

ZnCu Consulting, LLC
70 Sea Breeze Ave
Rancho Palos Verdes, California 90275
Phone: 424-206-9514
E-mail: ebrass@ucla.edu

Billed to:
Bernstein, Litowitz, Berger & Grossman LLP
Attn: Lauren Cruz

Invoice Date:
February 1, 2024

Subject of consulting:
Homyk v ChemoCentryx, Inc

Service date	Service	Amount
Consulting @ $600/hr		
Jan 2'24	Review Weisman Report (2.00 Hrs)	$1200.00
Jan 3'24	Rvw Rx label, ADVOCATE Ms, FDA BB (2.00 Hrs)	$1200.00
Jan 8'24	Videoconf Cruz, Uslaner et al (1.00 Hrs)	$ 600.00
Jan 11'24	Respond to NI Guidance question (0.50 Hrs)	$ 300.00
Jan 30'24	Respond to NI AdCom question (0.50 Hrs)	$ 300.00
	CONSULTING SUBTOTAL – $3600.00	
Expenses		
	NONE	
	EXPENSE SUBTOTAL - None	

Total : $3600.00

INVOICE TOTAL: $3,600.00

Exhibit 12B

Factual Research

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann, LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger &
Bernstein, Litowitz, Berger &Grossmann,LLP
1251 Avenue of the Americas
New York NY 10020-1104
USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **98611636**
Invoice date: **01.MAY.2021**

Billing notes:
Please note that Exchange data billing includes a 7% admin charge.

Welcome to your Refinitiv invoice

Product Summary

Product category	Net price sub total USD	Tax total USD	Total Period USD
EXCHANGE PRODUCTS	0.00	0.00	0.00
PRODUCTS & SERVICES	32,357.00	2,871.42	35,228.42
Total	**32,357.00**	**2,871.42**	**35,228.42**

Due date: 30.MAY.2021

Total due: USD
35,228.42

To see product details, refer to page 2 of this document

How to pay

To see payment options and details, refer to the last page of this invoice. You must include billing account number (A-01458712) and invoice number (98611636) when submitting payment.

News

Adv Mortgage Analytics DM 3 has been renamed to Adv Mortgage Analytics Basic; Adv Mortgage Analytics DM 6 has been renamed to Adv Mortgage Analytics Pro; Adv Mortgage Analytics DM 12 has been renamed to Adv Mortgage Analytics Premium. Pricing & functionality has not been impacted. For additional details, please contact your account manager

Contact

Telephone: +1 (888) 831 2455
https://my.refinitiv.com/billingsupport

REFINITIV™

TAX ID: 20-4530702

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann, LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger &
Bernstein, Litowitz, Berger &Grossmann,LLP
1251 Avenue of the Americas
New York NY 10020-1104
USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **98611636**
Invoice date: **01.MAY.2021**

Billing notes:
Please note that Exchange data billing includes a 7% admin charge.

Here's your invoice detail

EXCHANGE PRODUCTS

Product name	QTY	Unit price	Exchange rate	Price USD	Net price for total period USD	Tax Rate	Tax USD	Total Period USD
DOW JONES CASH INDICES DELAYED 01.MAY.2021 - 31.MAY.2021	4	0.00 USD	1.00000	0.00	0.00	0.000%	0.00	0.00
EXCHANGE PRODUCTS Sub-total					**0.00**		**0.00**	**0.00**

PRODUCTS & SERVICES

Product name	QTY	Unit price	Exchange rate	Price USD	Net price for total period USD	Tax Rate	Tax USD	Total Period USD
AFTER MARKET RESEARCH ADD ON FOR EIKON 01.MAY.2021 - 31.MAY.2021	67	381.00 USD	1.00000	381.00	25,527.00	8.875%	2,265.27	27,792.27
EIKON 01.MAY.2021 - 31.MAY.2021	5	1,366.00 USD	1.00000	1,366.00	6,830.00	8.875%	606.15	7,436.15
STREETSIGHT FOR EIKON ADD ON 01.MAY.2021 - 31.MAY.2021	5	0.00 USD	1.00000	0.00	0.00	8.875%	0.00	0.00
T1.COM IB DEALS MOD EIKON ADD ON 01.MAY.2021 - 31.MAY.2021	5	0.00 USD	1.00000	0.00	0.00	8.875%	0.00	0.00
T1.COM IB FOUNDATION AMERS EIKON ADD ON 01.MAY.2021 - 31.MAY.2021	5	0.00 USD	1.00000	0.00	0.00	8.875%	0.00	0.00

REFINITIV™

TAX ID: 20-4530702

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann, LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger &
Bernstein, Litowitz, Berger &Grossmann,LLP
1251 Avenue of the Americas
New York NY 10020-1104
USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **98611636**
Invoice date: **01.MAY.2021**

Billing notes:
Please note that Exchange data billing includes a 7% admin charge.

Here's your invoice detail

PRODUCTS & SERVICES (cont.)

Product name	QTY	Unit price	Exchange rate	Price USD	Net price for total period USD	Tax Rate	Tax USD	Total Period USD
T1.COM IB PRIV EQUITY MOD EIKON ADD ON 01.MAY.2021 - 31.MAY.2021	5	0.00 USD	1.00000	0.00	0.00	8.875%	0.00	0.00
PRODUCTS & SERVICES Sub-total					**32,357.00**		**2,871.42**	**35,228.42**

REFINITIV™

TAX ID: 20-4530702

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann, LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger &
Bernstein, Litowitz, Berger &Grossmann,LLP
1251 Avenue of the Americas
New York NY 10020-1104
USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **98611636**
Invoice date: **01.MAY.2021**

Billing notes:
Please note that Exchange data billing includes a 7% admin charge.

More information

How to pay

Remittance information:
You must include billing account number (A-01458712) and invoice number (98611636) when submitting payment.

Check payments should be sent via mail to:
Refinitiv US LLC
P.O. Box415983
BOSTON MA 02241
USA

Electronic payment:
Bank of America, NA
100 W 33rd Street
New York NY 10001
USA
Account name: REFINITIV US LLC
Bank account: 4426851172
Swift code: BOFAUS3N
ACH Account: 111000012
Wire: 026009593
Bank code: 111000012

If you have pre-authorized settlement through automated means, payment will not be taken before 20.MAY.2021
No further action is needed to settle this invoice.

Payment terms:
For payment terms please refer to the Agreement. If no payment terms are specified in the Agreement, client will pay the Charges and all applicable taxes and duties (including withholding taxes) within 30 days of the invoice date.

If payment is not received by the due date a finance charge may be imposed.

Additional billing information:

Tax rates

Tax rate	Taxable amount	Tax
STATE SALES&USE TAX@4.000%	USD 32,357.00	USD 1,294.28
COUNTY SALES&USE TAX@0.375%	USD 32,357.00	USD 121.41
CITY SALES&USE TAX@4.500%	USD 32,357.00	USD 1,455.73
Total Tax		USD 2,871.42

Exchange Rates:

Looking for more?

These items are controlled by the U.S. Government and authorized for export only to the country of ultimate destination for use by the ultimate consignee or end-user(s) herein identified. They may not be resold, transferred, or otherwise disposed of, to any other country or to any person other than the authorized ultimate consignee or end-user(s), either in their original form or after being incorporated into other items, without first obtaining approval from the U.S. government or as otherwise authorized by U.S. law and regulations

REFINITIV™

TAX ID: 20-4530702

Natalia O'Donnell

Subject: FW: FW: Refinitiv - New Invoice 0098611636 for value 35,228.42 USD for Account A-01458712 in US

From: Adam Weinschel <AdamW@blbglaw.com>
Sent: Monday, June 28, 2021 11:53 AM
To: Accounting@blbglaw.com
Subject: FW: Refinitiv - New Invoice 0098611636 for value 35,228.42 USD for Account A-01458712 in US

This is ok to pay. Breakdown:

Case	Price
[redacted]	
Chemocentryx 0888-001	$7,422.09
[redacted]	
Grand Total	**$27,792.27**
[redacted]	
Grand total	**$35,228.42**

From: Refinitiv Customer Administration <global.ordermanagement.refinitiv.com@mx.unifiedpost.com>
Sent: Monday, May 3, 2021 3:06 PM
To: Adam Weinschel <AdamW@blbglaw.com>
Subject: Refinitiv - New Invoice 0098611636 for value 35,228.42 USD for Account A-01458712 in US

[External]

Dear Adam Weinschel,

A new Invoice has been posted to Electronic Invoicing.

Number:	0098611636
Value:	35,228.42 USD
Account:	A-01458712
Document Delivery:	Paperless
User location:	US
Invoice address:	US
Download	
Pay Now:	

A PDF version of this invoice has been attached to this email.

To view and export invoice details and to see user details where available please login to MyRefinitiv https://my.refinitiv.com/content/mytr/en/billing.html and enter your user name and password.

All Account Balances will be updated within 24 hours.

If you do not know your MyRefinitiv password, please click Login then 'Forgot password?'

NOTE: if you have not registered for MyRefinitiv yet, please click Register and enter the same email address you use to access your invoices.

Regards,

Refinitiv Order Management

Please note that this is a system generated e-mail. Please do not reply to this e-mail address.

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann,LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger & Grossmann,LLP
1251 Avenue of the Americas
New York, NY, 10020-1104, USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **902224127**
Invoice date: **01.DEC.2024**

Billing notes:

Welcome to your Invoice

Product Summary

Product category	Net price sub total USD	Tax Total USD	Total Period USD
PRODUCTS & SERVICES	33,670.00	2,988.07	36,658.07
Total	**33,670.00**	**2,988.07**	**36,658.07**

Due date: 30.DEC.2024

Total due: USD
36,658.07

Invoice detail

Product name	QTY	Unit price	Exchange rate	Price USD	Net price for total period USD	Tax Rate	Tax USD	Total Period USD
PRODUCTS & SERVICES AFTERMARKET RESEARCH WORKSPACE FIRM-WIDE 01.DEC.2024 - 31.DEC.2024	57	390.00 USD	1.00000	390.00	22,230.00	8.875	1,972.77	24,202.77
PRODUCTS & SERVICES WORKSPACE FOR INVESTMENT BANKERS 01.DEC.2024 - 31.DEC.2024	22	520.00 USD	1.00000	520.00	11,440.00	8.875	1,015.30	12,455.30
Total								**36,658.07**

How to pay

To see payment options and details, refer to the next page of this invoice. You must include billing account number A-01458712 and invoice number 902224127 when submitting payment.

News

Adv Mortgage Analytics DM 3 has been renamed to Adv Mortgage Analytics Basic; Adv Mortgage Analytics DM 6 has been renamed to Adv Mortgage Analytics Pro; Adv Mortgage Analytics DM 12 has been renamed to Adv Mortgage Analytics Premium. Pricing & functionality has not been impacted. For additional details, please contact your account manager.

Contact

Telephone: +1 (888) 831 2455
https://myaccount.lseg.com/billingsupport

TAX ID: 20-4530702

INVOICE

Billing address:
Bernstein, Litowitz, Berger &Grossmann,LLP
Adam Weinschel
1251 Avenue of the Americas
New York NY 10020-1104
USA
Billing account number: **A-01458712**

User address:
Bernstein, Litowitz, Berger & Grossmann,LLP
1251 Avenue of the Americas
New York, NY, 10020-1104, USA
Location account number: A-00425033

Account name: **Bernstein, Litowitz, Berger & Grossmann,LLP**
Invoice number: **902224127**
Invoice date: **01.DEC.2024**

Billing notes:

More information

How to pay

Remittance information:
You must include billing account number (A-01458712) and invoice number (902224127) when submitting payment.

Refinitiv US LLC
P.O. Box415983

BOSTON MA 02241
USA

Electronic payment:
Bank of America
1401 Elm street 2nd floor
DALLAS TX 75202
USA
Account name: REFINITIV US LLC
Bank account.: 4426851172
Swift code:BOFAUS3N
ACH Account: 111000012
Bank code: 111000012
Bank branch:

If you have pre-authorized settlement through automated means, payment will not be taken before 20.DEC.2024
No further action is needed to settle this invoice.

Payment terms:
For payment terms please refer to the Agreement. If no payment terms are specified in the Agreement, client will pay the Charges and all applicable taxes and duties (including withholding taxes) within 030 days of the invoice date.

If payment is not received by the due date a finance charge may be imposed.

Tax rates

Tax rate	Taxable amount	Tax	Exchange Rates:
STATE SALES&USE TAX@4.000%	33,670.00	1,346.80	
CITY SALES&USE TAX@4.500%	33,670.00	1,515.15	
LOCAL SALES&USE TAX@0.375%	33,670.00	126.12	
Total tax		USD 2,988.07	

Looking for more?

These items are controlled by the U.S. Government and authorized for export only to the country of ultimate destination for use by the ultimate consignee or end-user(s) herein identified. They may not be resold, transferred, or otherwise disposed of, to any other country or to any person other than the authorized ultimate consignee or end-user(s), either in their original form or after being incorporated into other items, without first obtaining approval from the U.S. government or as otherwise authorized by U.S. law and regulations

TAX ID: 20-4530702

Ayrton Dimitri

From:	Adam Weinschel
Sent:	Monday, February 24, 2025 2:25 PM
To:	Accounting
Subject:	FW: New Invoice 0902224127 for value 36658.07 USD for Account A-01458712
Attachments:	A-01458712_20241201_0902224127_KZZVqWKMgTvCgSWu9Z7cFQ6lCr8Nfafp.pdf

This bill is ok to pay. Breakdown below.

Case	Amount
[redacted]	
2369-001 ChemoCentryx	$18,660.05
[redacted]	
Grand Total	**$36,658.07**

From: Lseg.Billing@mg.lseg.com <Lseg.Billing@mg.lseg.com>
Sent: Sunday, December 1, 2024 7:18 AM
To: Adam Weinschel <AdamW@blbglaw.com>
Subject: New Invoice 0902224127 for value 36658.07 USD for Account A-01458712

[This message is from an external sender]

Welcome to your Invoice

A PDF version of this invoice has bee n attached to this email.

Number: **0902224127**
Value: **36658.07**
Account: **A-01458712**
Country: **US**

Dear Adam Weinschel,
A new document has been posted to the MyAccount Portal

Total due: USD

36658.07

Due date: 2024-12-30

PAYMENT

To view and export your invoice and to see user details where available, please login to MyAccount and enter your user name and password.

All Account Balances will be updated within 24 hours.

If you do not know your MyAccount password, please click login then ‘Forget Password?’

NOTE: If you have not registered for MyAccount yet, please click Register and enter the same
email address you use to access your invoices.

LSEG Billing

Please note that this is a system generated e-mail. Please do not reply to this email address.

Legal Research

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
77,954.50

Payment Due by
March 2, 2024

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	71,600.00	6,354.50	77,954.50
TOTAL INVOICE AMOUNT	**71,600.00**	**6,354.50**	**77,954.50**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: March 2, 2024
Amount due in USD: 77,954.50

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0849720005 000000000000000000000000 20240201 ZCPG 007795450 0010 1000655554 5

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
January 1, 2024 - January 31, 2024				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,236.00	464.69	5,700.69
January 1, 2024 - January 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		63,208.00	5,609.72	68,817.72
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,056.00	93.72	1,149.72
Subtotal		**64,264.00**	**5,703.44**	**69,967.44**
January 1, 2024 - January 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,100.00	186.37	2,286.37
The charge reflects a prorated amount and not a full month's charge.				
January 1, 2024 - January 12, 2024				
Westlaw LiveNote Multi-Loc Agreement, Special offer (Unique Identifier 0000020260)				
DOWNLOADED SOFTWARE		0.00	0.00	0.00

Online/Software Subscription Charges Total USD
77,954.50

Total USD
77,954.50

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6159120336 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	2,769.97	0.00	245.84	3,015.81
1000655554 Reference # 6159120351 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	68,830.03	0.00	6,108.66	74,938.69

TOTAL USD
77,954.50

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6159120336 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
January 1, 2024 - January 31, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		97.75	8.67	106.42
January 1, 2024 - January 31, 2024 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		2,144.22	190.31	2,334.53
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		528.00	46.86	574.86
Subtotal		**2,672.22**	**237.17**	**2,909.39**
The charge reflects a prorated amount and not a full month's charge. January 1, 2024 - January 12, 2024 Westlaw LiveNote Multi-Loc Agreement, Special offer (Unique Identifier 0000020260)				
DOWNLOADED SOFTWARE		0.00	0.00	0.00

Online/Software Subscription Charges Total USD
3,015.81

Location Total USD
3,015.81

1000655554
Reference # 6159120351
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849720005
Account #: 1000655554
Invoice date: February 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
January 1, 2024 - January 31, 2024				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,138.25	456.02	5,594.27
January 1, 2024 - January 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		61,063.78	5,419.41	66,483.19
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		528.00	46.86	574.86
Subtotal		**61,591.78**	**5,466.27**	**67,058.05**
January 1, 2024 - January 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,100.00	186.37	2,286.37
The charge reflects a prorated amount and not a full month's charge.				
January 1, 2024 - January 12, 2024				
Westlaw LiveNote Multi-Loc Agreement, Special offer (Unique Identifier 0000020260)				
DOWNLOADED SOFTWARE		0.00	0.00	0.00

Online/Software Subscription Charges Total USD
74,938.69

Location Total USD
74,938.69

Total USD
77,954.50

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Charges cleared between January 2, 2024 and February 1, 2024

Document date	Document #		Description	Amount USD	Notes
12/01/2023	0849404914		Invoice	82,578.48	
12/29/2023	000038940	**	Payment Received	-82,578.48	PAYMENT RECEIVED - THANK YOU
01/01/2024	0849560054		Invoice	79,086.31	
01/30/2024	000039112	**	Payment Received	-79,086.31	PAYMENT RECEIVED - THANK YOU
12/26/2023	0849476581	**	Subscription Invoice	42.00	
12/28/2023	6158251771	**	New Sale Invoice	330.70	+ WCX Document Retrieval Fee
02/01/2024	000039073	**	Payment Received	-372.70	PAYMENT RECEIVED - THANK YOU
01/01/2024	6158490249	**	Late Fee Reference #: 6158028102	25.00	LATE FEE
01/01/2024	6158626469	**	Late Fee Reference #: 6158028102	-25.00	LATE FEE

Open charges as of February 1, 2024

Document date	Document #	Description	Amount USD	Notes	Due Date
04/01/2023	6153994038	Open Item Partial Balance	1,712.17		05/01/2023
05/01/2023	6154497215	Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	05/31/2023
06/01/2023	0848454107	Invoice	3,679.85		07/01/2023
06/01/2023	6155006808	Payment Received Partial Balance	944.07	+ WN PR SEARCHES 3	07/01/2023

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Open charges as of February 1, 2024 continued

Document date	Document #		Description	Amount USD	Notes	Due Date
07/01/2023	6155504512		Payment Received Partial Balance	4,623.92	+ WN DOC DISPLAY 03	07/31/2023
08/01/2023	6155979620		Payment Received Partial Balance	4,623.92	+ WN TIME CLASS 03	08/31/2023
09/01/2023	6156478851		Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	10/01/2023
10/01/2023	6156955726		Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	10/31/2023
10/26/2023	0849157346	**	Subscription Invoice	42.00		11/25/2023
11/01/2023	0849255677		Invoice	4,231.15		12/01/2023
11/01/2023	6157511906		Payment Received Partial Balance	350.77	+ WN PR SEARCHES 3	12/01/2023
11/26/2023	0849316727	**	Subscription Invoice	42.00		12/26/2023
11/26/2023	6157662865	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	11/26/2023
12/01/2023	6158028102		Payment Received Partial Balance	4,624.06	+ WN DOC DISPLAY 03	12/31/2023
12/26/2023	6158240814	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	12/26/2023
12/27/2023	6158246916	**	Late Fee Reference #: 6157361602	25.00	LATE FEE	12/27/2023

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Open charges as of February 1, 2024 continued

Document date	Document #		Description	Amount USD	Notes	Due Date
01/01/2024	0849560054		Invoice	3,492.11		01/31/2024
01/01/2024	6158608113		Payment Received Partial Balance	1,131.81	+ WN PR SEARCHES 3	01/31/2024
01/25/2024	6158729265	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	01/25/2024
01/26/2024	0849624033	**	Subscription Invoice	42.00		02/25/2024
01/26/2024	6158738619	**	Late Fee Reference #: 6157361602	25.00	LATE FEE	01/26/2024
01/30/2024	6158752089	**	New Sale Invoice	166.03	+ WCX MONTHLY WATCH	02/29/2024
02/01/2024	0849720005		Invoice	77,954.50		03/02/2024
02/02/2024	6159102219	**	Late Fee Reference #: 6157873648	25.00	LATE FEE	02/02/2024
02/02/2024	6159102220	**	Late Fee Reference #: 6158251771	25.00	LATE FEE	02/02/2024

Open charges in USD as of February 1, 2024 **121,707.12**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Client ID	Total	Narrative
[redacted]		

[redacted]	
2369-001	8471.72
[redacted]	
Grand Total	77,954.50

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
77,954.49

Payment Due by
March 31, 2024

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	71,600.00	6,354.49	77,954.49
TOTAL INVOICE AMOUNT	**71,600.00**	**6,354.49**	**77,954.49**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: March 31, 2024
Amount due in USD: 77,954.49

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0849807768 000000000000000000000000 20240301 ZCPG 007795449 0010 1000655554 4

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies

http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
February 1, 2024 - February 29, 2024				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,236.00	464.69	5,700.69
February 1, 2024 - February 29, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		63,208.00	5,609.71	68,817.71
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,056.00	93.72	1,149.72
Subtotal		**64,264.00**	**5,703.43**	**69,967.43**
February 1, 2024 - February 29, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,100.00	186.37	2,286.37

Online/Software Subscription Charges Total USD
77,954.49

Total USD
77,954.49

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6159516286 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	4,827.03	0.00	428.41	5,255.44
1000655554 Reference # 6159516304 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	66,772.97	0.00	5,926.08	72,699.05

TOTAL USD
77,954.49

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6159516286 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
February 1, 2024 - February 29, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		350.74	31.13	381.87
February 1, 2024 - February 29, 2024 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		3,948.29	350.42	4,298.71
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		528.00	46.86	574.86
Subtotal		**4,476.29**	**397.28**	**4,873.57**

Online/Software Subscription Charges Total USD
5,255.44

Location Total USD
5,255.44

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6159516304 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
February 1, 2024 - February 29, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		4,885.26	433.56	5,318.82

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 849807768
Account #: 1000655554
Invoice date: March 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
February 1, 2024 - February 29, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		59,259.71	5,259.29	64,519.00
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		528.00	46.86	574.86
Subtotal		**59,787.71**	**5,306.15**	**65,093.86**
February 1, 2024 - February 29, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,100.00	186.37	2,286.37

Online/Software Subscription Charges Total USD
72,699.05

Location Total USD
72,699.05

Total USD
77,954.49

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Charges cleared between February 2, 2024 and March 1, 2024

Document date	Document #		Description	Amount USD	Notes
01/26/2024	0849624033	**	Subscription Invoice	42.00	
01/30/2024	6158752089	**	New Sale Invoice	166.03	+ WCX MONTHLY WATCH
02/13/2024	000039178	**	Payment Received	-208.03	PAYMENT RECEIVED - THANK YOU
02/01/2024	0849720005		Invoice	77,954.50	
02/27/2024	000039269	**	Payment Received	-77,954.50	PAYMENT RECEIVED - THANK YOU
01/26/2024	6158738620	**	Late Fee Reference #: 6157873648	25.00	LATE FEE
01/26/2024	6159092889	**	Late Fee Reference #: 6157873648	-25.00	LATE FEE
01/28/2024	6158743315	**	Late Fee Reference #: 6158251771	25.00	LATE FEE
01/28/2024	6159092891	**	Late Fee Reference #: 6158251771	-25.00	LATE FEE
02/02/2024	6159102219	**	Late Fee Reference #: 6157873648	25.00	LATE FEE
02/02/2024	6159157953	**	Late Fee Reference #: 6157873648	-25.00	LATE FEE
02/02/2024	6159102220	**	Late Fee Reference #: 6158251771	25.00	LATE FEE
02/02/2024	6159158029	**	Late Fee Reference #: 6158251771	-25.00	LATE FEE

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Open charges as of March 1, 2024

Document date	Document #		Description	Amount USD	Notes	Due Date
04/01/2023	6153994038		Open Item Partial Balance	1,712.17		05/01/2023
05/01/2023	6154497215		Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	05/31/2023
06/01/2023	0848454107		Invoice	3,679.85		07/01/2023
06/01/2023	6155006808		Payment Received Partial Balance	944.07	+ WN PR SEARCHES 3	07/01/2023
07/01/2023	6155504512		Payment Received Partial Balance	4,623.92	+ WN DOC DISPLAY 03	07/31/2023
08/01/2023	6155979620		Payment Received Partial Balance	4,623.92	+ WN TIME CLASS 03	08/31/2023
09/01/2023	6156478851		Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	10/01/2023
10/01/2023	6156955726		Payment Received Partial Balance	4,623.92	+ WN PR SEARCHES 3	10/31/2023
10/26/2023	0849157346	**	Subscription Invoice	42.00		11/25/2023
11/01/2023	0849255677		Invoice	4,231.15		12/01/2023
11/01/2023	6157511906		Payment Received Partial Balance	350.77	+ WN PR SEARCHES 3	12/01/2023
11/26/2023	0849316727	**	Subscription Invoice	42.00		12/26/2023
11/26/2023	6157662865	**	Late Fee	25.00	LATE FEE	11/26/2023

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Open charges as of March 1, 2024 continued

Document date	Document #		Description	Amount USD	Notes	Due Date
			Reference #: 6156809813			
12/01/2023	6158028102		Payment Received Partial Balance	4,624.06	+ WN DOC DISPLAY 03	12/31/2023
12/26/2023	6158240814	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	12/26/2023
12/27/2023	6158246916	**	Late Fee Reference #: 6157361602	25.00	LATE FEE	12/27/2023
01/01/2024	0849560054		Invoice	3,492.11		01/31/2024
01/01/2024	6158608113		Payment Received Partial Balance	1,131.81	+ WN PR SEARCHES 3	01/31/2024
01/25/2024	6158729265	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	01/25/2024
01/26/2024	6158738619	**	Late Fee Reference #: 6157361602	25.00	LATE FEE	01/26/2024
02/24/2024	6159235746	**	Late Fee Reference #: 6156809813	25.00	LATE FEE	02/24/2024
02/25/2024	6159239510	**	Late Fee Reference #: 6157361602	25.00	LATE FEE	02/25/2024
02/26/2024	0849777135	**	Subscription Invoice	42.00		03/27/2024
03/01/2024	0849807768		Invoice	77,954.49		03/31/2024

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly **account summary**

Account #: 1000655554

Open charges in USD as of March 1, 2024 **121,541.08**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Row Labels	Sum of SPECIAL PRICING CHARGE
[redacted]	
2369-001 CHEMO	22319.71
[redacted]	
Grand Total	**77954.61**

Matter	Amount
[redacted]	
2369-001	22319.68
[redacted]	
	77954.49

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
105,935.37

Payment Due by
August 31, 2024

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	97,300.00	8,635.37	105,935.37
TOTAL INVOICE AMOUNT	**97,300.00**	**8,635.37**	**105,935.37**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: August 31, 2024
Amount due in USD: 105,935.37

Amount enclosed: ________________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0850630147 000000000000000000000000 20240801 ZCPG 010593537 0010 1000655554 6

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies

http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
July 1, 2024 - July 31, 2024				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,603.00	497.27	6,100.27
July 1, 2024 - July 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		88,259.00	7,832.98	96,091.98
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,191.00	105.70	1,296.70
Subtotal		**89,450.00**	**7,938.68**	**97,388.68**
July 1, 2024 - July 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
105,935.37

Total USD
105,935.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6162383873 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	2,496.19	0.00	221.51	2,717.70
1000655554 Reference # 6162383874 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	94,803.81	0.00	8,413.86	103,217.67

TOTAL USD
105,935.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6162383873 BERNSTEIN LITOWITZ BERGER ET AL CHARLIE CRUZ 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
July 1, 2024 - July 31, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		67.63	6.00	73.63
July 1, 2024 - July 31, 2024 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		1,833.06	162.66	1,995.72
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**2,428.56**	**215.51**	**2,644.07**

Online/Software Subscription Charges Total USD
2,717.70

Location Total USD
2,717.70

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6162383874 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
July 1, 2024 - July 31, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,535.37	491.27	6,026.64

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Invoice #: 850630147
Account #: 1000655554
Invoice date: August 1, 2024
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
July 1, 2024 - July 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		86,425.94	7,670.32	94,096.26
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**87,021.44**	**7,723.17**	**94,744.61**
July 1, 2024 - July 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
103,217.67

Location Total USD
103,217.67

Total USD
105,935.37

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Charges cleared between July 2, 2024 and August 1, 2024

Document date	Document #		Description	Amount USD	Notes
05/01/2024	0850159990		Invoice	105,935.41	
07/01/2024	000039885		Payment Received	-105,935.41	PAYMENT RECEIVED - THANK YOU
06/01/2024	0850316015		Invoice	105,935.38	
07/22/2024	000040085		Payment Received	-105,935.38	PAYMENT RECEIVED - THANK YOU
01/01/2024	0849560054		Invoice	3,492.11	
07/24/2024	6161958587		Online Credit Note Reference #: 6158608112	-3,492.11	+ WN PR SEARCHES 3
07/01/2024	6160705074		Payment Received Overpayment	-0.01	Overpayment -6160705074
07/03/2024			Reinstatement Write Off - Good Will Small Balance	0.01	
06/01/2024	6161120778	**	Late Fee Reference #: 6160705074	25.00	LATE FEE
06/01/2024	6161839006	**	Late Fee Reference #: 6160705074	-25.00	LATE FEE
07/01/2024	6161680533	**	Late Fee Reference #: 6160705074	25.00	LATE FEE
07/01/2024	6161841283	**	Late Fee Reference #: 6160705074	-25.00	LATE FEE
07/02/2024	6161831513	**	Late Fee Reference #: 6161257288	25.00	LATE FEE
07/02/2024	6161955391	**	Late Fee Reference #: 6161257288	-25.00	LATE FEE

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
610 Opperman Drive
Eagan, MN 55123-1396

Monthly account summary

Account #: 1000655554

Open charges as of August 1, 2024

Document date	Document #		Description	Amount USD	Notes	Due Date
11/01/2023	6157511906		Payment Received Partial Balance	350.77	+ WN PR SEARCHES 3	12/01/2023
01/01/2024	0849560054		Online Invoice Partial Balance	8.92		01/31/2024
06/26/2024	0850369250	**	Subscription Invoice	42.00		07/26/2024
07/01/2024	0850454528		Invoice	105,935.36		07/31/2024
07/26/2024	0850513710	**	Subscription Invoice	42.00		08/25/2024
07/27/2024	6161984178	**	Late Fee Reference #: 6161084013	25.00	LATE FEE	07/27/2024
08/01/2024	0850630147		Invoice	105,935.37		08/31/2024
08/01/2024	6162227680	**	Late Fee Reference #: 6161805933	25.00	LATE FEE	08/01/2024

Open charges in USD as of August 1, 2024 **212,364.42**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	

[redacted]

2369-001	5,821.06

[redacted]

105,935.52

Invoice

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
105,935.40

Payment Due by
March 31, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	97,300.00	8,635.40	105,935.40
TOTAL INVOICE AMOUNT	**97,300.00**	**8,635.40**	**105,935.40**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: March 31, 2025
Amount due in USD: 105,935.40

Amount enclosed: ________________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0851627734 000000000000000000000000 20250301 ZCPG 010593540 0010 1000655554 5

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers
CHE107904015MWST
EU: EU372043281
UK: 398 1554 53

Federal Tax ID
98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880
Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
February 1, 2025 - February 28, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,603.00	497.27	6,100.27
February 1, 2025 - February 28, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		88,259.00	7,833.00	96,092.00
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,191.00	105.70	1,296.70
Subtotal		**89,450.00**	**7,938.70**	**97,388.70**
February 1, 2025 - February 28, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.43	2,446.43

Online/Software Subscription Charges Total USD
105,935.40

Total USD
105,935.40

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6165925875 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	19,391.60	0.00	1,721.01	21,112.61
1000655554 Reference # 6165925878 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	77,908.40	0.00	6,914.39	84,822.79

TOTAL USD
105,935.40

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6165925875 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
February 1, 2025 - February 28, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		1,100.11	97.63	1,197.74
February 1, 2025 - February 28, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		16,652.08	1,477.88	18,129.96
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**17,247.58**	**1,530.73**	**18,778.31**
February 1, 2025 - February 28, 2025 WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		1,043.91	92.65	1,136.56

Online/Software Subscription Charges Total USD
21,112.61

Location Total USD
21,112.61

1000655554
Reference # 6165925878
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851627734
Account #: 1000655554
Invoice date: March 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
February 1, 2025 - February 28, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		4,502.89	399.64	4,902.53
February 1, 2025 - February 28, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		71,606.92	6,355.12	77,962.04
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**72,202.42**	**6,407.97**	**78,610.39**
February 1, 2025 - February 28, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		1,203.09	106.78	1,309.87

Online/Software Subscription Charges Total USD
84,822.79

Location Total USD
84,822.79

Total USD
105,935.40

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between February 2, 2025 and March 1, 2025

Document date	Document #		Description	Amount USD	Notes
01/01/2025	0851338959		Invoice	105,935.41	
02/12/2025	000041015		Payment Received	-105,935.41	PAYMENT RECEIVED - THANK YOU
01/01/2025	6165002234		Payment Received Partial Balance	0.13	+ WN TIME CLASS 03
02/14/2025			Write-Off Write Off - Good Will Small Balance	-0.13	
02/01/2025	6165360767	**	Late Fee Reference #: 6165002234	25.00	LATE FEE
02/01/2025	6165545727	**	Late Fee Reference #: 6165002234	-25.00	LATE FEE

Open charges as of March 1, 2025

Document date	Document #		Description	Amount USD	Notes	Due Date
01/16/2025	6165085051	**	New Sale Invoice	186.72	+ WCX Document Retrieval Fee	02/15/2025
01/26/2025	0851397439	**	Subscription Invoice	42.00		02/25/2025
02/01/2025	0851481745		Invoice	105,935.38		03/03/2025
02/16/2025	6165549520	**	Late Fee Reference #: 6165085051	25.00	LATE FEE	02/16/2025
02/26/2025	6165608127	**	Late Fee Reference #: 6164870658	25.00	LATE FEE	02/26/2025

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Open charges as of March 1, 2025 continued

Document date	Document #	Description	Amount USD	Notes	Due Date
03/01/2025	0851627734	Invoice	105,935.40		03/31/2025

Open charges in USD as of March 1, 2025 **212,149.50**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	
2369-001	18,900.79
[redacted]	

[redacted]

105,935.40

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
105,935.36

Payment Due by
May 1, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	97,300.00	8,635.36	105,935.36
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**97,300.00**	**8,635.36**	**105,935.36**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025

Invoice due date: May 1, 2025
Amount due in USD: 105,935.36

Amount enclosed: ________________________

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0851776605 000000000000000000000000 20250401 ZCPG 010593536 0010 1000655554 1

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
March 1, 2025 - March 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,603.00	497.26	6,100.26
March 1, 2025 - March 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		88,259.00	7,832.98	96,091.98
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,191.00	105.70	1,296.70
Subtotal		**89,450.00**	**7,938.68**	**97,388.68**
March 1, 2025 - March 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
105,935.36

Total USD
105,935.36

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6166447894 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	14,457.73	0.00	1,283.14	15,740.87
1000655554 Reference # 6166447903 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	82,842.27	0.00	7,352.22	90,194.49

TOTAL USD
105,935.36

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6166447894 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
March 1, 2025 - March 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		1,340.33	118.95	1,459.28
March 1, 2025 - March 31, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		12,521.90	1,111.34	13,633.24
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**13,117.40**	**1,164.19**	**14,281.59**

Online/Software Subscription Charges Total USD
15,740.87

Location Total USD
15,740.87

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6166447903 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
March 1, 2025 - March 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		4,262.67	378.31	4,640.98

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851776605
Account #: 1000655554
Invoice date: April 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
March 1, 2025 - March 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		75,737.10	6,721.64	82,458.74
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**76,332.60**	**6,774.49**	**83,107.09**
March 1, 2025 - March 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
90,194.49

Location Total USD
90,194.49

Total USD
105,935.36

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between March 2, 2025 and April 1, 2025

Document date	Document #	Description	Amount USD	Notes
02/01/2025	0851481745	Invoice	105,935.38	
03/03/2025	000041122	Payment Received	-105,935.38	PAYMENT RECEIVED - THANK YOU
03/01/2025	0851627734	Invoice	105,935.40	
03/31/2025	000041254	Payment Received	-105,935.40	PAYMENT RECEIVED - THANK YOU
02/01/2025	6165465086	Payment Received Partial Balance	0.10	+ WN PR SEARCHES 3
03/05/2025		Write-Off Write Off - Good Will Small Balance	-0.10	

Open charges as of April 1, 2025

Document date	Document #		Description	Amount USD	Notes	Due Date
01/16/2025	6165085051	**	New Sale Invoice	186.72	+ WCX Document Retrieval Fee	02/15/2025
01/26/2025	0851397439	**	Subscription Invoice	42.00		02/25/2025
02/16/2025	6165549520	**	Late Fee Reference #: 6165085051	25.00	LATE FEE	02/16/2025
02/26/2025	6165608127	**	Late Fee Reference #: 6164870658	25.00	LATE FEE	02/26/2025
03/18/2025	6166049819	**	Late Fee Reference #: 6165085051	25.00	LATE FEE	03/18/2025

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Open charges as of April 1, 2025 continued

Document date	Document #		Description	Amount USD	Notes	Due Date
03/28/2025	6166116314	**	Late Fee Reference #: 6164870658	25.00	LATE FEE	03/28/2025
04/01/2025	0851776605		Invoice	105,935.36		05/01/2025
04/01/2025	6166330264	**	Late Fee Reference #: 6165925875	25.00	LATE FEE	04/01/2025

Open charges in USD as of April 1, 2025 **106,289.08**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	
2369-001	33,263.57
[redacted]	

[redacted]

105,934.88

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.36

Payment Due by
May 31, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.36	109,112.36
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.36**	**109,112.36**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: May 31, 2025
Amount due in USD: 109,112.36

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0851924791 000000000000000000000000 20250501 ZCPG 010911236 0010 1000655554 4

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers
CHE107904015MWST
EU: EU372043281
UK: 398 1554 53

Federal Tax ID
98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit
https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880
Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

THOMSON REUTERS®

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	**Units**	**Charge USD**	**Tax USD**	**Total USD**
April 1, 2025 - April 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.16	6,528.16
April 1, 2025 - April 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.94	98,630.94
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.84**	**99,966.84**
April 1, 2025 - April 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.36

Online/Software Out of Plan Charges
Usage Period: April 1, 2025 - April 30, 2025

Product Detail	**Units**	**Charge USD**	**Tax USD**	**Total USD**
DOCUMENT DISPLAYS	1	0.00	0.00	0.00
WOLTERS KLUWER - CCH TIME CLASS	:01	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.36

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6166908596 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	20,037.29	0.00	1,778.30	21,815.59
1000655554 Reference # 6166908599 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	80,180.71	0.00	7,116.06	87,296.77

TOTAL USD
109,112.36

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6166908596 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
April 1, 2025 - April 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		3,407.85	302.44	3,710.29
April 1, 2025 - April 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		13,659.69	1,212.29	14,871.98
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**14,273.19**	**1,266.74**	**15,539.93**
April 1, 2025 - April 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,356.25	209.12	2,565.37

Online/Software Subscription Charges Total USD
21,815.59

Online/Software Out of Plan Charges
Usage Period: April 1, 2025 - April 30, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
DOCUMENT DISPLAYS	1	91.00		
LESS OFFER CREDIT		-91.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
21,815.59

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851924791
Account #: 1000655554
Invoice date: May 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6166908599 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
April 1, 2025 - April 30, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		2,588.15	229.72	2,817.87
April 1, 2025 - April 30, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		76,931.31	6,827.65	83,758.96
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**77,544.81**	**6,882.10**	**84,426.91**
April 1, 2025 - April 30, 2025 WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		47.75	4.24	51.99

Online/Software Subscription Charges Total USD
87,296.77

Location Total USD
87,296.77

Total USD
109,112.36

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between April 2, 2025 and May 1, 2025

Document date	Document #		Description	Amount USD	Notes
01/16/2025	6165085051	**	New Sale Invoice	186.72	+ WCX Document Retrieval Fee
01/26/2025	0851397439	**	Subscription Invoice	42.00	
04/10/2025	000041322	**	Payment Received	-228.72	PAYMENT RECEIVED - THANK YOU
04/01/2025	0851776605		Invoice	105,935.36	
04/30/2025	000041447	**	Payment Received	-105,935.36	PAYMENT RECEIVED - THANK YOU
04/01/2025	6166330264	**	Late Fee Reference #: 6165925875	25.00	LATE FEE
04/01/2025	6166460596	**	Late Fee Reference #: 6165925875	-25.00	LATE FEE
02/16/2025	6165549520	**	Late Fee Reference #: 6165085051	25.00	LATE FEE
02/16/2025	6166523181	**	Late Fee Reference #: 6165085051	-25.00	LATE FEE
02/26/2025	6165608127	**	Late Fee Reference #: 6164870658	25.00	LATE FEE
02/26/2025	6166523183	**	Late Fee Reference #: 6164870658	-25.00	LATE FEE
03/18/2025	6166049819	**	Late Fee Reference #: 6165085051	25.00	LATE FEE
03/18/2025	6166523626	**	Late Fee Reference #: 6165085051	-25.00	LATE FEE
03/28/2025	6166116314	**	Late Fee Reference #: 6164870658	25.00	LATE FEE
03/28/2025	6166523629	**	Late Fee Reference #: 6164870658	-25.00	LATE FEE

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between April 2, 2025 and May 1, 2025 continued

Document date	Document #	Description	Amount USD	Notes

Open charges as of May 1, 2025

Document date	Document #		Description	Amount USD	Notes	Due Date
04/26/2025	6166584864	**	New Sale Invoice	186.72	+ WCX Document Retrieval Fee	05/26/2025
05/01/2025	0851924791		Invoice	109,112.36		05/31/2025

Open charges in USD as of May 1, 2025 **109,299.08**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	

[redacted]

2369-001	10,377.80

[redacted]

[redacted]

109,112.28

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.36

Payment Due by
July 1, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.36	109,112.36
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.36**	**109,112.36**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: July 1, 2025
Amount due in USD: 109,112.36

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0852071558 000000000000000000000000 20250601 ZCPG 010911236 0010 1000655554 2

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
May 1, 2025 - May 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.15	6,528.15
May 1, 2025 - May 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.95	98,630.95
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.85**	**99,966.85**
May 1, 2025 - May 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.36

Total USD
109,112.36

Invoice

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6167397329 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	18,918.12	0.00	1,678.98	20,597.10
1000655554 Reference # 6167397332 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	81,299.88	0.00	7,215.38	88,515.26

TOTAL USD
109,112.36

Invoice

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6167397329 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
May 1, 2025 - May 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		3,618.41	321.13	3,939.54
May 1, 2025 - May 31, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		14,550.80	1,291.38	15,842.18
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**15,164.30**	**1,345.83**	**16,510.13**
May 1, 2025 - May 31, 2025 WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		135.41	12.02	147.43

Online/Software Subscription Charges Total USD
20,597.10

Location Total USD
20,597.10

1000655554
Reference # 6167397332
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852071558
Account #: 1000655554
Invoice date: June 1, 2025
Purchase order #:

Account location detail

Product Detail	**Units**	**Charge USD**	**Tax USD**	**Total USD**
May 1, 2025 - May 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		2,377.59	211.02	2,588.61
May 1, 2025 - May 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		76,040.20	6,748.57	82,788.77
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**76,653.70**	**6,803.02**	**83,456.72**
May 1, 2025 - May 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,268.59	201.34	2,469.93

Online/Software Subscription Charges Total USD
88,515.26

Location Total USD
88,515.26

Total USD
109,112.36

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between May 2, 2025 and June 1, 2025

Document date	Document #		Description	Amount USD	Notes
04/26/2025	6166584864	**	New Sale Invoice	186.72	+ WCX Document Retrieval Fee
05/01/2025	0851924791		Invoice	109,112.36	
05/28/2025	000041590	**	Payment Received	-109,299.08	PAYMENT RECEIVED - THANK YOU
05/27/2025	6167048397	**	Late Fee Reference #: 6166584864	25.00	LATE FEE
05/27/2025	6167061661	**	Late Fee Reference #: 6166584864	-25.00	LATE FEE

Open charges as of June 1, 2025

Document date	Document #	Description	Amount USD	Notes	Due Date
06/01/2025	0852071558	Invoice	109,112.36		07/01/2025

Open charges in USD as of June 1, 2025 **109,112.36**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	
2369-001	5,592.43
[redacted]	

[redacted]

109,113.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
105,935.41

Payment Due by
January 31, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	97,300.00	8,635.41	105,935.41
TOTAL INVOICE AMOUNT	**97,300.00**	**8,635.41**	**105,935.41**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: January 31, 2025
Amount due in USD: 105,935.41

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0851338959 000000000000000000000000 20250101 ZCPG 010593541 0010 1000655554 4

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw

• Manage payments online and review account balances
• Update addresses and review order status
• View and download invoice details
• Manage online users' access
• Manage Autopay

http://www.quickview.com

• Obtain free usage reporting for cost recovery
• Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

• Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

• Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

• Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

• Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers
CHE107904015MWST
EU: EU372043281
UK: 398 1554 53

Federal Tax ID
98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

• Terms: Net 30; products are shipped FOB shipping point
• We reserve the right to charge a late fee for each invoice not paid by the due date.
• Please do not enclose cash or additional correspondence
• Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
December 1, 2024 - December 31, 2024				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,603.00	497.27	6,100.27
December 1, 2024 - December 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		88,259.00	7,833.02	96,092.02
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,191.00	105.70	1,296.70
Subtotal		**89,450.00**	**7,938.72**	**97,388.72**
December 1, 2024 - December 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
105,935.41

Total USD
105,935.41

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6165002234 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	7,252.80	0.00	643.72	7,896.52
1000655554 Reference # 6165002239 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	90,047.20	0.00	7,991.69	98,038.89

TOTAL USD
105,935.41

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6165002234 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
December 1, 2024 - December 31, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		145.02	12.87	157.89
December 1, 2024 - December 31, 2024 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		6,512.28	578.00	7,090.28
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**7,107.78**	**630.85**	**7,738.63**

Online/Software Subscription Charges Total USD
7,896.52

Location Total USD
7,896.52

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6165002239 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
December 1, 2024 - December 31, 2024 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,457.98	484.40	5,942.38

Continued on next page

Invoice

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 851338959
Account #: 1000655554
Invoice date: January 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
December 1, 2024 - December 31, 2024				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		81,746.72	7,255.02	89,001.74
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		595.50	52.85	648.35
Subtotal		**82,342.22**	**7,307.87**	**89,650.09**
December 1, 2024 - December 31, 2024				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,247.00	199.42	2,446.42

Online/Software Subscription Charges Total USD
98,038.89

Location Total USD
98,038.89

Total USD
105,935.41

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly **account summary**

Account #: 1000655554

Charges cleared between December 2, 2024 and January 1, 2025

Document date	Document #		Description	Amount USD	Notes
11/01/2024	0851044914		Invoice	105,935.37	
12/01/2024	000040710	**	Payment Received	-105,935.37	PAYMENT RECEIVED - THANK YOU
08/29/2024	6162545048	**	New Sale Invoice	1,139.38	+ WCX Document Retrieval Fee
12/12/2024	000040760	**	Payment Received	-1,139.38	PAYMENT RECEIVED - THANK YOU
11/26/2024	0851102491	**	Subscription Invoice	42.00	
11/26/2024	6164117260	**	New Sale Invoice	189.44	+ WCX Document Retrieval Fee
11/26/2024	6164117261	**	New Sale Invoice	188.90	+ WCX Document Retrieval Fee
12/01/2024	0851185308		Invoice	105,935.38	
12/27/2024	000040856	**	Payment Received	-106,355.72	PAYMENT RECEIVED - THANK YOU
11/01/2024	6163920348		Payment Received Partial Balance	0.40	+ WN HOME
12/03/2024		**	Write-Off Write Off - Good Will Small Balance	-0.40	
09/29/2024	6163049159	**	Late Fee Reference #: 6162545048	25.00	LATE FEE
09/29/2024	6164565132	**	Late Fee Reference #: 6162545048	-25.00	LATE FEE
10/29/2024	6163564696	**	Late Fee Reference #: 6162545048	25.00	LATE FEE
10/29/2024	6164565146	**	Late Fee Reference #: 6162545048	-25.00	LATE FEE
11/28/2024	6164134790	**	Late Fee Reference #: 6162545048	25.00	LATE FEE
11/28/2024	6164565189	**	Late Fee	-25.00	LATE FEE

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between December 2, 2024 and January 1, 2025 continued

Document date	Document #		Description	Amount USD	Notes
			Reference #: 6162545048		
12/27/2024	6164672571	**	Late Fee Reference #: 6163763556	25.00	LATE FEE
12/27/2024	6164676907	**	Late Fee Reference #: 6163763556	-25.00	LATE FEE
12/27/2024	6164672572	**	Late Fee Reference #: 6164117260	25.00	LATE FEE
12/27/2024	6164677308	**	Late Fee Reference #: 6164117260	-25.00	LATE FEE
12/27/2024	6164672573	**	Late Fee Reference #: 6164117261	25.00	LATE FEE
12/27/2024	6164677309	**	Late Fee Reference #: 6164117261	-25.00	LATE FEE

Open charges as of January 1, 2025

Document date	Document #		Description	Amount USD	Notes	Due Date
12/26/2024	0851249322	**	Subscription Invoice	42.00		01/25/2025
01/01/2025	0851338959		Invoice	105,935.41		01/31/2025

Open charges in USD as of January 1, 2025 **105,977.41**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

** Charge from West Publishing Corporation

Matter	Amount
[redacted]	
2369-001	5,933.15

[redacted]

105,935.86

Invoice

THOMSON REUTERS

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.37

Payment Due by
July 31, 2025

Summary	Charge USD	Tax USD	Total USD
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.37	109,112.37
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.37**	**109,112.37**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: July 31, 2025
Amount due in USD: 109,112.37

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0852220638 000000000000000000000000 20250701 ZCPG 010911237 0010 1000655554 7

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers
CHE107904015MWST
EU: EU372043281
UK: 398 1554 53

Federal Tax ID
98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

THOMSON REUTERS®

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
June 1, 2025 - June 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.15	6,528.15
June 1, 2025 - June 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.96	98,630.96
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.86**	**99,966.86**
June 1, 2025 - June 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.37

Total USD
109,112.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025
Purchase order #:

Account totals by location

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6167884880 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	15,128.33	0.00	1,342.66	16,470.99
1000655554 Reference # 6167884890 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	85,089.67	0.00	7,551.71	92,641.38

TOTAL USD
109,112.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6167884880 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
June 1, 2025 - June 30, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		113.05	10.03	123.08
June 1, 2025 - June 30, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		14,121.95	1,253.34	15,375.29
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**14,735.45**	**1,307.79**	**16,043.24**
June 1, 2025 - June 30, 2025 WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		279.83	24.84	304.67

Online/Software Subscription Charges Total USD
16,470.99

Location Total USD
16,470.99

1000655554
Reference # 6167884890
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852220638
Account #: 1000655554
Invoice date: July 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
June 1, 2025 - June 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,882.95	522.12	6,405.07
June 1, 2025 - June 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		76,469.05	6,786.62	83,255.67
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**77,082.55**	**6,841.07**	**83,923.62**
June 1, 2025 - June 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,124.17	188.52	2,312.69

Online/Software Subscription Charges Total USD
92,641.38

Location Total USD
92,641.38

Total USD
109,112.37

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between June 2, 2025 and July 1, 2025

Document date	Document #	Description	Amount USD	Notes
06/01/2025	0852071558	Invoice	109,112.36	
06/30/2025	000041756	Payment Received	-109,112.36	PAYMENT RECEIVED - THANK YOU

Open charges as of July 1, 2025

Document date	Document #	Description	Amount USD	Notes	Due Date
07/01/2025	0852220638	Invoice	109,112.37		07/31/2025

Open charges in USD as of July 1, 2025 **109,112.37**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

Matter ID	Total
[redacted]	
2369-001	16,596.33
[redacted]	

[redacted]

Gramd Total	109,112.37

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.38

Payment Due by
August 31, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.38	109,112.38
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.38**	**109,112.38**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: August 31, 2025
Amount due in USD: 109,112.38

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0852367224 000000000000000000000000 20250801 ZCPG 010911238 0010 1000655554 6

Information and **payment details**

THOMSON REUTERS®

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
July 1, 2025 - July 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.15	6,528.15
July 1, 2025 - July 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.97	98,630.97
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.87**	**99,966.87**
July 1, 2025 - July 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.38

Online/Software Out of Plan Charges
Usage Period: July 1, 2025 - July 31, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
WN DRAFTING TRANSACTIONAL DOCUMENT DISPLAYS	1	0.00	0.00	0.00
WOLTERS KLUWER - CCH DOCUMENT DISPLAYS	1	0.00	0.00	0.00
WOLTERS KLUWER - CCH TIME CLASS	7:39	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025
Purchase order #:

Account totals **by location**

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6168364716 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	17,365.07	0.00	1,541.14	18,906.21
1000655554 Reference # 6168364726 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	82,852.93	0.00	7,353.24	90,206.17

TOTAL USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6168364716 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
July 1, 2025 - July 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		700.38	62.16	762.54
July 1, 2025 - July 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		16,051.19	1,424.53	17,475.72
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**16,664.69**	**1,478.98**	**18,143.67**

Online/Software Subscription Charges Total USD
18,906.21

Online/Software Out of Plan Charges
Usage Period: July 1, 2025 - July 31, 2025

	Units	Charge USD	Tax USD	Total USD
WOLTERS KLUWER - CCH DOCUMENT DISPLAYS	1	217.00		
LESS OFFER CREDIT		-217.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
18,906.21

1000655554
Reference # 6168364726
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Continued on next page

Invoice

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

BERNSTEIN LITOWITZ BERGER ET AL

Invoice #: 852367224
Account #: 1000655554
Invoice date: August 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
July 1, 2025 - July 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,295.62	469.99	5,765.61
July 1, 2025 - July 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		74,539.81	6,615.44	81,155.25
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**75,153.31**	**6,669.89**	**81,823.20**
July 1, 2025 - July 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
90,206.17

Online/Software Out of Plan Charges
Usage Period: July 1, 2025 - July 31, 2025

WN DRAFTING TRANSACTIONAL DOCUMENT DISPLAYS	1	403.00		
LESS FREE TRIAL SO DA		-403.00		
Subtotal		**0.00**	**0.00**	**0.00**
WOLTERS KLUWER - CCH TIME CLASS	7:39	1,124.55		
LESS OFFER CREDIT		-1,124.55		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
90,206.17

Total USD
109,112.38

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

THOMSON REUTERS®

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly **account summary**

Account #: 1000655554

Charges cleared between July 2, 2025 and August 1, 2025

Document date	Document #	Description	Amount USD	Notes
07/01/2025	0852220638	Invoice	109,112.37	
07/28/2025	000041909	Payment Received	-109,112.37	PAYMENT RECEIVED - THANK YOU

Open charges as of August 1, 2025

Document date	Document #	Description	Amount USD	Notes	Due Date
08/01/2025	0852367224	Invoice	109,112.38		08/31/2025

Open charges in USD as of August 1, 2025 **109,112.38**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

Clean Data	Total	Narrative
[redacted]		
2369-001	5,459.87	
[redacted]		

[redacted]

Grand Total	109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.33

Payment Due by
October 1, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.33	109,112.33
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.33**	**109,112.33**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: October 1, 2025
Amount due in USD: 109,112.33

Amount enclosed: ________________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0852513847 000000000000000000000000 20250901 ZCPG 010911233 0010 1000655554 6

Information and **payment details**

Thomson Reuters™

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers
CHE107904015MWST
EU: EU372043281
UK: 398 1554 53

Federal Tax ID
98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
August 1, 2025 - August 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.13	6,528.13
August 1, 2025 - August 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.94	98,630.94
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.84**	**99,966.84**
August 1, 2025 - August 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.33

Online/Software Out of Plan Charges
Usage Period: August 1, 2025 - August 31, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
TRANSACTIONAL SOFTWARE CHARGES	3	818.00	0.00	818.00
WN DRAFTING TRANSACTIONAL DOCUMENT DISPLAYS	1	0.00	0.00	0.00
WN PRO WL ADVANTAGE DOCUMENT DISPLAYS	4	0.00	0.00	0.00
WN PRO WL ADVANTAGE TRANSACTIONAL SEARCHES	12	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.33

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025
Purchase order #:

Account totals **by location**

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6168857730 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	21,259.86	0.00	1,886.81	23,146.67
1000655554 Reference # 6168857739 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	78,958.14	0.00	7,007.52	85,965.66

TOTAL USD
109,112.33

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6168857730 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
August 1, 2025 - August 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		816.00	72.42	888.42
August 1, 2025 - August 31, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		19,830.36	1,759.94	21,590.30
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**20,443.86**	**1,814.39**	**22,258.25**

Online/Software Subscription Charges Total USD
23,146.67

Location Total USD
23,146.67

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6168857739 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
August 1, 2025 - August 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,180.00	459.71	5,639.71

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852513847
Account #: 1000655554
Invoice date: September 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
August 1, 2025 - August 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		70,760.64	6,280.00	77,040.64
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**71,374.14**	**6,334.45**	**77,708.59**
August 1, 2025 - August 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
85,965.66

Online/Software Out of Plan Charges
Usage Period: August 1, 2025 - August 31, 2025

TRANSACTIONAL SOFTWARE CHARGES	3	818.00		
LESS FREETRIAL CCSL LEGAL		-818.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN DRAFTING TRANSACTIONAL DOCUMENT DISPLAYS	1	403.00		
LESS FREETRIAL CCSL LEGAL		-403.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE DOCUMENT DISPLAYS	4	40.00		
LESS FREETRIAL CCSL LEGAL		-40.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE TRANSACTIONAL SEARCHES	12	120.00		
LESS FREETRIAL CCSL LEGAL		-120.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
85,965.66

Total USD
109,112.33

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters™

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly account summary

Account #: 1000655554

Charges cleared between August 2, 2025 and September 1, 2025

Document date	Document #	Description	Amount USD	Notes
08/01/2025	0852367224	Invoice	109,112.38	
08/26/2025	000042024	Payment Received	-109,112.38	PAYMENT RECEIVED - THANK YOU

Open charges as of September 1, 2025

Document date	Document #	Description	Amount USD	Notes	Due Date
09/01/2025	0852513847	Invoice	109,112.33		10/01/2025

Open charges in USD as of September 1, 2025 **109,112.33**

Matter ID	Total	Narrative
[redacted]		
2369-001	8212.41	
[redacted]		

[redacted]

Grand Total	**109,112.33**

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters™

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.32

Payment Due by
October 31, 2025

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.32	109,112.32
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.32**	**109,112.32**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025

Invoice due date: October 31, 2025
Amount due in USD: 109,112.32

Amount enclosed: ______________________

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0852660342 000000000000000000000000 20251001 ZCPG 010911232 0010 1000655554 0

Information and **payment details**

Thomson Reuters™

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880
Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
September 1, 2025 - September 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.16	6,528.16
September 1, 2025 - September 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.90	98,630.90
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.80**	**99,966.80**
September 1, 2025 - September 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.32

Online/Software Out of Plan Charges

Usage Period: September 1, 2025 - September 30, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
DOCUMENT DISPLAYS	2	0.00	0.00	0.00
TRANSACTIONAL SEARCHES	16	0.00	0.00	0.00
WN PRO WL ADVANTAGE DOCUMENT DISPLAYS	5	0.00	0.00	0.00
WN PRO WL ADVANTAGE TRANSACTIONAL SEARCHES	9	0.00	0.00	0.00
WOLTERS KLUWER - CCH TIME CLASS	:43	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.32

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

Account totals **by location**

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6169314454 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	11,073.78	0.00	982.83	12,056.61
1000655554 Reference # 6169314464 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	89,144.22	0.00	7,911.49	97,055.71

TOTAL USD
109,112.32

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6169314454 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
September 1, 2025 - September 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		56.34	5.01	61.35
September 1, 2025 - September 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		10,403.94	923.37	11,327.31
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**11,017.44**	**977.82**	**11,995.26**

Online/Software Subscription Charges Total USD
12,056.61

Online/Software Out of Plan Charges
Usage Period: September 1, 2025 - September 30, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
TRANSACTIONAL SEARCHES	12	120.00		
LESS OFFER CREDIT		-120.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE TRANSACTIONAL SEARCHES	3	30.00		
LESS FREETRIAL CCSL LEGAL		-30.00		
Subtotal		**0.00**	**0.00**	**0.00**
WOLTERS KLUWER - CCH TIME CLASS	:43	105.35		
LESS OFFER CREDIT		-105.35		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
12,056.61

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6169314464 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
September 1, 2025 - September 30, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,939.66	527.15	6,466.81
September 1, 2025 - September 30, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		80,187.06	7,116.53	87,303.59
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**80,800.56**	**7,170.98**	**87,971.54**
September 1, 2025 - September 30, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
97,055.71

Online/Software Out of Plan Charges
Usage Period: September 1, 2025 - September 30, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
DOCUMENT DISPLAYS	2	20.00		
LESS OFFER CREDIT		-20.00		
Subtotal		**0.00**	**0.00**	**0.00**
TRANSACTIONAL SEARCHES	4	40.00		
LESS OFFER CREDIT		-40.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE DOCUMENT DISPLAYS	5	50.00		
LESS FREETRIAL CCSL LEGAL		-50.00		

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 852660342
Account #: 1000655554
Invoice date: October 1, 2025
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE TRANSACTIONAL SEARCHES	6	60.00		
LESS FREETRIAL CCSL LEGAL		-60.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
97,055.71

Total USD
109,112.32

** Indicates system credit*

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly **account summary**

Account #: 1000655554

Charges cleared between September 2, 2025 and October 1, 2025

Document date	Document #	Description	Amount USD	Notes
09/01/2025	0852513847	Invoice	109,112.33	
09/21/2025	000042161	Payment Received	-109,112.33	PAYMENT RECEIVED - THANK YOU

Open charges as of October 1, 2025

Document date	Document #	Description	Amount USD	Notes	Due Date
10/01/2025	0852660342	Invoice	109,112.32		10/31/2025

Open charges in USD as of October 1, 2025 **109,112.32**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

Matter ID	Total	Narrative
[redacted]		
2369-001	5,323.08	
[redacted]		

[redacted]

Grand Total	109,112.32

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.38

Payment Due by
January 31, 2026

Summary	Charge USD	Tax USD	Total USD
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.38	109,112.38
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.38**	**109,112.38**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: January 31, 2026
Amount due in USD: 109,112.38

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0853077092 000000000000000000000000 20260101 ZCPG 010911238 0010 1000655554 0

Information and **payment details**

Thomson Reuters™

Do more with your account online

http://myaccount.tr.com/westlaw
- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com
- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request
- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com
- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay
- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support
- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
December 1, 2025 - December 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.15	6,528.15
December 1, 2025 - December 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.97	98,630.97
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.87**	**99,966.87**
December 1, 2025 - December 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.38

Online/Software Out of Plan Charges
Usage Period: December 1, 2025 - December 31, 2025

Product Detail	Units	Charge USD	Tax USD	Total USD
TIME CLASS	:01	0.00	0.00	0.00
WN PRO WL ADVANTAGE AI ANALYZER	9	0.00	0.00	0.00
WN PRO WL ADVANTAGE AI SEARCH	82	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026
Purchase order #:

Account totals **by location**

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6170546216 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	7,892.13	0.00	700.41	8,592.54
1000655554 Reference # 6170546225 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	92,325.87	0.00	8,193.97	100,519.84

TOTAL USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6170546216 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
December 1, 2025 - December 31, 2025 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		734.80	65.21	800.01
December 1, 2025 - December 31, 2025 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		6,543.83	580.75	7,124.58
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**7,157.33**	**635.20**	**7,792.53**

Online/Software Subscription Charges Total USD
8,592.54

Online/Software Out of Plan Charges
Usage Period: December 1, 2025 - December 31, 2025

	Units	Charge USD	Tax USD	Total USD
WN PRO WL ADVANTAGE AI SEARCH	8	80.00		
LESS FREETRIAL CCSL LEGAL		-80.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
8,592.54

1000655554
Reference # 6170546225
BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK NY 10020-1104

Online/Software Subscription Charges

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853077092
Account #: 1000655554
Invoice date: January 1, 2026
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
December 1, 2025 - December 31, 2025				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,261.20	466.94	5,728.14
December 1, 2025 - December 31, 2025				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		84,047.17	7,459.22	91,506.39
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**84,660.67**	**7,513.67**	**92,174.34**
December 1, 2025 - December 31, 2025				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
100,519.84

Online/Software Out of Plan Charges
Usage Period: December 1, 2025 - December 31, 2025

TIME CLASS	:01	1.25		
LESS OFFER CREDIT		-1.25		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE AI ANALYZER	9	90.00		
LESS FREETRIAL CCSL LEGAL		-90.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE AI SEARCH	74	740.00		
LESS FREETRIAL CCSL LEGAL		-740.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
100,519.84

Total USD
109,112.38

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters™

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Monthly **account summary**

Account #: 1000655554

Charges cleared between December 2, 2025 and January 1, 2026

Document date	Document #	Description	Amount USD	Notes
12/01/2025	0852938833	Invoice	109,112.37	
12/26/2025	000042598	Payment Received	-109,112.37	PAYMENT RECEIVED - THANK YOU

Open charges as of January 1, 2026

Document date	Document #	Description	Amount USD	Notes	Due Date
01/01/2026	0853077092	Invoice	109,112.38		01/31/2026

Open charges in USD as of January 1, 2026 **109,112.38**

The Monthly account summary is a comprehensive report of all account activity for the current subscription billing period. Payments made within the last 48 hours may not be included. Go to http://myaccount.tr.com/westlaw if more details are needed around these invoices or payments.

Matter ID	Total	Narrative
[redacted]		
2369-001	13,485.43	
[redacted]		

[redacted]

Grand Total	**109,112.38**

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

BERNSTEIN LITOWITZ BERGER ET AL
CHRISTOPHER REDLICH
1251 AVENUE OF THE AMERICAS FL 44
NEW YORK, NY 10020-1104

Total Due in USD
109,112.38

Payment Due by
May 1, 2026

Summary	**Charge USD**	**Tax USD**	**Total USD**
ONLINE/SOFTWARE SUBSCRIPTION CHARGES	100,218.00	8,894.38	109,112.38
ONLINE/SOFTWARE OUT OF PLAN CHARGES	0.00	0.00	0.00
TOTAL INVOICE AMOUNT	**100,218.00**	**8,894.38**	**109,112.38**

Billing Note
Find information on how to read your invoice and other commonly asked billing questions under the Billing, payment, returns & refunds section online at legal.thomsonreuters.com/en/support.

Self-Service online resources

To manage your account sign up at MyAccount: http://myaccount.tr.com/westlaw

For online support contact us at http://legal.thomsonreuters.com/en/support

We reserve the right to charge a late fee for each invoice not paid by the due date. Avoid potential late fees by enrolling in Autopay at: www.tr.com/guestpay-autopay.

1000655554 Z

Include this portion with your payment - Folding and stapling may delay your payment.

BERNSTEIN LITOWITZ BERGER ET AL
Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026

Pay online:
To make a payment electronically log on to
https:/www.tr.com/guestpay-autopay
Set up your payment to be withdrawn electronically using direct debit or credit card.

Invoice due date: May 1, 2026
Amount due in USD: 109,112.38

Amount enclosed: ______________________

Please make checks payable to the following, as agent for Thomson Reuters Enterprise Centre GmbH:

Thomson Reuters - West
Payment Center
P.O. Box 6292
Carol Stream, IL 60197-6292

0853472764 000000000000000000000000 20260401 ZCPG 010911238 0010 1000655554 2

Information and **payment details**

Thomson Reuters™

Do more with your account online

http://myaccount.tr.com/westlaw

- Manage payments online and review account balances
- Update addresses and review order status
- View and download invoice details
- Manage online users' access
- Manage Autopay

http://www.quickview.com

- Obtain free usage reporting for cost recovery
- Obtain eDiscovery matter details

https://legal.thomsonreuters.com/billing-portal-request

- Sign up to recieve your invoice through a billing portal

http://ebilling.thomsonreuters.com

- Go Green with eInvoicing for time savings and convenience

https:// www.tr.com/guestpay-autopay

- Easily and quickly enroll in our Autopay program

Contact us online

https://legal.thomsonreuters.com/en/support

- Provides answers to commonly asked questions and web forms for submitting account-related requests

Thomson Reuters Enterprise Centre GmbH tax information

VAT Reg Numbers	Federal Tax ID
CHE107904015MWST EU: EU372043281 UK: 398 1554 53	98-0435183

Payment options and terms

Include your invoice number to assist with applying your payment or email the remittance to west.arpaymentcenter@thomsonreuters.com

Pay online

To make a payment online or sign up for Autopay, please visit https:// www.tr.com/guestpay-autopay

Electronic payments in US currency should be issued to The following, as agent for Thomson Reuters Enterprise Centre GmbH

West Publishing Corporation
BMO Harris Bank N.A.,
320 S. Canal Street Chicago IL 60606
Bank Routing #: 071000288
Bank Account #: 4445615
SWIFT Code: HATRUS44

Electronic payment details for other currencies
http://legal.tr.com/electronic-funds-transfer

Pay via phone

To make a payment via telephone, please call 1-800-328-4880 Say "*Account Services*," then provide account number, say "*make a payment*."

- Terms: Net 30; products are shipped FOB shipping point
- We reserve the right to charge a late fee for each invoice not paid by the due date.
- Please do not enclose cash or additional correspondence
- Payments marked "paid in full," or with any other restrictive language, shall not operate as an accord and satisfaction without the prior written approval of West (Thomson Reuters).

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

Product summary all locations

Online/Software Subscription Charges

Product Detail	Units	Charge USD	Tax USD	Total USD
March 1, 2026 - March 31, 2026				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,996.00	532.16	6,528.16
March 1, 2026 - March 31, 2026				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		90,591.00	8,039.96	98,630.96
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		1,227.00	108.90	1,335.90
Subtotal		**91,818.00**	**8,148.86**	**99,966.86**
March 1, 2026 - March 31, 2026				
WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD
109,112.38

Online/Software Out of Plan Charges
Usage Period: March 1, 2026 - March 31, 2026

Product Detail	Units	Charge USD	Tax USD	Total USD
WN PRO WL ADVANTAGE AI ANALYZER	7	0.00	0.00	0.00
WN PRO WL ADVANTAGE AI LITIGATION DOCUMENT ANALYZER	2	0.00	0.00	0.00
WN PRO WL ADVANTAGE AI SEARCH	298	0.00	0.00	0.00

The values displayed are net totals. If adjustments were applied see the Account location detail pages for additional information.

Online/Software Out of Plan Charges Total USD
0.00

Total USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

Account totals **by location**

Location	Subscription Charges USD	Out of Plan Charges USD	Tax USD	Total USD
1000590834 Reference # 6171755254 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104	6,290.61	0.00	558.30	6,848.91
1000655554 Reference # 6171755256 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104	93,927.39	0.00	8,336.08	102,263.47

TOTAL USD
109,112.38

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000590834 Reference # 6171755254 BERNSTEIN LITOWITZ BERGER ET AL ACCOUNTING DEPARTMENT 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
March 1, 2026 - March 31, 2026				
PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		44.01	3.91	47.92
March 1, 2026 - March 31, 2026				
WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		5,633.10	499.94	6,133.04
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**6,246.60**	**554.39**	**6,800.99**

Online/Software Subscription Charges Total USD
6,848.91

Online/Software Out of Plan Charges
Usage Period: March 1, 2026 - March 31, 2026

Product Detail	Units	Charge USD	Tax USD	Total USD
WN PRO WL ADVANTAGE AI ANALYZER	3	30.00		
LESS FREETRIAL WL ADVANT		-30.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE AI LITIGATION DOCUMENT ANALYZER	2	20.00		
LESS FREETRIAL WL ADVANT		-20.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE AI SEARCH	34	340.00		
LESS FREETRIAL WL ADVANT		-340.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD
0.00

Location Total USD
6,848.91

Continued on next page

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters
Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
1000655554 Reference # 6171755256 BERNSTEIN LITOWITZ BERGER ET AL CHRISTOPHER REDLICH 1251 AVENUE OF THE AMERICAS FL 44 NEW YORK NY 10020-1104				
Online/Software Subscription Charges				
March 1, 2026 - March 31, 2026 PRACTICAL LAW CONNECT PREFERRED DYNAMIC (Unique Identifier 0000246899)				
DATABASE CHARGES		5,951.99	528.25	6,480.24
March 1, 2026 - March 31, 2026 WL SPECIAL OFFER (Unique Identifier 0000044491)				
DATABASE CHARGES		84,957.90	7,540.02	92,497.92
SOFTWARE AS A SERVICE		0.00	0.00	0.00
DATABASE CHARGES		613.50	54.45	667.95
Subtotal		**85,571.40**	**7,594.47**	**93,165.87**
March 1, 2026 - March 31, 2026 WN SPECIAL OFFER SIMPLICITY ANALYTICAL CCH ALL IN (Unique Identifier 0000258949)				
DATABASE CHARGES		2,404.00	213.36	2,617.36

Online/Software Subscription Charges Total USD 102,263.47

Online/Software Out of Plan Charges
Usage Period: March 1, 2026 - March 31, 2026

Product Detail	Units	Charge USD	Tax USD	Total USD
WN PRO WL ADVANTAGE AI ANALYZER	4	40.00		
LESS FREETRIAL WL ADVANT		-40.00		
Subtotal		**0.00**	**0.00**	**0.00**
WN PRO WL ADVANTAGE AI SEARCH	264	2,640.00		
LESS FREETRIAL WL ADVANT		-2,640.00		
Subtotal		**0.00**	**0.00**	**0.00**

Online/Software Out of Plan Charges Total USD 0.00

Invoice

BERNSTEIN LITOWITZ BERGER ET AL

Thomson Reuters

Thomson Reuters
West Publishing Corporation, as agent for
Thomson Reuters Enterprise Centre GmbH
2900 Ames Crossing Rd
Eagan, MN 55121

Invoice #: 853472764
Account #: 1000655554
Invoice date: April 1, 2026
Purchase order #:

Account location detail

Product Detail	Units	Charge USD	Tax USD	Total USD
				Location Total USD 102,263.47
				Total USD 109,112.38

** Indicates system credit*

Client ID	Total	Narrative
[redacted]		
2369-001	34,261.08	
[redacted]		

[redacted]

Grand Total	109,112.38

Outside Copying & Printing

Invoice

KEY Discovery
40 Court Street
2nd Floor
Boston, MA 02108

Date	Invoice #
12/13/2024	2412064

Bill To
Bernstein Litowitz Berger & Grossmann LLP 1251 Avenue of the Americas, 44th Floor New York, New York 10020

Terms	Due Date
Net 15	12/28/2024

Project Received	Project #	Client Matter #
12/9/2024	2412-051	2369-001
Case Name	**Reference #**	**Contact Name**
ChemoCentryx		Melody Yaghoubzadeh

Description	Qty	Unit Price	Amount
B&W- Litigation Printing W/document assembly	15,114	0.18	2,720.52T
Color-Litigation Printing	5,320	0.49	2,606.80T
Regular Tabs	300	0.45	135.00T
3-ring binders (4")	8	26.99	215.92T
Coil Bind	2	8.99	17.98T
Custom Folders	107	2.50	267.50T
Custom Redwelds	10	3.50	35.00T
Delivery- Hotel; Back Bay	1	50.00	50.00
Sales Tax		6.25%	374.92

Please remit payment to PO Box 51118, Boston, MA 02205

Net payment is due within 15 days.
This account is subject to a FINANCE CHARGE for late payment. This charge is computed at an annual percentage rate of 18% (periodic monthly rate of 1.5%) on the total past due balance over 30 days. In the event of late payment, default, or litigation, it is agreed that the purchaser will be liable for reasonable attorneys' fees and costs of collection.

Tax ID # 26-2053106

Total	$6,423.64
Payments/Credits	$0.00
Balance Due	$6,423.64

INVOICE

Date	Invoice #
1/26/2026	104127
Fed. Tax ID	**Amount Due**
47-3380949	$16,878.78

Less $718.58
Due Amt--$16,160.20

COUNSEL PRESS

PO Box 25292
New York, NY 10087

DUE UPON RECEIPT

Important Notice
As part of our recent ERP system implementation, we have refreshed and modernized our invoice layout. These updates are designed to provide greater clarity and a more streamlined presentation of your billing details. We appreciate your understanding and continued partnership.

Bill To
Bernstein Litowitz Berger & Grossmann LLP
Jorge Tenreiro, Esq.
1251 Avenue of the Americas
New York, NY 10020

File #	Court	Case Name	Terms	Due Date
386122	U.S. - 9th Circuit	The Indiana Public Retirement System, et al. v. ChemoCentryx, Inc., et al.	Due on receipt	1/26/2026

Description	Quantity	Rate	Ext. Price
Excerpts - Of Record (Confidential and NonConfidential)			
Cover(s) - 1st Side - (cover and index)	9	$155.00	$1,395.00
Page(s) Table of Contents	13	$140.00	$1,820.00
Page(s)	1,351	$4.45	$6,011.95
Numbered Make Ready	1,349	$0.35	$472.15
Hour(s) Paralegal Time	10.25	$195.00	$1,998.75
Electronic File Production and Review	9	$165.00	$1,485.00
File Upload(s)	8	$55.00	$440.00
Filing of Documents	1	$120.00	$120.00
Shipping & Handling	1	$660.00	$660.00
Brief - Appellant's Opening			
Preparation of Brief	1	$825.00	$825.00
Page(s)	75	$0.00	$0.00
Electronic File Production and Review	1	$165.00	$165.00
File Upload(s)	1	$55.00	$55.00
Notice of Intent to Unseal			
File Upload(s)	1	$55.00	$55.00
File No. 2369-001			

This invoice is due upon receipt. Please show the invoice number on the check when submitting payment. Payment may be mailed to the address at the top of the invoice.

Credit card payments may be made by clicking the green "Pay Invoice" button below. A convenience fee of 3% is applied at the time of processing for credit card payments.

Subtotal	$15,502.85
Sales Tax	$1,375.93
Total	$16,878.78
Balance	**$16,878.78**

Less Adjustment ($718.58)
Amount Due -------- $16,160.20
===========

Pay Invoice

 ME

Discovery Costs

Print Date: August 8, 2024 11:22:36

Billing Rep: Maferima Kanhon

TROUTMAN PEPPER
Prebill #6105468
Thru 08/07/24

Client	111689	Precision Research, Inc.	Billing Attorney	25979	Zucker, Kenneth H
Matter	000002	Jonnie Homyk and Indiana Public Retirement System	Responsible Attorney	25979	Zucker, Kenneth H

MATTER TIMEKEEPER SUMMARY

Tkpr #	Name	Status	Rate	Hours	Fees
25597	McVey, Stephen	Associate	440.00	3.8	1,672.00
53406	Simmons, Stephen E.	PG Misc Tmkpr	290.00	1.2	348.00
25979	Zucker, Kenneth H	Partner	1,450.00	14.2	20,590.00
			Totals	**19.2**	**22,610.00**

UNBILLED FEE DETAIL

Date	Entry ID	Name	Narrative	Hours	Value	Edit
06/04/24	63872940	K H Zucker	Confer with N. Sobieck concerning ChemoCentryx subpoena, including review of subpoena	0.5	725.00	________
06/05/24	63872950	K H Zucker	Confer with S. McVey concerning production response to subpoena and review ChemoCentryx Master Services Agreement (MSA) and Statements of Work	1.0	1,450.00	________
06/05/24	63872958	K H Zucker	Review docket for litigation giving rise to subpoena, including evaluate parties for conflict check, and communicate with ChemoCentryx's counsel at Latham	0.8	1,160.00	________
06/06/24	63872964	K H Zucker	Further communications with ChemoCentryx counsel at Latham	0.2	290.00	________
06/07/24	63876830	K H Zucker	Communicate with counsel at ChemoCentryx, counsel for plaintiffs and also N. Sobieck concerning extension and production, including draft notice of production of confidential material pursuant to Master Services Agreement and related Confidentiality Agreement	1.3	1,885.00	________
06/10/24	63876890	K H Zucker	Further communications with N. Sobieck and discussions with counsel for plaintiffs and for ChemoCentryx	0.7	1,015.00	________

UNBILLED FEE DETAIL

Date	Entry ID	Name	Narrative	Hours	Value	Edit
06/11/24	63901154	S McVey	Conference with Ken Zucker regarding scope of subpoena, key deadlines, and materials identified for collection	0.2	88.00	___
06/11/24	63901155	S McVey	Conference with Ken Zucker and Nancy Sobieck regarding sources for collection, scope of collection, and production workflows	0.5	220.00	___
06/11/24	63877023	K H Zucker	Ongoing attention to and communications around production, including evaluate Stipulated Protective Order and confer with N. Sobieck and S. McVey	0.8	1,160.00	___
06/12/24	63901427	S McVey	Communications with Nancy Sobieck regarding scope of collections, productions, and costs regarding same	0.7	308.00	___
06/12/24	63877089	K H Zucker	Evaluate additional information from S. McVey concerning production, including confer with S. McVey	0.3	435.00	___
06/13/24	63877122	K H Zucker	Ongoing discussions and attention to satisfying subpoena	0.5	725.00	___
06/14/24	63901954	S McVey	Communications with Ken Zucker regarding scope of collections, productions, and options for proceeding	0.2	88.00	___
06/14/24	63877149	K H Zucker	Further discussions with counsel for ChemoCentryx and plaintiffs and S. McVey concerning production	0.3	435.00	___
06/17/24	63902254	S McVey	Compile MSA and Statements of Work for production in response to third-party subpoena	0.1	44.00	___
06/18/24	63902395	S McVey	Communications with Nancy Sobieck regarding scope of collections, productions, and options for proceeding	0.4	176.00	___
06/18/24	63906271	K H Zucker	Confer with S. McVey concerning production	0.2	290.00	___
06/20/24	63906272	K H Zucker	Review emails forwarded by N. Sobieck and confer with	0.7	1,015.00	___

UNBILLED FEE DETAIL

Date	Entry ID	Name	Narrative	Hours	Value	Edit
			S. McVey concerning same			
06/26/24	63983559	S McVey	Conference with Nancy Sobieck regarding download and production of SharePoint material	0.5	220.00	___________
06/26/24	63983563	S McVey	Communications with Nancy Sobieck and Ken Zucker regarding scope of collections, productions, and options for proceeding	0.4	176.00	___________
06/26/24	63983639	S E Simmons	Communicate with Steve McVey regarding best practices for download of SharePoint data using the SharePoint native download functionality and methods to ensure complete download of all requested files and folders	0.5	145.00	___________
06/27/24	63983808	S McVey	Confer with Stephen Simmons regarding collection errors from client SharePoint site and potential workarounds	0.2	88.00	___________
06/27/24	63983791	S E Simmons	Communicate with Steve McVey regarding best practices for download of SharePoint data using the SharePoint native download functionality and methods to ensure complete download of all requested files and folders	0.3	87.00	___________
07/03/24	64131651	S E Simmons	Communicate with Nancy Sobieck and Steve McVey regarding collection and download of Sharepoint documents	0.4	116.00	___________
07/08/24	64131986	S McVey	Confer with Ken Zucker regarding production status, IT impediments, and remaining roadblocks for completion	0.1	44.00	___________
07/08/24	64057150	K H Zucker	Communicate with plaintiffs' counsel concerning production	0.2	290.00	___________
07/10/24	64132562	S McVey	Conference with Ken Zucker regarding download and production of SharePoint material	0.1	44.00	___________

Billing Rep: Maferima Kanhon

Prebill #6105468

Thru 08/07/24

UNBILLED FEE DETAIL

Date	Entry ID	Name	Narrative	Hours	Value	Edit
07/10/24	64057154	K H Zucker	Communicate with plaintiffs' counsel and finalize production in response to subpoena	1.0	1,450.00	________
07/12/24	64133052	S McVey	Conference with Ken Zucker regarding decryption passwords for ZIP files included in production	0.2	88.00	________
07/12/24	64057157	K H Zucker	Evaluate communications concerning passwords and summarize for plaintiffs' counsel	0.3	435.00	________
07/19/24	64209846	S McVey	Conference with Ken Zucker, Stephen Boscolo, and Abe Alexander regarding Precision Research document production questions	0.2	88.00	________
07/19/24	64104201	K H Zucker	Confer with S. Boscio and A. Alexander concerning issues to be addressed at deposition and confer with N. Sobieck concerning same	0.5	725.00	________
07/22/24	64145609	K H Zucker	Communicate with plaintiffs' counsel and review emails to be used at upcoming deposition, including communicate with N. Sobieck	0.4	580.00	________
07/30/24	64171560	K H Zucker	Communicate with N. Sobieck and A. Alexander concerning deposition preparation.	0.3	435.00	________
08/02/24	64233813	K H Zucker	Prepare for and participate in call with plaintiffs' counsel, including follow-up with N. Sobieck	1.0	1,450.00	________
08/04/24	64233820	K H Zucker	Review communication from J. Briggs on behalf of plaintiffs, including commence review of documents supplied	0.4	580.00	________
08/05/24	64233821	K H Zucker	Prepare for and participate in discussions with N. Sobieck and counsel for both plaintiffs and a defendant concerning upcoming deposition	2.8	4,060.00	________
			Totals	**19.2**	**22,610.00**	

PAY ONLY $20,000 per Abe Alexander

Court Reporting & Transcripts

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

VERITEXT LEGAL SOLUTIONS

Bill To: Jonathan D. Uslaner
Bernstein Litowitz Berger & Grossmann LLP
2121 Avenue of the Stars
Suite 2575
Los Angeles, CA, 90067

Invoice #: **7652323**
Invoice Date: **8/21/2024**
Balance Due: **$6,638.05**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 6843046 | Job Date: 8/7/2024 | Delivery: Normal

Location: New York, NY

Billing Atty: Jonathan D. Uslaner

Scheduling Atty: Michele Johnson Esq | Latham & Watkins LLP

Witness: Edward A Tenthoff	Quantity	Price	Amount
Transcript Services - Certified Transcript	420.00	$3.95	$1,659.00
Transcript - Supplemental Surcharges*	420.00	$0.45	$189.00
Rough Draft	420.00	$2.10	$882.00
Realtime Services	420.00	$2.30	$966.00
Realtime Services	420.00	$2.30	$966.00
Realtime Services	420.00	$2.30	$966.00
Exhibits	997.00	$0.65	$648.05
Digital Exhibit Binder	1.00	$55.00	$55.00
Secure Hosting & Delivery of Veritext File Suite	1.00	$166.00	$166.00
Logistics & Processing	1.00	$55.00	$55.00
Equipment Rental	1.00	$165.00	$165.00
Smart Package - Over 100 Transcript Pages	1.00	$110.00	$110.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: **7652323**
Invoice Date: **8/21/2024**
Balance Due: **$6,638.05**

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

VERITEXT LEGAL SOLUTIONS

Notes: *Supplemental Surcharges Include: Video Proceeding		
	Invoice Total:	**$6,827.05**
	Payment:	**$0.00**
	Credit:	**($189.00)**
	Interest:	**$0.00**
	Balance Due:	**$6,638.05**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 7652323
Invoice Date: 8/21/2024
Balance Due: $6,638.05

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

Bill To: Jonathan D. Uslaner
Bernstein Litowitz Berger & Grossmann LLP
2121 Avenue of the Stars
Suite 2575
Los Angeles, CA, 90067

Invoice #:	**7662771**
Invoice Date:	**8/28/2024**
Balance Due:	**$8,673.12**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 6870281 | Job Date: 8/19/2024 | Delivery: Expedited

Location: New York, NY

Billing Atty: Jonathan D. Uslaner

Scheduling Atty: Jordan Davisson Cook | Latham & Watkins LLP

Witness: Edward Patrick White , II	Quantity	Price	Amount
Transcript Services - Priority Request	556.00	$3.82	$2,123.92
Transcript Services - Certified Transcript	556.00	$3.95	$2,196.20
Transcript - Supplemental Surcharges*	556.00	$0.45	$250.20
Rough Draft	556.00	$2.10	$1,167.60
Realtime Services	556.00	$2.30	$1,278.80
Realtime Services	556.00	$2.30	$1,278.80
Exhibits	372.00	$0.65	$241.80
Digital Exhibit Binder	1.00	$55.00	$55.00
Secure Hosting & Delivery of Veritext File Suite	1.00	$166.00	$166.00
Logistics & Processing	1.00	$55.00	$55.00
Smart Package - Over 100 Transcript Pages	1.00	$110.00	$110.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 7662771
Invoice Date: 8/28/2024
Balance Due: $8,673.12

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

VERITEXT LEGAL SOLUTIONS

Notes: *Supplemental Surcharges Include: Video Proceeding Matter No: 2369-001 ChemoCentryx	**Invoice Total:**	**$8,923.32**
	Payment:	**$0.00**
	Credit:	**($250.20)**
	Interest:	**$0.00**
	Balance Due:	**$8,673.12**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: **7662771**
Invoice Date: **8/28/2024**
Balance Due: **$8,673.12**

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

VERITEXT LEGAL SOLUTIONS

Bill To: Chloe Jasper
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
NEW YORK, NY, 10020

Invoice #:	**7943817**
Invoice Date:	**12/18/2024**
Balance Due:	**$8,569.15**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 7060535 | Job Date: 12/9/2024 | Delivery: Expedited

Location: New York, NY

Billing Atty: Chloe Jasper

Scheduling Atty: Jordan Davisson Cook | Latham & Watkins LLP

Witness: Ahmed Ragab	Quantity	Price	Amount
Transcript Services - Priority Request	475.00	$4.91	$2,332.25
Transcript Services - Certified Transcript	475.00	$3.95	$1,876.25
Transcript - Supplemental Surcharges*	475.00	$0.45	$213.75
Rough Draft	475.00	$2.10	$997.50
Realtime Services	475.00	$2.30	$1,092.50
Realtime Services	475.00	$2.30	$1,092.50
Exhibits	711.00	$0.65	$462.15
Digital Exhibit Binder	1.00	$55.00	$55.00
Secure Hosting & Delivery of Veritext File Suite	1.00	$166.00	$166.00
Logistics & Processing	1.00	$55.00	$55.00
Equipment Rental	2.00	$165.00	$330.00
Smart Package - Over 100 Transcript Pages	1.00	$110.00	$110.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 7943817
Invoice Date: 12/18/2024
Balance Due: $8,569.15

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

Notes: *Supplemental Surcharges Include: Video Proceeding Client Matter: 2369-001 ChemoCentryx	**Invoice Total:**	**$8,782.90**
	Payment:	**$0.00**
	Credit:	**($213.75)**
	Interest:	**$0.00**
	Balance Due:	**$8,569.15**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 7943817

Invoice Date: 12/18/2024

Balance Due: $8,569.15

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - Northeast Region
Tel. (516) 608-2400 Email: billing-li@veritext.com
Fed. Tax ID: 20-3132569

Bill To: Melody Yaghoubzadeh
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
NEW YORK, NY, 10020

Invoice #:	**8011920**
Invoice Date:	**1/17/2025**
Balance Due:	**$5,202.44**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 7075766 | Job Date: 1/11/2025 | Delivery: Expedited

Location: Naples, FL

Billing Atty: Melody Yaghoubzadeh

Scheduling Atty: Abe Alexander | Bernstein Litowitz Berger & Grossmann LLP

Witness: Robert D Gibbons	Quantity	Price	Amount
Transcript Services - Original Transcript(s)	294.00	$1.85	$543.90
Transcript Services - Priority Request	294.00	$2.75	$808.50
Rough Draft	294.00	$1.00	$294.00
Realtime Services	294.00	$1.25	$367.50
Attendance - Wknd/Holiday Surcharge (3 Hour Min)	8.00	$110.00	$880.00
Attendance - Full Day	1.00	$320.00	$320.00
Exhibits	344.00	$0.10	$34.40
Secure Hosting & Delivery of Veritext File Suite	1.00	$40.00	$40.00
Conference Suite & Amenities	1.00	$2,333.04	$2,333.04
Equipment Rental	1.00	$250.00	$250.00
Smart Package - Over 100 Transcript Pages	1.00	$99.00	$99.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 8011920
Invoice Date: 1/17/2025
Balance Due: $5,202.44

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - Northeast Region
Tel. (516) 608-2400 Email: billing-li@veritext.com
Fed. Tax ID: 20-3132569

Notes:		
	Invoice Total:	**$5,970.34**
	Payment:	**$0.00**
	Credit:	**($767.90)**
	Interest:	**$0.00**
	Balance Due:	**$5,202.44**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 8011920
Invoice Date: 1/17/2025
Balance Due: $5,202.44

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

Bill To: Salvatore J. Graziano Esq
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas
NEW YORK, NY, 10020

Invoice #:	**8015700**
Invoice Date:	**1/21/2025**
Balance Due:	**$5,378.50**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 7068619 | Job Date: 1/13/2025 | Delivery: Expedited

Location: Boston, MA

Billing Atty: Salvatore J. Graziano Esq

Scheduling Atty: Jordan Davisson Cook | Latham & Watkins LLP

Witness: Alan Bonder MD	Quantity	Price	Amount
Transcript Services - Certified Transcript	339.00	$3.95	$1,339.05
Transcript Services - Certified Transcript - Priority Request	339.00	$3.20	$1,084.80
Transcript - Supplemental Surcharges*	339.00	$0.45	$152.55
Rough Draft	339.00	$2.10	$711.90
Realtime Services	339.00	$2.30	$779.70
Exhibits	1657.00	$0.65	$1,077.05
Digital Exhibit Binder	1.00	$55.00	$55.00
Secure Hosting & Delivery of Veritext File Suite	1.00	$166.00	$166.00
Logistics & Processing	1.00	$55.00	$55.00
Smart Package - Over 100 Transcript Pages	1.00	$110.00	$110.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: **8015700**
Invoice Date: **1/21/2025**
Balance Due: **$5,378.50**

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

VERITEXT LEGAL SOLUTIONS

Notes: *Supplemental Surcharges Include: Video Proceeding	**Invoice Total:**	**$5,531.05**
	Payment:	**$0.00**
	Credit:	**($152.55)**
	Interest:	**$0.00**
	Balance Due:	**$5,378.50**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: 8015700
Invoice Date: 1/21/2025
Balance Due: $5,378.50

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

Bill To: Jonathan D. Uslaner
Bernstein Litowitz Berger & Grossmann LLP
2121 Avenue of the Stars
Suite 2575
Los Angeles, CA, 90067

Invoice #: **8007888**
Invoice Date: **1/24/2025**
Balance Due: **$8,310.25**

Case: Homyk, Jonnie v. Chemocentryx, Inc. (4:21cv03343JSTa) **Proceeding Type: Depositions**

Job #: 7086925 | Job Date: 1/13/2025 | Delivery: Expedited — Third Party: Amgen

Location: Philadelphia, PA — Matter #: 10947

Billing Atty: Jonathan D. Uslaner

Scheduling Atty: Jordan Davisson Cook | Latham & Watkins LLP

Witness: Marc Walton	Quantity	Price	Amount
Transcript Services - Certified Transcript	469.00	$4.10	$1,922.90
Transcript Services - Certified Transcript - Priority Request	469.00	$4.10	$1,922.90
Transcript - Supplemental Surcharges*	469.00	$0.45	$211.05
Rough Draft	469.00	$2.10	$984.90
Realtime Services	469.00	$2.30	$1,078.70
Realtime Services	469.00	$2.30	$1,078.70
Exhibits	1411.00	$0.65	$917.15
Digital Exhibit Binder	1.00	$55.00	$55.00
Secure Hosting & Delivery of Veritext File Suite	1.00	$180.00	$180.00
Logistics & Processing	1.00	$60.00	$60.00
Smart Package - Over 100 Transcript Pages	1.00	$110.00	$110.00

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name:BMO Harris Bank
Account No:4353454 **ABA:**071000288
Swift: HATRUS44

Invoice #: **8007888**
Invoice Date: **1/24/2025**
Balance Due: **$8,310.25**

Pay by Credit Card: www.veritext.com

B420260815

Veritext, LLC - California Region
Tel. 877-955-3855 Email: calendar-la@veritext.com
Fed. Tax ID: 20-3132569

Notes: *Supplemental Surcharges Include: Video Proceeding Client Matter # 2369-001 ChemoCentryx		**Invoice Total:**	**$8,521.30**
		Payment:	**$0.00**
		Credit:	**($211.05)**
		Interest:	**$0.00**
		Balance Due:	**$8,310.25**

TERMS: Payment is due upon receipt of invoice and is not contingent on client or third-party reimbursement. Accounts 30 days past due will bear a finance charge of 1.5% per month. Accounts unpaid after 90 days agree to pay all collection costs, including reasonable attorney's fees. The BILL TO identified above is the contracting party and is responsible for payment of this invoice unless agreed to in writing prior to the rendering of services. If you have questions about your invoice, please notify Veritext immediately. Invoices cannot be redirected or split after 90 days. For more information on charges related to our services, please consult: https://www.veritext.com/service-information-details/

Credit card payments may incur a surcharge. No surcharge applies to ACH, check, or debit card payments

Remit to:
Veritext, LLC
P.O. Box 71303
Chicago IL 60694-1303
Fed. Tax ID: 20-3132569

Pay By ACH (Include invoice numbers):
A/C Name: Veritext, LLC
Bank Name: BMO Harris Bank
Account No: 4353454 **ABA:** 071000288
Swift: HATRUS44

Invoice #: 8007888
Invoice Date: 1/24/2025
Balance Due: $8,310.25

Pay by Credit Card: www.veritext.com

B420260815

Independent Witness Counsel

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11294

Date	Sep 18, 2023
Terms	Due Upon Receipt
Service Thru	Aug 31, 2023

User Hours Summary

Billing Period: 08/15/2023 - 08/31/2023

Matter: Chao Wang

User	Hours Billed	Rate/Hour	Amount Billed
Adam Hollander	7.60	$ 695.00	$ 5,282.00

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11439

Date	Dec 19, 2023
Terms	Due Upon Receipt
Service Thru	Nov 30, 2023

In Reference To: Dr. Richard Glassock (Labor)

Date	By	Services	Hours	Rates	Amount
11/06/2023	AH	[redacted]	1.20	$ 695.00/hr	$ 834.00
11/07/2023	AH		2.80	$ 695.00/hr	$ 1,946.00
11/08/2023	AH		3.30	$ 695.00/hr	$ 2,293.50
11/09/2023	AH		3.00	$ 695.00/hr	$ 2,085.00
11/09/2023	LM		0.40	$ 200.00/hr	$ 80.00
11/13/2023	AH		3.80	$ 695.00/hr	$ 2,641.00
11/22/2023	AH		1.25	$ 695.00/hr	$ 868.75
11/29/2023	AH		3.75	$ 695.00/hr	$ 2,606.25
11/30/2023	AH		3.50	$ 695.00/hr	$ 2,432.50

In Reference To: Dr. Richard Glassock (Expenses)

Date	By	Expenses	Amount
11/14/2023	AH	Flights for CA trip	$ 643.98
11/30/2023	AH	Uber	$ 112.78
11/30/2023	AH	Taxi	$ 24.00
11/30/2023	AH	Partial charge from hotel	$ 37.35
11/30/2023	AH	Hotel	$ 413.26
11/30/2023	AH	Airport Wifi	$ 10.00
11/30/2023	AH	Airport Wifi	$ 10.00

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11439

Date	Dec 19, 2023
Terms	Due Upon Receipt
Service Thru	Nov 30, 2023

11/30/2023	AH	Lunch at airport	$ 26.64
11/30/2023	AH	Breakfast during return trip from deposition	$ 30.29

Total Hours	23.00 hrs
Total Labor	$ 15,787.00
Total Expenses	$ 1,308.30
Total Invoice Amount	$ 17,095.30
Previous Balance	**$ 2,919.00**
12/04/2023 Payment - Check Split Payment	($1,459.50)
12/04/2023 Payment - Check Split Payment	($1,459.50)
Balance (Amount Due)	**$ 17,095.30**

Notes:

Please indicate Invoice Number with instructions, and make wire or bank transfer payment to:
First Republic Bank
1230 Avenue of the Americas
New York, NY 10020
ABA/Routing No: 321081669
Credit Account No: 80002054543

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11446

Date	Jan 10, 2024
Terms	Due Upon Receipt
Service Thru	Dec 31, 2023

In Reference To: Dr. Richard Glassock (Labor)

Date	By	Services	Hours	Rates	Amount
12/01/2023	AH	[redacted]	11.50	$ 695.00/hr	$ 7,992.50

In Reference To: Dr. Richard Glassock (Expenses)

Date	By	Expenses	Amount
12/02/2023	AH	Uber to airport	$ 90.77
12/02/2023	AH	Uber	$ 16.96
12/14/2023	EB	Logikcull subscription	$ 293.10

Total Hours	11.50 hrs
Total Labor	$ 7,992.50
Total Expenses	$ 400.83
Total Invoice Amount	$ 8,393.33
Previous Balance	**$ 17,095.30**
12/21/2023 Payment - Check Split Payment	($17,095.30)
Balance (Amount Due)	**$ 8,393.33**

Notes:
Please indicate Invoice Number with instructions, and make wire or bank transfer payment to:
First Republic Bank
1230 Avenue of the Americas
New York, NY 10020
ABA/Routing No: 321081669
Credit Account No: 80002054543

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11535

Date	Mar 13, 2024
Terms	Due Upon Receipt
Service Thru	Feb 29, 2024

In Reference To: Dr. Richard Glassock (Labor)

Date	By	Services	Hours	Rates	Amount
02/13/2024	AH	[redacted]	3.25	$ 765.00/hr	$ 2,486.25
02/14/2024	AH		0.50	$ 765.00/hr	$ 382.50
02/16/2024	AH		1.25	$ 765.00/hr	$ 956.25
02/21/2024	AH		2.25	$ 765.00/hr	$ 1,721.25
02/23/2024	AH		0.50	$ 765.00/hr	$ 382.50
02/29/2024	AH		0.50	$ 765.00/hr	$ 382.50

Total Hours	8.25 hrs
Total Labor	$ 6,311.25
Total Invoice Amount	$ 6,311.25
Previous Balance	**$ 10,101.33**
02/20/2024 Payment - Check Split Payment	($8,393.33)

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11535

Date	Mar 13, 2024
Terms	Due Upon Receipt
Service Thru	Feb 29, 2024

03/04/2024	Payment - Check Split Payment	($1,708.00)
	Balance (Amount Due)	**$ 6,311.25**

Notes:

Please indicate Invoice Number with instructions, and make wire or bank transfer payment to:
First Republic Bank
1230 Avenue of the Americas
New York, NY 10020
ABA/Routing No: 321081669
Credit Account No: 80002054543

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11535

Date	Mar 13, 2024
Terms	Due Upon Receipt
Service Thru	Feb 29, 2024

User Hours Summary

Billing Period: 02/13/2024 - 02/29/2024

Matter: Dr. Richard Glassock

User	Hours Billed	Rate/Hour	Amount Billed
Adam Hollander	8.25	$ 765.00	$ 6,311.25

Lauren Ferguson

From:	Abe Alexander
Sent:	Wednesday, March 13, 2024 12:39 PM
To:	Accounting
Cc:	Salvatore Graziano
Subject:	Fw: February 2024 Invoices - Slarskey LLC
Attachments:	ChemoCentryx - Glassock invoice_11535.pdf; ChemoCentryx - Wang invoice_11534.pdf

Hi - please pay for Chemocentryx

From: William McCabe <wmccabe@nexfirm.com>
Sent: Wednesday, March 13, 2024 12:18 PM
To: Abe Alexander <Abe.Alexander@blbglaw.com>
Subject: February 2024 Invoices - Slarskey LLC

[External]

Hello,
Attached are our firm's invoices for time and expenses in February 2024.
Our team is available to address any billing questions or concerns at billing@slarskey.com.

Best regards,

Bill McCabe
Billing Administrator
SLARSKEY LLC

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
1251 Ave. of the Americas
New York, NY 10020

Invoice 11780

Date	Jun 10, 2024
Terms	Due Upon Receipt
Service Thru	May 31, 2024

User Hours Summary

Billing Period: 05/14/2024 - 05/31/2024

Matter: Chao Wang

User	Hours Billed	Rate/Hour	Amount Billed
Adam Hollander	23.75	$ 765.00	$ 18,168.75

Slarskey LLC
767 Third Avenue, 14th Floor
New York, NY 10017

INVOICE

Bernstein Litowitz Berger & Grossmann LLP
Abe Alexander
1251 Ave. of the Americas
New York, NY 10020

Invoice 11983

Date	Aug 15, 2024
Terms	Due Upon Receipt
Service Thru	Jul 31, 2024

In Reference To: Dr. Richard Glassock (Labor)

Date	By	Services	Hours	Rates	Amount
07/03/2024	ADH	[redacted]	1.75	$ 765.00/hr	$ 1,338.75
07/09/2024	ADH		2.00	$ 765.00/hr	$ 1,530.00
07/10/2024	ADH		5.25	$ 765.00/hr	$ 4,016.25
07/11/2024	ADH		3.50	$ 765.00/hr	$ 2,677.50

In Reference To: Dr. Richard Glassock (Expenses)

Date	By	Expenses	Amount
07/10/2024	ADH	In-flight wifi	$ 10.00
07/10/2024	ADH	Uber	$ 133.18
07/10/2024	ADH	Meal	$ 29.94
07/11/2024	ADH	Uber	$ 119.90
07/11/2024	ADH	Airfare	$ 556.48
07/18/2024	ADH	Wifi on flight	$ 25.00
07/18/2024	ADH	Uber	$ 21.95

Total Hours	12.50 hrs
Total Labor	$ 9,562.50
Total Expenses	$ 896.45
Total Invoice Amount	$ 10,458.95
Balance (Amount Due)	**$ 12,945.20**

HRS&C Hach Rose Schirripa & Cheverie LLP Attorneys At Law

12 Madison Avenue, 10th Floor
New York, New York 10016
Tel 212.213.8311
Fax 212.779.0028

INVOICE RE:

CHEMOCENTRYX 10B-5 SECURITIES CASE – CW REPRESENTATION

Attn: Jonathan Uslaner
Bernstein Litowitz Berger & Grossman
2121 Avenue of the Stars, Suite 2575
Los Angeles, California 90067

INVOICE DATE: September 8, 2025

See Attached Time Detail Report

Total Lodestar:	$84,672.00
Total Expenses:	$1,783.44
Invoice Total Due:	**$86,455.44**

Thank you for your trust in our legal services.

Sincerely,

/s/ Daniel B. Rehns

Daniel B. Rehns
Partner

Please remit payment to:

Hach Rose Schirripa & Cheverie LLP - Escrow Account
JPMorgan Chase
349 5th Avenue
New York, NY 10016

ABA Routing 021000021
Account Number: 601938611

Rule 54(d)(1) Taxable Costs

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA Form CAND 133 (Rev. 10/2021)	**BILL OF COSTS** *Please follow the instructions on page 3 when completing this form.*	COURT USE ONLY OBJECTION DEADLINE: 9/12/2025 OBJECTION FILED: YES ☐ No ☒

1. CASE NAME	2. CASE NUMBER	3. DATE JUDGMENT ENTERED	4. PARTY AGAINST WHOM JUDGMENT WAS ENTERED
Homyk, et al. v. ChemoCentryx, Inc. and Thomas J. Schall	4:21-cv-03343-JST	August 15, 2025	Lead Plaintiff Indiana Public Retirement System

5. NAME OF CLAIMING PARTY	6. NAME OF ATTORNEY FOR CLAIMING PARTY (or indicate "PRO SE")	7. PHONE AND EMAIL OF CLAIMING PARTY, IF PRO SE
ChemoCentryx, Inc. and Thomas J. Schall	Jordan D. Cook	

8. REQUEST TO TAX THE FOLLOWING AS COSTS: (SHADED AREAS ARE FOR COURT USE ONLY)

COST ITEM	AMOUNT CLAIMED	LIST SUPPORTING DOCUMENTATION	*Amt Allowed*	*Disallowed*	*Disallowance Reason*
a. FEES OF THE CLERK AND FOR SERVICE OF PROCESS					
Filing Fees and Docket Fees, Civil LR 54-3(a)(1), 28 U.S.C. 1923					
Service of Process, Civil LR 54-3(a)(2)					
b. REPORTERS' TRANSCRIPTS					
Transcripts for appeal, Civil LR 54-3(b)(1)					
Rulings from the bench, Civil LR 54-3(b)(2)	$1,281.05	Exhibit A			
Other transcripts (by order or stipulation), Civil LR 54-3(b)(3)					
c. DEPOSITIONS					
Deposition transcript/video recording, Civil LR 54-3(c)(1)	$189,584.71	Exhibit B			
Deposition exhibits, Civil LR 54-3(c)(3)	$20,092.50	Exhibit B			
Notary & reporter attendance fees, Civil LR 54-3(c)(4),(5)	$14,909.83	Exhibit B			
d. REPRODUCTION, EXEMPLIFICATION					
Government records, Civil LR 54-3(d)(1)					
Disclosure/formal discovery documents, Civil LR 54-3(d)(2)					
Trial exhibits, Civil LR 54-3(d)(4)					

Visual aids, Civil LR 54(d)(5)					
e. WITNESS FEES AND EXPENSES					
Total from itemized Witness Fees worksheet,* Civil LR 54(e)					
f. COURT-APPOINTED PROFESSIONALS, INTERPRETERS					
Fees for special masters & receivers, Civil LR 54-3(f)					
Court-appointed experts, 28 USC § 1920(6)					
Interpreters and special interpretation services, 28 USC §§ 1828, 1920(6)					
g. MISCELLANEOUS COSTS					
Costs on appeal, Civil LR 54-3(g) & FRAP 39					
Costs of bonds and security, Civil LR 54-3(h)					
TOTAL AMOUNT	$ 225,868.09		$139,246.01		Pursuant to stipulation and order at docket #355

9. ADDITIONAL COMMENTS, NOTES, ETC:

10. **AFFIDAVIT PURSUANT TO 28 USC § 1924**: I declare under penalty of perjury that the foregoing costs are correct and were necessarily incurred in this action and that the services for which fees have been charged were actually and necessarily performed.
Name of Attorney/Claiming Party:

SIGNATURE: /s/ Jordan D. Cook **DATE:** 8/29/2025

11. Costs are taxed in the amount of $139,246.01 and included in the judgment.

Mark B. Busby
Clerk of Court

BY: /s/ Kelly Collins Deputy Clerk **DATE:** September 23, 2025

*WITNESS FEES/EXPENSES COMPUTATION WORKSHEET FOR ITEM 8.e OF REQUEST TO TAX COSTS (28 USC 1821)

WITNESS NAME , CITY AND STATE OF RESIDENCE	ATTENDANCE # Days	ATTENDANCE $ Cost	SUBSISTENCE # Days	SUBSISTENCE $ Cost	TRAVEL/MILEAGE Travel Cost or # Miles POV	TRAVEL/MILEAGE $ Cost	TOTAL COST Per Witness
						TOTAL WITNESS FEES/EXPENSES	$ 0.00

Mediation Fees

Phillips ADR

2101 E. Coast Highway, Suite 250
Corona del Mar, CA 92625
(949) 718-4547

Invoice submitted via email to:

December 15, 2023
Invoice #24494

Bernstein Litowitz Berger & Grossmann LLP
Jonathan Uslander
jonathanu@blbglaw.com

Re: ChemoCentryx Securities Class Action Mediation
Client # 14482

	Amount
Mediation Services	**$42,500.00**
Your responsibility of the split charges	**$21,250.00**
BALANCE DUE	**$21,250.00**

Please remit payment using one of the following:

PLEASE SEND CHECK TO

Phillips ADR Enterprises, P.C.,
2101 East Coast Highway, Suite 250
Corona del Mar, CA 92625

FEDERAL TAX ID 47-1443680

WIRE INSTRUCTIONS

First Republic Bank
2800 East Coast Highway
Corona del Mar, CA 92625
Telephone (949) 721-0988
Routing No. 321081669
Account No. 80006571931
SWIFT Code FRBBUS6S

PAYMENT DUE UPON RECEIPT OF INVOICE

PLEASE RETURN THIS PAGE WITH YOUR PAYMENT.

Exhibit 13

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
(jonathanu@blbglaw.com)
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Salvatore J. Graziano (admitted *pro hac vice*)
(salvatore@blbglaw.com)
Katherine M. Sinderson (admitted *pro hac vice*)
(katiem@blbglaw.com)
John Esmay (admitted *pro hac vice*)
(john.esmay@blbglaw.com)
1251 Avenue of the Americas
New York, NY 10020
Tel: 212-554-1400
Fax: 212-554-1444

Lead Counsel for Lead Plaintiff Indiana Public Retirement System and the Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357 **[PROPOSED] JUDGMENT APPROVING CLASS ACTION SETTLEMENT**

WHEREAS, a securities class action is pending in this Court entitled *Homyk v. ChemoCentryx, Inc.*, Master File No. 4:21-cv-03343-JST ("Action");

WHEREAS, by Order dated March 6, 2024 (ECF No. 131), this Court certified the Action to proceed as a class action on behalf of all persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), and were damaged thereby ("Class").[1] The Court also appointed Lead Plaintiff Indiana Public Retirement System ("Class Representative") as Class Representative for the Class, and appointed Lead Counsel Bernstein Litowitz Berger & Grossmann LLP as Class Counsel for the Class;

WHEREAS, pursuant to the Court's Order dated October 17, 2024 (ECF No. 179), the Court (a) approved the proposed form and content of the Class Notice to be disseminated to the Class Members to notify them of, among other things: (i) the Action pending against Defendants; (ii) the Court's certification of the Action to proceed as a class action on behalf of the Class; and (iii) Class Members' right to request to be excluded from the Class by January 14, 2025, the effect of remaining in the Class or requesting exclusion, and the requirements for requesting exclusion; and (b) approved the method of dissemination of the Class Notice;

WHEREAS, the Class Notice was mailed beginning on November 13, 2024 to all potential Class Members who could be identified through reasonable effort, resulting in the mailing of 35,220 copies of the Class Notice, and two requests for exclusion from the Class were received by January 14, 2025 (ECF No. 187, at ¶¶ 4-5, 11, 15 & Ex. 5);

---

[1] Excluded from the Class are (a) Defendants; (b) their respective successors and assigns; (c) the past and current executive officers and directors of Defendants; (d) the Immediate Family Members of Defendant Thomas J. Schall; and (e) the legal representatives, heirs, successors, or assigns of any excluded person, and any entity in which any of the above excluded persons have or had a direct or controlling ownership interest, and the legal representatives, heirs, successors-in-interest or assigns of any such excluded persons or entities. Also excluded from the Class are the persons and entities listed in Exhibit 1.

WHEREAS, on August 15, 2025, the Court issued an Order granting Defendants' motion for summary judgment disposing of the case, ECF No. 345, and on the same day, the Court issued Judgment in favor of Defendants, ECF No. 346, and Class Representative thereafter appealed;

WHEREAS, Class Representative, on behalf of itself and the other members of the Class, and Defendants (together with Class Representative, the "Parties") has determined to settle all claims asserted against Defendants in the Action with prejudice on the terms and conditions set forth in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 ("Stipulation"), subject to the approval of this Court ("Settlement");

WHEREAS, unless otherwise defined in this Judgment, the capitalized terms herein shall have the same meaning as they have in the Stipulation;

WHEREAS, by Order dated June 12, 2026 ("Preliminary Approval Order"), this Court: (a) found, pursuant to Rule 23(e)(1)(B) of the Federal Rules of Civil Procedure, that it would likely be able to approve the Settlement as fair, reasonable, and adequate under Rule 23(e)(2); (b) ordered that notice of the proposed Settlement be provided to potential Class Members; (c) provided Class Members with the opportunity to opt back into the Class if they previously excluded themselves from the Class in connection with Class Notice or to object to the proposed Settlement; and (d) scheduled a hearing regarding final approval of the Settlement;

WHEREAS, due and adequate notice has been given to the Class;

WHEREAS, the Court conducted a hearing on October 29, 2026 ("Settlement Hearing") to consider, among other things: (a) whether the terms and conditions of the Settlement are fair, reasonable, and adequate to the Class, and should therefore be approved; and (b) whether a judgment should be entered dismissing the Action with prejudice as against Defendants; and

WHEREAS, the Court having reviewed and considered the Stipulation, all papers filed and proceedings held herein in connection with the Settlement, all oral and written comments received regarding the Settlement, and the record in the Action, and good cause appearing therefor,

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED:

1. **Jurisdiction** – The Court has jurisdiction over the subject matter of the Action, and all matters relating to the Settlement, as well as personal jurisdiction over all of the Parties and each of the Class Members.

2. **Incorporation of Settlement Documents** – This Judgment incorporates and makes a part hereof: (a) the Stipulation filed with the Court on May 15, 2026; and (b) the Postcard Notice, Settlement Notice, and Summary Settlement Notice, which were filed with the Court on September 10, 2026.

3. **Notice** – The Court finds that the dissemination and posting of the Postcard Notice and Settlement Notice and the publication of the Summary Settlement Notice: (a) were implemented in accordance with the Preliminary Approval Order; (b) constituted the best notice practicable under the circumstances; (c) constituted notice that was reasonably calculated, under the circumstances, to apprise Class Members of (i) the effect of the proposed Settlement (including the Releases to be provided thereunder); (ii) Class Counsel's motion for attorneys' fees and Litigation Expenses; (iii) their right to object to any aspect of the Settlement, the Plan of Allocation, and/or Class Counsel's motion for attorneys' fees and Litigation Expenses; (iv) their right to opt back into the Class if they previously excluded themselves from the Class in connection with Class Notice; and (v) their right to appear at the Settlement Hearing; (d) constituted due, adequate, and sufficient notice to all persons and entities entitled to receive notice of the proposed Settlement; and (e) satisfied the requirements of Rule 23 of the Federal Rules of Civil Procedure, the United States Constitution (including the Due Process Clause), the Private Securities Litigation Reform Act of 1995, 15 U.S.C. § 78u-4, as amended, and all other applicable law and rules.

4. **CAFA Notice** - The Court finds that the notice requirements set forth in the Class Action Fairness Act of 2005, 28 U.S.C. § 1715, *et seq.*, to the extent applicable to the Action, have been satisfied.

5. **[Objections** - The Court has considered each of the objections to the Settlement submitted pursuant to Rule 23(e)(5) of the Federal Rules of Civil Procedure. The Court finds and concludes that each of the objections is without merit, and each is hereby overruled.]

6. **Final Settlement Approval and Dismissal of Claims** – Pursuant to, and in accordance with, Rule 23(e)(2) of the Federal Rules of Civil Procedure, this Court hereby fully and finally approves the Settlement set forth in the Stipulation in all respects (including, without limitation: the amount of the Settlement; the Releases provided for therein; and the dismissal with prejudice of the claims asserted against Defendants in the Action), and finds that the Settlement is, in all respects, fair, reasonable, and adequate to the Class. Specifically, the Court finds that: (a) Class Representative and Class Counsel have adequately represented the Class; (b) the Settlement was negotiated by the Parties at arm's length; (c) the relief provided for the Class under the Settlement is adequate taking into account the costs, risks, and delay of trial and appeal; the proposed means of distributing the Settlement Fund to the Class; and the proposed attorneys' fee award; and (d) the Settlement treats members of the Class equitably relative to each other. The Parties are directed to implement, perform, and consummate the Settlement in accordance with the terms and provisions contained in the Stipulation.

7. The Action and all of the claims asserted against Defendants in the Action by Class Representative and the other Class Members are hereby dismissed with prejudice. The Parties shall bear their own costs and expenses, except as otherwise expressly provided in the Stipulation.

8. **Binding Effect** – The terms of the Stipulation and of this Judgment shall be forever binding on Defendants, Class Representative, and all other Class Members (regardless of whether or not any individual Class Member submits a Claim Form or seeks or obtains a distribution from the Net Settlement Fund), as well as their respective successors and assigns. The persons and entities listed on Exhibit 1 hereto are excluded from the Class pursuant to request and are not bound by the terms of the Stipulation or this Judgment.

9. **Releases** – The Releases set forth in paragraphs 5 and 6 of the Stipulation, together with the definitions contained in paragraph 1 of the Stipulation relating thereto, are expressly incorporated herein in all respects. The Releases are effective as of the Effective Date. Accordingly, this Court orders that:

(a) Without further action by anyone, upon the Effective Date of the Settlement, Class Representative and each of the other Class Members, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, shall be deemed to have, and by operation of law and of this Judgment shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Plaintiff's Claim (including, without limitation, Unknown Claims) against Defendants and the other Defendants' Releasees, and shall forever be barred and enjoined from prosecuting any or all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants' Releasees.

(b) Without further action by anyone, upon the Effective Date of the Settlement, Defendants, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, shall be deemed to have, and by operation of law and of this Judgment shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Defendants' Claim against Class Representative and the other Plaintiff's Releasees, and shall forever be barred and enjoined from prosecuting any or all of the Released Defendants' Claims directly or indirectly against any of the Plaintiff's Releasees. This release shall not apply to any person or entity listed on Exhibit 1.

10. Notwithstanding paragraphs 9(a) – (b) above, nothing in this Judgment shall bar any action by any of the Parties to enforce or effectuate the terms of the Stipulation or this Judgment.

11. **Rule 11 Findings** – The Court finds and concludes that the Parties and their respective counsel have complied in all respects with the requirements of Rule 11 of the Federal Rules of Civil Procedure in connection with the institution, prosecution, defense, and settlement of the Action.

12. **No Admissions** – Neither this Judgment, the Stipulation (whether or not consummated), including the exhibits thereto and the Plan of Allocation contained therein (or any other plan of allocation that may be approved by the Court), the MOU, the Parties' mediations and subsequent Settlement, the communications and/or discussions leading to the execution of the Stipulation or the MOU, nor any proceedings taken pursuant to or in connection with the Stipulation or MOU and/or approval of the Settlement (including any arguments proffered in connection therewith):

(a) shall be offered against any of the Defendants' Releasees as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Defendants' Releasees with respect to the truth of any fact alleged by Class Representative or the validity of any claim that was or could have been asserted or the deficiency of any defense that has been or could have been asserted in this Action or in any other litigation, or of any liability, negligence, fault, or other wrongdoing of any kind of any of the Defendants' Releasees, or in any way referred to for any other reason as against any of the Defendants' Releasees, in any arbitration proceeding or other civil, criminal, or administrative action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of the Stipulation;

(b) shall be offered against any of the Plaintiff's Releasees as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Plaintiff's Releasees that any of their claims are without merit, that any of the Defendants' Releasees had meritorious defenses, or that damages recoverable under the Complaint would not have exceeded the Settlement Amount, or with respect to any liability, negligence, fault, or wrongdoing of any kind, or in any way referred to for any other reason as against any of the Plaintiff's Releasees, in any arbitration proceeding or other civil, criminal, or administrative action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of the Stipulation; or

(c) shall be construed against any of the Releasees as an admission, concession, or presumption that the consideration to be given under the Stipulation represents the amount which could be or would have been recovered after trial;

provided, however, that the Parties and the Releasees and their respective counsel may refer to this Judgment and the Stipulation to effectuate the protections from liability granted hereunder and thereunder or otherwise to enforce the terms of the Settlement.

13. **Retention of Jurisdiction** – Without affecting the finality of this Judgment in any way, this Court retains continuing and exclusive jurisdiction over: (a) the Parties for purposes of the administration, interpretation, implementation, and enforcement of the Settlement; (b) the disposition of the Settlement Fund; (c) any motion for attorneys' fees and/or Litigation Expenses in the Action that will be paid from the Settlement Fund; (d) any motion to approve the Plan of Allocation; (e) any motion to approve the Class Distribution Order; and (f) the Class Members for all matters relating to the Action.

14. Separate orders shall be entered regarding approval of a plan of allocation and the motion of Class Counsel for attorneys' fees and Litigation Expenses. Such orders shall in no way affect or delay the finality of this Judgment and shall not affect or delay the Effective Date of the Settlement.

15. **Modification of the Agreement of Settlement** – Without further approval from the Court, Class Representative and Defendants are hereby authorized to agree to and adopt such amendments or modifications of the Stipulation or any exhibits attached thereto to effectuate the Settlement that: (a) are not materially inconsistent with this Judgment; and (b) do not materially limit the rights of Class Members in connection with the Settlement. Without further order of the Court, Class Representative and Defendants may agree to reasonable extensions of time to carry out any provisions of the Settlement.

16. **Termination of Settlement** – If the Settlement is terminated as provided in the Stipulation or the Effective Date of the Settlement otherwise fails to occur, this Judgment shall be vacated and rendered null and void, and shall be of no further force and effect, except as otherwise

provided by the Stipulation, and this Judgment shall be without prejudice to the rights of Class Representative, the other Class Members, and Defendants, and Class Representative and Defendants shall revert to their respective positions in the Action immediately before the execution of the MOU on January 26, 2026, as provided in the Stipulation.

17. **Entry of Final Judgment** – There is no just reason to delay the entry of this Judgment as a final judgment in this Action. Accordingly, the Clerk of the Court is expressly directed to immediately enter this final judgment in this Action.

SO ORDERED this _______ day of ______________, 2026.

____
The Honorable Jon S. Tigar
United States District Judge

Exhibit 1

1. Petrus Bekker
   Haiku, HI

2. RA Capital Healthcare Fund, L.P.
   Boston, MA

Exhibit 14

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
(jonathanu@blbglaw.com)
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Salvatore J. Graziano (admitted *pro hac vice*)
(salvatore@blbglaw.com)
Katherine M. Sinderson (admitted *pro hac vice*)
(katiem@blbglaw.com)
John Esmay (admitted *pro hac vice*)
(john.esmay@blbglaw.com)
1251 Avenue of the Americas
New York, NY 10020
Tel: 212-554-1400
Fax: 212-554-1444

Lead Counsel for Lead Plaintiff Indiana Public Retirement System and the Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

JONNIE HOMYK, et al., Plaintiffs, v. CHEMOCENTRYX, INC. et al., Defendants.	Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357 **[PROPOSED] ORDER APPROVING PLAN OF ALLOCATION OF NET SETTLEMENT FUND**

WHEREAS, this matter came on for hearing on October 29, 2026 (the "Settlement Hearing") on Lead Plaintiff's motion to approve the proposed plan of allocation ("Plan of Allocation") of the Net Settlement Fund created under the Settlement in the above-captioned class action (the "Action"). The Court having considered all matters submitted to it at the Settlement Hearing; and it appearing that notice substantially in the form approved by the Court, which advised Class Members of the Plan of Allocation, was mailed to all Class Members who or which could be identified with reasonable effort, and that a summary notice substantially in the form approved by the Court was published in the *Wall Street Journal* and transmitted over *PR Newswire* pursuant to the specifications of the Court; and the Court having considered and determined the fairness and reasonableness of the proposed Plan of Allocation,

NOW, THEREFORE, IT IS HEREBY ORDERED THAT:

1. This Order approving the proposed Plan of Allocation incorporates by reference the definitions in the Revised Stipulation and Agreement of Settlement, dated May 15, 2026 (Dkt. No. 366-1) (the "Stipulation") and all terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation.

2. The Court has jurisdiction to enter this Order approving the proposed Plan of Allocation, and over the subject matter of the Action and all Parties to the Action, including all Class Members.

3. Notice of Lead Plaintiff's motion for approval of the proposed Plan of Allocation was given to all Class Members who or which could be identified with reasonable effort. The form and method of notifying the Class of the motion for approval of the proposed Plan of Allocation satisfied the requirements of Rule 23 of the Federal Rules of Civil Procedure, the United States Constitution (including the Due Process Clause), the Private Securities Litigation Reform Act of 1995, 15 U.S.C. § 78u-4, as amended, and all other applicable laws and rules, constituted the best notice practicable under the circumstances, and constituted due and sufficient notice to all persons and entities entitled thereto.

4. Over 77,000 Postcard Notices and 1,500 Settlement Notice Packets (*i.e.*, the Settlement Notice and Claim Form) were mailed to potential Class Members and nominees, and the Settlement Notice, which included the Plan of Allocation, was posted on the case website. No objections to the Plan of Allocation were submitted.

5. The Court hereby finds and concludes that the formula for the calculation of the claims of Claimants as set forth in the Plan of Allocation provides a fair and reasonable basis upon which to allocate the proceeds of the Net Settlement Fund among Class Members with due consideration having been given to administrative convenience and necessity.

6. The Court hereby finds and concludes that the Plan of Allocation is, in all respects, fair and reasonable to the Class. Accordingly, the Court hereby approves the Plan of Allocation proposed by Lead Plaintiff.

7. Any appeal or any challenge affecting this Order approving the Plan of Allocation shall in no way disturb or affect the finality of the Judgment.

SO ORDERED this _______ day of ______________, 2026.

____
The Honorable Jon S. Tigar
United States District Judge

Exhibit 15

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
(jonathanu@blbglaw.com)
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3481

Salvatore J. Graziano (admitted *pro hac vice*)
(salvatore@blbglaw.com)
Katherine M. Sinderson (admitted *pro hac vice*)
(katiem@blbglaw.com)
John Esmay (admitted *pro hac vice*)
(john.esmay@blbglaw.com)
1251 Avenue of the Americas
New York, NY 10020
Tel: 212-554-1400
Fax: 212-554-1444

Lead Counsel for Lead Plaintiff Indiana Public Retirement System and the Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

JONNIE HOMYK, et al.,

Plaintiffs,

v.

CHEMOCENTRYX, INC. et al.,

Defendants.

Master File No. 4:21-cv-03343-JST *and related case*, No. 4:21-cv-04357

[PROPOSED] ORDER AWARDING ATTORNEYS' FEES AND LITIGATION EXPENSES

WHEREAS, this matter came on for hearing on October 29, 2026 (the "Settlement Hearing") on Lead Counsel's motion for an award of attorneys' fees and payment of Litigation Expenses. The Court having considered all matters submitted to it at the Settlement Hearing and otherwise; and it appearing that notice of the Settlement Hearing substantially in the form approved by the Court was mailed to all Class Members who or which could be identified with reasonable effort, and that a summary notice of the hearing substantially in the form approved by the Court was published in the *Wall Street Journal* and was transmitted over the *PR Newswire* pursuant to the specifications of the Court; and the Court having considered and determined the fairness and reasonableness of the award of attorneys' fees and Litigation Expenses requested,

NOW, THEREFORE, IT IS HEREBY ORDERED THAT:

1. This Order incorporates by reference the definitions in the Revised Stipulation and Agreement of Settlement, dated May 15, 2026 (Dkt. No. 366-1) (the "Stipulation") and all terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation.

2. The Court has jurisdiction to enter this Order and over the subject matter of the Action and all parties to the Action, including all Class Members.

3. Notice of Lead Counsel's motion for an award of attorneys' fees and payment of Litigation Expenses was given to all Class Members who could be identified with reasonable effort. The form and method of notifying the Class of the motion for an award of attorneys' fees and expenses satisfied the requirements of Rule 23 of the Federal Rules of Civil Procedure, the Private Securities Litigation Reform Act of 1995 (15 U.S.C. § 78u-4(a)(7)), due process, and all other applicable law and rules, constituted the best notice practicable under the circumstances, and constituted due and sufficient notice to all persons and entities entitled thereto.

4. Lead Counsel is hereby awarded attorneys' fees in the amount of 22% of the Settlement Fund (including interest earned on this amount at the same rate as the Settlement Fund). Lead Counsel is also hereby awarded $4,898,136.90 for payment of its Litigation Expenses. These attorneys' fees and expenses shall be paid from the Settlement Fund and the Court finds these sums to be fair and reasonable.

5. Lead Counsel shall be paid the approved Litigation Expenses and 90% of the attorneys' fees upon entry of the Judgment approving the Settlement and this Order. The remaining 10% of the attorneys' fees awarded (and any interest earned thereon) will be paid after Lead Plaintiff conducts the distribution of the Net Settlement Fund to eligible Claimants and files the Post-Distribution Accounting.

6. In making this award of attorneys' fees and Litigation Expenses to be paid from the Settlement Fund, the Court has considered and found that:

a. The Settlement has created a fund of $69,000,000 in cash that has been funded into escrow pursuant to the terms of the Stipulation, and that numerous Class Members who submit acceptable Claim Forms will benefit from the Settlement that occurred because of the efforts of Lead Counsel;

b. Lead Counsel litigated this case on a purely contingent basis, and has not received any compensation for its work on this matter over the last five years;

c. The fee sought is below the Ninth Circuit's benchmark fee award in percentage fee cases, *see In re Online DVD-Rental Antitrust Litig.*, 779 F.3d 934, 949 (9th Cir. 2015);

d. The requested fee is consistent with a retainer agreement entered into with a sophisticated institutional investor Lead Plaintiff at the outset of the litigation and was again reviewed and approved as reasonable by Lead Plaintiff after the Settlement was reached;

e. Over 77,000 Postcard Notices and 1,500 Settlement Notice Packets (*i.e.*, the Settlement Notice and Claim Form) were mailed to potential Class Members and nominees stating that Lead Counsel would apply for attorneys' fees in an amount not to exceed 22% of the Settlement Fund and payment of Litigation Expenses in an amount not to exceed $5 million and no objections to the requested award of attorneys' fees or Litigation Expenses were submitted;

f. Lead Counsel conducted the litigation and achieved the Settlement with skill, perseverance and diligent advocacy;

g. Had Lead Counsel not achieved the Settlement there would remain a significant risk that Lead Plaintiff and the other members of the Class may have recovered less or nothing from Defendants;

h. Lead Counsel devoted over 61,000 hours, with a lodestar value of approximately $40.4 million, to achieve the Settlement, and will continue to perform work on behalf of the Class in overseeing the Claims Administrator's processing of claims received and the distribution of the Net Settlement Fund; and

i. The amount of attorneys' fees awarded and expenses to be paid from the Settlement Fund are fair and reasonable and consistent with awards in similar cases.

7. Any appeal or any challenge affecting this Court's approval regarding any attorneys' fees and expense application shall in no way disturb or affect the finality of the Judgment.

8. Exclusive jurisdiction is hereby retained over the Parties and the Class Members for all matters relating to this Action, including the administration, interpretation, effectuation or enforcement of the Stipulation and this Order.

9. In the event that the Settlement is terminated or the Effective Date of the Settlement otherwise fails to occur, this Order shall be rendered null and void to the extent provided by the Stipulation.

10. There is no just reason for delay in the entry of this Order, and immediate entry by the Clerk of the Court is expressly directed.

SO ORDERED this _______ day of ______________, 2026.

____
The Honorable Jon S. Tigar
United States District Judge

Exhibit 16

EXHIBIT 16

***Homyk v. ChemoCentryx, Inc*., No. 4:21-cv-03343-JST**

COMPENDIUM OF UNPUBLISHED AUTHORITY
CITED IN FEE AND EXPENSE MOTION

Exhibit	
16A	Final Approval Order, *In re Nutanix Inc. Sec. Litig.*, No. 19-cv-01651-WHO (N.D. Cal. Oct. 6, 2023), Dkt. No. 326
16B	Revised Order, *In re SanDisk LLC Sec. Litig.*, No. 3:15-cv-01455-VC (N.D. Cal. Oct. 23, 2019), Dkt. No. 284
16C	Notice of Annual Hourly Rate Increase of Latham & Watkins LLP at 2, *In re AIG Fin. Prods. Corp.*, No. 22-11309-MFW (Bankr. D. Del. Dec. 23, 2025), Dkt. No. 750
16D	Supplement to Tenth Interim Fee Application of Latham & Watkins LLP at Ex. B, *In re AIG Fin. Prods. Corp.*, No. 22-11309-MFW (Bankr. D. Del. Dec. 3, 2025), Dkt. No. 737 (excerpt)
16E	Order, *In re Splunk Inc. Sec. Litig.*, No. 4:20-cv-08600-JST (N.D. Cal. Mar. 4, 2024), Dkt. No. 143

Exhibit 16A

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

IN RE NUTANIX INC. SECURITIES LITIGATION Norton, *et al*. Plaintiffs vs. NUTANIX, INC., *et al*. Defendants	Case No. 19-cv-01651-WHO Case No. 21-cv-04080-WHO **FINAL APPROVAL ORDER AND ORDER AWARDING FEES AND COSTS** Re: Dkt. Nos. 317, 318

This matter came before the Court for hearing on October 4, 2023. Due and adequate notice having been given to the Class as required in the Order, the Court having considered all papers filed and proceedings held herein and otherwise being fully informed in the premises and good cause appearing therefore, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that:

1. This Judgment incorporates by reference the definitions in the Stipulation, and all capitalized terms used herein shall have the same meanings as set forth in the Stipulation, unless otherwise stated herein.

2. This Court has jurisdiction over the subject matter of the Actions and over all parties to the Actions, including all members of the Class.

3. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, the Court hereby affirms its determination in the Preliminary Approval Order and finally certifies for purposes of the Settlement only a Class defined as: "all persons or entities who: (i) purchased or otherwise acquired Nutanix, Inc. ("Nutanix") securities between November 30, 2017 and May 30, 2019, inclusive (the "Class Period"), and/or (ii) transacted in publicly traded call options and/or put

options of Nutanix during the Class Period. Excluded from the Class are Nutanix and its subsidiaries and affiliates, the Individual Defendants, any of Defendants' respective officers and directors at all relevant times, and any of their immediate families, legal representatives, heirs, successors, or assigns, and any entity in which any Defendant has or had a Controlling Interest."

4. Also excluded from the Class is any Person who timely and validly sought exclusion from the Class, as identified in Dkt. No. 320-2.

5. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, this Court hereby approves the Settlement set forth in the Stipulation and finds that:

(a) in light of the benefits to the Class and the complexity and expense of further litigation, the Stipulation and the Settlement contained therein are, in all respects, fair, reasonable, and adequate;

(b) there was no collusion in connection with the Stipulation;

(c) Plaintiffs and Lead Counsel have adequately represented the Class;

(d) the Stipulation was the product of informed, arm's-length negotiations among competent, able counsel;

(e) the relief provided for the Class is adequate, having taken into account: (i) the costs, risks, and delay of trial and appeal; (ii) the effectiveness of any proposed method of distributing relief to the Class, including the method of processing Class Member's claims; (iii) the terms of any proposed award of attorneys' fees, including timing of payment; and (iv) any agreement required to be identified under Federal Rule of Civil Procedure 23(e)(3);

(f) the proposed Plan of Allocation treats Class Members equitably relative to each other; and

(g) the record is sufficiently developed and complete to have enabled Plaintiffs and Defendants to have adequately evaluated and considered their positions.

6. Pursuant to Federal Rule of Civil Procedure 23, this Court hereby finds and concludes that due and adequate notice was directed to Persons who are Class Members advising them of the Plan of Allocation and of their right to object thereto, and a full and fair opportunity

was accorded to such Persons and entities who are Class Members to be heard with respect to the Plan of Allocation.

7. The distribution of the Postcard Notice by email and mail (where no email was available), posting of the Notice and Proof of Claim, and publication of the Summary Notice as provided for in the Preliminary Approval Order constituted the best notice practicable under the circumstances, including individual notice to Class Members who could be identified through reasonable effort. The notice provided was the best notice practicable under the circumstances of those proceedings and of the matters set forth therein, including the proposed Settlement set forth in the Stipulation, to all Persons entitled to such notice, and said notice fully satisfied the requirements of Federal Rule of Civil Procedure 23, due process and any other applicable law, including the Private Securities Litigation Reform Act of 1995. No Class Member is relieved from the terms of the Settlement, including the releases provided for therein, based upon the contention or proof that such Class Member failed to receive actual or adequate notice. A full opportunity has been offered to the Class Members to object to the proposed Settlement and to participate in the hearing thereon. The Court further finds that the notice provisions of the Class Action Fairness Act, 28 U.S.C. §1715, were fully discharged and that the statutory waiting period has elapsed. Dkt. No. 321. Thus, it is hereby determined that all members of the Class are bound by this Judgment, except those persons listed on Exhibit A to this Judgment.

8. The Court hereby finds and concludes that the formula for the calculation of the claims of Authorized Claimants, which is set forth in the Notice of Pendency and Proposed Settlement of Class Actions (the "Notice") provided to Class Members, provides a fair and reasonable basis upon which to allocate the proceeds of the Net Settlement Fund provided by the Settlement among eligible Class Members, with due consideration having been given to administrative convenience and necessity.

8. The Court hereby finds and concludes that the Plan of Allocation, as set forth in the Notice, is, in all respects, fair and reasonable, and the Court hereby approves the Plan of Allocation.

9. Accordingly, the Court authorizes and directs implementation and performance of

United States District Court
Northern District of California

all the terms and provisions of the Stipulation, as well as the terms and provisions hereof. Except as to the one individual who has validly and timely requested exclusion from the Class (identified at Dkt. 320-2), the Actions and all claims contained therein are dismissed with prejudice as to the Plaintiffs, and the other Class Members and as against each and all of the Released Defendant Parties. The Settling Parties are to bear their own costs except as otherwise provided in the Stipulation.

10. No Person shall have any claim against the Plaintiffs, Lead Counsel, or the Claims Administrator, or any other Person designated by Lead Counsel based on determinations or distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further order(s) of the Court.

11. Upon the Effective Date, Plaintiffs, and each of the Class Members (whether or not such Class Members execute and deliver a Proof of Claim, but excluding Class Members who have validly opted out of the Class), on behalf of themselves, and each of their respective heirs, executors, administrators, predecessors, successors, assigns, parents, subsidiaries, affiliates, officers, directors, agents, fiduciaries, beneficiaries or legal representatives, in their capacities as such, and any other Person or entity legally entitled to bring Released Claims on behalf of a Class Member, in that capacity, shall be deemed to have, and by operation of this Judgment shall have, fully, finally, and forever compromised, settled, resolved, waived, released, discharged, and dismissed each and every one of the Released Claims (including, without limitation, Unknown Claims) against each and every one of the Released Defendant Parties with prejudice on the merits, whether or not Plaintiffs, or such Class Member executes and delivers the Proof of Claim and whether or not Plaintiffs, or each of the Class Members ever seeks or obtains any distribution from the Settlement Fund. Claims to enforce the terms of the Stipulation are not released.

12. Upon the Effective Date, Defendants shall be deemed to have, and by operation of this Judgment shall have, fully, finally, and forever waived, released, discharged, and dismissed the Released Plaintiff Parties from all Released Defendants' Claims (including, without limitation, Unknown Claims). Claims to enforce the terms of the Stipulation are not released. For the avoidance of doubt, the releases, relinquishments and discharges provided by the Released

United States District Court
Northern District of California

Defendant Parties in the Stipulation do not include the release, relinquishment or discharge of any claim or cause of action that any of the Released Defendant Parties may have against an insurer or reinsurer for, arising out of or related to insurance coverage for, arising out of or related to the Actions or any related matter or proceeding, including any derivative or ERISA actions based on similar allegations. Claims to enforce the terms of the Stipulation are not released.

13. Upon the Effective Date, Plaintiffs, all Class Members and anyone claiming through or on behalf of any of them are forever permanently barred and enjoined from commencing, instituting, maintaining, enforcing, asserting, or continuing to prosecute any action or proceeding in any court of law or equity, arbitration tribunal, administration forum or other forum of any kind any of the Released Claims (including, without limitation, Unknown Claims) against any of the Released Defendant Parties.

14. Neither the Stipulation nor the Settlement contained therein, nor any act performed or document executed pursuant to or in furtherance of the Stipulation or the Settlement: (i) is or may be deemed to be or may be used as an admission of, or evidence of, the validity of any Released Claim, or of any wrongdoing or liability of the Released Defendant Parties; or (ii) is or may be deemed to be or may be used as an admission of, or evidence of, any fault or omission of any of the Released Defendant Parties; or (iii) is or may be deemed to be or may be used as an admission or evidence that any claims asserted by Plaintiffs were not valid or that the amount recoverable was not greater than the Settlement Amount, in any civil, criminal, or administrative proceeding in any court, administrative agency, or other tribunal. For the avoidance of doubt, the Stipulation, this Settlement, the Exhibits, the Supplemental Agreement, and any other act performed or document executed pursuant to or in furtherance of the Stipulation of Settlement, as well as the negotiations leading to the execution of the Stipulation, and any proceedings, communications, drafts, documents or agreements taken pursuant to, or in connection with the Stipulation, (i) shall not be offered or received against the Released Defendant Parties as evidence of or construed as or deemed to be evidence of any presumption, concession, or admission by the Released Defendant Parties of the truth of any allegations by Plaintiffs, any member of the Class, or their Related Persons or the validity of any claim that has been or could have been asserted in

United States District Court
Northern District of California

United States District Court
Northern District of California

the Actions, or the deficiency of any defense that has been or could have been asserted in the Actions or in any other litigation, including, but not limited to, litigation of the Released Claims, or of any liability, negligence, fault, or wrongdoing of any kind of the Released Defendant Parties or in any way referred to for any other reason as against the Released Defendant Parties, in any civil, criminal, or administrative action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of the Stipulation; (ii) shall not be offered or received against or to the prejudice of Released Defendant Parties as evidence of a presumption, concession, or admission of liability for any fault, misrepresentation, or omission with respect to any statement or written document approved or made by Released Defendant Parties, or against Lead Counsel or any member of the Class or their Related Persons as evidence of any infirmity in the claims of Plaintiffs and the Class; and (iii) shall not be offered or received against Released Defendant Parties as evidence of a presumption, concession, or admission of any liability, negligence, fault, or wrongdoing or in any way referred to for any other reason as against any of the parties to the Stipulation, in any other civil, criminal, or administrative action or proceeding; provided, however, that if the Stipulation is approved by the Court, the Released Defendant Parties may refer to it to effectuate the releases granted them hereunder. The Released Defendant Parties may file the Stipulation and/or the Judgment in any action that may be brought against them in order to support a defense or counterclaim based on principles of res judicata, collateral estoppel, release, good faith settlement, judgment bar or reduction, or any other theory of claim preclusion, issue preclusion, or similar defense or counterclaim.

15. Notice of Lead Counsel's motion for attorneys' fees and payment of expenses was given to all Class Members who could be identified with reasonable effort. The form and method of notifying the Class of the motion for attorneys' fees and expenses met the requirements of Rules 23 and 54 of the Federal Rules of Civil Procedure, Section 21D(a)(7) of the Securities Exchange Act of 1934, 15 U.S.C. §78u-4(a)(7), as amended by the Private Securities Litigation Reform Act of 1995, due process, and any other applicable law, constituted the best notice practicable under the circumstances, and constituted due and sufficient notice to all persons and entities entitled thereto.

16. The Court hereby awards Lead Counsel attorneys' fees of 25% of the Settlement Amount (the benchmark in the Ninth Circuit), plus expenses in the amount of $638,213.52, together with the interest earned thereon for the same time period and at the same rate as that earned on the Settlement Fund until paid. The Court finds that the amount of fees awarded is appropriate, fair, and reasonable given the substantial risks of non-recovery, the contingent nature of the representation, awards in similar cases, the time and effort involved, and the result obtained for the Class.

17. In making this award of fees and expenses to Lead Counsel, the Court has considered and found that:

(a) the Settlement has created a fund of $71,000,000 in cash that is already on deposit, and numerous Class Members who submit, or have submitted, valid Proof of Claim forms will benefit from the Settlement created by Lead Counsel;

(b) over 154,700 copies of the Postcard Notice were disseminated to potential Class Members indicating that Lead Counsel would move for attorneys' fees not to exceed 30% of the Settlement Amount and for expenses in an amount not to exceed $750,000, plus interest thereon, and no objections to the fees or expenses were filed by Class Members;

(c) Lead Counsel have pursued the Actions and achieved the Settlement with perseverance and diligent advocacy;

(d) Lead Counsel have expended substantial time and effort pursuing the Actions on behalf of the Class;

(e) Lead Counsel pursued the Actions on a contingent basis, having received no compensation during the Actions, and any fee amount has been contingent on the result achieved;

(f) the Actions involve complex factual and legal issues and, in the absence of settlement, would involve lengthy proceedings whose resolution would be uncertain;

(g) had Lead Counsel not achieved the Settlement, there would remain a significant risk that the Class may have recovered less or nothing from Defendants;

(h) Plaintiffs' Counsel have devoted over 16,000 hours, with a lodestar value of $10,581,445.25 to achieve the Settlement, and after considering and excluding from the lodestar cross-check the hours spent on disputes over the appointment of lead counsel, and award of 25% of the Settlement Amount is appropriate;

(i) Class Representative approved an amount in excess of the attorneys' fees awarded as fair and reasonable; and

(j) the attorneys' fees and expenses awarded are fair and reasonable and consistent with awards in similar cases within the Ninth Circuit.

18. Pursuant to 15 U.S.C. §78u-4(a)(4), the Court awards Class Representative California Ironworkers Field Pension Trust $2,000.00 for its time and expenses representing the Class.

19. Without affecting the finality of this Judgment in any way, this Court hereby retains continuing jurisdiction over: (i) implementation of the Settlement and any award or distribution of the Settlement Fund, including interest earned thereon; (ii) disposition of the Settlement Fund; (iii) hearing and determining applications for attorneys' fees and expenses in the Actions; and (iv) all parties hereto for the purpose of construing, enforcing, and administering the Settlement.

20. In the event that the Settlement does not become effective in accordance with the terms of the Stipulation, or the Effective Date does not occur, or in the event that the Settlement Fund, or any portion thereof, is returned to the Defendants or their insurers, then this Judgment shall be rendered null and void to the extent provided by and in accordance with the Stipulation and shall be vacated; and in such event, all orders entered and releases delivered in connection herewith shall be null and void to the extent provided by and in accordance with the Stipulation.

21. The Settling Parties shall bear their own costs and expenses except as otherwise provided in the Stipulation or in this Judgment.

22. Without further order of the Court, the Settling Parties may agree to reasonable extensions of time to carry out any of the provisions of the Stipulation.

23. The Court's orders entered during these Actions relating to the confidentiality of

United States District Court
Northern District of California

information shall survive this Settlement.

24. Class counsel shall file a post-distribution accounting within 21 days after the settlement checks become stale (or, if no checks are issued, all funds have been paid to class members, cy pres beneficiaries, and others pursuant to the settlement agreement). In addition to the information contained in the Northern District of California's Procedural Guidance for Class Action Settlements, available at https://cand.uscourts.gov/forms/procedural-guidance-for-class-action-settlements/, the post-distribution accounting shall discuss any significant or recurring concerns communicated by class members to the settlement administrator or counsel since final approval, any other issues in settlement administration since final approval, and how any concerns or issues were resolved. Class Counsel shall also include a final accounting for the costs of the Settlement Administrator, reflecting the costs savings from the reduction in the mailing of claims packets and breaking down the other costs incurred in Settlement Administration.

25. The Court orders the Settlement Administrator to withhold 20% of the attorney's fees granted in this order until the post-distribution accounting has been filed. Class counsel shall file a proposed order releasing the remainder of the fees when they file their post-distribution accounting.

26. This matter is set for a further case management conference on April 9, 2024, with a case management statement due on April 2, 2024. The parties may request that the case management conference be continued if additional time is needed to complete the distribution. The conference will be vacated if the post-distribution accounting has been filed and the Court has released the remaining attorney's fees.

IT IS SO ORDERED.

Dated: October 6, 2023

William H. Orrick
United States District Judge

Exhibit 16B

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION

IN RE: SANDISK LLC SECURITIES LITIGATION	Case No. 3:15-cv-01455-VC Hon. Vince Chhabria **REVISED ~~[PROPOSED]~~ ORDER AWARDING ATTORNEYS' FEES, PAYMENT OF LITIGATION EXPENSES, AND REIMBURSEMENT OF CLASS REPRESENTATIVES' COSTS AND EXPENSES**

THIS MATTER having come before the Court for hearing on September 26, 2019 (the "Settlement Hearing") to determine, among other things, whether and in what amount to award (i) Plaintiffs' Counsel in the above-captioned consolidated securities class action (the "Action") attorneys' fees and litigation expenses in connection with their representation of the Class; and (ii) Class Representatives their costs and expenses pursuant to the Private Securities Litigation Reform Act of 1995 (the "PSLRA"); the Court, having considered all papers filed and proceedings had herein and otherwise being fully informed;

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that:

1. This Order operates by reference to the definitions in the Revised Stipulation and Agreement of Settlement filed on May 20, 2019 (ECF No. 274-1) (the "Stipulation"), and all capitalized terms used, but not defined, herein shall have the same meanings as those set forth in the Stipulation.

2. Pursuant to and in compliance with Rule 23 of the Federal Rules of Civil Procedure, this Court hereby finds and concludes that due and adequate notice was directed to Persons who are Class Members who could be identified with reasonable effort, advising them of Class Counsel's motion for an award of attorneys' fees, payment of litigation expenses and reimbursement of Class Representatives' costs and expenses and their right to object thereto, and

a full and fair opportunity was accorded to Persons who are Class Members to be heard. There were no objections to Class Counsel's motion.

3. Class Counsel are hereby awarded, on behalf of all Plaintiffs' Counsel, attorneys' fees in the amount of 25% of the Settlement Fund, plus accrued interest, and $885,149.36, plus accrued interest, in payment of Plaintiffs' Counsel's litigation expenses, which sums the Court finds to be fair and reasonable. Consistent with this Court's established practice, 10% of the total amount of attorneys' fees awarded is the percentage, proposed by Class Counsel given their demonstrated commitment to the Class and hereby deemed an appropriate amount, that shall be withheld until after a distribution of the Net Settlement Fund to Authorized Claimants has been made. Otherwise, the attorneys' fees and expenses awarded shall be paid from the Settlement Fund immediately upon entry of this Order, subject to the terms, conditions, and obligations of the Stipulation, which terms, conditions, and obligations are incorporated herein by reference.

4. Class Counsel shall allocate the attorneys' fees awarded amongst Plaintiffs' Counsel in a manner in which they, in good faith, believe reflects the contributions of such counsel to the institution, prosecution, and settlement of the Action.

5. In making this award of attorneys' fees and expenses to be paid from the Settlement Fund, the Court has considered and found that:

(a) the Settlement has created a fund of $50,000,000 in cash, and Class Members who submit acceptable Claim Forms will benefit from the Settlement that has been achieved as a result of the efforts of Plaintiffs' Counsel;

(b) the attorneys' fees sought by Class Counsel have been reviewed and approved as reasonable by Class Representatives, who are institutional investors that oversaw the prosecution and resolution of the Action;

(c) copies of the revised Settlement Notice (ECF No. 274-3) were mailed to over 203,000 potential Class Members and nominees, stating that Class Counsel would apply for attorneys' fees in an amount not to exceed 28% of the Settlement Fund and litigation expenses in an amount not to exceed $1,000,000, and there were no objections to the requested attorneys' fees and expenses, which are less than the amounts stated in the revised Settlement Notice;

(d) the Action raised a number of complex issues;

(e) had Plaintiffs' Counsel not achieved the Settlement, there was a significant risk that Class Representatives and the other members of the Class may have recovered less or nothing at all from Defendants;

(f) Plaintiffs' Counsel have devoted nearly 30,000 hours with a lodestar value of $15,950,994.50 to this Action and have advanced $885,149.36 in litigation expenses to achieve the Settlement; and

(g) the amount of attorneys' fees and litigation expenses to be paid from the Settlement Fund are fair and reasonable and consistent with awards in similar cases.

6. In accordance with the PSLRA, Class Representative City of Bristol Pension Fund is hereby awarded $7,300 from the Settlement Fund as reimbursement for its reasonable costs and expenses directly related to its representation of the Class.

7. In accordance with the PSLRA, Class Representative Pavers and Road Builders Pension, Annuity and Welfare Funds is hereby awarded $7,717.50 from the Settlement Fund as reimbursement for its reasonable costs and expenses directly related to its representation of the Class.

8. In accordance with the PSLRA, Class Representative the City of Newport News Employees' Retirement Fund is hereby awarded $7,474.44 from the Settlement Fund as reimbursement for its reasonable costs and expenses directly related to its representation of the Class.

9. In accordance with the PSLRA, Class Representative Massachusetts Laborers' Pension Fund is hereby awarded $8,557.50 from the Settlement Fund as reimbursement for its reasonable costs and expenses directly related to its representation of the Class.

10. Any appeal of or challenge to this Court's award of attorneys' fees, payment of litigation expenses, and reimbursement of Class Representatives' costs and expenses in

connection with their representation of the Class shall in no way disturb or affect the finality of the Judgment.

11. Exclusive jurisdiction is hereby retained over the Parties and Class Members for all matters relating to this Action, including administration, interpretation, effectuation, or enforcement of the Stipulation and this Order.

12. In the event that the Settlement is terminated or the Effective Date of the Settlement fails to occur, this Order shall be rendered null and void to the extent provided by the Stipulation.

Dated: October 23, 2019

HONORABLE VINCE CHHABRIA
UNITED STATES DISTRICT JUDGE

Exhibit 16C

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	:	Chapter 11
AIG FINANCIAL PRODUCTS CORP.,[1]	:	Case No. 22-11309 (MFW)
Debtor.	:	**Related to Docket No. 74**

NOTICE OF ANNUAL HOURLY RATE
INCREASE OF LATHAM & WATKINS LLP

PLEASE TAKE NOTICE that on December 22, 2022, the above-captioned debtor and debtor-in-possession (the "**Debtor**") filed an application to retain Latham & Watkins LLP ("**L&W**") as its bankruptcy co-counsel [Docket No. 74] (the "**Retention Application**"). In support of the Retention Application, L&W filed the Declaration of Keith A. Simon and Disclosure Statement (the "**Simon Declaration**") [Docket No. 74-3] and the Supplemental Declaration of Keith A. Simon [Docket No. 112]. On January 30, 2023, this Court entered an order (the "**Retention Order**")[2] [Docket No. 124] authorizing the Debtor to retain and employ L&W as its bankruptcy co-counsel.

PLEASE TAKE FURTHER NOTICE that in the ordinary course of L&W's business and in keeping with L&W's established billing practices and procedures, as described in the Retention Application, L&W's standard billing rates were adjusted firm-wide on January 1, 2026. Specifically, effective January 1, 2026, L&W's hourly rates for professionals and paraprofessionals who may work on matters related to the Debtor's chapter 11 case shall range as follows:

[1] The Debtor in this case, along with the last four digits of the Debtor's federal tax identification number, is: AIG Financial Products Corp. (9410). The Debtor's address is 50 Danbury Road, Wilton, Connecticut 06897.

[2] Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Retention Order.

Billing Category	Range
Partners	$1,895 - $3,050
Counsel	$1,815- $2,550
Associates	$945 - $1,850
Professional Staff	$280 - $1,410
Paralegals	$390 - $970

[Remainder of page intentionally left blank]

Dated: December 18, 2025
Wilmington, Delaware

Respectfully Submitted,

/s/ Kara Hammond Coyle

YOUNG CONAWAY STARGATT & TAYLOR, LLP
Michael R. Nestor (No. 3526)
Kara Hammond Coyle (No. 4410)
Rodney Square
1000 North King Street
Wilmington, Delaware 19801
Telephone: (302) 571-6600
Facsimile: (302) 571-1253
Emails: mnestor@ycst.com
kcoyle@ycst.com

-and-

George A. Davis (admitted *pro hac vice*)
Keith A. Simon (admitted *pro hac vice*)
Annemarie V. Reilly (admitted *pro hac vice*)
Madeleine C. Parish (admitted *pro hac vice*)
LATHAM & WATKINS LLP
1271 Avenue of the Americas
New York, New York 10020
Telephone: (212) 906-1200
Facsimile: (212) 751-4864
Emails: george.davis@lw.com
keith.simon@lw.com
annemarie.reilly@lw.com
madeleine.parish@lw.com

Counsel for Debtor and Debtor in Possession

Exhibit 16D

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re	Chapter 11
AIG FINANCIAL PRODUCTS CORP.,[1]	Case No. 22-11309 (MFW)
Debtor.	**Ref. Docket No. 736**

SUPPLEMENT TO TENTH INTERIM FEE
APPLICATION OF LATHAM & WATKINS LLP

Latham & Watkins LLP ("**L&W**"), co-counsel to the above-captioned debtor and debtor in possession (the "**Debtor**"), hereby files this supplement to the *Tenth Interim Fee Application of Latham & Watkins LLP* [Docket No. 736] (the "**Tenth Interim Application**") and attaches hereto: (a) as **Exhibit A**, L&W's summary cover sheet related to the Tenth Interim Application, (b) as **Exhibit B**, a summary of compensation by each professional of L&W that worked on the above-captioned chapter 11 case, (c) as **Exhibit C**, a summary of compensation by project category, (d) as **Exhibit D**, an expense summary, (e) as **Exhibit E**, L&W's customary and comparable compensation disclosures, (f) as **Exhibit F**, the *Budget for Latham & Watkins LLP, Bankruptcy Co-Counsel to the Debtor, for the Period from July 1, 2025 through September 30, 2025* and the *Staffing Plan for Latham & Watkins LLP, Bankruptcy Co-Counsel to the Debtor, for the Period from July 1, 2025 through September 30, 2025*, (g) as **Exhibit G**, a summary of fees and hours budgeted compared to fees and hours billed, and (h) as **Exhibit H**, a certification of Keith A. Simon in support of the Tenth Interim Application.

---

[1] The Debtor in this case, along with the last four digits of the Debtor's federal tax identification number, is: AIG Financial Products Corp. (9410). The Debtor's address is 50 Danbury Road, Wilton, Connecticut 06897.

Dated: December 3, 2025
Wilmington, Delaware

Respectfully Submitted,

/s/ Kara Hammond Coyle

YOUNG CONAWAY STARGATT & TAYLOR, LLP
Michael R. Nestor (No. 3526)
Kara Hammond Coyle (No. 4410)
Rodney Square
1000 North King Street
Wilmington, Delaware 19801
Telephone: (302) 571-6600
Facsimile: (302) 571-1253
Emails: mnestor@ycst.com
kcoyle@ycst.com

-and-

George A. Davis (admitted *pro hac vice*)
Keith A. Simon (admitted *pro hac vice*)
Annemarie V. Reilly (admitted *pro hac vice*)
Madeleine C. Parish (admitted *pro hac vice*)
LATHAM & WATKINS LLP
1271 Avenue of the Americas
New York, New York 10020
Telephone: (212) 906-1200
Facsimile: (212) 751-4864
Email: george.davis@lw.com
keith.simon@lw.com
annemarie.reilly@lw.com
madeleine.parish@lw.com

Co-Counsel for Debtor and Debtor in Possession

Exhibit A

Summary Cover Sheet of Tenth Interim Fee Application

Case Name: **AIG Financial Products Corp.**
Case Number: **22-11309 (MFW)**
Applicant's Name: **Latham & Watkins LLP**
Date of Application: **December 1, 2025**
Interim or Final: **Interim**

Name of Applicant	Latham & Watkins LLP
Name of Client	AIG Financial Products Corp.
Time Period Covered by the Tenth Interim Fee Period	Start: July 1, 2025 End: September 30, 2025
Total compensation sought for the Tenth Interim Fee Period	$373,455.50
Total expenses sought for the Tenth Interim Fee Period	$11,253.81
Petition date	December 14, 2022
Retention date	December 14, 2022
Date of order approving employment	January 30, 2023 [Docket No. 124]
Total allowed compensation paid to date	$26,843,595.81
Total allowed expenses paid to date	$606,030.03
Blended rate in the Tenth Interim Fee Period for all attorneys	$1,774.17
Blended rate in the Tenth Interim Fee Period for all timekeepers	$1,695.98
Compensation sought and already paid pursuant to a monthly fee application but not yet allowed	$0.00
Expenses sought and already paid pursuant to a monthly fee application but not yet allowed	$0.00
Number of professionals included in this Application	9
If applicable, number of professionals included in this Application but not included in staffing plan approved by client	0[1]
Difference between fees budgeted and compensation sought for the Tenth Interim Fee Period	Fees sought are $461,669.50 less

[1] The Budget and Staffing Plan approved by the client includes only the timekeepers expected to bill at least 15 hours to the Chapter 11 Case during the Tenth Interim Fee Period. Of the 9 timekeepers included in this Application, 3 billed 15 hours or more.

Number of professionals billing fewer than 15 hours to the case during the Tenth Interim Fee Period	6
Are any rates higher than those approved or disclosed at retention?	Yes[2]

[2] The billable rates for Latham attorneys are adjusted on January 1 of each year. Notice of Latham's rate increase effective as of January 1, 2025 was filed on December 30, 2024 [Docket No. 532].

Exhibit B

Compensation by Professional

Name of Professional	Position; Date of Hire; Year of Obtaining License to Practice	Hourly Billing Rate[1]	Total Hours Billed	Total Compensation
Simon, Keith A.	Partner. Joined firm in 2004. Member of Illinois Bar since 1999. Member of New York Bar since 2008.	$2,325.00	38.20	$88,815.00
Wine, Jamie L.	Partner. Joined firm in 1995. Member of California Bar since 1996. Member of District of Columbia Bar since 2007. Member of New York Bar since 2007. Member of Vermont Bar since 2020.	$2,070.00	2.40	$4,968.00
Reilly, Annemarie V.	Counsel. Joined firm in 2009. Member of New York Bar since 2010.	$1,775.00	106.80	$189,570.00
Gardiner, Drew T.	Partner. Joined firm in 2004. Member of California Bar since 2004.	$1,680.00	3.70	$6,216.00
Parish, Madeleine C.	Associate. Joined firm in 2019. Member of New York Bar since 2019.	$1,565.00	39.40	$61,661.00
Haley, Erin M.	Associate. Joined firm in 2022. Member of Massachusetts Bar since 2022.	$1,135.00	3.10	$3,518.50
Singh, Gursahibveer	Associate. Joined firm in 2024. Member of Illinois Bar since 2024.	$835.00	7.40	$6,179.00
Yoder, Alyssa M.	Associate. Joined firm in 2024. Member of New York Bar since 2025.	$835.00	4.60	$3,841.00
Tarrant, Christopher M.	Senior Paralegal. Joined firm in 2022.	$595.00	14.60	$8,687.00

Grand Total	**$373,455.50**
Total Hours	**220.20**
Blended Rate	**$1,695.98**

[1] The billable rates for L&W attorneys are adjusted on January 1 of each year. Notice of L&W's rate increase effective as of January 1, 2025 was filed on December 30, 2024 [Docket No. 532].

Exhibit 16E

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP
Jonathan D. Uslaner (Bar No. 256898)
jonathanu@blbglaw.com
Lauren M. Cruz (Bar No. 299964)
lauren.cruz@blbglaw.com
Caitlin C. Bozman (Bar No. 343721)
caitlin.bozman@blbglaw.com
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067
Tel: (310) 819-3470

Lead Counsel for Lead Plaintiff Louisiana Sheriffs' Pension & Relief Fund and the Settlement Class

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

IN RE SPLUNK INC. SECURITIES LITIGATION	Case No. 4:20-cv-08600-JST **~~[PROPOSED]~~ ORDER AWARDING ATTORNEYS' FEES AND LITIGATION EXPENSES** Judge: Hon. Jon S. Tigar Courtroom: 6

WHEREAS, this matter came on for hearing on February 22, 2024 (the "Settlement Hearing") on Lead Counsel's motion for an award of attorneys' fees and payment of Litigation Expenses. The Court having considered all matters submitted to it at the Settlement Hearing and otherwise; and it appearing that notice of the Settlement Hearing substantially in the form approved by the Court was mailed to all Settlement Class Members who or which could be identified with reasonable effort, and that a summary notice of the hearing substantially in the form approved by the Court was published in *The Wall Street Journal* and was transmitted over the *PR Newswire* pursuant to the specifications of the Court; and the Court having considered and determined the fairness and reasonableness of the award of attorneys' fees and Litigation Expenses requested,

NOW, THEREFORE, IT IS HEREBY ORDERED THAT:

1. This Order incorporates by reference the definitions in the Stipulation and Agreement of Settlement dated January 30, 2023 (ECF No. 117-1) (the "Stipulation") and all terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation.

2. The Court has jurisdiction to enter this Order and over the subject matter of the Action and all parties to the Action, including all Settlement Class Members.

3. Notice of Lead Counsel's motion for an award of attorneys' fees and payment of Litigation Expenses was given to all Settlement Class Members who could be identified with reasonable effort. The form and method of notifying the Settlement Class of the motion for an award of attorneys' fees and expenses satisfied the requirements of Rule 23 of the Federal Rules of Civil Procedure, the Private Securities Litigation Reform Act of 1995 (15 U.S.C. § 78u-4(a)(7)), due process, and all other applicable law and rules, constituted the best notice practicable under the circumstances, and constituted due and sufficient notice to all persons and entities entitled thereto.

4. Plaintiffs' Counsel are hereby awarded attorneys' fees in the amount of 25% of the Settlement Fund net of litigation expenses awarded, or $7,440,061 (plus interest earned on this amount at the same rate as the Settlement Fund). Plaintiffs' Counsel are also hereby awarded $239,754.85 for payment of their litigation expenses. These attorneys' fees and expenses shall be paid from the Settlement Fund and the Court finds these sums to be fair and reasonable.

5. Plaintiffs' Counsel shall be paid 90% of the attorneys' fees awarded and 100% of the approved expenses immediately upon entry of the Judgment approving the Settlement and this Order. The remaining 10% of the attorneys' fees awarded (and any interest earned thereon) will be paid after Lead Plaintiff conducts the distribution of the Net Settlement Fund to eligible claimants and files a Post-Distribution Accounting.

6. In making this award of attorneys' fees and reimbursement of expenses to be paid from the Settlement Fund, the Court has considered and found that:

a. The Settlement has created a fund of $30,000,000 in cash that has been funded into escrow pursuant to the terms of the Stipulation, and that numerous Settlement Class Members who submit acceptable Claim Forms will benefit from the Settlement that occurred because of the efforts of Lead Counsel;

b. Plaintiffs' Counsel litigated this case on a purely contingent basis, and have not received any compensation for their work on this matter over the last three years;

c. The fee sought is consistent with the Ninth Circuit's benchmark amount in percentage fee cases, *see In re Online DVD-Rental Antitrust Litig.*, 779 F.3d 934, 949 (9th Cir. 2015);

d. The fee sought is based on a retainer agreement entered into by Lead Counsel and Lead Plaintiff at the outset of the litigation and the requested fee has been again reviewed and approved as reasonable by Lead Plaintiff, a sophisticated institutional investor that actively supervised the Action, at the conclusion of the Action;

e. Copies of the Notice were mailed to over 298,000 potential Settlement Class Members and nominees stating that Lead Counsel would apply for attorneys' fees for Plaintiffs' Counsel in an amount not to exceed 25% of the Settlement Fund and payment of Litigation Expenses in an amount not to exceed $325,000 and no objections to the requested award of attorneys' fees or Litigation Expenses were submitted;

f. Lead Counsel conducted the litigation and achieved the Settlement with skill, perseverance and diligent advocacy;

g. Had Lead Counsel not achieved the Settlement there would remain a significant risk that Lead Plaintiff and the other members of the Settlement Class may have recovered less or nothing from Defendants;

h. Plaintiffs' Counsel devoted over 6,300 hours, with a lodestar value of approximately $3.5 million, to achieve the Settlement, and will continue to perform work on behalf of the Settlement Class in overseeing the Claims Administrator's processing of claim received and the distribution of the Net Settlement Fund; and

i. The amount of attorneys' fees awarded and expenses to be paid from the Settlement Fund are fair and reasonable and consistent with awards in similar cases.

7. Any appeal or any challenge affecting this Court's approval regarding any attorneys' fees and expense application shall in no way disturb or affect the finality of the Judgment.

8. Exclusive jurisdiction is hereby retained over the parties and the Settlement Class Members for all matters relating to this Action, including the administration, interpretation, effectuation or enforcement of the Stipulation and this Order.

9. In the event that the Settlement is terminated or the Effective Date of the Settlement otherwise fails to occur, this Order shall be rendered null and void to the extent provided by the Stipulation.

10. There is no just reason for delay in the entry of this Order, and immediate entry by the Clerk of the Court is expressly directed.

SO ORDERED this 4th day of March, 2024.

Jon S. Tigar

The Honorable Jon S. Tigar
United States District Judge